

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
26 May 2005 (26.05.2005)

PCT

(10) International Publication Number  
**WO 2005/047458 A2**

(51) International Patent Classification<sup>7</sup>: C12N

A. [CN/US]; 11111 Via Abajo #A, San Diego, CA 92129 (US). **ZHANG, Qian** [CN/US]; 88348D Via Sanoma, San Diego, CA 92037 (US).

(21) International Application Number:  
PCT/US2004/019866

(22) International Filing Date: 18 June 2004 (18.06.2004)

(74) Agents: **SEIDMAN, Stephanie, L.** et al.; Fish and Richardson P.C., 12390 El Camino Real, San Diego, CA 92130 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
03013826.7 18 June 2003 (18.06.2003) EP  
03018478.2 14 August 2003 (14.08.2003) EP  
03024283.8 22 October 2003 (22.10.2003) EP

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US (patent), UZ, VC, VN, YU, ZA, ZM, ZW.

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:

US 03013826.7 (CON)  
Filed on 18 June 2003 (18.06.2003)  
US 03018478.2 (CON)  
Filed on 14 August 2003 (14.08.2003)  
US 03024283.8 (CON)  
Filed on 22 October 2003 (22.10.2003)

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*):  
**GENELUX CORPORATION** [US/US]; 3030 Bunker Hill Street, Suite 310, San Diego, CA 92109 (US).

Published:

— *without international search report and to be republished upon receipt of that report*

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **SZALAY, Aladar, A.** [US/US]; 7704 North Fork Road, Highland, CA 92346 (US). **TIMIRYASOVA, Tatyana** [RU/US]; 7524 Charmant Drive #525, San Diego, CA 92122 (US). **YU, Yong,**

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: MICROORGANISMS FOR THERAPY

(57) Abstract: Recombinant *vaccinia* viruses useful as tumor-specific delivery vehicle for cancer gene therapy and vaccination. Therapeutic methods and microorganisms therefore are provided. The microorganisms are designed to accumulate in immunoprivileged tissues and cells, such as in tumors and other proliferating tissue and in inflamed tissues, compared to other tissues, cells and organs, so that they exhibit relatively low toxicity to host organism. The microorganisms also are designed or modified to result in leaky cell membranes of cells in which they accumulate, resulting in production of antibodies reactive against proteins and other cellular products and also permitting exploitation of proliferating tissues, particularly tumors, to produce selected proteins and other products. Methods for making tumor specific antibodies and also methods of making gene products encoded by the microorganism as well as antibodies reactive therewith are provided.

**BEST AVAILABLE COPY**

WO 2005/047458 A2

-1-

**MICROORGANISMS FOR THERAPY  
RELATED APPLICATIONS**

Benefit of priority is claimed to each of EP 03 013 826.7, filed 18 June 2003, entitled "Recombinant vaccinia viruses useful as tumor-specific delivery vehicle for cancer gene therapy and vaccination;" EP 03 018 478.2, filed 14 August 2003, entitled "Method for the production of a polypeptide, RNA or other compound in tumor tissue;" and EP 03 024 283.8, filed 22 October 2003, entitled "Use of a Microorganism or Cell to Induce Autoimmunization of an Organism Against a Tumor." Where permitted, the subject matter of each of these applications is incorporated by reference in its entirety.

This application also is related U.S. application Serial No. (Attorney docket number 17248-002wo1 (4802PC)), filed the same day herewith. This application also is related to U.S. Application filed June 10, 2004 (attorney docket number 17248-003002), entitled "Light emitting microorganisms and cells for diagnosis and therapy of tumors," which is a continuation of U.S. Application Serial No. 10/189,918, filed July 3, 2002; U.S. Application filed May 19, 2004 (attorney docket number 17248-004002), entitled, "Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue" which is a continuation of U.S. Application Serial No. 10/163,763, filed June 5, 2003; International PCT Application WO 03/014380, filed July 31, 2002, entitled "Microorganisms and Cells for Diagnosis and Therapy of Tumors;" PCT Application WO 03/104485, filed June 5, 2003, entitled, "Light Emitting Microorganisms and Cells for Diagnosis and Therapy of Diseases Associated with Wounded or Inflamed tissue;" EP Application No. 01 118 417.3, filed July 31, 2001, entitled "Light-emitting microorganisms and cells for tumour diagnosis/therapy;" EP Application No. 01 125 911.6, filed October 30, 2001, entitled "Light emitting microorganisms and cells for diagnosis and therapy of tumors;" EP Application No. 02 0794 632.6, filed January 28, 2004, entitled "Microorganisms and Cells for Diagnosis and Therapy of Tumors;" and EP Application No. 02 012 552.2, filed June 5, 2002, entitled "Light Emitting

-2-

Microorganisms and Cells for Diagnosis and Therapy of Diseases associated with wounded or inflamed tissue." Where permitted, the subject matter of each of these applications is incorporated by reference in its entirety.

## FIELD OF THE INVENTION

5 Vaccines that contain attenuated or modified microorganisms, including microbes and cells, and methods for preparing the microorganisms and vaccines are provided. In particular, modified bacteria, eukaryotic cells and viruses are provided and methods of use thereof for treatment of proliferative and inflammatory disorders and for production of products in tumors are provided.

## 10 BACKGROUND

In the late 19th century, a variety of attempts were made to treat cancer patients with microorganisms. One surgeon, William Coley, administered live *Streptococcus pyogenes* to patients with tumors with limited success. In the early 20th century, scientists documented vaccinia viral oncolysis in mice, which lead to  
15 administration of several live viruses to patients with tumors from the 1940s through the 1960s. These forays into this avenue of cancer treatment were not successful.

Since that time, a variety of genetically engineered viruses have been tested for treatment of cancers. In one study, for example, nude mice bearing nonmetastatic colon adenocarcinoma cells were systemically injected with a WR  
20 strain of vaccinia virus modified by having a vaccinia growth factor deletion and an enhanced green fluorescence protein inserted into the thymidine kinase locus. The virus was observed to have antitumor effect, including one complete response, despite a lack of exogenous therapeutic genes in the modified virus (McCart *et al.* (2001) *Cancer Res* 1:8751-8757). In another study, vaccinia melanoma oncolysate  
25 (VMO) was injected into sites near melanoma positive lymph nodes in a Phase III clinical trial of melanoma patients. As a control, New York City Board of Health strain vaccinia virus (VV) was administered to melanoma patients. The melanoma patients treated with VMO had a survival rate better than that for untreated patients, but similar to patients treated with the VV control (Kim *et al.* (2001) *Surgical Oncol*  
30 10:53-59).

-3-

Other studies have demonstrated limited success with this approach. This therapy is not completely effective, particularly for systemically delivered viruses or bacteria. Limitations on the control of microbial vehicle function in vivo result in ineffective therapeutic results as well as raising safety concerns. It would be desirable to improve this type of therapy or to develop more effective approaches for treatments of neoplastic disease. Therefore, among the objects herein, it is an object to provide therapeutic methods and microorganisms for the treatment of neoplastic and other diseases.

#### **SUMMARY**

Provided herein are therapeutic methods and microorganisms, including viruses, bacteria and eukaryotic cells, for uses in the methods for the treatment of neoplastic diseases and other diseases. Diseases for treatment are those in which the targeted tissues and/or cells are immunoprivileged in that they, and often the local environment thereof, somehow escape or are inaccessible to the immune system.

Such tissues include tumors and other tissues and cells involved in other proliferative disorders, wounds and other tissues involved in inflammatory responses. The microorganisms, which include bacterial cells, viruses and mammalian cells, are selected or are designed to be non-pathogenic and to preferentially accumulate in the immunoprivileged tissues. The microorganisms, once in the tissues or cells or vicinity thereof, affect the cell membranes of the cells in such tissues so that they become leaky or lyse, but sufficiently slowly so that the targeted cells and tumors leak enough antigen or other proteins for a time sufficient to elicit an immune response.

The microorganisms are administered by any route, including systemic administration, such as i.v. or using oral or nasal or other delivery systems that direct agents to the lymphatics. In exemplary methods, the microorganisms are used to treat tumors and to prevent recurrence and metastatic spread. Exemplary microorganisms include highly attenuated viruses and bacteria, as well as mammalian cells. The microorganisms are optionally modified to deliver other products, including other therapeutic products to the targeted tissues.



-4-

When the microorganisms are administered to a host that contains tumors, the tumors in the host essentially become antigen and protein factories. This can be exploited so that the tumors can be used to produce proteins or other cellular products encoded by or produced by the microorganisms. In addition, the host sera  
5 can be harvested to isolate antibodies to products produced by the microorganisms as well as the tumor cells. Hence also provided are methods for producing gene products by administering the microorganisms to an animal, generally a non-human animal, and harvesting the tumors to isolate the product. Also provided are methods for producing antibodies to selected proteins or cell products, such as metabolites or  
10 intermediates, by administering a microorganism that expresses or produces the protein or other product to a host, typically a non-human host; and harvesting serum from the host and isolating antibodies that specifically bind to the protein or other product.

Thus provided are methods and microorganisms for elimination of  
15 immunoprivileged cells or tissues, particularly tumors. The methods include administration, typically systemic administration, with a microorganism that preferentially accumulates in immunoprivileged cells, such as tumor cells, resulting in leakage proteins and other compounds, such as tumor antigens, resulting in vaccination of the host against non-host proteins and, such as the tumor antigens,  
20 providing for elimination of the immunoprivileged cells, such as tumor cells, by the host's immune system. The microorganisms are selected not for their ability to rapidly lyse cells, but rather for the ability to accumulate in immunoprivileged cells, such as tumors, resulting in a leakage of antigens in a sufficient amount and for a sufficient time to elicit an immune response.

25 Hence provided are uses of microorganism or cell containing heterologous DNA, polypeptides or RNA to induce autoimmunization of an organism against a tumor. In particular, the microorganisms are selected or designed to accumulate in tumors and to accumulate very little, if at all (to be non-toxic to the host) in non-tumorous cells, tissues or organs, and to in some manner result in the tumor cell  
30 lyses or cell membrane disruption such that tumor antigens leak. Exemplary of such

-5-

microorganism are the LIVP-derived vaccinia virus and the bacteria described herein and also mammalian cells modified to target the tumors and to disrupt the cells membrane. The microorganisms can be modified to express heterologous products that mediate or increase the leakage of the tumor cell antigens and/or that are therapeutic, such as anti-tumor compounds.

Also provided are methods for production of antibodies against a tumor by (a) injecting a microorganism or cell containing a DNA sequence encoding a desired polypeptide or RNA into an organism bearing a tumor and (b) isolating antibodies against the tumor.

Provided are attenuated microorganisms that accumulate in immunoprivileged tissues and cells, such as tumor cells, but do not accumulate to toxic levels in non-targeted organs and tissues, and that upon administration to an animal bearing the immunoprivileged tissues and cells, result in autoimmunity, such as by production of anti-tumor (or anti-tumor antigen) antibodies against the immunoprivileged cells or products thereof. The microorganisms are selected or produced to render the immunoprivileged cells leaky, such as by a slow lysis or apoptotic process. The goal is to achieve such leakiness, but to not lyse the cells so rapidly that the host cannot mount an immune response.

Uses of and methods of use of the microorganisms for eliminating immunoprivileged are provided. The microorganisms optionally include reporter genes and/or other heterologous nucleic acids that disrupt genes in the microorganism and can also encode and provide therapeutic products or products, such as RNA, including RNAi, that alter gene and/or protein expression in the cells or tissues where the microorganism accumulates. Among the viruses provided are attenuated pox viruses that contain a modified TK and HA gene and a modified F3 gene or locus that corresponds to the F3 gene in vaccinia. In particular, provided are recombinant vaccinia viruses that contain a modified TK and HA gene and optionally a modified F3 gene or locus, wherein the resulting virus does not accumulate to toxic levels in non-targeted organs. Vaccinia viruses where the TK gene and F3 gene are modified and vaccinia viruses where the HA and F3 gene are modified, and

-6-

viruses where all three genes are modified are provided. Modification includes inactivation by insertion, deletion or replacement of one or more nucleotide bases whereby an activity or product of the virus is altered. Included among the alterations is insertion of heterologous nucleic acid, such as therapeutic protein-  
5 encoding nucleic acids.

In exemplary embodiments, the vaccinia viruses are Lister strain viruses, particularly LVP strain viruses (LVP refers to the Lister virus from the Institute of Viral Preparations, Moscow, Russia, the original source for this now widely disseminated virus strain). Modifications include modification of the virus at the  
10 unique *NotI* site in the locus designed F3. In particular, the modification is at position 35 of the F3 gene or at position 1475 inside of the *HindIII*-F fragment of vaccinia virus DNA strain LVP.

The heterologous nucleic acid can include regulatory sequence operatively linked to the nucleic acid encoding the protein. Regulatory sequences include  
15 promoters, such as the vaccinia virus early/late promoter p7.5. and an early/late vaccinia pE/L promoter. The heterologous nucleic acid in the microorganism can encode a detectable protein or a product capable of inducing a detectable signal. Inclusion of detectable protein or a product that can generate a detectable signal permits monitoring of the distribution of the administered microorganism as well as  
20 monitoring therapeutic efficacy, since the microorganism will be eliminated when the immunoprivileged cells are eliminated.

Host cells containing the recombinant viruses, such as the triple mutant vaccinia virus exemplified herein are provided. Also contemplated are tumor cells that contain any of the microorganisms provided herein or used in the methods.

25 Pharmaceutical composition containing the microorganisms in a pharmaceutically acceptable vehicle for use in the methods herein are provided. The pharmaceutical compositions can be formulated for any mode of administration, including, but not limited to systemic administration., such as for intravenous administration or is formulated. The compositions can contain a delivery

-7-

vehicle, such as a lipid-based carrier, including liposomes and micelles associated with the microorganism.

Also provided are methods (and uses of the microorganisms) for eliminating immunoprivileged cells, such as tumor cells in an animal, by administering the pharmaceutical compositions to an animal, whereby the virus accumulates in the immunoprivileged cells, thereby mediating autoimmunization resulting in elimination of the cells or a reduction in their number

Therapeutic methods for eliminating immunoprivileged cells or tissues, in an animal, by administering a microorganism to an animal, where the microorganism accumulates in the immunoprivileged cells; the microorganism does not accumulate in unaffected organs and tissues and has low toxicity in the animal; and the microorganism results in leakage of the cell membranes in the immunoprivileged cells, whereby the animal produces autoantibodies against the cells or products of the cells are provided. These methods include tumor treatment, treatment for inflammatory conditions, including wounds, and proliferative disorders, including psoriasis, cancers, diabetic retinopathesis, restinosis and other such disorders. It is desirable for the microorganisms to not accumulate in unaffected organs, particularly the ovaries or testes

The microorganisms attenuated bacteria, an attenuated viruses and mammalian cells, such as pox viruses and other cytoplasmid viruses, bacterial such as vibrio, E. coli, salmonella, streptococcus and listeria and mammalian cells, such as immune cells, including B cells and lymphocytes, such as TIL cells, and stem cells.

Methods for a recombinant vaccinia virus by : (a) generating (i) a vaccinia shuttle plasmid containing the modified F3 gene inserted at restriction site x and (ii) a dephosphorylated wt VV (VGL) DNA digested at a restriction site; transfecting host cells infected with psoralen -UV (PUV)-inactivated helper VV (VGL) with a mixture of constructs (i) and (ii) of step a; and (c) isolating the recombinant vaccinia viruses from the transfectants. Host cells include CV-1 cells.

-8-

Also provided are methods for production of a polypeptide or RNA or compound, such as a cellular product and uses of the microorganism therefore are provided. Such methods can include the steps of : (a) administering a microorganism containing nucleic acid encoding the polypeptide or RNA or  
5 producing the product compound to tumor-bearing animal, where the microorganism accumulates in the immunoprivileged cells; and the microorganism does not accumulate to toxic levels in organs and tissues that do not comprise immunoprivileged cells or tissues; (b) harvesting the tumor tissue from the the animal; and (c) isolating the polypeptide or RNA or compound from the tumor.

10 As noted, the microorganisms include eukaryotic cells, prokaryotic cells and viruses., such as a cytoplasmic virus or an attenuated bacterium or a stem cell or an immune cell. The bacterium can be selected from among attenuated *vibrio*, *E. coli*, *lysteria*, salmonella and streptococcus strains. The microorganism can express or produce detectable products, such as a fluorescent protein (*i.e.*, green, red and  
15 blue flurorescent proteins and modified variants thereof), and/or luciferase which, when contacted with a Lucifer produces light, and also can encode additional products, such as therapeutic products. In the methods and uses provided herein, the animals can be non-human animals or can include humans.

Also provide are methods for simultaneously producing a polypeptide,  
20 RNA molecule or cellular compound and an antibody that specifically reactions with the polypeptide, RNA molecule or compound, by: a) administering a microorganism to a tumor-bearing animal, wherein the microorganism expresses or produces the compoiund, polypeptide or RNA molecule; and b) isolating the antibody from serum in the animal. The method optionallyincludes, after step a)  
25 harvesting the tumor tissue from the animal; and isolating the polypeptide, RNA molecule or cellular compound from the tumor tissue.

Also provided are methods for eliminating immunoprivileged cells or tissues in an animal, such as tumor cells, and uses of the microorganisms therefore by administering at least two microorganisms, wherein the microorganisms are  
30 administered simultaneously, sequentially or intermittently, wherein the

-9-

microorganisms accumulate in the immunoprivileged cells, whereby the animal is autoimmunized against the immunoprivileged cells or tissues.

Use of at least two microorganism for formulation of a medicament for elimination of immunoprivileged cells or tissues, wherein the accumulate in the immunoprivileged cells, whereby the animal is autoimmunized against the immunoprivileged cells or tissues are provided. Combinations containing at least two microorganisms formulated for administration to an animal for elimination of immunoprivileged cells or tissues are provided. Kits containing packaged combination optionally with instructions for administration and other reagents are provided.

Uses of a microorganism encoding heterologous nucleic acid for inducing autoimmunization against products produced in immunoprivileged cells, wherein, when administered, the microorganism accumulates in immunoprivileged tissues and does not accumulate or accumulates at a sufficiently low level in other tissues or organs to be non-toxic to an animal containing the immunoprivileged tissues are provided.

Methods for the production of antibodies against products produced in immunoprivileged tissues or cells by: (a) administering a microorganism containing nucleic acid encoding a selected protein or RNA into an animal containing the immunoprivileged tissues or cells; and (b) isolating antibodies against the protein or RNA from the blood or serum of the animal are provided.

Also provided are methods for inhibiting growth of immunoprivileged cells or tissue in a subject by: (a) administering to a subject a modified microorganism, wherein the modified microorganism encodes a detectable gene product; (b) monitoring the presence of the detectable gene product in the subject until the detectable gene product is substantially present only in immunoprivileged tissue or cells of a subject; and (c) administering to a subject a therapeutic compound that works in conjunction with the microorganism to inhibit growth of immunoprivileged cells or tissue or by: (a) administering to a subject a modified microorganism that encodes a detectable gene product; (b) administering to a subject

-10-

a therapeutic substance that reduces the pathogenicity of the microorganism; (c) monitoring the presence of the detectable gene product in the subject until the detectable gene product is substantially present only in immunoprivileged tissue or cells of a subject; and (d) terminating or suspending administration of the therapeutic compound, whereby the microorganism increases in pathogenicity and the growth of the immunoprivileged cells or tissue is inhibited.

### DESCRIPTION OF THE FIGURES

Figure 1A: Schematic representation of the recombinant vaccinia virus RVGL8 used. The recombinant vaccinia virus RVGL8 was constructed by using the in vivo recombination method described in Example 1. The complex of wild-type vaccinia virus DNA digested with *NotI* and non-digested plasmid DNA pNZ2 was transfected for in vivo recombination into PUV-VV-infected cells. VGL, wild type vaccinia virus (strain Lister ATCC VR-1549); RVGL8, recombinant vaccinia virus encoding the *lacZ* gene in the *NotI* site; *Not<sub>L</sub>* and *Not<sub>R</sub>*, left and right segments of unique *NotI* restriction site in vaccinia virus genome.; *pE/L*, synthetic early/late vaccinia virus promoter; *p7.5*, early/late vaccinia virus promoter; *lacZ*, *lacZ* gene of *E. coli*.

Figure 1B: Schematic of the various vaccinia strains described in the Examples. Results achieved the viruses are described in the Examples.

Figure 2 sets forth a flow chart for a method for producing products, such as nucleic acid molecules, proteins and metabolic compounds or other cellular products in tumors.

### DETAILED DESCRIPTION

#### A. Definitions

#### B. Microorganisms for Tumor-Specific Therapy

#### B. Microorganisms for Tumor-Specific Therapy

##### 1. Characteristics

##### a. Attenuated

##### i. Reduced toxicity

##### ii. Accumulate in tumor, not substantially in other organs

##### iii. Ability to Elicit or Enhance Immune Response to

##### iv. Balance of Pathogenicity and Release of Tumor

Tumor Cell

Antigens

-11-

- b. Immunogenicity
    - c. Replication Competent
    - d. Genetic Variants
      - i. Modified Characteristics
      - ii. Exogenous Gene Expression
      - iii. Detectable gene product
      - iv. Therapeutic gene product
      - v. Expressing a superantigen
      - vi. Expressing a gene product to be harvested
  - 2. Viruses
    - a. Cytoplasmic viruses
      - i. Poxviruses
        - a. Vaccinia Virus
        - b. Modified Vaccinia Viruses
        - c. The F3 Gene
        - d. Multiple Modifications
        - e. The Lister Strain
      - ii. Other cytoplasmic viruses
    - b. Adenovirus, Herpes, Retroviruses
  - 3. Bacteria
    - a. Aerobic bacteria
    - b. Anaerobic bacteria
  - 4. Eukaryotic cells
- C. Methods for Making an Attenuated Microorganism
  - 1. Genetic Modifications
  - 2. Screening for above characteristics
  - 3. Methods for developing such a microorganism in humans
- D. Therapeutic Methods
  - 1. Administration
    - a. Steps prior to administering the microorganism
    - b. Mode of administration
    - c. Dosage
    - d. Number of administrations
    - e. Co-administrations
      - i. Administering a plurality of microorganisms
      - ii. Therapeutic compounds
    - f. State of subject
  - 2. Monitoring
    - a. Monitoring microorganismal gene expression
    - b. Monitoring tumor size
    - c. Monitoring antibody titer
    - d. Monitoring general health diagnostics
    - e. Monitoring coordinated with treatment
- E. Methods of Producing Gene Products and Antibodies
  - 1. Production of Recombinant Proteins and RNA molecules
  - 2. Production of Antibodies
- F. Pharmaceutical Compositions, combinations and kits
  - 1. Pharmaceutical Compositions
  - 2. Host Cells
  - 3. Combinations
  - 4. Kits
- G. Examples
- A. Definitions



-12-

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the invention(s) belong. All patents, patent applications, published applications and publications, websites and other published materials referred to throughout the entire disclosure herein, unless noted otherwise, are incorporated by reference in their entirety. In the event that there are a plurality of definitions for terms herein, those in this section prevail. Where reference is made to a URL or other such identifier or address, it is understood that such identifiers can change and particular information on the internet can come and go, but equivalent information is known and can be readily accessed, such as by searching the internet and/or appropriate databases. Reference thereto evidences the availability and public dissemination of such information.

As used herein, microorganisms refers to isolated cells or viruses, including eukaryotic cells, such as mammalian cells, viruses and bacteria. The microorganisms are modified or selected for their ability to accumulate in tumors and other immunoprivileged cells and tissues, and to minimize accumulation in other tissues or organs. Accumulation occurs by virtue of selection or modification of the microorganisms for particular traits or by proper selection of cells. The microorganism can be further modified to alter a trait thereof and/or to deliver a gene product. The microorganisms provided herein are typically modified relative to wild type to exhibit one or more characteristics such as reduced pathogenicity, reduced toxicity, preferential accumulation in tumor relative to normal organs or tissues, increased immunogenicity, increased ability to elicit or enhance an immune response to tumor cells, increased lytic or tumor cell killing capacity, decreased lytic or tumor cell killing capacity.

As used herein, immunoprivileged cells and tissues refer to cells and tissues, such as solid tumors and wounded tissues, which are sequestered from the immune system. Generally administration of a microorganism elicits an immune response that clears the microorganism; immunoprivileged sites, however, are shielded or sequestered from the immune response, permitting the microorganisms to survive

-13-

and generally to replicate. Immunoprivileged tissues include inflamed tissues, such as wounded tissues, and proliferating tissues, such as tumor tissues.

As used herein, "modified" with reference to a gene refers to a deleted gene, or a gene encoding a gene product having one or more truncations, mutations,  
5 insertions or deletions, typically accompanied by at least a change, generally a partial loss of function.

As used herein F3 gene refers to a gene or locus in a virus, such as a vaccinia virus, that corresponds to the F3 gene of vaccinia virus strain LIVP. This includes the F3 gene of any vaccinia virus strain or poxvirus encoding a gene product having  
10 substantially the same or at least a related biological function or locus in the genome. F3 genes encompassed herein typically have at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 85%, at least about 90%, at least about 93%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity along the full  
15 length of the sequence of nucleotides set forth in SEQ ID No:1. The proteins encoded by F3 genes encompassed herein typically have at least about 50%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 85%, at least about 90%, at least about 93%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% identity to the sequence  
20 of amino acids set forth SEQ ID No. 2 along the full length thereof. Also included are corresponding loci in other viruses that when modified or eliminated result in reduced toxicity and/or enhanced accumulation in tumors (compared to non-tumorous cells, tissues and organs). The corresponding loci in other viruses equivalent to the F3 gene in LIVP can be determined by the structural location of the  
25 gene in the viral genome: the LIVP F3 gene is located on the HindIII-F fragment of vaccinia virus between open reading frames F14L and F15L as defined by Goebel *et al.*, Virology (1990) 179:247-266, and in the opposite orientation of ORFs F14L and F15L; thus corresponding loci in other viruses such as poxviruses including orthopoxviruses are included.

-14-

As used herein, attenuate toxicity of a microorganism means to reduce or eliminate deleterious or toxic effects to a host upon administration of the microorganism compared to the unattenuated microorganism.

5 As use herein, a microorganism with low toxicity means that upon administration a microorganism does not accumulate in organs and tissues in the host to an extent that results in damage or harm to organs or that impact on survival of the host to a greater extent than the disease being treated does.

As used herein, subject (or organism) refers to an animal, including a human being.

10 As used herein, animal includes any animal, such as, but are not limited to primates including humans, gorillas and monkeys; rodents, such as mice and rats; fowl, such as chickens; ruminants, such as goats, cows, deer, sheep; ovine, and other animals including pigs, horses, cats, dogs, and rabbits. Non-human animals exclude humans as the contemplated animal.

15 As used herein, accumulation of a microorganism in a targeted tissue refers to the distribution of the microorganism throughout the organism after a time period long enough for the microbes to infect the host's organs or tissues. As one skilled in the art will recognize, the time period for infection of a microbe will vary depending on the microbe, the targeted organ(s) or tissue(s), the immunocompetence of the  
20 host, and dosage. Generally, accumulation can be determined at time point from about 1 day to about 1 week after infection with the microbes. For purposes herein, the microorganisms preferentially accumulate in the target tissue, such as a tumor, but are cleared from other tissues and organs in the host to the extent that toxicity of the microorganism is mild or tolerable and at most not fatal.

25 As used herein, preferential accumulation refers to accumulation of a microorganism at a first location at a higher level than accumulation at a second location. Thus, a microorganism that preferentially accumulates in immunoproviledged tissue such as tumor relative to normal tissues or organs refers to a microorganism that accumulates in immunoproviledged tissue such as tumor at  
30 a higher level than the microorganism accumulates in normal tissues or organs.

-15-

As used herein, a "compound" produced in a tumor or other immunoprivileged site refers to any compound that is produced in the tumor by virtue of the presence of an introduced microorganism, generally a recombinant microorganism, expressing one or more genes. For example, a compound produced  
5 in a tumor can be, for example, a metabolite, an encoded polypeptide or RNA, or compound that is generated by a recombinant polypeptide (*e.g.*, enzyme) and the cellular machinery of the tumor or immunoprivileged tissue or cells.

As used herein, a delivery vehicle for administration refers to a lipid-based or other polymer based composition, such as liposome, micell or reverse micelle, that  
10 associates with an agent, such as a microorganism provided herein, for delivery into a host animal.

As used herein, the term "viral vector" is used according to its art-recognized meaning. It refers to a nucleic acid vector construct that includes at least one element of viral origin and can be packaged into a viral vector particle. The viral  
15 vector particles can be used for the purpose of transferring DNA, RNA or other nucleic acids into cells either *in vitro* or *in vivo*. Viral vectors include, but are not limited to, retroviral vectors, vaccinia vectors, lentiviral vectors, herpes virus vectors (*e.g.*, HSV), baculoviral vectors, cytomegalovirus (CMV) vectors, papillomavirus vectors, simian virus (SV40) vectors, vectors, semliki forest virus vectors, phage  
20 vectors, adenoviral vectors, and adeno-associated viral (AAV) vectors.

As used herein, oncolytic viruses refer to viruses that replicate selectively in tumor cells.

As used herein, "disease or disorder" refers to a pathological condition in an organism resulting from, *e.g.*, infection or genetic defect, and characterized by  
25 identifiable symptoms.

As used herein, neoplasm (neoplasia) refers to abnormal new growth, and thus means the same as tumor, which can be benign or malignant. Unlike hyperplasia, neoplastic proliferation persists even in the absence of the original stimulus.

-16-

As used herein, neoplastic disease refers to any disorder involving cancer, including tumor development, growth, metastasis and progression.

As used herein, cancer is a general term for diseases caused by or characterized by any type of malignant tumor.

5 As used herein, malignant, as applies to tumors, refers to primary tumors that have the capacity of metastasis with loss of growth control and positional control.

As used herein, metastasis refers to a growth of abnormal or neoplastic cells distant from the site primarily involved by the morbid process.

10 As used herein, an anti-cancer agent or compound (used interchangeably with "anti-tumor or anti-neoplastic agent") refers to any agents or compounds used in anti-cancer treatment. These include any agents, when used alone or in combination with other compounds, that can alleviate, reduce, ameliorate, prevent, or place or maintain in a state of remission of clinical symptoms or diagnostic markers associated with neoplastic disease, tumors and cancer, and can be used in  
15 methods, combinations and compositions provided herein. Exemplary anti-neoplastic agents include the microorganism provided herein used singly or in combination and/or in combination with other agents, such as alkylating agents, antimetabolite, certain natural products, platinum coordination complexes, anthracenediones, substituted ureas, methylhydrazine derivatives, adrenocortical  
20 suppressants, certain hormones, zantagonists and anti-cancer polysaccharides.

In general, for practice of the methods herein and when using the microorganisms provided herein, the original tumor is not excised, but is employed to accumulate the administered microorganism and as the cells become leaky or lyse to become an antigen or other product factor. The antigens can serve to elicit an  
25 immune response in the host. The antigens and products can be isolated from the tumor.

As used herein, angiogenesis is intended to encompass the totality of processes directly or indirectly involved in the establishment and maintenance of new vasculature (neovascularization), including, but not limited to,

-17-

neovascularization associated with tumors and neovascularization associated with wounds.

As used herein, by homologous means about greater than 25% nucleic acid sequence identity, such as 25%, 40%, 60%, 70%, 80%, 90% or 95%. If necessary  
5 the percentage homology will be specified. The terms "homology" and "identity" are often used interchangeably but homology for proteins can include conservative amino acid changes. In general, sequences (protein or nucleic acid) are aligned so that the highest order match is obtained (see, *e.g.*: Computational Molecular Biology, Lesk, A.M., ed., Oxford University Press, New York, 1988; Biocomputing:  
10 Informatics and Genome Projects, Smith, D.W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; Carillo *et al.* (1988)  
15 SIAM J Applied Math 48:1073). By sequence identity, the number of identical amino acids is determined by standard alignment algorithm programs, and used with default gap penalties established by each supplier. Substantially homologous nucleic acid molecules would hybridize typically at moderate stringency or at high stringency all along the length of the nucleic acid or along at least about 70%, 80%  
20 or 90% of the full length nucleic acid molecule of interest. Also provided are nucleic acid molecules that contain degenerate codons in place of codons in the hybridizing nucleic acid molecule. (For proteins, for determination of homology conservative amino acids can be aligned as well as identical amino acids; in this case percentage of identity and percentage homology vary). Whether any two nucleic  
25 acid molecules have nucleotide sequences that are at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% "identical" can be determined using known computer algorithms such as the "FASTA" program, using for example, the default parameters as in Pearson *et al.* (1988) Proc. Natl. Acad. Sci. USA 85:2444 (other programs include the GCG program package (Devereux, J., *et al.*, Nucleic Acids Research  
30 12(I):387 (1984)), BLASTP, BLASTN, FASTA Atschul, S.F., *et al.*, J Molec Biol

-18-

215:403 (1990); Guide to Huge Computers, Mrtin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo *et al.* (1988) SIAM J Applied Math 48:1073). For example, the BLAST function of the National Center for Biotechnology Information database can be used to determine identity. Other commercially or publicly  
5 available programs include, DNASTar "MegAlign" program (Madison, WI) and the University of Wisconsin Genetics Computer Group (UWG) "Gap" program (Madison WI)). Percent homology or identity of proteins and/or nucleic acid molecules can be determined, for example, by comparing sequence information using a GAP computer program (*e.g.*, Needleman *et al.* (1970) J. Mol. Biol. 48:443,  
10 as revised by Smith and Waterman ((1981) Adv. Appl. Math. 2:482).

Briefly, a GAP program defines similarity as the number of aligned symbols (*i.e.*, nucleotides or amino acids) that are similar, divided by the total number of symbols in the shorter of the two sequences. Default parameters for the GAP program can include: (1) a unary comparison matrix (containing a value of 1 for  
15 identities and 0 for non-identities) and the weighted comparison matrix of Gribskov *et al.* (1986) Nucl. Acids Res. 14:6745, as described by Schwartz and Dayhoff, eds., ATLAS OF PROTEIN SEQUENCE AND STRUCTURE, National Biomedical Research Foundation, pp. 353-358 (1979); (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for end gaps.  
20 Therefore, as used herein, the term "identity" represents a comparison between a test and a reference polypeptide or polynucleotide.

As used herein, recitation that amino acids of a polypeptide correspond to amino acids in a disclosed sequence, such as amino acids set forth in the Sequence listing, refers to amino acids identified upon alignment of the polypeptide with the  
25 disclosed sequence to maximize identity or homology (where conserved amino acids are aligned) using a standard alignment algorithm, such as the GAP algorithm.

As used herein, the term "at least 90% identical to" refers to percent identities from 90 to 100% relative to the reference polypeptides. Identity at a level of 90% or more is indicative of the fact that, assuming for exemplification purposes  
30 a test and reference polynucleotide length of 100 amino acids are compared, no

-19-

more than 10% (*i.e.*, 10 out of 100) of amino acids in the test polypeptide differs from that of the reference polypeptides. Similar comparisons can be made between a test and reference polynucleotides. Such differences can be represented as point mutations randomly distributed over the entire length of an amino acid sequence or  
5 they can be clustered in one or more locations of varying length up to the maximum allowable, *e.g.*, 10/100 amino acid difference (approximately 90% identity). Differences are defined as nucleic acid or amino acid substitutions, insertions or deletions. At the level of homologies or identities above about 85-90%, the result should be independent of the program and gap parameters set; such high levels of  
10 identity can be assessed readily, often without relying on software.

As used herein, primer refers to an oligonucleotide containing two or more deoxyribonucleotides or ribonucleotides, typically more than three, from which synthesis of a primer extension product can be initiated. Experimental conditions conducive to synthesis include the presence of nucleoside triphosphates and an agent  
15 for polymerization and extension, such as DNA polymerase, and a suitable buffer, temperature and pH.

As used herein, chemiluminescence refers to a chemical reaction in which energy is specifically channeled to a molecule causing it to become electronically excited and subsequently to release a photon thereby emitting visible light.  
20 Temperature does not contribute to this channeled energy. Thus, chemiluminescence involves the direct conversion of chemical energy to light energy.

As used herein, luminescence refers to the detectable EM radiation, generally, UV, IR or visible EM radiation that is produced when the excited product  
25 of an exergic chemical process reverts to its ground state with the emission of light. Chemiluminescence is luminescence that results from a chemical reaction. Bioluminescence is chemiluminescence that results from a chemical reaction using biological molecules (or synthetic versions or analogs thereof) as substrates and/or enzymes.



-20-

As used herein, bioluminescence, which is a type of chemiluminescence, refers to the emission of light by biological molecules, particularly proteins. The essential condition for bioluminescence is molecular oxygen, either bound or free in the presence of an oxygenase, a luciferase, which acts on a substrate, a luciferin.

5 Bioluminescence is generated by an enzyme or other protein (luciferase) that is an oxygenase that acts on a substrate luciferin (a bioluminescence substrate) in the presence of molecular oxygen, and transforms the substrate to an excited state, which, upon return to a lower energy level releases the energy in the form of light.

As used herein, the substrates and enzymes for producing bioluminescence  
10 are generically referred to as luciferin and luciferase, respectively. When reference is made to a particular species thereof, for clarity, each generic term is used with the name of the organism from which it derives, for example, bacterial luciferin or firefly luciferase.

As used herein, luciferase refers to oxygenases that catalyze a light emitting  
15 reaction. For instance, bacterial luciferases catalyze the oxidation of flavin mononucleotide (FMN) and aliphatic aldehydes, which reaction produces light. Another class of luciferases, found among marine arthropods, catalyzes the oxidation of Cypridina (Vargula) luciferin, and another class of luciferases catalyzes the oxidation of Coleoptera luciferin.

20 Thus, luciferase refers to an enzyme or photoprotein that catalyzes a bioluminescent reaction (a reaction that produces bioluminescence). The luciferases, such as firefly and Gaussia and Renilla luciferases, are enzymes which act catalytically and are unchanged during the bioluminescence generating reaction. The luciferase photoproteins, such as the aequorin photoprotein to which luciferin is  
25 non-covalently bound, are changed, such as by release of the luciferin, during bioluminescence generating reaction. The luciferase is a protein that occurs naturally in an organism or a variant or mutant thereof, such as a variant produced by mutagenesis that has one or more properties, such as thermal stability, that differ from the naturally-occurring protein. Luciferases and modified mutant or variant

-21-

forms thereof are well known. For purposes herein, reference to luciferase refers to either the photoproteins or luciferases.

Thus, reference, for example, to "Renilla luciferase" means an enzyme isolated from member of the genus *Renilla* or an equivalent molecule obtained from  
5 any other source, such as from another related copepod, or that has been prepared synthetically. It is intended to encompass *Renilla* luciferases with conservative amino acid substitutions that do not substantially alter activity. Suitable conservative substitutions of amino acids are known to those of skill in this art and can be made generally without altering the biological activity of the resulting  
10 molecule. Those of skill in this art recognize that, in general, single amino acid substitutions in non-essential regions of a polypeptide do not substantially alter biological activity (see, *e.g.*, Watson *et al.* Molecular Biology of the Gene, 4th Edition, 1987, The Benjamin/Cummings Pub. co., p.224).

As used herein, "Aequora GFP" refers to GFPs from the genus *Aequora* and  
15 to mutants or variants thereof. Such variants and GFPs from other species are well known and are available and known to those of skill in the art. This nomenclature encompasses GFPs with conservative amino acid substitutions that do not substantially alter activity and physical properties, such as the emission spectra and ability to shift the spectral output of bioluminescence generating systems. The luciferases and  
20 luciferin and activators thereof are referred to as bioluminescence generating reagents or components. Typically, a subset of these reagents will be provided or combined with an article of manufacture. Bioluminescence will be produced upon contacting the combination with the remaining reagents. Thus, as used herein, the component luciferases, luciferins, and other factors, such as  $O_2$ ,  $Mg^{2+}$ ,  $Ca^{2+}$  are also  
25 referred to as bioluminescence generating reagents (or agents or components).

As used herein, bioluminescence substrate refers to the compound that is oxidized in the presence of a luciferase, and any necessary activators, and generates light. These substrates are referred to as luciferins herein, are substrates that undergo oxidation in a bioluminescence reaction. These bioluminescence substrates  
30 include any luciferin or analog thereof or any synthetic compound with which a

-22-

luciferase interacts to generate light. Typical substrates include those that are oxidized in the presence of a luciferase or protein in a light-generating reaction. Bioluminescence substrates, thus, include those compounds that those of skill in the art recognize as luciferins. Luciferins, for example, include firefly luciferin, Cypridina (also known as Vargula) luciferin (coelenterazine), bacterial luciferin, as well as synthetic analogs of these substrates or other compounds that are oxidized in the presence of a luciferase in a reaction the produces bioluminescence.

As used herein, capable of conversion into a bioluminescence substrate means susceptible to chemical reaction, such as oxidation or reduction, that yields a bioluminescence substrate. For example, the luminescence producing reaction of bioluminescent bacteria involves the reduction of a flavin mononucleotide group (FMN) to reduced flavin mononucleotide (FMNH<sub>2</sub>) by a flavin reductase enzyme. The reduced flavin mononucleotide (substrate) then reacts with oxygen (an activator) and bacterial luciferase to form an intermediate peroxy flavin that undergoes further reaction, in the presence of a long-chain aldehyde, to generate light. With respect to this reaction, the reduced flavin and the long chain aldehyde are substrates.

As used herein, a bioluminescence generating system refers to the set of reagents required to conduct a bioluminescent reaction. Thus, the specific luciferase, luciferin and other substrates, solvents and other reagents that can be required to complete a bioluminescent reaction form a bioluminescence system. Thus a bioluminescence generating system refers to any set of reagents that, under appropriate reaction conditions, yield bioluminescence. Appropriate reaction conditions refers to the conditions necessary for a bioluminescence reaction to occur, such as pH, salt concentrations and temperature. In general, bioluminescence systems include a bioluminescence substrate, luciferin, a luciferase, which includes enzymes luciferases and photoproteins, and one or more activators. A specific bioluminescence system may be identified by reference to the specific organism from which the luciferase derives; for example, the Renilla bioluminescence system includes a Renilla luciferase, such as a luciferase isolated from the Renilla or

-23-

produced using recombinant means or modifications of these luciferases. This system also includes the particular activators necessary to complete the bioluminescence reaction, such as oxygen and a substrate with which the luciferase reacts in the presence of the oxygen to produce light.

5           As used herein, a fluorescent protein refers to a protein that possesses the ability to fluoresce (*i.e.*, to absorb energy at one wavelength and emit it at another wavelength). For example, a green fluorescent protein refers to a polypeptide that has a peak in the emission spectrum at about 510 nm.

10           As used herein, genetic therapy or gene therapy involves the transfer of heterologous nucleic acid, such as DNA, into certain cells, target cells, of a mammal, particularly a human, with a disorder or conditions for which such therapy is sought. The nucleic acid, such as DNA, is introduced into the selected target cells, such as directly or in a vector or other delivery vehicle, in a manner such that the heterologous nucleic acid, such as DNA, is expressed and a therapeutic product  
15           encoded thereby is produced. Alternatively, the heterologous nucleic acid, such as DNA, can in some manner mediate expression of DNA that encodes the therapeutic product, or it can encode a product, such as a peptide or RNA that in some manner mediates, directly or indirectly, expression of a therapeutic product. Genetic therapy also can be used to deliver nucleic acid encoding a gene product that replaces a  
20           defective gene or supplements a gene product produced by the mammal or the cell in which it is introduced. The introduced nucleic acid can encode a therapeutic compound, such as a growth factor inhibitor thereof, or a tumor necrosis factor or inhibitor thereof, such as a receptor therefor, that is not normally produced in the mammalian host or that is not produced in therapeutically effective amounts or at a  
25           therapeutically useful time. The heterologous nucleic acid, such as DNA, encoding the therapeutic product can be modified prior to introduction into the cells of the afflicted host in order to enhance or otherwise alter the product or expression thereof. Genetic therapy also can involve delivery of an inhibitor or repressor or other modulator of gene expression.

-24-

As used herein, heterologous nucleic acid is nucleic acid that is not normally produced *in vivo* by the microorganism from which it is expressed or that is produced by a microorganism but is at a different locus or expressed differently or that mediates or encodes mediators that alter expression of endogenous nucleic acid, such as DNA, by affecting transcription, translation, or other regulatable biochemical processes. Heterologous nucleic acid is often not endogenous to the cell into which it is introduced, but has been obtained from another cell or prepared synthetically. Heterologous nucleic acid, however, can be endogenous, but is nucleic acid that is expressed from a different locus or altered in its expression or sequence. Generally, although not necessarily, such nucleic acid encodes RNA and proteins that are not normally produced by the cell or in the same way in the cell in which it is expressed. Heterologous nucleic acid, such as DNA, also can be referred to as foreign nucleic acid, such as DNA. Thus, heterologous nucleic acid or foreign nucleic acid includes a nucleic acid molecule not present in the exact orientation or position as the counterpart nucleic acid molecule, such as DNA, is found in a genome. It also can refer to a nucleic acid molecule from another organism or species (*i.e.*, exogenous). Any nucleic acid, such as DNA, that one of skill in the art would recognize or consider as heterologous or foreign to the cell in which the nucleic acid is expressed is herein encompassed by heterologous nucleic acid; heterologous nucleic acid includes exogenously added nucleic acid that also is expressed endogenously. Examples of heterologous nucleic acid include, but are not limited to, nucleic acid that encodes traceable marker proteins, such as a protein that confers drug resistance, nucleic acid that encodes therapeutically effective substances, such as anti-cancer agents, enzymes and hormones, and nucleic acid, such as DNA, that encodes other types of proteins, such as antibodies. Antibodies that are encoded by heterologous nucleic acid can be secreted or expressed on the surface of the cell in which the heterologous nucleic acid has been introduced.

As used herein, a therapeutically effective product for gene therapy is a product that is encoded by heterologous nucleic acid, typically DNA, (or an RNA product such as dsRNA, RNAi, including siRNA, that, upon introduction of the

-25-

nucleic acid into a host, a product is expressed that ameliorates or eliminates the symptoms, manifestations of an inherited or acquired disease or that cures the disease. Also included are biologically active nucleic acid molecules, such as RNAi and antisense.

5           As used herein, cancer or tumor treatment or agent refers to any therapeutic regimen and/or compound that, when used alone or in combination with other treatments or compounds, can alleviate, reduce, ameliorate, prevent, or place or maintain in a state of remission of clinical symptoms or diagnostic markers associated with deficient angiogenesis.

10           As used herein, nucleic acids include DNA, RNA and analogs thereof, including peptide nucleic acids (PNA) and mixtures thereof. Nucleic acids can be single or double-stranded. When referring to probes or primers, which are optionally labeled, such as with a detectable label, such as a fluorescent or radiolabel, single-stranded molecules are provided. Such molecules are typically of a length such that  
15           their target is statistically unique or of low copy number (typically less than 5, generally less than 3) for probing or priming a library. Generally a probe or primer contains at least 14, 16 or 30 contiguous nucleotides of sequence complementary to or identical to a gene of interest. Probes and primers can be 10, 20, 30, 50, 100 or more nucleic acids long.

20           As used herein, operative linkage of heterologous nucleic to regulatory and effector sequences of nucleotides, such as promoters, enhancers, transcriptional and translational stop sites, and other signal sequences refers to the relationship between such nucleic acid, such as DNA, and such sequences of nucleotides. For example, operative linkage of heterologous DNA to a promoter refers to the physical  
25           relationship between the DNA and the promoter such that the transcription of such DNA is initiated from the promoter by an RNA polymerase that specifically recognizes, binds to and transcribes the DNA. Thus, operatively linked or operationally associated refers to the functional relationship of nucleic acid, such as DNA, with regulatory and effector sequences of nucleotides, such as promoters,  
30           enhancers, transcriptional and translational stop sites, and other signal sequences.

-26-

For example, operative linkage of DNA to a promoter refers to the physical and functional relationship between the DNA and the promoter such that the transcription of such DNA is initiated from the promoter by an RNA polymerase that specifically recognizes, binds to and transcribes the DNA. In order to optimize expression and/or in vitro transcription, it can be necessary to remove, add or alter 5' untranslated portions of the clones to eliminate extra, potentially inappropriate alternative translation initiation (*i.e.*, start) codons or other sequences that can interfere with or reduce expression, either at the level of transcription or translation. Alternatively, consensus ribosome binding sites (see, *e.g.*, Kozak J. Biol. Chem. 266:19867-19870 (1991)) can be inserted immediately 5' of the start codon and can enhance expression. The desirability of (or need for) such modification can be empirically determined.

As used herein, a sequence complementary to at least a portion of an RNA, with reference to antisense oligonucleotides, means a sequence of nucleotides having sufficient complementarity to be able to hybridize with the RNA, generally under moderate or high stringency conditions, forming a stable duplex; in the case of double-stranded antisense nucleic acids, a single strand of the duplex DNA (or dsRNA) can thus be tested, or triplex formation can be assayed. The ability to hybridize depends on the degree of complementarity and the length of the antisense nucleic acid. Generally, the longer the hybridizing nucleic acid, the more base mismatches with an encoding RNA it can contain and still form a stable duplex (or triplex, as the case can be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

As used herein, amelioration of the symptoms of a particular disorder such as by administration of a particular pharmaceutical composition, refers to any lessening, whether permanent or temporary, lasting or transient that can be attributed to or associated with administration of the composition.

As used herein, antisense polynucleotides refer to synthetic sequences of nucleotide bases complementary to mRNA or the sense strand of double-stranded

-27-

DNA. Admixture of sense and antisense polynucleotides under appropriate conditions leads to the binding of the two molecules, or hybridization. When these polynucleotides bind to (hybridize with) mRNA, inhibition of protein synthesis (translation) occurs. When these polynucleotides bind to double-stranded DNA, inhibition of RNA synthesis (transcription) occurs. The resulting inhibition of translation and/or transcription leads to an inhibition of the synthesis of the protein encoded by the sense strand. Antisense nucleic acid molecules typically contain a sufficient number of nucleotides to specifically bind to a target nucleic acid, generally at least 5 contiguous nucleotides, often at least 14 or 16 or 30 contiguous nucleotides or modified nucleotides complementary to the coding portion of a nucleic acid molecule that encodes a gene of interest.

As used herein, antibody refers to an immunoglobulin, whether natural or partially or wholly synthetically produced, including any derivative thereof that retains the specific binding ability of the antibody. Hence antibody includes any protein having a binding domain that is homologous or substantially homologous to an immunoglobulin binding domain. Antibodies include members of any immunoglobulin class, including IgG, IgM, IgA, IgD and IgE.

As used herein, antibody fragment refers to any derivative of an antibody that is less than full length, retaining at least a portion of the full-length antibody's specific binding ability. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab)2, single-chain Fvs (scFV), Fv, dsFV diabody and Fd fragments. The fragment can include multiple chains linked together, such as by disulfide bridges. An antibody fragment generally contains at least about 50 amino acids and typically at least 200 amino acids.

As used herein, a Fv antibody fragment is composed of one variable heavy chain domain (VH) and one variable light chain domain linked by noncovalent interactions.

As used herein, a dsFV refers to an Fv with an engineered intermolecular disulfide bond, which stabilizes the VH-VL pair.



-28-

As used herein, a F(ab)<sub>2</sub> fragment is an antibody fragment that results from digestion of an immunoglobulin with pepsin at pH 4.0-4.5; it can be recombinantly produced to produce the equivalent fragment.

As used herein, Fab fragments are antibody fragments that result from  
5 digestion of an immunoglobulin with papain; it can be recombinantly produced to produce the equivalent fragment.

As used herein, scFVs refer to antibody fragments that contain a variable light chain (VL) and variable heavy chain (VH) covalently connected by a polypeptide linker in any order. The linker is of a length such that the two variable  
10 domains are bridged without substantial interference. Included linkers are (Gly-Ser)<sub>n</sub> residues with some Glu or Lys residues dispersed throughout to increase solubility.

As used herein, humanized antibodies refer to antibodies that are modified to include human sequences of amino acids so that administration to a human does not  
15 provoke an immune response. Methods for preparation of such antibodies are known. For example, to produce such antibodies, the encoding nucleic acid in the hybridoma or other prokaryotic or eukaryotic cell, such as an E. coli or a CHO cell, that expresses the monoclonal antibody is altered by recombinant nucleic acid techniques to express an antibody in which the amino acid composition of the non-  
20 variable region is based on human antibodies. Computer programs have been designed to identify such non-variable regions.

As used herein, diabodies are dimeric scFV; diabodies typically have shorter peptide linkers than scFVs, and they generally dimerize.

As used herein, production by recombinant means by using recombinant  
25 DNA methods means the use of the well known methods of molecular biology for expressing proteins encoded by cloned DNA.

As used herein the term assessing or determining is intended to include quantitative and qualitative determination in the sense of obtaining an absolute value for the activity of a product, and also of obtaining an index, ratio, percentage, visual

-29-

or other value indicative of the level of the activity. Assessment can be direct or indirect.

As used herein, biological activity refers to the *in vivo* activities of a compound or microorganisms or physiological responses that result upon *in vivo* administration of thereof or of composition or other mixture. Biological activity, thus, encompasses therapeutic effects and pharmaceutical activity of such compounds, compositions and mixtures. Biological activities can be observed in *in vitro* systems designed to test or use such activities.

As used herein, an effective amount of a microorganism or compound for treating a particular disease is an amount that is sufficient to ameliorate, or in some manner reduce the symptoms associated with the disease. Such an amount can be administered as a single dosage or can be administered according to a regimen, whereby it is effective. The amount can cure the disease but, typically, is administered in order to ameliorate the symptoms of the disease. Repeated administration can be required to achieve the desired amelioration of symptoms.

As used herein equivalent, when referring to two sequences of nucleic acids, means that the two sequences in question encode the same sequence of amino acids or equivalent proteins. When equivalent is used in referring to two proteins or peptides or other molecules, it means that the two proteins or peptides have substantially the same amino acid sequence with only amino acid substitutions (such as, but not limited to, conservative changes) or structure and the any changes do not substantially alter the activity or function of the protein or peptide. When equivalent refers to a property, the property does not need to be present to the same extent (e.g., two peptides can exhibit different rates of the same type of enzymatic activity), but the activities are usually substantially the same. Complementary, when referring to two nucleotide sequences, means that the two sequences of nucleotides are capable of hybridizing, typically with less than 25%, 15% or 5% mismatches between opposed nucleotides. If necessary, the percentage of complementarity will be specified. Typically the two molecules are selected such that they will hybridize under conditions of high stringency.

-30-

As used herein, an agent or compound that modulates the activity of a protein or expression of a gene or nucleic acid either decreases or increases or otherwise alters the activity of the protein or, in some manner, up- or down-regulates or otherwise alters expression of the nucleic acid in a cell.

5 As used herein, a method for treating or preventing neoplastic disease means that any of the symptoms, such as the tumor, metastasis thereof, the vascularization of the tumors or other parameters by which the disease is characterized are reduced, ameliorated, prevented, placed in a state of remission, or maintained in a state of remission. It also means that the hallmarks of neoplastic disease and metastasis can  
10 be eliminated, reduced or prevented by the treatment. Non-limiting examples of the hallmarks include uncontrolled degradation of the basement membrane and proximal extracellular matrix, migration, division, and organization of the endothelial cells into new functioning capillaries, and the persistence of such functioning capillaries.

As used herein, a prodrug is a compound that, upon in vivo administration, is  
15 metabolized or otherwise converted to the biologically, pharmaceutically or therapeutically active form of the compound. To produce a prodrug, the pharmaceutically active compound is modified such that the active compound is regenerated by metabolic processes. The prodrug can be designed to alter the metabolic stability or the transport characteristics of a drug, to mask side effects or  
20 toxicity, to improve the flavor of a drug or to alter other characteristics or properties of a drug. By virtue of knowledge of pharmacodynamic processes and drug metabolism in vivo, those of skill in this art, once a pharmaceutically active compound is known, can design prodrugs of the compound (see, *e.g.*, Nogrady (1985) Medicinal Chemistry A Biochemical Approach, Oxford University Press,  
25 New York, pages 388-392).

As used herein, a promoter region or promoter element or regulatory region refers to a segment of DNA or RNA that controls transcription of the DNA or RNA to which it is operatively linked. The promoter region includes specific sequences that are sufficient for RNA polymerase recognition, binding and transcription  
30 initiation. This portion of the promoter region is referred to as the promoter. In

-31-

addition, the promoter region includes sequences that modulate this recognition, binding and transcription initiation activity of RNA polymerase. These sequences can be cis acting or can be responsive to trans acting factors. Promoters, depending upon the nature of the regulation, can be constitutive or regulated. Exemplary  
5 promoters contemplated for use in prokaryotes include the bacteriophage T7 and T3 promoters.

As used herein, a receptor refers to a molecule that has an affinity for a ligand. Receptors can be naturally-occurring or synthetic molecules. Receptors also can be referred to in the art as anti-ligands. As used herein, the receptor and anti-  
10 ligand are interchangeable. Receptors can be used in their unaltered state or bound to other polypeptides, including as homodimers. Receptors can be attached to, covalently or noncovalently, or in physical contact with, a binding member, either directly or indirectly via a specific binding substance or linker. Examples of receptors, include, but are not limited to: antibodies, cell membrane receptors  
15 surface receptors and internalizing receptors, monoclonal antibodies and antisera reactive with specific antigenic determinants (such as on viruses, cells, or other materials), drugs, polynucleotides, nucleic acids, peptides, cofactors, lectins, sugars, polysaccharides, cells, cellular membranes, and organelles.

As used herein, sample refers to anything that can contain an analyte for  
20 which an analyte assay is desired. The sample can be a biological sample, such as a biological fluid or a biological tissue. Examples of biological fluids include urine, blood, plasma, serum, saliva, semen, stool, sputum, cerebral spinal fluid, tears, mucus, amniotic fluid or the like. Biological tissues are aggregates of cells, usually of a particular kind together with their intercellular substance that form one of the  
25 structural materials of a human, animal, plant, bacterial, fungal or viral structure, including connective, epithelium, muscle and nerve tissues. Examples of biological tissues also include organs, tumors, lymph nodes, arteries and individual cell(s).

As used herein: stringency of hybridization in determining percentage mismatch is as follows:

30 1) high stringency: 0.1 x SSPE, 0.1% SDS, 65°C

-32-

2) medium stringency: 0.2 x SSPE, 0.1% SDS, 50°C

3) low stringency: 1.0 x SSPE, 0.1% SDS, 50°C

Those of skill in this art know that the washing step selects for stable hybrids and also know the ingredients of SSPE (see, *e.g.*, Sambrook, E.F. Fritsch, T. Maniatis, in: Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press (1989), vol. 3, p. B.13, see, also, numerous catalogs that describe commonly used laboratory solutions). SSPE is pH 7.4 phosphate-buffered 0.18 M NaCl. Further, those of skill in the art recognize that the stability of hybrids is determined by  $T_m$ , which is a function of the sodium ion concentration and temperature : ( $T_m = 81.50 \text{ } ^\circ\text{C} - 16.6(\log_{10}[\text{Na}^+]) + 0.41(\%G+C) - 600/1$ ), so that the only parameters in the wash conditions critical to hybrid stability are sodium ion concentration in the SSPE (or SSC) and temperature. Any nucleic acid molecules provided herein can also include those that hybridize under conditions of at least low stringency, generally moderate or high stringency, along at least 70, 80, 90% of the full length of the disclosed molecule. It is understood that equivalent stringencies can be achieved using alternative buffers, salts and temperatures. By way of example and not limitation, procedures using conditions of low stringency are as follows (see also Shilo and Weinberg, Proc. Natl. Acad. Sci. USA 78:6789-6792 (1981)):

Filters containing DNA are pretreated for 6 hours at 40°C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 µg/ml denatured salmon sperm DNA (10X SSC is 1.5 M sodium chloride, and 0.15 M sodium citrate, adjusted to a pH of 7). Hybridizations are carried out in the same solution with the following modifications: 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 µg/ml salmon sperm DNA, 10% (wt/vol) dextran sulfate, and  $5\text{--}20 \times 10^6$  cpm  $^{32}\text{P}$ -labeled probe is used. Filters are incubated in hybridization mixture for 18-20 hours at 40°C, and then washed for 1.5 hours at 55°C in a solution containing 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS. The wash solution is replaced with fresh solution and incubated an additional 1.5 hours at 60°C. Filters are blotted dry and

-33-

exposed for autoradiography. If necessary, filters are washed for a third time at 65-68°C and reexposed to film. Other conditions of low stringency which can be used are well known in the art (e.g., as employed for cross-species hybridizations).

By way of example and not way of limitation, procedures using conditions of moderate stringency include, for example, but are not limited to, procedures using such conditions of moderate stringency are as follows: Filters containing DNA are pretreated for 6 hours at 55°C in a solution containing 6X SSC, 5X Denhart's solution, 0.5% SDS and 100 µg/ml denatured salmon sperm DNA. Hybridizations are carried out in the same solution and 5-20 X 10<sup>6</sup> cpm <sup>32</sup>P-labeled probe is used. Filters are incubated in hybridization mixture for 18- 20 hours at 55°C, and then washed twice for 30 minutes at 60°C in a solution containing 1X SSC and 0.1% SDS. Filters are blotted dry and exposed for autoradiography. Other conditions of moderate stringency which can be used are well-known in the art. Washing of filters is done at 37°C for 1 hour in a solution containing 2X SSC, 0.1% SDS. By way of example and not way of limitation, procedures using conditions of high stringency are as follows: Prehybridization of filters containing DNA is carried out for 8 hours to overnight at 65°C in buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 µg/ml denatured salmon sperm DNA. Filters are hybridized for 48 hours at 65°C in prehybridization mixture containing 100 µg/ml denatured salmon sperm DNA and 5-20 X 10<sup>6</sup> cpm of <sup>32</sup>P-labeled probe. Washing of filters is done at 37°C for 1 hour in a solution containing 2X SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA. This is followed by a wash in 0.1X SSC at 50°C for 45 minutes before autoradiography. Other conditions of high stringency which can be used are well known in the art.

The term substantially identical or homologous or similar varies with the context as understood by those skilled in the relevant art and generally means at least 60% or 70%, preferably means at least 80%, more preferably at least 90%, and most preferably at least 95% , 96%, 97%, 98%, 99% or greater identity.

-34-

As used herein, substantially identical to a product means sufficiently similar so that the property of interest is sufficiently unchanged so that the substantially identical product can be used in place of the product.

As used herein, substantially pure means sufficiently homogeneous to appear  
5 free of readily detectable impurities as determined by standard methods of analysis, such as thin layer chromatography (TLC), gel electrophoresis and high performance liquid chromatography (HPLC), used by those of skill in the art to assess such purity, or sufficiently pure such that further purification would not detectably alter the physical and chemical properties, such as enzymatic and biological activities, of  
10 the substance. Methods for purification of the compounds to produce substantially chemically pure compounds are known to those of skill in the art. A substantially chemically pure compound can, however, be a mixture of stereoisomers or isomers. In such instances, further purification might increase the specific activity of the compound.

As used herein, a molecule, such as an antibody, that specifically binds to a polypeptide typically has a binding affinity ( $K_a$ ) of at least about  $10^6$  l/mol,  $10^7$  l/mol,  $10^8$  l/mol,  $10^9$  l/mol,  $10^{10}$  l/mol or greater and binds to a protein of interest generally with at least 2-fold, 5-fold, generally 10-fold or even 100-fold or greater, affinity than to other proteins. For example, an antibody that specifically binds to  
20 the protease domain compared to the full-length molecule, such as the zymogen form, binds with at least about 2-fold, typically 5-fold or 10-fold higher affinity, to a polypeptide that contains only the protease domain than to the zymogen form of the full-length. Such specific binding also is referred to as selective binding. Thus, specific or selective binding refers to greater binding affinity (generally at least 2-  
25 fold, 5-fold, 10-fold or more) to a targeted site or locus compared to a non-targeted site or locus.

As used herein, the terms a therapeutic agent, therapeutic compound, therapeutic regimen, or chemotherapeutic include conventional drugs and drug therapies, including vaccines, which are known to those skilled in the art.

-35-

As used herein, treatment means any manner in which the symptoms of a condition, disorder or disease are ameliorated or otherwise beneficially altered. Treatment also encompasses any pharmaceutical use of the microorganisms described and provided herein.

5 As used herein, proliferative disorders include any disorders involving abnormal proliferation of cells. Such disorders include, but are not limited to, neoplastic diseases, psoriasis, restenosis, macular degeneration, diabetic retinopathies, inflammatory responses and disorders, including wound healing responses.

10 As used herein, vector (or plasmid) refers to discrete elements that are used to introduce heterologous nucleic acid into cells for either expression or replication thereof. The vectors typically remain episomal, but can be designed to effect integration of a gene or portion thereof into a chromosome of the genome. Also contemplated are vectors that are artificial chromosomes, such as yeast artificial  
15 chromosomes and mammalian artificial chromosomes. Selection and use of such vectors are well known to those of skill in the art. An expression vector includes vectors capable of expressing DNA that is operatively linked with regulatory sequences, such as promoter regions, that are capable of effecting expression of such DNA fragments. Thus, an expression vector refers to a recombinant DNA or RNA  
20 construct, such as a plasmid, a phage, recombinant virus or other vector that, upon introduction into an appropriate host cell, results in expression of the cloned DNA. Appropriate expression vectors are well known to those of skill in the art and include those that are replicable in eukaryotic cells and/or prokaryotic cells and those that remain episomal or those which integrate into the host cell genome.

25 As used herein, a combination refers to any association between two or among more items.

As used herein, a composition refers to any mixture. It can be a solution, a suspension, an emulsion, liquid, powder, a paste, aqueous, non-aqueous or any combination thereof.



-36-

As used herein, fluid refers to any composition that can flow. Fluids thus encompass compositions that are in the form of semi-solids, pastes, solutions, aqueous mixtures, gels, lotions, creams and other such compositions.

As used herein, a kit is a packaged combination optionally including  
5 instructions for use of the combination and/or other reactions and components for such use.

For clarity of disclosure, and not by way of limitation, the detailed description is divided into the subsections that follow.

**B. Microorganisms for Tumor-Specific Therapy**

10 Provided herein are microorganisms, and methods for making and using such microorganisms for therapy of neoplastic disease and other proliferative disorders and inflammatory disorders. The microbe (or microorganism)-mediated treatment methods provided herein involve administration of microorganisms to hosts, accumulation of the microorganism in the targeted cell or tissue, such as in a tumor,  
15 resulting in leaking or lysing of the cells, whereby an immune response against leaked or released antigens is mounted, thereby resulting in an inhibition of the tissues or cells in which the microorganism accumulates.

In addition to the gene therapeutic methods of cancer treatment, live attenuated microorganisms can be used for vaccination, such as in cancer  
20 vaccination or antitumor immunity. Immunization, for example, against a tumor can include a tumor-specific T-cell-mediated response through microbe-delivered antigens or cytokines. To do so, the microbes can be specifically targeted to the tumor tissues, with minimal infection to any other key organs and also can be modified or provided to produce the antigens and/or cytokines.

25 The microorganisms provided herein and the use of such microorganisms herein can accumulate in immunoprivileged cells or immunoprivileged tissues, including tumors and/or metastases, and also including wounded tissues and cells. While the microorganisms provided herein can typically be cleared from the subject to whom the microorganisms are administered by activity of the subject's immune  
30 system, microorganisms can nevertheless accumulate, survive and proliferate in

-37-

immunoprivileged cells and tissues such as tumors because such immunoprivileged areas are sequestered from the host's immune system. Accordingly, the methods provided herein, as applied to tumors and/or metastases, and therapeutic methods relating thereto, can readily be applied to other immunoprivileged cells and tissues, including wounded cells and tissues.

### 1. Characteristics

The microorganisms provided herein and used in the methods herein are attenuated, immunogenic, and replication competent.

#### a. Attenuated

The microbes used in the methods provided herein are typically attenuated. Attenuated microbes have a decreased capacity to cause disease in a host. The decreased capacity can result from any of a variety of different modifications to the ability of a microbe to be pathogenic. For example, a microbe can have reduced toxicity, reduced ability to accumulate in non-tumorous organs or tissue, reduced ability to cause cell lysis or cell death, or reduced ability to replicate compared to the non-attenuated form thereof. The attenuated microbes provided herein, however, retain at least some capacity to replicate and to cause immunoprivileged cells and tissues, such as tumor cells to leak or lyse, undergo cell death, or otherwise cause or enhance an immune response to immunoprivileged cells and tissues, such as tumor cells.

#### i. Reduced toxicity

Microbes can be toxic to their hosts by manufacturing one or more compounds that worsen the health condition of the host. Toxicity to the host can be manifested in any of a variety of manners, including septic shock, neurological effects, or muscular effects. The microbes provided herein can have a reduced toxicity to the host. The reduced toxicity of a microbe of the present methods and compositions can range from a toxicity in which the host experiences no toxic effects, to a toxicity in which the host does not typically die from the toxic affects of the microbes. In some embodiments, the microbes are of a reduced toxicity such that a host typically has no significant long-term effect from the presence of the

-38-

microbes in the host, beyond any affect on tumorous, metastatic or necrotic organs or tissues. For example, the reduced toxicity can be a minor fever or minor infection, which lasts for less than about a month, and following the fever or infection, the host experiences no adverse affects resultant from the fever or infection. In another example, the reduced toxicity can be measured as an unintentional decline in body weight of about 5% or less for the host after administration of the microbes. In other examples, the microbe has no toxicity to the host.

Exemplary vaccinia viruses of the LIVP strain (a widely available attenuated Lister strain) that have reduced toxicity compared to other vaccinia viruses employed and are further modified. Modified LIVP were prepared. These LIVP include insertions in the TK and HA genes and optionally in the locus designed F3. As an example of reduced toxicity, these recombinant vaccinia viruses were tested for their toxicity to mice with impaired immune systems (nude mice) relative to the corresponding wild type vaccinia virus. Intervenuous (i.v.) injection of wild type vaccinia virus VGL (strain LIVP) at  $1 \times 10^7$  PFU/mouse causes toxicity in nude mice: three mice out of seven lost the weight and died (one mouse died in one week after virus injection, one mouse died ten days after virus injection). Rrecombinant vaccinia virus designated RVGL8 (LacZ inserted into F3 locus) did not show toxic effects in nude mice after i.v. injection of  $1 \times 10^7$  PFU/mouse. There were no readily detectable signs of RVGL8 virus-related toxicity. . Therefore, insertion into NotI site (located in F3 gene) of vaccinia virus genome strain LIVP reduces toxicity of the vaccinia virus to the host. Similar modifications can be made to other pox viruses and other viruses to reduce toxicity thereof. Such modifications can be empirically identified, if necessary.

**ii. Accumulate in immunoprivileged cells and tissues, such as tumor, not substantially in other organs**

Microbes can accumulate in any of a variety of tissues and organs of the host. Accumulation can be evenly distributed over the entire host organism, or can be concentrated in one or a few organs or tissues, The microbes provided herein can accumulate in targeted tissues, such as immunoprivileged cells and tissues, such as

-39-

tumors and also metastases. In some embodiments, the microbes provided herein exhibit accumulation in immunoprivileged cells and tissues, such as tumor cells relative to normal organs or tissues that is equal to or greater than the accumulation that occurs with wild type microbes. In other embodiments the microbes provided  
5 herein exhibit accumulation in immunoprivileged cells and tissues, such as tumor cells that is equal to or greater than the accumulation in any other particular organ or tissue. For example, the microbes provided herein can demonstrate an accumulation in immunoprivileged cells and tissues, such as tumor cells that is at least about 2-  
fold greater, at least about 5-fold greater, at least about 10-fold greater, at least about  
0 100-fold greater, at least about 1,000-fold greater, at least about 10,000-fold greater, at least about 100,000-fold greater, or at least about 1,000,000-fold greater, than the accumulation in any other particular organ or tissue.

In some embodiments, a microbe can accumulate in targeted tissues and cells, such as immunoprivileged cells and tissues, such as tumor cells, without  
5 accumulating in one or more selected tissues or organs. For example, a microbe can accumulate in tumor cells without accumulating in the brain. In another example, a microbe can accumulate in tumor cells without accumulating in neural cells. In another example, a microbe can accumulate in tumor cells without accumulating in ovaries. In another example, a microbe can accumulate in tumor cells without  
0 accumulating in the blood. In another example, a microbe can accumulate in tumor cells without accumulating in the heart. In another example, a microbe can accumulate in tumor cells without accumulating in the bladder. In another example, a microbe can accumulate in tumor cells without accumulating in testes. In another  
15 example, a microbe can accumulate in tumor cells without accumulating in the spleen. In another example, a microbe can accumulate in tumor cells without accumulating in the lungs.

One skilled in the art can determine the desired capability for the microbes to selectively accumulate in targeted tissue or cells, such as in a immunoprivileged cells and tissues, such as tumor rather than non-target organs or tissues, according to  
20 a variety of factors known in the art, including, but not limited to, toxicity of the

-40-

microbes, dosage, tumor to be treated, immunocompetence of host, and disease state of the host.

Provided herein as an example of selective accumulation in immunoprivileged cells and tissues, such as tumors relative to normal organs or tissues, presence of various vaccinia viruses was assayed in tumor samples and different organs. Wild type VGL virus was recovered from tumor, testes, bladder, and liver and as well as from brain. Recombinant virus RVGL8 was found mostly in tumors (in mouse #24, virus was found in testes, bladder and liver; in mouse #22 in testes), and no virus was recovered from brain tissue in six tested animals. Therefore, this finding demonstrates the tumor accumulation properties of a recombinant vaccinia virus of the LVP strain with an insertion in the F3 gene for tumor therapy purposes.

**iii. Ability to Elicit or Enhance Immune Response to Tumor Cells**

The microorganisms herein cause or enhance an immune response to antigens in the targeted tissues or cells, such as immunoprivileged cells and tissues, such as tumor cells. The immune response can be triggered by any of a variety of mechanisms, including the presence of immunostimulatory cytokines and the release antigenic compounds that can cause an immune response.

Cells, in response to an infection such as a microorganismal infection, can send out signals to stimulate an immune response against the cells. Exemplary signals sent from such cells include antigens, cytokines and chemokines such as interferon-gamma and interleukin-15. The microorganism provided herein can cause targeted cells to send out such signals in response to infection by the microbes, resulting in a stimulation of the host's immune system against the targeted cells or tissues, such as tumor cells.

In another embodiments, targeted cells or tissues, such as tumor cells, can contain one or more compounds that can be recognized by the host's immune system in mounting an immune response against a tumor. Such antigenic compounds can be compounds on the cell surface or the tumor cell, and can be protein, carbohydrate, lipid, nucleic acid, or combinations thereof. Microbe-mediated

-41-

release of antigenic compounds can result in triggering the host's immune system to mount an immune response against the tumor. The amount of antigenic compound released by the tumor cells is any amount sufficient to trigger an immune response in a subject ; for example, the antigenic compounds released from one or more  
5 tumor cells can trigger a host immune response. ations in the organism that is known to be accessible to leukocytes.

The time duration of antigen release is an amount of time sufficient for the host to establish an immune response to one or more tumor antigens. In some embodiments, the tduration is an amount of time sufficient for the host to establish a  
10 sustained immuned response to one or more tumor antigens. One skilled in the art can determine such a time duration based on a variety of factors affecting the time duration for a subject to develop an immune response, including the level of the tumor antigen in the subject, the number of different tumor antigens, the antigenicity of the antigen, the immunocompetence of the host, and the access of the antigenic  
15 material to the vasculature of the host. Typically, the duration of antigen release can be at least about a week, at least about 10 days, at least about two weeks, or at least about a month.

The microorganism provided herein can have any of a variety of properties that can cause target cells and tissues, such as tumor cells, to release antigenic  
20 compounds. Exemplary properties are the ability to lyse cells and the ability to elicit apoptosis in tumor cells. Microbes that are unable to lyse tumor cells or cause tumor cell death can nevertheless be used in the methods provided herein when such microbes can cause some release or display of antigenic compounds from tumor cells. A variety of mechanisms for antigen release or display without lysis or cell  
25 death are known in the art, and any such mechanism can be used by the microbes provided herein, including, but not limited to, secretion of antigenic compounds, enhanced cell membrane permeability, or altered cell surface expression or altered MHC presentation in tumor cells when the tumor cells can be accessed by the host's immune system. Regardless of the mechanism by which the host's immune system  
30 is activated, the net result of the presence of the microbes in the tumor is a

-42-

stimulation of the host's immune system, at least in part, against the tumor cells. In one example, the microbes can cause an immune response against tumor cells not infected by the microbes.

5 In one embodiment, the microbes provided herein can cause tumor cells to release an antigen that is not present on the tumor cell surface. Tumor cells can produce compounds such as proteins that can cause an immune response; however, in circumstances in which the antigenic compound is not on the tumor cell surface, the tumor can proliferate, and even metastasize, without the antigenic compound causing an immune response. Within the scope of the present methods, the microbes  
10 provided herein can cause antigenic compounds within the cell to release away from the cell and away from the tumor, which can result in triggering an immune response to such an antigen. Even if not all cells of a tumor are releasing antigens, the immune response can initially be targeted toward the "leaky" tumor cells, and the bystander effect of the immune response can result in further tumor cell death  
15 around the "leaky" tumor cells.

#### **iv. Balance of Pathogenicity and Release of Tumor Antigens**

Typical methods of involving treatment of targeted cells and tissues, such as immunoprivileged cells and tissues, such as tumors, are designed to cause rapid and  
20 complete removal thereof. For example, many viruses, bacterial or eukaryotic cells can cause lysis and/or apoptosis in a variety of cells, including tumor cells. Microorganisms that can vigorously lyse or cause cell death can be highly pathogenic, and can even kill the host. Furthermore, therapeutic methods based upon such rapid and complete lysis are typically therapeutically ineffective.

25 In contrast, the microorganisms provided herein are not aggressive in causing cell death or lysis. They can have only a limited or no ability to cause cell death as long as they accumulate in the target cells or tissues and result in alteration of cell membranes to cause leakage of antigens against which an immune response is mounted. It is desirable that their apoptotic or lytic effect is sufficiently slow or  
30 ineffective to permit sufficient antigenic leakage for a sufficient time for the host to mount an effective immune response against the target tissues. Such immune

-43-

response along or in combination with the lytic/apoptotic effect of the microorganism results in elimination of the target tissue and also elimination of future development, such as metastases and reoccurrence, of such tissues or cells. While the microbes provided herein can have a limited ability to cause cell death, the microbes provided herein can nevertheless stimulate the host's immune system to attack tumor cells. As a result, such microorganisms also are typically unlikely to have substantial toxicity to the host.

In one embodiment, the microbes have a limited, or no, ability to cause tumor cell death, while still causing or enhancing an immune response against tumor cells. In one example, the rate of microorganism-mediated tumor cell death is less than the rate of tumor cell growth or replication. In another example, the rate of microorganism-mediated tumor cell death is slow enough for the host to establish a sustained immune response to one or more tumor antigens. Typically, the time for of cell death is sufficient to establish an anti-tumor immune response and can be at least about a week, at least about 10 days, at least about two weeks, or at least about a month, depending upon the host and the targeted cells or tissues.

In another embodiment, the microbes provided herein can cause cell death in tumor cells, without causing substantial cell death in non-tumor tissues. In such an embodiment, the microbes can aggressively kill tumor cells, as long as no substantial cell death occurs in non-tumor cells, and optionally, so long as the host has sufficient capability to mount an immune response against the tumor cells.

In one embodiment, the ability of the microbes to cause cell death is slower than the host's immune response against the microbes. The ability for the host to control infection by the microbes can be determined by the immune response (e.g., antibody titer) against microorganismal antigens. Typically, after the host has mounted immune response against the microbes, the microbes can have reduced pathogenicity in the host. Thus, when the ability of the microbes to cause cell death is slower than the host's immune response against the microbes, microbe-mediated cell death can occur without risk of serious disease or death to the host. In one



-44-

example, the ability of the microbes to cause tumor cell death is slower than the host's immune response against the microbes.

**b. Immunogenicity**

The microorganisms provided herein also can be immunogenic. An immunogenic microorganism can create a host immune response against the microorganism. In one embodiment, the microorganisms can be sufficiently immunogenic to result in a large anti-(microorganism) antibody titer. The microorganisms provided herein can have the ability to elicit an immune response. The immune response can be activated in response to viral antigens or can be activated as a result of microorganismal-infection induced cytokine or chemokine production. Immune response against the microorganism can decrease the likelihood of pathogenicity toward the host organism.

Immune response against the microorganism also can result in target tissue or cell, such as tumor cell, killing. In one embodiment, the immune response against microorganismal infection can result in an immune response against tumor cells, including developing antibodies against tumor antigens. In one example, an immune response mounted against the microorganism can result in tumor cell killing by the "bystander effect," where uninfected tumor cells nearby infected tumor cells are killed at the same time as infected cells, or alternatively, where uninfected tumor cells nearby extracellular microorganisms are killed at the same time as the microorganisms. As a result of bystander effect tumor cell death, tumor cell antigens can be released from cells, and the host organism's immune system can mount an immune response against tumor cell antigens, resulting in an immune response against the tumor itself.

In one embodiment, the microorganism can be selected or modified to express one or more antigenic compounds, including superantigenic compounds. The antigenic compounds such as superantigens can be endogenous gene products or can be exogenous gene products. Superantigens, including toxoids, are known in the art and described elsewhere herein.

-45-

**c. Replication Competent**

The microorganisms provided herein can be replication competent. In a variety of viral or bacterial systems, the administered microorganism is rendered replication incompetent to limit pathogenicity risk to the host. While replication incompetence can protect the host from the microorganism, thalso is limits the ability of the microorganism to infect and kill tumor cells, and typically results in only a short-lived affect. In contrast, the microorganisms provided herein can be attenuated but replication competent, resulting in low toxicity to the host and accumulation mainly or solely in tumors. Thus, the microorganisms provided herein can be replication competent without creating a pathogenicity risk to the host.

Attenuation of the microorganisms provided herein can include, but is not limited to, reducing the replication competence of the microorganism. For example, a microorganism can be modified to decrease or eliminate an activity related to replication, such as a transcriptional activator that regulates replication in the microorganism. In an example, a microorganism, such as a virus, can have the viral thymidine kinase gene modified.

**d. Genetic Variants**

The microorganisms provided herein can be modified from their wild type form. Modifications can include any of a variety of changes, and typically include changes to the genome or nucleic acid molecules of the microorganisms. Exemplary nucleic acid molecular modifications include truncations, insertions, deletions and mutations. In an exemplary modification, a microorganismal gene can be modified by truncation, insertion, deletion or mutation. In an exemplary insertion, an exogenous gene can be inserted into the genome of the microorganism.

**i. Modified Characteristics**

Modifications of the microorganisms provided herein can result in a modification of microorganismal characteristics, including those provided herein such as pathogenicity, toxicity, ability to preferentially accumulate in tumor, ability to lyse cells or cause cell death, ability to elicit an immune response against tumor cells, immunogenicity, replication competence. Variants can be obtained by general

-46-

methods such as mutagenesis and passage in cell or tissue culture and selection of desired properties, as is known in the art, as exemplified for respiratory syncytial virus in Murphy *et al.*, Virus Res. 1994, 32:13-26.

5 Variants also can be obtained by mutagenic methods in which nucleic acid residues of the microorganism are added, removed or modified relative to the wild type. Any of a variety of known mutagenic methods can be used, including recombination-based methods, restriction endonuclease-based methods, and PCR-based methods. Mutagenic methods can be directed against particular nucleotide sequences such as genes, or can be random, where selection methods based on  
10 desired characteristics can be used to select mutated microorganisms. Any of a variety of microorganismal modifications can be made, according to the selected microorganism and the particular known modifications of the selected microorganism.

## ii. Exogenous Gene Expression

15 The microorganisms provided herein also can have the ability to express one or more exogenous genes. Gene expression can include expression of a protein encoded by a gene and/or expression of an RNA molecule encoded by a gene. In some embodiments, the microorganisms can express exogenous genes at levels high enough that permit harvesting products of the exogenous genes from the tumor.  
20 Expression of endogenous genes can be controlled by a constitutive promotor, or by an inducible promotor. Expression can also be influenced by one or more proteins or RNA molecules expressed by the microorganism. An exemplary inducible promotor system can include a chimeric transcription factor containing a progesterone receptor fused to the yeast GAL4 DNA-binding domain and to the  
25 activation domain of the herpes simplex virus protein VP16, and a synthetic promoter containing a series of GAL4 recognition sequences upstream of the adenovirus major late E1B TATA box, linked to one or more exogenous genes; in this exemplary system, administration of RU486 to a subject can result in induction of the exogenous genes. Exogenous genes expressed can include genes encoding a  
30 therapeutic gene product, genes encoding a detectable gene product such as a gene

-47-

product that can be used for imaging, genes encoding a gene product to be harvested, genes encoding an antigen of an antibody to be harvested. The microorganisms provided herein can be used for expressing genes in vivo and in vitro. Exemplary proteins include reporter proteins (*E. coli*  $\beta$ -galactosidase,  $\beta$ -glucuronidase, xanthineguanine phosphoribosyltransferase), proteins facilitating detection, *i.e.*, a detectable protein or a protein capable of inducing a detectable signal, (*e.g.*, luciferase, green and red fluorescent proteins, transferrin receptor), proteins useful for tumor therapy (*Pseudomonas* A endotoxin, diphtheria toxin, p53, Arf, Bax, tumor necrosis factor- $\alpha$ , HSV TK, *E. coli* purine nucleoside phosphorylase, angiostatin, endostatin, different cytokines) and many other proteins.

### iii. Detectable gene product

The microorganisms provided herein can express one or more genes whose products are detectable or whose products can provide a detectable signal. A variety of detectable gene products, such as detectable proteins are known in the art, and can be used with the microorganisms provided herein. Detectable proteins include receptors or other proteins that can specifically bind a detectable compound, proteins that can emit a detectable signal such as a fluorescence signal, enzymes that can catalyze a detectable reaction or catalyze formation of a detectable product.

In some embodiments, the microorganism expresses a gene encoding a protein that can emit a detectable signal or the can catalyze a detectable reaction. A variety of DNA sequences encoding proteins that can emit a detectable signal or the can catalyze a detectable reaction, such as luminescent or fluorescent proteins, are known and can be used in the microorganisms and methods provided herein. Exemplary genes encoding light-emitting proteins include genes from bacterial luciferase from *Vibrio harveyi* (Belas *et al.*, *Science* 218 (1982), 791-793), bacterial luciferase from *Vibrio fischerii* (Foran and Brown, *Nucleic acids Res.* 16 (1988), 177), firefly luciferase (de Wet *et al.*, *Mol. Cell. Biol.* 7(1987), 725-737), aequorin from *Aequorea victoria* (Prasher *et al.*, *Biochem.* 26 (1987), 1326-1332), Renilla luciferase from *Renilla reniformis* (Lorenz *et al.*, *PNAS USA* 88 (1991), 4438-4442) and green fluorescent protein from *Aequorea victoria* (Prasher *et al.*, *Gene* 111

-48-

(1987), 229-233). Transformation and expression of these genes in microorganisms can permit detection of microorganismal colonies, for example, using a low light imaging camera. Fusion of the lux A and lux B genes can result in a fully functional luciferase protein (Escher *et al.*, PNAS 86 (1989), 6528-6532). This fusion gene (Fab2) has introduced into a variety of microorganisms followed by microorganismal infection and imaging based on luciferase expression. In some embodiments, luciferases expressed in bacteria can require exogenously added substrates such as decanal or coelenterazine for light emission. In other embodiments, microorganisms can express a complete lux operon, which can include proteins that can provide luciferase substrates such as decanal. For example, bacteria containing the complete lux operon sequence, when injected intraperitoneally, intramuscularly, or intravenously, allowed the visualization and localization of bacteria in live mice indicating that the luciferase light emission can penetrate the tissues and can be detected externally (Contag *et al.*, Mol. Microbiol. 18 (1995), 593-603).

In other embodiments, the microorganism can express a gene that can bind a detectable compound or that can form a product that can bind a detectable compound. A variety of gene products, such as proteins, that can specifically bind a detectable compound are known in the art, including receptors, metal binding proteins, ligand binding proteins, and antibodies. Any of a variety of detectable compounds can be used, and can be imaged by any of a variety of known imaging methods. Exemplary compounds include receptor ligands and antigens for antibodies. The ligand can be labeled according to the imaging method to be used. Exemplary imaging methods include any of a variety of magnetic resonance methods such as magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS), and also include any of a variety of tomographic methods including computed tomography (CT), computed axial tomography (CAT), electron beam computed tomography (EBCT), high resolution computed tomography (HRCT), hypocycloidal tomography, positron emission tomography (PET), single-photon

-49-

emission computed tomography (SPECT), spiral computed tomography and ultrasonic tomography.

Labels appropriate for magnetic resonance imaging are known in the art, and include, for example, gadolinium chelates and iron oxides. Use of chelates in contrast agents is known in the art. Labels appropriate for tomographic imaging methods are known in the art, and include, for example,  $\beta$ -emitters such as  $^{11}\text{C}$ ,  $^{13}\text{N}$ ,  $^{15}\text{O}$  or  $^{64}\text{Cu}$  or (b)  $\gamma$ -emitters such as  $^{123}\text{I}$ . Other exemplary radionuclides that can, be used, for example, as tracers for PET include  $^{55}\text{Co}$ ,  $^{67}\text{Ga}$ ,  $^{68}\text{Ga}$ ,  $^{60}\text{Cu}(\text{II})$ ,  $^{67}\text{Cu}(\text{II})$ ,  $^{57}\text{Ni}$ ,  $^{52}\text{Fe}$  and  $^{18}\text{F}$ . Examples of useful radionuclide-labeled agents are  $^{64}\text{Cu}$ -labeled engineered antibody fragment (Wu *et al.*, PNAS USA 97 (2002), 8495-8500),  $^{64}\text{Cu}$ -labeled somatostatin (Lewis *et al.*, J. Med. Chem. 42(1999), 1341-1347),  $^{64}\text{Cu}$ -pyruvaldehyde-bis (N4methylthiosemicarbazone)( $^{64}\text{Cu}$ -PTSM) (Adonai *et al.*, PNAS USA 99 (2002), 3030-3035),  $^{52}\text{Fe}$ -citrate (Leenders *et al.*, J. Neural. Transm. Suppl. 43 (1994), 123-132),  $^{52}\text{Fe}/^{52\text{m}}\text{Mn}$ -citrate (Calonder *et al.*, J. Neurochem. 73 (1999), 2047-2055) and  $^{52}\text{Fe}$ -labeled iron (III) hydroxide-sucrose complex (Beshara *et al.*, Br. J. Haematol. 104 (1999), 288-295, 296-302).

#### iv. Therapeutic gene product

The microorganisms provided herein can express one or more genes whose products cause cell death or whose products cause an anti-tumor immune response, such genes can be considered therapeutic genes. A variety of therapeutic gene products, such as toxic or apoptotic proteins, or siRNA, are known in the art, and can be used with the microorganisms provided herein. The therapeutic genes can act by directly killing the host cell, for example, as a channel-forming or other lytic protein, or by triggering apoptosis, or by inhibiting essential cellular processes, or by triggering an immune response against the cell, or by interacting with a compound that has a similar effect, for example, by converting an less active compound to a cytotoxic compound.

In some embodiments, the microorganism can express a therapeutic protein. A large number of therapeutic proteins that can be expressed for tumor treatment are known in the art, including, but not limited to tumor suppressors, toxins, cytostatic

-50-

proteins, and cytokines. An exemplary, non-limiting list of such proteins includes WT1, p53, p16, Rb, BRCA1, cystic fibrosis transmembrane regulator (CFTR), Factor VIII, low density lipoprotein receptor, beta-galactosidase, alpha-galactosidase, beta-glucocerebrosidase, insulin, parathyroid hormone, alpha-1-antitrypsin, rsCD40L, Fas-ligand, TRAIL, TNF, antibodies, microcin E492, 5 diptheria toxin, Pseudomonas exotoxin, Escherichia coli Shig toxin, Escherichia coli Verotoxin 1, and hyperforin.

In other embodiments, the microorganism can express a protein that converts a less active compound into a compound that causes tumor cell death. Exemplary 10 methods of conversion of such a prodrug compound include enzymatic conversion and photolytic conversion. A large variety of protein/compound pairs are known in the art, and include, but are not limited to Herpes simplex virus thymidine kinase/gancyclovir, varicella zoster thymidine kinase/gancyclovir, cytosine deaminase/5-fluorouracil, purine nucleoside phosphorylase/6-methylpurine 15 deoxyriboside, beta lactamase/cephalosporin-doxorubicin, carboxypeptidase G2/4-[(2-chloroethyl)(2-mesuloxylethyl)amino]benzoyl-L-glutamic acid, cytochrome P450/acetaminophen, horseradish peroxidase/indole-3-acetic acid, nitroreductase/CB1954, rabbit carboxylesterase/7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycampothecin, mushroom tyrosinase/bis-(2- 20 chloroethyl)amino-4-hydroxyphenylaminomethanone 28, beta galactosidase/1-chloromethyl-5-hydroxy-1,2-dihydro-3H-benz[e]indole, beta glucuronidase/epirubicin-glucuronide, thymidine phosphorylase/5'-deoxy-5-fluorouridine, deoxycytidine kinase/cytosine arabinoside, and linamerase/linamarin.

In another embodiment, the therapeutic gene product can be an siRNA 25 molecule. The siRNA molecule can be directed against expression of a tumor-promoting gene, such as, but not limited to, an oncogene, growth factor, angiogenesis promoting gene, or a receptor. The siRNA molecule also can be directed against expression of any gene essential for cell growth, cell replication or cell survival. The siRNA molecule also can be directed against expression of any 30 gene that stabilizes the cell membrane or otherwise limits the number of tumor cell

-51-

antigens released from the tumor cell. Design of an siRNA can be readily determined according to the selected target of the siRNA; methods of siRNA design and downregulation of genes are known in the art, as exemplified in U.S. Pat. Pub. No. 20030198627.

5           In one embodiment, the therapeutic compound can be controlled by a regulatory sequence. Suitable regulatory sequences which, for example, are functional in a mammalian host cell are well known in the art. In one example, the regulatory sequence can contain a natural or synthetic vaccinia virus promoter. In another embodiment, the regulatory sequence contains a poxvirus promoter. When  
10   viral microorganisms are used, strong late promoters can be used to achieve high levels of expression of the foreign genes. Early and intermediate-stage promoters, however, can also be used. In one embodiment, the promoters contain early and late promoter elements, for example, the vaccinia virus early/late promoter p7.5, vaccinia late promoter p11, a synthetic early/late vaccinia pE/L promoter (Patel *et al.*, (1988), Proc. Natl. Acad. Sci. USA 85, 9431-9435; Davison and Moss, (1989), J  
15   Mol Biol 210, 749-769; Davison *et al.*, (1990), Nucleic Acids Res. 18, 4285-4286; Chakrabarti *et al.*, (1997), BioTechniques 23, 1094-1097).

#### **v.       Expressing a superantigen**

          The microorganisms provided herein can be modified to express one or more  
20   superantigens. Superantigens are antigens that can activate a large immune response, often brought about by a large response of T cells. A variety of superantigens are known in the art including, but not limited to, diphtheria toxin, staphylococcal enterotoxins (SEA, SEB, SEC1, SEC2, SED, SEE and SEH), Toxic Shock Syndrome Toxin 1, Exfoliating Toxins (EXft), Streptococcal Pyrogenic  
25   Exotoxin A, B and C (SPE A, B and C), Mouse Mammary Tumor Virus proteins (MMTV), Streptococcal M proteins, Clostridial Perfringens Enterotoxin (CPET), mycoplasma arthritis superantigens.

          Since many superantigens also are toxins, if expression of a microorganism of reduced toxicity is desired, the superantigen can be modified to retain at least  
30   some of its superantigenicity while reducing its toxicity, resulting in a compound



-52-

such as a toxoid. A variety of recombinant superantigens and toxoids of superantigens are known in the art, and can readily be expressed in the microorganisms provided herein. Exemplary toxoids include toxoids of diphtheria toxin, as exemplified in U.S. Pat. No. 6,455,673 and toxoids of Staphylococcal enterotoxins, as exemplified in U.S. Pat. Pub. No. 20030009015.

#### vi. Expressing a gene product to be harvested

Exemplary genes expressible by a microorganism for the purpose of harvesting include human genes. An exemplary list of genes includes the list of human genes and genetic disorders authored and edited by Dr. Victor A. McKusick and his colleagues at Johns Hopkins University and elsewhere, and developed for the World Wide Web by NCBI, the National Center for Biotechnology Information. Online Mendelian Inheritance in Man, OMIM<sup>TM</sup>. Center for Medical Genetics, Johns Hopkins University (Baltimore, Md.) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, Md.), 1999. and those available in public databases, such as pubmed and genbank (see, *e.g.*, (ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM) These genes include, but are not limited to: 239f2h9, 3pk, 4ebp1, 4ebp2, al1, al2m1, al2m2, al2m3, al2m4, al5, alb, albg, alst, a2m, a2mr, a2mrap, aa, aaa, aab, aabt, aac1, aac2, aact, aadac, aanat, aars, aas, aat, aavs1, abc1, abc2, abc3, abc7, abc8, abcr, abil, abl1, abl2, abl1, abo, abp, abp1, abpa, abpx, abr, acaa, acac, acaca, acacb, acad1, acadm, acads, acadsb, acadv1, acat, acat1, acat2, acc, accb, accn1, accn2, accpn, ace1, ach, ache, achm1, achm2, achrb, achrd, achrg, acis, acly, aco1, aco2, acox, acox1, acox2, acox3, acp1, acp2, acp5, acpp, acr, acrv1, acs3, acs3, acs4, act2, act35, acta1, acta2, acta3, actb, actc, actg1, actg2, act11, actn1, actn2, actn3, actsa, acug, acvr1, acvr2b, acvr11, acvr1k1, acvr1k2, acvr1k3, acy1, ad1, ad2, ad3, ad4, ad5, ada, adam10, adam11, adam12, adam3, adam3a, adam3b, adam8, adar, adarb1, adarb2, adcp1, adcp2, adcy1, adcy2, adcy3, adcy3, adcy4, adcy5, adcy6, adcy7, adcy8, adcy9, adcyap1, adcyap1r1, add1, add2, add3, add1, adfn, adh1, adh2, adh3, adh4, adh5, adh7, adhps, adhc1@, adhr, adhr, adk, ad1, adm, admlx, adora1, adora2a, adora2b, adora21, adora21, adora3, adprt, adra1a, adra1b, adra1c, adra1d, adra2a, adra2b,

-53-

adra2c, adra211, adra212, adra2r, adrb1, adrb1r, adrb2, adrb2r11, adrb3, adrbk1,  
adrbk2, ads1, adss, adtb1, adx, adxr, ae1, ae2, ae3, aegl1, aemk, aes, afl0, afl7, af4,  
af6, af8t, af9, afd1, afdn, afg3, afg311, afm, afp, afx1, aga, agc1, ager, ag1, agmx1,  
agmx2, agp1, agp7, agps, agrn, agrp, agrt, ags, agt, agt11, agtr1, agtr1a, agtr2, agtr11,  
5 agxt, ahc, ahcy, ahd, ahds, ahnak, aho2, ahr, ahsg, ahx, aib1, aic, aic1, aied, aih1,  
aih2, aih3, aim1, air, airc, aire, ak1, ak2, ak3, akap149, akt1, akt2, aku, alad, alas1,  
alas2, alb, alb2, alba, alcam, ald, aldh1, aldh10, aldh2, aldh3, aldh4, aldh5, aldh6,  
aldh9, ald11, aldoa, aldob, aldoci, aldr1, alds, alk, alk1, alk2, alk3, alk6, alms1,  
alox12, alox15, alox5, alp, alpi, alp1, alpp, alpp12, alr, alr, als1, als2, als4, als5, alss,  
10 ambn, ambp, amcd1, amcd2b, amcn, amcn1, amcx1, amd1, amdm, amelx, amely,  
amfr, amg, amg1, amgx, amh, amhr, amhr2, aml1, aml1t1, aml2, aml3, amog,  
ampd1, ampd2, ampd3, amph, amph1, ampk, amt, amy1a, amy1b, amy1c, amy2a,  
amy2b, an2, anc, ancr, ang, angl, anh1, ank1, ank2, ank3, anop1, anova, anp, anpep,  
anpra, anprb, anprc, ans, ant1, ant2, ant3, ant3y, anx1, anx11, anx13, anx2, anx214,  
15 anx3, anx4, anx5, anx6, anx7, anx8, aoah, aoc2, aox1, ap2tf, apah1, apba1, apba2,  
apbb1, apbb2, apc, apcs, ape, apeced, apeh, apex, api1, api2, api3, apj, aplp, aplp1,  
apl2, apnh, apo31, apoa1, apoa2, apoa4, apob, apobec1, apoc1, apoc2, apoc3,  
apoc4, apod, apoe, apoer2, apoh, apolmt, apolp1@, apolp2@, app, appbp1, appl1,  
aprf, aprt, aps, apt1, apt1g1, apx1, apy, aqdq, aqp0, aqp1, aqp2, aqp21, aqp3, aqp4,  
20 aqp5, aqp6, aqp7, ar, ar1, ara, araf1, araf2, arcn1, ard1, ard1, areg, arf1, arf2, arf3,  
arf41, arf5, arg, arg1, args, arh12, arh6, arh9, arha, arhb, arhc, arhg, arhgap2,  
arhgap3, arhgap6, arhgdia, arhgdib, arhh, arix, arl2, armd1, arnt, arnt1, aro, arp,  
arp1, arpkd, arr3, arrb1, arrb2, arsa, arsacs, arsb, arsc1, arsc2, arsd, arse, arsf, art,  
art1, art3, art4, arts, arvd1, arvd2, arvd3, arvd4, as, asat, asb, ascl1, ascl2, asct1,  
25 asd1, asd2, asgr1, asgr2, ash1, asip, as1, asln, asm1, asma, asmd, asmt, asmtlx,  
asmtly, asnrs, asns, aspa, ass, astm1, astn, asv, at, at1, at2r1, at3, ata, atbf1, atcay,  
atf1, ath1, aths, atm, atoh1, atox1, atp1a1, atp1a2, atp1a3, atp1a11, atp1b1, atp1b2,  
atp1b3, atp1b11, atp1g1, atp2a1, atp2a2, atp2a3, atp2b, atp2b1, atp2b2, atp2b2,  
atp2b3, atp2b4, atp4a, atp4b, atp5, atp5a, atp5b, atp5g1, atp5g2, atp5g3, atp5o,  
30 atp6a, atp6b1, atp6c, atp6e, atp6n1, atp7a, atp7b, atpm, atpsb, atpsk1, atpsk2, atq1,

-54-

atr, atr, atr1, atr1, atr2, atrc1, atrc2, atrx, ats, atsv, atx1, atx2, au, aufl, aufla, aut,  
 avcd, aved, avp, avpr1a, avpr1b, avpr2, avpr3, avrp, avsd, awa1, ax1, axl1g, axsf,  
 azfl, azf2, azgp1, azul, b120, b144, blg1, b29, b2m, b2mr, b3galt4, b4galt1, ba2r,  
 bab1, bag1, bai1, bai2, bai3, bak1, bam22, bap1, bap135, bapx1, bard1, bark2, bas,  
 5 bat1, bat2, bat3, bat4, bat5, bax, bb1, bbbg1, bbbg2, bbs1, bbs2, bbs3, bbs4, bbs5,  
 bcas1, bcat1, bcat2, bcate2, bcd1, bcei, bche, bckdha, bckdha, bcl1, bcl10, bcl2,  
 bcl2a1, bcl212, bcl3, bcl5, bcl6, bcl7, bcl7a, bcl8, bcl9, bclw, bcm, bcm1, bcma,  
 bcns, bcns, bcp, bcpm, bcpr, bcr, bcr12, bcr13, bcr14, bcs1, bct1, bct2, bdb, bdb1,  
 bdc, bde, bdkrb1, bdkrb2, bdmf, bdmr, bdnf, bed, bedp, bek, bene, bevi, bf, bf1, bf2,  
 10 bfhd, bfic, bfls, bfnc2, bfp, bfsp1, bft, bglap, bgmr, bgn, bgp, bhd, bhpcdh, bhr1,  
 bcd1, bid, bigh3, bin1, bir, bjs, bkma1, blast1, blau, blk, blm, blmh, bltr, blvra,  
 blvrb, blym, bma1, bmd, bmd, bma1, bmd, bma1, bmd, bma1, bmd, bma1, bmd, bma1,  
 bmp5, bmp6, bmp7, bmp8, bmp1a, bmp1b, bmx, bmyb, bn51t, bnc, bnc1, bnp,  
 bor, bpad, bpag1, bpag2, bpes, bpes1, bpes2, bpgm, bph1, bpi, br, br140, braf, brca1,  
 15 brca2, brca3, brcacox, brcd1, brcd2, brdt, brf1, brhc, bric, brks, brn3a, brn3b, brn3c,  
 brn1, brw1c, bs, bsap, bsep, bsf2, bsg, bsnd, bss1, bst1, bst2, btak, btc, btd, bteb,  
 bteb1, btg1, btg2, bths, btk, btk1, btn, bts, bub1b, bubr1, bw1a, bw1b, bws,  
 bwscr1a, bwscr1b, bzrp, bzx, c11orf13, c1nh, c1qa, c1qb, c1qbp, c1qg, c1r, c1s, c2,  
 c21orf1, c21orf2, c21orf3, c2ta, c3, c3br, c3dr, c3g, c4a, c4b, c4bpa, c4bpb, c4f, c4s,  
 20 c5, c5ar, c5r1, c6, c7, c8a, c8b, c8g, c9, ca1, ca12, ca125, ca2, ca21h, ca3, ca4, ca5,  
 ca6, ca7, ca8, ca9, caaf1, cabp9k, cac, cac@, caca, cacd, cacnala, cacnalb, cacnalc,  
 cacnald, cacnale, cacnalf, cacnals, cacna2, cacnb1, cacnb2, cacnb3, cacnb4, cacng,  
 cacn1a1, cacn1a2, cacn1a3, cacn1a4, cacn1a5, cacn1a6, cacn1a, cacn1b,  
 cacnlg, cacp, cact, cacy, cad, cad11, cadas1, cae1, cae3, caf, cafla, caga, cagb, cain,  
 25 cak, cak1, cal11, calb1, calb2, calb3, calc1, calc2, calca, calcb, calcr, cald1, calla,  
 calm1, calm2, calm3, calm11, calm13, calna, calna3, calnb, calnb1, calr, cals, calt,  
 calu, cam, camk4, camkg, caml1, camlg, camp, can, canp3, canx, cap2, cap3, cap37,  
 capb, capg, cap1, capn1, capn2, capn3, capn4, cappa2, cappb, capr, caps, capza2,  
 capzb, car, carp, cars, cart1, cas, cas2, cas1, casp1, casp10, casp2, casp3, casp3,  
 30 casp4, casp5, casp6, casp7, casp8, casq1, casq2, casr cast, cat, cat1, cat4, catf1,

catm, cav1, cav2, cav3, cbbm, cbd, cbfa1, cbfa2, cbfa2t1, cbfa3, cbfb, cbg, cb1, cb12, cbln2, cbp, cbp, cbp2, cbp68, cbr1, cbs, cbt, cbt1, cc10, cca, cca1, cca11, cca12, ccb11, ccckr5, ccg1, ccg2, cchl1a1, cchl1a2, cchl1a3, cchl1b1, cck, cckar, cckbr, cc1, ccm1, ccm2, ccm3, ccn1, ccna, ccnb1, ccnc, ccnd1, ccnd2, ccnd3, ccne, ccnf, ccng1, ccnh, cent, cent1, cco, ccr10, ccr2, ccr3, ccr9, ccsp, cct, ccv, cczs, cd, cd10, cd11a, cd11b, cd11c, cd13, cd137, cd14, cd15, cd151, cd156, cd16, cd164, cd18, cd19, cd1a, cd1b, cd1c, cd1d, cd1e, cd2, cd20, cd22, cd23, cd24, cd26, cd27, cd271, cd28, cd281g, cd281g2, cd30, cd32, cd33, cd34, cd36, cd3611, cd3612, cd37, cd38, cd39, cd3911, cd3d, cd3e, cd3g, cd3z, cd4, cd40, cd401g, cd41b, cd43, cd44, cd45, cd46, cd47, cd48, cd49b, cd49d, cd5, cd53, cd57, cd58, cd59, cd51, cd6, cd63, cd64, cd68, cd69, cd7, cd70, cd71, cd72, cd74, cd79a, cd79b, cd80, cd81, cd82, cd82, cd86, cd8a, cd8b, cd8b1, cd9, cd94, cd95, cd97, cd99, cda, cda1, cda3, cdan1, cdan2, cdan3, cdb2, cdc2, cdc20, cdc25a, cdc25b, cdc25c, cdc27, cdc211, cdc212, cdc214, cdc34, cdc42, cdc51, cdc7, cdc711, cdcd1, cdcd2, cdcd3, cdc11, cdcre1, cdg1, cdgd1, cdgg1, cdgs2, cdh1, cdh11, cdh12, cdh13, cdh14, cdh15, cdh16, cdh16, cdh17, cd2, cdh3, cdh3, cdh5, cdh7, cdh8, cdhb, cdhh, cdhp, cdhs, cdk2, cdk3, cdk4, cdk5, cdk7, cdk8, cdk9, cdkn1, cdkn1a, cdkn1b, cdkn1c, cdkn2a, cdkn2b, cdkn2d, cdkn3, cdkn4, cd11, cdm, cdmp1, cdm1, cdp1, cdp2, cdp3, cdp4, cdp5, cdp6, cdp7, cdp8, cdp9, cdp10, cdp11, cdp12, cdp13, cdp14, cdp15, cdp16, cdp17, cdp18, cdp19, cdp20, cdp21, cdp22, cdp23, cdp24, cdp25, cdp26, cdp27, cdp28, cdp29, cdp30, cdp31, cdp32, cdp33, cdp34, cdp35, cdp36, cdp37, cdp38, cdp39, cdp40, cdp41, cdp42, cdp43, cdp44, cdp45, cdp46, cdp47, cdp48, cdp49, cdp50, cdp51, cdp52, cdp53, cdp54, cdp55, cdp56, cdp57, cdp58, cdp59, cdp60, cdp61, cdp62, cdp63, cdp64, cdp65, cdp66, cdp67, cdp68, cdp69, cdp70, cdp71, cdp72, cdp73, cdp74, cdp75, cdp76, cdp77, cdp78, cdp79, cdp80, cdp81, cdp82, cdp83, cdp84, cdp85, cdp86, cdp87, cdp88, cdp89, cdp90, cdp91, cdp92, cdp93, cdp94, cdp95, cdp96, cdp97, cdp98, cdp99, cdp100, cdp101, cdp102, cdp103, cdp104, cdp105, cdp106, cdp107, cdp108, cdp109, cdp110, cdp111, cdp112, cdp113, cdp114, cdp115, cdp116, cdp117, cdp118, cdp119, cdp120, cdp121, cdp122, cdp123, cdp124, cdp125, cdp126, cdp127, cdp128, cdp129, cdp130, cdp131, cdp132, cdp133, cdp134, cdp135, cdp136, cdp137, cdp138, cdp139, cdp140, cdp141, cdp142, cdp143, cdp144, cdp145, cdp146, cdp147, cdp148, cdp149, cdp150, cdp151, cdp152, cdp153, cdp154, cdp155, cdp156, cdp157, cdp158, cdp159, cdp160, cdp161, cdp162, cdp163, cdp164, cdp165, cdp166, cdp167, cdp168, cdp169, cdp170, cdp171, cdp172, cdp173, cdp174, cdp175, cdp176, cdp177, cdp178, cdp179, cdp180, cdp181, cdp182, cdp183, cdp184, cdp185, cdp186, cdp187, cdp188, cdp189, cdp190, cdp191, cdp192, cdp193, cdp194, cdp195, cdp196, cdp197, cdp198, cdp199, cdp200, cdp201, cdp202, cdp203, cdp204, cdp205, cdp206, cdp207, cdp208, cdp209, cdp210, cdp211, cdp212, cdp213, cdp214, cdp215, cdp216, cdp217, cdp218, cdp219, cdp220, cdp221, cdp222, cdp223, cdp224, cdp225, cdp226, cdp227, cdp228, cdp229, cdp230, cdp231, cdp232, cdp233, cdp234, cdp235, cdp236, cdp237, cdp238, cdp239, cdp240, cdp241, cdp242, cdp243, cdp244, cdp245, cdp246, cdp247, cdp248, cdp249, cdp250, cdp251, cdp252, cdp253, cdp254, cdp255, cdp256, cdp257, cdp258, cdp259, cdp260, cdp261, cdp262, cdp263, cdp264, cdp265, cdp266, cdp267, cdp268, cdp269, cdp270, cdp271, cdp272, cdp273, cdp274, cdp275, cdp276, cdp277, cdp278, cdp279, cdp280, cdp281, cdp282, cdp283, cdp284, cdp285, cdp286, cdp287, cdp288, cdp289, cdp290, cdp291, cdp292, cdp293, cdp294, cdp295, cdp296, cdp297, cdp298, cdp299, cdp300, cdp301, cdp302, cdp303, cdp304, cdp305, cdp306, cdp307, cdp308, cdp309, cdp310, cdp311, cdp312, cdp313, cdp314, cdp315, cdp316, cdp317, cdp318, cdp319, cdp320, cdp321, cdp322, cdp323, cdp324, cdp325, cdp326, cdp327, cdp328, cdp329, cdp330, cdp331, cdp332, cdp333, cdp334, cdp335, cdp336, cdp337, cdp338, cdp339, cdp340, cdp341, cdp342, cdp343, cdp344, cdp345, cdp346, cdp347, cdp348, cdp349, cdp350, cdp351, cdp352, cdp353, cdp354, cdp355, cdp356, cdp357, cdp358, cdp359, cdp360, cdp361, cdp362, cdp363, cdp364, cdp365, cdp366, cdp367, cdp368, cdp369, cdp370, cdp371, cdp372, cdp373, cdp374, cdp375, cdp376, cdp377, cdp378, cdp379, cdp380, cdp381, cdp382, cdp383, cdp384, cdp385, cdp386, cdp387, cdp388, cdp389, cdp390, cdp391, cdp392, cdp393, cdp394, cdp395, cdp396, cdp397, cdp398, cdp399, cdp400, cdp401, cdp402, cdp403, cdp404, cdp405, cdp406, cdp407, cdp408, cdp409, cdp410, cdp411, cdp412, cdp413, cdp414, cdp415, cdp416, cdp417, cdp418, cdp419, cdp420, cdp421, cdp422, cdp423, cdp424, cdp425, cdp426, cdp427, cdp428, cdp429, cdp430, cdp431, cdp432, cdp433, cdp434, cdp435, cdp436, cdp437, cdp438, cdp439, cdp440, cdp441, cdp442, cdp443, cdp444, cdp445, cdp446, cdp447, cdp448, cdp449, cdp450, cdp451, cdp452, cdp453, cdp454, cdp455, cdp456, cdp457, cdp458, cdp459, cdp460, cdp461, cdp462, cdp463, cdp464, cdp465, cdp466, cdp467, cdp468, cdp469, cdp470, cdp471, cdp472, cdp473, cdp474, cdp475, cdp476, cdp477, cdp478, cdp479, cdp480, cdp481, cdp482, cdp483, cdp484, cdp485, cdp486, cdp487, cdp488, cdp489, cdp490, cdp491, cdp492, cdp493, cdp494, cdp495, cdp496, cdp497, cdp498, cdp499, cdp500, cdp501, cdp502, cdp503, cdp504, cdp505, cdp506, cdp507, cdp508, cdp509, cdp510, cdp511, cdp512, cdp513, cdp514, cdp515, cdp516, cdp517, cdp518, cdp519, cdp520, cdp521, cdp522, cdp523, cdp524, cdp525, cdp526, cdp527, cdp528, cdp529, cdp530, cdp531, cdp532, cdp533, cdp534, cdp535, cdp536, cdp537, cdp538, cdp539, cdp540, cdp541, cdp542, cdp543, cdp544, cdp545, cdp546,

-56-

clg3, clg4a, clg4b, cli, clim1, clim2, clk2, clk3, cln1, cln2, cln3, cln5, cln6, cln80,  
clns1a, clns1b, clp, clpp, clps, clta, cltb, cltc, cltc11, cltd, clth, clu, cma1, cmah,  
cmar, cmd1, cmd1a, cmd1b, cmd1c, cmd1d, cmd1e, cmd1f, cmd3a, cmdj, cmh1,  
cmh2, cmh3, cmh4, cmh6, cmkbr1, cmkbr2, cmkbr3, cmkbr5, cmkbr6, cmkbr7,  
5 cmkbr8, cmkbr9, cmkbr12, cmklr1, cmkr11, cmkr12, cml, cmm, cmm2, cmoat, cmp,  
cmpd1, cmpd2, cmpd2, cmpd3, cmpx1, cmt1a, cmt1b, cmt2a, cmt2b, cmt2d, cmt2d,  
cmt4a, cmt4b, cmtnd, cmtx1, cmtx2, cna1, cna2, cnbp1, cnc, cncg1, cncg2, cncg31,  
cnd, cng3, cnga1, cnga3, cngb1, cnn1, cnn2, cnn3, cnp, cnr1, cnstn, cntf, cntfr, cntn1,  
co, coca1, coca2, coch, cod1, cod2, coh1, coil, col10a1, col11a1, col11a2, col12a11,  
10 col13a1, col15a1, col16a1, col17a1, col18a1, col19a1, col1a1, col1a2, col1ar,  
col2a1, col3a1, col4a1, col4a2, col4a3, col4a4, col4a5, col4a6, col5a1, col5a2,  
col6a1, col6a2, col6a3, col7a1, col8a1, col8a2, col9a1, col9a1, col9a2, col9a3, colq,  
comp, comt, copeb, copt1, copt2, cord1, cord2, cord5, cord6, cort, cot, cox10, cox4,  
cox5b, cox6a1, cox6b, cox7a1, cox7a2, cox7a3, cox7am, cox8, cp, cp107, cp115,  
15 cp20, cp47, cp49, cpa1, cpa3, cpb2, cpb2, cpd, cpe, cpetr2, cpm, cpn, cpn1, cpn2,  
cpo, cpp, cpp32, cpp32, cppi, cps1, cpsb, cpsd, cpt1a, cpt1b, cpt2, cpu, cpx, cpx,  
cpxd, cr1, cr2, cr3a, crabp1, crabp2, crapb, crarf, crat, crbp1, crbp2, crd, crd1, creb1,  
creb2, crebbp, creb11, crem, crfb4, crfr2, crh, crhbp, crhr, crhr1, crhr2, crip, crk,  
crk1, crm1, crmp1, crmp2, crp, crp1, crs, crs1c, crs2, crs3, crsa, crt, crt11, crtm, crx,  
20 cry1, cry2, crya1, crya2, cryaa, cryab, cryb1, cryb2, cryb3, cryba1, cryba2, cryba4,  
crybb1, crybb2, crybb3, cryg1, cryg2, cryg3, cryg4, cryg8, cryg@, cryga, crygb,  
crygc, crygd, crygs, crym, cryz, cs, csa, csb, csbp1, csci, csd, csd2, csda, cse, cse11,  
csf1, csf1r, csf2, csf2ra, csf2rb, csf2ry, csf3, csf3r, csh1, csh2, csk, csmf, csn1,  
csn10, csn2, csn3, csnb1, csnb2, csnb3, csnk1a1, csnk1d, csnk1e, csnk1g2, csnk2a1,  
25 csnk2a2, csnk2b, csnu3, cso, cspb, cspg1, cspg2, cspg3, csr, csrb, csrp, csrp1, csrp2,  
cst1, cst1, cst2, cst3, cst4, cst4, cst5, cst6, csta, cstb, csx, ct2, ctaa1, ctaa2, ctag, ctb,  
ctbp1, ctbp2, ctgf, cth, cthm, ctk, ctla1, ctla3, ctla4, ctla8, ctm, cttna1, cttna2,  
ctnnb1, cttnnd, cttnnd1, cttnr, cttns, ctp, ctpct, ctps, ctr1, ctr2, ctrb1, ctrl1, ctsa, ctsb,  
ctsc, ctsd, ctse, ctsg, ctsg12, ctsh, ctsk, cts1, ctss, ctsw, ctsz, ctx, cubn, cul3, cul4b,  
30 cul5, cutl1, cvap, cvd1, cvl, cx26, cx31, cx32, cx37, cx40, cx43, cx46, cx50, cxb3s,

-57-

cxcr4, cxorf4, cyb5, cyb561, cyba, cybb, cyc1, cyk4, cyld1, cypmp, cyp1, cyp11a,  
cyp11b1, cyp11b2, cyp17, cyp19, cyp1a1, cyp1a2, cyp1b1, cyp21, cyp24, cyp27,  
cyp27a1, cyp27b1, cyp2a, cyp2a3, cyp2a6, cyp2b, cyp2c, cyp2c19, cyp2c9, cyp2d,  
cyp2d@, cyp2e, cyp2e1, cyp2f1, cyp2j2, cyp3a4, cyp4a11, cyp4b1, cyp51, cyp7,  
5 cyp7a1, cyr61, cym1, cym2, czp3, d10s105e, d10s170, d10s170, d11s302e,  
d11s636, d11s813e, d11s833e, d12s2489e, d12s53e, d13s1056e, d13s25, d14s46e,  
d15s12, d15s226e, d15s227e, d16s2531e, d16s469e, d17s136e, d17s811e, d18s892e,  
d19s204, d19s381e, d1s111, d1s155e, d1s166e, d1s1733e, d1s2223e, d1s61, d2h,  
d2s201e, d2s448, d2s488e, d2s69e, d3s1231e, d3s1319e, d3s48e, d4, d4s90,  
10 d5s1708, d5s346, d6, d6s1101, d6s207e, d6s2245e, d6s228e, d6s229e, d6s230e,  
d6s231e, d6s51e, d6s52e, d6s54e, d6s81e, d6s82e, d7s437, d8s2298e, d9s46e, dal,  
da2b, dab2, dac, dad1, daf, dag, dag1, dag2, dagk1, dagk4, dam10, dam6, damox,  
dan, dao, dap, dap3, dap5, dapk1, dar, dat1, dax1, daxe, daz, dazh, daz1, dba,  
dbccr1, dbcn, dbh, dbi, dbi, db1, dbm, dbn1, dbp, dbp, dbp1, dbp2, dbpa, dbt, dbx,  
15 dby, dcc, dce, dci, dck, dcn, dcoh, dcp1, dcr, dcr3, dct, dctn1, dcx, ddb1, ddb2, ddc,  
ddh1, ddh2, ddit1, ddit3, ddost, ddp, ddpac, ddr, ddx1, ddx10, ddx11, ddx12, ddx15,  
ddx16, ddx2a, ddx3, ddx5, ddx6, ddx9, dec, decr, def1, def4, def5, def6, defa1,  
defa4, defa5, defa6, defb1, defb2, dek, denn, dents, dep1, der12, des, dff1, dffa,  
dffrx, dffry, dfn1, dfn2, dfn3, dfn4, dfn6, dfna1, dfna10, dfna11, dfna12, dfna13,  
20 dfna2, dfna2, dfna4, dfna5, dfna6, dfna7, dfna8, dfna9, dfnb1, dfnb12, dfnb13,  
dfnb14, dfnb16, dfnb17, dfnb18, dfnb2, dfnb3, dfnb4, dfnb5, dfnb6, dfnb7, dfnb8,  
dfnb9, dgcr, dgcr2, dgcr2, dgcr6, dgi1, dgka, dgkq, dgpt, dgpt, dgs, dgs2, dgsi, dgu,  
dhc2, dhcr7, dhfr, dhlag, dhp, dhpr, dhps, dhrr, dhtr, di, di1, dia, dia1, dia2, dia4,  
diaph1, diaph2, dif2, diff6, dipi, dir, dkc, dkc1, dlc1, dld, dlgl, dlgl2, dlgl3, dlgl4, dlst,  
25 dlx1, dlx2, dlx2, dl3, dlx4, dlx5, dlx6, dlx7, dlx8, dm, dm2, dmahp, dmbt1, dmd,  
dmda1, dmd1, dmh, dmh, dmp1, dmpk, dmsfh, dmt, dmt1, dmtn, dna21, dnah,  
dnah1, dnah11, dnah12, dnah2, dnahc1, dnahc11, dnahc2, dnahc3, dnase1,  
dnase111, dnase113, dnase2, dnch2, dnc1, dncm, dnec1, dne11, dn1, dn11, dn111,  
dnm1, dnmt1, dnmt2, dnmpk1, dns, dnnt, do, doc1, doc2, dock1, dock180, dod, dok1,  
30 dom, dp1, dp1, dp2, dp3, dpagt2, dpc4, dpd, dpde1, dpde2, dpde3, dpde4, dpep1,

-58-

dph212, dpp, dpp4, dpp6, dpt, dpyd, dpys, dpys11, dpys12, dr1, dr3, dr31g, dr5, dra,  
drad, drada, dra1, drd1, drd1b, drd1b, drd112, drd2, drd3, drd4, drd5, dri11, drp1,  
drp1, drp2, drp2, drp3, drp1a, drt, dsc1, dsc2, dsc3, dsc3, dsc4, dscam, dscr, dsg1,  
dsg2, dsg3, dsp, dspg3, dspp, dss, dss1, dtd, dtdp2, dtdst, dtna, dtr, dts, dus, dusp1,  
5 dusp11, dusp2, dusp3, dusp4, dusp5, dusp6, dusp7, dusp8, dut, dv1, dv11, dv11,  
dv13, dxf68s1e, dxs1272e, dxs128, dxs1283e, dxs423e, dxs435e, dxs522e, dxs648,  
dxs707, dxs8237e, dxys155e, dylx2, dyrk, dys, dysf, dyt1, dyt3, dyt5, dyt6, dyt7,  
dyt8, dyt9, dyx1, dyx2, e11s, e14, e1b, e2a, e2f1, e2f2, e2f3, e2f4, e3, e4f, e4f1,  
e4tfla, e4tflb, eal, eaac1, eaat1, eaat2, eac, ead, eag, eap, earl, ear2, ear3, eba1, ebf,  
10 ebi1, ebm, ebn1, ebn1, ebn2, ebr2a, ebs1, ebvm1, ebvs1, ec1, eca1, ecb2, ece1,  
ecgf1, ech1, echs1, eck, ecm1, ecp, ecs1, ect2, ed1, ed2, ed3, ed4, eda, eda3, eddr1,  
edg3, edg6, edh, edh17b2, edh17b2, edh17b3, edm1, edm2, edm3, edmd, edmd2,  
edn, edn1, edn2, edn3, ednra, ednrb, eec1, eec2, eefla1, eefla2, eeflb1, eeflb2,  
eeflb3, eeflb4, eef2, eeg1, eegv1, eek, een, efla, ef2, efe2, efemp1, efl6, efmr,  
15 efna1, efna3, efna4, efnb1, efnb2, efnb3, efp, eftu, egf, egfr, egi, egr1, egr2, egr3,  
egr4, ehhadh, ehoc1, ei, eif1a, eif2g A, eif2s3 A, eif3s10, eif3s6, eif4a1, eif4a2,  
eif4c, eif4e, eif4ebp1, eif4e2, eif4e11, eif4e12, eif4g, eif4g1, eif4g2, eif5a, ejm1,  
el1, ela1, ela2, elam1, elanh2, elav11, elav12, elav14, elc, ele1, elf3, elk1, elk2, elk3,  
elk4, el1, eln, em9, emap, emap1, emd, emd2, emk 1, emp1, emp55, emr1, ems1,  
20 emt, emtb, emx1, emx2, en1, en2, ena78, end, endog, enfl2, eng, en1, eno1, eno2,  
eno3, enpep, ent1, entk, enur1, enur2, enx2, eos, ep3, ep300, epa, epb3, epb311,  
epb41, epb4112, epb42, epb49, epb72, epha1, epha2, epha3, epha8, ephb1, ephb2,  
ephb3, ephb4, ephb6, epht1, epht2, epht3, ephx1, ephx2, epim, eplg1, eplg2, eplg3,  
eplg4, eplg5, eplg8, epm1, epm2, epm2a, epmr, epo, epor, eppk, eprs, eps15, eps8,  
25 ept, erba1, erba2, erba12, erba13, erbb2, erbb3, erbb4, erc55, ercc1, ercc2, ercc3,  
ercc4, ercc5, ercc6, ercm1, erda1, erf1, erg, erg3, ergic53, erh, erk, erk1, erk2, erk3,  
erm, erp11, erv1, erv1, erv3, ervr, ervt1ervt2, ervt3, ervt4, ervt5, eryf1, es1, es130,  
esa, esa1, esa4, esat, esb3, esd, esg, esr, esr1, esr2, esr11, esr12, esrra, esrrb, esrrg,  
ess1, est, est, est2, est25263, esx, etfa, etfb, etfdh, etk1, etk2, etm1, etm2, eto, ets1,  
30 ets2, etv1, etv3, etv4, etv5, etv6, evc, evc1, evda, evdb, evi1, evi2, evi2a, evi2b,

-59-

evp1, evr1, evx1, evx2, ews, ewsr1, exlm1, ext1, ext2, ext3, ext11, ext12, eya1,  
eya2, eya3, eycl1, eycl3, ezh1, ezh1, ezh2, fl0, fl1, fl2, fl3a, fl3a1, fl3b, f2, f2r,  
f2rl2, f2rl3, f3, f5, f5f8d, f7, f7e, f7r, f8a, f8b, f8c, f8vwf, f9, fa, fa1, faa, fabp1,  
fabp2fabp3, fabp4, fabp6, fac1, faca, facc, facd, face, fac11, fac12, fac13, fac14,  
5 facv11, fad, fadd, fadk, fah, fak2, faldh, fal139, falz, fanca, fancc, fancd, fance,  
fancg, fap, fapa, farr, fas, fas1, fasn, fast1, fat, fau, fbln1, fbln2, fbn1, fbn2, fbn1,  
fbp1, fcar, fcc1, fce, fce2, fcer1a, fcer1b, fcer1g, fcer2, fcgr1a, fcgr1b, fcgr1c,  
fcgr2a, fcgr3a, fcgrt, fcmd, fcn1, fcn2, fcp, fcp1, fcpX, fct3a, fdc, fdft1, fdh, fdps11,  
fdps12, fdps13, fdps14, fdps15, fdx1, fdxR, fe65, fe6511, fea, feb1, feb2, fecb, fech,  
10 fen1, feo, feom, feom1, feom2, fer, fes, fet1, fevr, ffm, fga, fgarat, fgb, fgc@, fgd1,  
fgdy, fgfl, fgfl0, fgfl1, fgfl2, fgfl3, fgfl4, fgf2, fgf2, fgf3, fgf4, fgf5, fgf6, fgf7,  
fgf8, fag9, fgfa, fgfb, fgfr1, fgfr2, fgfr3, fgfr4, fgg, fgr, fgs1, fh, fh, fh3, fhc, fnf1,  
fhf3, fhf4, fhh2, fhit, fh11, fh12, fhr2, fic1, figf, fih, fim, fim1, fim3, fimg, fkbp12,  
fkbp1a, fkbp2, fkh2, fkh11, fkh110, fkh112, fkh115, fkh116, fkh117, fkh12, fkh15,  
15 fkh16, fkh17, fkh18, fkh19, fkhr, fkhr11, flg, fli1, flii, fln1, fln2, flna, flnb, flnms,  
flot2, flt1, flt2, flt3, flt4, fmf, fmn, fmo1, fmo2, fmo3, fmod, fmr1, fmr2, fms, fl1,  
fn12, fnra, fnrb, fnrb1, fnta, fntb, folh, folh1, folr1, folr2, folt, fos, fosb, fos11,  
fos12, fpah, fpc, fpd1, fpdmm, fpf, fpgs, fp1, fpp, fpr1, fprh1, fprh2, fpr11, fpr12,  
fprp, fps12, fps13, fps14, fps15, fr, frap1, fraxa, fraxe, fraxf, frda, freac2, freac6,  
20 freac9, frg1, frp1, frv1, frv2, frv3, fsg1, fsgs, fshb, fshd1a, fshmd1a, fshprh1, fshr,  
fssv, fth1, fth16, ft1, ftz1, ftzfl, fuca1, fuca2, fur, fus, fuse, fut1, fut2, fut3, fut4,  
fut5, fut6, fut7, fut8, fvt1, fxr1, fxy, fy, fyn, fzd1, fzd2, fzd3, fzd5, fzd6, fzd7, fZr,  
g0s8, g10p1, g10p2, g17, g17p1, g19p1, g1p1, g1p2, g1p3, g22p1, g6pc, g6pd,  
g6pd1, g6pd1, g6pt, g6pt1, g6s, g7p1, ga2, gaa, gabatr, gabpa, gabpb1, gabra1,  
25 gabra2, gabra3, gabra4, gabra5, gabra6, gabrb1, gabrb2, gabrb3, gabrd, gabre,  
gabrg1, gabrg2, gabrg3, gabrr1, gabrr2, gad1, gad2, gad3, gadd153, gadd45, gak,  
gal, galbp, galc, gale, galgt, galk1, galk2, galn, galnact, galnr, galnr1, galns, galnt1,  
galnt2, galnt3, galr1, galt, gan, gan1, ganab, ganc, gap, gap1m, gap43, gapd, gar22,  
garp, gars, gart, gas, gas1, gas2, gas41, gas6, gas7, gasr, gast, gata1, gata2, gata3,  
30 gata4, gata6, gay1, gba, gbas, gbbb1, gbbb2, gbe1, gbp1, gbx2, gc, gcap, gcap2,



gcdh, gcfl, gcf2, gcfx, gcg, gcgr, gch1, gck, gckr, gcn511, gcn512, gcnf, gent1,  
gent2, gcp, gcp2, gcs, gcs1, gcsf, gcsfr, gcsp, gctg, gcy, gda, gde, gdf5, gdf8, gdh,  
gdi1, gdi2, gdid4, gdld, gdnf, gdnfr, gdnfra, gdnfrb, gdx, gdxxy, ge, gem, geney, gey,  
gfl, gfl, gfap, gfer, gfer, gf11, gfpt, gfra1, gfra2, ggcx, ggt1, ggt2, ggta1, ggta1,  
5 ggta2, gh1, gh2, ghc.RTM., ghdx, ghn, ghr, ghrf, ghrh, ghrhr, ghs, ghv, gif, gifb,  
gip, gip, gipr, girk1, girk2, girk3, girk4, gja1, gja3, gja4, gja5, gja8, gjb1, gjb2, gjb3,  
gk, gk2, gla, glat, glb1, glb2, glc1a, glc1b, glc1c, glc1d, glc1f, glc3a, glc3b, glc1c,  
glc1r, glct2, glct3, glde, glepp1, glg1, gli, gli2, gli3, gli4, glnn, glns, glo1, glo2,  
glp1r, glra1, glra2, glra3, glrb, glrx, gls, glud1, glud2, glu1, glur1, glur2, glur3,  
10 glur4, glur5, glur6, glur7, glut1, glut2, glut3, glut4, glut5, glvr1, glvr2, gly96, glya,  
glyb, glysl, glyt1, glyt1, glyt2, gm2a, gma, gmcsf, gmds, gm1, gmp, gmps, gnai1,  
gnai5, gnai6, gnai1, gnai2, gnai2a, gnai2b, gnai21, gnai3, gna1, gnao1, gnaq, gnas,  
gnas1, gnat1, gnat2, gnaz, gnb1, gnb2, gnb3, gng5, gn11, gnpta, gnhr1, gnhr2, gnhr,  
gns, gnt1, golga4, got1, got2, gp130, gp1ba, gp1bb, gp2, gp2b, gp39, gp3a, gp75,  
15 gp78, gp9, gpa, gpam, gpat, gpb, gpc, gpc1, gpc3, gpc4, gpd, gpd1, gpd2, gpdsl,  
gpe, gpi, gpi2, gpm6a, gpm6b, gpoa, gpr1, gpr10, gpr11, gpr12, gpr13, gpr15,  
gpr17, gpr18, gpr19, gpr2, gpr20, gpr21, gpr22, gpr23, gpr25, gpr29, gpr3, gpr30,  
gpr31, gpr32, gpr35, gpr37, gpr39, gpr4, gpr5, gpr6, gpr7, gpr8, gpr9, gprcy4,  
gprk21, gprk4, gprk5, gprk6, gprv28, gpsa, gpse, gpt, gpx1, gpx2, gpx3, gpx4, gr2,  
20 grb1, grb10, grb2, grf2, gria1, gria2, gria3, gria4, grid2, gri1, gri2, gri3, gri4,  
gri5, grin1, grin2a, grin2b, grin2c, grin2d, grina, grk1, grk5, grk6, gr1, gr111,  
grm3, grm8, grmp, grn, gro1, gro2, gro3, grp, grp58, grp78, grpr, grx, gs, gs1, gsas,  
gsc, gsc1, gse, gshs, gs1, gsm1, gsn, gsp, gspt1, gsr, gss, gst12, gst11, gst2, gst2,  
gst3, gst4, gst5, gsta1, gsta2, gstm1, gstm11, gstm2, gstm3, gstm4, gstm5, gstp1,  
25 gstt2, gt1, gt335, gta, gtb, gtbp, gtd, gtf2e2, gtf2f1, gtf2h1, gtf2h2, gtf2h4, gtf2i,  
gtf2s, gtf3a, gtg, guc1a2, guc1a3, guc1b3, guc2c, guc2d, guc2f, guca1a, guca1b,  
guca2, guca2, guca2a, guca2b, guca3, gucsb3, gucy1a2, gucy1a3, gucy1b3, gucy2c,  
gucy2d, gucy2f, guk1, guk2, gulo, gulop, gusb, gusm, gust, gxp1, gypa, gypb, gypc,  
gype, gys, gys1, gys2, gzma, gzmb, gzmh, gzmm, h, h142t, h19, h1f0, h1f1, h1f2,  
30 h1f3, h1f4, h1f5, h1fv, h2a, h2ax, h2az, h2b, h2b, h3f2, h3f3b, h3ft, h3t, h4, h4f2,

-61-

h4f5, h4fa, h4fb, h4fe, h4fg, h4fh, h4fi, h4fj, h4fk, h4fl, h4fm, h4m, h6, ha2, habp1,  
 hadha, hadhb, hadhsc, haf, hagh, hah1, haip1, ha1, hap, hap1, hap2, hars, has2, hat1,  
 hausp, hb1, hb1, hb6, hba1, hba2, hbac@, hbb, hbbc@, hbd, hbe1, hbegf, hbf2,  
 hbg1, hbg2, hbgr, hbhr, hbm, hbp, hbq1, hbz, hc2, hc3, hca, hcat2, hccs, hcdh, hcf2,  
 5 hcf1, hcg, hck, h11, hc12, hc13, hcls1, hcp, hcp1, hcs, hcvs, hd, hdac1, hdc, hdgf,  
 hdhc7, hdlbp, hdld, hdldt1, hdr, hed, hed, hegfl, hek, hek3, heln1, hem1, hema,  
 hemb, hemc, hempas, hen1, hen2, hep, hep10, her2, her4, herg, herv1, hes1, hesx1,  
 het, hexa, hexb, hf1, hf10, hfc1, hfe, hfe2, hfh11, hfsp, hgd, hgf, hgf, hgfl, hg1, hh,  
 hh72, hhc1, hhc2, hhd, hhh, hhmjg, hhr23a, hht1, hht2, hiap2, higm1, hilda, hint,  
 10 hiomt, hip, hip1, hip116, hip2, hir, hira, his1, his2, hive1, hivep1, hivep2, hjcd, hk1,  
 hk2, hk3, hk33, hke4, hke6, hkr1, hkr2, hkr3, hkr4, hl11, hl19, hla-a, hla-b, hla-c,  
 hla-cda12, hla-dma, hla-dmb, hla-dna, hla-dob, hla-dpa1hla-dpb1, hla-dqa1, hla-  
 drlb, hla-dra, hla-e, hla-f, hla-g, hla-ha2, hlapd, hlaf, hlals, hlcs, hlm2, hlp, hlp3,  
 hlr1, hlr2, hlt, hlxl, hlxb9, hmaa, hmab, hmat1, hmbs, hmcs, hmg1, hmg14, hmg17,  
 15 hmg2, hmgc1, hmgcr, hmgcs1, hmgcs2, hmgic, hmgiy, hmgx, hmmr, hmn2, hmox1,  
 hmox2, hmr, hms1, hmsn1, hmx1, hmx2, hnd, hnf1a, hnf2, hnf3a, hnf3b, hnf4a,  
 hnp36, hnpcc6, hnrpa1, hnrpa2b1, hnrpd, hnrpf, hnrpg, hnrph1, hnrph2, hnrph3,  
 hnrpk, homg, hops, hox10, hox11, hox12, hox1@, hox1a, hox1b, hox1c, hox1d,  
 hox1e, hox1f, hox1g, hox1h, hox1i, hox1j, hox2@, hox2a, hox2b, hox2c, hox2d,  
 20 hox2e, hox2f, hox2g, hox2h, hox2i, hox3@, hox3a, hox3b, hox3c, hox3d, hox3e,  
 hox3f, hox3g, hox4@, hox4a, hox4b, hox4c, hox4d, hox4e, hox4f, hox4g, hox4h,  
 hox4i, hox7, hox8, hoxa1, hoxa10, hoxa11, hoxa13, hoxa3, hoxa4, hoxa5, hoxa6,  
 hoxa7, hoxa9, hoxa@, hoxb1, hoxb2, hoxb3, hoxb4, hoxb5, hoxb6, hoxb7, hoxb8,  
 hoxb9, hoxb@, hoxc12, hoxc13, hoxc4, hoxc5, hoxc6, hoxc8, hoxc9, hoxc@,  
 25 hoxd1, hoxd10, hoxd11, hoxd12, hoxd13, hoxd3, hoxd4, hoxd8, hoxd9, hoxd@,  
 hoxhb9, hp, hp4, hpafp, hpc1, hpc2, hpc4, hpcal1, hpcx, hpd, hpdr1, hpdr2, hpe1,  
 hpe2, hpe3, hpe4, hpe5, hpect1, hpfh, hpfh2, hpgd, hplh1, hplh2, hpn, hpr, hprr,  
 hprr1, hps, hpt, hpt1, hptp, hptx, hpv18i1, hpv18i2, hpx, hr, hras, hrb, hrc, hrc1,  
 hrca1, hrd, hres1, hrf, hrg, hrga, hrh1, hrh2, hrmt111, hrpt2, hrx, hrx, hry, hsa11,  
 30 hsa12, hsan1, hsa1, hscr2, hsd11, hsd11b1, hsd11b2, hsd11k, hsd111, hsd17b1,

-62-

hsd17b2, hsd17b3, hsd17b4, hsd3b1, hsd3b2, hsh, hsn1, hsorc1, hsp27, hsp73,  
hspa1a, hspa1b, hspa11, hspa2, hspa3, hspa4, hspa5, hspa6, hspa7, hspa8, hspa9,  
hsqb1, hspb2, hspc2, hspca11, hspca12, hspca13, hspca14, hspcb, hspg1, hspg2,  
hsr1, hsst, hstd, hstf1, htc2, htf4, htk, htk1, ht1, htlf, htivr, htn1, htn2, htn3, htnb,  
5 htor, htr1a, htr1b, htr1d, htr1e, htr1e1, htr1f, htr2a, htr2b, htr2c, htr3, htr4, htr5a,  
htr6, htr7, htrx1, hts1, htt, htx, htx1, hub, hud, hup2, hur, hus, hvls, hvbs1, hvbs6,  
hvbs7, hvem, hvh2, hvh3, hvh8, hxb, hxb1, hy, hya, hya11, hyd2, hygn1, hy1, hyp,  
hyplip1, hypp, hypx, hyr, hyrc1, hys, ia1, ia2, iap, iapp, iar, iars, ibd1, ibd2, ibm2,  
ibsp, ica1, icam1, icam2, icam3, icca, ich1, icr2, icr2b, ics1, id1, id2, id3, id4, ida,  
10 idd, iddm1, iddm10, iddm11, iddm12, iddm13, iddm15, iddm17, iddm2, iddm3,  
iddm4, iddm5, iddm6, iddm7, iddm8, iddmx, ide, idg2, idh1, idh2, idh3a, idh3g, ido,  
ids, idua, ier1, ier3, iex1, if, ifcr, ifgr2, ifi16, ifi27, ifi35, ifi4, ifi5111, ifi54, ifi56,  
ifi616, ifi78, ifna1, ifna10, ifna13, ifna14, ifna16, ifna17, ifna21, ifna6, ifna7, ifna8,  
ifna@, ifnail, ifnar1, ifnar2, ifnb1, ifnb2, ifnb3, ifng, ifngr1, ifngr2, ifngt1, ifnr,  
15 ifnw1, ifrd2, iga, igat, igb, igbp1, igd1, igda1, igdc1, igds2, iger, iges, igf1, igf1r,  
igf2, igf2r, igfbp1, igfbp10, igfbp2, igfbp3, igfbp4, igfbp6, igfbp7, igfr1, igfr2, igfr3,  
igh@, igha1, igha2, ighd, ighdy2, ighe, ighg1, ighg2, ighg3, ighg4, ighj, ighm,  
ighmbp2, ighr, ighv@, igi, igj, igk@, igkc, igkde1, igkj, igkjrb1, igkv, iglc, iglc1,  
igl1j, iglp1, iglp2, iglv, igm, igo1, igsf1, ihh, ik1, ikba, il10, il10r, il11, il11ra, il12a,  
20 il12b, il12rb1, il12rb2, il13, il13ra1, il13ra2, il15, il15ra, il17, il1a, il1b, il1bc, il1r1,  
il1r2, il1ra, il1rap, il1rb, il1rm, il2, il2r, il2ra, il2rb, il2rg, il3, il3ra, il3ray, il4, il4r,  
il4ra, il5, il5ra, il6, il6r, il6st, il7, il7r, il8, il8ra, il8rb, il9, il9r, ila, ilf1, illbp, imd1,  
imd2, imd4, imd5, imd6, impa1, impdh1, impdh2, impdh11, impg1, impt1, indx,  
infa2, infa4, infa5, ing1, inha, inhba, inhbb, inhbc, ini1, ink4b, inlu, inp10, inpp1,  
25 inpp5a, inpp5b, inpp5d, inpp11, ins, insig1, ins1, ins13, ins14, insr, insrr, int1,  
int111, int2, int3, int4, int6, iosca, ip2, ipf1, ip1, ipm150, ipox, ipp, ipp2, ipw,  
iqgap1, ir10, ir20, ireb1, ireb2, irf1, irf2, irf4, irf4, irr, irs1, isa, iscw, is11, islr, isot,  
issx, it15, itba1, itba2, itf, itf2, itga1, itga2, itga2b, itga4, itga5, itga6, itga7, itgad,  
itga1, itgam, itgav, itgax, itgb1, itgb2, itgb3, itgb4, itgb6, itgb7, iti, itih1, itih2, itih3,  
30 itih4, itih11, iti1, itk, itm1, itpa, itpka, itpkb, itpr1, itpr2, itpr3, itsn, ivd, iv1, jag1,

-63-

jak1, jak2, jak3, jbs, jcap, jh8, jip, jk, jme, jmj, joag, jpd, jrk, jrk1, jtk14, jtv1, jun,  
 junb, jund, jup, jv18, jws, k12t, kai1, kal1, kar, kars, katp1, kcna1, kcna10, kcna1b,  
 kcna2b, kcna3, kcna4, kcna5, kcna6, kcna7, kcna8, kcna9, kcnab1, kcnab2, kcnb1,  
 kenc1, kenc2, kenc3, kenc4, kcncl, kcnh1, kcnh2, kenj1, kenj10, kenj11, kenj12,  
 5 kenj15, kenj3, kenj4, kenj5, kenj6, kenj6, kenj7, kenj8, kenjn1, kenk1, kenk2,  
 kenk3, kenma1, kenq1, kenq2, kenq3, kenq4, kens2, kd, kdr, ke1, kera, kfl, kfs,  
 kfsd, kfs1, khk, k1aa0122, kid, kid1, kif2, kif3c, kif5b, kip1, kip2, kiss1, kit, klc2,  
 klk1, klk2, klk3, klk3, klkb1, klkr, klrb1, klrc1, klrc2, klrc3, klrc4, klrd1, klst, kms,  
 kms, kng, kno, kns1, kns2, kns11, kns14, kox1, kox11, kox12, kox13, kox15, kox16,  
 10 kox18, kox19, kox2, kox2, kox22, kox25, kox30, kox32, kox4, kox5, kox6, kox7,  
 kox9, kpna3, kpps1, kpps2, krag, kras1p, kras2, krev1, krg2, krn1, krn11, krox20,  
 krt1, krt10, krt12, krt13, krt14, krt15, krt16, krt17, krt18, krt19, krt2a, krt2e, krt3,  
 krt4, krt5, krt6a, krt6b, krt7, krt8, krt9, krtha2, krtha5, krthb1, krthb6, ks, ktn1, ku70,  
 kup, kvlqt1, kwe, 11.2, 11 cam, 123mrp, lab7, lab72, lac, laci, lacs, lad, lad, lad1,  
 15 laf4, lag3, lag5, lair1, lak1, lalba, lal1, lam1, lama1, lama2, lama3, lama3, lama4,  
 lama5, lamb1, lamb2, lamb2, lamb2t, lamb3, lambr, lamc1, lamc2, lamm, lamnb2,  
 lamp, lamp1, lamp2, lamr1, lams, lap, lap18, laptm5, lar, lar1, lard, large, lars, lbp,  
 lbr, lca, lca1, lcad, lcam, lcat, lccs, lcfs2, lch, lck, lcn1, lcn2, lco, lcp1, lcp2, lct, ld,  
 ld78, ldb1, ldb2, ldc, ldh1, ldh3, ldha, ldhb, ldhc, ldlr, le, lect2, lef1, lefty1, lefty2,  
 20 lep, lepr, lerk5, lerk8, leu1, leu7, leut, lfa1a, lfa3, lfhl1, lfp, lga1s1, lga1s3,  
 lga1s3bp, lga1s7, lgcr, lgmd1, lgmd1a, lgmd1b, lgmd1c, lgmd1d, lgmd2b, lgmd2c,  
 lgmd2d, lgmd2e, lgmd2f, lgmd2g, lgmd2h, lgs, lgtm, lhb, lhcgr, lhs, lhx1, lhx3, li,  
 li2, lif, lifr, lig1, lig3, lig4, lim1, lim2, limab1, limk1, limpii, lip2, lipa, lipb, lipc,  
 lipd, lipe, lipo, lis1, lis2, lisx, litaf, lkb1, lkn1, llg11, lman1, lmn1, lmn2, lmna,  
 25 lmn1b, lmn1b2, lmo1, lmo2, lmo3, lmo4, lmo5, lmp10, lmp2, lmp7, lmpx, lms, lmx1,  
 lmx1a, lmx1b, lmyc, lnhr, lnhr, locr, loh11cr2a, lor, lot1, lox, lox1, lox11, lpa, lpaab,  
 lpaata, lpap lpc1, lpc2d, lpd1, lph, lpi, lp1, lpna3, lpp, lps, lpsa, lqt1, lqt2, lqt3, lqt4,  
 lr3, lrel, lre2, lrp, lrp1, lrp2, lrp5, lrp7, lrp8, lrpap1, lrpr1, lrs1, lsamp, lsirf, ls1, lsn,  
 lsp1, lss, lst1, lta, lta4h, ltb, ltb4r, ltbp1, ltbp2, ltbp2, ltbp3, ltbp3, ltbr, ltc4s, ltf, ltk,  
 30 ltn, lu, lum, luxs, luzp, lw, ly64, ly6e, ly9, lyam1, lyb2, lyf1, ly11, lyn, lyp, lyst,

-64-

lyt10, lyz, lztr1, m11s1, m130, m17s1, m17s2, m195, m1s1, m3s1, m4s1, m6a, m6b, m6p2, m6pr, m6s1, m7v1, m7vs1, mab211, mac1a, mac2, mac25, macam1, macs, mad, mad211, madd, madh1, madh2, madh3, madh4, madh5, madh6, madh6, madh7, madh9, madm, madr1, maf, mafd1, mafd2, mag, mage1, mageb3, mageb4, 5 mage11, magoh, magp, magp1, magp2, mak, mal, mal1, man2a2, mana1, mana2, mana2x, manb, manb1, manba, maoa, maob, map1a, map1a1c3, map1b, map1b1c3, map2, map4, map80, map97, mapk1, mapkap3, mapkkk4, mapt, mar, mark3, mars, mas1, masp1, mat1a, mat2a, mata1, mata2, matk, matn1, matn3, max, maz, mb, mbd1, mb1, mb12, mbp, mbp1, mbs, mbs2, mcl1r, mc2r, mc3r, mc4r, mc5r, mcad, 10 mcc, mcdcl1, mcdrl1, mcf2, mcf3, mcfdl1, mch2, mch3, mch4, mch5, mckd, mcl1, mcl11, mcm, mcm2, mcm2, mcm3, mcm6, mcm7, mcmmt, mcop, mcor, mcp, mcp1, mcp3, mcph1, mcr, mcs, mcsf, mcspl, mct1, md1, mdb, mdc, mdcrl, mddc, mdeg, mdf1, mdg, mdgl, mdh1, mdh2, mdk, mdk, mdm2, mdm4, mdr1, mdr3, mdrsl, mdrv, mds, mds1, mdu1, mdu2, mdu3, mdx, mel, me2, mea, mea6, mec11, mecp2, 15 med, mef, mef2a, mef2b, mef2c, mef2d, mefv, mehmo, meis1, meis2, mekk, mekk1, mekk4, mel, mel18, melf, memol, men1, men2a, meox1, meox2, mep1a, mep1b, mer2, mer6, mest, met, metrs, mfap1, mfap2, mfap3, mfap4, mfd1, mfi2, mfs1, mfs2, mft, mfts, mg50, mga, mga1, mga3, mgat1, mgat2, mgat5, mgcl, mgcn, mgcr, mgct, mgdf, mgea, mgf, mgi, mgmt, mgp, mgsa, mgst1, mgst2, mhc, mhc2ta, mhp2, 20 mhs, mhs2, mhs3, mhs4, mhs6, mia, mic10, mic11, mic12, mic17, mic18, mic2, mic2x, mic2y, mic3, mic4, mic7, mica, micb, mid1, midas, mif, mif, mig, mip, mip2a, mip2b, mip3b, mipep, mitf, miwc, mjd, mk, mki67, mkks, mkp2, mkp3, mkpx, mks, mks, mks1, mks2, mla1, mlck, mlf1, mlf2, mlf1, mlk1, mlk3, ml1, ml12, ml1t1, ml1t2, ml1t3, ml1t4, ml1t6, ml1t7, mlm, mlm, mln, mlp, mlr, mlrg, 25 mlrw, mls, mltn, mlvar, mlvi2, mlvt, mmac1, mme, mmp1, mmp10, mmp11, mmp12, mmp13, mmp14, mmp15, mmp16, mmp17, mmp19, mmp2, mmp21, mmp22, mmp3, mmp7, mmp8, mmp9, mn, mn, mnb, mnbh, mnda, mng1, mnk, mns, mnt, mocod, mocs1, mocs2, mody1, mody3, mog, mok2, mom1, mos, mot2, mov34, mox1, mox2, mox44, moz, mp19, mpb1, mpd1, mpdz, mpe, mpe16, mpg, 30 mpi, mpif2, mp1, mp11g, mpo, mpp1, mpp2, mpp3, mppb, mpri, mprn, mps2,

-65-

mps3a, mps3c, mps4a, mpsh, mpts, mpv17, mpz, mr1, mr77, mrbc, mrc1, mre11, mre11a, mrg1, mrgh, mros, mrp, mrp1, mrp123, mrs, mrtd, mrsr, mrst, mrx1, mrx14, mrx2, mrx20, mrx21, mrx23, mrx29, mrx41, mrx48, mrx49, mrx9, mrxa, mrxs1, mrxs2, mrxs3, mrxs4, mrxs5, mrxs6, mrxs8, ms3315, ms336, msg1, msh2, msh3, msh4, msh6, msil, msk16, msk39, msk41, mslr1, msmb, msn, msr1, mss1, mss4, mss4, msse, mst, mst1, mst1r, mstd, mstn, msud1, msx1, msx2, mtl1a, mtl1b, mtl1e, mtl1f, mtl1g, mtl1h, mtl1i, mtl1j, mtl1k, mtl1l, mtl1x, mt2, mt2a, mt3, mtacr1, mtap, mtbt1, mtcp1, mterf, mtf1, mth1, mthfc, mthfd, mthfr, mtk1, mtm1, mtmr1, mtmx, mtnr1a, mtnr1b, mtp, mtpa, mtr, mtrns, mtrr, mts, mts, mts1, mts1, mts2, mttf1, mtz, mtzn, mu, muc1, muc2, muc3, muc4, muc5, muc5ac, muc5b, muc6, muc8, mu1, mum1, muppl, musk, mut, mvk, mvk, mvwf, mwfe, mx, mx1, mx2, mxil, mxs1, myb, myb11, myb12, mybpc1, mybpc2, mybpc3, mybpcf, mybph, myc, myc11, myc12, myclk1, mycn, myd88, myf3, myf4, myf5, myf6, myh1, myh10, myh11, myh12, myh2, myh3, myh4, myh6, myh7, myh8, myh9, myk1, myl1, myl11, myl12, myl3, myl4, myl5, mylk, mymy, myo10, myo15, myo1a, myo1c, myo1d, myole, myo5a, myo6, myo7a, myo9b, myoc, myod1, myog, myp1, myp2, myp3, myr5, mzfl, n33, nab1, nab2, nabcl, nacia, naca, naca, nacp, nadmr, naga, nage, naglu, nagr1, naip, namsd, nanta3, nap114, nap2, nap21, napb, naptb, nars, nat1, nat1, nat2, nb, nb4s, nbat, nbc3, nbccs, nbccs, nbial, nbs, nbs, nbs1, nca, ncad, ncam1, ncan, ncbp, ncc1, ncc2, ncc3, ncc4, ncct, ncf1, ncf2, ncf4, nck, nc1, ncst2, ncx1, ncx2, nd, ndhii, ndn, ndp, ndst1, ndufa1, ndufa2, ndufa5, ndufa6, ndufa7, ndufb8, ndufb9, ndufs1, ndufs2, ndufs4, ndufs7, ndufs8, ndufv1, ndufv2, ndufv3, neb, nec1, nec2, nedd1, nedd2, nedd4, nefh, nef1, negf1, negf2, nel11, nel112, nem1, neol, nep, net, net1, neu, neu, neud4, neurod, neurod2, neurod3, nfl, nfla, nf2, nfatc1, nfatc2, nfatp, nfe1, nfe2, nfe211, nfe212, nfe2u, nfia, nfib, nfic, nfix, nfkb1, nfkb2, nfkb3, nfkb1a, nfkb11, nfrkb, nfya, nfyb, nga1, ngbe, ngfb, ngfg, ngfic, ngfr, ng1, ngn, nhbp, nhcp1, nhcp2, nhe1, nhe3, nhe4, nhe5, nhhl1, nhhl2, nhp211, nhs, nid, niddm1, ninj1, nipp1, nipsnap1, nipsnap2, nis, nk1r, nkcc1, nkcc2, nkg2, nkg2a, nkg2c, nkg2e, nkg2f, nkhc, nkna, nkna, nknb, nknp1a, nks1, nksf2, nktr, nkx2a, nkx3.2, nkx3a, nkx6a, nli, nm, nm1, nm23, nmb, nmbr, nmdar1,

-66-

nmdar2a, nmdar2b, nmdar2c, nmdar2d, nmdara1, nme1, nme2, nme4, nmor1,  
nmor2, nms1, nmyc, nnat, nmnt, nno1, nog, noll, nos1, nos2a, nos2b, nos2c, nos3,  
not, notch1, notch2, notch3, notch4, nov, nov, nov2, noval, nova3, novp, np, np10,  
npat, npc, npc1, npd, nph1, nph2, nphl2, nphn, nphp1, nphp2, nphs1, npm1, nppa,  
5 nppb, nppc, npps, npr1, npr2, npr3, nps1, npt1, npt2, nptx2, npy, npy1r, npy2r,  
npy3r, npy5r, npy6r, nqo2, nramp, nramp1, nramp2, nrap, nras, nrb54, nrcam, nrd1,  
nrf1, nrf1, nrf2, nrgn, nrip1, nrk2, nr1, nrtn, nru, ns1, nsf, nsp, nsp11, nsrd9, nt4, nt5,  
nt5, ntcp1, ntcp2, ntf3, ntf4, ntf5, nth11, ntn, ntn, ntn21, ntrk1, ntrk2, ntrk3, ntrk4,  
ntrkr1, ntrkr3, nts, ntt, ntt, nuc1, nucb1, numa1, nup214, nup98, nurr1, nv1, nys1,  
10 nys2, nysa, oa1, oa2, oa3, oar, oas, oat, oat11, oat22, oat23, oatp, oaz, ob, ob10,  
obf1, obp, obr, oca2, ocm, ocp2, ocr1, ocr11, oct, oct1, oct1, oct2, oct2, oct3, oct7,  
octn2, octs3, odc1, odde, odf1, odg1, odod, ofc1, ofc2, ofc3, ofd1, ofe, og22, ogdh,  
ogg1, ogr1, ogs1, ogs2, ohds, ohs, oias, oip1, ok, olf1, olfmf, olfr1, olfr2, omg,  
omgp, omp, on, op2, opa1, opa2, opa3, opca3, opcm1, opd1, opgl, ophn1, op11,  
15 opn, oppg, oprd1, oprk1, oprm1, oprt, opta2, optb1, oqt1, orld2, orlf1, orc11, orc21,  
orc41, orc51, orfx, orm1, orm2, orw, osbp, osm, osp, ost, ost48, osx, otc, otf1, otf2,  
otf3, otm, otof, ots, otx1, otx2, ovc, ovcs, ovo11, ox40, oxa11, oxct, oxt, oxt, ozf, p,  
p, p1, p15, p16, p167, p28, p2rx3, p2rx4, p2ry1, p2ry2, p2ry4, p2ry7, p2u, p2x3,  
p2x4, p2y1, p2y2, p2y2, p2y4, p3p40phox, p450c11, p450c17, p450c2a, p450c2d,  
20 p450c2e, p450scc, p4ha, p4ha1, p4ha1, p4hb, p5cdh, p79r, pa2g4, pab1, pab2,  
pabp2, pabp11, pac1, pac1, pacapr, pace, pace4, paep, paf1, paf2, pafah, pafah1b1,  
pafah1b2, pafah1b3, paga, pah, pahx, pail, pai2, paics, pak1, pak3, palb, pals, pam,  
pang, pap, papa, papa2, pappa, par1, par1, par2, par3, par4, par4, par5, park1, park2,  
park3, pawr, pax1, pax2, pax3, pax4, pax5, pax6, pax7, pax8, pax9, pbca, pbca,  
25 pbfe, pbg pbt, pbx1, pbx2, pbx3, pc, pc1, pc2, pc3, pc3, pcal, pcad, pcap, pcar1,  
pcbc, pcdb, pcbp1, pcbp2, pcca, pccb, pcdh7, pcdx, pchc, pchc1, pci, pck1, pc1,  
pc1p, pcm1, pcm1, pcmt1, pcna, pcnt, pcolce, pcp, pcp4, pcs, pcsk1, pcsk2, pcsk3,  
pcsk4, pcsk5, pcsk6, pctk1, pctk3, pcyt1, pdb, pdb2, pdc, pdc, pdc1, pdc2, pddr,  
pde1a, pde1b, pde1b1, pde3b, pde4a, pde4b, pde4c, pde4d, pde5a, pde6a, pde6b,  
30 pde6c, pde6d, pde6g, pde6h, pde7a, pdea, pdea2, pdeb, pdeb, pdeg, pdes1b, pdgb,

-67-

pdgfa, pdgfb, pdgfr, pdgfra, pdgfrb, pdha1, pdha2, pdhb, pdj, pdk4, pdnp1, pdnp2,  
pdnp3, pdr, pds, pds1, pdx1, pdyn, pe1, pea15, pebp2a1, pebp2a3, pecam1, ped, ped,  
pedf, pee, peg1, peg3, pemp, penk, pent, peo, peo1, peo2, pepa, pepb, pepc, pepd,  
pepe, pepn, peps, per, per2, peta3, pets1, pex1, pex5, pex6, pex7, pf4, pf4v1, pfas,  
5 pfb1, pfc, pfd, pfhb1, pfic1, pfic2, pfkfb1, pfkfb2, pfk1, pfk-mn, pfkp, pfkx, pfl,  
pfm, pfn1, pfn2, pfrx, pga3, pga4, pga5, pgam1, pgam2, pgamm, pgc, pgd, pgf, pgft,  
pgk1, pgk2, pgka, pg1, pgl1, pgl2, pgm1, pgm2, pgm3, pgm5, pgn, pgp, pgp1, pgr,  
pgs, pgt, pgy1, pgy3, pha1, pha2, pha2a, pha2b, phap1, phb, phc, phe1a, phe3, phex,  
phf1, phhi, phhi, phk, phka1, phka2, phkb, phkd, phkg1, phkg2, ph1, phl11, phog,  
10 phox1, phox2a, php, php1b, php1, phyh, pi, pi10, pi3, pi4, pi5, pi6, pi7, pi8, pi9,  
piga, pigc, pigf, pigh, pigr, pik3c2b, pik3ca, pik3r1, pik4cb, pi1, pim1, pin, pin1,  
pin11, pip, pip5k1b, pir1, pir51, pit, pit1, pitpn, pitx1, pitx2, pitx3, pjs, pk1, pk120,  
pk3, pk428, pkca, pkcb, pkcc, pkcg, pkcs1, pkd1, pkd2, pkd4, pkdts, pkhd1, pklr,  
pkm2, pkp1, pks1, pks1, pks2, pku1, pl, pla2, pla2a, pla2b, pla2g1b, pla2g2a,  
15 pla2g4, pla2g4a, pla2g5, pla21, pla21, plag1, plag11, planh1, planh2, planh3, plat,  
plau, plaur, plb, plc, plc1, plcb3, plcb4, plcd1, plce, plc1, plc1, plc1, plc1, plc1,  
plg, plgf, plg1, pli, pln, plod, plod2, plos1, plp, pls, pls1, plt1, pltn, pltp, plzf, pmca1,  
pmca2, pmca3, pmca4, pmch, pmch11, pmch12, pmd, pme117, pmi1, pm1, pmm1,  
pmm2, pmp2, pmp22, pmp35, pmp69, pmp70, pms1, pms2, pms11, pms12, pmx1,  
20 pn1, pnd, pnem, pnkd, pnlip, pnmt, pnoc, pod1, podx1, pof, pof1, pol2rb, pola,  
polb, pold1, pold2, pole, polg, polr2a, polr2c, polr2e, polr2g, polr2i, polrmt, polz,  
pomc, pon, pon1, pon2, pon3, por, porc, potx, pou1f1, pou2af1, pou3f1, pou3f2,  
pou3f3, pou3f4, pou4f1, pou4f3, pou5f1, pp, ppl4, pp2, pp4, pp5, ppac, ppard,  
pparg, pparg1, pparg2, ppat, ppbp, ppcd, ppd, ppef1, ppef2, ppfia3, ppgb, pph, pph1,  
25 ppia, ppid, ppil1, ppkb, ppks1, ppks2, pp1, pp1a2, ppmx, ppnd, ppnoc, ppo1, ppox,  
ppp1a, ppp1ca, ppp1cb, ppp1cc, ppp1r2, ppp1r5, ppp1r7, pppd1r8, ppp2b, ppp2ca,  
ppp2cb, ppp2r1b, ppp2r4, ppp2r5a, ppp2r5b, ppp2r5c, ppp2r5d, ppp2r5e, ppp3ca,  
ppp3cb, ppp3cc, pp3r1, ppp4c, ppp5c, ppt, ppt2, ppx, ppy, ppyr1, pr@, prad1, prb1,  
prb2, prb3, prb4, prca1, prca2, prcc, prcp, pre1p, prep, prf1, prg, prg1, prg1, prgs,  
30 prh1, prh2, prim1, prim2a, prim2b, prip, prk1, prkaa1, prkaa2, prkab1, prkaca,



prkacb, prkacg, prkag1, prkag2, prkar1a, prkar1b, prkar2b, prkca, prkcb1, prkcd,  
prkcg, prkci, prkcl1, prkcnh1, prkcq, prkcsh, prkdc, prkg1, prkg1b, prkg2, prkgr1b,  
prkgr2, prkm1, prkm3, prkm4, prkm9, prkn, prkr, prkx, prky, prl, prlr, prml, prm2,  
prmt2, prnp, proa, proc, prodh, prohb, prop1, pros1, pros30, prox1, prp8, prph,  
5 prps1, prps2, pipsap1, prr1, prr2, prs, prsc1, prss1, prssl1, prss2, prss7, prss8, prss11,  
prtn3, prts, psa, psa, psach, psap, psbg1, psbg2, psc2, psc5, psca, psd, psen1, psen2,  
psf1, psf2, psg1, psg11, psg12, psg13, psg2, psg3, psg4, psg5, psg6, psg7, psg8,  
psg11, pskh1, psm, psma1, psma2, psma3, psma5, psmb1, psmb10, psmb2, psmb3,  
psmb4, psmb5, psmb8, psmb9, psmc1, psmc2, psmc3, psmc5, psmd7, psmd9,  
10 psme1, psme2, psors1, psors2, psors3, psp, psps1, psps2, pss1, psst, pst, pst, pst1,  
psti, ptafr, ptc, ptc, ptc, ptch, ptd, pten, ptgds, ptger1, ptger2, ptger3, ptgfr, ptgfrn,  
ptgir, ptgs1, ptgs2, pth, pthlh, pthr, pthr1, pthr2, ptk1, ptk2, ptk2b, ptk3, ptk7, ptlah,  
ptma, ptms, ptn, ptos1, ptp18, ptp1b, ptp4a1, ptp4a2, ptpa, ptpa, ptpd, ptpg, ptpg1,  
ptpgmc1, ptpn1, ptpn10, ptpn11, ptpn12, ptpn13, ptpn14, ptpn2, ptpn5, ptpn6,  
15 ptpn7, ptpra, ptprb, ptprc, ptprcap, ptprd, ptpre, ptp rf, ptp rg, ptp rh, ptp rj, ptp rk,  
ptprl1, ptp rl2, ptp rm, ptp rn, ptp ro, ptp rs, ptp rz1, ptp t, ptp ts, ptp slr, ptp x1, ptp x3, pujo,  
pum, pur1, pur1, pura, pvalb, pvr, pvr11, pvr12, pvrr1, pvrr2, pvs, pvt1, pwcr, pwp2,  
pwp2h, pws, pxaal1, pxe, pxe1, pxf, pxmp1, pxmp11, pxmp3, pxr1, pycr1, pycs,  
pygb, pyg1, pygm, pyk2, pyst1, pyst2, pzp, qars, qdpr, qin, qm, qpc, qprs, rab, rab1,  
20 rab13, rab1a, rab21, rab3a, rab3b, rab4, rab5, rab5a, rab6, rab7, rabgdla, rabgdib,  
rabggta, rabggtb, rabif, rac2, rac3, rad1, rad17, rad23a, rad23b, rad51a, rad51c,  
rad51d, rad5311, rad52, rad54, rad6a, rad6b, raf1, rafal, rag1, rag2, rage, rala, ralb,  
ralgds, ramp, ranbp211, ranbp3, rao, rap1a, rap1b, rap1ga1, rap1gds1, rap2a, rap74,  
rapsn, rara, rarb, rarg, rars, rasa1, rasa2, rasgfr3, rask2, rb1, rbbp2, rbbp5, rbbp6,  
25 rb11, rb12, rbm1, rbm2, rbm3, rbmy1a1, rbp1, rbp2, rbp3, rbp4, rbp5, rbp56, rbp6,  
rbq3, rbtn1, rbtn11, rbtn12, rc1, rcac@, rcc1, rccp1, rccp2, rcd1, rcd2, rcdp1, rcn1,  
rcn2, rcp, rcv1, rd, rdbp, rdc7, rdp, rdpa, rdrc, rds, rdt, rdx, reca, recc1, recq1, red1,  
red2, reg, reg1a, reg1, re1, rela, reln, ren, renbp, rens1, rent1, rep8, req, ret, rev3,  
rev31, rfc1, rfc2, rfc3, rfc4, rfc5, rfp, rfx1, rfx2, rfx5, rfxank, rfxap, rgc1, rgr, rgs,  
30 rgs1, rgs14, rgs16, rgs2, rgs2, rgs3, rgs5, rh50a, rhag, rhbd1, rhc, rhce, rhd, rheb2,

rho, rho7, rhogap2, rhogap3, rhoh12, rhoh6, rhoh9, rhok, rhom1, rhom2, rhom3,  
rieg1, rieg2, rige, rigui, ring1, ring10, ring11, ring12, ring3, ring31, ring4, ring5,  
ring6, ring7, rip, rip140, riz, rk, r1, r1bp1, rlf, rln1, rln2, rmch1, rmd1, rmrp, rmrpr,  
rn5s1@, rnase1, rnase2, rnase3, rnase4, rnase5, rnase6, rnase1, rnase1, rnel, rnfl,  
5 rnf3, rnf4, rnf5, rnh, rnpep, rnpulz, rnr1, rnr2, rnr3, rnr4, rnr5, rns1, rns2, rns3, rns4,  
rns4, rns4i, rntmi, rnu1, rnu15a, rnu17a, rnu17b, rnula, rnu2, rnu3, ro52, rom1,  
romk1, ron, ror1, rora, rorb, rorc, rorg, ros1, rosp1, rox, rp1, rp10, rp105, rp11, rp12,  
rp13, rp14, rp15, rp17, rp18, rp19, rp2, rp22, rp24, rp25, rp3, rp4, rp6, rp7, rp9,  
rpa1, rpa2, rpa3, rpd311, rpe, rpe65, rpe119rp122, rp123a, rp1231, rp129, rp130,  
10 rp135a, rp136a, rp17a, rpms12, rpn1, rpn2, rpo12, rps11, rps14, rps17, rps17a,  
rps17b, rps1711, rps1712, rps18, rps20a, rps20b, rps24, rps25, rps3, rps4x, rps4y,  
rps6, rps6ka1, rps6ka2, rps6ka3, rps8, rpsm12, rptpm, rpu1, rpx, rrad, rras, rrbp1,  
rreb1, rrm1, rrm2, rrp, rrp22, rs1, rs1, rscl1, rsk1, rsk2, rsk3, rsn, rss, rsts, rsu1, rt6,  
rtefl, rtkn, rtn1, rtn2, rts, rts, rtt, rws, rxra, rxrb, rxrg, ryr1, ryr2, ryr3, rzrb, rzrg,  
15 s100a1, s100a10, s100a11, s100a12, s100a13, s100a2, s100a3, s100a4, s100a5,  
s100a6, s100a7, s100a8, s100a9, s100b, s100d, s100e, s100, s100p, s152, s4, s7,  
saa1, saa2, saa4, sacs, safb, sag, sah, sahh, sail, sakap84, sal11, sal12, sams1,  
sams2, sap, sap1, sap1, sap2, sap62, sar, sar1, sar2, sard, sas, sat, satb1, satt, sbma,  
sc, sc1, sc5d1, sca1, sca10, sca2, sca2, sca3, sca4, sca5, sca6, sca7, sca8, sca8, scar,  
20 scca1, scca2, sccd, scd, sceh, scg1, scg2, scg3, schad, scida, scidx, scidx1, sc1, sclc1,  
scl1, scn, scn1a, scn1b, scn2a, scn2a1, scn2a2, scn2b, scn3a, scn4a, scn5a, scn6a,  
scn8a, scn11a, scn11b, scn11d, scn11g, scot, scp, scp1, scp2, scpn, scral, scral, scs,  
sctr, scya1, scya11, scya13, scya14, scya15, scya16, scya19, scya2, scya21, scya22,  
scya24, scya25, scya3, scya311, scya4, scya5, scya7, scya8, scyb5, scyb6, scyd1,  
25 sczd1, sczd2, sczd3, sczd4, sczd5, sczd6, sczd7, sczd8, sdc1, sdc2, sdc4, sdf1, sdf2,  
sdh1, sdh2, sdha, sdhb, sdhc, sdhd, sdhf, sds22, sdty3, sdys, se, sea, sec1311, sec13r,  
sec14l, sec7, sed1, sedt, sef2, sel11, sele, sel1, selp, selp1g, sema3f, sema4, sema5,  
semg, semg1, semg2, sen1, sep, sepp1, sercal, serca3, serk1, ses1, set, sex, sf, sfl,  
sfa1, sfd, sfmd, sfrs1, sfrs2, sfrs7, sftb3, sftp1, sftp2, sftp4, sftpa1, sftpa2, sftpb,  
30 sftpc, sftpd, sgb, sgca, sgcb, sgcd, sgcg, sgd, sgk, sglt1, sglt2, sgm1, sgne1, sgp2,

-70-

sgpa, sgsh, sh2d1a, sh3bp2, sh3d1a, sh3gbr, sh3p17, shb, shbg, shc1, shc11, shfd1, shfd2, shfm1, shfm2, shfm3, shh, ship, shmt1, shmt2, shoc2, shot, shox, shox2, shps1, shs, shsf1, si, siah1, siah2, siasd, siat1, siat4, siat4c, siat8, sids, si1, silv, sim1, sim2, sipa1, sis, siv, six1, six5, sja, sjs, ski, ski2, ski2w, skiv21, skp1a, skp1b, skp2, sla, slap, slbp, slc, slc10a1, slc10a2, slc12a1, slc12a2, slc12a3, slc14a1, slc14a2, slc15a1, slc16a1, slc16a2, slc17a1, slc17a2, slc18a1, slc18a2, slc18a3, slc19a1, slc1a1, slc1a2, slc1a3, slc1a4, slc1a5, slc20a1, slc20a2, slc20a3, slc21a2, slc21a3, slc22a1, slc22a2, slc22a5, slc2a1, slc2a2, slc2a3, slc2a4, slc2a5, slc2c, slc3a1, slc4a1, slc4a2, slc4a6, slc5a1, slc5a2, slc5a3, slc5a5, slc6a1, slc6a10, slc6a12, slc6a2, slc6a3, slc6a4, slc6a6, slc6a8, slc6a9, slc7a1, slc7a2, slc7a4, slc7a5, slc7a7, slc8a1, slc8a2, slc9a1, slc9a2, slc9a3, slc9a4, slc9a5, sld, sle1, sleb1, slim1, sln, slo, slos, slp76, sls, slug, sm1, sm22, sma4, smad1, smad1, smad2, smad3, smad4, smad5, smad6, smad7, smad9, sma1, smam1, smarcal, smarca2, smarca3, smarca5, smarcbl, smax2, smc1, smcc, smcr, smcx, smcy, sml1, smn, smn1, smn2, smnr, smo, smoh, smpd1, sms, smt3, smt3h1, smtn, smubp2, sn, snap25, snat, snca, sncb, sncg, snf2h, snf211, snf212, snf213, snf5, sn1, snn, snrp70, snrpa, snrpe, snrpn, snt1, snt2b1, snt2b2, sntb1, snt1, snx, soat, sod1, sod2, sod3, solh, son, sord, sor11, sos1, sos2, sox1, sox10, sox11, sox2, sox20, sox22, sox3, sox4, sox9, sp1, sp1, sp3, sp3, sp4, spa1, spag1, spag4, spam1, sparc, spat, spbp, spch1, spd, spf30, spg3a, spg4, spg5a, spg6, spg7, spg8, spg9, spgp, spgyla, sph2, spi1, spink1, spk, spmd, spn, spp1, spp2, sppm, spr, sprk, sprr1a, sprr1b, sprr2a, sprr2b, sprr2c, sprr3, sps1, spsma, spta1, sptan1, sptb, sptbn1, sra1, sra2, src, src1, src1, src2, srd5a1, srd5a2, srebf1, srebf2, sri, srk, srm, sm1, srp14, srp19, srp46, srpr, srpx, srs, srvx, sry, ss, ss, ssa, ssa1, ssa2, ssadh, ssav1, ssbp, ssdd, ssr2, ssr2, ssr3, sstr1, sstr2, sstr3, sstr4, sstr5, ssx1, ssxt, st2, st3, st4, st5, st6, st8, sta, stac, stam, star, stat, stat1, stat3, stat4, stat5, ssx1, stc1, stch, std, std, ste, step, stf1, stfa, stfb, stgd1, stgd2, stgd3, stgd4, sthe, stk1, stk11, stk15, stk2, stk6, st1, stm, stm2, stm7, stmy1, stmy2, stmy3, stp, stp1, stp2, sts, sts1, stx, stxbp1, stxbp2, sultlc1, supt6h, sur, sur1, surf1, surf2, surf3, surf4, surf5, surf6, svct2, svmt, sw, sxi2, syb1, syb2, syb11, sycp1, syk, sym1, syn1, syn2, syn3, syngap, syns1, syp, syt, syt1, syt2, syt3, syt4, syt5, t, t3d, taa16,

-71-

tac1r, tac2, tac2r, tac3, tacr1, tacr2, taf2, taf2a, taf2a, taf2d, taf2h, taf2n, tafii100,  
tagln, tak1, tal1, tal2, taldo1, tam, tan1, tap1, tap2, tapa1, tapbp, tapvr1, tars, tas,  
task, tat, taut, tax, tax1, taz, tbg, tbg, tdp1, tbs, tbx1, tbx2, tbx3, tbx5, tbxa2r, tbxas1,  
tc1, tc2, tcbp, tcd, tcea1, tceb11, tceb3, tcf1, tcf12, tcf13, tcf1311, tcf14, tcf15, tcf17,  
tcf19, tcf2, tcf20, tcf21, tcf3, tcf4, tcf5, tcf611, tcf612, tcf7, tcf8, tcf9, tcfef, tcf11,  
tcf14, tcl1, tella, tel2, tel3, tel4, tel5, tcn1, tcn2, tco, tcof1, tcp1, tcp10, tcp11,  
tcp228, tcpt, tcra, tcrb, tcrd, tcrq, tcrz, tes1, teta, tetel, tete3, tete11, tdf, tdfa, tdfx,  
tdg, tdgl1, tdn, tdo, tdo2, tdt, tead4, tec, tec, teck, tecta, tef, tegt, tek, tel, tem, tep1,  
terc, terfl, tert, tes1, tesk1, tex28, tf, tf2s, tf6, tfa, tfam, tfap2a, tfap2b, tfap2c, tfap4,  
tfecoup1, tfecoup2, tfep2, tfdp1, tfdp2, tfe3, tff1, tff2, tff3, tffiia, tfn, tfpi, tfpi2, tfr,  
tffc, tfs1, tft, tg, tg737, tgb1, tgb2, tgd, tgfa, tgfb1, tgfb2, tgfb3, tgfb4, tgfb, tgfb1,  
tgfb2, tgfb3, tgfbre, tgfr, tgm1, tgm2, tgm3, tgm4, tgn38, tgn46, th, thas, thbd,  
thbp1, thbs1, thbs2, thbs3, thc, thh, th1, thop1, thpo, thr1, thra, thra1, thra1, thrb,  
thrmm, thrsp, thy1, tia1, tiam1, tiar, tic, tie, tie1, tie2, tigr, til, til3, til4, tim, timp,  
timp1, timp2, timp3, tinur, titf1, titf2, tj1, tk1, tk2, tkc, tkcr, tkr, tkt, tkt2, tkt11,  
tila519, tlc, tile1, tile2, tile3, tlh1, tln, tlr1, tlr2, tlr3, tlr4, tlr5, tm4sf1, tm4sf2, tm7sf2,  
tmc, tmd, tmdci, tmem1, tmf1, tmip, tmod, tmp, tmpo, tmprss2, tms, tmsa, tmsb,  
tmvcf, tna, tandm, tn, tnfa, tnfaip1, tnfaip2, tnfaip4, tnfaip6, tnfar, tnfb, tnfb, tnfc,  
tnfcr, tnfr1, tnfr2, tnfrsf10b, tnfrsf12, tnfrsf14, tnfrsf16, tnfrsf17, tnfrsf1a, tnfrsf1b,  
tnfrsf4, tnfrsf5, tnfrsf6, tnfrsf6b, tnfrsf7, tnfrsf8, tnfrsf9, tnfrsf11, tnfrsf12, tnfrsf5,  
tnfrsf6, tnfrsf7, tnnc1, tnnc2, tnai1, tnai2, tnai3, tnnt1, tnnt2, tnnt3, tnp1, tnp2, tnr,  
tns, tn timer, toc, top1, top2, top2a, top2b, top3, tp1, tp120, tp250, tp53, tp53bp2,  
tp63, tp73, tpa, tpb, tpc, tpc, tph, tph2, tpi1, tp12, tpm1, tpm2, tpm3, tpm4, tpmt,  
tpo, tpo, tpp2, tpr, tpr1, tprd, tps1, tps2, tpsn, tpst1, tpst2, tpt, tpt1, ttps, tpx, tpx1,  
tr, tr2, tr4, tra1, traf1, traf5, trailr2, tran, trance, trap170, trec3, trec8, tre, treb36, trek,  
trf1, trg1, trh, trhr, tric5, trio, trip1, trip14, trip6, trk, trk1, trka, trkb, trkc, trke, trl1,  
trl2, trm1, trm1, trm2, trma, trmi1, trmi2, trn, trn1, tro, trp1, trp1, trp2, trp3, trpc1,  
trpm2, trpo, trps1, trps2, trq1, trr, trr3, trrap, trsp, trtl, trt2, trv1, trv2, trv3, trv4, trv5,  
try1, try2, ts, ts13, ts546, tsbn51, tsc tsc1, tsc2, tsd, tse1, tsg101, tsg7, tshb, tshr, tsix,  
ts3, tspy, tscc3, tst1, tst1, tsat3, tsy, ttcl, ttcl, ttcl, ttcl, ttcl, ttcl, ttcl, ttcl, ttcl, ttcl,

-72-

ttpa, ttr, tuba3, tuba11, tubb, tufm, tuft1, tulp1, tuple1, tw, tweak, twik1, twist,  
txgp11, txk, txn, txnr, txnrd1, tyh, tyk1, tyk2, tyk3, tyms, tyr, tyr1, tyro3, tyrp1,  
tyrp2, tys, u17hg, ulmp, u22hg, u2af1, u2af1rs1, u2af1rs2, u2af1rs3, uba52, ubb, ubc,  
ubc4, ubc7, ubc8, ubch2, ubc1, ube1, ube2, ube2a, ube2b, ube2e2, ube2g, ube2g2,  
5 ube2h, ube2i, ube211, ube2v1, ube3a, ubh1, ubid4, ub11, uch11, ucn, ucp1, ucp2,  
ucp3, udpgdh, uev1, ufd11, ufs, ugalt, ugb, ugcg, ugdh, ugn, ugp1, ugp2, ugpp2,  
ugt1, ugt1a1, ugt2b11, ugt2b15, ugt2b17, ugt2b4, ugt2b7, ugt2b8, ugt2b9, ugt1, uhg,  
uhx1, ukhc, umod, umph2, umpk, umps, unc18, unc18b, und, ung, unr, unr, uox, up,  
upk1b, ups, uqbp, uqcrb, uqcrc1, uqcrc2, uqcrfs1, uqor1, uqor13, uqor22, urk, urkr,  
10 uroc, urod, uros, usf1, usf2, ush1, ush1a, ush1b, ush1c, ush1d, ush1e, ush1f, ush2a,  
ush3, usp11, usp5, usp7, usp9x, usp9y, ut1, ut2, ute, utr, utrn, utx, uty, uv20, uv24,  
uvo, vacht, vacm1, vamp1, vamp2, vars1, vasp, vat1, vat2, vav, vav1, vav2, vbch,  
vbp1, vcam1, vcf, vc1, vcp, vdac1, vdac2, vdd1, vdi, vdr, vegf, vegfb, vegfd, vegfr3,  
vgf, vgl, vgr1, vh1, vhr, vil1, vil2, vim, vip, vipr1, vipr2, vis1, vla1, vla5a, vlacs,  
15 vlcad, vldlr, vmat1, vmcm, vmd1, vmd2, vnra, vnt, vp, vpp1, vpp3, vpreb1, vpreb2,  
vrf, vrk1, vrk2, vrnf, vrni, vsn11, vtn, vwf, vws, waf1, wars, was, wbs, wd1, wdr2,  
weel, wfrs, wfs, wfs1, wgn1, whcr, wi, wisp1, wisp2, wisp3, wnd, wnt1, wnt10b,  
wnt13, wnt14, wnt15, wnt2, wnt3, wnt5a, wnt7a, wnt7b, wnt8b, wrb, wrn, ws1,  
ws2a, ws2b, ws4, wsn, wss, wss, wt1, wt2, wt3, wt4, wt5, wts, wts1, wws, x11,  
20 xbp1, xbp2, xce, xdh, xe169, xe7, xe7y, xg, xgr, xh2, xiap, xic, xist, xk, xla, xla2,  
xlp, xlpd, xlrsl, xm, xpa, xpb, xpc, xpcc, xpct, xpf, xpf, xpg, xpmc2h, xpnpep2,  
xpo1, xrcc1, xrcc2, xrcc3, xrcc4, xrcc5, xrcc9, xrs, xs, xwnt2, yb1, yes1, yk140, y11,  
yrrm1, yt, ywha1, ywhab, ywhah, ywhaz, yy1, zac, zag, zan, zap70, zf87, zfm1,  
zfp3, zfp36, zfp37, zfx, zfy, zic1, zic2, zic3, zipk, znf1, znf10, znf117, znf11a,  
25 znf11b, znf12, znf121, znf123, znf124, znf125, znf126, znf13, znf14, znf141,  
znf144, znf146, znf147, znf157, znf16, znf160, znf162, znf163, znf165, znf169,  
znf173, znf179, znf189, znf19, znf192, znf193, znf195, znf198, znf2, znf20, znf200,  
znf204, znf217, znf22, znf23, znf24, znf25, znf26, znf27, znf29, znf3, znf32, znf34,  
znf35, znf36, znf38, znf4, znf40, znf41, znf42, znf44, znf45, znf46, znf5, znf6,  
30 znf69, znf7, znf70, znf71, znf72, znf73, znf74, znf75, znf75a, znf75c, znf76, znf77,

-73-

znf79, znf8, znf80, znf81, znf83, znf9, znfc150, znfc25, znfx, znt3, znt4, zp3a, zp3b, zpk, zws1, and zyx.

Furthermore, genes from bacteria, plants, yeast, and mammals (*e.g.*, mice) can be used with the microorganisms provided herein. Non-limiting examples of *E. coli* genes include:

5 aarF, aas, aat, abpS, abs, accA, accB, accC, accD, acd, aceA, aceB, aceE, aceF, aceK, ackA, ackB, acnA, acnB, acpD, acpP, acpS, acpX, acrA, acrB, acrC, acrD, acrE, acrF, acrR, acs, ada, add, adhB, adhC, adhE, adhR, adiA, adiY, adk, aegA, aer, aes, agaA, agaB, agaC, agaD, agaI, agaR, agaS, agaV, agaW, agaZ, agp, ahpC, ahpF, aidB, ais, alaS, alaT, alaU, alaV, alaW, alaX, aldA, aldB,

10 aldH, alkA, alkB, alpA, alr, alsA, alsB, alsC, alsE, alsK, alx, amiA, amiB, amn, ampC, ampD, ampE, ampG, ampH, amtB, amyA, ansA, ansB, apaG, apaH, aphA, appA, appB, appC, appY, apt, aqpZ, araA, araB, araC, araD, araE, araF, araG, araH, araJ, arcA, arcB, argA, argB, argC, argD, argE, argF, argG, argH, argI, argM, argP, argQ, argR, argS, argT, argU, argV, argW, argX, argY, argZ, aroA, aroB, aroC,

15 aroD, aroE, aroF, aroG, aroH, aroI, aroK, aroL, aroM, aroP, aroT, arsB, arsC, arsR, artI, artJ, artM, artP, artQ, ascB, ascF, ascG, asd, aslA, aslB, asmA, asnA, asnB, asnC, asnS, asnT, asnU, asnV, asnW, aspA, aspC, aspS, aspT, aspU, aspV, asr, asu, atoA, atoB, atoC, atoD, atoS, atpA, atpB, atpC, atpD, atpE, atpF, atpG, atpH, atpI, avtA, azaA, azaB, azl, bacA, baeR, baeS, barA, basR, basS, bax, bcp, bcr, betA,

20 betB, betI, betT, bfd, bfm, bfr, bglA, bglB, bglF, bglG, bglJ, bglT, bglX, bioA, bioB, bioC, bioD, bioF, bioH, bioP, bipA, birA, bisC, bisZ, blc, bolA, bRNQ, brnR, brnS brnT, btuB, btuc, btuD, btuE, btuR, bymA, cadA, cadB, cadC, cafA, caiA, caiB, caiC, caiD, caiE, caiF, caiT, calA, caiC, calD, can, carA, carB, cbl, cbpA, cbt, cca, ccmA, ccmB, ccmC, ccmD, ccmE, ccmF, ccmG, ccmH, cdd, cde, cdh, cdsA, cdsS,

25 cedA, celA, celB, celC, celD, celF, cfa, cfcA, chaA, chaB, chaC, cheA, cheB, cheR, cheW, cheY, cheZ, chpA, chpB, chpR, chpS, cirA, citA, citB, cld, cipA, clpB, clpP, clpX, cls, cmk, cmlA, cmr, cmtA, cmtB, coaA, cobS, cobT, cobU, codA, codB, cof, cog?, corA, cpdA, cpdB, cpsA, cpsB, cpsC, cpsD, cpsE, cpsF, cpsG, cpxA, cpxB, cpxP, cpxR, crcA, crcB, creA, creB, creC, creD, crg, crl, crp, crr, csdA, csgA, csgB,

30 csgD, csgE, csgF, csgG, csiA, csiB, csiC, csiD, csiE, csiF, cspA, cspB, cspC, cspD,

-74-

cspE, cspG, csrA, csrB, cstA, cstC, cup, cutA, cutC, cutE, cutF, cvaA(ColV),  
 cvaB(ColV), cvaC(Co-IV), cvi(ColV), cvpA, cxm, cyaA, cybB, cybC, cycA, cydA,  
 cydB, cydC, cydD, cynR, cynS, cynT, cynX, cyoA, cyoB, cyoC, cyoD, cyoE, cysA,  
 cysB, cysC, cysD, cysE, cysG, cysH, cysI, cysJ, cysK, cysM, cysN, cysP, cysQ,  
 5 cysS, cysT, cysU, cysW, cysX?, cysZ?, cytR, dacA, dacB, dacC, dacD, dadA, dadB,  
 dadQ, dadX, dam, dapA, dapB, dapD, dapE, dapF, dbpA, dcd, dcm, dcp, dcrB, dctA,  
 dctB, dcuA, dcuB, dcuC, ddIA, ddIB, ddpA, ddpB, ddpC, ddpD, ddpF, ddpX, deaD,  
 dedA, dedD, def, degP, degQ, degS, del, deoA, deoB, deoC, deoD, deoR, dfp, dgd,  
 dgkA, dgkR, dgoA, dgoD, dgoK, dgoR, dgoT, dgsA, dgt, dicA, dicB, dicC, dicF,  
 10 dinB, dinD, dinF, dinG, dinI, dinY, dipZ, djIA, dksA, dld, dmsA, dmsB, dmsC,  
 dnaA, dnaB, dnaC, dnaE, dnaG, dnaI, dnaJ, dnaK, dnaL, dnaN, dnaQ, dnaT, dnaX,  
 dppA, dppB, dppC, dppD, dppF, dppG, dps, dsbA, dsbB, dsbC, dsbG, dsdA, dsdC,  
 dsdX, dsrA, dsrB, dut, dvl, dxs, ebgA, ebgB, ebgC, ebgR, ecfa, eco, ecpD, eda, edd,  
 efp, enrA, emrB, emrD, emrE, endA, eno, entA, entB, entC, entD, entE, entF, envN  
 15 envP, envQ, envR, envT, envY, envZ, epd, EppA, minigene, EppB, minigene,  
 EppC, minigene, EppD, minigene, EppE, minigene, EppG, minigene, EppH,  
 minigene, era, esp, evgA, evgS, exbB, exbC, exbD, expA, exuR, exuT, fabA, fabB,  
 fabD, fabF, fabG, fabH, fabI, fabZ, fadA, fadB, fadD, fadE, fadH, fadL, fadR, farR,  
 fatA, fbaA, fbaB, fbp, fcl, fcsA, fdhD, fdhE, fdhF, fdnG, fdnH, fdnI, fdoG, fdoH,  
 20 fdoI, fdrA, fdx, feaB, feaR, fecA, fecB, fecC, fecD, fecE, fecI, fecR, feoA, feoB,  
 fepA, fepB, fepC, fepD, fepE, fepG, fes, fexB, ffh, ffs, fhIA, fhIB, fhuA, fhuB,  
 fhuD, fhuE, fhuF, fic, fimA, fimB, fimC, fimD, fimE, fimF, fimG, fimH, fimI, fipB,  
 fipC, fis, fiu, fixA, fixB, fixC, fixX, fklB, fkpA, fldA, flgA, flgB, flgC, flgD, flgE,  
 flgF, flgG, flgH, flgI, flgJ, flgK, flgL, flgM, flgN, flhA, flhB, flhc, flhD, fliA, fliC,  
 25 fliD, fliE, fliF, fliG, fliH, fliI, fliJ, fliK, fliL, fliM, fliN, fliO, flip, fliQ, fliR, fliS,  
 fliT, fliY, fliZ, flk, flu, fnt, fnr, focA, focB, folA, folC, folD, folE, folK, folP, folX,  
 fpr, frdA, frdB, frdC, frdD, fnr, fruA, fruB, fruK, fruR, fsr, ftn, ftsA, ftsE, ftsI, ftsJ,  
 ftsK, ftsL, ftsN, ftsQ, ftsW, ftsX, ftsY, ftsZ, fucA, fucI, fucK, fucO, fucP, fucR,  
 fumA, fumB, fumC, fur, fusA, fusB, gabC, gabD, gabP, gabT, gadA, gadB, gadR,  
 30 galE, galF, galK, galM, galP, gaiR, galS, galT, galU, gapA, gapC, garA, garB, gatA,

-75-

gatB, gatC, gatD, gatR, gatY, gatZ, gcd, gcl, gcpE, gcvA, gcvH, gcvP, gcvR, gcvT,  
 gdhA, gef, ggt, gidA, gidB, gip, glcB, glcC, glcD, glcE, glcG, gldA, glf, glgA, glgB,  
 glgC, glgP, glgS, glgX, glk, glmM, glmS, glmU, glmX, glnA, glnB, glnD, glnE,  
 glnG, glnH, glnK, glhL, glnP, glnQ, glnR, glnS, glnT, glnU, glnV, glnW, glnX,  
 5 gloA, glpA, glpB, glpC, glpD, gipE, gipF, gipG, glpK, glpQ, gipR, glpT, glpX,  
 gltA, gltB, gltD, gltE, gltF, gltH, gltJ, gltK, gltL, gltM, gltP, gltR, gltS, gltT, gltU,  
 gltv, gltW, gltX, glyA, glyQ, glyS, glyT, glyU, glyv, glyW, glyX, glyY, gmd, gmk,  
 gmm, gnd, gntK, gntP, gntR, gntS, gntT, gntU, gntV, goaG, gor, gph, gpmA, gpp,  
 gprA, gprB, gpsA, gpt, greA, greB, groL, groS, grpE, grxA, grxB, grxC, gshA,  
 10 gshB, gsk, gsp, gsp\*, gst, guaA, guaB, guaC, gurB, gurC, gutM, gutQ, gyrA, gyrB,  
 hcaB, hcaC, hcaD, hcaE, hcaF, hcaR, hcaT, hdeA, hdeB, hdeD, hdeH, hdeI, hdeJ, hdeK,  
 hemB, hemC, hemD, hemE, hemF, hemG, hemH, hemK, hemL, hemM, hemX,  
 hemY, hepA, het, hflB, hflC, hflK, hflX, hfq, hha, hipA, hipB, hisA, hisB, hisC,  
 hisD, hisF, hisG, hisH, hisI, hisJ, hisM, hisP, hisQ, hisR, hisS, hipA, hlyE, hmp, hns,  
 15 holA, holB, holC, holD, holE, hopB, hopC, hopD, hpt, hrpA, hrpB, hrsA, hscA,  
 hscB, hsdM, hsdR, hsdS, hslC, hslD?, hslE-H, hslJ, hslK, hslL-N, hslO-R, hslU,  
 hslV, hslW, htgA, htpG, htpX, htrB, htrC, htrE, htrL, hupA, hupB, hyaA, hyaB,  
 hyaC, hyaD, hyaE, hyaF, hybA, hybB, hybC, hybD, hybE, hybF, hybG, hycA,  
 hycB, hycC, hycD, hycE, hycF, hycG, hycH, hycI, hydA, hydG, hydH, hydN, hyfA,  
 20 hyfB, hyfC, hyfD, hyfE, hyfF, hyfG, hyfH, hyfI, hyfJ, hyfR, hypA, hypB, hypC,  
 hypD, hypE, hypF, iadA, iap, ibpA, ibpB, icd, iclR, ihfA, ihfB, ileR, ileS, ileT, ileU,  
 ileV, ileX, ileY, ilvA, ilvB, ilvC, ilvD, ilvE, ilvF, ilvG, ilvH, ilvI, ilvJ, ilvM, ilvN,  
 ilvR, ilvU, ilvY, imp, inaA, inaR?, infA, infB, infC, inm, insA(IS1), intA, isb(IS1),  
 isfA, ispA, ispB, KanR, katE, katG, kba, kbl, kch, kdgK, kdgR, kdgT, kdpA, kdpB,  
 25 kdpC, kdpD, kdpE, kdpF, kdsA, kdsB, kdtA, kdtB, kefB, kefC, kgtp, ksgA, ksgB,  
 ksgC, ksgD, lacA, lacI, lacY, lacZ, lamB, lar, ldcC, ldhA, lepA, lepB, leuA, leuB,  
 leuC, leuD, leuJ, leuO, leuP, leuQ, leuR, leuS, leuT, leuU, leuV, leuW, leuX, leuY,  
 leuZ, lev, lexA, lgt, lhr, ligA, ligT, linB, lipA, lipB, lit, livF, livG, livH, livJ, livK,  
 livM, lldD, lldP, lldR, lolA, lon, lpcA, lpcB, lpd, lplA, lpp, lpxA, lpxB, lpxC, lpxD,  
 30 lpxK, lrb, lrhA, lrp, lrs, lspA, lysA, lysC, lysP, lysQ, lysR, lysS, lysT, lysU, lysV,



-76-

lysW, lysX, lysY, lysZ, lytA, lytB, lyx, maa, mac, mae, mafA, mafB, malE, malF,  
 malG, malI, malK, malM, malP, malQ, malS, malT, malX, malY, malZ, manA,  
 manC, manX, manY, manZ, map, marA, marB, marR, mbrB, mcrA, mcrB, mcrC,  
 mcrD, mdaB, mdh, mdoB, mdoG, mdoH, meb, melA, melB, melR, menA, menB,  
 5 menC, menD, menE, menF, mepA, mesJ, metA, metB, metC, metD, metE, metF,  
 metG, metH, metJ, metK, metL, metR, metT, metU, metV, metW, metY, metZ, mfd,  
 mglA, mglB, mglC, mglR, mgsA, mgtA, mhpA, mhpB, mhpC, mhpD, mhpE, mhpF,  
 mhpR, miaA, miaD, micF, minC, minD, minE, mioC, mltA, mltB, mltC, mltD,  
 mmrA(rhlB?), mng, mntA, moaA, moaB, moaC, moaD, moaE, mobA, mobB, moc,  
 10 modA, modB, modC, modE, modF, moeA, moeB, mog, molR, motA, motB, mpl,  
 mppA, mprA, mraA--?, mraY, mrcA, mrcB, mrdA, mrdB, mreB, mreC, mreD, mrp,  
 mrr, msbA, msbB, mscL, msrA, msyB, mtg, mtgA, mtlA, mtlD, mtlR, mtr, mttA,  
 mttB, mttC, mukB, mukE, mukF, mul, murA, murB, murC, murD, murE, murF,  
 murG, murH, murI, mutG(putative), mutH, mutL, mutM, mutS, mutT, mutY, nac,  
 15 nadA, nadB, nadC, nadE, nagA, nagB, nagC, nagD, nagE, nalB, nalD, nanA, nanE,  
 nanK, nanR, nanT, napA, napB, napC, napD, napF, napG, napH, narG, narH, narI,  
 narJ, narK, narL, narP, narQ, narU, narV, narW, narX, narY, narZ, ndh, ndk, neaB,  
 nei, nemA, nfi, nfnA, nfnB, nfo, nfrA, nfrB, nfrD, nfsA, nhaA, nhaB, nhaR, nikA,  
 nikB, nikC, nikD, nikE, nirB, nirC, nirD, nlpA, nlpB, nlpC, nlpD, nmpC(qsr'), non,  
 20 npr, nrdA, nrdB, nrdD, nrdE, nrdF, nrdG, nrfA, nrfB, nrfC, nrfD, nrfE, nrfF, nrfG,  
 nth, ntpA, nuoA, nuoB, nuoC, nuoE, nuoF, nuoG, nuoH, nuoI, nuoJ, nuoK, nuoL,  
 nuoM, nuoN, nupC, nupG, nusA, nusB, nusG, nuvA, nuvC, ogrK, ogt, ompA,  
 ompC, ompF, ompG, ompR, ompT, ompX, oppA, oppB, oppC, oppD, oppE, oppF,  
 opr, ops, oraA, ordL, orf-23(purB, reg)orf195(nikA-reg), orn, osmB, osmC, osmE,  
 25 osmY, otsA, otsB, oxyR, oxyS, pabA, pabB, pabC, pac, pal, panB, panC, panD,  
 panF, parC, parE, pat, pbpG, pck, pcm, pcnB, pdhR, pdxA, pdxB, pdxH, pdxJ,  
 pdxK, pdxL, pdxY, pepA, pepD, pepE, pepN, pepP, pepQ, pepT, pfkA, pfkB, pflA,  
 pflB, pflC, pflD, pfs, pgi, pgk, pgl, pgm, pgpA, pgpB, pgsA, pheA, pheP, pheS,  
 pheT, pheU, pheV, phnC, phnD, phnE, phnF, phnG, phnH, phnI, phnJ, phnK, phnL,  
 30 phnM, phnN, phnO, phnP, phoA, phoB, phoE, phoH, phoP, phoQ, phoR, phoU,

-77-

phrB, phxB, pin, pioO, pit, pldA, pldB, plsB, plsC, plsX, pmbA, pncA, pncB, pnp,  
 pntA, pntB, pnuC, poaR, polA, polB, popD, potA, potB, potC, potD, potE, potF,  
 potG, potH, potI, poxA, poxB, ppa, ppc, pphA, pphB, ppiA, ppiB, ppiC, ppk, pppA,  
 pps, ppx, pqiA, pqiB, pqqL, pqqM, prc, prfA, prfB, prfC, priA, priB, priC, prlC,  
 5 prlZ, prmA, prmB, proA, proB, proC, proK, proL, proM, proP, proQ, proS, proT,  
 proV, proW, proX, prpA, prpC, prpR, prr, prs, psd, psiF, pspA, pspB, pspC, pspE,  
 pspF, pssA, pssR, pstA, pstB, pstC, pstS, psu, pta, pth, ptrA, ptrB, ptsG, ptsH, ptsI,  
 ptsN"-", ptsP, purA, purB, purC, purD, purE, purF, purH, purK, purL, purM, purN,  
 purP, purR, purT, purU, pus, putA, putP, pykA, pykF, pyrB, pyrC, pyrD, pyrE,  
 10 pyrF, pyrG, pyrH, pyrI, qmeC, qmeD, qmeE, qor, queA, racC, racR, radA, radC,  
 ranA, rarD, ras, rbfA, rbn, rbsA, rbsB, rbsC, rbsD, rbsK, rbsR, rcsA, rcsB, rcsC,  
 rcsF, rdgA, rdgB, recA, recB, recC, recD, recE, recF, recG, recJ, recN, recO, recQ,  
 recR, recT, relA, relB, relE, relF, relX, rep, rer, rfaB, rfaC, rfaD, rfaF, rfaG, rfaH,  
 rfaI, rfaJ, rfaK, rfaL, rfaP, rfaQ, rfaS, rfaY, rfaZ, rfbA, rfbB, rfbC, rfbD, rfbX, rfc,  
 15 rfe, rffA, rffC, rffD, rffE, rffG, rffH, rffM, rffT, rhaA, rhaB, rhaD, rhaR, rhaS, rhaT,  
 rhlB, rhlE, rho, ribA, ribB, ribC, ribD, ribE, ribF, ridA, ridB, rimB, rimC, rimD,  
 rimE, rimG, rimH, rimI, rimJ, rimK, rimL, rimM, rit, rlpA, rlpB, rluA, rluC, rluD,  
 rmf, rna, rnb, rnc, rnd, rne, rnhA, rnhB, rnk, rnpA, rnpB, rnr, rnt, rob, rorB, rpe, rph,  
 rpiA, rpiB, rpiR, rplA, rplB, rplC, rplD, rplE, rplF, rplI, rplJ, rplK, rplL, rplM, rplN,  
 20 rplO, rplP, rplQ, rplR, rplS, rplT, rplU, rplV, rplW, rplX, rplY, rpmA, rpmB, rpmC,  
 rpmD, rpmE, rpmF, rpmG, rpmH, rpmI, rpmJ, rpoA, rpoB, rpoC, rpoD, rpoE, rpoH,  
 rpoN, rpoS, rpoZ, rpsA, rpsB, rpsC, rpsD, rpsE, rpsF, rpsG, rpsH, rpsI, rpsJ, rpsK,  
 rpsL, rpsM, rpsN, rpsO, rpsP, rpsQ, rpsR, rpsS, rpsT, rpsU, rrfA, rrfB, rrfC, rrfD,  
 rrfE, rrfF, rrfG, rrfH, rrlA, rrlB, rrlC, rrlD, rrlE, rrlG, rrlH, rrmA, rrsA, rrsB, rrsC,  
 25 rrsD, rrsE, rrsG, rrsH, rsd, rseA, rseB, rseC, rspA, rspB, rssA, rssB, rsuA, rtcA, rtcB,  
 rtcR, rtn, rus(qsr'), ruvA, ruvB, ruvC, sad, sanA, sapA, sapB, sapC, sapD, sapF,  
 sbaA, sbcB, sbcC, sbcD, sbmA, sbmC(gyrI), sbp, sdaA, sdaB, sdaC, sdhA, sdhB,  
 sdhC, sdhD, sdiA, sds, secA, secB, secD, secE, secF, secG, secY, selA, selB, selC,  
 selD, semA, seqA, serA, serB, serC, serR, serS, serT, serU, serV, serW, serX, sfa,  
 30 sfcA, sfiC, sfsA, sfsB, shiA, sipC, sipD, sir, sixA, sloB, slp, slr, slt, slyD, slyX, smp,

-78-

smtA, sodA, sodB, sodC, sohA, sohB, solA, soxR, soxS, speA, speB, speC, speD, speE, speF, speG, spf, spoT, sppA, spr, srlA, srlB, srlD, srlE, srlR, srmB, srnA, ssaE, ssaG, ssaH, ssb, sseA, sseB, sspA, sspB, ssrA, ssrS, ssyA, ssyD stfZ, stkA, stkB, stkC, stkD, stpA, strC, strM, stsA, sucA, sucB, sucC, sucD, sufl, sugE, suhA, 5 suhB, sulA, supQ, surA, surE, syd, tabC, tag, talA, talB, tanA, tanB, tap, tar, tas, tauA, tauB, tauC, tauD, tbpA, tdcA, tdcB, tdcC, tdcD, tdcE, tdcF, tdcG, tdcR, tdh, tdi tdk, tehA, tehB, tesA, tesB, tgt, thdA, thdC, thdD, thiB?, thiC, thiD, thiE, thiF, thiG, thiH, thiI, thiJ, thiK, thiL, thiM, thrA, thrB, thrC, thrS, thrT, thrU, thrV, thrW, thyA, tig, tktA, tktB, tldD, tlnA, tmk, tnaA, tnaB, tnaC, tnm, tol-orf1, tol-orf2, tolA, 10 tolB, tolC, tolD, tolE, toll, tolJ, tolM, tolQ, toIR, tonB, topA, topB, torA, torC, torD, torR, torS, torT, tpiA, tpr, tpx, treA, treB, treC, treF, treR, trg, trkA, trkD, trkG, trkH, trmA, trmB, trmC, trmD, trmE, trmF, trmH, trmU, trnA, trpA, trpB, trpC, trpD, trpE, trpR, trpS, trpT, truA, truB, trxA, trxB, trxC, tsaA, tsf, tsmA, tsr, tsx, ttdA, ttdB, ttk, tufA, tuffB, tus, tynA, tyrA, tyrB, tyrP, tyrR, tyrS, tyrT, tyrU, tyrV, 15 ubiA, ubiB, ubiC, ubiD, ubiE, ubiF, ubiG, ubiH, ubiX, ucpA[], udk, udp, ugpA, ugpB, ugpC, ugpE, ugpQ, uhpA, uhpB, uhpC, uhpT, uidA, uidB, uidR, umuC, umuD, ung, upp, uppS, ups, uraA, usg-1, usbA, uspA, uup, uvh, uvrA, uvrB, uvrC, uvrD, uvs, uxaA, uxaB, uxaC, uxuA, uxuB, uxuR, valS, valT, valU, valV, valW, valX, valY, valZ, vsr, wrbA, xapA, xapB, xapR, xasA, xerC, xerD, xni, xseA, xseB, 20 xthA, xylA, xylB, xylE, xylF, xylG, xylH, xylR, yccA, yhhP, yihG, yjaB, fl47, yjaD, yohF, yqiE, yrfE, zipA, zntA, znuA, znuB, znuC, zur, and zwf.

Non-limiting examples of mouse genes include: Ilr1, Ilr2, Gas10, Tnp1, Inhbb, Inha, Creb1, Mpmv34, Acrd, Acrg, Il110, Otf1, Rab11b-r, Abl1, ald, Amh-rs1, Bcl2B, Cchla3, Ccnb1-rs2, Gpcr16, Htr5b, Idd5, Igfbp2, Igfbp5, Il18rb, Kras2-rs1, Mo-v7, Mpmv6, Mpmv16, Mpmv22, Mpmv25, Mpmv29, Mpmv42, Mtv7, 25 Mtv27, Mtv39, Oprk1, Otf3-rs1, Otf8, Otf11-rs1, Ptgs2, Ren1, Ren2, Ril3, Sxv, Taz4-rs1, Tgfb2, Wnt6, Xmmv6, Xmmv9, Xmmv36, Xmmv61, Xmmv74, Xmv21, Xmv32, Xmv41, Il12ra, Ab1, Mpmv3, Rap1a-ps2, anx, Mpmv43, Ryr3, Ras12-4, Adra2b, Avp, Glvr1, Il1a, Il1b, Mpmv28, Oxt, Pcsk2, a, Xmv10, Tcf4, Acra, Acra4, 30 Ak1, Bdnf, bs, Cyct, Cyp24, Dbh, Fshb, Gcg, Gdf5, Gnas, Gpcr8, Grin1, Hcs4,

-79-

Hior2, Hsp84-2, Idd12, Ilrn, Jund2, Kras3, Mc3r, Mpmv14, Mtv40, Mxi1-rs1, Otf3-rs2, Ptgs1, Ptpra, Rapsn, Src, Svp1, Svp3, Tcf3b, Wt1, Xmmv71, Xmv48, Ccna, Fgf2, Fth-rs1, Csfm, Mov10, Egf, Acrb2, Cap1, Crh, Fim3, Fps11, Glut2, Gpcr2, Gria2, Hsd3b-1, Hsd3b-2, Hsd3b-3, Hsd3b-4, Hsp86-ps2, Idd3, I12, I17, Mpmv9,

5 Mpmv20, Mtv4.8, Ngfb, Npra, Nras, Nras, Ntrk, Otf3-rs3, Otf3-rs4, Rap1a, Tshb, Xmmv22, Xmmv65, Mos, Ras12-7, Lyr, Ifa, Ifb, Jun, azh, db, Ipp, Mp1, Do1, Ak2, Ccnb1-rs4, Cdc211, Cga, Fgr, Foc1, Fps12, Gabrr1, Gabrr2, Gdf6, Glut1, Gnb1, Gpcr14, Grb2-ps, Grik3, Grik5, Hsp86-1ps4, Htr1da, Htr1db, Idd9, Ifa1, Ifa2, Ifa3, Ifa4, Ifa5, Ifa6, Ifa7, Ifa8, Ifa9, Ifa10, Lap18, Lmyc1, Mpmv19, Mpmv44,

10 Mtv13, Mtv14, Mtv17, Nppb, Otf6, Otf7, Ri12, Ski, Tnfr2, Wnt4, Xmmv8, Xmmv23, Xmmv62, Xmv1, Xmv2, Xmv8, Xmv9, Xmv14, Xmv44, Xpa, Tec, Fgf5, Nos1, Tcf1, Epo, Gnb2, Flt1, Flt3, Ache, Adra2c, Adrbk2, Afp, Alb1, Ccnb1-rs1, Clock, Cyp3, Cyp3a11, Cyp3a13, Drd1b, Drd5, Fgfr3, Flk1, Gc, Gnrhr, Gpcr1, Hcs5, Hnfl, Htr5a, I15r, I16, Kit, Ltrn3, Mgsa, Mpmv7, Mpmv13, Mpmv23,

15 Mtv32, Mtv41, Pdgfa, Pdgfra, Por, Txk, Xmmv3, Xmmv5, Xmmv52, Xmv17, Xmv28, Xmv34, Xmv38, Xmv45, Zp3, Trh, Raf1, Fth-rs2, Ntf3, Kras2, Pthlh, Mov1, Alox5, Braf2, Cftr, Egr4, Fps110, Fgf6, Gdf3, Ghrfr, Glut3, Grin2a, Hior3, Hoxa10, hop, Ica1, I15r, Int41, Itpr1, Krag, Mad, Met, Mi, Mtv8, Mtv23, Mtv29, Mtv33, Mtv34, Nkna, Npy, ob, Otf3-rs5, Tgfa, Tnfr1, Wnt2, Wnt5B, Wnt7A,

20 Xmmv27, Xmv24, Xmv61, Fosb, Ryr1, Ngfa, Ufo, Xrcc1, Abpa, Abpga, Gabra4, Gas2, Acra7, Ccnb1-rs7, Egfbp3, Xmv30, Zp2, Fes, Pcsk3, Calc, Ccnb1-rs10, Pth, Ad, Bc13, Cea, Cea2, Cea3, Cea4, Cea5, Cea6, Cebp, Dm9, Dm15, Drd4, Egfbp1, Egfbp2, Ercc2, Fgf3, Fgfr2, Gabra5, Gabrb3, Gtx, Hcs1, Igflr, Igf2, I14r, Ins2, Int40, Lhb, Mpmv1, Mtv1, Mtv35, Ngfg, Ntf5, Otf2, 2, Pkcc, Ras14, Rras, Ryr,

25 Svp2, Tcf3g, Tgfb1, tub, Xmmv31, Xmmv35, Xmmv73, Xmv33, Xmv53, Taz83, Adrb3, Junb, Jund1, Me1, Gpcr19-rs2, Agt, Cadp, Ccnb1-rs9, E, Fgfr1, Gas6, Gnb-rs1, Hcs2, Insr, Maf, Mov34, Mpmv21, Mpmv41, Mtv21, Mtnr1a, Plat, Ras15-2, Ras16, Sntb2, Xmmv29, Xmv12, Xmv26, Xmv62, Epdr, Gpcr13, Otf11, Pthr, Acra3, Acra5, Acrb4, Camk1, Cdc25Mm, Crbp, Crbp2, Csk, Cyp11a, Cyp19, Drd2,

30 Ets1, Fli1, Gnai2, Gnat1, Gpcr6, Gria4, Hgf1, Hior1, Hpx, Hsp86-1ps3, Hst2, Idd2,

-80-

I11bc, Lag-rs1, Lap18-rs1, M11, Mpmv27, Penk, Pgr, Ras12-2, Tp11, Trf, Xmmv2,  
 Xmmv67, Xmv15, Xmv16, Xmv25, Xmv60, Mgf, Amh, Braf, Cdc2a, Dmd1, Estr,  
 Fps13, Fps14, Fps15, Gli, Gpcr17, Grik2, Ifgr, Igf1, Mpmv5, Mpmv12, Mpmv40,  
 Myb, Oprm, Pg, Pmch, Ros1, Xmv31, Xmv51, Xmv54, Camk2b, Egfr, Int6, Lif,  
 5 Mtv44, Ews, Csfgm, Flt4, I13, I14, I15, Irf1, Gria1, Glut4, Crhr, Csfg, Mov9,  
 Xmv20, Acrb, Mpmv4, Mpmv15, Ngfr, Nos2, Rara, Taz4, Tcf2, Xmv42, Mtv3,  
 Adra1, Crko, df, Erbb2, Gabra1, Gabra6, Gabrg2, Gh, Glra1, Grb2, Hnflb, Hsp86-  
 ps1, Idd4, Igfbp1, Igfbp3, I113, Int4, Mpmv2, Mpmv8, Mpmv18, Mtv45, nu, Pkca,  
 Rab1, Re1, Shbg, Tcf7, Thra, Tnz1, Trp53, Wnt3, Wnt3A, Xmv4, Xmv5, Xmv47,  
 10 Xmv49, Xmv63, Akt, Amh-rs4, Ccs1, Fps16, Fos, Gdf7, Hcs3, Hsp70-2, Hsp84-3,  
 Hsp86-1, hyt, Ltrm1, Max, Mpmv11, Mpmv24, Mtv9, Mtv30, Pomc1, Tcf3a, Tda2,  
 Tgfb3, Tpo, Tshr, Xmmv21, Xmmv25, Xmmv34, Xmmv50, Gli3, Xmv55, Ryr2,  
 Inhba, Gas1, Pcsk1, Amh-rs2, Ccnb1-rs6, Ccnb1-rs13, Crhpb, Dat1, Drd1a, Fgfr4,  
 Fps17, Fim1, Gpcr15, Gpcr18, Hbvi, Hilda, Htr1a, Idd11, I19, Ltrm4, Mak, mes,  
 15 P11, P12, Pr1, Ra1, Rasa, Srd5a1, Tpbp, Xmv13, Xmv27, Rarb, Rbp3, Htr2, Rb1,  
 Acra2, Camkg, Cchl1a2, Ccnb1-rs5, Ccnb1-rs12, GnRh, Mtv11, Nras-ps, Otf3-rs6,  
 Plau, Ptprg, Trp53-ps, Wnt5A, Xmv19, Ghr, I17r, Lifr, Mlvi2, Prlr, Myc, Ril1,  
 cog, Amh-rs7, I12rb, Pdgb, Acr, CP2, Rarg, Sp1-1, Wnt1, Afr1, Atf4, Bzrp, Ccnb1-  
 rs11, Cyp11b, I13rb1, I13rb2, Ins3, Itga, Mlvi1, Mlvi3, Mtv36, Pdgbec, Svp5, Tef,  
 20 Trhr, Wnt7B, Xmmv55, Xmmv72, Xmv37, Tnp2, Ets2, Casr, Chuck-rs1, din, Drd3,  
 Erg, G22p1, Gap43, Gas4, Grik1, Htr1f, Ifgt, Int53, Ltrm2, Mpmv17, Mtv6, Mtvrl,  
 Pit1, Xmv3, Xmv35, Xmv50, Igf2r, Mas, Tcd3, Glp1r, Idd1, Tla, Aeg1, Ccnb1-rs3,  
 Cdc2b, Csi, Cyp21, Cyp21-ps1, Fps18, Gna-rs1, Gpcr19-rs1, Grr1, Grr2, Hom1,  
 Hsc70t, Hsp70, Hsp70-1, Hsp70-3, Hsp84-1, Hst1, Hst4, Hst5, Hst6, Hye, Int3,  
 25 Itpr3, Lap18-rs2, Otf3, Ptprs, Rab11b, Ras12-1, Ras12-3, Ras13, Rrs, Rxrb, Tas,  
 Tcd1, Tcd2, Tera1, Tla-rs, Tnfa, Tnfb, Tpx1, Tpx2, Xmmv15, Xmv36, Xmv57,  
 Csfmr, Pdgbf, Adrb2, Apc, Camk2a, Camk4, Dcc, Fgf1, Gna1, Gpcr7, Gr11, Grp,  
 Hsp74, Mcc, Mtv2, Mtv38, Ptpn2, Tp12, Xmv22, Xmv23, Xmv29, Fth, Csfgmra,  
 Mxi1, Adra2a, Adrb1, Adrbk1, Chuck, Cyp17, Gna14, Gnb-ps1, Hcs6, Htr7, Ide,  
 30 Ins1, Lpc1, Pomc2, Seao, Tlx1, Xmmv42, Xmv18, Tcf3, Araf, Avpr2, mdx, Ar,

-81-

Zfx, Otf9, Ccgl, Ccnb1-rs8, Fps19, Gabra3, Glra2, Glra4, Gria3, Grpr, Hsp74-ps1, Hst3, Htr1c, I12rg, Mov14, Mov15, Mtv28, Otf3-rs8, Sts, Sxa, Sxr, Xta, Tdy, Hya, Zfy1, Zfy2, Mov15, Mov24, Mtv31, Mtv42, Sdma, Spy, Sts, Sxa, Sxr, XmmvY, Xmv7, Xmv11, and Xmv40.

- 5 Non-limiting examples of *Phaseolus vulgaris* genes include: Acc, ace, Adk, Am, Amv-1, Amv-2, Ane, aph, Arc, Are, arg, Ar1 (Arc), asp, B, bc-u, bc-1.sup.1, bc-1.sup.2, bc-2.sup.1, bc-2.sup.2, bc-3, Bcm, Beg, Bip, blu, Bpm, Bsm, By-1, By-2, C, C/c, c.sup.cr, C.sup.cir, C.sup.ma (M, R.sup.ma), C.sup.r, C.sup.res, C.sup.rho, C.sup.st, [C.sup.st R Acc] (Aeq), c.sup.u (inh, i.sub.e), [c.sup.u Prp.sup.i] (Prp,
- 10 c.sup.ui, Nud), [c.sup.uprp.sup.st] (prp.sup.st), [C Prp] (Prp), c.sup.v, [C R] (R), [C r] (r), Ca, Cam, Cav, cc, ch1, c1, cm1, Co-1 (A), Co-2 (Are), Co-3 (Mexique 1), Co-3.sup.2, Co-4 (Mexique 2), Co-5 (Mexique 3), Co-6, Co-7, cr-1 cr-2, cry, cs, Ct, ctv-1 ctv-2, cyv (by-3), D (Can, Ins), Da, Db, def, dgs (g1, le), dia, Diap-1, Diap-2, diff, dis, D1-1 D1-2 (DL.sub.1 DL.sub.2), do, ds (te), dt-1.sup.a dt-2.sup.a, dt-1.sup.b dt-
- 15 2.sup.b, dw-1 dw-2, Ea Eb, ers (restr), ers-2, Est-1, Est-2, exp, F, Fa, fast, Fb Fc, fa fb fc, Fcr, Fcr-2, fd, Fe-1 Fe-2, Fin (in), Fop-1, Fop-2, Fr, Fr-2, G (Flav, Ca, Och), Ga, gas, glb, Gpi-c1, Gr, Hb1 (L.sub.HB-1), Hbnc (SC.sub.HB-1), Hbp (PD.sub.HB-1), hmb, Hss, Hsw, Ht-1 Ht-2 (L-1 L-2), I, Ia Ib, ian-1 ian-2 (ia), lbd, ico, Igr (lh), ilo, ip, iter, iv, iw, J (Sh), Ke, L, la, Lan, Ld, Lds (Ds), Lec, Li (L), lo,
- 20 Ir-1 Ir-2, mar, Me, Mel (Me), Mel-2 (Me-2), mel-3 (me-3), Mf, mi, mia, Mic (Mip), miv, Mrf, Mrf.sup.2, mrf, ms-1, Mue, mu mutator, Nag, Nd-1 Nd-2 (D-1 D-2), nie, nnd (sym-1), nnd-2, No, nts (nod), Nudus, ol, P, p.sup.gri (Gri, v.sup.Pal), pa, pc, pg (pa.sub.1), Pha, Pmv, ppd (neu), Pr, prc (pc), Prx, punc, ram, Rbcs (rbcS), rf-1, rf-2, rf-3, rfi (i), Rfs (m), Rk, rk, rk.sup.d (lin), rn-1 rn-2 (r r), rnd, Ro, Sal, sb, sb.sup.ms,
- 25 sb-2, sb-3, si1, Skdh, s1, Smv, St, Sur, sw-1 sw-2, T, t (z-1), Th-1 Th-2, Tm, To, Tor (T), Tr, tri, trv, Ts, tw, uni, Uni-2, uni.sup.nde, uni.sup.nie, Ur-1, Ur-2, Ur-2.sup.2, Ur-3 (Ur-3, Ur-4), Ur-3.sup.2, Ur-4, (Up-2, Ur-C), Ur-5, (B-190), Ur-6 (Ur.sub.a, Ur-G), Ur-7 (R.sub.B11), Ur-8 (Up-1), Ur-9 (Ur.sub.p), us, V (B1), v.sup.lae (Cor), v, var, vi (vir.sub.f), wb, Wmv, X.sup.su, y, and Z.

-82-

Non-limiting examples of *Saccharomyces cerevisiae* genes include: PRE3, PUP1, PUP3, PRE2, PRE10, PRE1, PRE8, SCL1, PUP2, PRE5, PRE7, PRE4, RPT2, RPT3, RPN3, RPN11, RPN12, RPT6, RPN1, RPN2, RPT1, RPT5, RPT4, SKI6, RRP4, DIS3, TSC10, RAT1, GND1, EXO70, ERG10, ACC1, RPP0, ACT1, 5 ARP100, ARP3, PAN1, ARP2, ARP4, ARP9, SPE2, CYR1, ALA1, TPS1, TUB1, ABF1, DED81, NIP1, YHC1, SNU71, ATM1, MAK5, ROK1, DED1, SPB4, AUR1, PSE1, ALG1, TUB2, BPL1, MSL5, ERG24, ERG26, ERG25, CMD1, HCA4, SHE9, SHE10, CAK1, PIS1, CHO1, CDS1, ESR1, NUD1, CDC47, CDC13, CDC37, CDC1, CDC4, CDC20, CDC6, CDC46, CDC3, KAR1, BBP1, HRP1, 10 CCT2, CCT3, HSP10, SMC1, SMC2, CHC1, CFT2, CLP1, COP1, SEC26, SEC27, RET2, SEC21, COF1, CCT4, CCT1, CCT6, SEC24, SEC7, PCF11, RNA15, RNA14, FIP1, YSH1, TFB4, TSM1, APC2, APC5, SEC31, TAF47, TAP42, MPP10, CDC53, CKS1, CDC28, KIN28, CNS1, ERG11, DBP10, DBP8, PRO3, DYS1, ALR1, TID3, DNA2, SSL2, RAD3, RFA3, RFA2, RFA1, RFC4, RFC5, 15 RFC3, RFC2, RFC1, TOP2, RAP1, RPC25, PRI2, PRI1, POL1, POL12, HUS2, CDC2, POL2, DPB2, RPB10, RPA135, RPA190, RPA43, RPB8, RPO26, RPB5, RPC40, RPC19, SRB7, SRB4, RGR1, RPB11, SRB6, RPB2, RPB7, RPO21, RET1, RPO31, RPC31, RPC34, RPC53, RPC82, RPB12, RPB3, DPM1, DIP2, RNT1, CDC8, CDC14, DUT1, UBA2, UBA1, UBC9, CDC34, ENP1, ERD2, SSS1, 20 SEC61, SEC63, SEC62, GNA1, GPI8, DAM1, DUO1, IRR1, PRP3, TIM9, HSH49, SUP35, EXM2, MEX67, ERG9, ERG20, FAS2, FAS1, NOP1, FAD1, AOS1, FBA1, NCB2, BRN1, TUB4, GDI1, GOG5, SRM1, CDC25, SPT16, YIF2, BET4, CDC43, MRS6, BET2, PRO1, GLN1, GLN4, GRS1, YIP1, FOL2, GPA1, CDC42, SAR1, YPT1, SEC4, GSP1, TEM1, RHO1, CDC24, RNA1, GUK1, VMA16, 25 PMA1, HKR1, SIS1, MGE1, HSP60, HSF1, HAS1, MOT3, HTS1, ESA1, HSL7, HOM6, RIB7, SLY1, CSL4, PUR5, CSE1, IPP1, MDM1, USO1, SOF1, MAK11, LAS1, TEL2, DPB11, SGD1, FAL1, MTR3, MTR4, SPP2, SIK1, RRP7, POP4, RRP1, POP3, BFR2, CDC5, NRD1, MET30, MCM6, RRP46, SAS10, SCC2, ECO1, PRP43, BET3, BET5, STN1, NFS1, IDI1, SRP1, KAP95, CBF2, SKP1, 30 CEP3, CTF13, ERG7, KRS1, PSA1, PMI40, ALG2, SSF1, MED7, RSC4, CDC54,

-83-

MCM2, AFG2, ERG12, MVD1, CDC48, MHP1, ERV1, SSC1, TIM44, TIM17,  
TIM23, TOM22, TOM40, MAS1, MCD1, MMC1, STU1, JAC1, ABD1, CEG1,  
PAB1, MTR2, SEC16, ROT1, INO1, MLC1, MYO2, GPI2, SPT14, NAT2, NMT1,  
TRM1, NCP1, NBP1, ACF2, SPP41, NUT2, LCP5, PRP19, NMD3, RFT1, NNF1,  
5 NDC1, CRM1, KAR2, NIP29, NAB2, NIC96, NUP145, NUP49, NUP57, NUP159,  
NSP1, NUP82, CDC39, NPL4, POP7, NTF2, MAK16, NPL3, NOP2, NOP4, NHP2,  
NOP10, GAR1, NBP35, WBP1, STT3, SWP1, OST2, OST1, ORC1, ORC6, ORC5,  
ORC4, ORC3, RRR1, SAT2, PWP2, PEX3, TOR2, PIK1, SEC14, STT4, MSS4,  
PCM1, GPM1, SEC53, ERG8, YPD1, PAP1, NAB3, RRN7, SEN1, CFT1, PRP11,  
10 PRP21, PRP39, PRP24, PRP9, SLU7, PRP28, PRP31, IFH1, PTA1, SUB2, FMI1,  
MAS2, ESS1, PFY1, POL30, POP1, PDI1, RAM2, CDC7, SMP3, CDC15, YTH1,  
QRI2, YAE1, SFI1, SEC1, BET1, SEC6, SEC13, SEC2, SEC8, CBF5, CDC19,  
YRB1, RHC18, DBF4, SDS22, MCM3, CEF1, ALG11, GAA1, MOB1, NIP7,  
TIP20, SEC5, SEC10, GPI10, RRP3, CDC45, DIB1, MIF2, HOP2, PBN1, NOP5,  
15 RPP1, POP5, POP8, POP6, ERO1, MPT1, DNA43, ESP1, SMC3, LST8, STS1,  
RPM2, RNR1, RNR2, RNR4, RPS20, RPL25, RPL3, RPL30, RPL32, RPL37A,  
RPL43A, RPL5, RPL10, RPS3, CET1, YRA1, SNM1, GLE1, DBP5, DRS1, DBP6,  
BRR2, RRN3, RRN6, RRN11, MED6, PRP16, RPR2, DIM1, RRP43, RRP42,  
RRP45, SEC20, BOS1, CDC12, GLC7, PKC1, IPL1, SGV1, NRK1, RAD53,  
20 LCB2, LCB1, MPS1, SES1, SPC3, SEC11, RIO1, ARP7, NEO1, YJU2, POB3,  
ARH1, IQG1, HRT1, HYM1, MAK21, FUN20, FUN9, NBN1, STB5, YIF1,  
SMX4, YKT6, SFT1, SMD1, PRP6, LSM2, NUF1, SPC97, SPC42, SPC98,  
CDC31, SPC19, SPC25, SPC34, SPC24, NUF2, PRP40, MCD4, ERG1, SMC4,  
CSE4, KRR1, SME1, TRA1, RLP7, SCH9, SMD3, SNP2, SSF2, SPC72, CDC27,  
25 CDC23, CDC16, APC1, APC11, APC4, ARC19, RPN6, RPN5, RSC6, RSC8,  
STH1, SFH1, TIM12, TIM22, TIM10, SQT1, SLS1, JSN1, STU2, SCD5, SSU72,  
ASM4, SED5, UFE1, SYF1, SYF2, CCT5, TBF1, TOA2, TOA1, SUA7, TAF90,  
TAF61, TAF25, TAF60, TAF17, TAF145, TAF19, TAF40, TAF67, TFA2, TFA1,  
FCP1, TFG1, TFG2, TFB1, CCL1, SSL1, TFB3, TFB2, PZF1, BRF1, TFC5, TFC4,  
30 TFC3, TFC7, TFC6, TFC1, SPT15, THI80, THS1, SPT6, SPT5, ROX3, REB1,



-84-

MCM1, MED4, MOT1, MED8, EFB1, YEF3, SUI1, CDC95, TIF11, SUI3, GCD11, SUI2, GCD6, GCD7, GCD2, GCD1, RPG1, GCD10, PRT1, TIF34, CDC33, TIF5, SUP45, GCD14, TIM54, SEC17, TPT1, TRL1, CCA1, SEN54, SEN2, SEN15, SEN34, WRS1, SLN1, TYS1, SNU56, PRP42, CUS1, PRP4, PRP8, SNU114,  
5 USS1, UFD1, SMT3, RSP5, QRI1, ALG7, UGP1, VTI1, VAS1, SEC18, CTR86, and ZPR1.

## 2. Viruses

The microorganisms provided herein include viruses. Such viruses typically have one or more of the microorganism characteristics provided herein. For  
10 example, viruses provided herein can have attenuated pathogenicity, reduced toxicity, preferential accumulation in immunoprivileged cells and tissues, such as tumor, ability to activate an immune response against tumor cells, immunogenic, replication competent, and are able to express exogenous proteins, and combinations thereof. In some embodiments, the viruses have an ability to activate an immune  
15 response against tumor cells without aggressively killing the tumor cells.

The viruses provided herein can be cytoplasmic viruses, such as poxviruses, or can be nuclear viruses such as adenoviruses. The viruses provided herein can have as part of their life cycle lysis of the host cell's plasma membrane. Alternatively, the viruses provided herein can have as part of their life cycle exit of  
20 the host cell by non-lytic pathways such as budding or exocytosis. The viruses provided herein can cause a host organism to develop an immune response to virus-infected tumor cells as a result of lysis or apoptosis induced as part of the viral life cycle. The viruses provided herein also can be genetically engineered to cause a host organism to develop an immune response to virus-infected tumor cells as a  
25 result of lysis or apoptosis, regardless of whether or not lysis or apoptosis is induced as part of the viral life cycle. In some embodiments, the viruses provided herein can cause the host organism to mount an immune response against tumor cells without lysing or causing cell death of the tumor cells.

One skilled in the art can select from any of a variety of viruses, according to  
30 a variety of factors, including, but not limited to, the intended use of the virus (*e.g.*,

-85-

exogenous protein production, antibody production or tumor therapy), the host organism, and the type of tumor.

**a. Cytoplasmic viruses**

5 The viruses provided herein can be cytoplasmic viruses, where the life cycle of the virus does not require entry of viral nucleic acid molecules in to the nucleus of the host cell. A variety of cytoplasmic viruses are known, including, but not limited to, pox viruses, African swine flu family viruses, and various RNA viruses such as picorna viruses, calici viruses, toga viruses, corona viruses and rabdo viruses. In some embodiments, viral nucleic acid molecules do not enter the host cell nucleus  
10 throughout the viral life cycle. In other embodiments, the viral life cycle can be performed without use of host cell nuclear proteins. In other embodiments, the virulence or pathogenicity of the virus can be modulated by modulating the activity of one or more viral proteins involved in viral replication.

**i. Poxviruses**

15 In one embodiment, the virus provided herein is selected from the pox virus family. Pox viruses include Chordopoxvirinae such as orthopoxvirus, parapoxvirus, avipoxvirus, capripoxvirus, leporipoxvirus, suipoxvirus, molluscipoxvirus and yatapoxvirus, as well as Entomopoxvirinae such as entomopoxvirus A, entomopoxvirus B, and entomopoxvirus A. Chordopoxvirinae are vertebrate  
20 poxviruses and have similar antigenicities, morphologies and host ranges; thus, any of a variety of such poxviruses can be used herein. One skilled in the art can select a particular genera or individual chordopoxvirinae according to the known properties of the genera or individual virus, and according to the selected characteristics of the virus (e.g., pathogenicity, ability to elicit an immune response, preferential tumor  
25 localization), the intended use of the virus, the tumor type and the host organism. Exemplary chordopoxvirinae genera are orthopoxvirus and avipoxvirus.

Avipoxviruses are known to infect a variety of different birds and has been administered to humans. Exemplary avipoxviruses include canarypox, fowlpox, juncopox, mynahpox, pigeonpox, psittacinepox, quailpox, peacockpox, penguinpox,  
30 sparrowpox, starlingpox, and turkeypox viruses.

-86-

Orthopoxviruses are known to infect a variety of different mammals including rodents, domesticated animals, primates and humans. Several orthopoxviruses have a broad host range, while others have narrower host range. Exemplary orthopoxviruses include buffalopox, camelpox, cowpox, ectromelia, monkeypox, raccoon pox, skunk pox, tatera pox, uasin gishu, vaccinia, variola and volepox viruses. In some embodiments, the orthopoxvirus selected can be an orthopoxvirus known to infect humans, such as cowpox, monkeypox, vaccinia or variola virus. Optionally, the orthopoxvirus known to infect humans can be selected from the group of orthopoxviruses with a broad host range, such as cowpox, monkeypox, or vaccinia virus.

**a. Vaccinia Virus**

One exemplary orthopoxvirus is vaccinia virus. A variety of vaccinia virus strains are available, including Western Reserve (WR), Copenhagen, Tashkent, Tian Tan, Lister, Wyeth, IHD-J, and IHD-W, Brighton, Ankara, MVA, Dairen I, L-IPV, LC16M8, LC16MO, L1VP, WR 65-16, Connaught, New York City Board of Health. Exemplary vaccinia viruses are Lister or L1VP vaccinia viruses. Any known vaccinia virus, or modifications thereof that correspond to those provided herein or known to those of skill in the art to reduce toxicity of a vaccinia virus. Generally, however, the mutation will be a multiple mutant and the virus will be further selected to reduce toxicity.

The linear dsDNA viral genome of vaccinia virus is approximately 200 kb in size, encoding a total of approximately 200 potential genes. Viral gene expression can be divided into three stages. In the early stage, gene expression is mainly for viral replication, and for defense against the host's immune system. In the intermediate stage, genes not available for expression in the early stage can be expressed, including late stage transactivators. In the late stage, active transcription is mainly for viral structural components for building mature viruses.

Vaccinia virus possesses a variety of features for use in cancer gene therapy and vaccination. It has a broad host and cell type range. Vaccinia is a cytoplasmic virus, thus, it does not insert its genome into the host genome during its life cycle.

-87-

Unlike many other viruses that require the host's transcription machinery, vaccinia virus can support its own gene expression in the host cell cytoplasm using enzymes encoded in the viral genome. The vaccinia virus genome has a large carrying capacity for foreign genes, where up to 25 kb of exogenous DNA fragments (approximately 12% of the vaccinia genome size) can be inserted. The genomes of several of the vaccinia strains have been completely sequenced, and many essential and nonessential genes identified. Due to high sequence homology among different strains, genomic information from one vaccinia strain can be used for designing and generating modified viruses in other strains. Finally, the techniques for production of modified vaccinia strains by genetic engineering are well established (Moss, Curr. Opin. Genet. Dev. 3 (1993), 86-90; Broder and Earl, Mol. Biotechnol. 13 (1999), 223-245; Timiryasova *et al.*, Biotechniques 31 (2001), 534-540).

Historically, vaccinia virus was used to immunize against smallpox infection. More recently, modified vaccinia viruses are being developed as vaccines to combat a variety of diseases. Attenuated vaccinia virus can trigger a cell-mediated immune response. Strategies such as prime/boost vaccination, vaccination with nonreplicating vaccinia virus or a combination of these strategies, have shown promising results for the development of safe and effective vaccination protocols. Mutant vaccinia viruses from previous studies exhibit a variety of shortcomings, including a lack of efficient delivery of the viral vehicle to the desired tissue only (*e.g.*, specific accumulation in a tumor), a lack of safety because of possible serious complications (*e.g.*, in young children, eczema vaccinatum and encephalitis, and in adults disseminated or progressive vaccinia may result if the individual is severely immunodeficient).

#### **b. Modified Vaccinia Viruses**

Provided herein are vaccinia viruses with insertions, mutations or deletions, as described more generally elsewhere herein. The vaccinia viruses are modified or selected to have low toxicity and to accumulate in the target tissue. Exemplary of such viruses are those from the LVP strain.

-88-

Exemplary insertions, mutations or deletions are those that result in an attenuated vaccinia virus relative to the wild type strain. For example, vaccinia virus insertions, mutations or deletions can decrease pathogenicity of the vaccinia virus, for example, by reducing the toxicity, reducing the infectivity, reducing the ability to replicate, or reducing the number of non-tumor organs or tissues to which the vaccinia virus can accumulate. Other exemplary insertions, mutations or deletions include, but are not limited to, those that increase antigenicity of the microorganism, those that permit detection or imaging, those that increase toxicity of the microorganism (optionally, controlled by an inducible promotor). For example, modifications can be made in genes that are involved in nucleotide metabolism, host interactions and virus formation. Any of a variety of insertions, mutations or deletions of the vaccinia virus known in the art can be used herein, including insertions, mutations or deletions of: the thymidine kinase (TK) gene, the hemagglutinin (HA) gene, the VGF gene (as taught in U.S. Pat. Pub. No. 20030031681); a hemorrhagic region or an A type inclusion body region (as taught in U.S. Pat. No. 6,596,279); Hind III F, F13L, or Hind III M (as taught in U.S. Pat. No. 6,548,068); A33R, A34R, A36R or B5R genes (see, *e.g.*, Katz *et al.*, J. Virology 77:12266-12275 (2003)); SalF7L (see, *e.g.*, Moore *et al.*, EMBO J. 1992 11:1973-1980); N1L (see, *e.g.*, Kotwal *et al.*, Virology 1989 171:579-587); M1 lambda (see, *e.g.*, Child *et al.*, Virology. 1990 174:625-629); HR, HindIII-MK, HindIII-MKF, HindIII-CNM, RR, or BamF (see, *e.g.*, Lee *et al.*, J Virol. 1992 66:2617-2630); or C21L (see, *e.g.*, Isaacs *et al.*, Proc Natl Acad Sci U S A. 1992 89:628-632).

### c. The F3 Gene

In addition to the mutations known in the art, the vaccinia viruses provided herein can have an insertion, mutation or deletion of the F3 gene (SEQ ID No: 1; an exemplary F3 gene is provided in GenBank Accession No. M57977, which contains the nucleotide and predicted amino acid sequences for L1VP strain F3; see also Mikryukov *et al.*, Biotekhnologiya 4:442-449 (1988)). For example, the F3 gene has been modified at the unique single NotI restriction site located within the F3 gene at position 35 or at position 1475 inside of the HindIII-F fragment of

-89-

vaccinia virus DNA strain LIVP (Mikryukov *et al.*, Biotekhnologiy 4 (1988), 442-449) by insertion of a foreign DNA sequence into the NotI digested virus DNA. As provided herein, an insertion of a nucleic acid molecule containing lacZ or luciferase/GFP into the NotI site of the F3 gene of the LIVP strain (nucleotides 1473-1480 in M57977, or nucleotides 33-40 of SEQ ID NO: 1) can result in decreased accumulation of vaccinia viruses in non-tumorous organs of nude mice, including brain and heart, relative to wild type vaccinia virus. Thus for use in the methods provided herein, vaccinia viruses can contain an insertion, mutation or deletion of the F3 gene or a mutation of a corresponding locus.. For example, as provided herein, F3-interrupted modified LIVP vaccinia virus can selectively replicate in tumor cells in vivo. Therefore, modified vaccinia viruses (*e.g.*, modified strain LIVP) with the interrupted F3 gene can be used in the methods provided herein, such as methods of tumor-directed gene therapy and for detection of tumors and metastases.

Thus, provided herein are vaccinia viruses having a modification of the F3 gene. For example, the vaccinia viruses provided herein can contain an insertion of foreign DNA into the F3 gene. An exemplary insertion of foreign DNA is an insertion at a site equivalent to the NotI site of the F3 gene in vaccinia strain LIVP, or at position 35 of SEQ ID No:1. An F3-modified vaccinia virus provided herein can colonize in tumors specifically, and therefore, can be used tumor-specific therapeutic gene delivery. A GenBank data analysis with BLAST (Basic Local Alignment Search Tool) on nucleotide sequences of different strains of vaccinia virus was performed. Based on this analysis, it was found that in vaccinia virus strain Copenhagen (Goebel *et al.*, Virology 179 (1990), 247-266) the NotI restriction site is located between two open reading frames (ORF) encoding F14L and F15L genes. Therefore, insertion of foreign genes into NotI site of the VV genome strain Copenhagen will not interrupt any vital genes. In VV strain LIVP, the NotI restriction site is located in the ORF encoding the F3 gene with unknown function (Mikryukov *et al.*, Biotekhnologiya 4 (1988), 442-449). Thus, the insertion of foreign genes into the NotI site of the F3 gene interrupted the F3 gene. The ability

-90-

to modify the F3 gene suggests that it may have a nonessential role for virus replication. Although the F3 gene is likely nonessential for virus replication, the results of the animal experiments suggest that interruption of the F3 gene is correlated with decreased viral virulence, the inability to replicate in brain or ovary, and the ability to replicate preferentially in tumor tissue.

The F3 gene is conserved in a variety of different vaccinia virus strains, including WR (nucleotides 42238-42387 of GenBank Accession No. AY243312.1, Ankara (nucleotides 37155-37304 of GenBank Accession No. U94848.1), Tian Tan (nucleotides 41808-41954 of GenBank Accession No. AF095689), Acambis 3000 (nucleotides 31365-31514 of GenBank Accession No. AY603355.1) and Copenhagen (nucleotides 45368-45517 of GenBank Accession No. M35027.1) strains. The F3 gene also is conserved in the larger family of poxviruses, particularly among orthopoxviruses such as cowpox (nucleotides 58498-58647 of GenBank Accession No. X94355.2), rabbitpox (nucleotides 46969-47118 of GenBank Accession No. AY484669.1), camelpox (nucleotides 43331-43480 of GenBank Accession No. AY009089.1), ectromelia (nucleotides 51008-51157 of GenBank Accession No. AF012825.2), monkeypox (nucleotides 42515-42660 of GenBank Accession No. AF380138.1), and variola viruses (nucleotides 33100-33249 of GenBank Accession No. X69198.1). Accordingly, also provided are modifications of the equivalent of the F3 gene in poxviruses, such as orthopoxviruses including a variety of vaccinia virus strains. One skilled in the art can identify the location of the equivalent F3 gene in a variety of poxviruses, orthopoxviruses and vaccinia viruses. For example, an equivalent of the F3 gene in poxviruses, orthopoxviruses and vaccinia viruses can include a gene that contains at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with the nucleotide sequence of the F3 gene in SEQ ID No:1. In another example, an equivalent of the F3 gene in poxviruses, orthopoxviruses and vaccinia viruses can include a gene that contains at least 80%, at least 85%, at least 90%, at least 92%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity with the amino

-91-

acid sequence of F3 in SEQ ID No:2. In another example, the equivalent to the F3 gene in LIVP can be determined by its structural location in the viral genome: the F3 gene is located on the HindIII-F fragment of vaccinia virus between open reading frames F14L and F15L as defined by Goebel *et al.*, Virology (1990) 179:247-266, and in the opposite orientation of ORFs F14L and F15L; one skilled in the art can readily identify the gene located in the structurally equivalent region in a large variety of related viruses, such as a large variety of pox viruses.

Comparative protein sequence analysis revealed some insight into protein function. The closest match with the protein encoded by the F3 gene (strain LIVP) is a prolyl 4-hydroxylase alpha subunit precursor (4-PH alpha) from the nematode *Caenorhabditis elegans* (Veijola *et al.*, J. Biol. Chem. 269 (1994), 26746-26753). This alpha subunit forms an active alpha-beta dimer with the human protein disulfide isomerase beta subunit. Prolyl 4-hydroxylase (EC 1.14.11.2) catalyzes the formation of 4-hydroxyproline in collagen. The vertebrate enzyme is an alpha 2-beta 2 tetramer, the beta subunit of which is identical to the protein disulfide-isomerase (PDI). The importance of this protein for vaccinia viral replication is unknown, but a deficiency of this protein can result in retargeting vaccinia virus to tumor tissue.

#### d. Multiple Modifications

The vaccinia viruses provided herein also can contain two or more insertions, mutations or deletions. Thus, included are vaccinia viruses containing two or more insertions, mutations or deletions of the loci provided herein or other loci known in the art. In one embodiment, a vaccinia virus contains an insertion, mutation or deletion in the F3 gene, and one or more additional insertions, mutations or deletions. In one embodiment of the modified vaccinia virus, at least the F3 gene has been modified by insertion of a foreign nucleotide sequence. Modifications such as modification of the F3 gene will typically result in at least partial inactivation of the gene or gene product. In one example, the F3 gene and the TK gene have been modified by insertion of a foreign nucleotide sequence. In another example, the F3 gene and the HA gene have been modified by insertion of a foreign nucleotide



-92-

sequence. In another example, the F3 gene and both the TK and HA genes have been modified by insertion of a foreign nucleotide sequence. In another example, the HA gene and the TK gene have been modified by insertion of a foreign nucleotide sequence. Accordingly, the present compositions and methods include a modified vaccinia virus wherein two or more of (a) the F3 gene, (b) the TK gene, and (c) the HA gene have been modified. In one embodiment, at least two of the F3 gene, TK gene and HA gene have been inactivated, for example by insertion, deletion and/or replacement of nucleotide(s) within the coding region, or regulatory sequences of two or more of these genes have been inactivated by insertion, deletion or mutation.

**e. The Lister Strain**

In another embodiment, the viruses and methods provided herein can be based on modifications to the Lister strain of vaccinia virus. Lister (also referred to as Elstree) vaccinia virus is available from any of a variety of sources. For example, the Elstree vaccinia virus is available at the ATCC under Accession Number VR-1549. The Lister vaccinia strain has high transduction efficiency in tumor cells with high levels of gene expression.

In one embodiment, the Lister strain can be an attenuated Lister strain, such as the LIVP (Lister virus from the Institute of Viral Preparations, Moscow, Russia) strain, which was produced by further attenuation of the Lister strain. The LIVP strain was used for vaccination throughout the world, particularly in India and Russia, and is widely available.

The LIVP strain has a reduced pathogenicity while maintaining a high transduction efficiency. For example, as provided herein, F3-interrupted modified LIVP vaccinia virus can selectively replicate in tumor cells in vivo. In one embodiment, provided herein are modified LIVP viruses, including viruses having a modified TK gene, viruses having a modified HA gene, viruses having a modified F3 gene, and viruses having two or more of: modified HA gene, modified TK gene, and modified F3 gene.

30

-93-

**ii. Other cytoplasmic viruses**

Also provided herein are cytoplasmic viruses that are not poxviruses.

Cytoplasmic viruses can replicate without introducing viral nucleic acid molecules into the nucleus of the host cell. A variety of such cytoplasmic viruses are known in the art, and include African swine flu family viruses and various RNA viruses such as arenaviruses, picornaviruses, caliciviruses, togaviruses, coronaviruses, paramyxoviruses, flaviviruses, reoviruses, and rhaboviruses. Exemplary togaviruses include Sindbis viruses. Exemplary arenaviruses include lymphocytic choriomeningitis virus. Exemplary rhaboviruses include vesicular stomatitis viruses. Exemplary paramyxoviruses include Newcastle Disease viruses and measles viruses. Exemplary picornaviruses include polio viruses, bovine enteroviruses and rhinoviruses. Exemplary flaviviruses include Yellow fever virus; attenuated Yellow fever viruses are known in the art, as exemplified in Barrett *et al.*, *Biologicals* 25:17-25 (1997), and McAllister *et al.*, *J. Virol.* 74:9197-9205 (2000).

Also provided herein are modifications of the viruses provided above to enhance one or more characteristics relative to the wild type virus. Such characteristics can include, but are not limited to, attenuated pathogenicity, reduced toxicity, preferential accumulation in tumor, increased ability to activate an immune response against tumor cells, increased immunogenicity, increased or decreased replication competence, and are able to express exogenous proteins, and combinations thereof. In some embodiments, the modified viruses have an ability to activate an immune response against tumor cells without aggressively killing the tumor cells. In other embodiments, the viruses can be modified to express one or more detectable genes, including genes that can be used for imaging. In other embodiments, the viruses can be modified to express one or more genes for harvesting the gene products and/or for harvesting antibodies against the gene products.

**b. Adenovirus, Herpes, Retroviruses**

Further provided herein are viruses that include in their life cycle entry of a nucleic acid molecule into the nucleus of the host cell. A variety of such viruses are

-94-

known in the art, and include herpesviruses, papovaviruses, retroviruses, adenoviruses, parvoviruses and orthomyxoviruses. Exemplary herpesviruses include herpes simplex type 1 viruses, cytomegaloviruses, and Epstein-Barr viruses. Exemplary papovaviruses include human papillomaviruses and SV40 viruses.

5 Exemplary retroviruses include lentiviruses. Exemplary orthomyxoviruses include influenza viruses. Exemplary parvoviruses include adeno associated viruses.

Also provided herein are modifications of the viruses provided above to enhance one or more characteristics relative to the wild type virus. Such characteristics can include, but are not limited to, attenuated pathogenicity, reduced toxicity, preferential accumulation in tumor, increased ability to activate an immune response against tumor cells, increased immunogenicity, increased or decreased replication competence, and are able to express exogenous proteins, and combinations thereof. In some embodiments, the modified viruses have an ability to activate an immune response against tumor cells without aggressively killing the tumor cells. In other embodiments, the viruses can be modified to express one or more detectable genes, including genes that can be used for imaging. In other embodiments, the viruses can be modified to express one or more genes for harvesting the gene products and/or for harvesting antibodies against the gene products.

### 20 3. Bacteria

Bacteria can also be used in the methods provided herein. Any of a variety of bacteria possessing the desired characteristics can be used. In one embodiment, aerobic bacteria can be used. In another embodiment, anaerobic bacteria can be used. In another embodiment, extracellular bacteria can be used. In another embodiment, intracellular bacteria can be used.

In some embodiments, the bacteria provided herein can be extracellular bacteria. A variety of extracellular bacteria are known in the art and include vibrio, lactobacillus, streptococcus, escherichia. Exemplary bacteria include *Vibrio cholerae*, *Streptococcus pyogenes*, and *Escherichia coli*. In other embodiments, the bacteria provided herein can be intracellular bacteria. A variety of intracellular

-95-

bacteria are known in the art and include listeria, salmonella, clostridium, and bifodobacterium. Exemplary intracellular bacteria include *Listeria monocytogenes*, *Salmonella typhimurium*, *Clostridium histolyticus*, *Clostridium butyricum*, *Bifodobacterium longum*, and *Bifodobacterium adolescentis*. Additional bacteria  
5 include plant bacteria such as *Clavibacter michiganensis* subsp. *michiganensis*, *Agrobacterium tumefaciens*, *Ervinia herbicola*, *Azorhisobium caulinodans*, *Xanthomonas campestris* pv. *vesicatoria*, and *Xanthomonas campestris* pv. *campestris*.

A further example of a bacteria provided herein are magnetic bacteria. Such  
10 bacteria allow tumor detection through the accumulation of iron-based contrast agents. Magnetic bacteria can be isolated from fresh and marine sediments. Magnetic bacteria can produce magnetic particles (Fe<sub>3</sub>O<sub>4</sub>) (Blakemore, Annu. Rev. Microbiol. 36 (1982), 217-238). To do so, the magnetic bacteria have efficient iron uptake systems, which allow them to utilize both insoluble and soluble forms of  
15 iron. *Magnetospirillum magnetic* AMB-1 is an example of such magnetic bacteria that has been isolated and cultured for magnetic particle production (Yang *et al.*, Enzyme Microb. Technol. 29 (2001), 13-19). As provided herein, these magnetic bacteria (naturally occurring or genetically modified), when injected intravenously, can selectively accumulate in tumor. Accordingly, these bacteria can be used for  
20 accumulating iron-based contrast agents in the tumors, which in turn allows tumor detection by MRI. Similarly, other naturally isolated metal accumulating strains of bacteria can be used for tumor targeting, absorption of metals from contrast agents, and tumor imaging.

Also provided herein are modifications of bacteria to enhance one or more  
25 characteristics relative to the wild type bacteria. Such characteristics can include, but are not limited to, attenuated pathogenicity, reduced toxicity, preferential accumulation in tumor, increased ability to activate an immune response against tumor cells, increased immunogenicity, increased or decreased replication competence, and are able to express exogenous proteins, and combinations thereof.  
30 In some embodiments, the modified bacteria have an ability to activate an immune

-96-

response against tumor cells without aggressively killing the tumor cells. In other embodiments, the bacteria can be modified to express one or more detectable genes, including genes that can be used for imaging. In other embodiments, the bacteria can be modified to express one or more genes for harvesting the gene products and/or for harvesting antibodies against the gene products.

**a. Aerobic bacteria**

Previous studies have postulated that anaerobic bacteria are preferred for administration to tumors (Lemmon *et al.*, 1997 Gene Therapy 4:791-796). As provided herein, it has been determined that aerobic bacteria can survive and grow in tumors. Accordingly, a bacteria used in the methods provided herein can include a bacteria that can survive and grow in an oxygenated environment. In some embodiments, the bacteria must be in an oxygenated environment in order to survive and grow. A variety of aerobic bacteria are known in the art, including lactobacilli, salmonella, streptococci, staphylococci, vibrio, lysteria, and escherichia. Exemplary bacteria include *Vibrio cholerae*, *Listeria monocytogenes*, *Salmonella typhimurium*, *Streptococcus pyogenes*, *Escherichia coli*, *Lactobacillus bulgaricus*, *Lactobacillus casei*, *Lacto bacillus acidophilus*, *Lactobacillus brevis*, *Lactobacillus paracasei*, *Lactobacillus plantarum*, *Lactobacillus rhamnosus*, *Lactobacillus salivarius*, *Lactobacillus sporogenes*, *Lactobacillus lactis*, *Lactobacillus fermentum*, *Streptococcus thermophilus*, *Bacillus subtilis*, *Bacillus megaterium*, *Bacillus polymyxa*, *Myobacterium smegmatis*, *Mycobacterium vaccae*, *Mycobacterium microti*, *Mycobacterium habana*, *Enterococcus faecalis*, *Pseudomonas fluorescens*, and *Pseudomonas putida*.

**b. Anaerobic bacteria**

A bacteria used in the methods provided herein can include a bacteria that does not require oxygen to survive and grow. In some embodiments, the bacteria must be in an oxygen-free environment in order to survive and grow. A variety of aerobic bacteria are known in the art, including clostridium, bifodobacterium. Exemplary bacteria include *Clostridium histolyticus*, *Clostridium butyricum*, *Clostridium novyi*, *Clostridium sordellii*, *Clostridium absonum*, *Clostridium*

-97-

bifermentans, *Clostridium difficile*, *Clostridium histolyticum*, *Clostridium perfringens*, *Clostridium beijerinckii*, *Clostridium sporogenes*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Bifidobacterium longum*, *Bifidobacterium adolescentis*, *Bifidobacterium bifidum*, *Bifidobacterium infantis*, *Bifidobacterium laterosporus*, *Bifidobacterium animalis*, *Actinomyces israelii*, *Eubacterium lentum*, *Peptostreptococcus anaerobis*, *Peptococcus prevotti*, and *Acidaminococcus fermentans*.

#### 4. Eukaryotic cells

Also encompassed within the microorganisms provided herein and the methods of making and using such microorganisms are eukaryotic cells, including cells from multicellular eukaryotes, including mammals such as primates, where exemplary cells are human cells. Typically the cells are isolated cells. For example, eukaryotic cells can be tumor cells, including mammalian tumor cells such as primate tumor cells, where exemplary primate tumor cells are human tumor cells such as human breast cancer cells. In another example, eukaryotic cells can include fibrosarcoma cells such as human fibrosarcoma cells. Exemplary human fibrosarcoma cells include HT1080 (ATCC Accession Nos. CCL-121, CRL-12011 or CRL-12012). In another example, eukaryotic cells can include stem cells, including mammalian stem cells such as primate stem cells, where exemplary primate stem cells are human stem cells.

Also provided herein are modifications of eukaryotic cells to enhance one or more characteristics relative to the wild type cells. Such characteristics can include, but are not limited to, attenuated pathogenicity, reduced toxicity, preferential accumulation in tumor, increased ability to activate an immune response against tumor cells, increased immunogenicity, increased or decreased replication competence, and are able to express exogenous proteins, and combinations thereof. In some embodiments, the modified eukaryotic cells have an ability to activate an immune response against tumor cells without aggressively killing the tumor cells. In other embodiments, the eukaryotic cells can be modified to express one or more detectable genes, including genes that can be used for imaging. In other

-98-

embodiments, the eukaryotic cells can be modified to express one or more genes for harvesting the gene products and/or for harvesting antibodies against the gene products.

**C. Methods for Making a Modified Microorganism**

5 The microorganisms provided herein can be formed by standard methodologies well known in the art for modifying microorganisms such as viruses, bacteria and eukaryotic cells. Briefly, the methods include introducing into microorganisms one or more genetic modification, followed by screening the microorganisms for properties reflective of the modification or for other desired  
10 properties.

**1. Genetic Modifications**

Standard techniques in molecular biology can be used to generate the modified microorganisms provided herein. Such techniques include various nucleic acid manipulation techniques, nucleic acid transfer protocols, nucleic acid  
15 amplification protocols, and other molecular biology techniques known in the art. For example, point mutations can be introduced into a gene of interest through the use of oligonucleotide mediated site-directed mutagenesis. Alternatively, homologous recombination can be used to introduce a mutation or exogenous sequence into a target sequence of interest. Nucleic acid transfer protocols include  
20 calcium chloride transformation/transfection, electroporation, liposome mediated nucleic acid transfer, N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulfate mediated transformation, and others. In an alternative mutagenesis protocol, point mutations in a particular gene can also be selected for using a positive selection pressure. See, e.g., Current Techniques in Molecular Biology,  
25 (Ed. Ausubel, *et al.*). Nucleic acid amplification protocols include but are not limited to the polymerase chain reaction (PCR). Use of nucleic acid tools such as plasmids, vectors, promoters and other regulating sequences, are well known in the art for a large variety of viruses and cellular organisms. Further a large variety of nucleic acid tools are available from many different sources including ATCC, and various  
30 commercial sources. One skilled in the art will be readily able to select the

-99-

appropriate tools and methods for genetic modifications of any particular virus or cellular organism according to the knowledge in the art and design choice.

Any of a variety of modifications can be readily accomplished using standard molecular biological methods known in the art. The modifications will typically be one or more truncations, deletions, mutations or insertions of the microorganismal genome. In one embodiment, the modification can be specifically directed to a particular sequence. The modifications can be directed to any of a variety of regions of the microorganismal genome, including, but not limited to, a regulatory sequence, to a gene-encoding sequence, or to a sequence without a known role. Any of a variety of regions of microorganismal genomes that are available for modification are readily known in the art for many microorganisms, including the microorganisms specifically listed herein. As a non-limiting example, the loci of a variety of vaccinia genes provided herein elsewhere exemplify the number of different regions that can be targeted for modification in the microorganisms provided herein. In another embodiment, the modification can be fully or partially random, whereupon selection of any particular modified microorganism can be determined according to the desired properties of the modified the microorganism.

In some embodiments, the microorganism can be modified to express an exogenous gene. Exemplary exogenous gene products include proteins and RNA molecules. The modified microorganisms can express a detectable gene product, a therapeutic gene product, a gene product for manufacturing or harvesting, or an antigenic gene product for antibody harvesting. The characteristics of such gene products are described herein elsewhere. In some embodiments of modifying an organism to express an exogenous gene, the modification can also contain one or more regulatory sequences to regulate expression of the exogenous gene. As is known in the art, regulatory sequences can permit constitutive expression of the exogenous gene or can permit inducible expression of the exogenous gene. Further, the regulatory sequence can permit control of the level of expression of the exogenous gene. In some examples, inducible expression can be under the control of cellular or other factors present in a tumor cell or present in a microorganism-



-100-

infected tumor cell. In other examples, inducible expression can be under the control of an administerable substance, including IPTG, RU486 or other known induction compounds. Any of a variety of regulatory sequences are available to one skilled in the art according to known factors and design preferences. In some  
5   embodiments, such as gene product manufacture and harvesting, the regulatory sequence can result in constitutive, high levels of gene expression. In some embodiments, such as anti-(gene product) antibody harvesting, the regulatory sequence can result in constitutive, lower levels of gene expression. In tumor therapy embodiments, a therapeutic protein can be under the control of an internally  
10   inducible promotor or an externally inducible promotor.

In other embodiments, organ or tissue-specific expression can be controlled by regulatory sequences. In order to achieve expression only in the target organ, for example, a tumor to be treated, the foreign nucleotide sequence can be linked to a tissue specific promoter and used for gene therapy. Such promoters are well known  
15   to those skilled in the art (see *e.g.*, Zimmermann *et al.*, (1994) *Neuron* 12, 11-24; Vidal *et al.*; (1990) *EMBO J.* 9, 833-840; Mayford *et al.*, (1995), *Cell* 81, 891-904; Pinkert *et al.*, (1987) *Genes & Dev.* 1, 268-76).

In some embodiments, the microorganisms can be modified to express two or more proteins, where any combination of the two or more proteins can be one  
20   more detectable gene products, therapeutic gene products, gene products for manufacturing or harvesting, or antigenic gene products for antibody harvesting. In one embodiment, a microorganism can be modified to express a detectable protein and a therapeutic protein. In another embodiment, a microorganism can be modified to express two or more gene products for detection or two or more therapeutic gene  
25   products. For example, one or more proteins involved in biosynthesis of a luciferase substrate can be expressed along with luciferase. When two or more exogenous genes are introduced, the genes can be regulated under the same or different regulatory sequences, and the genes can be inserted in the same or different regions of the microorganismal genome, in a single or a plurality of genetic manipulation  
30   steps. In some embodiments, one gene, such as a gene encoding a detectable gene

-101-

product, can be under the control of a constitutive promotor, while a second gene, such as a gene encoding a therapeutic gene product, can be under the control of an inducible promotor. Methods for inserting two or genes in to a microorganism are known in the art and can be readily performed for a wide variety of microorganisms using a wide variety of exogenous genes, regulatory sequences, and/or other nucleic acid sequences.

In an example of performing microorganismal modification methods, vaccinia virus strain LIVP was modified to contain insertions of exogenous DNA in three different locations of the viral genome. Using general methods known in the art, known molecular biology tools, and sequences known in the art or disclosed herein can be used to create modified vaccinia virus strains, including viruses containing insertions in the F3 gene, TK gene and/or HA gene. See, *e.g.*, Mikryukov, *et al.*, *Biotekhnologiya* 4 (1998), 442-449; Goebel *et al.*, *Virology* 179 (1990), 247-266; Antoine *et al.*, *Virology* 244 (1998), 365-396; Mayr *et al.*, *Zentbl. Bakteriол. Hyg. Abt 1 Orig. B* 167 (1978), 375-390; Ando and Matumoto, *Jpn. J. Microbial.* 14 (1979), 181-186; Sugimoto *et al.*, *Microbial. Immuol.* 29 (1985), 421-428; Takahashi-Nishimaki *et al.*, *J. Gen. Virol.* 68 (1987), 2705-2710). These methods include, for example, in vitro recombination techniques, synthetic methods and in vivo recombination methods as described, for example, in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2nd edition, Cold Spring Harbor Laboratory Press, cold Spring Harbor NY (1989), and in the Examples disclosed herein. The person skilled in the art can isolate the gene encoding the gene product of F3 (or a related gene product) from any vaccinia strain using, for example, the nucleotide sequence of the F3 gene of SEQ ID No:1 or SEQ ID NOs:10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 or 32, or a fragment thereof as a probe for screening a library.

Methods of producing recombinant microorganisms are known in the art. Provided herein for exemplary purposes are methods of producing a recombinant vaccinia virus. A recombinant vaccinia virus with an insertion in the F3 gene can be prepared by the following steps: (a) generating (i) a vaccinia shuttle plasmid

-102-

containing the modified F3 gene inserted at restriction site X and (ii) a dephosphorylated wt VV (VGL) DNA digested at restriction site X; (b) transfecting host cells infected with PUV-inactivated helper VV (VGL) with a mixture of the constructs of (i) and (ii) of step a; and (c) isolating the recombinant vaccinia viruses from the transfectants. One skilled in the art knows how to perform such methods, for example by following the instructions given in Example 1 and the legend to Figure 1; see also Timiryasova *et al.*, *Biotechniques* 31 (2001), 534-540. In one embodiment, restriction site X is a unique restriction site. A variety of suitable host cells also are known to the person skilled in the art and include many mammalian, avian and insect cells and tissues which are susceptible for vaccinia virus infection, including chicken embryo, rabbit, hamster and monkey kidney cells, for example, HeLa cells, RK<sub>13</sub>, CV-1, Vero, BSC40 and BSC-1 monkey kidney cells.

## 2. Screening for above characteristics

Modified microorganisms can be screened for any desired characteristics, including the characteristics described herein such as attenuated pathogenicity, reduced toxicity, preferential accumulation in tumor, increased ability to activate an immune response against tumor cells, increased immunogenicity, increased or decreased replication competence, and are able to express exogenous proteins, and combinations thereof. For example, the modified microorganisms can be screened for the ability to activate an immune response against tumor cells without aggressively killing the tumor cells. In another example, the microorganisms can be screened for expression of one or more detectable genes, including genes that can be used for imaging, or for expression of one or more genes for manufacture or harvest of the gene products and/or for harvest of antibodies against the gene products.

Any of a variety of known methods for screening for such characteristics can be performed, as demonstrated in the Examples provided herein. One Exemplary method for screening for desired characteristics includes, but is not limited to, monitoring growth, replication and/or gene expression (including expression of an exogenous gene) in cell culture or other invitro medium. The cell culture can be from any organism, and from any tissue source, and can include tumorous tissues.

-103-

Other exemplary methods for screening for desired characteristics include, but are not limited to, administering a microorganism to animal, including non-human animals such as a mouse, monkey or ape, and optionally also including humans, and monitoring the microorganism, the tumor, and or the animal; monitoring can be performed by in vivo imaging of the microorganism and/or the tumor (*e.g.*, low light imaging of microorganismal gene expression or ultrasonic tumor imaging), external monitoring of the tumor (*e.g.*, external measurement of tumor size), monitoring the animal (*e.g.*, monitoring animal weight, blood panel, antibody titer, spleen size, or liver size). Other exemplary methods for screening for desired characteristics include, but are not limited to, harvesting a non-human animal for the effects and location of the microorganism and expression by the microorganism, including methods such as harvesting a variety of organs including a tumor to determine presence of the microorganism and/or gene expression by the microorganism in the organs or tumor, harvesting of organs associated with an immune response or microorganismal clearance such as the spleen or liver, harvesting the tumor to determine tumor size and viability of tumor cells, harvesting antibodies or antibody producing cells. Such screening and monitoring methods can be used in any of a variety of combinations, as is known in art. In one embodiment, a microorganism can be screened by administering the microorganism to an animal such as a non-human animal or a human, followed by monitoring by in vivo imaging. In another embodiment, a microorganism can be screened by administering the microorganism to an animal such as a non-human animal, monitoring by in vivo imaging, and then harvesting the animal. Thus, provided herein are methods for screening a microorganism for desired characteristics by administering the microorganism to an animal such as an animal with a tumor, and monitoring the animal, tumor (if present), and/or microorganism in the animal for one or more characteristics. Also provided herein are methods for screening a microorganism for desired characteristics by administering the microorganism to a non-human animal such as a non-human animal with a tumor, harvesting the animal, and assaying the animal's organs, antibody titer, and/or tumor (if present) for one or more characteristics.

-104-

Provided herein are methods for screening a microorganism for attenuated pathogenicity or reduced toxicity, where the pathogenicity or toxicity can be determined by a variety of techniques, including, but not limited to, assessing the health state of the subject, measuring the body weight of a subject, blood or urine analysis of a subject, and monitoring tissue distribution of the microorganism within the subject; such techniques can be performed on a living subject in vivo, or can be performed post mortem. Methods also can include the ability of the microorganisms to lyse cells or cause cell death, which can be determined in vivo or in vitro.

When a subject drops below a threshold body weight, the microorganism can be considered pathogenic to the subject. Exemplary thresholds can be a drop of about 5% or more, a drop of about 10% or more, or a drop of about 15% or more in body weight relative to a reference. A body weight reference can be selected from any of a variety of references used in the art; for example, a body weight reference can be the weight of the subject prior to administration of the microorganism, the body weight reference can be a control subject having the same condition as the test subject (*e.g.*, normal or tumor-injected), where the change in weight of the control is compared to the change in weight of the test subject for the time period after administration of the microorganism.

Blood or urine analysis of the subject can indicate level of immune response, level of toxins in the subject, or other levels of stress to cells, tissues or organs of the subject such as kidneys, pancreas, liver and spleen. Levels increased above established threshold levels can indicate pathogenicity of the microorganism to the subject. Threshold levels of components of blood or urine for indicating microorganismal pathogenicity are well known in the art, and any such thresholds can be selected herein according to the desired tolerance of pathogenicity or toxicity of the microorganism.

Tissue distribution of a microorganism in a subject can indicate pathogenicity or toxicity of the microorganism. In one embodiment, tissue distribution of a microorganism that is not pathogenic or toxic can be mostly in tumor relative to other tissues or organs. Microorganisms located mostly in tumor

-105-

can accumulate, for example, at least about 2-fold greater, at least about 5-fold greater, at least about 10-fold greater, at least about 100-fold greater, at least about 1,000-fold greater, at least about 10,000-fold greater, at least about 100,000-fold greater, or at least about 1,000,000-fold greater, than the microorganism accumulate in any other particular organ or tissue.

Provided herein are methods for screening a microorganism for tissue distribution or accumulation, where the tissue distribution can be determined by a variety of techniques, including, but not limited to, harvesting a non-human subject, in vivo imaging a detectable gene product in subject. Harvesting can be accomplished by euthanizing the non-human subject, and determining the accumulation of microorganisms in tumor and, optionally, the accumulation in one or more additional tissues or organs. The accumulation can be determined by any of a variety of methods, including, but not limited to, detecting gene products such as detectable gene products (*e.g.*, gfp or beta galactosidase), histological or microscopic evaluation of tissue, organ or tumor samples, or measuring the number of plaque or colony forming units present in a tissue, organ or tumor sample. In one embodiment, the desired amount of tissue distribution of a microorganism can be mostly in tumor relative to other tissues or organs. Microorganisms located mostly in tumor can accumulate, for example, at least about 2-fold greater, at least about 5-fold greater, at least about 10-fold greater, at least about 100-fold greater, at least about 1,000-fold greater, at least about 10,000-fold greater, at least about 100,000-fold greater, or at least about 1,000,000-fold greater, than the microorganism accumulate in any other particular organ or tissue.

Also provided herein are methods of screening for microorganisms that can elicit an immune response, where the immune response can be against the tumor cells or against the microorganisms. A variety of methods for measuring the ability to elicit an immune response are known in the art, and include measuring an overall increase in immune activity in a subject, measuring an increase in anti-microorganism or anti-tumor antibodies in a subject, testing the ability of a microorganism-treated (typically a non-human) subject to prevent later

-106-

infection/tumor formation or to rapidly eliminate microorganisms or tumor cells. Methods also can include the ability of the microorganisms to lyse cells or cause cell death, which can be determined in vivo or in vitro.

Also provided herein are methods for determining increased or decreased replication competence, by monitoring the speed of replication of the microorganisms. Such measurements can be performed in vivo or in vitro. For example, the speed of replication in a cell culture can be used to determine replication competence of a microorganism. In another example, the speed of replication in a tissue, organ or tumor in a subject can be used to measure replication competence. In some embodiments, decreased replication competence in non-tumor tissues and organs can be the characteristic to be selected in a screen. In other embodiments, increased replication competence in tumors can be the characteristic to be selected in a screen.

Also provided herein are methods for determining the ability of a microorganism to express genes, such as exogenous gene. Such methods can be performed in vivo or in vitro. For example, the microorganisms can be screened on selective plates for the ability to express a gene that permits survival of the microorganism or permits the microorganism to provide a detectable signal, such as turning X-gal blue. Such methods also can be performed in vivo, where expression can be determined, for example, by harvesting tissues, organs or tumors a non-human subject or by in vivo imaging of a subject.

Also provided herein are methods for determining the ability of a microorganism to express genes toward which the subject can develop antibodies, including exogenous genes toward which the subject can develop antibodies. Such methods can be performed in vivo using any of a variety of non-human subjects. For example, gene expression can be determined, for example, by bleeding a non-human subject to which a microorganism has been administered, and assaying the blood (or serum) for the presence of antibodies against the microorganism-expressed gene, or by any other method generally used for polyclonal antibody harvesting, such as production bleeds and terminal bleeds.

-107-

Also provided herein are methods for screening a microorganism that has two or more characteristics provided herein, including screening for attenuated pathogenicity, reduced toxicity, preferential accumulation in tumor, increased ability to activate an immune response against tumor cells, increased immunogenicity, increased or decreased replication competence, ability to express exogenous proteins, and ability to elicit antibody production against a microorganismally expressed gene product. A single monitoring technique, such as in vivo imaging, can be used to verify two or more characteristics, or a variety of different monitoring techniques can be used, as can be determined by one skilled in the art according to the selected characteristics and according to the monitoring techniques used.

#### **D. Therapeutic Methods**

Provided herein are therapeutic methods, including methods of treating or preventing immunoprivileged cells or tissue, including cancerous cells, tumor and metastasis. The methods provided herein include administering a microorganism to a subject containing a tumor and/or metastases. The methods provided herein do not require the microorganism to kill tumor cells or decrease the tumor size. Instead, the methods provided herein include administering to a subject a microorganism that can cause or enhance an anti-tumor immune response in the subject. In some embodiments, the microorganisms provided herein can be administered to a subject without causing microorganism-induced disease in the subject. In some embodiments, the microorganisms can accumulate in tumors or metastases. In some embodiments, the microorganisms can elicit an anti-tumor immune response in the subject, where typically the microorganism-mediated anti-tumor immune response can develop over several days, such a week or more, 10 days or more, two weeks or more, or a month or more, as a result of little or no microorganism-cause tumor cell death. In some exemplary methods, the microorganism can be present in the tumor, and can cause an anti-tumor immune response without the microorganism itself causing enough tumor cell death to prevent tumor growth.

In some embodiments, provided herein are methods for eliciting or enhancing antibody production against a selected antigen or a selected antigen type



-108-

in a subject, where the methods include administering to a subject a microorganism that can accumulate in a tumor and/or metastasis, and can cause release of a selected antigen or selected antigen type from the tumor, resulting in antibody production against the selected antigen or selected antigen type. The administered  
5 microorganisms can possess one or more characteristics including attenuated pathogenicity, low toxicity, preferential accumulation in tumor, ability to activate an immune response against tumor cells, immunogenicity, replication competence, ability to express exogenous genes, and ability to elicit antibody production against a microorganismally expressed gene product.

10 Any of a variety of antigens can be targeted in the methods provided herein, including a selected antigen such as an exogenous gene product expressed by the microorganism, or a selected antigen type such as one or more tumor antigens release from the tumor as a result of microorganism infection of the tumor (*e.g.*, by lysis, apoptosis, secretion or other mechanism of causing antigen release from the  
15 tumor). In at least some embodiments, it can be desirable to maintain release of the selected antigen or selected antigen type over a series of days, for example, at least a week, at least ten days, at least two weeks or at least a month.

Also provided herein are methods for providing a sustained antigen release within a subject, where the methods include administering to a subject a  
20 microorganism that can accumulate in a tumor and/or metastasis, and can cause sustained release of an antigen, resulting in antibody production against the antigen. The sustained release of antigen can last for several days, for example, at least a week, at least ten days, at least two weeks or at least a month. The administered microorganisms can possess one or more characteristics including attenuated  
25 pathogenicity, low toxicity, preferential accumulation in tumor, ability to activate an immune response against tumor cells, immunogenicity, replication competence, ability to express exogenous genes, and ability to elicit antibody production against a microorganismally expressed gene product. The sustained release of antigen can result in an immune response by the microorganism-infected host, in which the host  
30 can develop antibodies against the antigen, and/or the host can mount an immune

-109-

response against cells expressing the antigen, including an immune response against tumor cells. Thus, the sustained release of antigen can result in immunization against tumor cells. In some embodiments, the microorganism-mediated sustained antigen release-induced immune response against tumor cells can result in complete  
5 removal or killing of all tumor cells.

Also provided herein are methods for inhibiting tumor growth in a subject, where the methods include administering to a subject a microorganism that can accumulate in a tumor and/or metastasis, and can cause or enhance an anti-tumor immune response. The anti-tumor immune response induced as a result of tumor or  
10 metastases-accumulated microorganisms can result in inhibition of tumor growth. The administered microorganisms can possess one or more characteristics including attenuated pathogenicity, low toxicity, preferential accumulation in tumor, ability to activate an immune response against tumor cells, immunogenicity, replication competence, ability to express exogenous genes, and ability to elicit antibody  
15 production against a microorganismally expressed gene product.

Also provided herein are methods for inhibiting growth or formation of a metastasis in a subject, where the methods include administering to a subject a microorganism that can accumulate in a tumor and/or metastasis, and can cause or enhance an anti-tumor immune response. The anti-tumor immune response induced  
20 as a result of tumor or metastasis-accumulated microorganisms can result in inhibition of metastasis growth or formation. The administered microorganisms can possess one or more characteristics including attenuated pathogenicity, low toxicity, preferential accumulation in tumor, ability to activate an immune response against tumor cells, immunogenicity, replication competence, ability to express exogenous  
25 genes, and ability to elicit antibody production against a microorganismally expressed gene product.

Also provided herein are methods for decreasing the size of a tumor and/or metastasis in a subject, where the methods include administering to a subject a microorganism that can accumulate in a tumor and/or metastasis, and can cause or  
30 enhance an anti-tumor immune response. The anti-tumor immune response induced

-110-

as a result of tumor or metastasis-accumulated microorganisms can result in a decrease in the size of the tumor and/or metastasis. The administered microorganisms can possess one or more characteristics including attenuated pathogenicity, low toxicity, preferential accumulation in tumor, ability to activate an immune response against tumor cells, immunogenicity, replication competence, ability to express exogenous genes, and ability to elicit antibody production against a microorganismally expressed gene product.

Also provided herein are methods for eliminating a tumor and/or metastasis from a subject, where the methods include administering to a subject a microorganism that can accumulate in a tumor and/or metastasis, and can cause or enhance an anti-tumor immune response. The anti-tumor immune response induced as a result of tumor or metastasis-accumulated microorganisms can result in elimination of the tumor and/or metastasis from the subject. The administered microorganisms can possess one or more characteristics including attenuated pathogenicity, low toxicity, preferential accumulation in tumor, ability to activate an immune response against tumor cells, immunogenicity, replication competence, ability to express exogenous genes, and ability to elicit antibody production against a microorganismally expressed gene product.

Methods of reducing inhibiting tumor growth, inhibiting metastasis growth and/or formation, decreasing the size of a tumor or metastasis, eliminating a tumor or metastasis, or other tumor therapeutic methods provided herein include causing or enhancing an anti-tumor immune response in the host. The immune response of the host, being anti-tumor in nature, can be mounted against tumors and/or metastases in which microorganisms have accumulated, and can also be mounted against tumors and/or metastases in which microorganisms have not accumulated, including tumors and/or metastases that form after administration of the microorganisms to the subject. Accordingly, a tumor and/or metastasis whose growth or formation is inhibited, or whose size is decreased, or that is eliminated, can be a tumor and/or metastasis in which the microorganisms have accumulated, or also can be a tumor and/or metastasis in which the microorganisms have not accumulated. Accordingly,

-111-

provided herein are methods of reducing inhibiting tumor growth, inhibiting metastasis growth and/or formation, decreasing the size of a tumor or metastasis, eliminating a tumor or metastasis, or other tumor therapeutic methods, where the method includes administering to a subject a microorganism, where the

5 microorganism accumulates in at least one tumor or metastasis and causes or enhances an anti-tumor immune response in the subject, and the immune response also is mounted against a tumor and/or metastasis in which the microorganism cell did not accumulate. In another embodiment, methods are provided for inhibiting or preventing recurrence of a neoplastic disease or inhibiting or preventing new tumor

10 growth, where the methods include administering to a subject a microorganism that can accumulate in a tumor and/or metastasis, and can cause or enhance an anti-tumor immune response, and the anti-tumor immune response can inhibit or prevent recurrence of a neoplastic disease or inhibit or prevent new tumor growth.

The tumor or neoplastic disease therapeutic methods provided herein, such as

15 methods of reducing inhibiting tumor growth, inhibiting metastasis growth and/or formation, decreasing the size of a tumor or metastasis, eliminating a tumor or metastasis, or other tumor therapeutic methods, also can include administering to a subject a microorganism that can cause tumor cell lysis or tumor cell death. Such a microorganism can be the same microorganism as the microorganism that can cause

20 or enhance an anti-tumor immune response in the subject. Microorganisms, such as the microorganisms provided herein, can cause cell lysis or tumor cell death as a result of expression of an endogenous gene or as a result of an exogenous gene. Endogenous or exogenous genes can cause tumor cell lysis or inhibit cell growth as a result of direct or indirect actions, as is known in the art, including lytic channel

25 formation or activation of an apoptotic pathway. Gene products, such as exogenous gene products can function to activate a prodrug to an active, cytotoxic form, resulting in cell death where such genes are expressed.

Such methods of antigen production or tumor and/or metastasis treatment can include administration of a modified microorganism described herein or a

30 microorganism having modifications with a functional equivalence to the vaccinia

-112-

virus provided herein containing a modification of the F3 gene and the TK gene and/or the HA gene, for therapy, such as for gene therapy, for cancer gene therapy, or for vaccine therapy. Such a microorganism can be used to stimulate humoral and/or cellular immune response, induce strong cytotoxic T lymphocytes responses in subjects who may benefit from such responses. For example, the microorganism can provide prophylactic and therapeutic effects against a tumor infected by the microorganism or other infectious diseases, by rejection of cells from tumors or lesions using microorganisms that express immunoreactive antigens (Earl *et al.* (1986), *Science* 234, 728-831; Lathe *et al.* (1987), *Nature (London)* 326, 878-880), cellular tumor-associated antigens (Bernards *et al.*, (1987), *Proc. Natl. Acad. Sci. USA* 84, 6854-6858; Estin *et al.* (1988), *Proc. Natl. Acad. Sci. USA* 85, 1052-1056; Kantor *et al.* (1992), *J. Natl. Cancer Inst.* 84, 1084-1091; Roth *et al.* (1996), *Proc. Natl. Acad. Sci. USA* 93, 4781-4786) and/or cytokines (*e.g.*, IL-2, IL-12), costimulatory molecules (B7-1, B7-2) (Rao *et al.* (1996), *J. Immunol.* 156, 3357-3365; Chamberlain *et al.* (1996), *Cancer Res.* 56, 2832-2836; Oertli *et al.* (1996), *J. Gen. Virol.* 77, 3121-3125; Qin and Chatterjee (1996), *Human Gene Ther.* 7, 1853-1860; McAneny *et al.* (1996), *Ann. Surg. Oncol.* 3, 495-500), or other therapeutic proteins.

Provided herein, solid tumors can be treated with microorganisms, such as vaccinia viruses, resulting in an enormous tumor-specific microorganism replication, which can lead to tumor protein antigen and viral protein production in the tumors. As provided herein, vaccinia virus administration to mice resulted in lysis of the infected tumor cells and a resultant release of tumor-cell-specific antigens. Continuous leakage of these antigens into the body led to a very high level of antibody titer (in approximately 7-14 days) against tumor proteins, viral proteins, and the virus encoded engineered proteins in the mice. The newly synthesized antitumor antibodies and the enhanced macrophage, neutrophils count were continuously delivered via the vasculature to the tumor and thereby provided for the recruitment of an activated immune system against the tumor. The activated immune system then eliminated the foreign compounds of the tumor including the

-113-

viral particles. This interconnected release of foreign antigens boosted antibody production and continuous response of the antibodies against the tumor proteins to function like an autoimmunizing vaccination system initiated by vaccinia viral infection and replication, followed by cell lysis, protein leakage and enhanced antibody production. Thus, the present methods can provide a complete process that can be applied to all tumor systems with immunoprivileged tumor sites as site of privileged viral, bacterial, and mammalian cell growth, which can lead to tumor elimination by the host's own immune system.

In other embodiments, methods are provided for immunizing a subject, where the methods include administering to the subject a microorganism that expresses one or more antigens against which the subject will develop an immune response. The immunizing antigens can be endogenous to the microorganism, such as vaccinia antigens on a vaccinia virus used to immunize against smallpox. Or the immunizing antigens can be exogenous antigens expressed by the microorganism, such as influenza or HIV antigens expressed on a viral capsid or bacterial cell surface. Thus, the microorganisms provided herein, including the modified vaccinia viruses can be used as vaccines.

#### **1. Administration**

In performing the methods provided herein, a microorganism can be administered to a subject, including a subject having a tumor or having neoplastic cells, or a subject to be immunized. An administered microorganism can be a microorganism provided herein or any other microorganism known for administration to a subject, for example, any known microorganism known for therapeutic administration to a subject, including antigenic microorganisms such as any microorganism known to be used for vaccination. In some embodiments, the microorganism administered is a microorganism containing a characteristic such as attenuated pathogenicity, low toxicity, preferential accumulation in tumor, ability to activate an immune response against tumor cells, high immunogenicity, replication competence, and ability to express exogenous proteins, and combinations thereof.

30

-114-

**a. Steps prior to administering the microorganism**

In some embodiments, one or more steps can be performed prior to administration of the microorganism to the subject. Any of a variety of preceding steps can be performed, including, but not limited to diagnosing the subject with a condition appropriate for microorganismal administration, determining the immunocompetence of the subject, immunizing the subject, treating the subject with a chemotherapeutic agent, treating the subject with radiation, or surgically treating the subject.

For embodiments that include administering a subject to a tumor-bearing subject for therapeutic purposes, the subject has typically been previously diagnosed with a neoplastic condition. Diagnostic methods also can include determining the type of neoplastic condition, determining the stage of the neoplastic conditions, determining the size of one or more tumors in the subject, determining the presence or absence of metastatic or neoplastic cells in the lymph nodes of the subject, or determining the presence of metastases of the subject. Some embodiments of therapeutic methods for administering a microorganism to a subject can include a step of determination of the size of the primary tumor or the stage of the neoplastic disease, and if the size of the primary tumor is equal to or above a threshold volume, or if the stage of the neoplastic disease is at or above a threshold stage, a microorganism is administered to the subject. In a similar embodiment, if the size of the primary tumor is below a threshold volume, or if the stage of the neoplastic disease is at or below a threshold stage, the microorganism is not yet administered to the subject; such methods can include monitoring the subject until the tumor size or neoplastic disease stage reaches a threshold amount, and then administering the microorganism to the subject. Threshold sizes can vary according to several factors, including rate of growth of the tumor, ability of the microorganism to infect a tumor, and immunocompetence of the subject. Generally the threshold size will be a size sufficient for a microorganism to accumulate and replicate in or near the tumor without being completely removed by the host's immune system, and will typically also be a size sufficient to sustain a microorganismal infection for a time long

-115-

enough for the host to mount an immune response against the tumor cells, typically about one week or more, about ten days or more, or about two weeks or more.

Exemplary threshold tumor sizes for viruses such as vaccinia viruses are at least about 100 mm<sup>3</sup>, at least about 200 mm<sup>3</sup>, at least about 300 mm<sup>3</sup>, at least about 400 mm<sup>3</sup>, at least about 500 mm<sup>3</sup>, at least about 750 mm<sup>3</sup>, at least about 1000 mm<sup>3</sup>, or at least about 1500 mm<sup>3</sup>. Threshold neoplastic disease stages also can vary according to several factors, including specific requirement for staging a particular neoplastic disease, aggressiveness of growth of the neoplastic disease, ability of the microorganism to infect a tumor or metastasis, and immunocompetence of the subject. Generally the threshold stage will be a stage sufficient for a microorganism to accumulate and replicate in a tumor or metastasis without being completely removed by the host's immune system, and will typically also be a size sufficient to sustain a microorganismal infection for a time long enough for the host to mount an immune response against the neoplastic cells, typically about one week or more, about ten days or more, or about two weeks or more. Exemplary threshold stages are any stage beyond the lowest stage (*e.g.*, Stage I or equivalent), or any stage where the primary tumor is larger than a threshold size, or any stage where metastatic cells are detected.

In other embodiments, prior to administering to the subject a microorganism, the immunocompetence of the subject can be determined. The methods of administering a microorganism to a subject provided herein can include causing or enhancing an immune response in a subject. Accordingly, prior to administering a microorganism to a subject, the ability of a subject to mount an immune response can be determined. Any of a variety of tests of immunocompetence known in the art can be performed in the methods provided herein. Exemplary immunocompetence tests can examine ABO hemagglutination titers (IgM), leukocyte adhesion deficiency (LAD), granulocyte function (NBT), T and B cell quantitation, tetanus antibody titers, salivary IgA, skin test, tonsil test, complement C3 levels, and factor B levels, and lymphocyte count. One skilled in the art can determine the desirability to administer a microorganism to a subject according to the level of



-116-

immunocompetence of the subject, according to the immunogenicity of the microorganism, and, optionally, according to the immunogenicity of the neoplastic disease to be treated. Typically, a subject can be considered immunocompetent if the skilled artisan can determine that the subject is sufficiently competent to mount an immune response against the microorganism.

In some embodiments, the subject can be immunized prior to administering to the subject a microorganism according to the methods provided herein.

Immunization can serve to increase the ability of a subject to mount an immune response against the microorganism, or increase the speed at which the subject can mount an immune response against a microorganism. Immunization also can serve to decrease the risk to the subject of pathogenicity of the microorganism. In some embodiments, the immunization can be performed with an immunization microorganism that is similar to the therapeutic microorganism to be administered. For example, the immunization microorganism can be a replication-incompetent variant of the therapeutic microorganism. In other embodiments, the immunization material can be digests of the therapeutic microorganism to be administered. Any of a variety of methods for immunizing a subject against a known microorganism are known in the art and can be used herein. In one example, vaccinia viruses treated with, for example, 1 microgram of psoralen and ultraviolet light at 365 nm for 4 minutes, can be rendered replication incompetent. In another embodiment, the microorganism can be selected as the same or similar to a microorganism against which the subject has been previously immunized, *e.g.*, in a childhood vaccination.

In another embodiment, the subject can have administered thereto a microorganism without any previous steps of cancer treatment such as chemotherapy, radiation therapy or surgical removal of a tumor and/or metastases. The methods provided herein take advantage of the ability of the microorganisms to enter or localize near a tumor, where the tumor cells can be protected from the subject's immune system; the microorganisms can then proliferate in such an immunoprotected region and can also cause the release, typically a sustained release, of tumor antigens from the tumor to a location in which the subject's immune

-117-

system can recognize the tumor antigens and mount an immune response. In such methods, existence of a tumor of sufficient size or sufficiently developed immunoprotected state can be advantageous for successful administration of the microorganism to the tumor, and for sufficient tumor antigen production. If a tumor is surgically removed, the microorganisms may not be able to localize to other neoplastic cells (e.g., small metastases) because such cells may not yet have matured sufficiently to create an immunoprotective environment in which the microorganisms can survive and proliferate, or even if the microorganisms can localize to neoplastic cells, the number of cells or size of the mass may be too small for the microorganisms to cause a sustained release of tumor antigens in order for the host to mount an anti-tumor immune response. Thus, for example, provided herein are methods of treating a tumor or neoplastic disease in which microorganisms are administered to a subject with a tumor or neoplastic disease without removing the primary tumor, or to a subject with a tumor or neoplastic disease in which at least some tumors or neoplastic cells are intentionally permitted to remain in the subject. In other typical cancer treatment methods such as chemotherapy or radiation therapy, such methods typically have a side effect of weakening the subject's immune system. This treatment of a subject by chemotherapy or radiation therapy can reduce the subject's ability to mount an anti-tumor immune response. Thus, for example, provided herein are methods of treating a tumor or neoplastic disease in which microorganisms are administered to a subject with a tumor or neoplastic disease without treating the subject with an immune system-weakening therapy, such as chemotherapy or radiation therapy.

In an alternative embodiment, prior to administration of a microorganism to the subject, the subject can be treated in one or more cancer treatment steps that do not remove the primary tumor or that do not weaken the immune system of the subject. A variety of more sophisticated cancer treatment methods are being developed in which the tumor can be treated without surgical removal or immune-system weakening therapy. Exemplary methods include administering a compound that decreases the rate of proliferation of the tumor or neoplastic cells without

-118-

weakening the immune system (e.g., by administering tumor suppressor compounds or by administering tumor cell-specific compounds) or administering an angiogenesis-inhibiting compound. Thus, combined methods that include administering a microorganism to a subject can further improve cancer therapy.

5 Thus, provided herein are methods of administering a microorganism to a subject, along with prior to or subsequent to, for example, administering a compound that slows tumor growth without weakening the subject's immune system or a compound that inhibits vascularization of the tumor.

**b. Mode of administration**

10 Any mode of administration of a microorganism to a subject can be used, provided the mode of administration permits the microorganism to enter a tumor or metastasis. Modes of administration can include, but are not limited to, intravenous, intraperitoneal, subcutaneous, intramuscular, topical, intratumor, multipuncture (e.g., as used with smallpox vaccines), inhalation, intranasal, oral, intracavity (e.g.,  
15 administering to the bladder via a catheter, administering to the gut by suppository or enema), aural, or ocular administration. One skilled in the art can select any mode of administration compatible with the subject and the microorganism, and that also is likely to result in the microorganism reaching tumors and/or metastases. The route of administration can be selected by one skilled in the art according to any of a  
20 variety of factors, including the nature of the disease, the kind of tumor, and the particular microorganism contained in the pharmaceutical composition. Administration to the target site can be performed, for example, by ballistic delivery, as a colloidal dispersion system, or systemic administration can be performed by injection into an artery.

25 **c. Dosage**

The dosage regimen can be any of a variety of methods and amounts, and can be determined by one skilled in the art according to known clinical factors. As is known in the medical arts, dosages for any one patient can depend on many factors, including the subject's species, size, body surface area, age, sex,  
30 immunocompetence, and general health, the particular microorganism to be

-119-

administered, duration and route of administration, the kind and stage of the disease, for example, tumor size, and other compounds such as drugs being administered concurrently. In addition to the above factors, such levels can be affected by the infectivity of the microorganism, and the nature of the microorganism, as can be

5 determined by one skilled in the art. At least some of the viruses used in the methods provided herein can be more infectious than the bacteria used herein. Thus, in some embodiments of the present methods, virus can be administered at lower levels than bacteria. In the present methods, appropriate minimum dosage levels of microorganisms can be levels sufficient for the microorganism to survive, grow and

10 replicate in a tumor or metastasis. Exemplary minimum levels for administering a virus to a 65 kg human can include at least about  $5 \times 10^5$  plaque forming units (pfu), at least about  $1 \times 10^6$  pfu, at least about  $5 \times 10^6$  pfu, at least about  $1 \times 10^7$  pfu, or at least about  $1 \times 10^8$  pfu. Exemplary minimum levels for administering a bacterium to a 65 kg human can include at least about  $5 \times 10^6$  colony forming units (cfu), at least

15 about  $1 \times 10^7$  cfu, at least about  $5 \times 10^7$  cfu, at least about  $1 \times 10^8$  cfu, or at least about  $1 \times 10^9$  cfu. In the present methods, appropriate maximum dosage levels of microorganisms can be levels that are not toxic to the host, levels that do not cause splenomegaly of 3x or more, levels that do not result in colonies or plaques in normal tissues or organs after about 1 day or after about 3 days or after about 7 days.

20 Exemplary maximum levels for administering a virus to a 65 kg human can include no more than about  $5 \times 10^{10}$  pfu, no more than about  $1 \times 10^{10}$  pfu, no more than about  $5 \times 10^9$  pfu, no more than about  $1 \times 10^9$  pfu, or no more than about  $1 \times 10^8$  pfu. Exemplary maximum levels for administering a bacterium to a 65 kg human can include no more than about  $5 \times 10^{11}$  pfu, no more than about  $1 \times 10^{11}$  pfu, no

25 more than about  $5 \times 10^{10}$  pfu, no more than about  $1 \times 10^{10}$  pfu, or no more than about  $1 \times 10^9$  pfu.

**d. Number of administrations**

The methods provided herein can include a single administration of a microorganism to a subject or multiple administrations of a microorganism to a

30 subject. In some embodiments, a single administration is sufficient to establish a

-120-

microorganism in a tumor, where the microorganism can proliferate and can cause or enhance an anti-tumor response in the subject; such methods do not require additional administrations of a microorganism in order to cause or enhance an anti-tumor response in a subject, which can result, for example in inhibition of tumor growth, inhibition of metasis growth or formation, reduction in tumor or metasis size, elimination of a tumor or metastasis, inhibition or prevention of recurrence of a neoplastic disease or new tumor formation, or other cancer therapeutic effects. In other embodiments, a microorganism can be administered on different occasions, separated in time typically by at least one day. Separate administrations can increase the likelihood of delivering a microorganism to a tumor or metastasis, where a previous administration may have been ineffective in delivering a microorganism to a tumor or metastasis. Separate administrations can increase the locations on a tumor or metastasis where microorganism proliferation can occur or can otherwise increase the titer of microorganism accumulated in the tumor, which can increase the scale of release of antigens or other compounds from the tumor in eliciting or enhancing a host's anti-tumor immune response, and also can, optionally, increase the level of microorganism-based tumor lysis or tumor cell death. Separate administrations of a microorganism can further extend a subject's immune response against microorganismal antigens, which can extend the host's immune response to tumors or metastases in which microorganisms have accumulated, and can increase the likelihood a host mounting an anti-tumor immune response.

When separate administrations are performed, each administration can be a dosage amount that is the same or different relative to other administration dosage amounts. In one embodiment, all administration dosage amounts are the same. In other embodiments, a first dosage amount can be a larger dosage amounts than one or more subsequent dosage amounts, for example, at least 10x larger, at least 100x larger, or at least 1000x larger than subsequent dosage amounts. In one example of a method of separate administrations in which the first dosage amount is greater than

-121-

one or more subsequent dosage amounts, all subsequent dosage amounts can be the same, smaller amount relative to the first administration.

5        Separate administrations can include any number of two or more administrations, including two, three, four, five or six administrations. One skilled in the art can readily determine the number of administrations to perform or the desirability of performing one or more additional administrations according to methods known in the art for monitoring therapeutic methods and other monitoring methods provided herein. Accordingly, the methods provided herein include methods of providing to the subject one or more administrations of a  
10    microorganism, where the number of administrations can be determined by monitoring the subject, and, based on the results of the monitoring, determining whether or not to provide one or more additional administrations. Deciding of whether or not to provide one or more additional administrations can be based on a variety of monitoring results, including, but not limited to, indication of tumor  
15    growth or inhibition of tumor growth, appearance of new metastases or inhibition of metastasis, the subject's anti-microorganism antibody titer, the subject's anti-tumor antibody titer, the overall health of the subject, the weight of the subject, the presence of microorganism solely in tumor and/or metastases, the presence of microorganism in normal tissues or organs.

20        The time period between administrations can be any of a variety of time periods. The time period between administrations can be a function of any of a variety of factors, including monitoring steps, as described in relation to the number of administrations, the time period for a subject to mount an immune response, the time period for a subject to clear microorganism from normal tissue, or the time  
25    period for microorganismal proliferation in the tumor or metastasis. In one example, the time period can be a function of the time period for a subject to mount an immune response; for example, the time period can be more than the time period for a subject to mount an immune response, such as more than about one week, more than about ten days, more than about two weeks, or more than about a month; in  
30    another example, the time period can be less than the time period for a subject to

-122-

mount an immune response, such as less than about one week, less than about ten days, less than about two weeks, or less than about a month. In another example, the time period can be a function of the time period for a subject to clear microorganism from normal tissue; for example, the time period can be more than the time period for a subject to clear microorganism from normal tissue, such as more than about a day, more than about two days, more than about three days, more than about five days, or more than about a week. In another example, the time period can be a function of the time period for microorganismal proliferation in the tumor or metastasis; for example, the time period can be more than the amount of time for a detectable signal to arise in a tumor or metastasis after administration of a microorganism expressing a detectable marker, such as about 3 days, about 5 days, about a week, about ten days, about two weeks, or about a month.

**e. Co-administrations**

Also provided are methods in which an additional therapeutic substance, such as a different therapeutic microorganism or a therapeutic compound is administered. These can be administered simultaneously, sequentially or intermittently with the first microorganism. The additional therapeutic substance can interact with the microorganism or a gene product thereof, or the additional therapeutic substance can act independently of the microorganism.

**i. Administration of a plurality of microorganisms**

Methods are provided for administering to a subject two or more microorganisms. Administration can be effected simultaneously, sequentially or intermittently. The plurality of microorganisms can be administered as a single composition or as two or more compositions. The two or more microorganisms can include at least two bacteria, at least two viruses, at least two eukaryotic cells, or two or more selected from among bacteria, viruses and eukaryotic cells. The plurality of microorganisms can be provided as combinations of compositions containing and/or as kits that include the microorganisms packaged for administration and optionally including instructions therefore. The compositions can contain the

-123-

microorganisms formulated for single dosage administration (*i.e.*, for direct administration) can require dilution or other additions.

In one embodiment, at least one of the microorganisms is a modified microorganism such as those provided herein, having a characteristic such as low pathogenicity, low toxicity, preferential accumulation in tumor, ability to activate an immune response against tumor cells, immunogenic, replication competent, ability to express exogenous proteins, and combinations thereof. The microorganisms can be administered at approximately the same time, or can be administered at different times. The microorganisms can be administered in the same composition or in the same administration method, or can be administered in separate composition or by different administration methods.

In one example, a bacteria and a virus can be administered to a subject. The bacteria and virus can be administered at the same time, or at different times. For example, the virus can be administered prior to administering the bacteria, or the bacteria can be administered prior to administering the virus; typically the virus is administered prior to administering the bacteria. As provided herein, administering to a subject a virus prior to administering to the subject a bacterium can increase the amount of bacteria that can accumulate and/or proliferate in a tumor, relative to methods in which bacteria alone are administered.

Accordingly, the methods provided herein that include administration of virus prior to administration of bacteria permit the administration of a lower dosage amount of bacteria than would otherwise be administered in a method in which bacteria alone are administered or a method in which bacteria are administered at the same time as or prior to administration of a virus. For example, in some embodiments, a bacterium to be administered can have one or more properties that limit the ability of the bacterium to be used, such properties can include, but are not limited to toxicity, low tumor specificity of accumulation, and limited proliferation capacity. A bacterium to be administered that has one or more limiting properties can require administration in lower dosage amounts, or can require assistance in tumor-specific accumulation and/or proliferation. Provided herein are methods of



-124-

administering such a bacterium with limiting properties, where prior to administering the bacterium, a virus is administered such that the limited bacterium can be administered in smaller quantities, can accumulate in tumor with increased specificity, and/or can have an increased ability to proliferate in a tumor.

5           The time period between administrations can be any time period that achieves the desired effects, as can be determined by one skilled in the art. Selection of a time period between administrations of different microorganisms can be determined according to parameters similar to those for selecting the time period between administrations of the same microorganism, including results from  
10   monitoring steps, the time period for a subject to mount an immune response, the time period for a subject to clear microorganism from normal tissue, or the time period for microorganismal proliferation in the tumor or metastasis. In one example, the time period can be a function of the time period for a subject to mount an immune response; for example, the time period can be more than the time period for  
15   a subject to mount an immune response, such as more than about one week, more than about ten days, more than about two weeks, or more than about a month; in another example, the time period can be less than the time period for a subject to mount an immune response, such as less than about one week, less than about ten days, less than about two weeks, or less than about a month. In another example, the  
20   time period can be a function of the time period for a subject to clear microorganism from normal tissue; for example, the time period can be more than the time period for a subject to clear microorganism from normal tissue, such as more than about a day, more than about two days, more than about three days, more than about five days, or more than about a week. In another example, the time period can be a  
25   function of the time period for microorganismal proliferation in the tumor or metastasis; for example, the time period can be more than the amount of time for a detectable signal to arise in a tumor or metastasis after administration of a microorganism expressing a detectable marker, such as about 3 days, about 5 days, about a week, about ten days, about two weeks, or about a month. In one example a  
30   virus can first be administered, and a bacteria can be administered about 5 days after

-125-

administration of the virus. In another example, a virus can be first administered, and a bacterium can be administered upon detection of a virally-encoded detectable gene product in the tumor of the subject, optionally when the virally-encoded detectable gene product is detected only in the tumor of the subject.

5

**ii. Therapeutic compounds**

The methods can include administering one or more therapeutic compounds to the subject in addition to administering a microorganism or plurality thereof to a subject. Therapeutic compounds can act independently, or in conjunction with the microorganism, for tumor therapeutic affects. Therapeutic compounds that can act  
10 independently include any of a variety of known chemotherapeutic compounds that can inhibit tumor growth, inhibit metastasis growth and/or formation, decrease the size of a tumor or metastasis, eliminate a tumor or metastasis, without reducing the ability of a microorganism to accumulate in a tumor, replicate in the tumor, and cause or enhance an anti-tumor immune response in the subject.

15

Therapeutic compounds that act in conjunction with the microorganisms include, for example, compounds that alter the expression of the microorganism or compounds that can interact with a microorganism-expressed gene, or compounds that can inhibit microorganismal proliferation, including compounds toxic to the microorganism. Therapeutic compounds that can act in conjunction with the  
20 microorganism include, for example, therapeutic compounds that increase the proliferation, toxicity, tumor cell killing, or immune response eliciting properties of a microorganism, and also can include, for example, therapeutic compounds that decrease the proliferation, toxicity, or cell killing properties of a microorganism. Thus, provided herein are methods of administering to a subject one or more  
25 therapeutic compounds that can act in conjunction with the microorganism to increase the proliferation, toxicity, tumor cell killing, or immune response eliciting properties of a microorganism. Also provided herein are methods of administering to a subject one or more therapeutic compounds that can act in conjunction with the microorganism to decrease the proliferation, toxicity, or cell killing properties of a  
30 microorganism.

-126-

In one embodiment, therapeutic compounds that can act in conjunction with the microorganism to increase the proliferation, toxicity, tumor cell killing, or immune response eliciting properties of a microorganism are compounds that can alter gene expression, where the altered gene expression can result in an increased killing of tumor cells or an increased anti-tumor immune response in the subject. A gene expression-altering compound can, for example, cause an increase or decrease in expression of one or more microorganismal genes, including endogenous microorganismal genes and/or exogenous microorganismal genes. For example, a gene expression-altering compound can induce or increase transcription of a gene in a microorganism such as an exogenous gene that can cause cell lysis or cell death, that can provoke an immune response, that can catalyze conversion of a prodrug-like compound, or that can inhibit expression of a tumor cell gene. Any of a wide variety of compounds that can alter gene expression are known in the art, including IPTG and RU486. Exemplary genes whose expression can be up-regulated include proteins and RNA molecules, including toxins, enzymes that can convert a prodrug to an anti-tumor drug, cytokines, transcription regulating proteins, siRNA, and ribozymes. In another example, a gene expression-altering compound can inhibit or decrease transcription of a gene in a microorganism such as an exogenous gene that can reduce microorganismal toxicity or reduces microorganismal proliferation. Any of a variety of compounds that can reduce or inhibit gene expression can be used in the methods provided herein, including siRNA compounds, transcriptional inhibitors or inhibitors of transcriptional activators. Exemplary genes whose expression can be down-regulated include proteins and RNA molecules, including microorganismal proteins or RNA that suppress lysis, nucleotide synthesis or proliferation, and cellular proteins or RNA molecules that suppress cell death, immunoreactivity, lysis, or microorganismal replication.

In another embodiment, therapeutic compounds that can act in conjunction with the microorganism to increase the proliferation, toxicity, tumor cell killing, or immune response eliciting properties of a microorganism are compounds that can interact with a microorganism-expressed gene product, and such interaction can

-127-

result in an increased killing of tumor cells or an increased anti-tumor immune response in the subject. A therapeutic compound that can interact with a microorganism-expressed gene product can include, for example a prodrug or other compound that has little or no toxicity or other biological activity in its subject-administered form, but after interaction with a microorganism-expressed gene product, the compound can develop a property that results in tumor cell death, including but not limited to, cytotoxicity, ability to induce apoptosis, or ability to trigger an immune response. A variety of prodrug-like substances are known in the art and an exemplary set of such compounds are disclosed elsewhere herein, where such compounds can include gancyclovir, 5-fluorouracil, 6-methylpurine deoxyriboside, cephalosporin-doxorubicin, 4-[(2-chloroethyl)(2-mesuloxoethyl)amino]benzoyl-L-glutamic acid, acetaminophen, indole-3-acetic acid, CB1954, 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycampothecin, bis-(2-chloroethyl)amino-4-hydroxyphenylaminomethanone 28, 1-chloromethyl-5-hydroxy-1,2-dihydro-3H-benz[e]indole, epirubicin-glucoronide, 5'-deoxy-5-fluorouridine, cytosine arabinoside, and linamarin.

In another embodiment, therapeutic compounds that can act in conjunction with the microorganism to decrease the proliferation, toxicity, or cell killing properties of a microorganism are compounds that can inhibit microorganismal replication, inhibit microorganismal toxins, or cause microorganismal death. A therapeutic compound that can inhibit microorganismal replication, inhibit microorganismal toxins, or cause microorganismal death can generally include a compound that can block one or more steps in the microorganismal life cycle, including, but not limited to, compounds that can inhibit microorganismal DNA replication, microorganismal RNA transcription, viral coat protein assembly, outer membrane or polysaccharide assembly. Any of a variety of compounds that can block one or more steps in a microorganismal life cycle are known in the art, including any known antibiotic, microorganismal DNA polymerase inhibitors, microorganismal RNA polymerase inhibitors, inhibitors of proteins that regulate microorganismal DNA replication or RNA transcription. In one example, when a

-128-

microorganism is a bacteria, a compound can be an antibiotic. In another example, a microorganism can contain a gene encoding a microorganismal life cycle protein, such as DNA polymerase or RNA polymerase that can be inhibited by a compound that is, optionally, non-toxic to the host organism.

5                    **f.        State of subject**

                  In another embodiment, the methods provided herein for administering a microorganism to a subject can be performed on a subject in any of a variety of states, including an anesthetized subject, an alert subject, a subject with elevated body temperature, a subject with reduced body temperature, or other state of the  
10                   subject that is known to affect the accumulation of microorganism in the tumor. As provided herein, it has been determined that a subject that is anesthetized can have a decreased rate of accumulation of a microorganism in a tumor relative to a subject that is not anesthetized. Further provided herein, it has been determined that a subject with decreased body temperature can have a decreased rate o accumulation  
15                   of a microorganism in a tumor relative to a subject with a normal body temperature. Accordingly, provided herein are methods of administering a microorganism to a subject, where the methods can include administering a microorganism to a subject where the subject is not under anesthesia, such as general anesthesia; for example, the subject can be under local anesthesia, or can be unanesthetized. Also provided  
20                   herein are methods of administering a microorganism to a subject, where the methods can include administering a microorganism to a subject with altered body temperature, where the alteration of the body temperature can influence the ability of the microorganism to accumulate in a tumor; typically, a decrease in body temperature can decrease the ability of a microorganism to accumulate in a tumor.  
25                   Thus, in one exemplary embodiment, a method is provided for administering a microorganism to a subject, where the method includes elevating the body temperature of the subject to a temperature above normal, and administering a microorganism to the subject, where the microorganism can accumulate in the tumor more readily in the subject with higher body temperature relative to the ability of the

-129-

microorganism to accumulate in a tumor of a subject with a normal body temperature.

## **2. Monitoring**

The methods provided herein can further include one or more steps of  
5 monitoring the subject, monitoring the tumor, and/or monitoring the microorganism administered to the subject. Any of a variety of monitoring steps can be included in the methods provided herein, including, but not limited to, monitoring tumor size, monitoring anti-(tumor antigen) antibody titer, monitoring the presence and/or size of metastases, monitoring the subject's lymph nodes, monitoring the subject's  
10 weight or other health indicators including blood or urine markers, monitoring anti-(microorganismal antigen) antibody titer, monitoring microorganismal expression of a detectable gene product, and directly monitoring microorganismal titer in a tumor, tissue or organ of a subject.

The purpose of the monitoring can be simply for assessing the health state of  
15 the subject or the progress of therapeutic treatment of the subject, or can be for determining whether or not further administration of the same or a different microorganism is warranted, or for determining when or whether or not to administer a compound to the subject where the compound can act to increase the efficacy of the therapeutic method, or the compound can act to decrease the  
20 pathogenicity of the microorganism administered to the subject.

### **a. Monitoring microorganismal gene expression**

In some embodiments, the methods provided herein can include monitoring one or more microorganismally expressed genes. Microorganisms, such as those provided herein or otherwise known in the art, can express one or more detectable  
25 gene products, including but not limited to, detectable proteins.

As provided herein, measurement of a detectable gene product expressed in a microorganism can provide an accurate determination of the level of microorganism present in the subject. As further provided herein, measurement of the location of the detectable gene product, for example, by imaging methods including  
30 tomographic methods, can determine the localization of the microorganism in the

-130-

subject. Accordingly, the methods provided herein that include monitoring a detectable microorganismal gene product can be used to determine the presence or absence of the microorganism in one or more organs or tissues of a subject, and/or the presence or absence of the microorganism in a tumor or metastases of a subject.

5 Further, the methods provided herein that include monitoring a detectable microorganismal gene product can be used to determine the titer of microorganism present in one or more organs, tissues, tumors or metastases. Methods that include monitoring the localization and/or titer of microorganisms in a subject can be used for determining the pathogenicity of a microorganism; since microorganismal

10 infection, and particularly the level of infection, of normal tissues and organs can indicate the pathogenicity of the probe, methods of monitoring the localization and/or amount of microorganisms in a subject can be used to determine the pathogenicity of a microorganism. Since methods provided herein can be used to monitor the amount of microorganisms at any particular location in a subject, the

15 methods that include monitoring the localization and/or titer of microorganisms in a subject can be performed at multiple time points, and, accordingly can determine the rate of microorganismal replication in a subject, including the rate of microorganismal replication in one or more organs or tissues of a subject; accordingly, the methods of monitoring a microorganismal gene product can be used

20 for determining the replication competence of a microorganism. The methods provided herein also can be used to quantitate the amount of microorganism present in a variety of organs or tissues, and tumors or metastases, and can thereby indicate the degree of preferential accumulation of the microorganism in a subject; accordingly, the microorganismal gene product monitoring methods provided herein

25 can be used in methods of determining the ability of a microorganism to accumulate in tumor or metastases in preference to normal tissues or organs. Since the microorganisms used in the methods provided herein can accumulate in an entire tumor or can accumulate at multiple sites in a tumor, and can also accumulate in metastases, the methods provided herein for monitoring a microorganismal gene

30 product can be used to determine the size of a tumor or the number of metastases are

-131-

present in a subject. Monitoring such presence of microorganismal gene product in tumor or metastasis over a range of time can be used to assess changes in the tumor or metastasis, including growth or shrinking of a tumor, or development of new metastases or disappearance of metastases, and also can be used to determine the rate of growth or shrinking of a tumor, or development of new metastases or disappearance of metastases, or the change in the rate of growth or shrinking of a tumor, or development of new metastases or disappearance of metastases. Accordingly, the methods of monitoring a microorganismal gene product can be used for monitoring a neoplastic disease in a subject, or for determining the efficacy of treatment of a neoplastic disease, by determining rate of growth or shrinking of a tumor, or development of new metastases or disappearance of metastases, or the change in the rate of growth or shrinking of a tumor, or development of new metastases or disappearance of metastases.

Any of a variety of detectable proteins can be detected in the monitoring methods provided herein; an exemplary, non-limiting list of such detectable proteins includes any of a variety of fluorescence proteins (*e.g.*, green fluorescence proteins), any of a variety of luciferases, transferring or other iron binding proteins; or receptors, binding proteins, and antibodies, where a compound that specifically binds the receptor, binding protein or antibody can be a detectable agent or can be labeled with a detectable substance (*e.g.*, a radionuclide or imaging agent).

**b. Monitoring tumor size**

Also provided herein are methods of monitoring tumor and/or metastasis size and location. Tumor and or metastasis size can be monitored by any of a variety of methods known in the art, including external assessment methods or tomographic or magnetic imaging methods. In addition to the methods known in the art, methods provided herein, for example, monitoring microorganismal gene expression, can be used for monitoring tumor and/or metastasis size.

Monitoring size over several time points can provide information regarding the increase or decrease in size of a tumor or metastasis, and can also provide information regarding the presence of additional tumors and/or metastases in the



-132-

subject. Monitoring tumor size over several time points can provide information regarding the development of a neoplastic disease in a subject, including the efficacy of treatment of a neoplastic disease in a subject.

**c. Monitoring antibody titer**

5           The methods provided herein also can include monitoring the antibody titer in a subject, including antibodies produced in response to administration of a microorganism to a subject. The microorganisms administered in the methods provided herein can elicit an immune response to endogenous microorganismal antigens. The microorganisms administered in the methods provided herein also can  
10       elicit an immune response to exogenous genes expressed by a microorganism. The microorganisms administered in the methods provided herein also can elicit an immune response to tumor antigens. Monitoring antibody titer against microorganismal antigens, microorganismally expressed exogenous gene products, or tumor antigens can be used in methods of monitoring the toxicity of a  
15       microorganism, monitoring the efficacy of treatment methods, or monitoring the level of gene product or antibodies for production and/or harvesting.

          In one embodiment, monitoring antibody titer can be used to monitor the toxicity of a microorganism. Antibody titer against a microorganism can vary over the time period after administration of the microorganism to the subject, where at  
20       some particular time points, a low anti-(microorganismal antigen) antibody titer can indicate a higher toxicity, while at other time points a high anti-(microorganismal antigen) antibody titer can indicate a higher toxicity. The microorganisms used in the methods provided herein can be immunogenic, and can, therefore, elicit an immune response soon after administering the microorganism to the subject.

25       Generally, a microorganism against which a subject's immune system can quickly mount a strong immune response can be a microorganism that has low toxicity when the subject's immune system can remove the microorganism from all normal organs or tissues. Thus, in some embodiments, a high antibody titer against microorganismal antigens soon after administering the microorganism to a subject  
30       can indicate low toxicity of a microorganism. In contrast, a microorganism that is

-133-

not highly immunogenic may infect a host organism without eliciting a strong immune response, which can result in a higher toxicity of the microorganism to the host. Accordingly, in some embodiments, a high antibody titer against microorganismal antigens soon after administering the microorganism to a subject can indicate low toxicity of a microorganism.

5 In other embodiments, monitoring antibody titer can be used to monitor the efficacy of treatment methods. In the methods provided herein, antibody titer, such as anti-(tumor antigen) antibody titer, can indicate the efficacy of a therapeutic method such as a therapeutic method to treat neoplastic disease. Therapeutic methods provided herein can include causing or enhancing an immune response against a tumor and/or metastasis. Thus, by monitoring the anti-(tumor antigen) antibody titer, it is possible to monitor the efficacy of a therapeutic method in causing or enhancing an immune response against a tumor and/or metastasis. The therapeutic methods provided herein also can include administering to a subject a microorganism that can accumulate in a tumor and can cause or enhance an anti-tumor immune response. Accordingly, it is possible to monitor the ability of a host to mount an immune response against microorganisms accumulated in a tumor or metastasis, which can indicate that a subject has also mounted an anti-tumor immune response, or can indicate that a subject is likely to mount an anti-tumor immune response, or can indicate that a subject is capable of mounting an anti-tumor immune response.

15 In other embodiments, monitoring antibody titer can be used for monitoring the level of gene product or antibodies for production and/or harvesting. As provided herein, methods can be used for producing proteins, RNA molecules or other compounds by expressing an exogenous gene in a microorganism that has accumulated in a tumor. Further provided herein are methods for producing antibodies against a protein, RNA molecule or other compound produced by exogenous gene expression of a microorganism that has accumulated in a tumor. Monitoring antibody titer against the protein, RNA molecule or other compound can indicate the level of production of the protein, RNA molecule or other compound by

-134-

the tumor-accumulated microorganism, and also can directly indicate the level of antibodies specific for such a protein, RNA molecule or other compound.

**d. Monitoring general health diagnostics**

The methods provided herein also can include methods of monitoring the health of a subject. Some of the methods provided herein are therapeutic methods, including neoplastic disease therapeutic methods. Monitoring the health of a subject can be used to determine the efficacy of the therapeutic method, as is known in the art. The methods provided herein also can include a step of administering to a subject a microorganism. Monitoring the health of a subject can be used to determine the pathogenicity of a microorganism administered to a subject. Any of a variety of health diagnostic methods for monitoring disease such as neoplastic disease, infectious disease, or immune-related disease can be monitored, as is known in the art. For example, the weight, blood pressure, pulse, breathing, color, temperature or other observable state of a subject can indicate the health of a subject. In addition, the presence or absence or level of one or more components in a sample from a subject can indicate the health of a subject. Typical samples can include blood and urine samples, where the presence or absence or level of one or more components can be determined by performing, for example, a blood panel or a urine panel diagnostic test. Exemplary components indicative of a subject's health include, but are not limited to, white blood cell count, hematocrit, c-reactive protein concentration.

**e. Monitoring coordinated with treatment**

Also provided herein are methods of monitoring a therapy, where therapeutic decisions can be based on the results of the monitoring. Therapeutic methods provided herein can include administering to a subject a microorganism, where the microorganism can preferentially accumulate in a tumor and/or metastasis, and where the microorganism can cause or enhance an anti-tumor immune response. Such therapeutic methods can include a variety of steps including multiple administrations of a particular microorganism, administration of a second microorganism, or administration of a therapeutic compound. Determination of the

-135-

amount, timing or type of microorganism or compound to administer to the subject can be based on one or more results from monitoring the subject. For example, the antibody titer in a subject can be used to determine whether or not it is desirable to administer a microorganism or compound, the quantity of microorganism or compound to administer, and the type of microorganism or compound to administer, where, for example, a low antibody titer can indicate the desirability of administering additional microorganism, a different microorganism, or a therapeutic compound such as a compound that induces microorganismal gene expression. In another example, the overall health state of a subject can be used to determine whether or not it is desirable to administer a microorganism or compound, the quantity of microorganism or compound to administer, and the type of microorganism or compound to administer, where, for example, determining that the subject is healthy can indicate the desirability of administering additional microorganism, a different microorganism, or a therapeutic compound such as a compound that induces microorganismal gene expression. In another example, monitoring a detectable microorganismally expressed gene product can be used to determine whether or not it is desirable to administer a microorganism or compound, the quantity of microorganism or compound to administer, and the type of microorganism or compound to administer. Such monitoring methods can be used to determine whether or not the therapeutic method is effective, whether or not the therapeutic method is pathogenic to the subject, whether or not the microorganism has accumulated in a tumor or metastasis, and whether or not the microorganism has accumulated in normal tissues or organs. Based on such determinations, the desirability and form of further therapeutic methods can be derived.

In one embodiment, determination of whether or not a therapeutic method is effective can be used to derive further therapeutic methods. Any of a variety of methods of monitoring can be used to determine whether or not a therapeutic method is effective, as provided herein or otherwise known in the art. If monitoring methods indicate that the therapeutic method is effective, a decision can be made to maintain the current course of therapy, which can include further administrations of

-136-

a microorganism or compound, or a decision can be made that no further administrations are required. If monitoring methods indicate that the therapeutic method is ineffective, the monitoring results can indicate whether or not a course of treatment should be discontinued (*e.g.*, when a microorganism is pathogenic to the subject), or changed (*e.g.*, when a microorganism accumulates in a tumor without harming the host organism, but without eliciting an anti-tumor immune response), or increased in frequency or amount (*e.g.*, when little or no microorganism accumulates in tumor).

In one example, monitoring can indicate that a microorganism is pathogenic to a subject. In such instances, a decision can be made to terminate administration of the microorganism to the subject, to administer lower levels of the microorganism to the subject, to administer a different microorganism to a subject, or to administer to a subject a compound that reduces the pathogenicity of the microorganism. In one example, administration of a microorganism that is determined to be pathogenic can be terminated. In another example, the dosage amount of a microorganism that is determined to be pathogenic can be decreased for subsequent administration; in one version of such an example, the subject can be pre-treated with another microorganism that can increase the ability of the pathogenic microorganism to accumulate in tumor, prior to re-administering the pathogenic microorganism to the subject. In another example, a subject can have administered thereto a bacteria or virus that is pathogenic to the subject; administration of such a pathogenic microorganism can be accompanied by administration of, for example an antibiotic, anti-microorganismal compound, pathogenicity attenuating compound (*e.g.*, a compound that down-regulates the expression of a lytic or apoptotic gene product), or other compound that can decrease the proliferation, toxicity, or cell killing properties of a microorganism, as described herein elsewhere. In one variation of such an example, the localization of the microorganism can be monitored, and, upon determination that the microorganism is accumulated in tumor and/or metastases but not in normal tissues or organs, administration of the antibiotic, anti-microorganismal compound or pathogenicity attenuating compound can be

-137-

terminated, and the pathogenic activity of the microorganism can be activated or increased, but limited to the tumor and/or metastasis. In another variation of such an example, after terminating administration of an antibiotic, anti-microorganismal compound or pathogenicity attenuating compound, the presence of the  
5 microorganism and/or pathogenicity of the microorganism can be further monitored, and administration of such a compound can be reinitiated if the microorganism is determined to pose a threat to the host by, for example, spreading to normal organs or tissues, releasing a toxin into the vasculature, or otherwise having pathogenic effects reaching beyond the tumor or metastasis.

10 In another example, monitoring can determine whether or not a microorganism has accumulated in a tumor or metastasis of a subject. Upon such a determination, a decision can be made to further administer additional microorganism, a different microorganism or a compound to the subject. In one example, monitoring the presence of a virus in a tumor or metastasis can be used in  
15 deciding to administer to the subject a bacterium, where, for example, the quantity of bacteria administered can be reduced according to the presence and/or quantity of virus in a tumor or metastasis. In a similar example, monitoring the presence of a virus in a tumor or metastasis can be used in deciding when to administer to the subject a bacterium, where, for example, the bacteria can be administered upon  
20 detecting to the presence and/or a selected quantity of virus in a tumor or metastasis. In another example, monitoring the presence of a microorganism in a tumor can be used in deciding to administer to the subject a compound, where the compound can increase the pathogenicity, proliferation, or immunogenicity of a microorganism or the compound can otherwise act in conjunction with the microorganism to increase  
25 the proliferation, toxicity, tumor cell killing, or immune response eliciting properties of a microorganism; in one variation of such an example, the microorganism can, for example have little or no lytic or cell killing capability in the absence of such a compound; in a further variation of such an example, monitoring of the presence of the microorganism in a tumor or metastasis can be coupled with monitoring the  
30 absence of the microorganism in normal tissues or organs, where the compound is

-138-

administered if the microorganism is present in tumor or metastasis and not at all present or substantially not present in normal organs or tissues; in a further variation of such an example, the amount of microorganism in a tumor or metastasis can be monitored, where the compound is administered if the microorganism is present in  
5 tumor or metastasis at sufficient levels.

#### **E. Methods of Producing Gene Products and Antibodies**

Provided herein are microorganisms, and methods for making and using such microorganisms for production products of exogenous genes and/or for production of antibodies specific for exogenous gene products. The methods provided herein  
10 result in efficient recombinant production of biologically active proteins. In EP A1 1 281 772, it is disclosed that when vaccinia virus (LIVP strain) carrying the light emitting fusion gene construct rVV-ruc-gfp was injected intravenously into nude mice, the virus particles were found to be cleared from all internal organs within 4 days, as determined by extinction of light emission. In contrast, when the fate of the  
15 injected vaccinia virus was similarly followed in nude mice bearing tumors grown from subcutaneously implanted C6 rat glioma cells, virus particles were found to be retained over time in the tumor tissues, resulting in lasting light emission. The presence and amplification of the virus-encoded fusion proteins in the same tumor were monitored in live animals by observing GFP fluorescence under a  
20 stereomicroscope and by detecting luciferase-catalyzed light emission under a low-light video-imaging camera. Tumor-specific light emission was detected 4 days after viral injection in nude mice carrying subcutaneous C6 glioma implants. Tumor accumulation of rVV-ruc-gfp virus particles was also seen in nude mice carrying subcutaneous tumors developed from implanted PC-3 human prostate cells, and in  
25 mice with orthotopically implanted MCF-7 human breast tumors. Further, intracranial C6 rat glioma cell implants in immunocompetent rats and MB-49 human bladder tumor cell implants in C57 mice were also targeted by the vaccinia virus. In addition to primary breast tumors, small metastatic tumors were also detected externally in the contralateral breast region, as well as in nodules on the exposed  
30 lung surface, suggesting metastasis to the contralateral breast and lung. In summary

-139-

it was shown that light-emitting cells or microorganisms, for example, vaccinia virus can be used to detect and treat metastatic tumors.

Similar results were obtained with light-emitting bacteria (*Salmonella*, *Vibrio*, *Listeria*, *E. coli*) which were injected intravenously into mice and which could be visualized in whole animals under a low light imager immediately. No light emission was detected twenty four hours after bacterial injection in both athymic (nu/nu) mice and immunocompetent C57 mice as a result of clearing by the immune system. In nude mice bearing tumors developed from implanted C6 glioma cells, light emission was abolished from the animal entirely twenty four hours after delivery of bacteria, similar to mice without tumors. However, forty eight hours post-injection, a strong, rapidly increasing light emission originated only from the tumor regions was observed. This observation indicated a continuous bacterial replication in the tumor tissue. The extent of light emission was dependent on the bacterial strain used. The homing-in process together with the sustained light emission was also demonstrated in nude mice carrying prostate, bladder, and breast tumors. In addition to primary tumors, metastatic tumors could also be visualized as exemplified in the breast tumor model. Tumor-specific light emission was also observed in immunocompetent C57 mice, with bladder tumors as well as in Lewis rats with brain glioma implants. Once in the tumor, the light-emitting bacteria were not observed to be released into the circulation and to re-colonize subsequently implanted tumors in the same animal. Further, mammalian cells expressing the Ruc-GFP fusion protein, upon injection into the bloodstream, were also found to home in to, and propagate in, glioma tumors. These findings opened the way for designing multifunctional viral vectors useful for the detection of tumors based on signals such as light emission, for suppression of tumor development and angiogenesis signaled by, for example, light extinction and the development of bacterial and mammalian cell-based tumor targeting systems in combination with therapeutic gene constructs for the treatment of cancer. These systems have the following advantages: (a) They target the tumor specifically without affecting normal tissue; (b) the expression and secretion of the therapeutic gene constructs can be, optionally, under the control of



-140-

an inducible promoter enabling secretion to be switched on or off; and (c) the location of the delivery system inside the tumor can be verified by direct visualization before activating gene expression and protein delivery.

As provided herein, the system described above based on the accumulation of bacteria, viruses and eukaryotic cells in tumors can be used for simple, quick, and inexpensive production of proteins and other biological compounds originating from cloned nucleotide sequences. This system also is useful for the concomitant overproduction of polypeptides, RNA or other biological compounds (in tumor tissue) and antibodies against those compounds (in the serum) in the same animal.

As provided herein, after intravenous injection, a microorganism such as vaccinia virus can enter the tumor of an animal and, due to the immunoprivileged state of the tumor, can replicate preferentially in the tumor tissues and thereby can overproduce the inserted gene encoded protein in the tumors. After harvesting the tumor tissues, the localized and overexpressed protein can be isolated by a simple procedure from tumor homogenates. In addition, based on the findings that only 0.2 to 0.3% of the desired proteins produced in the tumor were found in the blood stream of the same animal, a simultaneous vaccination of the mouse and efficient antibody production against the overproduced protein was achieved. Thus, serum from the same mouse (or any other animal) can be harvested and used as mouse-derived antibodies against the proteins or other products overproduced in the tumor.

Thus, provided herein are methods of producing gene products and or antibodies in a non-human subject, by administering to a subject containing a tumor, a microorganism, where the microorganism expresses a selected protein or RNA to be produced, a protein or RNA whose expression can result in the formation of a compound to be produced, or a selected protein or RNA against which an antibody is to be produced. The methods provided herein can further include administering to a subject containing a tumor, a microorganism expressing an exogenous gene encoding a selected protein or RNA to be produced, a protein or RNA whose expression can result in the formation of a compound to be produced, or a selected protein or RNA against which an antibody is to be produced. The methods provided

-141-

herein can further include administering to a subject containing a tumor, a microorganism expressing an gene encoding a selected protein or RNA to be produced, a protein or RNA whose expression can result in the formation of a compound to be produced, or a selected protein or RNA against which an antibody is to be produced, where such gene expression can be regulated, for example, by a transcriptional activator or inducer, or a transcriptional suppressor. The methods provided herein for producing a protein, RNA, compound or antibody can further include monitoring the localization and/or level of the microorganism in the subject by detecting a detectable protein, where the detectable protein can indicate the expression of the selected gene, or can indicate the readiness of the microorganism to be induced to express the selected gene or for suppression of expression to be terminated or suspended. Also provided herein are methods of producing gene products and or antibodies in a non-human subject, by administering to a subject containing a tumor, a microorganism, where the microorganism expresses a selected protein or RNA to be produced, a protein or RNA whose expression can result in the formation of a compound to be produced, or a selected protein or RNA against which an antibody is to be produced, where the subject to which the microorganism is administered is not a transgenic animal. Also provided herein are methods of producing gene products and or antibodies in a non-human subject, by administering to a subject containing a tumor, a microorganism, where the microorganism expresses a selected protein to be produced, where the tumor within the subject is selected according to its ability to post-translationally process the selected protein.

The advantages of the system, include:

- (a) No production of a transgenic animal carrying the novel polypeptide-encoding cassette is required;
- (b) the tumor system is more efficient than tissue culture;
- (c) proteins interfering with animal development and other toxic proteins can be overproduced in tumors without negative effects to the host animal;
- (d) the system is fast: within 4 to 6 weeks from cDNA cloning to protein and antisera purification;

-142-

- (e) the system is relatively inexpensive and can be scaled up easily;
- (f) correct protein folding and modifications can be achieved;
- (g) high antigenicity can be achieved, which is beneficial for better antibody production; and
- 5 (h) species-specific-cell-based production of proteins in animals such as mice, with tumors as fermentors can be achieved.

Depiction of an exemplary method for production of gene products and/or antibodies against gene products is provided in Figure 2.

- 10 In one embodiment, methods are provided for producing a desired polypeptide, RNA or compound, the method including the following steps: (a) injecting a microorganism containing a nucleotide sequence encoding the desired polypeptide or RNA into an animal bearing a tumor; (b) harvesting the tumor tissue from the animal; and (c) isolating the desired polypeptide, RNA or compound from the tumor tissue.

- 15 Steps of an exemplary method can be summarized as follows (shown for a particular embodiment, *i.e.* vaccinia virus additionally containing a gene encoding a light-emitting protein):

- (1) Insertion of the desired DNA or cDNA into the vaccinia virus genome;
- (2) modification of the vaccinia virus genome with light-emitting protein
- 20 construct as expression marker;
- (3) recombination and virus assembly in cell culture;
- (4) screening of individual viral particles carrying inserts followed by large scale virus production and concentration;
- (5) administration of the viral particles into mice or other animals bearing
- 25 tumors of human, non-human primate or other mammalian origins;
- (6) verification of viral replication and protein overproduction in animals based on light emission;
- (7) harvest of tumor tissues and, optionally, the blood (separately); and
- (8) purification of overexpressed proteins from tumors and, optionally, antisera
- 30 from blood using conventional methods.

-143-

Any microorganism can be used in the methods provided herein, provided that they replicate in the animal, are not pathogenic for the animal, for example, are attenuated, and are recognized by the immune system of the animal. In some embodiments, such microorganisms also can express exogenous genes. Suitable microorganisms and cells are, for example, disclosed in EP A1 1 281 772 and EP A1 1 281 767. The person skilled in the art also knows how to generate animals carrying the desired tumor (see, *e.g.*, EP A1 1 281 767 or EP A1 1 281 777).

Also provide is a method for simultaneously producing a desired polypeptide, RNA or compound and an antibody directed to the polypeptide, RNA or compound, the method having the following steps: (a) administering a microorganism containing a nucleotide sequence encoding the desired polypeptide or RNA into an animal bearing a tumor; (b) harvesting the tumor tissue from the animal; (c) isolating the desired polypeptide, RNA or compound from the tumor tissue; and (d) isolating the antibody directed to the polypeptide, RNA or compound from the serum obtained from the animal. This approach can be used for generating polypeptides and/or antibodies against the polypeptides which are toxic or unstable, or which require species specific cellular environment for correct folding or modifications.

In another embodiment, the microorganism can further contain a nucleotide sequence encoding a detectable protein, such as a luminescent or fluorescent protein, or a protein capable of inducing a detectable signal.

Typically in methods for transfecting the microorganisms or cells with nucleotide sequences encoding the desired polypeptide or RNA and, optionally, a nucleotide sequence encoding a detectable protein such as a luminescent or fluorescent protein, or a protein capable of inducing a detectable signal, the nucleotide sequences are present in a vector or an expression vector. A person skilled in the art is familiar with a variety of expression vectors, which can be selected according to the microorganism used to infect the tumor, the cell type of the tumor, the organism to be infected, and other factors known in the art. In some embodiments, the microorganism can be a virus, including the viruses disclosed

-144-

herein. Thus, the nucleotide sequences can be contained in a recombinant virus containing appropriate expression cassettes. Suitable viruses for use herein, include, but are not limited to, baculovirus, vaccinia, Sindbis virus, Sendai virus, adenovirus, an AAV virus or a parvovirus, such as MVM or H-1. The vector can also be a retrovirus, such as MoMULV, MoMuLV, HaMuSV, MuMTV, RSV or GaLV. For expression in mammalian cells, a suitable promoter is, for example, human cytomegalovirus immediate early promoter (pCMV). Furthermore, tissue and/or organ specific promoters can be used. For example, the nucleotide sequences can be operatively linked with a promoter allowing high expression. Such promoters can include, for example, inducible promoters; a variety of such promoters are known to persons skilled in the art.

For generating protein or RNA-encoding nucleotide sequences and for constructing expression vectors or viruses that contain the nucleotide sequences, it is possible to use general methods known in the art. These methods include, for example, in vitro recombination techniques, synthetic methods and in vivo recombination methods as known in the art, and exemplified in Sambrook *et al.*, Molecular Cloning, A Laboratory Manual, 2nd edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. Methods of transfecting cells, of phenotypically selecting transfectants cells, of phenotypically selecting transfectants and of expressing the nucleotide sequences by using vectors containing protein or RNA-encoding DNA are known in the art.

In some embodiments, the protein or RNA to be produced in the tumor can be linked to an inducible promoter, such as a promoter that can be induced by a substance endogenous to the subject, or by a substance that can be administered to a subject. Accordingly, provided herein are methods of producing a protein or RNA in a tumor, where the production can be induced by administration of a substance to a subject, and, optionally, harvesting the tumor and isolating the protein or RNA from the tumor. Such induction methods can be coupled with methods of monitoring a microorganism in a subject. For example, a microorganism can be monitored by detecting a detectable protein. In methods that include monitoring,

-145-

detection of a desired localization and/or level of microorganism in the subject can be coordinated with induction of microorganismal gene expression. For example, when a microorganismally expressed detectable protein is detected in tumor, but not appreciably in normal organs or tissues, an inducer can be administered to the  
5 subject. In another example, when a microorganismally expressed detectable protein is detected in tumor, and also in normal organs or tissues, administration of an inducer can be suspended or postponed until the detectable protein is no longer detected in normal organs or tissues. In another example, when a microorganismally expressed detectable protein is detected at sufficient levels in tumor, an inducer can  
10 be administered to the subject. In another example, when a microorganismally expressed detectable protein is not detected at sufficient levels in tumor administration of an inducer can be suspended or postponed until the detectable protein is detected at sufficient levels in the tumor.

Also provided herein are methods of producing a protein or RNA in a tumor,  
15 by administering a microorganism encoding the protein or RNA, and a suppressor of gene expression. The suppressor of gene expression can be administered for a pre-defined period of time, or until the microorganism accumulated in tumor but not in normal organs or tissues, or until sufficient levels of the microorganism have accumulated in the tumor, at which point administration of the suppressor can be  
20 terminated or suspended, which can result in expression of the protein or RNA. As will be recognized by one skilled in the art, methods similar to those provided herein in regard to monitoring a detectable protein and administering an inducer, can also apply for terminating or suspending administration of a suppressor.

In one embodiment, the microorganism is a bacterium, for example, an  
25 attenuated bacterium, such as those provided herein. Exemplary bacteria include attenuated *Salmonella typhimurium*, attenuated *Vibrio cholerae*, attenuated *Listeria monocytogenes* or *E. coli*. Alternatively, viruses such as vaccinia virus, AAV, a retrovirus can be used in the methods provided herein. In exemplary methods, the virus is vaccinia virus. Other cells that can be used in the present methods include

-146-

mammalian cells, such as fibroma cells, including human cells such as human fibroma cells.

Any of a variety of animals, including laboratory or livestock animals can be used, including for example, mice, rats and other rodents, rabbits, guinea pigs, pigs, sheep, goats, cows and horses. Exemplary animals are mice. The tumor can be generated by implanting tumor cells into the animal. Generally, for the production of a desired polypeptide, RNA, or compound, any solid tumor type can be used, such as a fast growing tumor type. Exemplary fast growing tumor types include C6 rat glioma and HCT116 human colon carcinoma. Generally, for the production of a desired antibody, a relatively slow growing tumor type can be used. Exemplary slow growing tumor types include HT1080 human fibrosarcoma and GI-101A human breast carcinoma. For T-independent antibody production, nu-/nu- mice bearing allogenic tumor or xenografts can be used; while for T-dependent antibody production, immunocompetent mice with syngenic tumors can be used. In some embodiments, such as where the compound to be produced is a protein, the microorganism selected can be a microorganism that uses the translational components (*e.g.*, proteins, vesicles, substrates) of the tumor cells, such as, for example, a virus that uses the translational components of a tumor cell. In such instances, the tumor cell type can be selected according to the desired post-translational processing to be performed on the protein, including proteolysis, glycosylation, lipidylation, disulfide formation, and any refolding or multimer assembly that can require cellular components for completing. In some examples, the tumor cell type selected can be the same species as the protein to be expressed, thus resulting in species-specific post-translational processing of the protein; an exemplary tumor cell type-expressed protein species is human.

#### **1. Production of Recombinant Proteins and RNA molecules**

The tumor tissue can be surgically removed from the animal. After homogenization of the tumor tissue, the desired polypeptide, RNA or other biological compound can be purified according to established methods. For example, in the case of a recombinant polypeptide, the polypeptide might contain a

-147-

bindable tag such as a his-tag, and can be purified, for example, via column chromatography. The time necessary for accumulation of sufficient amounts of the polypeptide or RNA in the tumor of the animal depends on many factors, for example, the kind of animal or the kind of tumor, and can be determined by the skilled person by routine experimentation. In general, expression of the desired polypeptide can be detected two days after virus injection. The expression peaks approximately two weeks after injection, and lasts up to two months. In some embodiments, the amount of desired polypeptide or RNA in the tumor can be determined by monitoring a microorganismally expressed detectable substance, where the concentration of the detectable substance can reflect the amount of desired polypeptide or RNA in the tumor.

In another embodiment, the desired polypeptide, RNA or other compound can be manufactured in the subject, and provide a beneficial effect to the subject. In one example, a microorganism can encode a protein or RNA, or a protein that manufactures a compound that is not manufactured by the subject. In one example, a microorganism can encode a peptide hormone or cytokine, such as insulin, which can be released into the vasculature of a subject lacking the ability to produce insulin or requiring increased insulin concentrations in the vasculature. In another example, blood clotting factors can be manufactured in a subject with blood clotting deficiency, such as a hemophiliac. In some embodiments, the protein or RNA to be produced in the tumor can be linked to an inducible promotor, such as a promotor that can be induced by increased glucose concentrations. In such instances, the manufacture of the protein or RNA can be controlled in response to one or more substances in the subject or by one or more substances that can be administered to a subject, such as a compound that can induce transcription, for example, RU486. Thus, in some embodiments, the methods provided herein can include administering to a subject having a tumor, a microorganism that can express one or more genes encoding a beneficial gene product or a gene product that can manufacture a beneficial compound.

30



-148-

## 2. Production of Antibodies

Also provided are methods for producing a desired antibody, the method comprising the following steps: (a) administering a microorganism containing a nucleotide sequence encoding an antigen into an animal bearing a tumor; and (b) isolating the antibody directed to the antigen from the serum obtained from the animal. The antibodies directed to the antigen can be isolated and purified according to well known methods. Antibodies that are directed against specific contaminating antigens (*e.g.*, bacteria antigens) can be removed by adsorption, and the antibodies directed against the target antigen can be separated from contaminating antibodies by affinity purification, for example, by immuno affinity chromatography using the recombinant antigen as the ligand of the column, by methods known in the art. Antibodies can be collected from the animal in a single harvest, or can be collected over time by collection bleeds, as is known in the art.

### F. Pharmaceutical Compositions, combinations and kits

Provided herein are pharmaceutical compositions, combinations and kits containing a microorganism provided herein and one or more components. Pharmaceutical compositions can include a microorganism and a pharmaceutical carrier. Combinations can include two or more microorganisms, a microorganism and a detectable compound, a microorganism and a microorganism expression modulating compound, a microorganism and a therapeutic compound. Kits can include the pharmaceutical compositions and/or combinations provided herein, and one or more components such as instructions for use, a device for detecting a microorganism in a subject, a device for administering a compound to a subject, and a device for administering a compound to a subject.

#### 1. Pharmaceutical Compositions

Also provided herein are pharmaceutical compositions containing a modified microorganism and a suitable pharmaceutical carrier. Examples of suitable pharmaceutical carriers are known in the art and include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions, etc. Such carriers can be formulated by conventional

-149-

methods and can be administered to the subject at a suitable dose. Colloidal dispersion systems that can be used for delivery of microorganisms include macromolecule complexes, nanocapsules, microspheres, beads and lipid-based systems including oil-in-water emulsions (mixed), micelles, liposomes and lipoplexes. An exemplary colloidal system is a liposome. Organ-specific or cell-specific liposomes can be used in order to achieve delivery only to the desired tissue. The targeting of liposomes can be carried out by the person skilled in the art by applying commonly known methods. This targeting includes passive targeting (utilizing the natural tendency of the liposomes to distribute to cells of the RES in organs which contain sinusoidal capillaries) or active targeting (for example by coupling the liposome to a specific ligand, for example, an antibody, a receptor, sugar, glycolipid, protein etc., by well known methods). In the present methods, monoclonal antibodies can be used to target liposomes to specific tissues, for example, tumor tissue, via specific cell-surface ligands.

## 2. Host Cells

Also provided herein are host cells that contain a microorganism provided herein such as a modified vaccinia virus. These host cells can include any of a variety of mammalian, avian and insect cells and tissues that are susceptible to microorganism, such as vaccinia virus, infection, including chicken embryo, rabbit, hamster and monkey kidney cells, for example, CV-1, BSC40, Vero, BSC40 and BSC-1, and human HeLa cells. Methods of transforming these host cells, of phenotypically selecting transformants etc., are known in the art.

## 3. Combinations

Combinations can include a microorganism and one or more components. Any combination herein also can, in place of a microorganism, contain a pharmaceutical composition and/or a host cell containing a microorganism and one or more components.

Exemplary combinations can contain two or more microorganisms, a microorganism and a detectable compound, a microorganism and a microorganism expression modulating compound, or a microorganism and a therapeutic compound.

-150-

Combinations that contain two or more microorganisms can contain, for example, two or more microorganisms that can both be administered to a subject in performing the methods provided herein, including sequentially administering the two microorganisms. In one example, a combination can contain a virus and a  
5 bacterium, where, for example, the virus can first be administered to the subject, and the bacterium can be subsequently administered to the subject.

Combinations provided herein can contain a microorganism and a detectable compound. A detectable compound can include a ligand or substrate or other compound that can interact with and/or bind specifically to a microorganismally  
10 expressed protein or RNA molecule, and can provide a detectable signal, such as a signal detectable by tomographic, spectroscopic or magnetic resonance techniques. Exemplary detectable compounds can be, or can contain, an imaging agent such as a magnetic resonance, ultrasound or tomographic imaging agent, including a radionuclide. The detectable compound can include any of a variety of compounds  
15 as provided elsewhere herein or are otherwise known in the art. Typically, the detectable compound included with a microorganism in the combinations provided herein will be a compound that is a substrate, a ligand, or can otherwise specifically interact with, a protein or RNA encoded by the microorganism; in some examples, the protein or RNA is an exogenous protein or RNA. Exemplary  
20 microorganisms/detectable compounds include a microorganism encoding luciferase/luciferin,  $\beta$ -galactosidase/(4,7,10-tri(acetic acid)-1-(2- $\beta$ -galactopyranosylethoxy)-1,4,7,10-tetraazacyclodecane) gadolinium (Egad), and other combinations known in the art.

Combinations provided herein can contain a microorganism and a  
25 microorganism gene expression modulating compound. Compounds that modulate gene expression are known in the art, and include, but are not limited to, transcriptional activators, inducers, transcriptional suppressors, RNA polymerase inhibitors, and RNA binding compounds such as siRNA or ribozymes. Any of a variety of gene expression modulating compounds known in the art can be included  
30 in the combinations provided herein. Typically, the gene expression modulating

-151-

compound included with a microorganism in the combinations provided herein will be a compound that is a can bind, inhibit, or react with one or more compounds active in gene expression such as a transcription factor or RNA, of the microorganism of the combination. An exemplary microorganism/expression modulator can be a microorganism encoding a chimeric transcription factor complex having a mutant human progesterone receptor fused to a yeast GAL4 DNA-binding domain an activation domain of the herpes simplex virus protein VP16 and also containing a synthetic promoter containing a series of GAL4 recognition sequences upstream of the adenovirus major late E1B TATA box, where the compound can be RU486 (see, *e.g.*, Yu *et al.*, Mol Genet Genomics 2002 268:169-178). A variety of other microorganism/expression modulator combinations known in the art also can be included in the combinations provided herein.

Combinations provided herein can contain a microorganism and a therapeutic compound. Therapeutic compounds can include compounds that are substrates for microorganismally expressed enzymes, compound that can kill or inhibit microorganism growth or toxicity, or other therapeutic compounds provided herein or known in the art to act in concert with a microorganism. Typically, the therapeutic compound included with a microorganism in the combinations provided herein will be a compound that can act in concert with a microorganism, such as a substrate of an enzyme encoded by the microorganism, or an antimicroorganismal agent known to be effective against the microorganism of the combination. Exemplary microorganism/therapeutic compound combinations can include a microorganism encoding Herpes simplex virus thymidine kinase/gancyclovir, and streptococcus pyrogenes/penicillin. Any of a variety of known combinations provided herein or otherwise known in the art can be included in the combinations provided herein.

#### 4. Kits

Kits are packaged in combinations that optionally include other reagents or devices, or instructions for use. Any kit provided herein also can, in place of a

-152-

microorganism, contain a pharmaceutical composition, a host cell containing a microorganism, and/or a combination, and one or more components.

Exemplary kits can include the microorganisms provided herein, and can optionally include one or more components such as instructions for use, a device for  
5 detecting a microorganism in a subject, a device for administering a compound to a subject, and a device for administering a compound to a subject.

In one example, a kit can contain instructions. Instructions typically include a tangible expression describing the microorganism and, optionally, other components included in the kit, and methods for administration, including methods  
10 for determining the proper state of the subject, the proper dosage amount, and the proper administration method, for administering the microorganism. Instructions can also include guidance for monitoring the subject over the duration of the treatment time.

In another example, a kit can contain a device for detecting a microorganism  
15 in a subject. Devices for detecting a microorganism in a subject can include a low light imaging device for detecting light, for example emitted from luciferase, or fluoresced from green fluorescence protein, a magnetic resonance measuring device such as an MRI or NMR device, a tomographic scanner, such as a PET, CT, CAT, SPECT or other related scanner, an ultrasound device, or other device that can be  
20 used to detect a protein expressed by the microorganism within the subject. Typically, the device of the kit will be able to detect one or more proteins expressed by the microorganism of the kit. Any of a variety of kits containing microorganisms and detection devices can be included in the kits provided herein, for example, a microorganism expressing luciferase and a low light imager, or a microorganism  
25 expressing green fluorescence protein and a low light imager.

Kits provided herein also can include a device for administering a microorganism to a subject. Any of a variety of devices known in the art for administering medications or vaccines can be included in the kits provided herein. Exemplary devices include a hypodermic needle, an intravenous needle, a catheter, a  
30 needle-less injection device, an inhaler, and a liquid dispenser such as an

-153-

eyedropper. Typically, the device for administering a microorganism of the kit will be compatible with the microorganism of the kit; for example, a needle-less injection device such as a high pressure injection device can be included in kits with microorganisms not damaged by high pressure injection, but is typically not included in kits with microorganisms damaged by high pressure injection.

Kits provided herein also can include a device for administering a compound to a subject. Any of a variety of devices known in the art for administering medications to a subject can be included in the kits provided herein. Exemplary devices include a hypodermic needle, an intravenous needle, a catheter, a needle-less injection an inhaler, and a liquid dispenser. Typically the device for administering the compound of the kit will be compatible with the desired method of administration of the compound. For example, a compound to be delivered subcutaneously can be included in a kit with a hypodermic needle and syringe.

#### **F. Examples**

The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention.

##### **Example 1**

##### **Generation of recombinant viruses**

A Wild type vaccinia virus (VV) strain LIVP (the well known viral strain, originally derived by attenuation of the strain Lister from the ATCC under Accession Number VR-1549, from the Lister Institute of Viral Preparations, Moscow, Russia; see, Al'tshtein *et al.*, (1983) Dokl. Akad. Nauk USSR 285:696-699) designed as VGL was used as a parental virus for the construction of recombinant viruses designated RVGLX herein. All vaccinia viruses were purified using sucrose gradient (Yoklik). VVs were propagated and titers were determined by plaque assays using CV-1 cells (ATCC No. CCL-70). Methods for constructing recombinant vaccinia viruses are known to those of skill in the art (see, *e.g.*, Chakrabarti *et al.*, (1985 Mol. Cell Biol. 5:3403 and U.S. Patent No.4,722,848. Table 1 summarizes the recombinant VV strains described in this Example.

##### **Inactivation of VV by PUV treatment**

-154-

LIVP VV (3 x 10<sup>8</sup> pfu/ml) was incubated with 1 µg/ml psoralen (Calbiochem, La Jolla, CA), suspended in Hank's buffer at room temperature for 10 min, and then irradiated for 5 min in Stratalinker 1800 UV crosslinking unit (Stratagent, La Jolla CA) equipped with five 365 nm long wave UV bulb to produce PUV-VV.

#### **RVGL8: LacZ insertion into F3 of LIVP**

Construction of recombinant vaccinia virus RVGL8 containing a lacZ gene inserted the NotI site was prepared as described in Timiryasova *et al.* (2001), BioTechniques 31, 534-540. Briefly it was prepared as follows. The BamHI/SmaI fragment (3293 bp) of pSC65 (see, Chakrabarti *et al.* (1997), BioTechniques 23, 1094-1097; see, also Current Protocols in Molecular Biology, Green Publishing and Wiley-Interscience Supplement 15:16.17.2 (1992); see also SEQ ID No. 5 herein and SEQ ID No. 57 in PCT International application No. WO 99/32646) containing the lacZ gene under the control of the vaccinia p7.5 promoter and strong synthetic vaccinia pE/L promoter was isolated by digestion with restriction enzymes, blunted with Klenow enzyme, and cloned into SmaI site of pNT8 plasmid (Timiryasova *et al.* (2001), BioTechniques 31: 534-540) to produce pNZ2 a shuttle plasmid.

To construct pNT8, the NotI region of the wild type VV strain LIVP was amplified using the following primers:

Forward: 5'-GGGAATTCTTATACATCCTGTTCTATC - 3' (SEQ ID No. 3);  
Reverse: 5'-CCAAGCTTATGAGGAGTATTGCGGGGCTAC-3' (SEQ ID No. 4)  
with the VV as a template. The resulting 972 bp fragment contained flanking EcoRI and HindIII sites at the 5' and 3' ends, respectively. The PCR product was cleaved with EcoRI and HindIII and inserted in pUC28 (Benes *et al.*, (1993) Gene 130: 151. Plasmid pUC28 is prepared from pUC18 (available from the ATCC under Accession Number 37253 by introducing a synthetic oligo adaptor using primers: pUC28 I: 5'AATTCAGATCTCCATGGATCGATGAGCT 3' (SEQ ID NO.6); pUC28 II: 3'GTCTAGAGGTACCTAGCTAC 5' (SEQ ID No. 7) into the EcoRI and SstI sites of pUC18. This introduces BglII, ClaI, and NcoI sites into the polylinker of pUC18.

-155-

Plasmid pNZ2 contains cDNA encoding the *E. coli* lacZ gene under the control of the vaccinia virus early/late promoter p7.5 and a synthetic early/late vaccinia pE/L promoter derived from the plasmid pSC65 (see, Chakrabarti *et al.* (1997), BioTechniques 23, 1094-1097; see, also Current Protocols in Molecular Biology, Green Publishing and Wiley-Interscience Supplement 15:16.17.2 (1992); see also SEQ ID No. 5 herein and SEQ ID No. 57 in PCT International application No. WO 99/32646). Plasmid pNZ2 provides for homologous recombination of lacZ into the NotI site of the VGL virus (ATCC VR-1549), to produce in the recombinant vaccinia virus designated RVGL8. The complex of wild type vaccinia virus DNA digested with NotI and not digested plasmid DNA pNZ2 was transfected for in vivo recombination into PUV VV infected cells to produce RVGL8 (see Figure 1A and Figure 1B). RVGL8 and the other recombinant vaccinia viruses described herein are listed in Table 1, below.

#### Mutant Virus Formation/Transfection

CV-1 African green monkey kidney fibroblasts (ATCC No. CCL-70) grown on 60 mm dishes (Corning, Corning, NY, USA) were infected with PUV-VV (strain LIVP treated with psoralen and UV; see, *e.g.*, Tsung *et al.* (1996), J. Virol. 70, 165-171; Timiryasova *et al.* (2001), BioTechniques 31, 534-540; Timiryasova *et al.* (2001), J. Gene 3 Med. 3, 468-477) at multiplicity of infection (MOI) of 1.

Two hours post-infection, the cells were transfected with a mixture of NotI-digested viral DNA (4 µg) and intact plasmid DNA (4 µg). Lipid-mediated transfection of cells was carried out using 5 µl of GenePORTER reagent (Gene Therapy Systems, San Diego, CA, USA) per µg of the DNA according to manufacturers' instructions. Cells were incubated in transfection mixture for 4 h and then supplemented with a medium containing 20% of fetal bovine serum. Cytopathic effects were monitored daily by light microscopy. Cells were incubated for 5-7 days until formation of the virus plaques and complete cytopathic effect. Then, infected cells were harvested, resuspended in 0.5 ml of medium, and frozen and thawed three times to release the virus. Single virus plaques were selected for



-156-

the preparation of small and large recombinant virus stocks and analyzed for the insertion and expression of the genes.

#### Confirm Mutant

Viral DNA was analyzed by Southern blots. Briefly, to isolate viral DNA, 5  
confluent monolayers of CV-1 cells, grown on 10 cm plates, were infected with the  
wild type VV (strain L1VP) or VV of the virus stock obtained from a single  
recombinant plaque. When the cytopathic effect was complete, cells were harvested  
and the pellet was resuspended in 3 ml of 10 mM Tris-HCl, pH 9.0. Viral particles  
were lysed, treated with proteinase K, and the virus DNA was isolated by  
10 phenol/chloroform extraction, followed by ethanol precipitation. The DNA was  
resuspended in 100  $\mu$ l of sterile water. The viral DNA samples were digested by  
NotI overnight at 37°C, followed by phenol-chloroform treatment, precipitated and  
10  $\mu$ g of DNA samples were separated through a 0.8% agarose gel. The DNA was  
transferred to a positively charged nylon membrane (Roche Diagnostics  
15 Corporation, Indianapolis, IN, USA) and fixed to the membrane using a GS Gene  
Linker (Bio-Rad Laboratories, Hercules, CA, USA). The DIG-labeling of DNA was  
performed using a nonradioactive DNA labeling and detection kit (Roche  
Diagnostics Corporation) and incubating for 60 min at 37°C. The membrane was  
hybridized with a denatured DIG-labeled 3357 bp NotI-NotI DNA fragment of the  
20 plasmid pNZ2 encoding the lacZ gene. Hybridization conditions and blot  
development were performed as suggested by the manufacturer.

The predicted size of the band is 3357 bp. The hybridization of NotI  
digested viral DNAs with a 3357 bp DNA probe confirmed the integration of the  
1 lacZ gene into NotI site of virus genome.

#### 25 Construction of RVGL2 and RVGL23 viruses with a single TK gene mutation

Vaccinia virus L1VP was used for the construction of recombinant virus  
RVGL2. Vaccinia virus Western Reserve (WR) was used for the construction of  
recombinant virus RVGL23. The cDNA of *Renilla* luciferase and *Aequorea* GFP  
fusion (*ruc-gfp*; 1788 bp; see, Wang *et al.*, (1996) Bioluminescence  
30 Chemiluminescence 9:419-422; Wang *et al.*, (2002) Mol. Genet. Genomics 268:160-

-157-

168; Wang *et al.* (1997) pp 419-422 in Bioluminescence and Chemiluminescence: molecular reporting with photons, Hastings *et al.*, eds., Wiley, Chichester UK ; see, also U.S. Patent No. 5,976,796; see also SEQ ID No. 8 herein, which sets forth a sequence for a *ruc-gfp* construct) was excised from plasmid pcDNA-*ruc-gfp* (RG),  
5 which is described in Wang *et al.*, (1996) Bioluminescence Chemiluminescence 9:419-422 and Wang *et al.*, (2002) Mol. Genet. Genomics 268:160-168 and briefly below, by restriction endonuclease PmeI and inserted into the SmaI site of pSC65 plasmid (see SEQ ID No. 5; see, also herein and SEQ ID No. 57 in PCT International application No. WO 99/32646), resulting in pSC65-RG-1 plasmid  
10 DNA.

Briefly to prepare pcDNA-*ruc-gfp*, the *EcoRI-NotI* fragment encoding the modified *Renilla* luciferase-ending DNA (see, Wang *et al.* (1997) pp 419-422 in Bioluminescence and Chemiluminescence: molecular reporting with photons, Hastings *et al.*, eds., Wiley, Chichester UK) was cloned into the pcDNA3.1 vector  
15 (Invitrogen, Carlsbad, CA), placing expression of the *Renilla* luciferase under control of the CMV promoter. The stop codon at the end of the *Renilla* luciferase ORF was removed, and the resulting plasmid digested with *NotI*. The *NotI* fragment containing the ORF encoding humanized *Aequorea* GFP (Zolotukhin *et al.*, (1996) *J. Virol.* 70:4646-4654) was excised from the pTR- $\beta$ -actin plasmid and  
20 inserted into the *NotI* site of the plasmid encoding the *Renilla* luciferase. The resulting plasmid was designated pcDNA-*ruc-gfp*.

New plasmid pSC65-RG-1 containing *ruc-gfp* fusion under the control of the vaccinia PE/L promoter and *E. coli*  $\beta$ -galactosidase under control of p7.5 promoter of VV was used for the construction of a single *TK* gene interrupted virus RVGL2 of  
25 strain LIVP and RVGL23 of strain WR. CV-1 cells were infected with wt LIVP or wt WR virus at MOI of 0.1, and two hours later, pSC65-RG-1 plasmid DNA was transfected using FuGene6 transfection reagent (Roche). After 24 h of incubation, cells were three times frozen and thawed to release the virus. Recombinant viruses were screened on CV-cells in the presence of substrate 5-bromo-4-chloro-3-indolyl- $\beta$ -D-galactopyranoside (X-gal, Stratagene, Cedar Creek, TX, USA). After four  
30

-158-

cycles of virus purification, all virus plaques were positive for  $\beta$ -galactosidase expression. The expression of the *ruc-gfp* fusion protein was confirmed by luminescence assay and fluorescence microscopy, respectively. Schematic maps of the viruses are set forth in Figure 1B

5           **Construction of RVGL5 and RVGL9 viruses with single gene mutations**

Recombinant vaccinia virus RVGL5 contains the *lacZ* gene under the control of the vaccinia late p11 promoter inserted into the HA gene of vaccinia genome (Timiryasova *et al.* (1993) Mol Biol 27:392-402; see, also, Timiryasova *et al.*, (1992) Oncol. Res 11:133-144.). Recombinant vaccinia virus RVGL9 contains a  
10 fusion of the Renilla luciferase gene (*ruc*) and cDNA of green fluorescence protein (*gfp*) under the control of a synthetic early/late vaccinia promoter (PE/L) inserted into the F3 gene of the VV genome (Timiryasova *et al.*, (2000) ) pp. 457-459 in Proceedings of the 11th International Symposium on Bioluminescence and Chemiluminescence, Case *et al.*, eds). RVGLP5 and RVGLP9 were constructed as  
15 described for RVGLP2 and RVGLP23.

**Construction of RVGL20 virus with double *TK* and F3 gene mutations**

The cDNA of human transferrin receptor (*hTR*) (2800 bp) with polyA sequence was isolated from pCDTR1 plasmid (ATCC Accession No. 59324 and 59325) by *Bam*HI, treated with *Klenow* and inserted into *Sal*I site of pSC65 plasmid  
20 (SEQ ID No. 5 herein and SEQ ID No. 57 in PCT International application No. WO 99/32646), resulting in pSC-TfR and pSC-rTfR. Plasmid pSC-rTfR contains cDNA *hTR* in an orientation opposite to the vaccinia PE/L promoter and *E.coli*  $\beta$ -galactosidase under control of the early/late vaccinia p7.5 promoter flanked by vaccinia sequences for insertion into vaccinia *TK* gene. pSC-rTfR was used for the  
25 construction of RVGL20 virus. RVGL9, a recombinant virus with single deletion carrying *ruc-gfp* fusion in the F3 gene locus, which contains a unique *Not*I site in the L1VP strain (see above, see, also, Timiryasova *et al.*, (2000) pp. 457-459 in Proceedings of the 11<sup>th</sup> International Symposium on Bioluminescence and Chemiluminescence, Case *et al.*, eds), was used as a parental virus for the creation

-159-

of RVGL20 virus by homologous recombination as described above. A schematic of RVGL20 virus is set forth in Figure 1B

**Construction of RVGL21 virus with triple *TK*, *F3* and *HA* gene mutations**

5           The cDNA of the  $\beta$ -glucuronidase (*gus*) of *E. coli* (1879 bp) was released from pLacGus plasmid (Invitrogen; see SEQ ID No. 9 herein) with *Xba*I (blunt ended with Klenow fragment) and *Hind*III, and cloned into pSC11 plasmid pSC65 (Chakrabarti *et al.* (1985) Mol. Cell Biol. 5:3403-3409; SEQ ID 5 herein and SEQ ID No. 57 in PCT International application No. WO 99/32646) digested with *Xho*I

10           (treated with Klenow) and *Hind*III under the control of a vaccinia p11 late promoter, resulting in a plasmid pSC-GUS. The *Sma*I-*Hind*III fragment from pSC-GUS plasmid was inserted into pVY6 plasmid, a vector for inserting antigen genes into the hemagglutinin gene of vaccinia (see, *e.g.*, Flexner *et al.*, (1988) Nature 355:259-262; Flexner *et al.*, (1988) Virology 166: 339-349; see also U.S. Patent No.

15           5,718,902) digested with *Sma*I and *Bam*HI, resulting in pVY-GUS plasmid. The resulting plasmid, designated pVY-GUS plasmid, contains the cDNA encoding *gus* under the control of the vaccinia late promoter p11 flanked by vaccinia sequences for insertion into the hemagglutinin (*HA*) gene. Recombinant virus RVGL20 with double deletions was used as the parental virus for the construction of RVGL21

20           virus. CV-1 cells were infected with RVGL20 virus at MOI of 0.1. Two hours after infection, cells were transected with pVY-GUS plasmid DNA using FuGene6 transfection reagent (Roche). Recombinant virus plaques were selected in CV-1 cells by color screening upon addition of  $\beta$ -glucuronidase substrate 5-bromo-4-chloro-3-indolyl- $\beta$ -D-glucuronic acid (X-GlcA) (Research Products Int. Co., Mt.

25           Prospect, IL, USA) into agar medium. After eight cycles of purification in agar medium in the presence of X-GlcA pure recombinant virus RVGL21 was selected. RVGL21 virus has interruptions of *TK*, *F3* and *HA* genes and is presented schematically in Figure 1B.

***In vitro* virus growth**

-160-

CV-1, C6 (ATCC No. CCL-107), B16-F10 (ATCC No. CRL-6475), and GI-101A (Rumbaugh-Goodwin Institute for Cancer Research Inc. Plantation, FL; U.S. Pat. No. 5,693,533) cells were seeded in 24-well plates at the density of  $1 \times 10^5$ ,  $2 \times 10^5$ ,  $4 \times 10^5$ , and  $2 \times 10^5$  cells/well, respectively. The next day, the cells were

5 simultaneously infected with 0.001 or 0.01 PFU/cell of a wild type LIVP and its mutants. The virus suspension was added to cell monolayer (0.15 ml/well) and incubated at 37°C for 1 h with brief agitation every 10 min. Then, the virus was removed, appropriate complete growth medium was added (1 ml/well), and the cells

10 were then incubated at 37°C for 24, 48, 72 and 96.h after virus infection. To establish resting cell culture, a confluent monolayer of CV-1 cells was incubated for 6 days in DMEM with 5 % FBS at 37°C. These resting cells were infected and harvested at the same time points after infection as described above. Virus from the infected cells was released by one cycle of freezing and thawing. Viral titers were determined in duplicates by plaque assay on CV-1 cells and expressed as PFU/ml.

15

-161-

**Table1****List of recombinant vaccinia viruses (VV)**

<b>Designation</b>	<b>Prior Designation</b>	<b>Description</b>	<b>InsertionLocus/loci</b>	<b>Reference</b>
VGL	wt VV	strain LIVP VV	No Insertions	Publicly available
RVGL1	recVV2	(p7.5) Luc-(p11) LacZ of LIVP VV	HindIII-N-Interrupted	Timiryasova TM, Kopylova-Sviridova TN, Fodor I. Mol. Biol. (Russian) 27:392-401 (1993); Timiryasova TM, Li J, Chen B. Chong D. Langridge WHR, Gridley DS, Fodor I. Oncol. Res. 11:133-144 (1999)
RVGL5	recVV8	(p11) LacZ of LIVP VV	HA-Interrupted	Timiryasova TM, Kopylova-Sviridova TN, Fodor I. Mol. Biol. (Russian) 27:392-401 (1993)
RVGL7	rVV-EGFP or rVV-GFP	(PE/L) EGFP-(p7.5) LacZ of LIVP VV	TK-Interrupted	Umphress S, Timiryasova T., Arakawa T, Hilliker S, Fodor I, Langridge W. Transgenics 4:19-33 (2003)
RVGL8	rVV-Not-LacZ or rVV-Not-LZ	(p7.5) LacZ of LIVP VV	NotI (F3)-Interrupted	Timiryasova TM, Chen B, Fodor N, Fodor I. BioTechniques 31:534-540 (2001)
RVGL9	rVV-RG or rVV-ruc-gfp	(PE/L) Ruc-GFP of LIVP VV	NotI (F3)-Interrupted	Timiryasova TM, Yu Ya, Shabahang S, Fodor I, Szalay AA. Proceedings of the 11 <sup>th</sup> International Symposium on Bioluminescence & Chemiluminescence pp.457-460 (2000)
RVGL12		Same as RVGL7, except that HSV TK is inserted in place of gfp		
RVGL19		(PE/L) Trf-(p7.5) LacZ in Tk locus (PE/L) Ruc-GFP in	TK- and NotI (F3)-Interrupted	Herein

-162-

		F3 locus of LIVP VV		
RVGL20		(PE/L) rTrf-(p7.5) LacZ in TK locus (PE/L) Ruc-GFP in F3 locus of LIVP V	Tk- and NotI (F3)- Interrupted	Herein
RVGL21		(PE/L) rTrf-(p7.5) LacZ in TK locus, (p11) LacZ in HA locus, (PE/L) Ruc-GFP in F3 locus of LIVP VV	Tk-, HA- interrupted and NotI (F3)- Interrupted	Herein
RVGL23		(PE/L) rTrf-(p7.5) LacZ in TK locus of WR VV	Tk- Interrupted	Herein

### Example 2

#### **In vitro analysis of virus levels**

##### **LacZ**

- 5 Analysis of *lacZ* expression induced by recombinant vaccinia virus was performed as described previously (Timiryasova *et al.* (2001), BioTechniques 31, 534-540). Briefly, CV-1 cells grown 6-well plates (Corning, Corning, NY, USA) were infected with ten-fold dilutions of the virus stock. The virus was allowed to absorb for 1 h at 37°C with occasional rocking. Then, the virus inoculum was
- 10 replaced with a complete medium containing 1% of agar, and the incubation was carried out for 48 h. To visualize the virus plaques, 300 µg of X-Gal (Molecular Probes, Eugene, Oregon, USA) per ml and 0.1% of neutral red (Sigma, St. Louis, MO, USA) were added to the second agar overlay, and plaques were counted and isolated after 12 h incubation at 37°C. Levels of vaccinia virus in cells in vitro could
- 15 also be determined by measuring the plaque forming units (PFU) in the cells.

#### ***In vitro* infectivity of VV's measured by Plaque Forming Units**

-163-

The ability of wt LIVP virus and its mutants to infect and replicate was analyzed in dividing and resting CV-1 cells as well as in three tumor cell lines (C6, GI-101A, B16-F10). The results demonstrate that vaccinia mutants can efficiently infect and replicate in dividing CV-1 cells at an MOI of 0.001. A significant yield of vaccinia virus was obtained from dividing CV-1 cells. The yield of wt VV and its mutants in dividing CV-1 cells was about 10 times higher than in resting CV-1 cells. There was no significant difference in viral recovery between vaccinia mutants and wt virus *in vitro* studies. The interruption of *TK*, *F3* and *HA* genes made no difference to VV mutants replication in the dividing CV-1 cells. Three tumor cells were tested. The relative sensitivities to cytopathic effects at MOI of 0.001 were follows: CV-1 (dividing, highest), CV-1 (resting), C6, GI-101A, B16-F10 (lowest). Mouse B16-F10 melanoma cells were not sensitive to virus infection at MOI of 0.001. Very low viral titer was recovered from melanoma cells infected at MOI of 0.01. Also observed was that wt WR strain was able to infect melanoma cells *in vitro* more efficiently compared to LIVP strain and virus recovery was higher compared to LIVP strain.

### Example 3

#### Animal models and assays

##### Animal Models

Athymic nude mice (*nu/nu*) and C57BL/6 mice (Harlan Animal Res., Inc., Wilmington, MA) at 6-8 weeks of age were used for animal studies. Mice in groups of five or four were infected i.v. with  $10^7$  PFU of VV in a volume of 0.1 ml i.v. Mice were imaged by low-light imager and fluorescence imager for *ruc* and for *gfp* expression, respectively. The study was approved prior to initiation by the Animal Research Committee of LAB Research International Inc. (San Diego, CA, USA). All animal care was performed under the direction of a licensed veterinarian of LAB Research International Inc. (San Diego, CA, USA).

##### Glioma Model

To establish subcutaneous glioma tumor, rat glioma C6 cells (ATCC No. CCL-107) were collected by trypsinization, and  $5 \times 10^5$  cells/0.1 ml/mouse were



-164-

injected subcutaneously (s.c.) into right hind leg of 6-8 week old male athymic mice. On day 7 after C6 cell implantation when median tumor size was about 150 mm<sup>3</sup>, viruses at the dose of 10<sup>7</sup> PFU/0.1 ml/mouse were injected intravenously (i.v.). Mice were sacrificed 14 days after virus injection. In the kinetic studies using of RVGL9 virus, mice were sacrificed at 20 min, 1 h, 4 h, 18 h, 36 h, 3 d, 5 d, 7 d and 14 days after virus injection.

#### **Breast Tumor Model**

To develop sub cutaneous (s.c). breast tumor, human breast cancer GI-101 A cells (Rumbaugh-Goodwin Institute for Cancer Research Inc. Plantation, FL; U.S. Pat. No. 5,693,533) at the dose of 5 x 10<sup>6</sup> cells/0.1 ml/mouse were injected s.c. into the right hind leg of 6-8 week old female athymic mice. On day 30 after GI-101A cell implantation, when median tumor size was about 500 mm<sup>3</sup>, viruses at the dose of 10<sup>7</sup> PFU/mouse were injected i.v. Mice were sacrificed on day 14 after virus injection. Mice for survival experiments and breast tumor therapy studies were kept for long time periods (more than 100 days after virus injection). Mice that developed tumor with the size about 4000 mm<sup>3</sup>, and/or lost 50% of body weight were sacrificed.

#### **Melanomal Model**

For a melanoma model, mouse melanoma B16-F10 cells (ATCC No. CRL-6475) at the dose of 2 x 10<sup>5</sup> cells/0.04 ml/mouse were injected into the foot pad of 6-8 week old male C57BL/6 mice. When the tumor was established (median size of tumor about 100 mm<sup>3</sup>), on day 18 after cell implantation, viruses at the dose of 10<sup>7</sup>/mouse were injected i.v. Mice were sacrificed 10 days after virus injection.

#### **Vaccinia Virus in Animal Models**

Vaccinia virus recovery from tumor and organs of nude mice

From sacrificed animals blood was collected, and organs (lung, liver, spleen, kidneys, testes, ovaries, bladder, brain, heart) and tumors were harvested and homogenized in PBS containing a mixture of protease inhibitors. Scissors and forceps were changed after each organ dissection or incision to avoid cross-contamination of the tissues. Samples were frozen and thawed, centrifuged at 1,000

-165-

g for 5 min. Viral titer was determined in the supernatant diluted in serum-free medium on CV-1 cells by plaque assay and staining them with 1% (wt/vol) crystal violet solution after 48 h incubation. Each sample was assayed in duplicate and viral titer was expressed as mean PFU/g of tissue.

## 5 Assay Measurements

Survival studies were performed on 6-week old nude mice bearing s.c.. human breast tumor. Mice were injected i.v. with  $10^7$  of vaccinia viruses and followed for survival. Individual body weight was measured twice a week. Gain/loss of body weight after virus infection was calculated as the percentage: body weight (g) - tumor weight (g) on day of virus injection / body weight (g) - tumor weight (g) on day of monitoring x 100%. Spleens were excised from euthanized animals and weighed. The RSW was calculated as follows: RSW = weight of spleen (g) x  $10^4$  / animal body weight (g) - tumor weight (g). Mice were euthanized when the mean tumor volume reached 3000 mm<sup>3</sup> or developed the signs of disease. Rapid CO<sub>2</sub> euthanasia was humanely performed in compliance with the *NIH Guide for the*

10  
15

*Care and Use of Laboratory Animals.*

## Reporter genes assays

### LacZ

*E. coli*  $\beta$ -galactosidase activity in tissue samples and in the serum of the mice was determined using chemiluminescent Galcto-Light Plus™ Assay system (Applied Biosystems, Bedford, MA, USA) according to the instructions of the kit manufacturer. Briefly, 1-20  $\mu$ l of the sample was transferred into the tube with 200  $\mu$ l of 1:100 diluted Reaction Buffer Diluent and incubated at RT for 30 min. A 300 $\mu$ l aliquot of accelerator (-II) was added into the tube with the sample, mixed quickly and the signal was read using luminometer.  $\beta$ -galactosidase activity was expressed as relative light units (RLU) per g of tissue. Purified *E. coli*  $\beta$ -galactosidase (Sigma) was used as a positive control and to generate a standard curve.

20  
25  
30

-166-

### Luciferase

*Renilla* luciferase activity was measured in the supernatant of the tissue samples after they had been homogenized using a Turner TD 20e luminometer (Turner Designs, Sunnyvale, CA, USA) as described previously (Yu and Szalay, 2002) with some modifications. In brief, 20 µl of the samples was added into 500 µl of luciferase assay buffer (0.5 M NaCl, 1 mM EDTA, 0.1 M potassium phosphate pH 7.4) containing a substrate coelentraxine. Luciferase activity was measured during 10-s interval and expressed as RLU per g of tissue.

### Assay Results

#### 10 Tumor-selective replication of vaccinia virus RVGL8.

Recovery of wt LVP (VGL) and RVGL8 from tumor samples and different organs from six mice and from normal organs. VGL was recovered from tumor, testes, bladder, and liver and as well as from brain. Recombinant virus RVGL8, however, was found mostly in tumor only (in mouse #24 virus was found in testes, bladder and liver; in mouse #22 in testes) and no virus was recovered from brain tissue in six tested animals. This finding demonstrates the safety of RVGL8 with the interruption of the NotI site ,

#### Presence of RVGL9 over time

A vaccinia virus RVGL9 with a single *F3* gene mutation and carrying *ruc-gfp* was used to assess the pattern of vector tissue distribution following i.v. administration into immunocompromised athymic mice bearing s.c. glioma tumors. The tissue distribution data using this recombinant virus was showed virus distribution and tumor targeting by this VV strain. Kinetics studies were performed by noninvasive imaging of virus replication in the mice based on *ruc* and *gfp* expression. Four to five animals per group bearing s.c. rat glioma C6 tumor were injected with  $10^7$  of RVGL9 virus via the tail vein. The animals were sacrificed at 20 min, 1,4, 18 and 36 hours, 3, 5, and 14 days after virus injection. No viable viral particles were recovered from brain, bladder or testes at any time point after i.v. injection of virus. Some viral particles were recovered from spleen, heart and lung at early time points after virus injection. After 18 h post-infection, the titer of

-167-

RVGL9 virus in these organs decreased. No virus was recovered in the heart tissue after 18 h; around 156.5 and 44 PFU/g tissue was recovered from spleen and lung, respectively, on day 14 as compared to 3221.0 and 3521.9 PFU/g tissue at 20 min after virus injection, respectively. The pattern of virus recovery from liver and kidneys was different from the pattern in the spleen, heart, or lung. No virus in the kidneys and 174.9 PFU/g tissue of virus was recovered from liver at an early time after virus injection. On day 5 after virus injection, the titer of virus in these organs increased and went down on day 14 post virus injection. In tumor tissue virus was detected starting 18 h after virus administration ( $1.6 \times 10^3$  PFU/g tissue), and dramatically increased over the time of observation ( $1.8 \times 10^8$  PFU/g tissue on day 7). Virus in the tumor tissue was detectable for more than 60 days after a single i.v. virus injection. The results demonstrate tumor-specific replication of these vaccinia mutants. A correlation was observed between the virus recovery and the transgene expression in tumors and in organs. Based on the data of RVGL9 virus kinetics, day 10 or day 14 was used for tissue distribution studies of different vaccinia mutants in melanoma and glioma and breast tumor models, respectively.

#### Presence of various VV in mice bearing a glioma tumor

To examine tissue distribution of vaccinia virus in immunodeficient mice bearing an s.c. glioma tumor, viruses were injected i.v. at a dose of  $1 \times 10^7$  PFU/0.1 ml/mouse on day 7 after C6 rat glioma cell implantation. Fourteen days after virus injection, mice were sacrificed and virus titer was determined in different tissues. Mice injected with wt WR virus were were sick and dying due to viral pathogenicity. Hence, WR-injected mice were sacrificed on day 7 after virus injection. Wild type L1VP virus was recovered from all analyzed tissues as well as from brain. The amount of recovered virus particles from the mice injected with wt L1VP was much lower than wt WR strain of VV. The results presented in Table 1A

**Table 1A. Viral recovery from nude mice tissues in glioma model.<sup>a</sup>**

	L1VP Wt	RVGL2 TK-	RVGL5 HA-	RVGL9 F3-	RVGL20 TK-, F3-	RVGL21 TK-, F3-, HA-	WR <sup>b</sup> Wt	RVGL23 TK-, WR
Brain	$1.2 \times 10^3$	$1.4 \times 10^3$	0	0	0	0	$1.4 \times 10^7$	$1.9 \times 10^6$
Kidneys	$6.1 \times 10^2$	$6.7 \times 10^2$	$1.6 \times 10^2$	34.6	33.3	36.6	$5.4 \times 10^6$	$7.9 \times 10^2$

-168-

	LIVP Wt	RVGL2 TK-	RVGL5 HA-	RVGL9 F3-	RVGL20 TK-, F3-	RVGL21 TK-, F3-, HA-	WR <sup>b</sup> Wt	RVGL23 TK-, WR
Lung	$2.9 \times 10^3$	0	$1.6 \times 10^2$	$1.4 \times 10^4$	$6.7 \times 10^3$	$2.4 \times 10^3$	$1.9 \times 10^6$	$2.1 \times 10^3$
Spleen	$1.9 \times 10^2$	0	$1.8 \times 10^2$	$1.0 \times 10^3$	$1.0 \times 10^2$	$1.7 \times 10^2$	$1.6 \times 10^6$	$1.8 \times 10^3$
Testes	$5.8 \times 10^4$	64.3	$6.4 \times 10^2$	$7.5 \times 10^2$	0	0	$9.8 \times 10^4$	$1.7 \times 10^3$
Bladder	$6.4 \times 10^3$	0	0	$2.9 \times 10^3$	0	0	$2.8 \times 10^5$	$1.2 \times 10^3$
Liver	$3.4 \times 10^4$	63.6	$4.2 \times 10^2$	33.6	96.6	30.8	$7.1 \times 10^3$	$5.6 \times 10^3$
Heart	$6.0 \times 10^3$	0	0	0	0	0	$1.4 \times 10^5$	0
Serum <sup>c</sup>	0	0	0	0	0	0	$6.0 \times 10^2$	0
Tumor	$5.4 \times 10^7$	$1.5 \times 10^7$	$3.8 \times 10^7$	$2.9 \times 10^7$	$3.9 \times 10^7$	$1.9 \times 10^7$	$1.9 \times 10^8$	$3.7 \times 10^7$

The results demonstrate that 10000-fold more virus was recovered in the brain of mice injected with WR strain versus wt LIVP strain. Wild type WR strain virus was recovered from the serum (600 PFU/20  $\mu$ l) of mice on day 7 after virus injection.

5 No virus was recovered in the serum of the mice injected with LIVP mutants on day 14. The level of wt LIVP in serum was not tested on day 7. About  $1.9 \times 10^6$  PFU/g tissue of TK-mutant of WR strain (RVGL23) was found in the brain tissue compared to  $1.4 \times 10^3$  PFU/g tissue for mice injected with the TK- mutant of LIVP strain (RVGL2).

10 All other mutants of VV strain LIVP were found mostly in tumor only and no virus was recovered from brain tissue of mice injected with a double or triple mutant (Table 1A). Three times as many virus particles were recovered from the tumors of mice injected with WR compared to wt LIVP. The mean of viral recovery in tumor tissue of the mutants of LIVP strain was similar to the wt LIVP and  
15 equivalent to TK- mutant of WR strain.

#### Presence of various VV in mice bearing a breast tumor

Data for tissue distribution in immunocompromised mice bearing s.c. GI-101A human breast are presented in Table 1B:

20 **Table 1B. Viral recovery from nude mice tissues in breast cancer model.**

	LIVP Wt	RVGL2 TK-	RVGL5 HA-	RVGL9 F3-	RVGL20 TK-, F3-	RVGL21 TK-, F3-, HA-	WR <sup>b</sup> Wt	RVGL23 TK-, WR
Brain	0	0	0	0	0	0	$7.2 \times 10^6$	$1.6 \times 10^4$
Kidneys	$3.6 \times 10^3$	38.3	27	$3.3 \times 10^2$	25.8	0	$3.2 \times 10^7$	$2.8 \times 10^5$
Lung	$8.6 \times 10^3$	$5.5 \times 10^2$	29.1	$1.6 \times 10^3$	$1.6 \times 10^3$	$1.0 \times 10^3$	$2.1 \times 10^6$	$3.7 \times 10^3$
Spleen	$5.5 \times 10^3$	99.5	0	$1.8 \times 10^2$	0	0	$1.6 \times 10^6$	$1.8 \times 10^3$
Ovaries	$1.6 \times 10^3$	0	0	0	0	0	$8.0 \times 10^7$	$2.7 \times 10^7$

-169-

	LIVP Wt	RVGL2 TK-	RVGL5 HA-	RVGL9 F3-	RVGL20 TK-, F3-	RVGL21 TK-, F3-, HA-	WR <sup>b</sup> Wt	RVGL23 TK-, WR
Bladder	$3.9 \times 10^3$	0	0	0	0	0	$2.8 \times 10^4$	$1.2 \times 10^3$
Liver	$1.2 \times 10^4$	0	$1.7 \times 10^2$	$5.2 \times 10^2$	$1.7 \times 10^2$	$1.0 \times 10^2$	$4.0 \times 10^5$	$4.8 \times 10^5$
Heart	$1.4 \times 10^2$	0	0	58.2	$4.6 \times 10^2$	0	$6.3 \times 10^4$	$2.2 \times 10^3$
Serum <sup>c</sup>	0	0	0	0	0	0	$2.4 \times 10^3$	0
Tumor	$8.6 \times 10^8$	$1.0 \times 10^9$	$2.5 \times 10^8$	$1.1 \times 10^9$	$5.6 \times 10^8$	$1.0 \times 10^9$	$2.9 \times 10^9$	$6.6 \times 10^8$

About 10-fold more viral particles were recovered from breast tumor tissue compared to glioma tumor tissue. No virus particles were recovered from the brain tissue of mice injected with either wt LIVP or its mutants.  $7.2 \times 10^6$  and  $1.6 \times 10^4$  PFU/g was recovered from brain tissue of mice injected with wt WR and TK-virus of WR strain VV, respectively (Table). During the dissection of organs from euthanized mice, it was found that the ovaries from the mice being injected with wt WR and TK- of WR virus were drastically enlarged as compared to all other groups of mice. The analysis of viral recovery from ovaries demonstrated high titer of wt WR and TK- WR strain in ovaries, for example,  $8.0 \times 10^7$  and  $2.7 \times 10^7$  PFU/g, respectively. About  $1.6 \times 10^3$  PFU/g was recovered from the ovaries of the mice injected with wt LIVP virus, however no virus particles at all were recovered from either ovaries or from brain of mice injected with the mutants derived from LIVP strain (Table 1B).

#### 15 Presence of various VV in mice bearing a melanoma tumor

The tissue distribution of VV in the immunocompetent mice bearing melanoma tumors on foot pads also were studied. BL/6 mice on day 17 after B16F10 melanoma cell implantation were i.v. injected with the viruses at the dose of  $10^7$  PFU/mouse via the tail vein. All groups of mice were sacrificed on day 10 after virus injection due to huge tumor size in the PBS-injected control group. The results are set forth in Table 1C:

**Table 1C. Viral recovery from C57BL/6 mice tissues in melanoma model.**

	LIVP Wt	RVGL2 TK-	RVGL5 HA-	RVGL9 F3-	RVGL20 TK-, F3-	RVGL21 TK-, F3-, HA-	WR <sup>b</sup> Wt	RVGL23 TK-, WR
Tumor	$5.4 \times 10^6$	$3.9 \times 10^6$	$3.7 \times 10^5$	$9.5 \times 10^5$	$2.5 \times 10^5$	$2.4 \times 10^5$	$9.9 \times 10^6$	$2.2 \times 10^6$
Tissues <sup>c</sup>	0	0	0	0	0	0	0	0

-170-

- <sup>a</sup> Mean of viral recovery PFU/g of tissue for 3-5 mice/group.  
<sup>b</sup> Mice were sacrificed on day 7 after virus injection.  
<sup>c</sup> PFU/20  $\mu$ l of serum  
<sup>d</sup> Mice were sacrificed on day 9 after virus injection.  
<sup>e</sup> No virus was recovered in all tested tissue.

. No virus was recovered from kidneys, lung, spleen, brain, testes, bladder, liver, heart, and serum of the immunocompetent mice injected with the viruses. Virus was only recovered from the tumor tissue. About 10-fold virus particles were recovered from the tumors of mice injected with wt LIVP, TK- LIVP, wt WR, and TK- WR compared to other groups.

### Example 5

#### Reduction of human breast tumor implanted in nude mice by recombinant vaccinia viruses RVGL7, RVGL9 and RVGL21

##### 10 RVGL7 and RVGL9

Figure 1B shows a schematic representation of the recombinant vaccinia viruses used for these experiments. RVGL7 was prepared as described for the preparation of RVGL9. RVGL7 contains nucleic acid encoding EGFP and lacZ, and includes pE/L and p7.5 regulator regions inserted into the TK gene.

##### 15 Luminescence and fluorescence images of tumors in a nude mouse

Human breast GI-101A cancer cells ( $5 \times 10^6$  cells/mouse) were subcutaneously implanted into the right thigh of the mice. Thirty days after cell implantation RVGL9, the *NotI* (F3)-interrupted virus expressing a fusion of *Renilla* luciferase and green fluorescence protein (RVGL9 = rVV-RG = rVVruc-gfp) was injected intravenously via tail vein at a dose of  $1 \times 10^7$  PFU/mouse. A fluorescence image of GFP and low-light image of luciferase expression were taken nine days after virus injection, *i.e.* 39 days post cell implantation showing dissemination of the virus.

##### 25 Reduction of human breast tumor implanted into nude mice by vaccinia viruses RVGL7 or RVGL9

Human breast GI-101A cancer cells ( $5 \times 10^6$  cells/mouse) were subcutaneously implanted into the right thigh of the mice. Mice were injected i.v. with RVGL7=rVV-GFT=TK- or RVGL9-rVV-*ruc-gfp*=*NotI* (3) -interrupted viruses

-171-

( $1 \times 10^7$  PFU/mouse in 0.1 ml) and PBS control on day 30 after cell implantation. Images were taken on day 65 after GI-101A cell implantation and 35 days after virus or PBS injection. The results demonstrate drastic reduction of tumor volume in the mice injected with TK- or NotI (F3) -interrupted vaccinia viruses to compared with the tumor in the mice injected with PBS.

#### **GFP in Human Breast Tumor after Viral Administration**

Human breast GI-101A cancer cells ( $5 \times 10^6$  cells/mouse) were subcutaneously implanted into right thigh of the mice. Mice were injected i.v. with RVGL7=rVV-GFP=TK- or RVGL9=rVV-RG-rVV-ruc-gfp-NotI (F3) -interrupted viruses ( $1 \times 10^7$  PFU/mouse in 0.1 ml) on day 30 after cell implantation. The data demonstrate GFP expression in tumor area in the mice injected with TK- or NotI (F3) -interrupted vaccinia viruses. No GFP signals were observed in other parts of mice body. The results also showed that expression of GFP can be visualized as early as 48 h after virus injection through tail vein. On day 16 after virus injection very strong signals of GFP which correspond to a tumor volume of about 1300-1620 mm<sup>3</sup> for TK- or NotI (F3) -interrupted virus, respectively were observed. Reduced GFP signals were observed on day 25 (1218-1277 mm<sup>3</sup> for TK- or NotI (F3) -interrupted virus, respectively) and 32 (514-887 mm<sup>3</sup> for TK- or NotI (F3) -interrupted virus, respectively) due to reduction of tumor volume.

#### **Time course of Breast Tumor Volume over Time**

GI-101A breast cancer cells were implanted subcutaneously into the right thigh of 4-5-week old female athymic (nu/nu) mice in the dose of  $5 \times 10^6$  cells/mouse. Thirty days after tumor implantation, when the tumor reached about 500 mm<sup>3</sup> in volume, a single dose ( $1 \times 10^7$  PFU/mouse in 0.1 ml) of RVGL7 = rVV-GFP = TK- or RVGL9 = rVV-RG = rVV-ruc-gfp = NotI (F3) -interrupted vaccinia viruses or PBS control was injected intravenously (via tail vein). Tumor dimensions were measured with vernier caliper twice a week and volumes were calculated as  $(L \times H \times W) / 2$ , where L, H and W represent the length, width, and height of the tumor, respectively and expressed in mm<sup>3</sup>. The data demonstrate significant (60-80% on day 65) tumor reduction in the mice injected with TK-, NotI (F3) -interrupted



-172-

vaccinia viruses. In contrast, tumors grew very rapidly in the mice injected with PBS.

#### **Monitoring of tumor regression by light extinction.**

Subcutaneous GI-101A breast tumor reduction occurred in 100% of immunocompromised mice treated with a single i.v. injection of wt LIVP, single F3-, single TK-, and double F3-, TK-, mutants of LIVP strain. Some degree of toxicity was seen in the mice treated with above viruses. RVGL21 virus with the triple deletions TK, F3 and HA genes which showed no toxicity in nude mice; hence this virus was used for long-term studies. The difference in antitumor activity and survival between high and low doses of treatment using the triple mutant RVGL21 virus was not significant. GFP expression in tumor area in the mice injected with RVGL21 was monitored. No GFP signals were observed in other parts of mice body. Expression of GFP can be visualized as early as 48 h after virus injection through tail vein. On day 16 after virus injection we observed very strong signals of GFP, which correspond to tumor volume about 1300-1620 mm<sup>3</sup> and reduced GFP signals on days 25 (1218-1277 mm<sup>3</sup>) and 32 (514-887 mm<sup>3</sup>) due to reduction of tumor volume. Tumor volume reduction also was apparent by visual inspection of the mice.

#### **Example 6**

##### **: Reduction of vaccinia virus toxicity and virulence**

##### **Reduction of vaccinia virus pathogenicity by monitoring mouse body weight and survival**

The percentage of body weight change in athymic and immunocompetent mice bearing different s.c. tumors after i.v. administration of the viruses was examined. Injection of wt LIVP and wt WR and some mutants at the dose of 10<sup>7</sup> pfu/mouse via the tail vein led to a progressive vaccinia virus infection within a two week observation period. At one week after challenge, the mice showed typical blister formation on the tail and footpad. Later, weight loss, sometimes accompanied by swelling of the mouth region, in several cases led to death of the mice. In the case of wt WR strain of VV, mice started to die on day 7 after i.v.

-173-

injection of virus. While mice receiving the recombinant LVP viruses gained weight or remained the same weight over the same time period.

#### **Body weight in glioma model nude mice**

Rat glioma C6 cells at the dose of  $5 \times 10^5$ /0.1 ml/mouse were implanted s.c. into the right thigh of nude mice (5-6 old male mice) on day 0. Vaccinia viruses were injected i.v. (via tail vein) at the dose of  $1 \times 10^7$  PFU/0.1 ml/mouse on day 7. Animals were weighed twice a week. Gain/loss of body weight on day 14 post infection was calculated as the percentage:  $\frac{\text{body weight} - \text{tumor weight on day of virus injection (g)}}{\text{body weight-tumor weight on day 14 (g)}} \times 100\%$ . Injection of VGL (wild type vaccinia virus, strain LVP) and RVGL5 (HindIII-N-interrupted) causes toxicity in nude mice: mice continue to lose the weight. Recombinant vaccinia viruses RVGL5 (HA-interrupted), RVGL7 (TK-interrupted), RVGL8 (NotI(F3) -interrupted), RVGL19 (double, TK- and NotI (F3) -interrupted) were less toxic in nude mice: after losing some body weight, 10 days post-infection, mice started to gain the body weight .

Nude mice with glioma that were injected with wild type WR strain of VV lost 31.9% of body weight on day 7 after virus injection. Mice injected with TK-virus of WR strain lost 22.4% of body weight on day 14 after virus injection compared to 1.5% in the group of mice injected with TK- virus of LVP strain of VV. All mice injected with wild type LVP strain survived for at least 14 days (the duration of the experiment). Mice without tumor injected with VGL (wt VV, strain LVP) lost 11.23 % of body weight. Mice bearing tumor injected with VGL (wt VV) or with RVGL1 (HindIII-N-interrupted) lost 15.79% and 10.18% of body weight, respectively. Mice in the wt LVP group lost 15.8% of body weight versus 9.4% in the PBS injected group. Tumor-bearing mice injected with RVGL2 (TK-), RVGL5 (HA-), RVGL7 (TK-), RVGL8 (F3-), RVGL9 (F3-), RVGL20 (TK-, F3-), RVGL21 (TK-, F3-, HA-) on day 14 after virus injection lost only 1.5%, 0.4%, 2.1%, 5.0%, 7.3%, 2.4%, and 3.2% of body weight, respectively. Tumor-bearing mice injected with virus carrying double gene interruption, RVGL19 (TK- and F3-) demonstrated 0.73% gain of body weight compared to the body weight on day 0.

-174-

Based on the results of body weight, a single interruption of HA, TK, F3 (NotI site) and double interruption of TK, F3 (NotI site) genes in vaccinia virus genome reduces virulence and toxicity of the vaccinia virus strain LVP.

Injection of wt VV strain WR, however, was extremely toxic to nude mice, which died on day 7 after virus injection. Wild type and mutant VVs of strain LVP were less toxic in nude mice. Although nude mice injected with various LVP strains lost some body weight, after day 10 post infection mice started to gain the body weight.

#### **Body weight in breast tumor model athymic mice**

The body weight change of athymic mice with s.c. GI-101A human breast tumor after i.v. injection of vaccinia viruses was monitored. Mice injected with wt WR strain lost 25.6% of body weight and died due to virus toxicity. Although mice injected with wt LVP virus survived for longer time, mice lost 26.4% of body weight. Mice injected with TK-WR strain lost 17.8% of body weight, while mice injected with TK- LVP virus gained 1.9% of body weight. All mice injected with other mutants of LVP strain were stable; no virus related toxicity was observed in these mice.

#### **Body weight in melanoma model immunocompetent mice**

The toxicity of the vaccinia viruses in immunocompetent C57BL/6 mice bearing mouse B16-F10 melanoma on their foot pad was studied. Although mice in all groups survived during the experiment, wt WR strain was more toxic in immunocompetent mice compared to wt LVP and recombinant strains. Mice injected with wt WR strain lost about 11.4% of body weight on day 10 after i.v. injection of virus, while mice injected with wt LVP strain and its double (RVGL20) and triple (RVGL21) mutants lost only 2.2%, 1.3%, and 0.6% of body weight, respectively, versus to 7.1% of body weight lost in PBS injected mice. Mice administered i.v. with RVGL2 (TK-), RVGL5 (HA-), RVGL9 (F3-), and RVGL23 (TK-WR strain) continued to gain weight over this same period.

#### **Long-term survival after viral infection for breast tumor-bearing mice**

-175-

To examine the effect of different mutations on long-term survival, mice bearing s.c. GI-101A human breast tumor received doses of  $10^7$  virus i.v., and were observed for survival after viral infection. The results showed that there are differences in survival depending upon the virus injected. Injection of the nude mice bearing s.c. breast tumor with wt WR strain (i.v.,  $1 \times 10^7$ /mouse) resulted in 100% mortality: four mice of five died on day 9 and one mouse died on day 11 after virus injection. Mice injected with strain L1VP survived for 35 days. Mice injected with a single mutated virus RVGL9 (F3-) developed the toxicity and 25% of mice died on day 34 after virus injection, however the deletion of F3 gene in L1VP strain prolonged the survival of mice up to 57 days. Mice injected with double mutant virus RVGL20 (F3-, TK-) began to die on day 34 after virus injection, but survived longer than F3- injected mice. The RVGL20 virus injected mice reached 50% survival point on day 65 and showed significantly longer survival time up to 116 days. The single mutant TK-virus of L1VP virus was less pathogenic than the single mutant F3- or double mutant F3-, TK- viruses; all mice were alive on day 80 after injection with TK- virus and 14.3% of the mice survived 130 days. All mice injected with the triple mutant TK-, F3-, and HA-virus (RVGL21) survived 130 days (duration of the experiment) and continued to live without any signs of virus toxicity compared to other groups of mice.

## 20 Splenomegaly in various mice

### Immunocompetent C57BL/6 mice

Several groups of the animals demonstrated enlargement of the spleen; therefore the relative spleen weight (RSW) was calculated. The results are shown in Table 2 as follows:

25 **Table 2. Relative spleen weight (RSW) in mice with or without tumors.**

Groups	Glioma model nu/nu mice	Breast cancer model nu/nu mice	Melanoma model C57BL/6 mice
No tumor, PBS	$43.6 \pm 4.1^a$	$50.5 \pm 11.2^d$	$30.1 \pm 2.8^g$
No tumor, L1VP	$67.2 \pm 11.9$	$48.0 \pm 13.1$	$68.1 \pm 9.4$
Tumor, PBS	$92.4 \pm 7.4^b$	$84.1 \pm 14.6^e$	$106.0 \pm 46.1^h$
L1VP	$98.2 \pm 28.2^c$	$108.4 \pm 39.4^f$	$148.4 \pm 44.8^i$
RVGL2	$96.0 \pm 34.9$	$112.7 \pm 15.6$	$51.9 \pm 6.6$

-176-

Groups	Glioma model nu/nu mice	Breast cancer model nu/nu mice	Melanoma model C57BL/6 mice
RVGL5	143.8 ± 20.5	169.6 ± 31.7	61.6 ± 2.9
RVGL9	73.9 ± 10.5	151.8 ± 27.9	63.3 ± 34.9
RVGL20	84.9 ± 6.6	159.9 ± 22.7	106.7 ± 36.0
RVGL21	114.4 ± 12.5	117.7 ± 15.3	63.0 ± 24.6
WR	37.3 ± 3.5	57.9 ± 10.9	70.5 ± 1.8
RVGL23	46.9 ± 15.7	73.1 ± 19.3	97.0 ± 43.9

Mean ± SD for n=4-8 mice/group.

RSW = weight of spleen (g) x 10<sup>4</sup>/(animal body weight (g) – tumor weight (g)).

<sup>a</sup> p ≤ 0.02 vs. all groups, except no tumor LVP, WR, RVGL23

<sup>b</sup> p ≤ 0.039 vs. no tumor PBS, no tumor LVP, RVGL5, WR, RVGL23

<sup>c</sup> p ≤ 0.046 vs. all groups, except PBS, RVGL2, RVGL20, RVGL21

<sup>d</sup> p ≤ 0.006 vs. all groups except no tumor LVP, PBS, WR, RVGL23

<sup>e</sup> p ≤ 0.048 vs. all groups, except no tumor PBS, LVP, RVGL2, WR, RVGL23

<sup>f</sup> p ≤ 0.045 vs. all groups, except PBS, RVGL2, RVGL21

<sup>g</sup> p ≤ 0.035 vs. P'BS, LVP, RVGL20, WR, RVGL23

<sup>h</sup> p ≤ 0.049 vs. all other groups, except no tumor LVP, RVGL20, WR, RVGL23

<sup>i</sup> p ≤ 0.049 vs. all other groups.

As shown in the Table 2 above, some degree of splenomegaly was observed in mice. For immunocompetent C57BL/6 mice, a statistically significant difference (p < 0.035) was found in tumorous mice injected with PBS, LVP, RVGL20, WR and RVGL23 compared to non-tumorous mice. In mice injected with wt VV strain LVP spleen was enlarged greatly (p < 0.049) versus all other groups. In contrast, the smallest spleens were found in the mice without tumor.

#### Nude mice with a glioma tumor

In nude mice with or without s.c. glioma tumor, mice injected with wt WR or TK- of WR virus had the lowest RSW 37.3 or 46.9, respectively, which was similar to the RSW from the mice without tumor and injected with PBS (43.6). The largest RSW 143.8 and 114.4 was observed in RVGL5 (HA-) and RVGL21 (TK-, F3-, HA-) groups, respectively. No statistically significant difference was found among the groups of mice injected with wt LVP, RVGL2, RVGL9, RVGL20 versus to PBS injected group.

-177-

**Nude mice with breast tumor**

The results of RSW in the immunocompromised mice bearing s.c human breast tumor indicate that all mice injected with wt LIVP and its mutants have an enlarged spleen compared to the mice injected with wt WR or TK- WR viruses (p<0.045). The largest spleen was found in the mice injected with single HA-, single F3-, double F3-, TK- mutants of LIVP strain.

**Other results using RVGL21 for injection**

Two mice #437 and #458 survived more then 190 days after RVGL21 injection ( $10^7$  and  $4 \times 10^5$ , respectively, i.v.) without any signs of diseases or virus related toxicities.

On day 30 after GI-101A cell implantation (tumor volume=594.9 mm<sup>3</sup>),  $10^7$  of RVGL21 was injected i.v. into mouse #437. On day 101 after virus injection (s.c. tumor size=220.4 mm<sup>3</sup>), metastasis (hard tissue) in chest area under the skin was observed. The size of the tumor was 1223.6 mm<sup>3</sup>, which disappeared by day 148. The, s.c. tumor did not disappear, it started to grow back, but the mouse remained metastasis-free.

Mouse #458 had a first s.c. tumor (GI-101A) on the right hind quarter. When the first tumor started to shrink (day 29 after RVGL21 virus injection, tumor size=1924.3 mm<sup>3</sup>), a second syngeneic tumor was implanted s.c. on the left hind quarter. The second tumor grew slowly, reached the size of 1205.7 mm<sup>3</sup> and started to shrink. The mouse was free of first tumor on day 127 post virus injection; the size of the second tumor was 439.6 mm<sup>3</sup>. The tumor continued to shrink and the cells died. The body gradually absorbed remaining tumor tissues that were contributed by the host (such as the tumor vascular skeleton that was coming from the host). Since these remains are not considered foreign, the immune system doesn't destroy them. The tumor cells, on the other hand, were long gone and cleared by the immune system and the virus. Reduction of second syngeneic tumor demonstrates that this mouse developed antibodies against the tumor cells. The antibodies resulted in the reduction of the second syngeneic tumor.

30

-178-

**EXAMPLE 7****Use of a Microorganism or Cell to Induce Autoimmunization of an Organism Against a Tumor**

5 This example shows that the method provided herein and in priority application EP 03 018 478.2 relating to "The production of a polypeptide, RNA or other compound in a tumor tissue" also can be used for the production of antibodies against the tumor tissue. These antibodies provide for autoimmunization of the organism bearing the tumor. Furthermore, these antibodies can be isolated and used for the treatment of tumors in other organisms.

10 Methods and uses of microorganisms, including cells, which can contain DNA encoding a desired polypeptide or RNA, to induce autoimmunization of an organism against a tumor are provided. Also provided are methods for the production of antibodies against a tumor by: (a) injecting a microorganism, such as a virus or cell, optionally containing a DNA sequence encoding a desired  
15 polypeptide or RNA, into an organism bearing a tumor and (b) isolating antibodies against the tumor.

This Example further demonstrates that administration of microorganisms, such as the triple mutant vaccinia virus strain provided herein, which accumulate in tumors, causing them to release tumor antigens for a sufficient time to permit  
20 production of antibodies by the host. This is exemplified by showing a reduction and elimination of xenogeneic GI-101A solid breast carcinoma tumors and their metastases in nu-/nu- mice (T cell deficient mice).

**Step#1:** Female nu-/nu- mice of 5 weeks age were chosen, and the GI-101A cells grown in RPMI1640 medium, supplemented with estrogen and progesterone. The  
25 confluence was reached, cells were harvested, washed with phosphate buffered saline. Cells ( $5 \times 10^6$  cells per mouse) were then injected subcutaneously into mice. The tumor growth was carefully monitored every two days.

**Step#2:** At two stages of tumor growth (at tumor size of  $400-600\text{mm}^3$ , and at tumor size of  $\sim 1700\text{mm}^3$ ), purified vaccinia viral particles (RVGL12) were delivered to  
30 each tumorous mice by intravenous injection through tail vein. The colony purified virus was amplified in CV-1 cell line and the intracellular viral particles were

-179-

purified by centrifugation in sucrose gradient. Two concentrations of virus ( $10^6$  pfu/100  $\mu$ l and  $10^7$  pfu/100  $\mu$ l resuspended in PBS solution) were injected. The viral replication was monitored externally by visualization of virus-mediated green fluorescence protein expression. The tumor development was monitored by tumor volume determination with a digital caliper.

Vaccinia viruses RVGL12+GCV(gancyclovir) , and RVGL12 (RVGL12 is the same as RVGL7, except that the nucleic acid encoding gfp is replaced by herpes simplex virus thymidine kinase (HSV TK; see, SEQ ID Nos. 35 and 36) were injected 67 days after GI-101A cellular implantation. A second administration referred to as RVGL12a, was injected 30 days after cellular implantation. .

**Step#3:** After viral administration , it was determined that first the tumors continued to grow to a size of  $\sim 900 \text{ mm}^3$  (from  $400\text{-}600 \text{ mm}^3$  at the time of viral injection), and to a size of  $\sim 2400 \text{ mm}^3$  (from  $1700 \text{ mm}^3$ ). Then the growth rate leveled off for approximately 6-8 days.

**Step#4:** Approximately 14 days after viral injection, the tumor volume started to decline rapidly. Forty days after viral application, all the treated animals showed more than 60% tumor regression. Sixty-five days after viral treatment and many of the animals had complete regression of tumors.

**Step#5:** Some of the animals were completely tumor-free for several weeks and their body weight returned to normal. RVGL-12+GCV treatment resulted in 86.3% reduction of tumor size (Day 52 after viral injection) from their peak volumes on Day 13, RVGL-12 treatment resulted in 84.5% reduction of tumor size (Day 52) from their peak volumes (Day 13). RVGL-12a treatment resulted in 98.3% reduction of tumor size (Day 89) from their peak volumes (Day 12). After PBS+GCV control treatment, the average volume of tumors were increased by 91.8% in 38 days

**Step#6:** The level of immune activation was determined. Sera were obtained from the animals with regressing tumors and the immune titer determined against a foreign protein (e.g. green fluorescent protein), vaccinia viral proteins, and GI-101A



-180-

cancer cell proteins were determined. The following antisera obtained from the following sources were used to analyze the following listed samples.

Samples:

- 1). Mouse cell lysate (control);
- 5 2). Purified and denatured vaccinia viral particles;
- 3). GI-101A tumor cell lysate;
- 4). Purified green fluorescent protein;
- 5). Purified luciferase protein;
- 6). Purified beta-galactosidase protein.

10 Antisera:

- a). Antiserum from nontumorous mouse;
- b). Antiserum from GI-101A tumorous mouse;
- c). Antiserum from GI-101A tumorous mouse 14 days after vaccinia i.v. injection;
- d). Antiserum from GI-101A tumorous mouse 65 days after vaccinia i.v. injection;
- 15 e). Antiserum from tumor-free mouse (after elimination of GI-101A tumor) 80 days after vaccinia i.v. injection.

The results showed that there was enormous tumor-specific vaccinia virus replication in the tumors, which led to tumor protein antigen and viral protein production in the tumors. In addition, the vaccinia virus did lyse the infected tumor cells thereby releasing tumor-cell-specific antigens. The continuous leakage of these antigens into the body led to a very high level of antibody titer (in approximately 7-14 days) against foreign cell proteins (tumor proteins), viral proteins, and the virus encoded engineered proteins in the mouse body. The newly synthesized antitumor antibodies and the enhanced macrophages, neutrophils counts were continuously delivered via the vasculature into the tumor and thereby providing for the recruitment of an activated immune system in the inside of the tumor. The active immune system then eliminated the tumor including the viral particles. This interconnected release of foreign antigens boosted antibody production and continuous return of the antibodies against the tumor-contained proteins function as

-181-

an autoimmunization vaccination system, initiated by vaccinia viral replication, followed by cell lyses, protein leakage and enhanced antibody production .

### EXAMPLE 8

#### 5 **Production of $\beta$ -Galactosidase and Anti $\beta$ -Galactosidase via Vaccinia Virus Delivered lacZ in Tumor Bearing Mice**

Thirty five athymic nu/nu mice (5 weeks old, 25g, male) were used to demonstrate the biodistribution and tumor targeting of vaccinia virus (strain LIVP) with different deletions in the genome. Mice were divided into 7 groups with 5 in each group as presented in Table 1

Group	No. mice	Tumor implanted	Virus Injected	Insertion locus
1	5	None	VGL	wtLIVP
2	5	C6, s.c. $5 \times 10^5$ cells	VGL	wtLIVP
3	5	C6, s.c. $5 \times 10^5$ cells	RVGL1	N- <i>luc</i> , <i>lacZ</i>
4	5	C6, s.c. $5 \times 10^5$ cells	RVGL5	HA- <i>lacZ</i>
5	5	C6, s.c. $5 \times 10^5$ cells	RVGL7	TK- <i>egfp</i> , <i>lacZ</i>
6	5	C6, s.c. $5 \times 10^5$ cells	RVGL8	<i>NotI-lacZ</i>
7	5	C6, s.c. $5 \times 10^5$ cells	RVGL19	TK- <i>rTrf</i> , <i>lacZ</i> , <i>NotI</i> -RG

10

C6 gliomas were subcutaneously developed in Groups 2 to 7. Five days after tumor cell implantation ( $5 \times 10^5$  cells/mouse), each animal was treated with 0.1 ml of virus at a multiplicity of infection (MOI) of  $1 \times 10^7$  via tail vein injection. Two weeks after virus injection, all mice were sacrificed and blood samples were collected. Various organs and tumors also were taken from animals for virus titer and  $\beta$ -galactosidase analysis.

15

The  $\beta$ -galactosidase analysis was performed using the Galacto-Light Plus system (Applied Biosystems), a chemiluminescent reporter gene assay system for the detection of  $\beta$ -galactosidase, according to the manufacturer's instructions.

20

#### **$\beta$ -galactosidase Expression Measurements**

In non-tumorous mice as well as in tumorous mice injected with wild type vaccinia virus (without reporter genes and without  $\beta$ -galactosidase gene) no  $\beta$ -galactosidase expression was detected in organs, blood and tumor samples. By contrast, in the tumors of mice infected with  $\beta$ -galactosidase expressing virus, high

-182-

Levels of  $\beta$ -galactosidase was expressed.  $\beta$ -galactosidase also was detected in blood samples as shown in Table 2, but no virus recovered from blood samples.

**Table 2. Production of  $\beta$  galactosidase by vaccinia virus in tumor and blood from tumor bearing mice (day 14 after virus injection)**

Group	Virus Injected	$\beta$ -gal in tumor $\mu\text{g}/\text{mg}$ of total protein	$\beta$ -gal in serum $\mu\text{g}/\text{ml}$ of total protein	Est. total $\beta$ -gal/tumor ( $\mu\text{g}$ )	Est. total $\beta$ -gal/5ml blood ( $\mu\text{g}$ )
3	RVGL1	$1.59 \pm 0.41$	$1.38 \times 10^{-2} \pm 1.09 \times 10^{-2}$	489.84	4.00
4	RVGL5	$1.51 \pm 0.37$	$1.16 \times 10^{-2} \pm 1.08 \times 10^{-2}$	330.21	3.62
5	RVGL7	$1.35 \pm 0.59$	$0.95 \times 10^{-2} \pm 1.47 \times 10^{-2}$	616.60	1.83
6	RVGL8	$1.81 \pm 0.42$	$0.86 \times 10^{-2} \pm 0.33 \times 10^{-2}$	962.36	2.38
7	RVGL19	$1.30 \pm 0.44$	$0.26 \times 10^{-2} \pm 0.16 \times 10^{-2}$	463.75	0.60

5

#### Anti- $\beta$ -galactosidase antibody production

To determine whether the amount of  $\beta$ -galactosidase presented in mouse blood was sufficient to elicit antibody production, sera taken from two mice (mouse #116 from Group 5, and #119 from Group 6) were collected and tested for primary antibodies against  $\beta$ -galactosidase in Western analysis.  $\beta$ -galactosidase from *E. coli* (Roche, 567 779) was used as the antigen standard, and the mouse monoclonal anti  $\beta$ -galactosidase from *E. coli* (Sigma, G6282) was used as the antibody positive control. As additional sources of  $\beta$ -galactosidase, total protein was obtained from CV-1 cells 24 hours after infection with RVGL7 at MOI of 1 pfu/cell, and the tumor protein sample from mouse designated #143 (treated with RVGL7) was obtained.

The protein samples were prepared in triplicate, each set including a  $\beta$ -galactosidase antigen control, a cell lysate from RVGL7 infected CV-1 cells, and tumor lysate from mouse #143. All protein samples were separated by electrophoresis using a 10% polyacrylamide gel, and transferred to NitroBind nitrocellulose membrane (MSI) using a BioRad semidry blotting system. Immunoblotting was performed with either 1:3000 mouse monoclonal anti  $\beta$ -galactosidase, or 1:3000 mouse serum taken from either mouse #116 or #119, and 1:3000 Goat AntiMouse IgG-HRP (BioRad). An Amplified Opti-4CN Detection Kit (BioRad) was used for detection.

The results showed that sera taken from mouse #116 and #119 exhibited similar levels of antibody when compared to a commercial mouse anti- $\beta$ -

-183-

galactosidase standard , and demonstrated that the tumor bearing mice #116 and #119 produced antibodies against  $\beta$ -galactosidase.

#### EXAMPLE 9

Mamalian cells for tumor therapy

5 As shown herein, certain bacteria, viruses, and mammalian cells (BVMC), when administered systemically, again entry and selectively replicate in tumors. Hence, systemically injected mammalian cells and certain bacterial (anerobic bacteria, such as Salmonella, Clostridium sp., Vibrio, *E. coli* ) cells gain entry into solid tumors and replicate in tumor-bearing organisms. Genetically-labeled cells  
10 can be used for tumor detection and therapy. In addition to gene expression in tumors through BVMC targeting, tumor-specific gene expression can be achieved by linking transgenes to tissue/tumor-specific promoters. To obtain tumor specific gene expression, a variety of systemic targeting schemes can be employed. These strategies include the use of tissue/tumor-specific promoters that allow the activation  
15 of gene expression only in specific organs, such as prostate-specific promoter-directed viral gene expression; the use of extracellular matrix (*i.e.* collagen)-targeted viral vectors; and the use of antibody-directed viral vectors. Conditionally-replicating viruses have also been explored as tumor-specific delivery vehicles for marker genes or therapeutic genes, such as oncolytic adenovirus vector particles,  
20 replication-selective HSV, vaccinia viruses and other such viruses.

When light-emitting protein encoded BVMC are injected systemically into rodents, tumor-specific marker gene expression is achieved and is detected in real time based on light emission. Consequently, the locations of primary tumors and previously unknown metastases in animals are revealed in vivo. Hence diagnosis can  
25 be coupled to therapy and to monitoring of therapy. The impaired lymphatic system in tumors may be responsible for the lack of clearance of bacteria from tumors by the host immunosurveillance after escaping the vascular system.

#### EXAMPLE 10

**Tumor Development is inhibited following *S.pyrogenes* administration**

-184-

This Example and following examples demonstrate the use of bacterial cells to colonize tumors, use of reporter in the cells to quantitate colonization; use of the colonized attenuated bacterial cells for tumor inhibition. Co-administration or sequential administration of bacteria and viruses. Administration of virus before bacteria increase tumor colonization by the bacteria. Administer bacteria that expresses an enzyme that will activate a prodrug, thereby targeting colonized cells.

#### **Bacterial Strains**

*Streptococcus pyogenes* M-type 1 T-type 1 (ATCC catalog no. 700294) was transformed with pDC123-luxF plasmid ) that contains the bacterial luciferase expression cassette (Lamberton GR, Pereau MJ, Illes K, Kelly IL, Chrisler J, Childers BJ, Oberg KC, Szalay AA. 2002. *Construction and characterization of a bioluminescent Streptococcus pyogenes*. Proceedings of the 12th International Symposium on Bioluminescence and Chemiluminescence, Case JF, Herring PJ, Robison BH, Haddock SHD, Kricka LJ, Stanley PE (eds). Chichester: Wiley, pp 85-88. Luciferase can be detected in the presence of exogenous decanal.

Transformed *S.pyogenes* were grown overnight in BH1 media in the presence of in the presence of 20 µg/ml of chloramphenicol at 37°C. After overnight growth, the bacteria were counted at OD<sub>600</sub> and bacteria were resuspended in BH1 media at the indicated density for injection.

#### **Tumor Development and Bacterial Injection**

Twenty 5-week old mice were injected subcutaneously in the right lateral thigh. Each mouse was injected with 5 x 10<sup>5</sup> C6 glioma cells transformed with pLEIN-derived retrovirus (Clontech; see also WO 03/14380). The subcutaneous tumors were developed for 7 days after implantation before bacterial injection.

For bacterial injection, the tumor-bearing mice were anesthetized with isofluorene. The suspensions were injected intravenously with a 1-cc insulin syringe equipped with a 29 ½ -gauge needle through a surgically exposed femoral vein. After the injections, the incisions were sutured.

Tumor growth was monitored on twice a week following bacterial injection using a digital caliper. In addition, fluorescence imaging and photographic images

-185-

of the animals were taken at the end time points. The presence of luminescent bacteria was analyzed by intravenously injecting the animals with 30  $\mu$ l of decanal. Analysis of whole animals for bacterial luciferase activity, followed methods similar to Yu *et al.* (2004) *Nature Biotechnology* 22(3): 313-20. Briefly, anesthetized animals were placed inside the dark box for photon counting (ARGUS 100 low light Imager, Hamamatsu). Photon collection was for 1 minute from ventral and dorsal sides of the animal and the images were recorded with Image Pro Plus 3.1 software (Media Cybernetics) and/or Lighttools® macroimaging system. A light image also was recorded. The luminescent images were superimposed on the light image to localize the luminescent activity on the animal. Total intensity of photon emission in localized regions, *e.g.* in the tumor region, also was recorded. *S. pyrogenes* was isolated from removed tumors and ground tissue was plated on LB-chloamphenicol (20  $\mu$ g/ml) plates. Luminescent bacteria were counted in the presence of decanal vapor.

## Results

Four groups of mice were tested. Each group contained five mice.

Group	<i>S. Pyrogenes</i>
1	None
2	$1 \times 10^6$
3	$1 \times 10^7$
4	$5 \times 10^7$

Tumor volume was measured after 7 days of tumor development and the injection of *S.pyrogenes*, through 21 days post-tumor development.

The control group of mice with no *S. pyrogenes* had continuous and accelerating tumor growth over the 2-week period. The mice injected with *S. pyrogenes* had slower tumor growth. Groups 3 and 4 had the slowest tumor growth rates. Both groups maintained a slower linear rate throughout the monitoring period, whereas the control group, not injected with bacteria, exhibited tumor growth that accelerated at later time periods.

At all time points following bacterial injection, tumor volumes were smaller in Groups 3 and 4 mice than in the control mice (Group 1). At day 21, the average

-186-

tumor volume of the control group was approximately 2.5-3 fold greater than the average tumor volumes in Groups 3 and 4. Group 2, injected with the lowest titer of bacteria, also had a reduced tumor volume from the control group at the later time points, although the tumor volume was larger than Groups 3 and 4.

5           Bacterial colonization and tumor inhibition also is assayed in a fibrosarcoma model. HT1080 fibrosarcoma cells transformed with the pLEIN retrovirus are injected subcutaneously into the right lateral thigh of five week old nude male mice  $5 \times 10^5$  cells/mouse). *S. pyrogenes* transformed with pDC123-luxF is injected into  
10       the femoral vein of the animals after 8 or 14 days of tumor growth (5 animals on each day). A group of 5 animals are not injected as serve as a control group. Tumor growth and luciferase activity is monitored at subsequent time points. *S. pyrogenes* is isolated from tumors and cultured on BH1 + chloramphenicol (20 µg/ml) plates. Luminescent bacterial colonies are counted in the presence of decanal vapor.

#### Example 11

##### 15    **Vibrio Cholera localization to tumors** **Plasmids and Bacterial Strains**

Attenuated *Vibrio Cholerae*, strain Bengal 2 serotype 0139, M010 DattRS1, was transformed with pLITE201 which contains the luxCDABE cassette (Voisey *et al.* (1998) *Biotechniques* 24:56-58). The transformed strain is a light emitting strain  
20       due to the expression of the luciferase genes.

##### **Tumor Development and Bacterial Injection**

Groups of nude mice (n>20) were implanted with C6 glioma tumors ( $500\text{mm}^3$ ) as described in the Examples herein.  $1 \times 10^8$  transformed bacteria (*V. Cholerae*) were suspended in 100 µl of phosphate buffered saline (PBS). The  
25       bacterial suspension was injected into the right hind leg of each mouse. The animals were then monitored after injection under a low light imager as described in Example A.

In a separate experiment, for comparison, groups of nude mice (n>20) were implanted with C6 glioma tumors ( $500\text{mm}^3$ ) as described in the Examples herein.

-187-

These mice were injected with  $1 \times 10^8$  pfu/mouse of rVV-RUC-GFP virus (see Examples 1 and 4).

## Results

### Titer and luciferase activity

5 Mice from each of the two injected groups were sacrificed at time points after injection. Tumors were excised and homogenized. Bacterial and viral titers and luciferase activities were measured as described in the Examples herein.

Both bacterial and viral titer increased following injection. The increase in bacterial growth over time was proportional to luciferase levels in the tumors. A  
10 log-log plot of bacterial titer versus luciferase activity in tumors in the mice injected with *V. cholera* demonstrated a linear relationship between bacterial titer and luciferase activity. The groups of mice injected with rVV-RUC-GFP virus, also demonstrated a linear relationship between virus titer and luciferase activity.

	Time after <i>V. Cholera</i> /pLITE injection			
	4 hrs	8 hrs	16 hrs	32 hrs
<b>Bacterial Titer</b> (cfu/tumor)	$3.79 \times 10^4 \pm 2.93$	$3.14 \times 10^6 \pm 2.45$	$1.08 \times 10^8 \pm 1.3$	$5.97 \times 10^8 \pm 4.26$

	Time after rVV-ruc-gfp virus injection			
	36 hrs	Day 3	Day 5	Day 7
<b>Viral Titer</b> (pfu/tumor)	$3.26 \times 10^6 \pm 3.86$	$7.22 \times 10^7 \pm 3.67$	$1.17 \times 10^8 \pm 0.76$	$3.77 \times 10^8 \pm 1.95$

The experiments demonstrated a linear relationship between titer and luciferase activity. Thus, luciferase activity of the injected bacteria and/or virus can be used a correlative measurement of titer.

### 20 Localization

Localization of *V. cholera* was performed as detailed in the Examples herein for virus. Briefly, organs and blood samples were isolated from animals euthanized



-188-

with CO<sub>2</sub> gas. The organs were ground and plated on agar plates with chloramphenicol drug selection for analysis of bacterial titer.

Bacterial titer was assayed in tumor, liver, testes, spleen, kidney, lung, heart, bladder and brain of the injected mice. Samples were taken from mice sacrificed at zero, and subsequent times up to 150 hours following *V.cholera* injection.

At the time point immediately following injection (t=0), *V. cholera* was present in all samples, with the highest levels in the liver and spleen. By 50 hours post-injection, titer of *V.cholera* in all tissues had reduced with the exception of tumor tissue. In contrast, *V.cholera* titer had increased about 4 orders of magnitude as compared to time zero. This level increased slightly and then stayed constant throughout the remainder of the experiment. By 150 hours post-infection, titer in all samples except tumor had decreased. For example, the titer in liver had decreased by approximately 5 orders of magnitude from the time zero point. At the 150 hour point, the *V.cholera* titer in the tumor tissue was about 6 orders of magnitude greater than any other tissue sample.

### Example 12

#### Co-administration and sequential administration of bacteria and virus

*V.Cholera*/pLITE (see Example B) and vaccinia virus VV-TK<sup>-</sup>-gfp-lacZ (see Example 4) were administered together or sequentially. Groups of nude mice with C6 glioma tumors were injected with bacteria and/or virus as shown in the Table below. Three male mice were injected per group. Bacteria and/or virus were injected on day 11 and day 16 following tumor implantation. Tumor growth, luciferase and GFP activity were monitored as described in the Examples herein.

Group	Day 11 injection	Day 16 injection
1	1 X 10 <sup>7</sup> VV-TK <sup>-</sup> -gfp-lacZ	1 X 10 <sup>7</sup> <i>V.Cholera</i> /pLITE
2	None	1 X 10 <sup>7</sup> <i>V.Cholera</i> /pLITE
3	1 X 10 <sup>7</sup> <i>V.Cholera</i> /pLITE	1 X 10 <sup>7</sup> VV-TK <sup>-</sup> -gfp-lacZ
4	None	1 X 10 <sup>7</sup> VV-TK <sup>-</sup> -gfp-lacZ
5	None	1 X 10 <sup>7</sup> VV-TK <sup>-</sup> -gfp-lacZ and 1 X 10 <sup>7</sup> <i>V.Cholera</i> /pLITE

-189-

## Results

On day 21 (21 days post tumor implantation) animal were sacrificed. Tumors were excised from each animal and ground. Viral titer was assayed on Groups 3, 4 and 5. Bacterial titer was assayed on Groups 1, 2 and 5. Titers (colony forming units and plaque forming units) were performed as previously described in the Examples.

A comparison of the bacterial titer in tumors Groups 1, 2 and 5 demonstrated that bacterial titer was highest in Group 1 that had been injected first with vaccinia virus at day 11, and followed by *V.cholera* injection on day 16. Co-injection of bacteria and virus at day 16 (Group 5) gave an intermediate bacterial titer. Group 2, injected only with *V.cholera* at day 16, had a lower bacterial titer in the tumor tissue than either of groups 1 or 5. Thus, tumors were more susceptible to bacterial colonization when first colonized by VV-TK<sup>-</sup>-gfp-lacZ virus.

A comparison of the viral titer in Groups 3, 4 and 5 demonstrated that Group 4, with only virus injection at day 16, had the highest viral titer followed by Groups 5 and 3. The viral titer of Group 5 was slightly higher than Group 3, but not apparently significantly different. One mouse in Group 4 had a viral titer that was an extreme outlier in comparison to the viral titer of the other 2 mice in Group 4. When the numbers were reassessed without this mouse, the general trend remained the same. The average viral titer in Group 4 was much closer to the viral titers of Groups 3 and 5. The data from the three groups in this analysis was not significantly different. Thus, pre-administration of bacteria followed by administration of virus did not significantly change the viral colonization of the tumor as compared with viral administration alone.

### Example 13

**Tumor Inhibition by Administering PNP-expressing bacteria and prodrug Plasmids** pSOD-DeoD contains the bacterial purine nucleoside phosphorylase gene (PNP) (Sorcher *et al.* (1994) GeneTher. 1(4):223-238), under the control of the constitutive SOD (superoxide dismutase) promoter. Plasmid pSOD-DeoD-lux,

-190-

contains the luxCDABE expression cassette (Voisey *et al.* (1998) *Biotechniques* 24:56-58) inserted into pSOD-DeoD.

PNP converts the non-toxic prodrug 6-methylpurine deoxyribose (6-MPDR) to 6-methyl purine which inhibits DNA replication, transcription and translation (Sorcher *et al.* (1994) *GeneTher.* 1(4):223-238).

#### **Tumor Growth inhibition**

Nude mice were injected with pLEIN retrovirus transformed C6 glioma cells. The pLEIN retrovirus expresses EGFP under the control of the viral promoter LTR (Clontech; see also WO 03/14380). *E. coli* DH5 $\alpha$  expressing the bacterial purine nucleoside phosphorylase gene was injected at day 8 following tumor implantation with or without prodrug (6-methylpurine deoxyribose (6-MPDR)). Tumor volume was monitored at subsequent time points (as performed in previous examples).

Group	Administered
1	<i>E.coli</i> /PNP + prodrug
2	<i>E.coli</i> /PNP
3	<i>E.coli</i> control + prodrug

Groups 2 and 3 exhibited equal tumor growth over time points from 8 to 21 days post tumor implantation. Group 1, which received both the *E.coli* expressing PNP and the prodrug exhibited ~20% reduction in tumor size as compared to the control Groups 2 and 3 at the end time points.

To further test bacterial colonization and prodrug effects on tumor growth, a human breast cancer model, GI-101A adenocarcinoma in nude mice, was chosen. GI-101A was derived from GI-101. GI-101 originated from a local first recurrence of an infiltrating duct adenocarcinoma (stage IIIa, T3N2MX) in a 57 year old female patient by researchers at Rumbaugh-Goodwin Institute for Cancer Research. In the subcutaneous xenograft nude mice model, the tumor consistently metastasizes to the lungs. The GI-101A is a slower growing tumor model as compared to the C6 glioma tumor model.

-191-

Fifteen 4 week old female nude mice are each injected subcutaneously in the right lateral thigh with GI-101A cells. Thirty days after tumor development, bacteria are injected. *Escherichia coli* DH5 $\alpha$  is transformed with pSOD-DeoD or pSOD-DeoD-lux. The bacteria are grown overnight in LB media in the presence of  
5 20  $\mu$ g/ml of chloramphenicol at 37°C. After overnight growth, the bacteria are counted at OD<sub>600</sub> and bacteria resuspended in BH1 media at the indicated density. The suspensions are injected intravenously with a 1-cc insulin syringe equipped with a 29 ½ -gauge needle into the animal through a surgically exposed vein or as otherwise indicated. After the injections, the incisions are sutured.

10 Prodrug is administered to groups of mice every four days following injection of bacteria. Tumor growth is monitored twice per week using a digital caliper. Luciferase imaging is performed as described in the Examples herein. At the end point, the animal are sacrificed and organs are assayed as described in  
15 Example B. Histological analyses are performed to determine the degree of tumor necrosis due to bacterial colonization and/or drug treatment.

Since modifications will be apparent to those of skill in this art, it is intended that this invention be limited only by the scope of the appended claims.

-192-

**What is claimed is:**

1. A recombinant vaccinia virus, comprising a modified TK and HA gene and optionally a modified F3 gene or locus, wherein the resulting virus does not accumulate to toxic levels in non-targeted organs.
- 5 2. A recombinant vaccinia virus of claim 1, wherein (a) the F3 gene and (b) the TK gene and/or HA gene are modified.
3. The recombinant vaccinia virus of claim 1, wherein (a) the F3 gene and (b) the TK gene and/or HA gene are inactivated.
- 10 4. The recombinant vaccinia virus of claim 1 or 2, wherein at least the F3 gene is inactivated by insertion of heterologous nucleic acid therein..
5. The recombinant vaccinia virus of claim 3, wherein the F3 gene and the TK gene are inactivated by insertion of heterologous nucleic acid.
6. The recombinant vaccinia virus of claim 1, wherein the vaccinia virus is a Lister strain.
- 15 7. The recombinant virus of claim 6, where the strain is the LIVP strain.
- 8.. The recombinant vaccinia virus of any of claims 1 to 7, wherein the modification of the F3 gene is at the NotI site within the F3 gene or a corresponding locus.
- 20 9. The recombinant vaccinia virus of claim 8, wherein the modification is at position 35 of the F3 gene or at position 1475 inside of the HindIII-F fragment of vaccinia virus DNA strain LIVP.
10. The recombinant vaccinia virus of any of claims 1 to 9, wherein the TK, HA and/or F3 gene comprises an insertion of heterologous nucleic acid that  
25 encodes a protein.
11. The recombinant vaccinia virus of claim 9, wherein the heterologous nucleic acid comprises a regulatory sequence operatively linked to the nucleic acid encoding the protein.
12. The recombinant vaccinia virus of claim 11, wherein the regulatory  
30 sequence comprises the vaccinia virus early/late promoter p7.5.

-193-

13. The recombinant vaccinia virus of claim 11 or 12, wherein the regulatory sequence comprises an early/late vaccinia pE/L promotor.

14. The recombinant vaccinia virus of any of claims 10 to 13, wherein the heterologous nucleic acid encodes a detectable protein or a protein capable of inducing a detectable signal.

15. A host cell containing a recombinant vaccinia virus of any of claims 1 to 14.

16. A tumor cell, comprising a recombinant vaccinia virus of any of claims 1 to 14.

17. A pharmaceutical composition containing a recombinant vaccinia virus of any of claims 1 to 14 in a pharmaceutically acceptable vehicle.

18. The pharmaceutical compositions of claim 17 that is formulated for systemic administration.

19. The pharmaceutical composition of claim 12 that is formulated for intravenous administration or is formulated in a delivery vehicle.

20. A method for eliminating immunoprivileged cells in an animal, comprising administering the pharmaceutical composition of claim 18 or claim 19 to an animal, whereby the virus accumulates in the immunoprivileged cells, thereby mediating autoimmunization resulting in elimination of the cells or a reduction in their number.

21. The method of claim 20, wherein the immunoprivileged cells comprise tumor cells.

22. The method of claim 20, wherein:

the pharmaceutical composition comprises a vaccinia virus of the Lister strain, comprising a modified TK and HA gene and optionally a modified F3 gene or locus; and

the resulting virus does not accumulate to toxic levels in non-targeted organs

23. A therapeutic method for eliminating immunoprivileged cells or tissues, in an animal, comprising:

administering a microorganism to an animal, wherein:

-194-

the microorganism accumulates in the immunoprivileged cells;  
the microorganism does not accumulate in unaffected organs and  
tissues and has low toxicity in the animal;

the microorganism results in leakage of the cell membranes in the  
immunoprivileged cells, whereby the animal produces autoantibodies against the  
cells or products of the cells.

24. The method of claim 23, wherein the unaffected organs comprise the  
ovaries or testes.

25. The method of claim 23 or claim 24, wherein the immunoprivileged  
cells or tissues comprise tumor cells.

26. The method of any of claims 21-25, wherein the microorganism is an  
attenuated bacterium, an attenuated virus or a mammalian cell.

27. The method of claim 26, wherein the microorganism comprises or  
expresses a therapeutic product.

28. The method of claim 26 or 27, wherein the microorganism comprises  
nucleic acid encoding a therapeutic product.

29. The method of any of claims 23-29, wherein the autoantibodies  
comprise anti-tumor antibodies.

30. Use of a microorganism for formulation of a medicament for  
eliminating immunoprivileged cells or tissues, in an animal, wherein:

the microorganism accumulates in the immunoprivileged cells;  
the microorganism does not accumulate to toxic levels in organs and  
tissues that do not comprise immunoprivileged cells or tissues.

31. Use of the pharmaceutical composition of claim 18 or 19 for  
eliminating immunoprivileged cells or tissues.

32. A recombinant pox virus, comprising a modified TK and HA gene  
and a modified F3 gene or locus that corresponds to the F3 gene in vaccinia.

33. Use of (a) a recombinant virus of any of claims 1 to 14 and 32 or  
(b) a recombinant vaccinia virus having a modified F3 gene, TK gene or HA gene,

-195-

for the preparation of a pharmaceutical composition for gene therapy or vaccine therapy.

34. The use of claim 33, wherein the F3 gene, TK gene and/or HA gene are inactivated.

5 35. The use of claim 34, wherein the F3 gene, TK gene and/or HA gene are inactivated by insertion of heterologous nucleic acid.

36 The use of any one of claims 33 to 3, wherein the gene therapy is cancer gene therapy.

10 37. A method of producing a recombinant vaccinia virus of any one of claims 1 to 14, comprising :

(a) generating (i) a vaccinia shuttle plasmid containing the modified F3 gene inserted at restriction site x and (ii) a dephosphorylated wt VV (VGL) DNA digested at a restriction site;

15 (b) transfecting host cells infected with psoralen -UV (PUV)-inactivated helper VV (VGL) with a mixture of constructs (i) and (ii) of step a; and

(c) isolating the recombinant vaccinia viruses from the transfectants.

38. The method of claim 37, wherein the host cells are CV-1 cells.

20 39. A method for production of a polypeptide or RNA or compound, comprising:

(a) administering a microorganism containing nucleic acid encoding the polypeptide or RNA or producing the product compound to tumor-bearing animal, wherein:

25 the microorganism accumulates in the immunoprivileged cells; and the microorganism does not accumulate to toxic levels in organs and tissues that do not comprise immunoprivileged cells or tissues;

(b) harvesting the tumor tissue from the the animal; and

(c) isolating the polypeptide or RNA or compound from the tumor

30 40. The method of claim 39, wherein the microorganism is a eukaryotic cell, a prokaryotic cell or a virus.



-196-

41. The method of claim 39 or claim 40, wherein the microorganism is a cytoplasmic virus or an attenuated bacterium

42. The method of claim 41, wherein the bacterium is selected from among attenuated *vibrio*, *E. coli*, *lysteria*, salmonella and streptococcus strains.

5 43. The method of any of claims 39-43, wherein the animal is a non-human animal.

44. A method for simultaneously producing a polypeptide, RNA molecule or cellular compound and an antibody that specifically reacts with the polypeptide, RNA molecule or compound, comprising:

10 a) administering a microorganism to a tumor-bearing animal, wherein the microorganism expresses or produces the compound, polypeptide or RNA molecule; and

b) isolating the antibody from serum in the animal.

15 45. The method of claim 44, further comprising after step a) harvesting the tumor tissue from the animal; and isolating the polypeptide, RNA molecule or cellular compound from the tumor tissue.

46. The method of claim 44 or 45, wherein the animal is a non-human animal.

20 47. The method of any of claims 44-46, wherein the microorganism is a bacterium, mammalian cell or a virus.

48. The method of any of claims 44-47, wherein:  
the microorganism accumulates in the immunoprivileged cells; and  
the microorganism does not accumulate to toxic levels in organs and  
25 tissues that do not comprise immunoprivileged cells or tissues.

49. The method of any of claims 44-47, wherein the microorganism is a virus selected from among pox viruses, herpes viruses, adenoviruses and sindbis virus.

30 50. The method of any of claims 44-47, wherein the microorganism is a cytoplasmic virus.

-197-

51. The method of any of claims 44-47, wherein the microorganism is a eukaryotic cell.

52. The method of claim 41, wherein the cell is an immune cell.

53. The method of claim 52 wherein the cell is a stem cell.

5 54. The method of any of claims 39-53, wherein the microorganism comprises a DNA molecule that encodes a reporter gene construct.

55. The method of claim 54, wherein the reporter gene construct encodes a detectable protein or a protein that induces or produces a detectable signal..

10 56. The method of claim 55, wherein the protein is a luciferase or a fluorescent protein.

57. The method of claim 54, wherein the reporter gene construct encodes a bioluminescence generating system and optionally encodes a fluorescent protein.

58. The method of any of claims 39-57, wherein the microorganism is a mammalian cell.

15 59. The method of any of claims 39-57, wherein the microorganism is a bacterial cell.

60. The method of any of claims 39-57, wherein the microorganism is a virus.

61. The method of claims 60, wherein the virus is a vaccinia virus.

20 62. The method of claim 61, wherein the vaccinia virus is a LIVP strain.

63. The method of claim 59, wherein the bacterium is attenuated *Vibrio cholerae*.

64. The method of any of claims 39-63, wherein the tumor is a solid tumor..

25 65. A method for eliminating immunoprivileged cells or tissues in an animal, comprising:

administering at least two microorganisms, wherein the microorganisms are administered simultaneously, sequentially or intermittently, wherein the microorganisms accumulate in the immunoprivileged cells, whereby the animal is  
30 autoimmunized against the immunoprivileged cells or tissues.

-198-

66. The method of claim 65, wherein the immunoprivileged cells or tissues comprises tumor cells.

5 67. Use of at least two microorganism for formulation of a medicament for elimination of immunoprivileged cells or tissues, wherein the accumulate in the immunoprivileged cells, whereby the animal is autoimmunized against the immunoprivileged cells or tissues.

68. The use of claim 67, wherein the immunoprivileged cells or tissues comprises tumor cells.

10 69. A combination, comprising at least two microorganisms formulated for administration to an animal for elimination of immunoprivileged cells or tissues.

70. The combination of claim 69, wherein the immunoprivileged cells or tissues comprises tumor cells.

71. The combination of claim 69, wherein the microorganisms are formulated in separate compositions.

15 72. A kit comprising the combination of any of claims 69-71, wherein each composition is formulated and packaged for single dosage administration.

20 73. Use of a microorganism encoding heterologous nucleic acid for inducing autoimmunization against products produced in immunoprivileged cells, wherein, when administered, the microorganism accumulates in immunoprivileged tissues and does not accumulate or accumulates at a sufficiently low level in other tissues or organs to be non-toxic to an animal containing the immunoprivileged tissues.

74. The use of claim 73, wherein the immunoprivileged tissue or cells comprise tumor cells.

25 75. The use of claim 74, wherein the products produced in the immunoprivileged cells comprise tumor antigens.

76 The use of any of claims 73-75, wherein the microorganism is a eukaryotic cell, a bacterium or a virus.

77. The use of any of claims 73-75, wherein the microorganism is a mammalian cell.

-199-

78.. The use of any of claims 73-75, wherein the microorganism is an attenuated pox virus.

79. The use of any of claims 73-75, wherein the microorganism is a vaccinia virus.

5 80.. The use of claim 79, wherein the virus is a Lister strain.

81. The use of claim 80, wherein the virus is an LIVP strain.

82. The use of any of ckauns 79-81, wherein the virus contains an insertion in the F3 gene or a locus corresponding to the F3 locus of LIVP (SEQ ID No. 34).

10 83. A method for the production of antibodies against products produced in immunoprivileged tissues or cells comprising:

(a) administering a microorganism containing nucleic acid encoding a selected protein or RNA into an animal containing the immunoprivileged tissues or cells ; and

15 (b) isolating antibodies against the protein or RNA from the blood or serum of the animal.

84. The method of claim 83, wherein the animal is a non-human animal.

85.. The method of claim 83, wherein the animal is a human animal.

20 86. The method of any of claims 83-85, wherein the immunoprivileged tissues or cells comprise tumor cells.

87. The method of any of claims 83-86 wherein the products produced in the immunoprivileged cells comprise tumor antigens.

88. The method of any of claims 83-87, wherein the microorganism is a eukaryotic cell, a bacterium or a virus.

25 89. The method of any of claims 83-87, wherein the microorganism is a mammalian cell.

90. The method of any of claims 83-87, wherein the microorganism is an attenuated cytoplasmic virus.

30 91. The method of any of claims 83-87, wherein the microorganism is an attenuated pox virus.

-200-

92. The method of any of claims 83-87, wherein the microorganism is a vaccinia virus.

93. The method of claim 92, wherein the virus is a Lister strain.

94.. The method of claim 93, wherein the virus is an LVP strain.

5 95. The method of any of claims 90-94, wherein the virus contains an insertion in the F3 gene or a locus corresponding to the F3 locus of LVP (SEQ ID No. 34).

96. A method of inhibiting growth of immunoprivileged cells or tissue in a subject, comprising the steps of:

10 (a) administering to a subject a modified microorganism, wherein the modified microorganism encodes a detectable gene product;

(b) monitoring the presence of the detectable gene product in the subject until the detectable gene product is substantially present only in immunoprivileged tissue or cells of a subject; and

15 (c) administering to a subject a therapeutic compound that works in conjunction with the microorganism to inhibit growth of immunoprivileged cells or tissue.

20 97. The method of claim 96, wherein growth of immunoprivileged cells or tissue is inhibited by inducing or enhancing an immune response against the immunoprivileged cells.

98. The method of claim 96, wherein the therapeutic compound increases expression of one or more genes encoded by the microorganism that cause cell lysis or apoptosis.

25 99. The method of claim 96, wherein the therapeutic compound is a prodrug that is activated by a protein expressed by the microorganism.

100. A method of inhibiting growth of immunoprivileged cells or tissue in a subject, comprising the steps of:

(a) administering to a subject a modified microorganism that encodes a detectable gene product;

-201-

(b) administering to a subject a therapeutic substance that reduces the pathogenicity of the microorganism;

5 (c) monitoring the presence of the detectable gene product in the subject until the detectable gene product is substantially present only in immunoprivileged tissue or cells of a subject; and

(d) terminating or suspending administration of the therapeutic compound, whereby the microorganism increases in pathogenicity and the growth of the immunoprivileged cells or tissue is inhibited.

10 101. The method of claim 100, wherein growth of immunoprivileged cells or tissue is inhibited by inducing or enhancing an immune response against the immunoprivileged cells.

15 102. The method of claim 100, wherein the therapeutic compound decreases expression of one or more genes encoded by the microorganism that cause cell lysis or apoptosis.




Figure 1A




Figure 1B






Figure 2

-1-

## SEQUENCE LISTING

<110> Genenlux  
 Szalay, Aladar A.  
 Timiryasova, Tatyana  
 Yu, Yong A.  
 Zhang, Qian

<120> Microorganisms for Therapy

<130> 17248-002wo1 (4802PC)

<140> Unassigned

<141>

<150> EP03013826.7

<151> 2003-06-18

<150> EP03018478.2

<151> 2003-08-14

<150> EP03024283.8

<151> 2003-10-22

<160> 36

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 148

<212> DNA

<213> Artificial Sequence

<220>

<223> LIPV F3

<400> 1

aatatagcaa cagtagttct tgctctctct tgattctagc atcctcttca ttattttctt 60  
 ctacgtacat aaacatgtcc aatacgtag acaacacacc gacgatggcg gccgctacag 120  
 acacgaatat gactaaaccg atgaccat 148

<210> 2

<211> 49

<212> PRT

<213> Artificial Sequence

<220>

<223> Translation LIPV F3

<400> 2

Met	Val	Ile	Gly	Leu	Val	Ile	Phe	Val	Ser	Val	Ala	Ala	Ala	Ile	Val
1				5				10					15		
Gly	Val	Leu	Ser	Asn	Val	Leu	Asp	Met	Phe	Met	Tyr	Val	Glu	Glu	Asn
		20					25				30				
Asn	Glu	Glu	Asp	Ala	Arg	Ile	Lys	Glu	Glu	Gln	Glu	Leu	Leu	Leu	Leu

-2-

35 40 45  
Tyr

<210> 3  
<211> 27  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Forward primer

<400> 3  
gggaattctt atacatcctg ttctatc 27

<210> 4  
<211> 30  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Reverse primer

<400> 4  
ccaagcttat gaggagtatt gcggggctac 30

<210> 5  
<211> 7252  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> psc65

<300>  
<308> GenBank No. AX003206  
<309> 2000-08-24

<400> 5  
agcttttgcg atcaataaat ggatcacaa cagtatctct taacgatggt cttcgcagat 60  
gatgattcat tttttaagta tttggctagt caagatgatg aaatcttcoat tatctgatat 120  
attgcaaatac actcaatatc tagactttct gttattatta ttgatccaat caaaaaataa 180  
attagaagcc gtgggtcatt gttatgaatc tctttcagag gaatacagac aattgacaaa 240  
attcacagac tttcaagatt ttaaaaaact gtttaacaag gtccctattg ttacagatgg 300  
aagggtcaaa ctttaataaag gataatttgt cgactttgtg attagtttga tccatctcga 360  
aaaagaatcc tctctagcta ccaccgcaat agatcctgtt agatacatag ccctcgtcg 420  
caatatcgca ttttctaacg tgatggatat attaaagtgc aataaagtga acaataatta 480  
attcttttatt gtcacatga acggcggaca tattcagttg ataatcggcc ccatgttttc 540  
aggtaaaagt acagaattaa ttagacgagt tagacgttat caaatagctc aatataaatg 600  
cgtgactata aaatattcta acgataatag atacggaacg ggactatgga cgcattgataa 660  
gaataatttt gaagcattgg aagcaactaa actatgtgat ctcttggaat caattacaga 720  
tttctccgtg ataggtatcg atgaaggaca gttctttcca gacattgttg aattagatcg 780  
ataaaaaatta attaattacc cgggtaccag gcctagatct gtcgacttcg agcttattta 840  
tattccaaaa aaaaaaataa aaatttcaat ttttaagctt tcactaattc caaaccacc 900

-3-

cgctttttat	agtaagtttt	tcacccataa	ataataaata	caataattaa	tttctcgtaa	960
aagtagaaaa	tatatcttaa	tttattgcac	ggtaagggaag	tagatcataa	ctcgagcatg	1020
ggagatcccg	tcgtttttaca	acgtcgtgac	tgggaaaacc	ctggcgttac	ccaacttaat	1080
cgccttgcag	cacatcccc	tttcgccagc	tggcgtaata	gcgaagaggc	ccgcaccgat	1140
cgcccttccc	aacagttgcg	cagcctgaat	ggcgaatggc	gctttgcctg	gtttccggca	1200
ccagaagcgg	tgccggaaaag	ctggctggag	tgcgatcttc	ctgaggccga	tactgtcgtc	1260
gtccctcaa	actggcagat	gcacggttac	gatgcgcca	tctacaccaa	cgtaacctat	1320
cccattacgg	tcaatccgcc	gtttgttccc	acggagaatc	cgacgggttg	ttactcgctc	1380
acatttaatg	ttgatgaaaag	ctggctacag	gaaggccaga	cgcgaattat	ttttgatggc	1440
gttaactcgg	cgtttcatct	gtggtgcaac	gggcgctggg	tcggttacgg	ccaggacagt	1500
cgtttgcggt	ctgaatttga	cctgagcgca	tttttacggc	ccggagaaaa	ccgcctcgcg	1560
gtgatggtgc	tgcgttggag	tgacggcagt	tatctggaag	atcaggatat	gtggcggatg	1620
agcggcattt	tccgtgacgt	ctcgttgctg	cataaaccga	ctacacaaat	cagcgatttc	1680
catgttgcca	ctcgctttaa	tgatgatttc	agccgcgctg	tactggaggc	tgaagttcag	1740
atgtgcggcg	agttgcgtga	ctacctacgg	gtaacagttt	ctttatggca	gggtgaaacg	1800
caggtcgcca	gcggcaccgc	gcctttcggc	ggtgaaatta	tcgatgagcg	tggtggttat	1860
gccgatcgcg	tcacactacg	tctcaactcg	gaaaaccgga	aactgtggag	cgccgaaatc	1920
ccgaatctct	atcgtcggtt	ggttgaactg	cacaccggcg	acggcacgct	gattgaagca	1980
gaagcctgcg	atgtcgggtt	ccgcgagggtg	cggattgaaa	atggtctgct	gctgctgaac	2040
ggcaagccgt	tgctgattcg	aggcgttaac	cgtcacgagc	atcatcctct	gcatggtcag	2100
gtcatggatg	agcagacgat	ggtgcaggat	atcctgctga	tgaagcagaa	caactttaac	2160
gccgtgcgct	gttcgcatta	tccgaaccat	ccgctgtggt	acacgctgtg	cgaccgctac	2220
ggcctgtatg	tggtggatga	agccaatatt	gaaaccacag	gcatggtgcc	aatgaatcgt	2280
ctgaccgatg	atccgcgctg	gctaccggcg	atgagcgaac	gcgtaacgcg	aatggtgcag	2340
cgcgatcgta	atcacccgag	tgtgatcctc	tggtcgctgg	ggaatgaatc	aggccacggc	2400
gctaatacag	acgcgctgta	tcgctggatc	aaatctgtcg	atccttcccg	cccgggtgag	2460
tatgaaggcg	gcggagccga	caccacggcc	accgatatta	tttgcccgat	gtacgcgcgc	2520
gtggatgaag	accagccctt	cccggctgtg	ccgaaatggt	ccatcaaaaa	atggctttcg	2580
ctacctggag	agacgcgccc	gctgatcctt	tgogaatacg	cccacgcgat	gggtaacagt	2640
cttggcggtt	tcgctaaata	ctggcaggcg	tttcgtcagt	atccccgttt	acagggcggc	2700
ttcgtctggg	actgggtgga	tcagtcgctg	attaaatatg	atgaaaacgg	caaccctgtg	2760
tcggcttacg	gcggtgattt	tggcgatacg	ccgaacgatc	gccagttctg	tatgaacggg	2820
cttggctttg	ccgaccgcac	gccgcatacca	gcgctgacgg	aagcaaaaaca	ccagcagcag	2880
tttttccagt	tcggtttatc	cgggcaaacc	atcgaaagtga	ccagcgaata	cctgttccgt	2940
catagcgata	acgagctcct	gcactggatg	gtggcgctgg	atggtaagcc	gctgggaacc	3000
ggtgaagtgc	ctctggatgt	cgctccacaa	ggtaaacagt	tgattgaact	gcctgaacta	3060
ccgcagccgg	agagcgccgg	gcaactctgg	ctcacagtac	gcgtagtgca	accgaacgcg	3120
accgcatggt	cagaagccgg	gcacatcagc	gcctggcagc	agtggcgtct	ggcggaaaac	3180
ctcagtgtga	cgctccccgc	cgctcccac	gccatccccg	atctgaccac	cagcgaaatg	3240
gattttttgca	tcgagctggg	taataagcgt	tggcaattta	accgccagtc	aggctttctt	3300
tcacagatgt	ggattggcga	taaaaaacaa	ctgctgacgc	cgctgcgcga	tcagttcacc	3360
cgtgcaccgc	tggataacga	cattggcgta	agtgaagcga	cccgcattga	ccctaaccgc	3420
tgggtcgaac	gctggaaggc	ggcgggccat	taccaggccg	aagcagcggt	gttgacgtgc	3480
acggcagata	cacttgctga	tgcggtgctg	attacgaccg	ctcacgcgtg	gcagcatcag	3540
gggaaaacct	tatttatcag	ccggaaaacc	taccggattg	atggtagtgg	tcaaattggc	3600
attaccgttg	atggtgaagt	ggcgagcgat	acaccgcac	cggcgcggtg	tggcctgaac	3660
tgccagctgg	cgcaggtagc	agagcgggta	aactggctcg	gattagggcc	gcaagaaaac	3720
tatcccgacc	gccttactgc	cgctgtttt	gaccgctggg	atctgccatt	gtcagacatg	3780
tataccccgt	acgtcttccc	gagcgaaaac	ggtctgcgct	gcgggacgcg	cgaattgaat	3840
tatggccac	accagtggcg	cggcgacttc	cagttcaaca	tcagccgcta	cagtcaacag	3900
caactgatgg	aaaccagcca	tcgccatctg	ctgcacgcgg	aagaaggcac	atggctgaat	3960
atcgacgggt	tccatatggg	gattggtggc	gacgactcct	ggagcccgtc	agtatcggcg	4020
gaattcagct	gagcgccggg	cgctaccatt	accagttggt	ctgggtgtcaa	aaataataat	4080
aaccgggcag	gggggatcct	tctgtgagcg	tatggcaaac	gaaggaaaaa	tagttatagt	4140
agccgcactc	gatgggacat	ttcaacgtaa	accgtttaat	aatattttga	atcttatttc	4200

-4-

```

attatctgaa atggtggttaa aactaactgc tgtgtgtatg aaatgcttta aggaggcttc 4260
cttttctaaa cgattgggtg aggaaaccga gatagaaata ataggaggta atgatatgta 4320
tcaatcgggtg tgtagaaagt gttacatcga ctcataatat tatatttttt atctaaaaaa 4380
ctaaaaataa acattgatta aattttaata taataacttaa aaatggatgt tgtgtcgtta 4440
gataaacctg ttatgtattt tgaggaaatt gataatgagt tagattacga accagaaagt 4500
gcaaatgagg tcgcaaaaaa actgccgtat caaggacagt taaaactatt actaggagaa 4560
ttattttttc ttagtaagtt acagcgacac ggtatattag atggtgccac cgtagtgtat 4620
ataggatctg ctcccgttac acatatacgt tatttgagag atcattttcta taatttagga 4680
gtgatcatca aatggatgct aattgacggc cgccatcatg atcctatttt aaatggattg 4740
cgtgatgtga ctctagtgc tcggttcggt gatgaggaat atctacgatc catcaaaaaa 4800
caactgcata cttctaagat tattttaatt tctgatgtga gatccaaacg aggaggaaat 4860
gaacctagta cggcggattt actaagtaat tacgctctac aaaatgtcat gattagtatt 4920
ttaaaccccg tggcgtctag tcttaaatgg agatgcccg ttccagatca atggatcaag 4980
gacttttata tcccacacgg taataaaaatg ttacaacctt ttgctccttc atattcagct 5040
gaaatgagat tattaagtat ttataccggt gagaacatga gactgactcg ggccgcgttg 5100
ctggcggttt tccataggct ccgccccctt gacgagcatc acaaaaaatcg acgctcaagt 5160
cagagggtgg gaaacccgac aggactataa agataccagg cgtttccccc tggaaagctc 5220
ctcgtgcgct ctccgtgttc gaccctgcgc ctaccggat acctgtccgc ctttctccct 5280
tcgggaagcg tggcgctttc tcaatgctca cgctgtaggt atctcagttc ggtgtaggtc 5340
gttcgctcca agctgggctg tgtgcacgaa ccccccgttc agcccgaccg ctgcgcctta 5400
tccggttaact atcgtcttga gtccaacccg gtaagacacg acttatcgcc actggcagca 5460
gccactggta acaggattag cagagcgagg tatgtaggcg gtgctacaga gttcctgaag 5520
tggtggccta actacggcta cactagaagg acagtatttg gtatctgcgc tctgctgaag 5580
ccagttacct tcggaaaaag agttggtagc tcttgatccg gcaaacaac caccgctggt 5640
agcgggtggt tttttgtttg caagcagcag attacgcgca gaaaaaagg atctcaagaa 5700
gatcctttga tcttttctac ggggtctgac gctcagtgga acgaaaactc acgttaaggg 5760
attttgggtc tgagattatc aaaaaggatc ttcacctaaga tcctttttaa ttaaaaatga 5820
agttttaaat caatctaaag tatatatgag taaacttgggt ctgacagtta ccaatgctta 5880
atcagtgagg cacctatctc agcgatctgt ctatttcgtt catccatagt tgctgactc 5940
cccgtcgtgt agataactac gatacgggag ggcttaccat ctggccccag tgctgcaatg 6000
ataccgcgag acccacgctc accggctcca gatttatcag caataaaacca gccagccgga 6060
agggccgagc gcagaagtgg tcctgcaact ttatccgcct ccatccagtc tattaattgt 6120
tgccgggaag ctagagtaag tagttcgcca gttaatatgt tgcgcaacgt tggtgccatt 6180
gctgcaggca tcgtggtgtc acgctcgtcg ttggtatgg atgttgtgca cttcattcag ctccggttcc 6240
caacgatcaa ggcgagttac atgatcccc gccgcagtgt tatcactcat ggttatggca 6300
ggtcctccga tcgttgtcag aagtaagttg gctcagtgt tccgtaagat gcttttctgt gactggtgag 6360
gcactgcata attctcttac tgtcatgcca atgcggcgac cgagttgctc ttgcccggcg 6420
tactcaacca agtcattctg agaatagtgt atgcggcgac agagttgctc cattggaaaa 6480
tcaacacggg ataataccgc gccacatagc agaactttaa aagtgtcat ttcgatgtaa 6540
cgttcttcgg ggcgaaaact ctcaaggatc ttaccgctgt tgagatccag ttcgatgtaa 6600
cccactcgtg cacccaactg atcttcagca tcttttactt tcaccagcgt tctgggtgta 6660
gcaaaaacag gaaggcaaaa tgccgcaaaa aagggaataa gggcgacacg gaaatggtga 6720
atactcatal tcttcctttt tcaatattat tgaagcattt atcaggggtta ttgtctcatg 6780
agcgataaca tatttgaatg tatttagaaa aataaaacaaa taggggttcc gcgcacattt 6840
ccccgaaaag tgccacctga cgtctaagaa accattatta tcatgacatt aacctataaa 6900
aataggcgta tcacgaggcc ctttcgtctt cgaataaata cctgtgacgg aagatcactt 6960
cgcagaataa ataaatcctg gtgtccctgt tgataccggg aagccctggg ccaacttttg 7020
gcgaaaatga gacgttgatc ggcacgtaag aggttccaac tttcaccata atgaaataag 7080
atcactaccg ggcgtatctt ttgagttatc gagattttca ggagctaagg aagctaaaat 7140
ggagaaaaaa atcactggat ataccaccgt tgatatatcc caatggcatc gtaaagaaca 7200
ttttgaggca tttcagtcag ttgctcaatg tacctataac cagaccgttc ag 7252

```

&lt;210&gt; 6

&lt;211&gt; 28

&lt;212&gt; DNA

-5-

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Primer pUC28 I

&lt;400&gt; 6

aattcagatc tccatggatc gatgagct

28

&lt;210&gt; 7

&lt;211&gt; 20

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Primer pUC28 II

&lt;400&gt; 7

catcgatcca tggagatctg

20

&lt;210&gt; 8

&lt;211&gt; 1665

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Renilla luciferase-Aequorea GFP fusion gene

&lt;400&gt; 8

```

atgacttcga aagtttatga tccagaacaa aggaaacgga tgataactgg tccgcagtgg 60
tggggccagat gtaaacaaat gaatgttctt gattcattta ttaattatta tgattcagaa 120
aaacatgcag aaaatgctgt tattttttta catggtaacg cggcctcttc ttatttatgg 180
cgacatgttg tgccacatat tgagccagta gcgcggtgta ttataaccaga tcttattggt 240
atgggcaaat caggcaaatc tggtaatggg tcttataggt tacttgatca ttacaaatat 300
cttactgcat ggtttgaact tcttaattta ccaaagaaga tcatttttgt cggccatgat 360
tgggggtgctt gtttggcatt tcattatagc tatgagcatc aagataagat caaagcaata 420
gttcacgctg aaagtgtagt agatgtgatt gaatcatggg atgaatggcc tgatattgaa 480
gaagatatgg cggtgatcaa atctgaagaa ggagaaaaaa tggtttttga gaataacttc 540
ttcgtggaaa ccatgttgcc atcaaaaatc atgagaaagt tagaaccaga agaatttgca 600
gcatactctg aaccattcaa agacaaaagg gaagttcgtc gtccaacatt atcatggcct 660
cgtgaaatcc cgttagttaa aggtggtaaa cctgacgttg taaaaattgt taggaattat 720
aatgcttatc tacgtgcaag tgatgattta caaaaaatgt ttattgaatc ggatccagga 780
ttcttttcca atgctattgt tgaaggcgcc aagaagtttc ctaatactga atttgtcaaa 840
gtaaaaggtc ttcatttttc gcaagaagat gcacctgatg aaatgggaaa atatatcaaa 900
tcgttcgttg agcgagttct caaaaatgaa caagcggccg caccgcatat gagtaaagga 960
gaagaacttt tcaactggagt tgtcccaatt cttgttgaat tagatgggtga tgttaatggg 1020
cacaaathtt ctgtcagtgg agagggtgaa ggtgatgcaa catacggaaa acttaccctt 1080
aaatttatht gcactactgg aaaactacct gttccatggc caacacttgt cactactttc 1140
tcttatgggt ttcaatgctt ttcaagatac ccagatcata tgaaacagca tgactttttc 1200
aagagtgcca tgcccgaagg ttatgtacag gaaagaacta tttttttcaa agatgacggg 1260
aactacaaga cactgtctga agtcaagttt gaaggtgata cccttggtta tagaatcgag 1320
ttaaaaggta ttgattttta agaagatgga aacattcttg gacacaaatt ggaatacaac 1380
tataactcac acaatgtata catcatggca gacaaacaaa agaatggaat caaagttaac 1440
ttcaaaatta gacacaacat tgaagatgga agcgttcaac tagcagacca ttatcaacaa 1500
aatactccaa ttggcgatgg ccctgtcctt ttaccagaca accattacct gtccacacaa 1560
tctgcccttt cgaaagatcc caacgaaaag agagaccaca tggtccttct tgagtttgta 1620

```

-6-

acagctgctg ggattacaca tggcatggat gaactataca aataa

1665

&lt;210&gt; 9

&lt;211&gt; 11096

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; pLacGus Plasmid

&lt;400&gt; 9

```

aagcttgcat gcctgcagca attcccagagg ctgtagccga cgatgggtgcg ccaggagagt 60
tggttgattca ttgtttgcoct ccttgctgctg gtttttcacc gaagttcatg ccagtccagc 120
gtttttgcag cagaaaagcc gccgacttcg gtttgcggtc gcgagtgaag atccctttct 180
tgttaccgcc aacgcgcaat atgccttgctg aggtcgcaaa atcggcgaaa ttccatacct 240
gttcaccgac gacggcgctg acgcgatcaa agacgcgggtg atacatatcc agccatgcac 300
actgatactc ttcaactccac atgtcgggtg acattgagtg cagcccggct aacgtatcca 360
cgccgtattc ggtgatgata atcggctgat gcagtttctc ctgccaggcc agaagttctt 420
tttccagttac cttctctgcc gtttccaaat cgccgctttg gacataccat ccgtaataac 480
ggttcaggca cagcacatca aagagatcgc tgatgggtatc ggtgtgagcg tcgcagaaca 540
ttacattgac gcaggtgatc ggacgcgtcg ggtcgagttt acgcgttgct tccgccagt 600
gcgcgaaata ttcccgtaga ccttgccggac gggtagtccg ttcggttgca atactccaca 660
tcaccacgct tgggtgggtt ttgtcacgcg ctatcagctc tttaatcgcc tgtaagtgcg 720
cttgctgagt ttccccgttg actgcctctt cgctgtacag ttctttcggc ttgttgccc 780
cttcgaaacc aatgcctaaa gagagggttaa agccgacagc agcagtttca tcaatcacca 840
cgatgccatg ttcatctgcc cagtcgagca tctcttcagc gtaagggtaa tgcgaggtac 900
ggtaggagtt ggccccaatc cagtccatta atgcgtgggtc gtgcaccatc agcacgttat 960
cgaatccttt gccacgcaag tccgcatctt catgacgacc aaagccagta aagtagaacg 1020
gtttgtgggtt aatcaggaac tgttcgccct tcaactgccac tgaccggatg ccgacgcgaa 1080
gcgggtagat atcacactct gtctggcttt tggctgtgac gcacagttca tagagataac 1140
cttcacccgg ttgccagagg tgcggattca ccacttgcaa agtcccgtta gtgccttgct 1200
cagttgcaac cacctggtga tccgcatcac gcagttcaac gctgacatca ccattggcca 1260
ccacctgcca gtcaacagac gcgtgggttac agtcttgccg gacatgcgtc accacgggtga 1320
tatcgtccac ccaggtgttc ggctgggtgt agagcattac gctgcgatgg attccggcat 1380
agttaaagaa atcatggaag taagactgct ttttcttgcc gtttctgctg gtaatcacca 1440
ttccggcggt gatagctgc cagttcagtt cgttggtcac acaaacgggtg atacgtacac 1500
ttttcccggt aataacatac ggctgacat cggcttcaaa tggcgtatag ccgccctgat 1560
gctccatcac ttcttgatta ttgaccaca ctttgccgta atgagtgacc gcacgaaac 1620
gcagcacgat acgctggcct gcccaacctt tcggtataaa gacttcgcgc tgataaccaga 1680
cgttgcccgc ataattacga atatctgcat cggcgaactg atcggtaaaa ctgcctggca 1740
cagcaattgc ccggtttctt tgtaacgcgc tttcccacca acgctgatca attccacagt 1800
tttcgcgatc cagactgaat gcccacaggc cgtcgagttt tttgatttca cgggttgagg 1860
tttctacagg acgtaacatt ctagacatta tagttttttc tccttgacgt taaagtatag 1920
aggtatatta acaatttttt gttgatactt ttattacatt tgaataagaa gtaatacaaa 1980
ccgaaaatgt tgaaagtatt agttaaagtg gttatgcagt ttttgcatth atatatctgt 2040
taatagatca aaaatcatcg gttcgtgat taattacccc agaaataagg ctaaaaaact 2100
aatcgcatta tcatccctcg agctatcacc gcaagggtata aatatctaac accgtgcgtg 2160
ttgactatth tacctctggc ggtgataatg ctcgaggtaa gattagatat ggatatgtat 2220
atggatatgt atatgggtgg aatgccatgt aatatgatta ttaaacttct ttgcgtccat 2280
ccaaaaaaaa agtaagaatt tttgaaaatt caatataaat gacagctcag ttacaaagt 2340
aaagtacttc taaaattggt ttggttacag gtggtgctgg atacattggg tcacacactg 2400
tggtagagct aattgagaat ggatatgact gtggtgttgc tgataacctg tcgaatagat 2460
cgacctgaag tctaggtccc tatttattht tttatagtta tgtagtatt aagaacgtta 2520
tttatattht aaatthttct tttthttctg tacagacgcg tgtacgaatt tcgacctcga 2580
ccggccgggtt ttacaaatca gtaagcaggt cagtgcgtac gccatggccg gagtgggtca 2640

```

-7-

cagtcggttg	tccggcagta	caatggattt	ccttacgcga	aatacgggca	gacatggcct	2700
gcccggttat	tattatTTTT	gacaccagac	caactggtaa	tggtagcgac	cggcgctcag	2760
ctggaattcc	gCcgatactg	acgggctcca	ggagtcgtcg	ccaccaatcc	ccatatggaa	2820
accgtcgata	ttcagccatg	tgccttcttc	cgctgcagc	agatggcgat	ggctgggttc	2880
catcagttgc	tgttgactgt	agcggctgat	gttgaactgg	aagtcgccgc	gccactgggtg	2940
tggggcataa	ttcaattcgc	gcgtcccgc	gcgcagaccg	ttttcgctcg	ggaagacgta	3000
cggggtatac	atgtctgaca	atggcagatc	ccagcgggtca	aaacaggcgg	cagtaaggcg	3060
gtcgggtag	ttttcttgcg	gccctaatac	gagccagttt	acccgctctg	ctacctgcgc	3120
cagctggcag	ttcaggccaa	tccgcgcggg	atgcgggtga	tcgctcgcca	cttcaacatc	3180
aacggtaatc	gccatttgac	cactaccatc	aatccggtag	gttttcgggc	tgataaataa	3240
ggttttcccc	tgatgctgcc	acgcgtgagc	ggtcgtaatc	agcaccgcat	cagcaagtgt	3300
atctgccgtg	cactgcaaca	acgctgcttc	ggcctggtaa	tggcccgcgc	ccttcacagc	3360
ttcgaccag	gcgttagggg	caatgctggg	cgcttcactt	acgccaatgt	cgttatccag	3420
cgggtgcacg	gtgaactgat	cgcgacgagg	cgtcagcagt	tgttttttat	cgccaatcca	3480
catctgtgaa	agaaagcctg	actggcggtt	aaattgccaa	cgcttattac	ccagctcgat	3540
gcaaaaatcc	atttcgctgg	tggtcagatg	cgggatggcg	tgggacgcgg	cggggagcgt	3600
cacactgagg	ttttccgcca	gacgccactg	ctgccaggcg	ctgatgtgcc	cggcttctga	3660
ccatgcggtc	gcgttcgggt	gcactacgcg	tactgtgagc	cagagtgtgc	cggcgctctc	3720
cggctgcggg	agttcaggca	gttcaatcaa	ctgtttacct	tgaggagcga	catccagagg	3780
cacttcaccg	cttgccagcg	gcttaccatc	cagcgccacc	atccagtgca	ggagctcggt	3840
atcgctatga	Cggaacagg	attcgctggg	cacttcgatg	gtttgcccg	ataaacggaa	3900
ctggaaaaac	tgctgctggg	gttttgcttc	cgtcagcgct	ggatgcggcg	tgccggtcggc	3960
aaagaccaga	cogttcatac	agaactggcg	atcgctcggc	gtatcgccaa	aatcacgcgc	4020
gtaagccgac	cacgggttgc	cgttttcatc	atattttaatc	agcgactgat	ccaccacgtc	4080
ccagacgaag	ccgccctgta	aacggggata	ctgacgaaac	gcctgccagt	atttagcgaa	4140
accgccaaga	ctgttaccga	tccgctgggc	gtattcgcaa	aggatcagcg	ggcgctctc	4200
tccaggtagc	gaaagccatt	ttttgatgga	ccatttcggc	acagccggga	agggctgggtc	4260
ttcatccacg	cgcgctgaca	tccggcaaat	aatatcggtg	gcggtgggtg	cggctccgcc	4320
gccttcatac	tgcaccgggc	gggaaggatc	gacagatttg	atccagcgat	acagcgcgctc	4380
gtgattagcg	ccgtggcctg	attcattccc	cagcgaccag	atgatcacac	tcgggtgatt	4440
acgatcgcg	tgcaccatcc	gcgttacgcg	ttcgctcatc	gccggtagcc	agcgcggtatc	4500
atcggtcaga	cgattcattg	gcaccatgcc	gtgggtttca	atattggctt	catccaccac	4560
atacaggccg	tagcggctgc	acagcggtga	ccacagcgga	tggttcggat	aatgcgaaca	4620
gcgcacggcg	ttaaagtgtg	tctgcttcat	cagcaggata	tcctgcacca	tcgtctgctc	4680
atccatgacc	tgaccatgca	gaggatgatg	ctcgtgacgg	ttaacgcctc	gaatcagcaa	4740
cggcttgccg	ttcagcagca	gcagaccatt	ttcaatccgc	acctcgcgga	aaccgacatc	4800
gcaggcttct	gcttcaatca	gcgtgcccgc	ggcggtgtgc	agttcaacca	ccgcacgata	4860
gagattcggg	atttcggcgc	tccacagttt	cgggttttcg	acgttcagac	gtagtgtgac	4920
gcgatcggca	taaccaccac	gctcatcgat	aatttcaccg	ccgaaaggcg	cgggtgccgct	4980
ggcgacctgc	gtttcacccct	gccataaaga	aactgttacc	cgtaggtagt	cacgcaactc	5040
gccgcacatc	tgaacttcag	cctccagtac	agcgcggtcg	aatcatcat	taaagcgagt	5100
ggcaacatgg	aaatcgctga	tttgtgtagt	cggtttatgc	agcaacgaga	cgtcacggaa	5160
aatgcgcgtc	atccgccaca	tatcctgatc	ttccagataa	ctgccgtcac	tccagcgag	5220
caccatcacc	gcgaggcggt	tttctccggc	gcgtaaaaat	gcgctcaggt	caaattcaga	5280
cggcaaacga	ctgtcctggc	cgtaaccgac	ccagcggcg	ttgcaccaca	gatgaaacgc	5340
cgagttaacg	ccatcaaaaa	taattcgctg	ctggccttcc	tgtagccagc	tttcatcaac	5400
attaaatgtg	agcgagtaac	aaccgcgtcg	attctccgtg	ggaacaaacg	gcggattgac	5460
cgtaatggga	taggtcacgt	tggtgtagat	gggcgcacgc	taaccgtgca	tctgccagtt	5520
tgaggggacg	acgacagtat	cggcctcagg	aagatcgcac	tccagccagc	tttcgggac	5580
cgcttctggg	gccggaaacc	aggcaaagcg	ccattcgcca	ttcaggctgc	gcaactgttg	5640
ggaagggcga	tcgggtgcggg	cctcttcgct	attacgccag	ctggcgaaag	ggggatgtgc	5700
tgcaaggcga	ttaagtcggg	aaacctgtcg	tgccagctgc	attaatgaat	cggccaacgc	5760
gcgggggagag	gcgggtttgcg	tattgggcgc	cagggtgggt	tttcttttca	ccagtgaagc	5820
gggcaacagc	caagctccgg	atccgggctt	ggccaagctt	ggaattccgc	acttttcggc	5880
caatggtctt	ggtaattcct	ttgcgctaga	attgaactca	ggtacaatca	cttcttctga	5940



-8-

atgagattta gtcattatag ttttttctcc ttgacgttaa agtatagagg tatattaaca 6000  
attttttggt gatactttta ttacatttga ataagaagta atacaaaccg aaaatggtga 6060  
aagtattagt taaagtgggt atgcagtttt tgcattttata tatctgttaa tagatcaaaa 6120  
atcatcgctt cgctgattaa ttaccccaga aataaggcta aaaaactaat cgcattatca 6180  
tcccctcgac gtactgtaca tataaccact ggtttttatat acagcagtac tgtacatata 6240  
accactgggt ttatatagag cagtcgacgt actgtacata taaccactgg ttttatatac 6300  
agcagtactg gacatataac cactggtttt atatacagca gtcgaggtaa gattagatat 6360  
ggatatgtat atggatatgt atatgggtgg aatgccatgt aatatgatta ttaaacttct 6420  
ttgcgtccat ccaaaaaaaa agtaagaatt tttgaaaatt ttggttacag gtggtgctgg 6480  
ttacaaagtg aaagtacttc taaaattggt ttggttacag gtggtgctgg atacattgggt 6540  
tcacacactg tggtagagct aattgagaat ggatatgact gtgttgttgc tgataacctg 6600  
tcgaattcca agctcggatc cccgagctcg gatcccccta agaaaccatt attatcatga 6660  
cattaaccta taaaaatagg cgtatcacga ggccctttcg tctcgcgcgt ttcggtgatg 6720  
acggtgaaaa cctctgacac atgcagctcc cggagacggg cacagcttgt ctgtaagcgg 6780  
atgccgggag cagacaagcc cgtcagggcg cgtcagcggg tgttggcggg tgcgggggtg 6840  
ggcttaacta tgcggcatca gagcagattg tactgagagt gcaccataac gcatttaagc 6900  
ataaacacgc actatgccgt tcttctcctg tatatatata tacaggcaac acgcagatat 6960  
aggtgcgacg tgaacagtga gctgtatgtg cgcagctcgc gttgcatttt cggagcgt 7020  
cgttttcgga aacgctttga agttcctatt ccgaagtcc tattctctag ctagaagta 7080  
taggaacttc agagcgcttt tgaaaaccaa aagcgtctg aagacgcact ttcaaaaaac 7140  
caaaaacgca ccggactgta acgagctact aaaatattgc gaataccgct tccacaaaac 7200  
ttgctcaaaa gtatctcttt gctatatatc tctgtgctat atccctatat aacctacca 7260  
tccacctttc gctccttgaa cttgcatcta aactcgacct ctacattttt tatgtttatc 7320  
tctagtatta ctcttttagac aaaaaaattg tagtaagaac tattcataga gtgaatcga 7380  
aacaatacga aaatgtaaac atttccctata cgtagtatat agagacaaaa tagaagaac 7440  
cgttcataat tttctgacca atgaagaatc atcaacgcta tcactttctg ttcacaaagt 7500  
atgcgcgaatc cacatcggtg tagaatataa tcggggatgc ctttatcttg aaaaaatgca 7560  
cccgcagctt cgctagtaat cagtaaacgc gggaagtggg gtcaggcttt ttttatggaa 7620  
gagaaaaatag acaccaaagt agccttcttc taaccttaac ggacctacag tgcaaaaagt 7680  
tatcaagaga ctgcattata gagcgcacaa aggagaaaaa aagtaatcta agatgctttg 7740  
ttagaaaaat agcgtctctg ggatgcattt ttgtagaaca aaaaagaagt atagattctt 7800  
tgttggtaaa atagcgtctc cgcgttgcat ttctgttctg taaaaatgca gctcagattc 7860  
tttgtttgaa aaattagcgc tctcgcgttg catttttgtt ttacaaaaat gaagcacaga 7920  
ttcttcggtg gtaaaaatagc gctttcgcgt tgcatttctg ttgttctaca aaatgaagca 8040  
gattctttgt ttgaaaaatt agcgtctctg cgttgcattt aggtgttctc ctctgaggac 8100  
cagatgcttc gttgcttccg tgtggaagaa cgattacaac aggtgttctc acaattcaga 8160  
ataaaatata caccgagatt catcaactca ttgctggagt tagcatatct atcgggagcg 8220  
agaactcgtc aagaaggcga tagaaggcga tgcgctgcga atcgggagcg gccataaccg 8280  
aaagcacgag gaagcgggtc gccattcgc cgccaagctc ttacagcaata tcacgggtag 8340  
ccaacgctat gtcctgatag cggctccgca caccagccg gccacagtcg atgaatccag 8400  
aaaagcggcc attttccacc atgatattcg gcaagcagcg atcgccatgg gtcacgacga 8460  
gatcctcgcc gtcgggcatg ctgccttga gcctggcgaa cagttcgggt ggccgagcgc 8520  
cctgatgctc ttctgtccaga tcatcctgat cgacaagacc ggcttccatc cgagtacgtg 8580  
ctcgtctgat gcgatgttcc gcttgggtgg cgaatgggca ggtagccgga tcaagcgtat 8640  
gcagccgccc cattgcatca gccatgatgg atactttctc ggcaggagca aggtgagatg 8700  
acaggagatc ctgccccggc acttcgcccc atagcagcca gtcccttccc gcttcagtg 8760  
caacgtcgag cacagctgcg caaggaacgc ccgtcgtggc cagccacgat agccgcgctg 8820  
cctcgtcttg cagttcatte agggcaccgg acaggtcggg cttgacaaaa agaaccgggc 8880  
gccctgccc tgacagccgg aacacggcgg catcagagca gccgattgtc tgttgtgcc 8940  
agtcatagcc gaatagcctc tccacccaag cggccggaga acctgcgtgc aatccatctt 9000  
gttcaatcat gcgaaacgat cctcatcctg tctcttgatc agagcttgat cccctgcgcc 9060  
atcagatcct tggcggcaag aaagccatcc agtttacttt gcagggtctc ccaaccttac 9120  
cagagggcgc cccagctggc aattccggtt cgcttctgtt ccataaaacc gccagctcta 9180  
gctatcgcca tgtaagccca ctgcaagcta cctgctttct ctttgcgctt gcgttttccc 9240  
ttgtccagat agcccagtag ctgacattca tccgggggtc gcaccggttc tgcggactgg

-9-

```

ctttctacgt gaaaaggatc taggtgaaga tccttttttga taatctcatg accaaaatcc 9300
cttaacgtga gttttcgttc cactgagcgt cagaccccggt agaaaagatc aaaggatctt 9360
cttgagatcc tttttttctg cgcgtaatct gctgcttgca aacaaaaaaa ccaccgctac 9420
cagcgggtggt ttgtttgccc gatcaagagc taccaactct ttttccgaag gtaactggct 9480
tcagcagagc gcagatacca aatactgttc ttctagtgtg gccgtagtta ggccaccact 9540
tcaagaactc tgtagcaccg cctacatacc tcgctctgct aatcctgtta ccagtggctg 9600
ctgccagtgg cgataagtcg tgtcttaccg gggttggaactc aagacgatag ttaccggata 9660
aggcgcagcg gtcgggctga acgggggggtt cgtgcacaca gcccagcttg gagcgaacga 9720
cctacaccca actgagatac ctacagcgtg agctatgaga aagcgccacg cttcccgaag 9780
ggagaaaaggc ggacagggtat ccggtaaagc gcagggtcgg aacaggagag cgcacgaggg 9840
agcttccagg gggaaaacgcc tgggtatcttt atagtctgtt cgggttttcgc cacctctgac 9900
ttgagcgtcg atttttgtga tgctcgtcag gggggcggag cctatggaaa aacgccagca 9960
acgcggcctt tttacgggttc ctggcctttt gctggccttt tgctcacatg atataattca 10020
attgaagctc taatttgtga gtttagtata catgcattta cttataatac agtttttttag 10080
ttttgctggc cgcattcttct caaatatgct tcccagcctg cttttctgta acgttcaccc 10140
tctaccttag catcccttcc ctttgcaaat agtctcttcc caacaataat aatgtcagat 10200
cctgtagaga ccacatcatc cacggttcta tactgttgac ccaatgcgtc tcccttgctca 10260
tctaaaccca caccgggtgt cataatcaac caatcgtaac cttcatctct tccaccatg 10320
tctcttttag caataaagcc gataacaaaa tctttgtcgc tcttcgcaat gtcaacagta 10380
cccttagtat attotccagt agataggag ccttgcctg acaattctgc taacatcaaa 10440
aggcctctag gttcctttgt tacttcttct gccgcctgct tcaaaccgct aacaatacct 10500
gggcccacca caccgtgtgc attcgtaatg tctgcccatt ctgctattct gtatacacc 10560
gcagagtact gcaatttgac tgtattacca atgtcagcaa attttctgtc ttcgaagagt 10620
aaaaaattgt acttggcgga taatgccttt agcggtctaa ctgtgccctc catggaaaaa 10680
tcagtcaaga tatccacatg tgtttttagt aaacaaattt tgggacctaa tgcttcaact 10740
aactccagta attccttggg ggtacgaaca tccaatgaag cacacaagtt tgtttgcttt 10800
tgctgcatag tattaaatag cttggcagca acaggactag gatgagtagc agcacgttcc 10860
ttatatgtag ctttcgacat gatttatctt cgtttcctgc aggtttttgt tctgtgcagt 10920
tgggttaaga atactgggca atttcatgtt tcttcaacac tacatatgcy tatatatacc 10980
aatctaagtc tgtgctcctt ccttcgttct tcttctgtt cggagattac cgaatcaaaa 11040
aaatttcaag gaaaccgaaa tcaaaaaaaaa gaataaaaaa aaaatgatga attgaa 11096

```

&lt;210&gt; 10

&lt;211&gt; 150

&lt;212&gt; DNA

&lt;213&gt; Vaccinia Virus/LIVP

&lt;300&gt;

&lt;308&gt; GenBank No. M57977

&lt;309&gt; 2000-04-14

&lt;400&gt; 10

```

atgggtcatcg gtttagtcat attcgtgtct gtggcgcccg ccatcgctcg tgtgttgtct 60
aacgtattgg acatgcttat gtacgtagaa gaaaataatg aagaggatgc tagaatcaag 120
gaggagcaag aactactgtt gctatattga

```

&lt;210&gt; 11

&lt;211&gt; 49

&lt;212&gt; PRT

&lt;213&gt; Vaccinia Virus/LIVP

&lt;300&gt;

&lt;308&gt; GenBank No. AAA48282

&lt;309&gt; 2000-04-14

-10-

&lt;400&gt; 11

```

Met Val Ile Gly Leu Val Ile Phe Val Ser Val Ala Ala Ala Ile Val
 1           5           10           15
Gly Val Leu Ser Asn Val Leu Asp Met Leu Met Tyr Val Glu Glu Asn
          20           25           30
Asn Glu Glu Asp Ala Arg Ile Lys Glu Glu Gln Glu Leu Leu Leu
      35           40           45
Tyr

```

&lt;210&gt; 12

&lt;211&gt; 150

&lt;212&gt; DNA

&lt;213&gt; Vaccinia Virus/WR

&lt;300&gt;

&lt;308&gt; GenBank No. AY243312

&lt;309&gt; 2003-04-10

&lt;400&gt; 12

```

tcaatatagc aacagtagtt cttgctcctc cttgattcta gcacccctctt cattattttc 60
ttctacgtac ataagcatgt ccaatacgtt agacaacaca ccgacgatgg cggccgccac 120
agacacgaat atgactagac cgatgaccat                                150

```

&lt;210&gt; 13

&lt;211&gt; 49

&lt;212&gt; PRT

&lt;213&gt; Vaccinia Virus/WR

&lt;400&gt; 13

```

Met Val Ile Gly Leu Val Ile Phe Val Ser Val Ala Ala Ala Ile Val
 1           5           10           15
Gly Val Leu Ser Asn Val Leu Asp Met Leu Met Tyr Val Glu Glu Asn
          20           25           30
Asn Glu Glu Asp Ala Arg Ile Lys Glu Glu Gln Glu Leu Leu Leu Leu
      35           40           45
Tyr

```

&lt;210&gt; 14

&lt;211&gt; 150

&lt;212&gt; DNA

&lt;213&gt; Vaccinia Virus/Ankara

&lt;300&gt;

&lt;308&gt; GenBank No. U94848.1

&lt;309&gt; 2003-04-14

&lt;400&gt; 14

```

tcaatatagc aacagtagtt cttgctcctc cttgattcta gcacccctctt cattattttc 60
ttctacgtac ataaacatgt ccaatacgtt agacaacaca ccgacgatgg cggccgccac 120
agacacgaat atgactaaac cgatgaccat                                150

```

-11-

<210> 15  
 <211> 49  
 <212> PRT  
 <213> Vaccinia Virus/Ankara

<400> 15  
 Met Val Ile Gly Leu Val Ile Phe Val Ser Val Ala Ala Ala Ile Val  
 1 5 10 15  
 Gly Val Leu Ser Asn Val Leu Asp Met Phe Met Tyr Val Glu Asn  
 20 25 30  
 Asn Glu Glu Asp Ala Arg Ile Lys Glu Glu Gln Glu Leu Leu Leu Leu  
 35 40 45  
 Tyr

<210> 16  
 <211> 146  
 <212> DNA  
 <213> Vaccinia Virus/Tian Tan

<300>  
 <308> GenBank No. AF095689  
 <309> 2000-02-14

<400> 16  
 caatatagca acagtagttc ttgctcctcc ttgattctag catcctcttc attatatttct 60  
 tctacgtaca taaacatgtc caatacggtta gacaacacac cgacgatggc cgccacagac 120  
 acgaatatga ctagaccgat gaccat 146

<210> 17  
 <211> 48  
 <212> PRT  
 <213> Vaccinia Virus/Tian Tan

<400> 17  
 Met Val Ile Gly Leu Val Ile Phe Val Ser Val Ala Ala Ile Val Gly  
 1 5 10 15  
 Val Leu Ser Asn Val Leu Asp Met Phe Met Tyr Val Glu Glu Asn Asn  
 20 25 30  
 Glu Glu Asp Ala Arg Ile Lys Glu Glu Gln Glu Leu Leu Leu Leu Tyr  
 35 40 45

<210> 18  
 <211> 150  
 <212> DNA  
 <213> Vaccinia Virus/Acambis 3000 MVA

<300>  
 <308> GenBank No. AY603355  
 <309> 2004-05-15

<400> 18

-12-

```
tcaatatagc aacagtagtt cttgctcctc cttgattcta gcatcctctt cattattttc 60
ttctacgtac ataaacatgt ccaatacgtt agacaacaca ccgacgatgg cggccgccac 120
agacacgaat atgactaaac cgatgaccat                                     150
```

&lt;210&gt; 19

&lt;211&gt; 49

&lt;212&gt; PRT

&lt;213&gt; Vaccinia Virus/Acambis 3000 MVA

&lt;400&gt; 19

```
Met Val Ile Gly Leu Val Ile Phe Val Ser Val Ala Ala Ala Ile Val
 1           5           10           15
Gly Val Leu Ser Asn Val Leu Asp Met Phe Met Tyr Val Glu Glu Asn
      20           25           30
Asn Glu Glu Asp Ala Arg Ile Lys Glu Glu Gln Glu Leu Leu Leu Leu
 35           40           45
Tyr
```

&lt;210&gt; 20

&lt;211&gt; 150

&lt;212&gt; DNA

&lt;213&gt; Vaccinia Virus/Copenhagen

&lt;300&gt;

&lt;308&gt; GenBank No. M35027.1

&lt;309&gt; 1993-08-03

&lt;400&gt; 20

```
tcaatatagc aacagtagtt cttgctcctc cttgattcta gcatcctctt cattattttc 60
ttctacgtac ataaacatgt ccaatacgtt agacaacaca ccgacgatgg cggccgccac 120
agacacgaat atgactagac cgatgaccat                                     150
```

&lt;210&gt; 21

&lt;211&gt; 49

&lt;212&gt; PRT

&lt;213&gt; Vaccinia Virus/Copenhagen

&lt;400&gt; 21

```
Met Val Ile Gly Leu Val Ile Phe Val Ser Val Ala Ala Ala Ile Val
 1           5           10           15
Gly Val Leu Ser Asn Val Leu Asp Met Phe Met Tyr Val Glu Glu Asn
      20           25           30
Asn Glu Glu Asp Ala Arg Ile Lys Glu Glu Gln Glu Leu Leu Leu Leu
 35           40           45
Tyr
```

&lt;210&gt; 22

&lt;211&gt; 150

&lt;212&gt; DNA

&lt;213&gt; Cowpox Virus

-13-

&lt;300&gt;

&lt;308&gt; GenBank No. X94355.2

&lt;309&gt; 2003-05-09

&lt;400&gt; 22

```
tcaatatagc aacagtagtt cttgctcctc cttgattcta gcatcctctt cattatcttc 60
ttctacgtac ataagcatgt ccaatacgtt agacaacaca ccgacgatgg cggccgccac 120
agacacgaat atgactagac cgatgaccat                                     150
```

&lt;210&gt; 23

&lt;211&gt; 49

&lt;212&gt; PRT

&lt;213&gt; Cowpox Virus

&lt;400&gt; 23

```
Met Val Ile Gly Leu Val Ile Phe Val Ser Val Ala Ala Ala Ile Val
 1           5           10          15
Gly Val Leu Ser Asn Val Leu Asp Met Leu Met Tyr Val Glu Glu Asn
      20          25          30
Asn Glu Glu Asp Ala Arg Ile Lys Glu Glu Gln Glu Leu Leu Leu Leu
      35          40          45
Tyr
```

&lt;210&gt; 24

&lt;211&gt; 150

&lt;212&gt; DNA

&lt;213&gt; Rabbitpox Virus

&lt;300&gt;

&lt;308&gt; GenBank No. AY484669

&lt;309&gt; 2004-03-30

&lt;400&gt; 24

```
tcaatatagc aacagtagtt cttgctcctc cttgattcta gcatcctctt cattatcttc 60
ttctacgtac ataagcatgt ccaatacgtt agacaacaca ccgacgatgg cggccgccac 120
agacacgaat atgactagac cgatgaccat                                     150
```

&lt;210&gt; 25

&lt;211&gt; 49

&lt;212&gt; PRT

&lt;213&gt; Rabbitpox Virus

&lt;400&gt; 25

```
Met Val Ile Gly Leu Val Ile Phe Val Ser Val Ala Ala Ala Ile Val
 1           5           10          15
Gly Val Leu Ser Asn Val Leu Asp Met Leu Met Tyr Val Glu Glu Asn
      20          25          30
Asn Glu Glu Asp Ala Arg Ile Lys Glu Glu Gln Glu Leu Leu Leu Leu
      35          40          45
Tyr
```

-14-

<210> 26  
 <211> 150  
 <212> DNA  
 <213> Camelpox Virus/CMS

<300>  
 <308> GenBank No. AY009089  
 <309> 2002-07-30

<400> 26  
 tcaatatagc aacagtagtt cttgctcctc cttaattcta gcatcctctt cattatcttc 60  
 ttctacatac ataagcatgt ccaatacgtt agacaacaca ccgacgatgg cggccgccac 120  
 agacacgaat atgactagac cgatgacct 150

<210> 27  
 <211> 49  
 <212> PRT  
 <213> Camelpox Virus/CMS

<400> 27  
 Met Val Ile Gly Leu Val Ile Phe Val Ser Val Ala Ala Ala Ile Val  
 1 5 10 15  
 Gly Val Leu Ser Asn Val Leu Asp Met Leu Met Tyr Val Glu Glu Asn  
 20 25 30  
 Asn Glu Glu Asp Ala Arg Ile Lys Glu Glu Gln Glu Leu Leu Leu Leu  
 35 40 45  
 Tyr

<210> 28  
 <211> 150  
 <212> DNA  
 <213> Ectromelia Virus/Moscow

<300>  
 <308> GenBank No. AF012825  
 <309> 2002-08-06

<400> 28  
 tcaatatagc aacaacagtt cttgctcctc cttgattcta gcatcctctt cattatcttc 60  
 ttctacgtac ataagcatgt ccaatacgtt agacaacaca ccgacaatgg cggccgccac 120  
 agacacgaat atgactagac cgaggacct 150

<210> 29  
 <211> 49  
 <212> PRT  
 <213> Ectromelia Virus/Moscow

<400> 29  
 Met Val Leu Gly Leu Val Ile Phe Val Ser Val Ala Ala Ala Ile Val  
 1 5 10 15  
 Gly Val Leu Ser Asn Val Leu Asp Met Leu Met Tyr Val Glu Glu Asn  
 20 25 30  
 Asn Glu Glu Asp Ala Arg Ile Lys Glu Glu Gln Glu Leu Leu Leu Leu

-15-

Tyr                    35                    40                    45

<210> 30  
 <211> 146  
 <212> DNA  
 <213> Monkeypox Virus/Zaire

<300>  
 <308> GenBank No. AF380138  
 <309> 2001-12-13

<400> 30  
 tatagcaaca gtaattcttg ctcttccttg atttttagcat cctcttcatt attttcttct 60  
 acgtacataa gcatgtccaa tacgttagac aacacaccga cgatgggtggc cgccacagac 120  
 acgaatatga ctagaccgat gaccat 146

<210> 31  
 <211> 48  
 <212> PRT  
 <213> Monkeypox Virus/Zaire

<400> 31  
 Met Val Ile Gly Leu Val Ile Phe Val Ser Val Ala Ala Thr Ile Val  
 1                    5                    10                    15  
 Gly Val Leu Ser Asn Val Leu Asp Met Leu Met Tyr Val Glu Glu Asn  
 20                    25                    30  
 Asn Glu Glu Asp Ala Lys Ile Lys Glu Glu Gln Glu Leu Leu Leu Leu  
 35                    40                    45

<210> 32  
 <211> 150  
 <212> DNA  
 <213> Variola Virus

<300>  
 <308> GenBank No. X69198.1  
 <309> 1996-12-13

<400> 32  
 tcaatatagc aacagtagtt cttgctcctc cttaattcta gcatcttctt cattatatttc 60  
 ttctacatac ataagcatct ccaatacgtt agacagcaca ccgatgatgg cggccgccac 120  
 agacacgaat atgactagac tgatgaccat 150

<210> 33  
 <211> 49  
 <212> PRT  
 <213> Variola Virus

<400> 33  
 Met Val Ile Ser Leu Val Ile Phe Val Ser Val Ala Ala Ala Ile Ile  
 1                    5                    10                    15



-16-

Gly Val Leu Ser Asn Val Leu Glu Met Leu Met Tyr Val Glu Glu Asn  
 20 25 30  
 Asn Glu Glu Asp Ala Arg Ile Lys Glu Glu Gln Glu Leu Leu Leu Leu  
 35 40 45  
 Tyr

&lt;210&gt; 34

&lt;211&gt; 186854

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; LIPV Complete Genome

&lt;400&gt; 34

```

ttccactatc tgtggtacga acggtttcat cttctttgat gccatcaccc agatgttcta 60
taaacttggt atcctcgccc gatttcatat cctttgccc ccaatacata tagctaaact 120
caggcatatg ttccacacat cctgaacaat gaaattctcc agaagatgtt acaatgtcta 180
gatttggaaca tttggtttca accgcggttaa catatgagtg aacacaccca tacatgaaag 240
cgatgagaaa taggattctc atcttgccaa aatatcacta gaaaaaattt atttatcaat 300
tttaaaggta taaaaaatac ttattgttgc tcgaatattt tgtatttgat ggtatacggg 360
agattagaaa tgtaggtatt atcatcaact gattctatgg ttttatgtat tctatcatgt 420
ttcactattg cggttggaat aatatcatat gcttcacat atattttatt ttgttttaac 480
tcataatact cacgtaattc tggattattg gcatactctat gaataatttt agctccatga 540
tcagtaataa ttaatgagaa catagtatta ccacctacca ttattttttt catctcattc 600
aattcttaat tgcaaagatc tatataatca ttatagcgtt gacttatgga ctctggaatc 660
ttagacgatg tacagtcac tataatcatg gcataatttaa tacattgttt tatagcatag 720
tcgttatcta cgatgttaga tatttctctc aatgaatcaa tcacacaatc taatgtaggt 780
ttatgacata atagcatttt cagcagttca atgttttttag attcgttgat ggcaatggct 840
atacatgtat atccgttatt tgatctaata ttgacatctg aaccggattc tagcagtaaa 900
gatactagag attgtttatt atatctaaca gccttgtgaa gaagtgtttc tcctcgtttg 960
tcaatcatgt taatgtcttt aagataagggt aggc aaatgt ttatagtact aagaattggg 1020
caagcataag acatgtcaca aagacccttt tttgtatgta taagtgtaaa aattataaca 1080
tccatagttg gatttacata ggtgtccaat cgggatctct ccatcatcga gataattgat 1140
ggcatctccc ttccctttttt agtagatatt tcatcgtgta agaatacaata ttaatatattc 1200
taaagtatcc gtgtatagcc tctttattta ccacagctcc atattccact agagggatat 1260
cgccgaatgt catatactca attagtatat gttggaggac atccgagttc attgttttca 1320
atatcaaaga gatggtttcc ttatcatttc tccatagtgg tacaatacta cacattattc 1380
cgtgcgggctt tccattttcc aaaaacaatt tgaccaaata taaatctaca tctttattgt 1440
atctataatc actatttaga taatcagcca taattcctcg agtgcaacat gttagatcgt 1500
ctatatatga ataagcagtg ttatctattc ctttcattaa caatttaacg atgtctatat 1560
ctatatgaga tgacttaata taatattgaa gagctgtaca atagttttta tctataaaaag 1620
acggcttgat tccgtgatta attagacatt taacaacttc cggacgcaca tatgctctcg 1680
tatccgactc tgaatacaga tgagagatga tatacagatg caatacggta ccgcaatttc 1740
gtagttgata atcatcatat gcgtatcagt actcgctcctc ataaagaaca ctgcagccat 1800
tttctatgaa caaatcaata attttagaaa caggatcatt gtcattacat aattttctat 1860
aactgaacga tgggtttcac atttaacact caagtcaaat ccatgttcta ccaacacctt 1920
tatcaagtca acgtctacat ttttggtatt catatagctg aatatattaa agttatttat 1980
gttgctaaat ccagtggcct ctagtagagc catcgctata tccttattaa ctttaacatg 2040
tctactatct gtgtattctt ctaatggggg aagctgtctc caatttttgc gtaatggatt 2100
agtgccactg tctagtagta gtttgacgac ctgcacatta ttacaatgct cattaataaag 2160
gtatgcgtgt aaagcattat tcttgaattg gttcctggta tcattaggat ctctgtcttt 2220
caacatctgt ttaagttcat caagagccac ctctcattt tccaaatagt caaacatttt 2280

```

-17-

gactgaatga	gctactgtga	actctatata	cccacacaac	taatgtcatt	aaatatcatg	2340
tcaaaaactt	gtacaattat	taataaaaaat	aatttagtgt	ttaaatttta	ccagttccag	2400
attttacacc	tccgttaata	cctccattaa	cccactgga	cgatcctcct	ccccacattc	2460
caccgccacc	agatgtataa	gttttagatc	ctttattact	accatcatgt	ccatggataa	2520
agacactcca	catgccgcca	ctacccctt	tagaagacat	attaataaga	cttaaggaca	2580
agtttaacaa	taaaattaat	cacgagtacc	ctactaccaa	cctacactat	tatatgatta	2640
tagtttctat	ttttacagta	ccttgactaa	agtttctagt	cacaagagca	atactaccaa	2700
cctacactat	tatatgatta	tagtttctat	ttttatagga	acgcgtacga	gaaaatcaaa	2760
tgtctaattt	ctaacggtag	tgttgataaa	cgattgttat	ccgcggatac	ctcctctatc	2820
atgtcgtcta	ttttcttact	ttgttctatt	aacttattag	cattatata	tatttgatta	2880
taaaacttat	attgottatt	agcccaatct	gtaaatatcg	gattattaac	atatcgtttc	2940
tttgtaggtt	tatttaacat	gtacatcact	gtaagcatgt	ccttaccatt	tattttaatt	3000
tgacgcatat	ccgcaatttc	tttttcgcag	tcggttataa	attctatata	tgatggatac	3060
atgctacatg	tgtacttata	atcgactaat	atgaagtact	tgatacatat	tttcagtaac	3120
gatttattat	taccacctat	gaataagtac	ctgtgatcgt	ctaggtaatc	aactgttttc	3180
ttaatacatt	cgatggttgg	taatttactc	agaataattt	ccaatatctt	aatatataat	3240
tctgctattt	ctgggatata	tttatctgcc	agtataacac	aaatagtaat	acatgtaaac	3300
ccatattttg	ttattatatt	aatgtctcgc	ccattatcta	ttaaccattc	tactaggctg	3360
acactatgcy	actcaatata	atgataaagt	atactacatc	catgtttatc	tattttgttt	3420
atatcatcaa	tatacggtt	acaaagtttt	agtatcgata	acacatccaa	ctcacgcata	3480
gagaaggtag	ggaataatgg	cataatattt	attaggttat	catcattgtc	attatctaca	3540
actaagtttc	cattttttta	aatatactcg	acaactttag	gatctctatt	gccaaatttt	3600
tgaaaatatt	tatttatatg	cttaaactcta	tataatgtag	ctccttcatc	aatcatacat	3660
ttaataacat	tgatgtatac	tgtatgataa	gatacatatt	ctaacaatag	atcttgtata	3720
gaatctgtat	atcttttaag	aattgtggat	attaggatat	tattacataa	actattacac	3780
aattctaaaa	tataaaacgt	atcacggtcg	aataatagtt	gatcaactat	ataattatcg	3840
attttgtgat	ttttcttcct	aaactgttta	cgtaaatagt	tagatagaat	attcattagt	3900
tcatgaccac	tatagttact	atcgaataac	gcgtcaaata	tttcccgttt	aatatcgcat	3960
ttgtcaagat	aataatagag	tgtggtatgt	tcacgataag	tataataacg	catctctttt	4020
tcgtgtgaaa	ttaaatagtt	tattacgtcc	aaagatgtag	cataaccatc	ttgtgacctt	4080
gtaataatat	aataatagag	aactgtttta	cccattctat	catcataatc	agtgggtgtag	4140
tcgtaatcgt	aatcgtotaa	ttcatcatcc	caattataat	attcaccagc	acgtctaatc	4200
tgttctattt	tgatcttcta	tcatactgt	atgttgctac	atgtagggtat	tccttttatcc	4260
aataatagtt	taaacacatc	tacattggga	tttgatgttg	tagcgtattt	ttctacaata	4320
ttaataccat	ttttgatact	atttatttct	atacctttcg	aaattagtaa	tttcaataag	4380
tctatattga	tgttatcaga	acatagatat	tcgaatatat	caaaatcatt	gatattttta	4440
tagtcgactg	acgacaataa	caaaatcaca	acatcgtttt	tgatattatt	atttttcttg	4500
gtaacgtatg	cctttaatgg	agtttcacca	tcatactcat	ataatggatt	tgcaccactt	4560
tctatcaatg	attgtgcact	gctggcatcg	atgttaaagt	ttttacaact	atcatagagt	4620
atcttatcgt	taaccatgat	tgggtgttga	tgctatcgca	ttttttgggt	tcctttcattt	4680
cagttatgta	tggatttagc	acgtttggga	agcatgagct	catatgattt	cagtaactgta	4740
gtgtcagtac	tattagtttc	aataagatca	atctctagat	ctatagaatc	aaaacacgat	4800
aggtcagaag	ataatgaata	tctgtaggct	tcttggttga	ctgtaacttc	tgggtttgtt	4860
agatggttgc	atcgtgcttt	aacgtcaatg	gtacaaattt	tatcctcgct	ttgtgtatca	4920
tattcgtccc	tactataaaa	ttgtatatcc	agattatcat	gcgatgtgta	tacgctaacy	4980
gtatcaataa	acggagcaca	ccatttagtc	ataaccgtaa	tccaaaaatt	tttaaagtat	5040
atcttaacga	aagaagtgtg	gtcattgtct	acggtgtatg	gtactagatc	ctcataagtg	5100
tatatatcta	gagtaatggt	taattttatta	aatgggtgat	aatatggatc	ctcgtgacaa	5160
tttccgaaga	tggaaataag	acataaacac	gcaataaatc	taattgcgga	catgggttact	5220
ccttaaaaaa	atacgaataa	tcaccttggt	tatttagtaa	gtgtcattta	acactatact	5280
catattaatc	catggactca	taatctctat	acgggattaa	cggatgttct	atatacgggg	5340
atgagtagtt	ctcttcttta	actttatact	ttttactaat	catattttaga	ctgatgtatg	5400
ggtaatagtg	tttgaagagc	tcgttctcat	catcagaata	aatcaatata	tctgtttttt	5460
tgttatcacg	atgtattaca	goccatata	ttacgtaata	gaacgtgtca	tctaccttat	5520
taactttcac	cgcatagttg	tttgcaaata	cgggttaatcc	tttgacctcg	tcgattttccg	5580

-18-

accaatctgg	gcgataatg	aatctaaact	ttaattgctt	gtaatcattc	gaaataattt	5640
ttagtttgca	tccgtagtta	tcccctttat	gtaactgtaa	atctctcaac	gcgatatctc	5700
cattaataat	gatgtcgaat	tcgtgctgta	taccataact	gaatggatga	acgaataaccg	5760
acggcggttaa	tagtaattta	ctttttcatc	tttacaatatt	gggtactagt	tttactatca	5820
taagtttata	aattccacaa	gctactatgg	aataagccaa	ccatcttagt	ataccacaca	5880
tgtcttaaag	tttattaatt	aattacatgt	tgtttttatat	atctcgctac	gaatttaaag	5940
agaaattagt	ttaggaagaa	aaattatcta	tctacatcat	cacgtctctg	tattctacga	6000
tagagtgccta	ctttaagatg	cgacagatcc	gtgtcatcaa	atatatactc	cattaaaaatg	6060
attattccgg	cagcgaactt	gatattggat	atatcacaac	ctttgttaat	atctacgaca	6120
atagacagca	gtccccaggt	tccataaaca	gtgagtttat	ctttctttga	agagatatatt	6180
tgtagagatc	ttataaaact	gtcgaatgac	atcgcattta	tatcttttagc	taaatcgat	6240
atgtttaccat	cgtaatatct	aaccgcgtct	atcttaaacg	tttccatcgc	tttaaagacg	6300
tttccgatag	atggtctcat	ttcatcagtc	atactgagcc	aacaaatata	atcgtgtata	6360
acatctttga	tagaatcaga	ctctaaagaa	aacgaatcgg	ctttattata	cgcatcctatg	6420
ataaaacttaa	tgaaaaatgt	ttttcggtgt	tttaagttgga	tgaatagtat	gtcttaataa	6480
ttgttattat	ttcattaatt	aatatttagt	aacgagtaca	ctctataaaa	acgagaatga	6540
cataactaat	cataactagt	tatcaaagtg	tctaggacgc	gtaatttttca	tatggtatag	6600
atcctgtaag	cattgtctgt	attctggagc	tattttctct	atcgcattag	tgagttcaga	6660
atatgttata	aattttaaat	gaataacgaa	cataacttta	gtaaagtcgt	ctatatataac	6720
tcttttattt	cttagccatc	gtaataccat	gtttaagata	gtatattctc	tagttactac	6780
gatctcatcg	ttgtctagaa	tatcacatac	tgaatctaca	tccaatttta	gaaattgggtc	6840
tgtgttacat	atctcttcta	tattattgtt	gatgtattgt	cgtagaaaac	tattacgtag	6900
accattttct	ttataaaacg	aatatatagt	actccaatta	tctttacoga	tatatttgca	6960
cacataatcc	attctctcaa	tactacatc	tttaagattt	tcgttggttaa	gatatttggc	7020
taaaactatat	aattctatta	gatcatcaac	agaatcagta	tatatttttc	tagatccaaa	7080
gacgaactct	ttggcgctct	ctataatatt	cccagaaaag	atattttcgt	gttttagttt	7140
atcgagatct	gatctgttca	tatacgccat	gattgtacgg	tacgttatga	taaccgcata	7200
aaataaaaaat	ccattttcat	ttttaaccac	tactattcat	aattgagatt	gatgtaatac	7260
tttgttactt	tgaacgtaaa	gacagtacac	ggatccgtat	ctccaacaag	cacgtagtaa	7320
tcaaattttgg	tgttgttaaa	cttcgcaata	ttcatcaatt	tagatagaaa	cttataactca	7380
tcatctgttt	taggaatcca	tgtattatta	ccactttcca	acttatcatt	atcccaggct	7440
atgtttcgtc	catcatcggt	gcgcagagtg	aataattctt	ttgtattcgg	tagttcaaat	7500
atatgatcca	tgcatagatc	ggcaaagcta	ttgtagatgt	gatttttctt	aaatctaata	7560
taaaactcgt	ttactagcaa	acactttcct	gatttatcga	ccaagacaca	tatggtttct	7620
aaatctatca	agtgggtggg	atccatagtt	atgacgcagt	aacatatatt	attacattct	7680
tgactgtcgc	taatatctaa	atatttattg	ttatcgtatt	ggattctgca	tatagattggc	7740
ttgtatgtca	aagataataga	acacataacc	aatttatagt	cgcgctttac	attctcgaat	7800
ctaaagttaa	gagattttaga	aaacattata	tcctcggatg	atgttatcac	tgtttctgga	7860
gtaggatata	ttaaagtctt	tacagatttc	gtccgattca	aataaatcac	taaataatat	7920
cccacattat	catctgttag	agtagtatca	ttaaatctat	tatattttat	gaaagatata	7980
tcaactgctca	cctctatatt	tcgtacattt	ttaaactggt	tgtataatat	ctctctgata	8040
caatcagata	tatctattgt	gtcggtagac	gataccgtta	catttgaatt	aatgggtgtt	8100
catttttaca	cttttaacaa	gttgaccaat	tcatttctaa	tagtatcaaa	ctctccatga	8160
ttaaatattt	taatagtatc	catttttatat	cactacggac	acaaagtagc	tgacataaac	8220
cattgtataa	tttttatgtt	ttatgtttat	tactgtacac	attttggaag	ttccggcttc	8280
catgtatttc	ctggagagca	agtagatgat	gaggaaccag	atagtttata	tccgtacttg	8340
cacttaaagt	ctacattgtc	gttgtatgag	tatgatcttt	taaaccgct	agacaagtat	8400
ccgtttgata	ttgtaggatg	tggaacattta	acaatctgac	acgtgggtgg	atcggaccat	8460
tctcctcctg	aacacaggac	actagagtta	ccaatcaacg	aatatccact	attgcaacta	8520
taagttacaa	cgctcccac	ggtataaaaa	tcctcgtatc	cgttatgtct	tccgttggat	8580
atagatggag	gggattggca	tttaacagat	tcacaaatag	gtgcctcggg	attccatacc	8640
atagatccag	tagatcctaa	ttcacaatac	gatttagatt	caccgatcaa	ctgatattccg	8700
ctattacaag	agtagcttat	actagagcca	aagtctactc	caccaataatc	aagtggcca	8760
ttatcgatat	ctcgaggcga	tgggcatctc	cgtttaatac	attgattaaa	gagtgtccat	8820
ccagtaacctg	tacatttagc	atatataggt	cccatttttt	gctttctgta	tccaggtaga	8880

-19-

catagatatt	ctatagtgtc	tccatagtgtg	taattagcat	tagcatcagt	ctccacacta	8940
ttcttaaatt	tcatattaat	gggtcgtgac	ggaatagtag	agcatgatag	aacgcacact	9000
attcccaaca	atgtcaggaa	cgtcacgctc	tccaccttca	tatttattta	tccgtaaaaa	9060
tgttatcctg	gacatcgtac	aaataataaa	aagcccatat	atgttcgcta	ttgtagaaat	9120
tgtttttcac	agttgctcaa	aaacgatggc	agtgacttat	gagttacgtt	acacttttga	9180
gtctcatctt	tagtaaacad	atcataatat	tcgatattac	gagttgacat	atcgaacaaa	9240
ttccaagtat	ttgatttttg	ataatattcg	tattttgcat	ctgctataat	taagatataa	9300
tcaccgcaag	aacacacgaa	catcttttct	acatgggtta	agtacatgta	caattctatc	9360
catttgcctt	ccttaactat	atatttgtat	agataattac	gagtcctcgt	agtaattcca	9420
gtaattacat	agatgtcgcc	gtcgtactct	acagcataaa	ctatactatg	atgtctaggc	9480
atgggagact	tttttatcca	acgattttta	gtgaaacatt	ccacatcggt	taatactaca	9540
tatttctcat	acgtgggtata	aactccaccc	attacatata	tatcatcggt	tacgaatacc	9600
gacgcgcctg	aatatctagg	agtaattaag	tttggaagtc	ttatccattt	cgaagtgccg	9660
tgtttcaaat	attctgccac	accggttgaa	atagaaaatt	ctaactctcc	tattacatat	9720
aactttccat	cggttaacaca	agtactaact	tctgattttt	acgacgacat	attagtaacc	9780
gttttccatt	ttttcgtttt	aagatctacc	cgcgatacgg	aataaacatg	tctattgtta	9840
atcatgccgc	caataatgta	tagacaatta	tgtaaaacat	ttgcattata	gaattgtcta	9900
tctgtattac	cgactactcg	ccaatattct	gttctaggag	agtaatgggt	tattgtggat	9960
atataaacag	agtttttaat	gactactata	ttatgtttta	taccatttcg	tgctactggc	10020
tttgtagatt	tggtatatgt	taatcccaac	aatgatatag	cattgcgcac	agtattagtc	10080
ataaacttgg	gatgtaaaat	gttgatgata	tctacatcgt	ttggattttt	atgtatccac	10140
tttaataata	tcatagctgt	aacatcctca	tgattttacgt	taacgtcttc	gtgggataag	10200
atagttgtca	gttcatcctt	tgataatttt	ccaaattctg	gatcggatgt	caccgcagta	10260
atattgttga	ttatttctga	catcgacgca	ttatatagtt	ttttaattcc	atatctttta	10320
gaaaagttaa	acatccttat	acaatttgtg	aaattaatat	tatgaatcat	agttttttaca	10380
catagatcta	ctacaggcgg	aacatcaatt	attatggcag	caactagtat	catttctaca	10440
ttgtttatgg	tgatgtttat	cttcttccag	cgcataatag	ctaatagcga	ttcaaacgcg	10500
tgaatgttta	taccattcaa	tataatcgct	tcatccctta	gatgggtgat	ctgaatgcgt	10560
ttaaaaaaat	tatacggaga	cgcgtaata	atttccttat	tcacttgtat	aatttcccca	10620
ttgatagaaa	atattacgct	ttccattctt	aaagtactat	aagtaattat	agtataatgt	10680
aaacgtttat	atattcaata	tttttataaa	aatcattttg	acattaattc	cttttttaaat	10740
ttccgtctat	catctataga	aacgtattct	atgaatttat	aaaatgcttt	tacgtgtcct	10800
atcgtaggcg	atagaaccgc	taaaaagcct	atcgaatttc	tacaaaagaa	tctgttatat	10860
ggtataggga	gagtataaaa	cattaaatgt	ccgtacttat	taaagtattc	agtagccaat	10920
cctaactctt	tcgaataact	attaatggct	cttgttctgt	acgaatctat	ttttttgaac	10980
aacggaccta	gtggatatac	ttgttctatg	tatctaaaat	aatgtctgac	tagatccggt	11040
agtttaatat	ccgcagtcac	cttgtctaga	atggcaaatc	taactgcggg	tttaggcttt	11100
agtttagttt	ctatatctac	atctatgtct	ttatctaaca	ccaaaaatat	aatagctaata	11160
attttattac	aatcatccgg	atattcttct	acgatctcac	taactaatgt	ttctttgggt	11220
atactagtat	agtcactatc	ggacaaataa	agaaaatcag	atgatcgatg	aataatacat	11280
ttaaattcat	catctgtaag	atttttgaga	tgtctcatta	gaatattatt	aggggttagta	11340
ctcattatca	ttcggcagct	attacttatt	ttattatttt	tcacatata	gatcaatcat	11400
tagatcatca	aaatatgttt	caatcatcct	aaagagtatg	gtaaatgact	cttcccatct	11460
aatttctgaa	cgttcaccaa	tgtctctagc	cactttggca	ctaatagcga	tcatttcgctt	11520
agcgtcttct	atattattaa	ctgggttgatt	caatctatct	agcaatggac	cgtcggacag	11580
cgtcattctc	atgttcttaa	tcaatgtaca	tacatcgccg	tcactctacca	attcatccaa	11640
caacataagc	ttttttaaata	catcattata	ataggtttga	tcgttgtcat	ttctccaaag	11700
aatatatcta	ataagtagag	tctcatgct	tagttaacaa	ctattttttta	tgttaaatca	11760
attagtagac	cgctatgttt	aatacttatt	catatttttag	tttttaggat	tgagaatcaa	11820
tacaaaaaatt	aatgcacat	taatttttaga	aatacttagt	ttccacgtag	tcaatgaaac	11880
atttgaactc	atcgtacagg	acgttctcgt	acaggacgta	actataaaacc	ggttttatatt	11940
tgttcaagat	agatacaaat	ccgataaact	tttttacgaa	ttctacggga	tcacttttaa	12000
aagtgtcata	ccgggttctt	tttatttttt	taaacagatc	aatgggtgtga	tggttgattag	12060
gtctttttacg	aattttgatat	agaatagcgt	ttacatatcc	tccataatgg	tcaatcgcca	12120
tttgttcgta	tgtcataaat	tctttaatta	tatgacactg	tgtattattt	agttcatcct	12180

-20-

tggtcattgt	taggaatcta	tccaaaatgg	caattatact	agaactatag	gtgcggttga	12240
tacacatatt	gatgtgtctg	tttataacaat	caatgctact	accttcgggt	aaaattgtag	12300
catcatatac	cattttctagt	acttttaggtt	cattattatc	cattgcagag	gacgtcatga	12360
tcgaatcata	aaaaaatata	ttatTTTTt	gttattttgt	taaaaataat	catcgaatac	12420
ttcgtaagat	actccttcat	gaacataatc	agttacaaaa	cgtttatatg	aagtaaagta	12480
tctacgattt	ttacaaaagt	ccggatgcat	aagtacaaaag	tacgcgataa	acggaataat	12540
aatagattta	tctagtctat	ctttttctat	agctttcata	gttagataca	tgggtctcaga	12600
agtaggatta	tgtaacatca	gcttcgataa	aatgactggg	ttatttagtc	ttacacattc	12660
gctcatacat	gtatgaccgt	taactacaga	gtctacacta	aaatgattga	acaatagata	12720
gtctaccatt	gtttcgtatt	cagatagtag	agcgtagtag	atggcatcct	cacaaattat	12780
atcattgtct	aatagatatt	tgacgcacat	tatggatccc	acttcaacag	ccatctttaa	12840
atcggtagaa	tcatattgct	ttcctttatc	attaataaatt	tctagaacat	catctctatc	12900
ataaaagata	caaataattaa	ctgtttgatc	cgtaataaca	ttgctagtcg	atagcaattt	12960
gttaataaga	tgcgctgggc	tcaatgtctt	aataagaagt	gtaagaggac	tatctccgaa	13020
tttgTTTTgt	ttattaacat	ccgttgatgg	aagtaaaaga	tctataatgt	ctacattcct	13080
gactgtttta	gagcatacaa	tatggagagg	tgtatttcca	tcatgatctg	gttttgaggg	13140
actaattcct	agtttcatca	tccatgagat	tctagaagct	tttggttgt	ctgacataag	13200
atgtctatga	atatgatttt	tgccaaattt	atccactatc	ctggcttcga	atccgatgga	13260
cattattttt	ttaaacactc	tttctgaagg	atctgtacac	gccaaacaacg	gaccacatcc	13320
ttcttcatca	accgagttgt	taatcttggc	tccatactgt	accaataaat	ttattctctc	13380
tatgacttca	tcatctgttc	ccgagagata	atatagaggc	gttttatgct	gtttatcaca	13440
cgcgTTTTga	tctgcgcgct	gcgtcagcag	catcgcgact	attctattat	tattaatttt	13500
agaagctata	tgcaatggat	aatttccatc	atcatccgtc	tcaattggag	agtatcctct	13560
atgaagaagt	tcttcgacaa	atcgttcatc	tagtccctta	attccacaat	acgcatgtag	13620
aatgtgataa	ttatttccag	aaggttcgtat	agcttgtagc	atattccctaa	atacatctaa	13680
atTTTTacta	ttatatTTtg	cataaagaga	tagataatac	tcggccgaca	taatgttgct	13740
cattgttagta	taaaaattaa	tatttctatt	tctgtatatt	tgcaacaatt	tactctctat	13800
aacaaatatc	ataacttagt	tcttttatgt	caagaaggca	ctggtttagt	tcatctataa	13860
atgtcacgcc	ataactacca	cgcatgccat	actcagaatt	atgataaaga	tatttatcct	13920
tgggggtgtag	gtaatgggga	ttaatctttg	ttggatcagt	ctctaagtta	acacatgtca	13980
cacatgatcc	atTTtatagtt	atatcacacg	atgatgattt	atgaattgat	tccggaagat	14040
cgctatcgta	ttttgtgggt	ccacaattca	tttccataca	tgttattgtc	acactaatat	14100
tatgatgaac	tttatctagc	cgctgagtgg	taaacaacag	aacagatagt	ttattatcct	14160
taccaacacc	tctcagccgt	gccacaaatc	tctgatccgt	atccatgatg	gtcatgttta	14220
tttctagtcc	gtatccagtc	aacactatgt	tagcatttct	gtcgatatag	ctttcactca	14280
tatgacactc	accaataata	gtagaattaa	tgtcgttaatt	tacaccaata	gtgagttcgg	14340
cggcaaagta	ccaataccgg	taatcttgtc	gaggaggaca	tatagtattc	ttgtattcta	14400
ccgaataccc	gagagatgcg	atacaaaaaga	gcaagactaa	tttgtaaacc	atcttactca	14460
aaatatgtaa	caatagtagc	atgcaatgag	taagacaata	ggaaatctat	cttatataca	14520
cataattatt	ctatcaattt	taccaattag	ttagtgtaat	gttaacaaaa	atgtgggaga	14580
atctaattag	tttttcttta	cacaattgac	gtacatgagt	ctgagttcct	tgtttttgtc	14640
aattattttca	tccaattttat	tattcttgac	gatatcgaga	tcttttgtat	aggagtcaaa	14700
cttgatttca	acatgctttt	ctataatcat	tttagctatt	tcggcatcat	ccaatagtag	14760
atTTtccaga	ttagcagaat	agatatatta	gtcgtatttg	aacagagcct	gtaacatctc	14820
aatgtcttta	ttatctatag	ccaattttaat	gtccggaatg	aagagaaggg	aattattgggt	14880
gtttgtcgac	gtcatatagt	cgagcaagag	aatcatcata	tccacgtgtc	cattttttat	14940
agtgatgtga	atacaactaa	ggagaatagc	cagatcaaaa	gtagatggta	tctctgaaag	15000
aaagtaggaa	acaatactta	catcatthaag	catgacggca	tgataaaaatg	aagttttcca	15060
tccagttttc	ccatagaaca	tcagttctca	atTTttctta	acaaacagtt	ttaccgtttg	15120
catgttacca	ctatcaaccg	cataatacaa	tgcggtgttt	cccttgtcat	caaattgtga	15180
atcatccagt	ccactgaata	gcaaaatctt	tactattttg	gtatcttcca	atgtggctgc	15240
ctgatgtaat	ggaaattcat	tctctagaag	atTTttcaat	gtccagcgt	tcaacaacgt	15300
acatactaga	cgcacgttat	tatcagctat	tgcataatac	aaggcactat	gtccatggac	15360
atccgcctta	aatgtatctt	tactagagag	aaagcttttc	agctgcttag	acttccaagt	15420
attaattcgt	gacagatcca	tgtctgaaac	gagacgctaa	ttagtgtata	ttttttcatt	15480

-21-

ttttataaatt	ttgtcatatt	gcaccagaat	taataatatc	tttaatatagat	ctgattagta	15540
gatacatggc	tatcgcaaaa	caacatatat	acattttaata	aaaataaatat	ttattaagaa	15600
aattcagatt	tcacgtaccc	atcaatataa	ataaaataat	gattccttac	accgtaccca	15660
tattaaggag	attccacctt	acccataaac	aatataaatc	cagtaatatc	atgtctgatg	15720
atgaacacaa	atgggtgtatt	aaattccagt	ttttcaggag	atgatctcgc	cgtagctacc	15780
ataatagtag	atgcctctgc	tacagttcct	tggtcgtcga	catctatctt	tgcattctga	15840
aacatttttat	aaatatataa	tgggtcccta	gtcatatgtt	taaacgcgc	attatctgga	15900
ttaaacatac	taggagccat	catttcggct	atcgacttaa	tatccctctt	attttcgata	15960
gaaaatttag	ggagtttaag	attgtacact	ttattcccta	attgagacga	ccaatagtct	16020
aattttgcag	ccgtgataga	atctgtgaaa	tgggtcatat	tatcacctat	tgccaggtag	16080
atactaatat	tagcatcctt	atagcgaagg	cgtaccatgt	catattcttt	gtcatcgatt	16140
gtgattgtat	ttccttgcaa	tttagtaact	acgttcatca	tgggaaccgt	tttcgtaccg	16200
tacttattag	taaaactagc	attgctgtgt	ttagtगतat	caaacggata	ttgccatata	16260
cctttaaaat	atatagtatt	aatgattgcc	catagagtat	tattgtcgag	catattagaa	16320
tctactacat	tagacatacc	ggatctacgt	tctactatag	aattaatttt	attaaccgca	16380
tctcgtctaa	agtttaattct	atataggccg	aatctatgat	attgttgata	atacgacggt	16440
ttaatgcaca	cagtattatc	tacgaaactt	tgataagtta	gatcagtgtg	cgtatattta	16500
gatgttttca	gcttagctaa	tcttgatatt	aattctgtaa	atgctggacc	cagatctctt	16560
tttctcaaat	ccatagctctt	caataattct	attctgatgt	tacctgatgc	aggcaatagc	16620
gacataaaca	tagaaaacga	ataaccaaac	gggtgagaaga	caatattatc	atcttgaata	16680
tttttatatc	ctactatacc	ggcattggta	aatccttgta	gacgataggc	ggacgctgaa	16740
cacgctaacc	atagtatcaa	taacgcaatc	atgattttat	ggtattaata	attaacctta	16800
tttttatgtt	cgggtataaaa	aaattattga	tgtctacaca	tccttttgta	attgacatct	16860
atatatcctt	ttgtataatc	aactctaatc	actttaactt	ttacagtttt	ccctaccagt	16920
ttatccctat	attcaacata	tctatccata	tgcactctaa	cactctctgc	caagatagct	16980
tcagagttag	gatagtcaaa	aagataaata	tatatagcat	aatcattctc	gtatactctg	17040
ccctttatta	catcacccgc	attgggcaac	gaataacaaa	atgcaagcat	cttggttaacg	17100
ggctcgtaaa	ttgggataaa	aattatgttt	atttgtctt	atatctatct	tattcaagag	17160
aatattcagg	aatttctttt	tccggttgta	tctcgtcgca	gtatatatca	tttgtacatt	17220
gtttcatatt	ttttaatagt	ttacaccttt	tagtaggact	agtatcgtac	aattcatagc	17280
tgtattttga	attccaatca	cgcataaaaa	tatcttccaa	ttgttgacga	agacctaatc	17340
catcatccgg	tgtaatatata	atagatgtct	cacatgtatc	cgtaaagtaa	tttctgtctc	17400
aatttgagg	acctatatag	gccgttttat	cggttaccat	atatttggca	tgggtttacc	17460
tagaatacgg	aatgggagga	tcagcatctg	gtacaataaa	tagctttact	tctatatatta	17520
tgttttttag	ttttagcata	gcgatagatc	ttaaaaagtt	tctcatgata	aacgaagatc	17580
gttgccagca	actaatcaat	agcttaacgg	atacttgtct	gtctatagcg	gatcttctta	17640
attcatcttc	tatataaggc	caaaacaaaa	ttttaccgcg	cttcgaataa	ataataggga	17700
taaagtcat	aacagataca	taaacgaatt	tactcgcatt	tctaatacat	gacaataaag	17760
cggttaaatc	attggttctt	tccatagtag	atagttgttg	cgggtgcagaa	gcaataaata	17820
cagagtgtgg	aacgcgcgtt	acgttaatac	taagaggatg	atctgtatta	taatacgacg	17880
gataaaaagt	tttccaatta	tatggtagat	tgttaaactc	aagataccag	tataacctca	17940
aaatttgagt	gagatccgct	gccaaagtcc	tattattgaa	gatcgcaata	cccaattcct	18000
tgacctgagt	tagtgatctc	caatccatgt	tagcgttcc	taaataaata	tgtgtattat	18060
cagatatcca	aaattttgta	tgaagaactc	ctcctaggat	atttgtaata	tctatgtatc	18120
gtacttcaac	tccggccatt	tgtagtcttt	caacatcctt	taatgggttg	ttagatttat	18180
taacggctac	tctaactcgt	actcctcttt	tgggttaattg	tacaatctcg	tttaatatta	18240
tcgtgccgaa	attcgtaccc	acttcatccg	ataaaactcca	ataaaaagat	gatatatcta	18300
gtgtttttgt	ggtattggat	agaatttccc	tccacatggt	aaatgtagac	aaatatactt	18360
tatcaaattg	catacctata	ggaatagttt	ctgtaatcac	tgcgattgta	ttatccggat	18420
tcatttttatt	tgttaaaaga	ataatcctat	atcacttcac	tctattaaaa	atccaagttt	18480
ctatttcttt	catgactgat	tttttaactt	catccgtttc	cttatgaaga	tgatgttttg	18540
caccttcata	aattttttatt	tctctattac	aatttgcacg	ttgcatgaaa	taatatgcac	18600
ctaaaacatc	gctaacttta	ttgtttgttc	cctggagtat	gagagtcggg	gggggtgttaa	18660
tcttggaat	tattttttcta	accttggttg	tagccttcaa	gacctgacta	gcaaatccag	18720
ccttaatttt	ttcatgattg	actaatgggt	cgtattggta	tttataaact	ttatccatat	18780

-22-

ctctagatac	tgattctgga	catagctttc	cgactggcgc	atttggtgtg	atggttccca	18840
taagtttggc	agctagcaga	ttcagtcttg	aaacagcatc	tgcattaact	agaggagaca	18900
ttagaatcat	tgctgtaaac	aagtttggat	tatcgtaaga	ggctagctcc	catggaatga	18960
ccaataagt	agatttaata	gttaccacgt	gctgtaccaa	agtcatcaat	catcattttt	19020
tcaccattac	ttcttccatg	tccaatatga	tcatgtgaga	atactaaaat	tcctaacgat	19080
gatatgtttt	cagctagttc	gtcataacgt	ccagaatgtt	taccagctcc	atgacttatg	19140
aataactaat	ccttaggata	tgtaataggt	ttccaatatt	tacaatatat	gtaatcattg	19200
tccagattga	acatacagtt	tgcaactcatg	attcacgtta	tataactatc	aatattaaca	19260
gttcgtttga	tgatcatatt	atthtttatgt	tttattgata	attgtaaaaa	catacaatta	19320
aatcaatata	gaggaaggag	acggctactg	tctttttgtaa	gatagtcatg	gcgactaaat	19380
tagattatga	ggatgctgtt	ttttactttg	tggatgatga	taaaatatgt	agtcgcgact	19440
ccatcatcga	tctaatagat	gaatatatta	cgtggagaaa	tcatgttata	gtgtttaaca	19500
aagatattac	cagttgtgga	agactgtaca	aggaattgat	gaagttcgat	gatgtcgcta	19560
tacggtagta	tggtattgat	aaaattaatg	agattgtcga	agctatgagc	gaaggagacc	19620
actacatcaa	ttttacaaaa	gtccatgata	aggaaagttt	attcgctacc	ataggaatat	19680
gtgctaaaaat	cactgaacat	tggggatata	aaaagatttc	agaatctaga	ttccaatcat	19740
tgggaaacat	tacagatttg	atgaccgacg	ataatataaa	catcttgata	ctttttctag	19800
aaaaaaaaatt	gaattgatga	tataggggtc	ttcataacgc	ataattatta	cgtttagcat	19860
ctatatocgt	gttaaaaaaa	attatcctat	catgtatttg	agagttttat	atgtagcaaa	19920
catgatagct	gtgatgccaa	taagcttttag	atattcacgc	gtgctagtgt	tagggatggg	19980
attatctggg	gggtgaaatgt	ccgttatata	atctacaaaa	caatcatcgc	atatagtatg	20040
cgatagtaga	gtaaacattt	ttatagtttt	tactggatcc	atacatcgtc	tacccaattc	20100
gggtataaat	gaaattgtcg	ccaatcttac	acccaacccc	ttgttatcca	ttagcatagt	20160
attaacttcg	ttatttatgt	cataaacgtg	aaatgatttt	gtagatgcca	tatcatacat	20220
gatattcatg	tccttattat	aatcattact	aaactttatca	caatatatgt	tgataaatatc	20280
tatatatgat	ctagtctttg	tgggcaactg	tctatacaag	tcgtctaaac	gttgtttact	20340
catatagtat	cgaacagcca	tcattacatg	gtcccgttcc	gttgatagat	aatcgagtat	20400
gttagtggac	ttgtcaaadc	tatataccat	atthttctgga	agtggatata	catagtcgtg	20460
atcaacatta	ttgctagcct	catcttctat	atcctgtact	ataccattat	ctatatcatc	20520
tacataatct	atgatattat	tacacataaa	catcgacaac	atactattgt	ttattatcta	20580
agtctgtgtg	atccaaaccc	ttgatctcct	ctatttgtac	tatctagaga	ttgtacttct	20640
tccagttctg	gataatatat	acgttgatag	attagctgag	ctattctatc	tccagtattt	20700
acattaaacg	tacattttcc	attattaata	agaatgactc	ctatgtttcc	cctataatct	20760
tcgtctatta	caccacctcc	tatatcaatg	cttttttagtg	acagaccaga	cctaggagct	20820
attctaccat	agcagaactt	aggcatggac	atactaatat	ctgtcttaat	taactgtcct	20880
tctcctggag	ggatagtata	atcgtaagcg	ctatacaaat	catatccggc	agcaccgccg	20940
gattgcctag	taggagattt	agctctgtta	gtttcccttaa	caaacttaac	tgggtgagtta	21000
atattcatgt	tgaacataaa	actaatattt	tatttcaaaa	ttattttacca	tcccatatat	21060
tccatgaata	agtgtgatga	ttgtacactt	ctatagtatc	tatatacgat	ccacgataaa	21120
atcctcctat	caatagcagt	ttattatcca	ctatgatcaa	ttctggatta	tccctcggat	21180
aaataggatc	atctatcaga	gtccatgtat	tgctggattc	acaataaaaat	tccgcatttc	21240
taccaacca	gaataacctt	ctaccgaaca	ctaacgcgca	tgattttata	tgaggataat	21300
aagtggatgg	tccaaactgc	cactgatcat	gattgggtag	caaataattct	gtagttgtat	21360
cagtttcaga	atgtcctccc	attacgtata	taacattgtt	tatggatgcc	actgctggat	21420
tacatctagg	tttcagaaga	ctcggcatat	taacccaagc	agcatccccg	tggaaaccaac	21480
gctcaacaga	tgtgggattt	ggtagacctc	ctactacgta	taattttattg	ttagcgggta	21540
tcccgtctagc	atacagctctg	gggctattca	tccggaggaa	tggaaatccaa	ttgttttgata	21600
tataatthac	cgctatagca	ttgttatgta	tttcattgtt	catccatcca	ccgatgagat	21660
atactacttc	tccaacatga	gtacttgtac	acatatggaa	tatatctata	atthtgatcca	21720
tgthcatagg	atactctatg	aatggatact	tgtatgattt	gcgtgggtgt	ttatcacaat	21780
gaaatatttt	ggtagactct	agtatccatt	ttacattatt	tatacctctg	ggagaaagat	21840
aatttgacct	gattacattt	ttgataagga	gtagcagatt	tcctaattta	ttcttctcgt	21900
ttatatacca	cttaatgaca	aatcaacta	cataatcttc	atctggaaca	tttagttcat	21960
cgctttctag	aataagtttc	atagatagat	aatcaaaaat	gtctatgatg	tcactttcca	22020
gttccaaaaa	gtgtttggca	ataaagtttt	tagtatgaca	taagagattg	gatagtcctg	22080



-23-

attctataacc	catcatgtaa	cactcgacac	aatattcctt	tctaaaatct	cgtaagataa	22140
agtttataca	agtgtagatg	ataaattcta	cagaggttaa	tatagaagca	cgtaataaat	22200
tgacgacgtt	atgactatct	atatatacct	ttccagtata	cgagtaaata	actatagaag	22260
ttaaactgtg	aatgtcaagg	tctagacaaa	ccctcgtaac	tggatcttta	tttttcgtgt	22320
atTTTTgacg	taaatgtgtg	cgaaagtaag	gagataactt	tttcaatatc	gtagaattga	22380
ctatttatatt	gcctcctatg	gcatcaataa	ttgttttgaa	tttcttagtc	atagacaatg	22440
ctaatatatt	cttacagtac	acagtattga	caaatatcgg	catttatgtt	tctttaaaag	22500
tcaacatcta	gagaaaaatg	attatctttt	tgagacataa	ctcccathtt	ttggtattca	22560
cccacacgtt	tttcgaaaaa	attagttttt	ccttccaatg	atataattttc	catgaaatca	22620
aacggattgg	taacattata	aattttttta	aatcccaatt	cagaaatcaa	tctatccgcg	22680
acgaattcta	tatatgtttt	catcatttca	caattcattc	ctataagttt	aactggaaga	22740
gccgcagtaa	gaaattcttg	ttcaatggat	actgcatctg	ttataataga	tctaacgggt	22800
tcttctactg	gtggatgcaa	taaatgttta	aacatcaaac	atgcgaaatc	gcagtgcaga	22860
ccctcgtctc	tactaattag	ttcgttggaa	aacgtgagtc	cgggcattag	gccacgcttt	22920
ttaagccaaa	atatggaagc	gaatgatccg	gaaaagaaga	ttccttctac	tgacgcaaag	22980
gcaataagtc	tctctccata	accggcgcgtg	tcatgtatcc	acttttgagc	ccaatcggcc	23040
ttctttttta	cacaaggcat	cgtttctatg	gcattaaaga	gatagttttt	ttcattacta	23100
tcttttaact	agtgatcgat	caaaagacta	tacatttccg	aatgaatgtt	ttcaatggcc	23160
atctgaaatc	cgtagaaaca	tctagcctcg	gtaattctgta	cttctgtaca	aaatcgttcc	23220
gccaaatttt	cattcactat	tccgtcactg	gctgcaaaaa	acgccaatac	atgttttata	23280
aaatatTTTT	cgtctgggtg	tagtttatct	caatcattga	tatctttaga	tatatctact	23340
tcttccactg	tccaaaatga	tgctctgccc	tttttataca	tgttccagat	gtcatgatat	23400
tggtattggga	aaataacaaa	tctatttgga	tttggtgcaa	ggatgggttc	cataactaaa	23460
ttaacaataa	caataaattt	tttttcagtt	atctatatgc	ctgtacttgg	attttttgta	23520
catcgatato	gccgcaatca	ctacaataat	tacaagtatt	attgatagca	ttgttattag	23580
tactatcata	attaaattat	ctacattcat	gggtgctgaa	taatcgttat	tatcatcatt	23640
atcattttgt	aattgtgaca	tcatactaga	taaatcgttt	gcgagattgt	tgtgggaagc	23700
gggcattggg	gatgcattat	cattatttatt	taacgccttc	catttggatt	cacaaatgtt	23760
acgcacatto	aacattttat	ggaaactata	attttgtgaa	aacaaataac	aagaaaactc	23820
gtcatcgttc	aaatttttaa	cgatagtaaa	ccgattaaac	gtcgagctaa	tttctaacgc	23880
tagcgactct	gttggaatag	ggtttccaga	tatatatctt	ttcagttccc	ctacgtatct	23940
ataatcatct	gtaggaaatg	gaagatattt	ccatttatct	actgttctta	atatcatatg	24000
tggtgggtgta	gtagaaccat	taagcgcgaa	agatgttatt	tgcacatcgt	ttttaacttc	24060
gcaataattt	ctgggttagat	aacgcactct	accagtcaag	tcaatgatat	tagcctttac	24120
agatatattc	atagtagtcg	taacgatgac	tccatctttt	agatgcgata	ctcctttgta	24180
tgtaccagaa	tcttcgtacc	tcaaaactcg	tatattttaa	caagttaatg	agatattaac	24240
gcgtttttatg	aatgatgata	tataaccaga	agttttatcc	tgggtggcta	gcgctataac	24300
cttatcatta	taataccaac	tagtgtgatt	aatatgtgac	acgtcagtg	gggtacaaat	24360
atgtacatta	togtctacgt	cgtattcgat	acatccgcac	acagccaaca	aatataaaat	24420
gacaaatact	ctaacgccgt	tctgtacccat	cttgatgcgg	tttaataaat	gttttgattt	24480
caattttattg	taaaaaaaaga	ttcggtttta	tactgttcga	tattctcatt	gcttatattt	24540
tcatctatca	tctccacaca	gtcaaatccg	tggttagcat	gcacctcatc	aaccggtaaa	24600
agactatcgg	actcttctat	cattataact	ctagaatatt	taatttggtc	attattaatc	24660
aagtcaatta	tcttatTTTT	aacaaacgtg	agtattttac	tcatttttta	taaaaacttt	24720
tagaaatata	cagactctat	cgtgtgtcta	tatcttcttt	ttatatccaa	tgtattttatg	24780
tctgattttt	cttcattttat	catatataat	gggtccaaatt	ctacacgtgc	ttcggattca	24840
tccagatcat	taaggttctt	ataattgtaa	catccttctc	ttccctcttc	tacatcttcc	24900
ttcttattct	tattcttagc	gtcacagaat	ctaccacagc	aggatcccat	gacgagcgtc	24960
atattaaact	aatccatttt	caattataat	atatgattag	taatgaccat	taaaaataaa	25020
aatattcttc	ataaccggca	agaaagtga	aagttcacat	tgaaactatg	tcagtagtat	25080
acatcatgaa	atgatgatag	atatatactc	tattttgggtg	gaggattata	tgatataatt	25140
cgtggataat	catttttaag	acacatttct	ttattcgtaa	atcttttcac	gttaaatgag	25200
gtcccatatt	ttgcaatttc	ttcatatgat	ggcgggtgac	gtggacgagg	ctgctcctgt	25260
tcttggtgtg	gtcgccgact	gtcgtgtctg	cgtttagatc	cctccattat	cgcgattgcg	25320
tagatggagt	actattttat	accttgtaat	taaatttttt	tattaattaa	acgtataaaa	25380



-24-

acgttccgta	tctgtatttta	agagccagat	ttcgtctaata	agaacaaata	gctacagtaa	25440
aaataactag	aataattgct	acacccacta	gaaaccacgg	atcgtaatac	ggcaatcggg	25500
tttcgataat	aggtggaacg	tatatTTTTat	tttaaggactt	aacaattgtc	tgtaaaccac	25560
aatttgcttc	cgcggatcct	gtatttaacta	tctgtaaaag	catatgttga	ccgggaggag	25620
ccgaacattc	tccgatatct	aattttctgta	tatctataat	attattaacc	tccgcatacg	25680
cattacagtt	cttttctagc	ttggataccg	cactaggtac	atcgctctaga	tctattccta	25740
tttcctcagc	gatagctctt	ctatcctttt	ccggaagcaa	tgaaatcact	tcaataaatg	25800
attcaacat	gagtgtgaaa	ctaagtcgag	aattactcat	gcatttggtta	gttattcggg	25860
gcgcgcaatt	tttaaactgt	cctataacct	ctcctatatg	aatagcaca	gtgacattag	25920
tagggataga	atggtgagct	aatttttTga	aataactatc	tataaaaaga	ttatacaaa	25980
ttttaaaactc	tttagtttcc	gccatTTtatc	cagtcctgaga	aaatgtctct	cataataaat	26040
ttttccaaga	aactaattgg	gtgaagaatg	gaaaccttta	atctatatatt	atcacagtct	26100
gttttggtac	acatgatgaa	ttcttccaat	gccgtactaa	attcgatatc	tttttcgatt	26160
tctggatatg	tttttaataa	agtatgaaca	aagaaatgga	aatcgtaata	ccagttatgt	26220
ttaacttttga	aattgTTTTt	tattttcttg	ttaatgattc	cagccacttg	ggaaaagtca	26280
aagtcgttta	atgcogattt	aatacgttca	ttaaaaacaa	acttttttatc	cttttagatga	26340
attattattg	gttcattgga	atcaaaaagt	aagatattat	cgggtttaag	atctgcgtgt	26400
aaaaagtTgt	cgcaacaggg	tagttcgtag	attttaatgt	ataacagagc	catctgtaaa	26460
aagataaact	ttatgtattg	taccaaagat	ttaaatccta	atttgatagc	taactcggta	26520
tctactttat	ctgccgaata	cagtgcctagg	ggaaaaatta	taatgtttcc	tctttcatat	26580
tcgtagttag	ttctcttttc	atgttcgaaa	aagtgaacaa	tgcggttaaa	atagttttata	26640
acattaatat	tactgttaat	aactgccgga	taaaagtggg	atagtaattt	cacgaatttg	26700
atactgtcct	ttctctcggt	aaacgccttt	aaaaaaactt	tagaagaata	tctcaatgag	26760
agttcctgac	catccatagt	ttgtatcaat	aatagcaaca	tatgaagaac	acgtttatac	26820
agagtatgta	aaaatgttaa	tttatagttt	aatcccatgg	cccacgcaca	cacgattaat	26880
tttttttcat	ctcccttttag	attgttTgat	agaaatttgg	gtactgtgaa	ctccgccgta	26940
gtttccatgg	gactatataa	ttttgtggcc	tcgaatacaa	attttactac	atagttatct	27000
atcttaaaga	ctataccata	tcctcctgta	gatatgtgat	aaaaatcgtc	gttttatagga	27060
taaaatcggt	tatccttttg	ttggaaaaag	gatgaattaa	tgtaatcatt	ctcttctatc	27120
tttagtagtg	tttcottatt	aaaattctta	aaataattta	acaatctaac	tgacggagcc	27180
caattttggg	gtaaatctaa	ttgggacatt	atattgttaa	aatacaacaa	gtctccta	27240
ataacagtat	ctgataatct	atggggagac	atccattgat	attcagggga	tgaatcattg	27300
gcaacaccca	tttattgtac	aaaaagcccc	aatttacaaa	cgaaagtcca	ggtttgatag	27360
agacaaacaa	ttactatttt	tgtctctggt	tttaacacct	ccacagtttt	taatttcttt	27420
agtaatgaaa	ttatttcacaa	tatcagtatc	ttcttttatct	accagagatt	ttactaactt	27480
gataaccttg	gctgtctcat	tcaatagggt	agtaaatattt	gtatgtgtga	tattgatatc	27540
tttttgaatt	gtttcttttta	gaagtgaattc	tttgatgggtg	ccagcatacg	aattacaata	27600
atgcagaaac	tcggttaaca	tgacggaatt	atagtaagcc	aattccaatt	gttgccgtgtg	27660
ttgtattaga	gtgtcaatat	gagcaatggg	gtccttgctg	ttctctgata	gaatgcgagc	27720
agcgattttg	gcgttatcat	ttgacgatat	ttctggaatg	acgaatcctg	tttctactaa	27780
ctttttggta	ggacaaagtg	aaacaatcaa	gaagatagct	tctcctccta	tttgtggaag	27840
aaattgaact	cctctagatg	atctactgac	gatagtatct	cottgacaga	tattggaccg	27900
aattacagaa	gtacctggaa	tgtaaagccc	tgaaaccccc	tcatttttta	agcagattgt	27960
tgccgtaaat	ctgcactat	gcccaagata	gagagctcct	ttggtgaatc	catctctatg	28020
tttcagttta	accaagaac	agtcagctgg	tctaaaattt	ccatctctat	ctaatacagc	28080
atctaacttg	atgtcaggaa	ctatgaccgg	tttaattgta	tatgtaacat	tgagtaaata	28140
cttaagttca	taatcatcac	tgatcatcagt	tatgtacgat	ccaaacaatg	tttctaccgg	28200
catagtggat	acgaagatgc	tatccatcag	aatgtttccc	tgatttagtat	tttctatata	28260
gctattcttc	tttaaacgat	tttccaaatc	agtaactatg	ttcatttttt	taggagtagg	28320
acgcctagcc	agtatggaag	aggattttct	agatcctctc	ttcaacatct	ttgatctcga	28380
tggaatgcaa	aaccccatag	tgaaacaacc	aacgataaaa	ataatattgt	ttttcacttt	28440
ttataatttt	accatctgac	tcatggattc	attaatatct	ttataagagc	tactaacgta	28500
taattcttta	taactgaact	gagatatata	caccggatct	atgggtttcca	taattgagta	28560
aatgaatgct	cggcaataac	taatggcaaa	tgtatagaac	aacgaaatta	tactagagtt	28620
gttaaagtta	atattttcta	tgagctgttc	caataaatta	tttggttgta	ctgcgttcaa	28680

-25-

gtcataaate	atcttgatac	tatccagtaa	accgttttta	agttctggaa	tattatcate	28740
ccattgtaaa	gcccctaatt	cgactatcga	atatacctgct	ctgatagcag	tttcaatate	28800
gacggacgtc	aatactgtaa	taaaggtggt	agtattgtca	tcacgtgat	aaactacggg	28860
aatatggctc	ttagtaggta	cggtaacttt	acacaacgcg	atatataact	ttccttttgt	28920
accattttta	acgtagttgg	gacgtcctgc	agggtattgt	tttgaagaaa	tgatatcgag	28980
aacagatttg	atacgatatt	tgttggattc	ctgattattc	actataatat	aatctagaca	29040
gatagatgat	tcgataaata	gagaagggtat	atcgttggta	ggataataca	tccccattcc	29100
agtattctcg	gatactctat	tgatgacact	agttaagaac	atgtcttcta	ttctagaaaa	29160
cgaaaacatc	ctacatggac	tcattaaaac	ttctaacgct	cctgatttg	tctcgaatgc	29220
ctcgtacaag	gattttcaagg	atgccataga	ttctttgacc	aacgatttag	aattgcgttt	29280
agcatctgat	ttttttatta	aatcgaatgg	tcggctctct	ggtttgctac	cccaatgata	29340
acaatagtct	tgtaaagata	aaccgcaaga	aaattttatac	gcataccatcc	aaataaccct	29400
agcaccatcg	gatgatatta	atgtattatt	atagattttc	catccacaat	tattgggcca	29460
gtatactggt	agcaacggta	tatcgaatag	attactcatg	taacctacta	gaatgatagt	29520
tcgtgtacta	gtcataaatat	ctttaatcca	atctaaaaaa	tttaaaatta	gattttttac	29580
actgttaaag	ttaacaaaag	tattaccggg	gtacgtggat	atcatatatg	gcattgggtcc	29640
attatcagta	atagctccat	aaactgatac	ggcgaatggt	tttataatgt	tttgatctaa	29700
cgaggaagaa	attcgcgccc	acaattcatc	ctagatatg	tatttaatat	caaacggtaa	29760
cacatcaatt	tcgggacgcg	tatatgtttc	ttaaattttta	atccaaatat	aatgatgacc	29820
tatatgccct	attatcatac	tgtcaactat	agtacaccta	gggaacttac	gatacatctg	29880
tttctataaa	tcgttaaatt	ttacaaatct	ataacatgct	aaaccttttg	acgacagcca	29940
ttcattaatt	tctgatatgg	aatctgtatt	ctcgataccg	tatcgttcta	aagccagtgc	30000
tatatctccc	tgttcgtggg	aacgctttcg	tataatatcg	atcaacggat	aatctgaagt	30060
ttttggagaa	taatatgact	catgatctat	ttcgtccata	aacaatctag	acataggaat	30120
tggaggcgat	gatcttaatt	ttgtgcaatg	agtcgtcaat	cctataactt	ctaactctgt	30180
aatattcatc	atcgacataa	tactatctat	gttatcatcg	tatattagta	taccatgacc	30240
ttcttcattt	cgtgccaaaa	tgatatacag	tcttaaatag	ttacgcaata	tctcaatagt	30300
ttcataattg	ttagctgttt	tcatacaagg	ttgtatcctg	tttaacatga	tggcgttcta	30360
taacgtctct	attttctatt	tttaattttt	taaattttta	acgattttact	gtggctagat	30420
acccaatctc	tctcaaatat	tttttttagcc	tcgcttacaa	gctgtttatc	tatactatta	30480
aaactgacga	atccgtgatt	ttggtaaatgg	gttccgtcga	aatttgccga	agtgatatga	30540
acataattcgt	cgtcgactat	caacaatttt	gtattattct	gaatagtga	aaccttcaca	30600
gatagatcat	tttgaacaca	caacgcacat	agactttttg	cggttgccat	agaatatacg	30660
tcgttcttat	cccaattacc	aactagaagt	ctgatcttaa	ctcctctatt	aatggctgct	30720
tctataatgg	agttgtaaat	gtcggggccaa	tagtagctat	taccgtcgac	acgtgtatgt	30780
ggaactatgg	ccaaatgttc	aatatctata	ctagtcttag	ctgacctgag	tttatcaata	30840
actacatcgg	tatctagatc	tctagaatat	cccaatagg	gttcgggaga	atcagtaaa	30900
aacactccac	ctataggatt	cttaatatga	tacgcagtgc	taactggcaa	acaacaagcc	30960
gcagagcata	aattcaacca	tgaatttttt	gcgctattaa	aggcttttaa	agtatcaaat	31020
cttctacgaa	gatctgtggc	cagcggggga	taatcagaat	atacacctaa	cgttttaate	31080
gtatgtatag	atcctccagt	aaatgacgcg	tttctctacat	aacatctttc	atcatctgac	31140
acccaaaaac	aaccgagtag	tagtccaca	ttattttttt	tatctatatt	aacggttata	31200
aaatttatat	ccgggcagtg	actttgtagc	tctccagat	ttcttttccc	tcgttcatct	31260
agcaaaacta	ttattttta	ccctttttca	gatgcctctt	ttagtttatc	aaaaataagc	31320
gctcccctag	tcgtactcag	aggattacaa	caaaaagatg	ctatgtatat	atattttctta	31380
gctagagtga	taatttcggt	aaaacattca	aatggtgtta	aatgatcgga	tctaaaaatcc	31440
atattttctg	gtagtgtttc	taccagccta	catttttgctc	ccgcagggtac	cgatgcaaat	31500
ggccacattt	agttaacata	aaaacttata	catcctgttc	tatcaacgat	tctagaatat	31560
catcggctat	atcgctaaaa	ttttcatcaa	agtcgacatc	acaacctaac	tcagtcaata	31620
tattaagaag	ttcccttagt	tcactctcgt	ctattttctat	atccgtatcc	attgtagatt	31680
gttgacgat	tatcgagttt	aaatcattac	taataactcaa	tccttcagaa	tacaatctgt	31740
gtttcattgt	aaatttatag	gcggtgtatt	taagttggta	gattttcaat	tatgtattaa	31800
tatagcaaca	gtagttcttg	ctcctccttg	attctagcat	cctcttcatt	attttcttct	31860
acgtacataa	acatgtccaa	tacgttagac	aacacaccga	cgatggcggc	cgctacagac	31920
acgaatatga	ctaaaccgat	gaccatttaa	aaaccctct	ctagctttca	cttaaactgt	31980

-26-

atcgatcatt	cttttagcac	atgtataata	taaaaacatt	attctatttc	gaatttaggc	32040
ttccaaaaat	ttttcatccg	taaaccgata	ataatatata	tagacttggt	aatagtcgga	32100
ataaatagat	taatgcttaa	actatcatca	tctccacgat	tagagataca	atattttacat	32160
tctttttgct	gtttcgaaac	tttatcaata	cacgttaata	caaaccagc	aaggagatat	32220
tgaaactgag	gctgttgaaa	atgaaacggg	gaatacaata	attcagataa	tgtaaaatca	32280
tgattccgta	ttctgatgat	attagaactg	ctaattggatg	tcgatgggat	gtatctagga	32340
gtatctatct	taacaaagca	tcgattttgct	aatatacaat	tatccttttg	attaattggt	32400
atttttattca	tattctttaa	aggtttcata	tttatcaatt	cttctacatt	aaaaatttcc	32460
attttttaatt	tatgtagccc	cgcaatactc	ctcattacgt	ttcatttttt	gtctataata	32520
tccattttgt	tcctctcggt	acatagatta	tccaattgag	aagcgcattt	agtagttttg	32580
tacattttta	gtttattgac	gaatcgctga	aaactagtta	tagttaacat	tttattattt	32640
gataccctga	tattaatacc	cctgccgtta	ctattattta	taactgatgt	aatccacgta	32700
acattggaat	taactatcga	tagtaatgca	tcgacgcttc	caaaattgtc	tattataaac	32760
tcaccgataa	tttttttatt	gcatgttttc	atattcatta	ggattatcaa	atctttaatc	32820
ttattacgat	tgtatgcgtt	gatattacaa	gacgtcattc	taaaagacgg	aggatctcca	32880
tcaaagccca	gacaatcacg	tacaaagtac	atggaaatag	gttttggtct	attgcgcatc	32940
atagattttat	atagaacacc	cgtagaataa	ctaatttggt	ttactctata	aaatactaat	33000
gcctctatct	catcgttttg	tataacgtct	ttccaagtgt	caaatcccaa	atttttttca	33060
ttgatagtac	caaattcttc	tatctcttta	actacttgca	tagataggta	attacagtga	33120
tgcctacatg	ccgttttttg	aaactgaata	gatgcgtcta	gaagcgatgc	tacgctagtc	33180
acaatcacca	ctttcatatt	tagaatatat	atatgtaaaa	atatagtaga	atttcatttt	33240
gtttttttct	atgctataaa	tgaattctca	ttttgcatct	gctcatactc	cgttttatat	33300
taataccaaa	gaaggaagat	atctggttct	aaaagccggt	aaagtatgcg	atgttagaac	33360
tgtagaatgc	gaaggaagta	aagcttccgt	cgtactcaaa	gtagataaac	cctcatcgcc	33420
cgcgtgtgag	agaagacctt	cgccccgtc	catagcgag	agaatgaata	accctggaaa	33480
acaagttccg	tttatgagga	cggacatgct	acaaaatatg	ttcgcggtta	atcgcgataa	33540
tgtagcttct	agacttttgt	cctaaaatac	tattatatcc	ttttcgatat	taataaatcc	33600
gtgtcgtcca	ggttttttat	ctctttcagt	atgtgaatag	ataggatatt	tatctctatt	33660
catcatcgaa	tttaagagat	ccgataaaca	ttgtttgat	tctccagatg	tcagcatctg	33720
atacaacaat	atatgtgcac	ataaacctct	ggcacttatt	tcattgtacct	tccccttatc	33780
actaaggaga	atagtatttg	agaaatatgt	atacatgata	ttatcatgaa	ttagatatac	33840
agaatttgta	acactctcga	aatcacacga	tgtgtcggcg	ttaaagatcta	atatatcaact	33900
cgataacaca	ttttcatcta	gatacactag	acatttttta	aagctaaaat	agtctttagt	33960
agtaacagta	actatgcat	tattttcatc	gatgatatac	ttcatcgga	tattattacg	34020
cttaccatca	aagactatac	catgtgtata	tctaactgat	tctagcatgg	ttgccatag	34080
cgcattaaac	ttttcaggat	ctttggatag	atcttccaat	ctatctattt	gagaaaacat	34140
ttttatcatg	ttcaatagtt	gaaacgtcgg	atccactata	tagatattat	ctataaagat	34200
tttaggaact	acgttcatgg	tatcctggcg	aatattaaaa	ctatcaatga	tatgattatc	34260
gttttcatct	tttatcacca	tatagtttct	aagatatggg	attttactta	atataatatt	34320
atttcccggtg	ataaatttta	ttagaaaggg	caaactctata	agaaaagtc	tagaattagt	34380
ctgaagaata	tctatatcgc	cgtatagtat	atttggatta	attagatata	gagaatatga	34440
tcgtaacat	atacaacttt	tattatggcg	tctaagatat	tcttccatca	acttattaac	34500
atttttgact	aggaagata	cattatgacg	tcccattact	tttgccctgt	ctattactgc	34560
gacgttcata	gaatttagca	tatctcttgc	caattcttcc	attgatgtta	cattataaga	34620
aatttttagat	gaaattacat	ttggagcttt	aatagtaaga	actcctaata	tgtccgtgta	34680
tgtggtcact	aatacagatt	gtagtctctat	aatcgtaaat	aatttaccta	tattatatgt	34740
ttgagtctgt	ttagaaaagt	agctaagtat	acgatctttt	atttctgatg	cagatgtatt	34800
aacatcgga	aaaaatcttt	ttttattctt	ttttactaaa	gatacaaaata	tgtctttggt	34860
aaaaacagtt	attttctgaa	tatttctagc	ttgtaatttt	aacatatgat	attcgttcac	34920
actaggtact	ctgcctaaat	aggtttctat	aatctttaat	gtaatatatt	gaaaagtatt	34980
ctgatcagga	ttcctattca	ttttgaggat	ttaaaactct	gattattgtc	taatatggct	35040
tctacgcaaa	ctttttcaca	gagcgataga	gtttttgata	actcggtttt	cttaagaaat	35100
ataaaaactac	tgtctccaga	gctcgctcta	tcttttattt	tatctaattc	gatacaaaact	35160
cctgatactg	gttcagaaaag	taattcatta	attttctagtc	ctttatagaa	gatattttaat	35220
atagataata	caaaatcttc	agtttttgat	atcgatctga	ttgatccgat	aactagatat	35280

-27-

attaataacg	tgtcattag	gcagtttatg	gcagcttgat	aattagatat	agtatattcc	35340
agttcatatt	tattagatac	cgcattgccc	agatttttgat	attctatgaa	ttcctctgaa	35400
aataaatcca	aaataactag	acattctatt	ttttgtggat	tagtgtactc	tcttccctct	35460
atcatgttca	ctactgggtg	ccacgatgat	aaatatctag	agggaatata	atatagtcca	35520
taggatgcca	atctagcaat	gtcgaataac	tgtaatttta	ttcttcgctc	ttcattatga	35580
attgattctt	gaggtataaa	cctaacacaa	attatattat	tagacttttc	gtatgtaatg	35640
tctttcatgt	tataagtttt	taatcctgga	atagaatcta	ttttaatgag	gcttttaaac	35700
gcagagttct	ccaacgagtc	aaagcataat	actctgtgtg	ttttcttata	tacgatgtta	35760
cgattttctt	ctttgaatgg	aataggtttt	tgaattagtt	tataattaca	acataataga	35820
taaggaagtg	tgcaaatagt	acgcggaaaa	aacataatag	ctcccctggt	ttcatccatg	35880
gttttaagta	aatgatcact	ggcttcttta	gtcaatggat	attcgaacat	taaccgtttc	35940
atcatcattg	gacagaatcc	atattttctta	atgtaaagag	tgatcaaate	attgtgttta	36000
ttgtaccatc	ttgttgtaaa	tgtgtattcg	gttatcggat	ctgctccttt	ttctattaaa	36060
gtatcgatgt	caatctcgtc	taagaattca	actatatcga	catatttcat	ttgtatacac	36120
ataaccatta	ctaacgtaga	atgtatagga	agagatgtaa	cggaacagg	gtttgttgat	36180
tcgcaacta	ttctaataca	taattcttct	gttaatacgt	cttgacgta	atctattata	36240
gatgccaaga	tatctatata	attattttgt	aagatgatgt	taactatgtg	atctatataa	36300
gtagtgtaat	aattcatgta	ttttgatata	tgttccaact	ctgtctttgt	gatgtctagt	36360
ttcgtaatat	ctatagcatc	ctcaaaaaat	atattcgcac	atattcccaa	gtcttcagtt	36420
ctatcttcta	aaaaatcttc	aacgtatgga	atataataat	ctattttacc	tcttctgata	36480
tcattaatga	tatagttttt	gacactatct	tctgtcaatt	gattcttatt	cactatatct	36540
aagaaacgga	tagcgtccct	aggacgaact	actgccatta	atatctctat	tatagcttct	36600
ggacataatt	catctattat	accagaatta	atgggaacta	ttccgtatct	atctaacata	36660
gttttaagaa	agtcagaatc	taagacttga	tgttcatata	ttggttcata	catgaaatga	36720
tctctattga	tgatagtgc	tatttcatc	tctgaaaatt	ggtaactcat	tctatatatg	36780
ctttccttgt	tgatgaagga	tagaatatac	tcaattagaat	ttgtaccaac	aaactgttct	36840
cttatgaatc	gtatatcatc	atctgaaata	atcatgtaag	gcatacatct	aacaattaga	36900
gacttgtctc	ctgttatcaa	tatactattc	ttgtgataat	ttatgtgtga	ggcaaatttg	36960
tccacgttct	ttaatTTTTgt	tatagtagat	atcaaattcca	atggagctac	agttcttggc	37020
ttaaacagat	atagttttttc	tggaacaaat	tctacaacat	tattataaag	gactttgggt	37080
aaataagttg	gatgaaatcc	tattttaatt	aatgcgatag	ccttgtcctc	gtgcagatat	37140
ccaaacgctt	ttgtgatagt	atggcattca	ttgtctagaa	acgotctacg	aatatctgtg	37200
acagatatca	tcttttagaga	atatactaga	cgcgttaata	gtactacaat	ttgtattttt	37260
taatctatct	caataaaaaa	attaatatgt	atgattcaat	gtataactaa	actactaact	37320
gttattgata	actagaatca	gaatctaatt	atgacgtacc	caagaagtgt	atctactgcc	37380
aatttagctg	cattatttttt	agcatctcgt	ttagattttc	catctgcctt	atcgaatact	37440
cttccgtcga	tatctacaca	ggcataaaaat	gtaggagagt	tactaggccc	aactgattca	37500
atacgaaaag	accaatctct	cttagttatt	tggcagtact	cattaataac	ggtgacaggg	37560
ttagcatctt	tccaatcaat	aatttttttt	gccggaataa	catcatcaaa	agacttatga	37620
tctctctca	ttgattttttc	gcgggatata	tcatctatta	tgacgtcagc	cataacatca	37680
gcattccggct	tatccgcctc	cgttgtcata	aaccaacgag	gaggaatata	gtcggagctg	37740
tacaccatag	cactacgttg	aagatcgtac	agagctttat	taacttctcg	cttctccata	37800
ttagttgtc	tagttagtgt	tcgagcagta	gctccttcga	ttccaatggg	tttaatagcc	37860
tcacacacaa	tctctgcgtt	agaacgttcg	tcgatataga	tttttagacat	tttttagagag	37920
aactaacaca	accagcaata	aaactgaacc	tacttttatca	ttttttttatt	catcatcctc	37980
tggtggttcg	tcgttccctat	caaattgtagc	tctgattaac	ccgtcatcta	taggtgatgc	38040
tggttctgga	gattctggag	gagatggatt	attatctgga	agaatctctg	ttatttccct	38100
gttttcatgt	atcgattgcg	ttgtaacatt	aagattgcga	aatgctctaa	atttgggagg	38160
cttaaagtgt	tgtttgcaat	ctctacacgc	gtgtctaact	agtggagggt	cgtcagctgc	38220
tctagtttga	atcatcatcg	cgtagtattt	cctagtttta	cagttaggac	acggtgtatt	38280
gtatttctcg	tcgagaacgt	taaaataatc	gttgtaactc	acatccttta	ttttatctat	38340
attgtattct	actcctttct	taatgcattt	tataccgaat	aagagatagc	gaaggaaattc	38400
tttttcggtg	ccgctagtac	ccttaatcat	atcacatagt	gttttatatt	ccaaatttgt	38460
ggcaatagac	ggtttatttc	tatacgatag	tttgtttctg	gaatcctttg	agtattctat	38520
accaatatta	ttctttgatt	cgaatttagt	ttcttcgata	ttagattttg	tattacctat	38580

-28-

attcttggatg	tagtactttg	atgatttttc	catggcccat	tctattaagt	cttccaagtt	38640
ggcatcatcc	acataattgtg	atagtaattc	tcggatatca	gtagcggcta	ccgccattga	38700
tgtttggttca	ttggatgagt	aactactaat	gtatacattt	tccattttata	acactttatgt	38760
attaactttg	ttcattttata	ttttttcatt	attatgttga	tattaacaaa	agtgaatata	38820
tatatatggt	aataattgta	ttgtgggttat	acggctacaa	ttttataatg	agtgaagatc	38880
agtgtccgat	gatcaatgac	gatatgcttta	ctctgaaaag	aaagtatcaa	atcgatagtg	38940
cggagtcaac	aataaaaaatg	gataagaaga	ggataaagtt	tcagaataga	gccaaaatgg	39000
taaaagaaat	aaatcagaca	ataagagcag	cacaaactca	ttacgagaca	ttgaaactag	39060
gatacataaa	attttaagaga	atgattagga	ctactactct	agaagatata	gcaccatcta	39120
ttccaaataa	tcagaaaact	tataaaactat	tctcggacat	ttcagccatc	ggc aaagcat	39180
cacagaatcc	gagtaagatg	gtatatgctc	tgctgcttta	catgtttccc	aatttgtttg	39240
gagatgatca	tagattcatt	cgttatagaa	tgcatccaat	gagtaaaatc	aaacacaaga	39300
tcttctctcc	tttcaaactt	aatcttatta	gaatattagt	ggaagaaaga	ttctataata	39360
atgaatgcag	atctaataaa	tggaaaataa	ttggaacaca	agttgataaa	atgttgatag	39420
ctgaatctga	taaatataca	atagatgcaa	ggataaacct	aaaacccatg	tatagaatca	39480
agggagaaatc	tgaagaagat	accctcttca	tcaaacagat	ggtagaacia	tgtgtgacat	39540
cccaggaatt	ggtggaaaaa	gtgttgaaaga	tactgtttag	agatttggtc	aagagtggag	39600
aatacaaaagc	gtacagatac	gatgatgatg	tagaaaaatgg	atttattgga	ttggatacac	39660
taaaattaaa	cattgttcat	gatatagttg	aaccatgtat	gcctgttcgt	aggccagtgg	39720
ctaagatact	gtgtaaagaa	atggtaaata	aatactttga	gaatccgcta	catattattg	39780
gtaagaatct	tcaagagtg	attgactttg	ttagtgaata	ggcatttcat	ctttctccaa	39840
tactaattca	aattgttaaa	ttaataatgg	atagtataaa	tagtaaaaaat	aattattaga	39900
ataagagtgt	agtatcatag	ataactctct	tctataaaaa	tggattttat	tcgtagaaag	39960
tatcttatat	acacagtaga	aaataatata	gatttttttaa	aggatgatac	attaagtaaa	40020
gtaaaacaatt	ttaccctcaa	tcatgtacta	gctctcaagt	atctagttag	caattttcct	40080
caacacgtta	ttactaagga	tgtattagct	aataccaatt	tttttgtttt	catacatatg	40140
gtacgatgtt	gtaaagtgtg	cgaagcgggt	ttacgacacg	catttgatgc	accacagtgt	40200
tacgttaaag	cattgactaa	gaattattta	tcgttttagta	acgcaataca	atcgatacaag	40260
gaaaccgtgc	ataaactaac	acaagatgaa	aaatttttag	agggttgccga	atacatggac	40320
gaattaggag	aacttatagg	cgtaaattat	gacttagttc	ttaatccatt	atttcacgga	40380
ggggaaccca	tcaaagatat	ggaaatcatt	tttttaaaac	tgtttaagaa	aacagacttc	40440
aaagttgtta	aaaaattaa	tgttataaga	ttacttattt	gggcatacct	aagcaagaaa	40500
gatacaggca	tagagtttgc	ggataatgat	agacaagata	tataactct	atttcaacaa	40560
actggtagaa	tcgtccatag	caatctaaca	gaaacgttta	gagattatat	ctttcccggga	40620
gataagacta	gctattgggt	gtgggttaaac	gaaagtatag	ctaattgatgc	ggatatcggt	40680
cttaatagac	ccgccattac	catgtatgat	aaaattctta	gttatatata	ctctgagata	40740
aaacaaggac	gcgttaataa	aaacatgctt	aagttagttt	atatctttga	gcctgaaaaa	40800
gatatcagag	aacttctgct	agaaatcata	tatgatattc	ctggagatat	cctatctatt	40860
attgatgcaa	aaaacgacga	ttggaaaaaa	tatttttatta	gtttttataa	agctaatttt	40920
attaacggta	atacatttat	tagtgataga	acgtttaacg	aggacttatt	cagagttggt	40980
gttcaaatag	atcccgaata	tttcgataat	gaacgaatta	tgtctttatt	ctctacgagt	41040
gctgcggaca	ttaaacgatt	tgatgagtta	gatattaata	acagttatat	atctaataata	41100
atztatgagg	tgaacgatat	cacattagat	acaatggatg	atatgaagaa	gtgtcaaata	41160
tttaacgagg	atacgtcgta	ttatgttaag	gaatacaata	catacctgtt	tttgacagag	41220
tcggatccca	tggtcataga	gaacggaata	ctaaagaaac	tgatcatctat	aaaatccaag	41280
agtagacggc	tgaacttggt	tagcaaaaaac	atttttaaaat	attattttaga	cggacaattg	41340
gctcgtctag	gtcttgtggt	agatgattat	aaaggagact	tgtagtttaa	aatgataaac	41400
catcttaagt	ctgtggagga	tgtatccgca	ttcgttcgat	tttctacaga	taaaaaccct	41460
agtattcttc	catcgctaatt	caaaactatt	ttagctagtt	ataatatattc	catcatcgtc	41520
ttattttcaaa	ggttttttgag	agataatcta	tatcatgtag	aagaattctt	ggataaaagc	41580
atccatctaa	ccaagacgga	taagaaatat	atacttcaat	tgataagaca	cggtagatca	41640
tagaacagac	caaataatatt	attaataatt	tgtatatata	tagatataat	tatcacacat	41700
ttttgataaa	tgggaactgc	tgcaacaatt	cagactocca	ccaaattaat	gaataaagaa	41760
aatgcagaaa	tgatttttggg	aaaaattggt	gatcatatag	ttatgtatat	tagtgacgaa	41820
tcaagtgatt	cagaaaaataa	tcttgaatat	attgatttttc	gtaacagata	cgaagactat	41880

-29-

agatctctca	ttataaaaag	tgatcacgag	tttgtaaagc	tatgtaaaaa	tcatgcggag	41940
aaaagttctc	cagaaacgca	acaaatgatt	atcaaacaca	tatacgaaca	atatcttatt	42000
ccagtatctg	aagtactatt	aaaacctata	atgtccatgg	gtgacataat	tacatataac	42060
ggatgtaaag	acaatgaatg	gatgctagaa	caactctcta	ccctaaactt	taacaatctc	42120
cgcacatgga	actcatgtag	cataggcaat	gtaacgcgtc	tgtttttatac	atTTTTtagt	42180
tatctgatga	aagataaact	aaatatataa	gtataatccc	attctaatac	tttaacctga	42240
tgtatttagca	tcttattaga	atattaacct	aactaaaaga	cataacataa	aaactcatta	42300
catagttgat	aaaaagcggg	aggatataaa	tattatggct	gccaccgttc	cgcgttttga	42360
cgacgtgtac	aaaaatgcac	aaagaagaat	tctagatcaa	gaaacatttt	ttagtagagg	42420
tctaagtaga	ccgttaatga	aaaacacata	tctatttgat	aattacgcgt	atggatggat	42480
accagaaact	gcaatttgga	gtagtagata	cgcaaaactta	gatgcaagtg	actattatcc	42540
catttcggtg	ggattactta	aaaagttcga	gtttctcatg	tctctatata	aaggctctat	42600
tccagtatac	gaagaaaaag	taaaacttga	attcattgct	aatggatctt	tctccggtag	42660
atacgtatca	tatcttagaa	agttttctgc	tcttccaaca	aacgagttta	ttagtTTTT	42720
gttactgact	tccattccaa	tctataatat	cttgttctgg	tttaaaaaata	ctcagtttga	42780
tattactaaa	cacacattat	tcagatacgt	ctatacagat	aatgccaaac	acctggcggt	42840
ggctaggtat	atgtatcaaa	caggagacta	taagcctttg	tttagtcgtc	tcaaagagaa	42900
ttatatatTT	accggtcccg	ttccaatatg	tatcaaagat	atagatcacc	ctaactctag	42960
tagagcaaga	agtcocatccg	attatgagac	attagctaata	attagtacta	tattgtactt	43020
taccaagtat	gatccggtat	taatgtTTTT	attgttttac	gtacctgggt	attcaattac	43080
tacaaaaatt	actccagccg	tagaatatct	aatggataaa	ctgaatctaa	caaagagcga	43140
cgtacaactg	ttgtaaatta	ttttatgctt	cgtaaaaatgt	aggTTTTgaa	ccaaacattc	43200
tttcaaagaa	tgagatgcac	aaaactttat	tatccaatag	attgactatt	toggacgtca	43260
atcgttttaa	gtaaaacttcg	taaaatattc	tttgatcact	gccgagttta	aaacttctat	43320
cgataattgt	ttcatatggt	ttaatattta	caagtttttt	ggtccatggt	ccattaggac	43380
aaatatatgc	aaaataatat	cgttctccaa	gttctatagt	ctctggatta	tttttattat	43440
attcagtaac	caaatacata	ttagggttat	ctgcggattt	ataatttgag	tgatgcattc	43500
gactcaacat	aaataattct	agaggagacg	atctactatc	aaattcggat	cgtaaatctg	43560
tttctaaaga	acggagaata	tctatacata	cctgattaga	attcatccgt	ccttcagaca	43620
acatctcaga	cagtctgggt	ttgtacatct	taatcatatt	cttatgaaac	ttggaaacat	43680
ctcttctagt	ttcactagta	cctttatttaa	ttctctcagg	tacagatttt	gaattcgacg	43740
atgctgagta	tttcactggt	gtatattttc	tcttcgattg	cataatcaga	ttcttatata	43800
ccgctcaaaa	ctctattttta	aaattatttaa	acaatactct	attattaatc	agtcgttcta	43860
actctttcgc	tattttctata	gacttatcta	catcttgact	gtctatctct	gtaaacacgg	43920
agtcgggtatc	tccatacacg	ctacgaaaac	gaaatctgta	atctataggc	aacgatgttt	43980
tcacaatcgg	attaatatct	ctatcgtcca	tataaaatgg	attactttaat	ggattggcaa	44040
accgtaacat	accggttagat	aactctgctc	catttagtac	cgattctaga	tacaagatca	44100
ttctacgtcc	tatggatgtg	caactcttag	ccgaagcgta	tgagtataga	gcactatttc	44160
taaatcccat	cagaccatat	actgagttgg	ctactatctt	gtacgtatat	tgcatggaat	44220
catagatggc	cttttcagtt	gaactggtag	cctgtttttg	catcttttta	tatctggctc	44280
tctctgccaa	aaatgttctt	aatagcttag	gaatggttcc	ttctatcgat	ctatcgaaaa	44340
ttgctattttc	agagatgagg	ttcggtagtc	taggttcaca	atgaaccgta	atatatctag	44400
gaggtggata	tttctgaagc	aatagctgat	tattttatttc	ttcttccaat	ctattggtac	44460
taacaacgac	accgactaat	gtttccggag	atagattttcc	aaagatacac	acattaggat	44520
acagactggt	ataatcaaag	attaatacat	tattactaaa	cattttttgt	tttggagcaa	44580
ataccttacc	gccttcataa	ggaaactttt	gttttgtttc	tgatctaact	aagatagttt	44640
tagtttccaa	caatagcttt	aacagtggac	ccttgatgac	tgtactcgct	ctatatctga	44700
ataccatgga	ttgaggaagc	acatatgttg	acgcaccgcg	gtctgttttt	gtttctactc	44760
cataatactc	ccacaaatag	tgacacaaac	aagcatcatg	aatacagtat	ctagccatat	44820
ctaaagctat	gttttagatta	taatccttat	acatctgagc	taaatcaacg	tcatcctttc	44880
cgaaagataa	tttatatgta	tcattaggta	aagtaggaca	taatagtacg	acttttaaact	44940
cattttccca	aatatcttta	cgaattactt	tacatataat	atcctcatca	acagtcacat	45000
aattacctgt	ggttaaaacc	tttgcaaatg	cagcggcttt	gccttttcgog	tctgtagtat	45060
cgtcacccgat	gaacgtcatt	tctctaactc	ctctatttaa	tactttaccc	atgcaactga	45120
acgcgttctt	ggatatagaa	tccaatttgt	acgaatccaa	tttttcaaat	ttttgaatga	45180



-30-

atgaatatag	atcgaaaaat	atagttccat	tattgttatt	aacgtgaaac	gtagtattgg	45240
ccatgccgcc	tactccctta	tgactagact	gatttctctc	ataaatacag	agatgtacag	45300
cttccttttt	gtccggagat	ctaaagataa	ttttctctcc	tgtaataaac	tctagacgat	45360
tagtaatata	tctcagatca	aagttatgtc	cgtaaagggt	aacgacgtag	tcgaacgtta	45420
gttccaacaa	ttgttttagct	attcgtaaca	aaactatttc	agaacataga	actagtctctc	45480
gttcgtaatc	catttccatt	agtgactgta	tcctcaaaca	tcctctatcg	acggcttctt	45540
gtatttctctg	ttccgttaac	atctcttcat	taatgagcgt	aaacaataat	cgttttaccac	45600
ttaaatcgat	ataacagtaa	cttgtatgcy	agattggggt	aataaataca	gaaggaaact	45660
tcttatcgaa	gtgacactct	atatctagaa	ataagtacga	tcttgggata	tcgaatctag	45720
gtattttttt	agcgaaacag	ttacgtggat	cgtcacatg	ataacatcca	ttgttaatct	45780
ttgtcaaata	ttgctcgctc	aacgagtaac	atccgtctgg	agatatcccg	ttagaaatat	45840
aaaaccaact	aattattgaga	aattcatcca	tggtggcatt	ttgtatgctg	cgtttctttg	45900
gctcttctat	caaccacata	tctgcgacgg	agcattttct	atctttaata	tctagattat	45960
aacttattgt	ctcgtcaatg	tctatagttc	tcatctttcc	caacggcctc	gcattaaatg	46020
gaggaggaga	caatgactga	tatatttctg	ccgtcactac	gtaataaaaag	taatgaggaa	46080
atcgataaaa	tacggctctca	ccatttctgac	atctggattt	cagatataaaa	aatctgtttt	46140
caccgtgact	ttcaaaccaa	ttaatgcacc	gaacatccat	ttatagaatt	tagaaatata	46200
ttttcattta	aatgaatccc	aaacattggg	gaagagccgt	atggaccatt	attttttatag	46260
tactttcgca	agcgggttta	gacggcaaca	tagaagcgtg	taaacgaaaa	ctatatacta	46320
tagttagcac	tcttccatgt	cctgcatgta	gacggcacgc	gactatcgct	atagaggaca	46380
ataatgtcat	gtctagcgat	gatctgaatt	atattttatta	ttttttcatc	agattattta	46440
acaatttggc	atctgatccc	aaatacgcga	tcgatgtgac	aaaggttaac	cctttataaaa	46500
cttaaccctat	tataaaaactt	atgattagtc	acaactgaaa	taaccgcgtg	attattttttt	46560
ggtataattc	tacacggcat	ggtttctgtg	actatgaatt	caacccccgt	tacatttagtg	46620
aaatctttaa	caaacagcaa	gggttcgtca	aagacataaa	actcattggt	tacaatcgaa	46680
atagaccccc	tatcacactt	aaaataaaaa	atatccttat	cctttaccac	caaataaaaat	46740
tctgattggg	caatgtgaat	gtattcactt	aacagttcca	caaattttatt	tattaactcc	46800
gaggcacata	catcgctcgg	attttttatg	gcaaacttta	ctcttccagc	atccgtttct	46860
aaaaaaatat	taacgagttc	cattttatctc	atccaatatt	attgaaatga	cgttgatgga	46920
cagatgatac	aaataagaag	gtacgggtacc	tttgtccacc	atctcctcca	attcatgctc	46980
tattttgtca	ttaaacttta	tgtatgaaaa	cagtacgcca	catgcttcca	tgacagtgtg	47040
taacactttg	gatacaaaat	gtttgacatt	agtataattg	ttcaagactg	tcaatctata	47100
atagatagta	gctataatat	attctatgat	ggtattgaag	aagatgacaa	ccttggcata	47160
ttgatcattt	aacacagaca	tggtatcaac	agatagcttg	aatgaaagag	aatcagtaat	47220
tggaataagc	gtcttctoga	tagagtgtcc	gtataccaac	atgtctgata	ttttgatgta	47280
ttccattaaa	ttatttagtt	ttttcttttt	attctcgttt	aacagcattt	ctgtcaacgg	47340
accccaacat	cgttgacoga	ttaaagttttg	attgattttt	ccgtgtaagg	cgatatctagt	47400
cagatcgat	agcctatcca	ataatccatc	atctgtgcgt	agatcacatc	gtacactttt	47460
taattctcta	tagaagagcg	acagacatct	ggagcaatta	cagacagcaa	tttcttttatt	47520
ctctacagat	gtaagatact	tgaagacatt	cctatgatga	tgcagaattt	tggataaacac	47580
ggtattgatg	gtatctgtta	ccataattcc	tttgatggct	gatagtgtca	gagcacaaga	47640
tttccaatct	ttgacaattt	ttagcaccat	tatctttggt	ttgatatact	tatcagacag	47700
catggtgcgt	ctgacaacac	agggattaag	acggaaagat	gaaatgattc	tctcaacatc	47760
ttcaatagat	accttgctat	tttttctggc	attatctata	tgtgcgagaa	tatcctctag	47820
agaatcagta	tcctttttga	tgatagtggg	tctcaatgac	atgggacggt	taaaccttct	47880
tattctatca	ccagattgca	tggtgatttg	tcttctttct	tttatcataa	tgtaatctct	47940
aaattcatcg	gcaaattgtc	tatatctaaa	atcataatat	gagatgttta	cctctacaaa	48000
tatctgttcg	tccaatgtta	gagtattttac	atcagttttg	tattccaaat	taaacatggc	48060
aacggattta	atttttatatt	cctctattaa	gtcctcgctg	ataataacag	aatgtagata	48120
atcatttaat	ccatcgtaaca	tggttggaag	atgcttggtg	acaaaatctt	taattgtctt	48180
gatgaagggtg	ggactatatc	taacatcttg	attaataaaa	tttataacat	tgtccatagg	48240
atactttgta	actagtttta	tacacatctc	ttcatcggtg	agtttagaca	gaatatctgtg	48300
aacaggtggg	atatttatatt	catcagatat	acgaagaaca	atgtccaaat	ctatatgtgt	48360
taatatatta	tatagatgta	gcgtagctcc	tacaggaata	tctttaacta	agtcaatgat	48420
ttcatcaacc	gttagatcta	ttttaaaagt	aatcatatag	gcattgattt	ttaaaaggta	48480

-31-

tgtagccttg	actacattct	cattaattaa	ccattccaag	tcactgtgtg	taagaagatt	48540
atattctatc	ataagcttga	ctacatttgg	tcccgatacc	attaaagaat	tcttatgata	48600
taaggaaaca	gcttttaggt	actcatctac	tctacaagaa	ttttggagag	ccttaacgat	48660
atcagtgacg	tttattat	caggaggaaa	aaacctaaca	ttgagaatat	cggaattaat	48720
agcttccaga	tacagtga	ttggcaatag	tccgtgta	ccataatcca	gtaacacgag	48780
ctgggtgctg	ctagacacct	tttcaatgtt	taattttttt	gaaataagct	ttgataaagc	48840
cttcctcgca	aattccggat	acatgaacat	gtcggcgaca	tgattaagta	ttgttttttc	48900
attattttct	caatacccca	atagatgata	gaatatcacc	caatgcgtcc	atgttgtcta	48960
tttccaacag	gtcgctatat	ccaccaatag	aagtttttcc	aaaaaagatt	ctaggaacag	49020
ttctaccacc	agtaatttgt	tcaaaatagt	cacgcaattc	attttcgggt	ttaaattctt	49080
taatatcgac	aatttcatac	gtcctctttt	tgaaactaaa	cttattttaga	atatccagtg	49140
cattttctaca	aaaaggacat	gtatacttga	caaaaattgt	cactttgtta	ttggccaacc	49200
tttgttgtac	aaattcctcg	gccattttta	tattttaagt	atataaaact	atctcgactt	49260
atttaactct	ttagtgcaga	tatatggacg	cagatagcta	tatgatagcc	aactacagaa	49320
ggcaaacgct	ataaaaaaca	taattacgac	gagcatat	ataaatat	ttattcagca	49380
ttacttgata	tagtaatat	aggcacagtc	aaacattcaa	ccactctcga	tacattaact	49440
ctctcat	ctttaacaaa	ttctgcaata	tcttcgtaaa	aagattcctg	aaacttttta	49500
gaatatctat	cgactctaga	tgaaatagcg	tctcgtaaca	tactatgttt	tgtatacata	49560
aaggcgccca	ttttaacagt	ttctagtgc	aaaatgctag	cgatcctagg	atccttttaga	49620
atcacataga	ttgacgattc	gtctctctta	gtaactctag	taaaataatc	atacaatcta	49680
gtacgcgaaa	taatattatc	cttgacttga	ggagatctaa	acaatctagt	tttgagaaca	49740
tcgataagtt	catcgggaat	gacatacata	ctatcttta	tagaactctt	ttcatccagt	49800
tgaatggatt	cgctcttaac	caactgatta	atgagatctt	ctatcttatc	atcttccaga	49860
tgatatgtat	gtccattaaa	gttaaattgt	gtagcgcttc	tttttagtct	agcagccaat	49920
actttaacat	cactaatatc	gatatacaaa	ggagatgatt	tatctatgg	attaagaatt	49980
cgtttttcga	catccgtcaa	aaaccaattcc	tttttgctg	tatcatccag	ttttccatcc	50040
tttgtaaaga	aattattttt	tactagacta	ttaataagac	tgataaggat	tcttccataa	50100
ttgcacaatc	caaacttttt	cacaaaacta	gacttttaca	gatctacagg	aatgcgtact	50160
tcagggtttt	tagcttgtga	ttttttcttt	tgccggacatt	ttcttgtgac	caactcatct	50220
accatttcat	tgatttttagc	agtgaataaa	gctttcaatg	cacgggcact	gatactattg	50280
aaaacgagtt	gatcttcaaa	ttccgccatt	taagttcacc	aaacaacttt	taaatacaaa	50340
tatatcaata	gtagtagaat	aagaactata	aaaaaaataa	taattaacca	ataccaacc	50400
caacaaccgg	tattattagt	tgatgtgact	gttttctcat	cacttagaac	agatttaaca	50460
attttctataa	agtctgtcaa	atcatcttcc	ggagacccca	taaatacacc	aaatatagcg	50520
gogtacaact	tatccattta	tacattgaat	attggctttt	ctttatcgct	atcttcatca	50580
tattcatcat	caatatcaac	aagtcccaga	tacgagcca	gatcttcttc	tacattttca	50640
gtcattgata	cacgttcact	atctccagag	agtcggataa	cgttagccac	cacttctcta	50700
tcaatgatta	gtttcttgag	cgcgaaagta	atttttgttt	ccgttccgga	tctatagaag	50760
acgatagggt	tgataattgc	cttggccaat	tgtctttctc	ttttactgag	tgattctagt	50820
tcaccttcta	tagatctgag	aatggatgat	tctccagtcg	aaacatat	taccatggat	50880
ccgttttaatt	tgttgatgaa	gatggattca	tccttaaatg	ttttctctgt	aatagtttcc	50940
accgaaagac	tatgcaaaga	atttggaatg	cgttccttgt	gcttaatgtt	tccatagacg	51000
gcttctagaa	gttgatacaa	cataggacta	gccgcggtaa	cttttat	tagaaagtat	51060
ccatcgcttc	tatcttgttt	agatttat	ttataaagtt	tagtctctcc	ttccaacata	51120
ataaaagtgg	aagtcatttt	actagataaa	ctatcagtaa	gttttataga	gatagacgaa	51180
caattagcgt	attgagaagc	atttagtgt	acgtattcga	tacattttgc	attagattta	51240
ctaatacgatt	ttgcatactc	tataacaccc	gcacaagtct	gtagagaatc	gctagatgca	51300
gtagggtctg	gtgaagt	aactctcttc	ttgattacct	tactcatgat	taaacctaaa	51360
taattgtact	ttgtaatata	atgatata	ttttcacttt	atctcat	agaataaaaa	51420
tgtttttgtt	taaccactgc	atgatgtaca	gatttcggaa	tcgcaaacca	ccagtggttt	51480
tattttatcc	ttgtccaatg	tgaattgaat	gggagcggat	gcggttttcg	tacgtagata	51540
gtacattccc	gtttttagac	cgagactcca	tccgtaaaaa	tgcatactcg	ttagtttggg	51600
ataactcgga	tctgctatat	ggatattcat	gagttgactt	tgatcgatga	aggctccct	51660
gtctgcagcc	atttttatga	tcgtcttttg	tggaatttcc	caaatagttt	tataaactcg	51720
cttaatatct	tctggaaggt	ttgtattctg	aatggatcca	ccatctgcca	taatcctatt	51780



-32-

cttgatctca	tcattccata	atcttctctc	ggttaaaact	ctaaggagat	gcggattaac	51840
tacttgaaat	tctccagaca	atactctccg	agtgtaaata	ttactgggat	acggttccac	51900
cgactcatta	tttcccaaaa	tttgagcagt	tgatgcagtc	ggcataagggtg	ccaccaataa	51960
actattttota	agaccgtatg	ttctgatttt	atctttttaga	ggttcccaat	tccaaagatc	52020
cgacgggtaca	acattccaaa	gatcatattg	tagaataaccg	ttactggcgt	acgatcctac	52080
atatgtatcg	tatggtcctt	ccttctcagc	tagttcacaa	ctcgcctcta	atgcaccgta	52140
ataaatgggt	tcgaagatct	tcttatttag	atcttgtgct	tccagggtat	caaatggata	52200
atttaagaga	ataaacgcgt	ccgctaatcc	ttgaacacca	ataccgatag	gtctatgtct	52260
cttatttagag	atcttcagctt	ctggaatagg	ataataatta	atatctataa	ttttatttag	52320
atctctgaca	attactttga	ccacatcctt	cagtttgaga	aaatcaaata	gcccattctat	52380
tacaaacatg	ttcaaggcaa	cagatgccag	attacaaaacg	gctacctcat	tagcatccgc	52440
atattgtatt	atctcagtc	aaagattact	acacttgata	gttcctaaat	tttgttgatt	52500
actctttttg	ttacacgcat	ccttataaag	aatgaatgga	gtaccagttt	caatctgaga	52560
ttctataatc	gctttccaga	cgactcgagc	ccttattata	gatttgtatc	tcctttctct	52620
ttcgtatagt	gtatacaatc	gttcgaactc	gtctccccaa	acattgtcca	atccaggaca	52680
ttcatccgga	cacatcaacg	accactctcc	gtcatccttc	actcgtttca	taaagagatc	52740
aggaatccaa	agagctataa	atagatctct	ggttctatgt	tcctcgtttc	ctgtattctt	52800
tttaagatcg	aggaacgcca	taatatcaga	atgccacggg	tccaagtata	tggccataac	52860
tccaggccgt	ttgtttccct	cctgatctat	ggtatcgcg	gtgttattat	aaactctcaa	52920
cattggaata	ataccgtttg	atataccatt	ggtaaccggag	atatagcttc	cactggcacg	52980
aatattacta	attgatagac	ctattccccc	tgccatttta	gagattaatg	cgcacgtttt	53040
taacgtgtca	tagataccct	ctatgctatc	atcgatcatg	ttaagtagaa	aacagctaga	53100
catttggtga	cgactagttc	ccgcattaaa	taaggtagga	gaagcgtgcg	taaaccattt	53160
ttcagaaagt	agattgtacg	tctcaatagc	tgagtctata	tcccattgat	gaattcctac	53220
tgcgacacgc	attaacatgt	gctgaggtct	ttcaacgatc	ttgttggtta	ttttcaacaa	53280
gtaggatttt	tccaaagttt	taaaacccaa	atagttgtat	gaaaagtctc	gttcgtaaat	53340
aataaccgag	ttgagtttat	ccttataatt	gttaactata	tccatgggtga	tacttgaat	53400
aatcggagaa	tgtttcccat	ttttaggatt	aacatagtgt	aataaatcct	ccatcacttc	53460
actaaatagt	ttttttgttt	ccttggtgtag	atgtgatacg	gctattctgg	cggctagaat	53520
ggcataatcc	ggatggtgtg	tagtacaagt	ggctgctatt	tcggctgcca	gagtgtccaa	53580
ttctaccgtt	gttactccat	tatatattcc	ttgaataacc	ttcatagcta	ttttaatagg	53640
atctatatga	tccgtgttta	agccataaca	taattttcta	atacgagacg	tgattttatc	53700
aaacatgaca	ttttccttgt	atccatttcc	tttaatgaca	aacattttttg	ttgggtgta	53760
aaaaaaatta	tttaactttt	cattaatagg	gatttgacgt	atgtagcgta	caaatgatc	53820
gttcctggta	tatagataaa	gagtcctata	tatttgaaaa	tcgttacggc	tcgattaaac	53880
tttaatgatt	gcatagtgaa	tatatcatta	ggattttaa	ccttgactat	catggcggcg	53940
ccagaaatta	ccatcaaaag	cattaataca	gttatgccga	tcgcagttaa	aacgggtata	54000
gcataccacca	tttatatcta	aaaattagat	caaagaatat	gtgacaaagt	cctagtgtga	54060
tactgagaat	tgacgaaaca	atgtttctta	catatttttt	tcttattagt	aactgactta	54120
atagtaggaa	ctggaaagct	agacttgatt	attctataag	tatagatacc	cttcagata	54180
atgttctctt	tgataaaagt	tccagaaaat	gtagaatttt	ttaaaaagtt	atcttttgc	54240
attaccaaga	ttgtgttttag	acgcttatta	ttaatatgag	tgatgaaatc	cacaccgcct	54300
ctagatatcg	cctttattttc	cacattagat	ggtaaatcca	atagtgaac	tatcttttta	54360
ggaatgtatg	gactcgcgtt	tagaggagtg	aacgtcttgg	gcgtcggaaa	ggatgattcg	54420
tcaaacgaat	aaacaatttc	acaaatggat	gttaatgtat	tagtaggaaa	ttttttgacg	54480
ctagtggaa	tgaagattct	aatggatgat	gttctaccta	tttcatccga	taacatgtta	54540
atctccgaca	ccaacggttt	taatatattcg	atgatatacg	gtagtctctc	tttcggactt	54600
atatagctta	ttccacaata	cgagtcatta	tatactccaa	aaaacaaaat	aactagtata	54660
aaatctgtat	cgaatgggaa	aaacgaaatt	atcgacatag	gtatagaatc	cggaacattg	54720
aacgtattaa	tacttaattc	tttttctgtg	gtaagtaccg	ataggttatt	gacattgtat	54780
ggtttttaaat	attctataac	ttgagacttg	atagatatta	gtgatgaatt	gaaaattatt	54840
tttatcacca	cgtgtgtttc	aggatcatcg	tgcagcccg	tcaaccaacc	gaatggagta	54900
aaataaatat	cattaatatata	tgcctatagat	atagtatttt	ttattaatcc	tttgattatc	54960
atcttctcgt	aggcgaatga	ttocatgatc	aagagtgtat	tgagaacatc	ctccggagta	55020
ttaatgggct	tagtaaacag	tccatcggtg	caataataaa	agttatccaa	gttaaaggat	55080

-33-

attatgcatt	cgtttaaaga	tatcacctca	tctgacggag	acaatttttt	ggtaggtttt	55140
agagactttg	aagctacttg	tttaacaaag	ttattcatcg	tcgtctacta	ttctatttta	55200
ttttgtagtt	aatttatcac	atatcacatt	aattgacttt	ttggtccatt	tttccatacg	55260
tttatattct	tttaatcctg	cgttatccgt	ttccgttata	tccagggata	gatccttgca	55320
gttaaataga	atgctcttaa	ataatgtcat	tttcttatcc	gctaaaaatt	taaagaatgt	55380
ataaaccttt	ttcagagatt	tgaaactcct	aggtgggtgc	ctagtacaca	atatcataaa	55440
caaactaata	aacattccac	attcagattc	caacagctga	tttaactcca	cattaataca	55500
gcctattttc	gctccaaatg	tacattcgaa	aaatctgaat	aaaacatcga	tgtcacaatt	55560
tgtattatcc	aatacagaat	gtttgtgatt	cggtttaaaa	ccatcggaga	aggaatagaa	55620
ataaaaaatta	ttatagtggg	ggaattcagt	tggaatattg	cctccggagt	cataaaagga	55680
tactaaacat	tgttttttat	cataaattac	acatttccaa	tgagacaaat	aacaaaatcc	55740
aaacattaca	aatctagagg	tagaactttt	aattttgtct	ttaagtatat	acgataagat	55800
atgtttatcc	ataaacgcgt	caaatttttt	atgaatcgct	aaggagttta	agaatctcat	55860
gtcaaattgt	cctatataat	ccacttcgga	tccataagca	aactgagaga	ctaagttcct	55920
aatacttcga	ttgctcatcc	aggctcctct	ctcaggctct	attttcatct	tgacgacctt	55980
tggattttca	ccagtatgta	ttcctttacg	tgataaatca	tcgattttca	aatccatttg	56040
tgagaagtct	atcgcccttag	atactttttc	ccgtagtcca	ggtttaaaaa	aatacgctaa	56100
cggtatacta	gtaggttaact	caaagacata	atatatagaa	tggtaacgcg	tctttaactc	56160
gtcggttaac	tctttctttt	gatcgagttc	gtcgctacta	ttgggtctgc	tcagggtccc	56220
cgactctact	agttccaaca	tcataccgat	aggaatacaa	gacactttgc	cagcggttgt	56280
agatttatca	tattttctcca	ctacatatcc	gttacaattt	gttaaaaaat	tagatacatc	56340
tatatgtcta	cataatccag	ctagtgaata	tatatgacat	aataaattgg	taaatcctag	56400
ttctgggtatt	ttactaatta	ctaaatctgt	atatctttcc	atttatcatg	gaaaagaatt	56460
taccagatat	cttctttttt	ccaaactgcg	ttaatgtatt	ctcttacaaa	tattcacaaag	56520
atgaattcag	taatatgagt	aaaacggaac	gtgatagttt	ctcattggcc	gtgtttccag	56580
ttataaaaca	tagatggcat	aacgcacacg	ttgtaaaaca	taaaggaata	tacaaagtta	56640
gtacagaagc	acgtggaaaa	aaagtatctc	ctccatcact	aggaaaaccc	gcacacataa	56700
acctaaccgc	gaagcaatat	atatacagtg	aacacacaat	aagctttgaa	tgttatagtt	56760
ttctaaaatg	tataacaaat	acagaaatca	attcgttcga	tgagtatata	ttaagaggac	56820
tattagaagc	tggtaatagt	ttacagatat	tttccaattc	cgtaggtaaa	cgaacagata	56880
ctataggtgt	actaggggat	aagtatccat	ttagcaaaat	tccattggcc	tcattaactc	56940
ctaaagcaca	acgagagata	ttttcagcgt	ggatttctca	tagacctgta	gttttaactg	57000
gaggaactgg	agtgggtaag	acgtcacagg	tacccaagtt	attgcttttg	tttaattatt	57060
tatttggtgg	attctctact	ctagataaaa	tcactgactt	tcacgaaaga	ccagtcattc	57120
tatctcttcc	taggatagct	ttagttagat	tgcatagcaa	taccatttta	aatcatttgg	57180
gatttaagggt	actagatgga	tctcctattt	ctttacggta	cggatctata	ccggaagaat	57240
taataaaaca	acaaccaaaa	aaatatggaa	ttgtattttc	taccataaag	ttatctctaa	57300
caaaactatt	tagttatggc	actcttatta	tagacgaagt	tcatgagcat	gatcaaatag	57360
gagatattat	tatagcagta	gcgagaaagc	atcatacgaa	aatagattct	atgtttttta	57420
tgactgccac	gttagaggat	gacaggggaa	ggctaaaagt	atttttacct	aatcccgcac	57480
ttatacatat	tcctggagat	acactgttta	aaattagcga	ggtattttat	cataataaga	57540
taaatccatc	ttccagaatg	gcatacatag	aagaagaaaa	gagaaattta	gttactgcta	57600
tacagatgta	tactcctcct	gatggatcat	ccggtatagt	ctttgtggca	tcggttgcac	57660
agtgtcacga	atataaatca	tatttagaaa	aaagattacc	gtatgatatg	tatattatcc	57720
atggtaagggt	cttagatata	gacgaaatat	tagaaaaagt	gtattcatca	cctaattgtat	57780
cgataattat	ttctactcct	tattttggaat	ccagcgttac	tatacgcaat	gttacacaca	57840
tttatgatat	gggtagagtt	tttgtccccg	ctccttttgg	aggatcgcaa	caattttatt	57900
ctaaatctat	gagagatcaa	cgaaaaggaa	gagtaggaag	agttaatcct	ggtacatacg	57960
tctattttcta	tgatctgtct	tatatgaagt	ctatacagcg	aatagattca	gaattttctac	58020
ataattatat	attgtacgct	aataagttta	atctaacact	ccccgaagat	ttgtttataa	58080
tccatacaaa	tttggaatatt	ctatggcgta	caaaggaata	tatagactcg	ttcgatatta	58140
gtacagaaac	atggaataaa	ttattatcca	attattatat	gaagatgata	gagtatgcta	58200
aactttatgt	actaagtcct	attctcgctg	aggagtggga	taactttgag	aggacggggag	58260
aattaactag	tattgtacga	gaagccattt	tatctctaaa	tttacaattt	aagattttta	58320
attttaaaca	taaagatgat	gatacgtata	tacacttttg	taaaatatta	ttcgggtgtct	58380

-34-

ataacggaac	aaacgctact	atatattatc	atagacctct	aacgggatat	atgaatatga	58440
tttcagatac	tatatattgtt	cctgtagata	ataactaaaa	atcaaactct	aatgaccaca	58500
tcttttttta	gagatgaaaa	attttccaca	tctccttttg	tagacacgac	taaacatttt	58560
gcagaaaaaa	gtttattagt	gtttagataa	tcgtatactt	catcagtgtg	gatagtaa	58620
gtgaacagat	aaaaggtatt	cctgtctcaat	agattggtaa	attccataga	atatattaat	58680
cctttcttct	tgagatccca	catcattttca	accagagacg	ttttatccaa	tgattttacct	58740
cgtactatac	cacatacaaa	actagattttt	gcagtgcgct	cgtacctggg	attcctacca	58800
aacaaaattt	tactttttagt	tcttttagaa	aattctaagg	tagaatctct	atttgccaat	58860
atgtcatcta	tggaattacc	actagcaaaa	aatgatagaa	atatataattg	atacatcgca	58920
gctgggtttg	atctactata	ccttaaaaaac	gaatcagatt	ccataattgc	ctgtatatca	58980
tcagctgaaa	aactatgttt	tacacgtatt	ccttcggcat	ttcttttttaa	tgatataatct	59040
tgtttagaca	atgataaagt	tatcatgtcc	atgagagacg	cgtctccgta	tcgtataaat	59100
atttcattag	atgttagacg	ccttcattagg	gggtatacttc	tataagggttt	cttaatcagt	59160
ccatcattgg	ttgcgtcaag	aactactatc	ggatgttggt	gggtatctct	agtgttacac	59220
atggccttac	taaagtttgg	gtaaataact	atgatatactc	tattaattat	agatgcata	59280
atttcattcg	tcaaggatat	tagtatcgac	ttgctatcgt	cattaatacg	tgtaatgtaa	59340
tcataataat	catgcgatag	ccaaggaaaa	tttaaataga	tgttcatcat	ataatcgctg	59400
ctataattca	tattaatacg	ttgacattga	ctaatttgta	atatagcctc	gccacgaaga	59460
aagctctcgt	attcagtttc	atcgataaag	gataccggtta	aatataactg	gttgccgata	59520
gtctcatagt	ctattaagtg	gtaagtttgc	tacaaataca	gaatccctaa	aatattatct	59580
aatgttggat	taatctttac	cataactgta	taaaatggag	acggagtcac	aactatttta	59640
ccgtttgtac	ttactggaat	agatgaagga	ataatctccg	gacatgctgg	taaagaccca	59700
aatgtctgtt	tgaagaaatc	caatgttcca	ggctcctaac	tcttaacaaa	aattacgata	59760
ttcgatcccg	atatcctttg	cattctatatt	accagcatat	cacgaactat	attaagatta	59820
tctatcatgt	ctattctccc	accgttatat	aaatcgctc	cgttaagaaa	cgttagtata	59880
tccatacaat	ggaatacttc	atcttctaaaa	tagtattcgt	tttctaattc	tttaattgtga	59940
aatcgtatac	tagaaaggga	aaaattatct	ttgagttttc	cgttagaaaa	gaaccacgaa	60000
actaatgttc	tgattgcgtc	cgattccggt	gctgaattaa	tggaatttaca	ccaaaaactc	60060
atataacttc	tagatgtaga	agcattcgct	aaaaaattag	tagaatcaaa	ggatataagt	60120
agatgttcca	acaagtgcgc	aattcccaag	atttcaccta	tatcattctc	gaatccgaaa	60180
ttagaaattc	ccaagtagat	atcctttttc	atccgatcgt	tgatgaaaat	acgaacttta	60240
ttcggttaaga	caatcattta	ctaaggagta	aaataggaag	taatgttcgt	atgtcggttat	60300
catcgtataa	attaaagggtg	tgtttttttac	cattaagtga	cattataatt	ttaccaatat	60360
tggaattata	atataggtgt	atgttgcgcac	tcgcgcacgg	tgatgcacg	gtaaatatag	60420
ctgtatctaa	tgttctagtc	ggtatttcat	catttcgctg	tctaataata	gcggttttctc	60480
tatctgtttc	cattacagct	gcctgaagtt	tatttggtcg	ataatatgta	aaataataag	60540
aaatacatatc	gaataacaaa	aataaaataa	gatataataa	agatgccatt	tagagatcta	60600
attttgttta	acttgtccaa	attcctactt	acagaagatg	aggaatcggt	ggagatagtg	60660
tcttccttat	gtagaggatt	tgaaatatct	tataatgact	tgataactta	ctttccagat	60720
aggaaatacc	ataaatatat	ttataaagta	tttgaacatg	tagattttatc	ggaggaatta	60780
agtatggaat	tccatgatac	aactctgaga	gattttagtct	atccttagatt	gtacaagtat	60840
tccaagtgtg	tacggccgtg	ttataaatta	ggagataatc	taaaaggcat	agttgttata	60900
aaggacagga	atattttatat	tagggaagca	aatgatgact	tgatagaata	tctcctcaag	60960
gaatacactc	ctcagattta	tacataattct	aatgagcgcg	tccccataac	tggttcaaaa	61020
ttaaattcttt	gtggatttttc	tcaagttaca	tttatggcgt	atacaacgtc	gcatataaca	61080
acaaataaaa	aggtagatgt	tctcgtttcc	aaaaaatgta	tagatgaact	agtcgatcca	61140
ataaattatc	aaataacttca	aaattttattt	gataaaggaa	gcggaacaat	aaacaaaata	61200
ctcaggaaga	tatttttatc	ggtaacaggt	ggccaaactc	cataggtagc	tttttctatt	61260
tcggattttta	gaattttccaa	attcaccagc	gatttatcgg	ttttgggtgaa	atccaaggat	61320
ttattaatgt	ccacaaatgc	catttgtttt	gtctgtggat	tgtattttgaa	aatggaaacg	61380
atgtagttag	atagatgcgc	tgogaagttt	cctattaggg	ttccgcgctt	cacgtcacc	61440
agcatacttg	aatcaccatc	ccttaaaaaa	aatgataaga	tatcaacatg	gagtatatca	61500
tactcggatt	tttaattcttc	tactgcacat	ctgacatttt	cacaaatact	acaatacggg	61560
ttaccgaaaa	taatcagtac	gttcttcatt	tatgggtatc	aaaaacttaa	aatcgttact	61620
gctggaaaaat	aaatcactga	cgatattaga	tgataattta	tacaaagtat	acaatggaat	61680

-35-

atgtgtggat	acaatgagta	tttatatago	cgtcgccaat	tgtgtcagaa	acttagaaga	61740
gttaactacg	gtattcataa	aatacgtaaa	cggatgggta	aaaaagggag	ggcatgtaac	61800
cctttttatc	gatagaggaa	gtataaaaaat	taaacaagac	gtagagagaca	agagacgtaa	61860
atattctaaa	ttaaccaagg	acagaaaaaat	gttagaatta	gaaaagtgtg	catccgaaat	61920
acaaaatggt	accggattta	tggagaaga	aataaaggca	gaaatgcaat	taaaaatcga	61980
taaactcaca	tttcaaatat	atattatctga	ttctgataac	ataaaaaatat	cattgaatga	62040
gatactaaca	catttcaaca	ataatgagaa	tgttacatta	ttttattgtg	atgaacgaga	62100
cgcagaattc	gttatgtgtc	tcgaggctaa	aacacatttc	tctaccacag	gagaatggcc	62160
gttgataata	agtaccgatc	aggatactat	gctatttgca	tctgctgata	atcatcctaa	62220
gatgataaaa	aacttaactc	aactgtttta	atgtgttccc	tcggcagagg	ataactatct	62280
agcaaaatta	acggcggttag	tgaatggatg	tgatttcttt	cctggactct	atggggcatc	62340
tataacaccc	accaacttaa	acaaaatata	attgttttagt	gatttttaca	tcgataatat	62400
agtcactagt	ttggcaatta	aaaattatta	tagaaagact	aactctaccg	tagacgtgcg	62460
taatatgtgt	acgtttataa	acgattacgc	taatttagac	gatgtctact	cgtatatctc	62520
tccttgtcaa	tgactgtgtc	aagaatttat	attttccgca	ttagatgaaa	aatggaatga	62580
atttaaatca	tcttatttag	aaagcgtgcc	gttaccctgc	caattaatgt	acgcgttaga	62640
accacgcaag	gagattgatg	tttcagaagt	ttaaacttta	tcattcttata	tagatttcga	62700
aaataactaaa	tcagatatcg	atgttataaa	atctatatcc	tcgatcttcg	gatattctaa	62760
cgaaaactgt	aacacgatag	tattcggcat	ctataaggat	aatttactac	tgagtataaa	62820
taattcattt	tactttaacg	atagtctgtt	aataaccaat	actaaaagtg	ataatataat	62880
aaatataggt	tactagatta	aaaatgggtg	tccaactcgt	gtgctctaca	tgcggtaaag	62940
atatttctca	cgaacgatat	aaattgatta	tacgaaaaaa	atcattaaag	gatgtactcg	63000
tcagtgtaaa	gaacgaatgt	tgtagggtta	aattatctac	acaaatagaa	cctcaacgta	63060
acttaacagt	gcaacctcta	ttggatataa	actaatatgg	atccgggtta	ttttatcaag	63120
acatatgcgc	ctagagggtt	tattattttt	atattattat	ccatgtcatt	aacaagtcac	63180
ttgaatccat	cgatagaaaa	acatgtgggt	atattattat	gtacgttatt	atcggaacac	63240
ttggtagttg	aatctaccta	tagaaaagga	gttcgaatag	tccatttggg	tagttttttt	63300
gaaggatatc	ttagtcaaaa	agtatacatg	ttagagaata	ttcaagttat	gaaaatagca	63360
gctgatacgt	cattaacttt	attgggtatt	ccgtatggat	ttggtcataa	tagaatgtat	63420
tgttttaaat	tggtagctga	ctgttataaa	aatgccggta	ttgataacat	gtctaaacga	63480
atattgggca	aagatatttt	tctgagccaa	aacttcacag	acgataatag	atggataaag	63540
atatatgatt	ctaataattt	aacatttttg	caaattgatt	acottaaagg	gtgagttaat	63600
atgcataact	actcctccgt	tgttttttcc	ctcgttcttt	ttcttaacgt	tgtttgccat	63660
cactctcata	atgtaaagat	attctaaaaa	ggtaaaactt	tgcatatcgg	acgcagaaat	63720
tggtataaat	gttgtaattg	tattattttc	cgtcaatgga	ctagtcacag	ctccatcagt	63780
tttatatcct	ttagagtatt	tctcactcgt	gtctaacatt	ctagagcatt	ccatgatctg	63840
tttatcgttg	atattggccg	gaaagataga	ttttttattt	tttattatat	tactattggc	63900
aattgtagat	ataacttctg	gtaaatatat	ttctaccttt	tcaatctctt	ctattttcaa	63960
gccggctata	tattctgcta	tattgtttgt	agtatcaata	ccttttctgg	ctaagaagtc	64020
atatgtggta	ttcactatat	cagtttttaac	tggtagtctc	attagccttt	ccacttctgc	64080
agaataatca	gaaattgggt	ctttaccaga	aaatccagct	actataatag	gctcaccgat	64140
gatcattggc	aaaatcctat	attgtaccag	attaatgaga	gcataatttc	tttccaataa	64200
ttctgctagt	tcttgagaca	ttgatttatt	tgatgaatct	agttgggtct	ctagatactc	64260
taccatttct	gccgcataca	ataacttggt	agataaaatc	agggttatca	aagtgttttag	64320
cgtggctaga	atagtgggct	tgcatgtatt	aaagaatgcg	gtagtatgag	taaaaccgtt	64380
taacgaatta	tatagtctcc	agaaatctgt	ggcgttacat	acatgagccg	aatgacatcg	64440
aagattgtcc	aatattttta	atagctgctc	tttgtccatt	atctctatat	ttgactcgca	64500
acaattgtag	ataccattaa	tcaccgatcc	cttttttcgat	gccggacaat	agcacaattg	64560
tttagctttg	gactctatgt	attcagaatt	aatagatata	tctctcaata	cagattgcac	64620
tatacatttt	gaaactatgt	caaaaattgt	agaacgcgcg	tggtctgcag	ccatttaact	64680
ttaaataatt	tacaaaaatt	taaaatgagc	atccgtataa	aaatcgataa	actgcgccaa	64740
attgtggcat	atttttcaga	gttcagtgaa	gaagtatcta	taaatgtaga	ctcgagccat	64800
gagttaaatgt	atattttttg	cgccttgggc	ggatctgtaa	acatttgggc	cattataacct	64860
ctcagtgcac	cagtgtttta	ccgaggagcc	gaaaatatgt	tgtttaaatct	tcctgtgtcc	64920
aaggtaaaat	cgtgtttgtg	tagttttcac	aatgatgcca	tcatagatat	agaacctgat	64980

-36-

ctggaaaata	atctagtaaa	acttttctagt	tatcatgtag	taagtgtcga	ttgtaacaag	65040
gaactgatgc	ctattaggac	agatactact	atttgtctaa	gtatagatca	aaagaaatct	65100
tacgtgttta	attttcacaa	gtatgaagaa	aaatgttgtg	gtagaaccgt	cattcattaa	65160
gtgacattat	aattttacca	atattggaat	tataatatag	gtgtatttgc	gcacttgcga	65220
cggttgatgc	atcggtaa	atagctgtat	ctaagtgtct	agtcggtatt	tcatcatttc	65280
gctgtcta	aatagcggtt	tctctatctg	tttccattac	agctgcctga	agtttattgg	65340
tcggataata	tgtaaaataa	taagaaatac	atacgaataa	caaaaataaa	ataagatata	65400
ataaagatgc	catttagaga	tctaattttg	tttaacttgt	ccaaattcct	acttacagaa	65460
gatgaggaat	cgttggagat	agtgtcttcc	ttatgtagag	gatttgaaat	atcttataat	65520
gacttgataa	cttactttcc	agataggaaa	taccataaat	atatttataa	agtatttgaa	65580
catgtagatt	tatcggagga	attaagtatg	gaattccatg	atacaactct	gagagattta	65640
gtctatctta	gattgtacaa	gtattccaag	tgtatacggc	cgtgttataa	attaggagat	65700
aatctaaaag	gcatagttgt	tataaaggac	aggaatattt	atattaggga	agcaa	65760
gacttgatag	aatatctcct	caaggaatac	actcctcaga	tttatacata	ttcta	65820
cgcgtcccca	taactgggtc	aaaattaatt	ctttgtggat	tttctcaagt	tacatttatg	65880
gcgtatacaa	cgtcgcatat	aacaacaaat	aaaaaggtag	atgttctcgt	ttccaaaaaa	65940
tgtatagatg	aactagtcca	tccaataaat	tatcaaatac	ttcaaaattt	atgtgataaa	66000
ggaagcggaa	caataaccaa	aataactcag	aagatatttt	attcggtaac	aggtggccaa	66060
actccatagg	tagctttttc	tatttcggat	tttagaattt	ccaaattcac	cagcgattta	66120
tcggttttgg	tgaatccaa	ggatttatta	atgtccacaa	atgccatttg	ttttgtctgt	66180
ggattgtatt	tgaatggga	aacgatgtag	ttagatagat	gcgctgcgaa	gtttcctatt	66240
agggttccgc	gcttcacgtc	accagcata	cttgaatcac	catccttta	aaaaatgat	66300
aagatatcaa	catggagtat	atcatactcg	gattttaatt	cttctactgc	atcactgaca	66360
ttttcacaaa	tactacaata	cggtttaccg	aaaataatca	gtacgttctt	catttatggg	66420
tatcaaaaac	ttaaaatcgt	tactgctgga	aaataaatca	ctgacgatat	tagatgataa	66480
tttatacaaa	gtatacaatg	gaatatttgt	ggatacaatg	agtatttata	tagccgtcgc	66540
caattgtgtc	agaaacttag	aagagttaac	tacggtattc	ataaaatacg	taaacggatg	66600
ggtaaaaaag	ggagggcatg	taaccctttt	tatcgataga	ggaagtataa	aaattaaaca	66660
agacgttaga	gacaagagac	gtaaatatto	taaattaacc	aaggacagaa	aaatgctaga	66720
attagaaaag	tgtacatccg	aaatacaaaa	tgttaccgga	tttatggaag	aagaaataaa	66780
ggcagaaatg	caattaaaaa	tcgataaact	cacatttcaa	atataattat	ctgattctga	66840
taacataaaa	atatcattga	atgagatact	aacacatttc	aacaataatg	agaatgttac	66900
attattttat	tgtgatgaac	gagacgcaga	attcgttatg	tgtctcgagg	ctaaaacaca	66960
tttctctacc	acaggagaat	ggcgttgat	aataagtacc	gatcaggata	ctatgctatt	67020
tgcactctgct	gataatcatc	ctaagatgat	aaaaaactta	actcaactgt	ttaaatatgt	67080
tccatctgca	gaggataaact	atttagcaaa	attaacggcg	ttagtgaatg	gatgtgattt	67140
ctttcctgga	ctctatgggg	catctataac	accacccaac	ttaaacaaaa	tacaattggt	67200
tagtgatttt	acaatcgata	atatagtcac	tagtttgcca	attaaaaatt	attatagaaa	67260
gactaactct	accgtagacg	tgcgtaatat	tgttacgttt	ataaacgatt	acgctaattt	67320
agacgatgtc	tactcgtatg	ttcctccttg	tcaatgcact	gttcaagaat	ttatattttc	67380
cgcattagat	gaaaaatgga	atgaatttaa	atcatcttat	ttagagaccg	tgccgttacc	67440
ctgtcaatta	atgtacgcgt	tagaaccacg	taaggagatt	gatgtttcag	aagttaaaaa	67500
tttatcatct	tatatagatt	tcgaaaatac	taaatcagat	atcgatgtta	taaaatctat	67560
atcctcgatc	ttcggatatt	ctaacgaaaa	ctgtaacacg	atagtattcg	gcatctataa	67620
ggataattta	ctactgagta	taaataatct	attttacttt	aacgatagtc	tgtaataaac	67680
caataactaaa	agtgataata	taataaatat	aggttactag	attaaaaatg	gtgttccaac	67740
tcgtgtgctc	tacatgcggt	aaagatatatt	ctcacgaacg	atataaattg	attatacgaa	67800
aaaaatcatt	aaaggatgta	ctcgtcagtg	taaagaacga	atgttgtagg	ttaaaattat	67860
ctacacaaat	agaacctcaa	cgtaacttaa	cagtgcaacc	tctattggat	ataaactaat	67920
atggatccgg	ttaattttat	caagacatat	gcgcctagag	gttctattat	ttttattaat	67980
tataccatgt	cattaacaag	tcatttgaat	ccatcgatag	aaaaacatgt	gggtatttat	68040
tatggtagct	tattatcgga	acacttggta	gttgaatcta	cctatagaaa	aggagttcga	68100
atagtcccat	tggatagttt	ttttgaagga	tatcttagtg	caaaagtata	catgttagag	68160
aatattcaag	ttatgaaaat	agcagctgat	acgtcattaa	ctttattggg	tattccgtat	68220
ggatttggtc	ataatagaat	gtattgtttt	aaattggtag	ctgactgtta	taaaaatgcc	68280

-37-

ggtattgata	catcgtctaa	acgaatattg	ggcaaagata	tttttctgag	ccaaaacttc	68340
acagacgata	atagatggat	aaagatatat	gattctaata	atttaacatt	ttggcaaat	68400
gattacotta	aagggtgagt	taatatgcat	aactactcct	cggttgtttt	ttccctcggt	68460
ctttttctta	acgttgtttg	ccatcactct	cataatgtaa	agatattcta	aatgggtaaa	68520
cttttgcata	toggacgcag	aaattggtat	aaatgttgta	attgtattat	ttccatatta	68580
ttatgaagac	tcctggtaat	actgatggcg	ttttccaggg	aatattctat	gactgaatgt	68640
tctcaagaac	tacaaaagtt	ttctttcaaa	atagctatct	cgtctctcaa	caaactacga	68700
ggattcaaaa	agagagtcaa	tgtttttgaa	actagaatcg	taatggataa	tgacgataac	68760
attttaggaa	tgttgttttt	ggatagagtt	caatccttta	agatcaacat	ctttatggcg	68820
tttttagatt	aatactttca	atgagataaa	tatgggtggc	ggagtaagt	ttgagctccc	68880
taaacgggat	cgcgaccggy	gagtaccac	tgatgagatg	ttattaaacg	tggataaaat	68940
gcatgacgtg	atagctcccg	ctaagctttt	agaatatgtg	catataggac	cactagcaaa	69000
agataaagag	gataaagtaa	agaaaagata	tccagagttt	agattagtca	acacaggacc	69060
cgggtggtctt	tcggcattgt	taagacaatc	gtataatgga	accgcacca	attgctgtcg	69120
cacttttaat	cgtactcatt	attggaagaa	ggatggaaag	atatcagata	agtatgaaga	69180
gggtgcagta	ttagaatcgt	gttgccaga	cgttcacgac	actggaaaat	gcatgttga	69240
ttttatcgac	tgggtgtcagg	gggatacgtt	cgatagaaac	atatgccatc	agtggatcgg	69300
ttcagccttt	aataggagta	atagaactgt	agaggggtcaa	caatcgtaa	taaatctgta	69360
taataagatg	caaacattat	gtagttaaag	tgtagtgta	ccaatatgcy	aatcattttt	69420
gcattattta	cgcgcacaca	atacagaaga	tagcaaagag	atgatcgatt	atattctaag	69480
acaacagtct	gcggaacttta	aacagaaata	tatgagatgt	agttatccca	ctagagataa	69540
gttagaagag	tcattaaaat	atgcggaacc	tcgagaatgt	tgggatccag	agtgttcgaa	69600
tgccaatggt	aatttcttac	taacacgtaa	ttataataat	ttaggacttt	gcaatattgt	69660
acgatgtaat	accagcgtga	acaacttaca	gatggataaa	acttctcat	taagattgtc	69720
atgtggatta	agcaatagtg	atagattttc	tactgttccc	gtcaatagag	caaaagtagt	69780
tcaacataat	attaaacact	cgttcgacct	aaaattgcat	ttgatcagtt	tattatctct	69840
cttggttaata	tggatactaa	ttgtagctat	ttaaatgggt	gccgcggcaa	gcatacagac	69900
gacggtgaat	acactcagcg	aacgtatctc	gtctaaatta	gaacaagaag	cgaacgctag	69960
tgctcaaaca	aaatgtgata	tagaaatcgg	aaatttttat	atccgacaaa	accatggatg	70020
taacctcact	gttaaaaata	tgtgctctgc	ggacgcggat	gctcagttgg	atgctgtgtt	70080
atcagccgct	acagaaacat	atagtggatt	aacaccggaa	caaaaagcat	acgtgccagc	70140
tatgtttact	gctgcgttaa	acattcagac	gagtgtaaac	actgttggtta	gagattttga	70200
aaattatgtg	aaacagactt	gtaattctag	cgcggtcgte	gataacaaat	taaagataca	70260
aaacgtaatc	atagatgaat	gttacggagc	cccaggatct	ccaacaaatt	tggaaatttat	70320
taatacagga	tctagcaaa	gaaattgtgc	cattaaagcg	ttgatgcaat	tgacgactaa	70380
ggccactact	caaatagcac	ctagacaagt	tgctggtaca	ggagttcagt	tttatatgat	70440
tgttatcggg	gtttataatat	tggcagcggt	ttttatgtac	tatgccaaagc	gtatgttgtt	70500
cacatccacc	aatgataaaa	tcaaaacttat	tttagccaat	aaggaaaacg	tccattggac	70560
tacttacatg	gacacattct	ttagaacttc	tccgatgggt	attgctacca	cggatatgca	70620
aaactgaaaa	tatattgata	atattttaat	agattaacat	ggaagttatc	gctgatcgte	70680
tagacgatat	agtgaacaaa	aatatagcgg	atgaaaaatt	tgtagatttt	gttatcacg	70740
gtctagagca	tcaatgtcct	gctatacttc	gaccattaat	taggttgttt	attgatatac	70800
tattatttgt	tatagtaatt	tatattttta	cggtagctct	agtaagtaga	aattatcaaa	70860
tgttggtggg	ggtgctagtc	atcacattaa	ctatttttta	ttactttata	ctataatagt	70920
actagactga	cttctaacaa	acatctcacc	tgccataaat	aaatgcttga	tattaaagtc	70980
ttctattttct	aacactattc	catctgtgga	aaataatact	ctgacattat	cgctaattga	71040
cacatcggtg	agtgatatgc	ctataaagta	ataatcttct	ttgggcacat	ataccagtgt	71100
accaggttct	aacaacctat	ttactggtgc	tcctgtagca	tactttttct	ttaccttgag	71160
aatatccatc	gtttgcttgg	tcaatagcga	tatgtgatgt	tttatcaacc	actcaaaaaa	71220
gtaattggag	tgttcatatc	ctctacgggc	tattgtctca	tggccgtgta	tgaaatttaa	71280
gtaacacgac	tgtggtagat	ttgttctata	gagccgattg	ccgcaaatag	atagaactac	71340
caatatgtct	gtacaaatgt	taaacattaa	gttagtaaca	gaaaaaacia	tgttcgttct	71400
gggaatagaa	accagatcaa	aacaaaattc	gttagaatat	atgccacggt	tatacatgga	71460
atataaaaata	actacagttt	gaaaaataac	agtatcattt	aaacatttaa	cttgcggggt	71520
taatctcaca	actttactgt	ttttgaactg	ttcaaaatat	agcatcgatc	cgtgagaaat	71580



-38-

acgttttagcc	gcctttaata	gaggaaatcc	caccgccttt	ctggatctca	ccaacgacga	71640
tagttctgac	cagcaactca	tttcttcate	atccacctgt	tttaacatat	aataggcagg	71700
agatagatat	ccgtcattgc	aatattcctt	ctcgtaggca	cacaatctaa	tattgataaa	71760
atctccatto	tcttctctgc	atttattatc	ttgtctcggt	ggctgattag	gctgtggtct	71820
tggtttaggc	cttgggtotat	cgttgttgaa	tctattttgg	tcattaaatc	tttcattttct	71880
tcttggtata	tttctatcac	ctcgtttggt	tggatttttg	tctatattat	cgtttgtaac	71940
atcggtagcg	gtattcattt	atcacaaaaa	aaacttctct	aaatgagtct	actgctagaa	72000
aacctcatcg	aagaagatac	catatttttt	gcaggaagta	tatctgagta	tgatgattta	72060
caaattggtta	ttgcgcggcg	aaaatccaaa	tttccaagat	ctatgctttc	tatttttaat	72120
atagtaccta	gaacgatgtc	aaaatatgag	ttggagttga	ttcataacga	aaatatcaca	72180
ggagcaatgt	ttaccacaat	gtataatata	agaaacaatt	tgggtctagg	agatgataaa	72240
ctaactattg	aagccattga	aaactatttc	ttggatccta	acaatgaagt	tatgcctctt	72300
attattaata	atacggatat	gactgccgtc	attcctaaaa	aaagtggtag	gagaaagaat	72360
aagaacatgg	ttatcttccg	tcaaggatca	tcacctatct	tgtgcatttt	cgaaactcgt	72420
aaaaagatta	atatttataa	agaaaatatg	gaatccgcgt	cgactgagta	tacacctatc	72480
ggagacaaca	aggctttgat	atctaaatat	gcgggaatta	atgtcctgaa	tgtgtattct	72540
ccttcacat	ccataagatt	gaatgccatt	tacggattca	ccaataaaaa	taaactagag	72600
aaacttagta	ctaataagga	actagaatcg	tatagttcta	gccctcttca	agaacctcatt	72660
aggttaaatg	attttctggg	actattggaa	tgtgttaaaa	agaatatctc	tctaacagat	72720
attccgacaa	aggattgatt	actataaatg	gagaatgttc	ctaattgtata	ctttaatcct	72780
gtgtttatag	agcccacgtt	taaacattct	ttattaagtg	tttataaaca	cagattaata	72840
gttttatttg	aagtattcgt	tgtattcatt	ctaatatatg	tatttttttag	atctgaatta	72900
aatatgttct	tcatgcctaa	acgaaaaata	cccgatccta	ttgatagatt	acgacgtgct	72960
aatctagcgt	gtgaagacga	taaattaatg	atctatggat	taccatggat	gacaactcaa	73020
acatctgcgt	tatcaataaa	tagtaaacgg	atagtgtata	aagattgtgc	aaagcttttg	73080
cgatcaataa	atggatcaca	accagtatct	cttaacgatg	ttcttcgcag	atgatgattc	73140
attttttaag	tatttggtca	gtcaagatga	tgaatcttca	ttatctgata	tattgcaaat	73200
cactcaatat	ctagactttc	tgttattatt	attgatccaa	tcaaaaaata	aattagaagc	73260
tgtgggtcat	tgttatgaat	ctctttcaga	ggaatacaga	caattgacaa	aattcacaga	73320
ctttcaagat	tttaaaaaac	tgtttaacaa	ggtccctatt	gttacagatg	gaaggggtcaa	73380
acttaataaa	ggatatttgt	tcgaactttg	gattagtttg	atgcgattca	aaaaagaatc	73440
ctctctagct	accaccgcaa	tagatcctgt	tagatacata	gatcctcgtc	gtgatattcg	73500
attttctaac	gtgatggata	tattaaagtg	gaataaagtg	aacaataatt	aattctttat	73560
tgtcatcatg	aacggcggac	atattcagtt	gataaatcgg	cccatgtttt	caggtaaaag	73620
tacagaatta	attagacgag	ttagacgtta	tcaaatagct	caatataaat	gcgtgactat	73680
aaaatattct	aacgataata	gatacggaac	gggactatgg	acgcatgata	agaataaatt	73740
tgaagcattg	gaagcaacta	aactatgtga	tgtcttgtaa	tcaattacag	atctctcogt	73800
gataggatc	gatgaaggac	agttctttcc	agacattggt	taattctgtg	agcgtatggc	73860
aaacgaagga	aaaatagtta	tagtagccgc	actcgatggg	acatttcaac	gtaaaccggt	73920
taataatatt	ttgaatctta	ttccattatc	tgaatgggtg	gtaaaactaa	ctgctgtgtg	73980
tatgaaatgc	tttaaggagg	cttccttttc	taaacgattg	ggtgaggaaa	ccgagataga	74040
gataatagga	ggtaatgata	tgtatcaatc	ggtgtgtaga	aagtgttacg	tcggctcata	74100
atattatatt	ttttatctaa	aaaactaaaa	ataaacattg	attaaatttt	aatataatac	74160
ttaaaaatgg	atgttgtgtc	gttagataaa	cogtttatgt	attttgagga	aattgataat	74220
gagtttagatt	acgaaccaga	aagtgcaaat	gagggtcgaa	aaaaactgcc	gtatcaagga	74280
cagttaaaac	tattactagg	agaattattt	tttcttagta	agttacagcg	acacgggtata	74340
ttagatggtg	ccaccgtagt	gtatatagga	tcggtcctcg	gtacacatat	acgttatattg	74400
agagatcatt	tctataattt	aggagtgatc	atcaaatgga	tgctaattga	cggccgccat	74460
catgatccta	ttttaaatgg	attgcgtgat	gtaacctctag	tgactcggtt	cgttgatgag	74520
gaatatctac	gatccatcaa	aaaacaactg	catccttcta	agattatttt	aatttctgat	74580
gtaagatcca	aacgaggagg	aatgaacct	agtacggcgg	atttactaag	taattacgct	74640
ctacaaaatg	tcatgattag	tatttttaaac	cccgtggcat	ctagtcttaa	atggagatgc	74700
ccgtttccag	atcaatggat	caaggacttt	tatatccac	acggtaataa	aatgtttaca	74760
ccttttgctc	cttcatattc	agctgaaatg	agattattaa	gtattttatac	cggtgagAAC	74820
atgagactga	ctcagagttac	caaattagac	gctgtaaatt	atgaaaaaaa	gatgtactac	74880

-39-

cttaataaga	tcgtccgtaa	caaagtagtt	gttaactttg	attatcctaa	tcaggaatat	74940
gactattttc	acatgtactt	tatgctgagg	accgtgtact	gcaataaaac	atttcctact	75000
actaaagcaa	aggtactatt	tctacaacaa	tctatatttc	gtttctttaa	tattccaaca	75060
acatcaactg	aaaaagttag	tcatgaacca	atacaacgta	aaatatctag	caaaaattct	75120
atgtctaaaa	acagaaatag	caagagatcc	gtacgcggta	ataaatagaa	acgtactact	75180
gagatatact	accgatatag	agtataatga	tttagttact	ttaataaccg	ttagacataa	75240
aattgattct	atgaaaactg	tgtttcaggt	atttaacgaa	tcatccataa	attatactcc	75300
ggttgatgat	gattatggag	aaccaatcat	tataacatcg	tatcttcaaa	aaggtcataa	75360
caagtttctt	gtaaattttc	tatacataga	tgtggtaata	tctgacttat	ttcctagctt	75420
tgttagacta	gatactacag	aaactaatat	agttaatagt	gtactacaaa	caggcgatgg	75480
taaaaagact	cttcgtcttc	ccaaaatggt	agagacggaa	atagttgtca	agattctcta	75540
tcgccctaata	ataccattaa	aaattgttag	atTTTTccgc	aataacatgg	taactggagt	75600
agagatagcc	gatagatctg	ttattttcagt	cgctgattaa	tcaattagta	gagatgagat	75660
aagaacatta	taataatcaa	taatatatct	tatatcttat	atcttatatc	ttatatcttg	75720
tttagaaaaa	tgctaataatt	aaaatagcta	acgctagtaa	tccaatcgga	agccatttga	75780
tatctataat	aggggtatcta	atttcctgat	ttaaatagcg	gacagctata	ttctcggtag	75840
ctactcgttt	ggaatcacaa	acattatttt	catctaattt	actatctgta	atggaaacgt	75900
ttcccaatga	aatggtacaa	tccgatacat	tgcattttgt	tatatTTTTt	tttaaagagg	75960
ctggtaacaa	cgcctcgctt	cgttttacatg	gctcgtaaca	acaataatag	ggtaattcttg	76020
tatctattcc	tatccgtact	atgcttttat	caggataaaat	acattttacat	cgtatatcgt	76080
ctttgttagc	atcacagaat	gcataaattt	gttcgtccgt	catgataaaa	atttaaagtg	76140
taaatataac	tattattttt	atagttgtaa	taaaaaggga	aatttgattg	tatactttcg	76200
gttctttaa	agaaactgac	ttgataaaaa	tggctgtaat	ctctaagggt	acgtatagtc	76260
tatatgatca	aaaagagatt	aatgctacag	atattatcat	tagtcatggt	aaaaatgacg	76320
acgatatcgg	taccgttaaa	gatggtagac	taggtgctat	ggatggggca	ttatgtaaga	76380
cttgtgggaa	aacggaattg	gaatgtttcg	gtcactgggg	taaagtaagt	atttataaaa	76440
ctcatatagt	taagcctgaa	tttatttcag	aaattattcg	tttactgaat	catatatgta	76500
ttcactgcgg	attattgcgt	tcacgagaa	cgtattccga	cgatattaac	ctaaaagagt	76560
tatcgggaca	cgctcttagg	agattaaagg	ataaaatatt	atccaagaaa	aagtcatggt	76620
ggaacagtga	atgtatgcaa	ccgtatcaaa	aaattacttt	ttcaaagaaa	aaggtttggt	76680
tcgtcaacaa	gttggtatgat	attaacgttc	ctaattctct	catctatcaa	aagttaattt	76740
ctattcatga	aaagttttgg	ccattatttag	aaattcatca	atatccagct	aacttatttt	76800
atacagacta	ctttcccatc	cctccgttga	ttatttagacc	ggctattagt	ttttggatag	76860
atagtatacc	caaagagacc	aatgaattaa	cttacttatt	aggtatgata	gttaagaatt	76920
gtaacttgaa	tgctgatgaa	cagggttatcc	agaaggcggt	aatagaatac	gatgatatta	76980
aaattatttc	taataacact	accagtatca	atttatcata	tattacatcc	ggcaaaaata	77040
atagtattag	aagtttatatc	gtcgcccgac	gaaaagatca	gaccgctaga	tctgtaattg	77100
gtcccagtac	atctatcacc	gttaatgagg	taggaatgcc	cgcataatatt	agaaatacac	77160
ttacagaaaa	gatattttgtt	aatgccttta	cagtggataa	agttaaacaa	ctattagcgt	77220
caaaccaagt	taaatttttac	tttaataaac	gattaaacca	attaacaaga	atacgccaag	77280
gaaagtttat	taaaaataaa	atacatttat	tgctgggtga	ttgggtagaa	gtagctgttc	77340
agaatataac	aagtattatt	tttggaagac	agccgtctct	acatagatac	aacgtcatcg	77400
cttcatctat	cagagctacc	gaaggagata	ctatcaaaat	atctcccga	attgccaact	77460
ctcaaaatgc	tgattttcgac	ggggatgagg	aatggatgat	attagaacaa	aatcctaaag	77520
ctgtaattga	acaaagtatt	cttatgtatc	cgacgacgtt	actcaaacac	gatattcatg	77580
gagccccgt	ttatggatct	attcaagatg	aaatcgtagc	agcgtattca	ttgttttagga	77640
tacaagatct	ttgttttagat	gaagtattga	acatcttggg	gaaatatgga	agagagttcg	77700
atcctaaagg	taaatgtaaa	ttcagcggtg	aagatatcta	tacttacttg	ataggtgaaa	77760
agattaatta	tccgggtctc	ttaaaggatg	gtgaaattat	tgcaaacgac	gtagatagta	77820
atTTTgtTgt	ggctatgagg	catctgtcat	tggctggact	cttatccgat	cataagtcga	77880
acgtggaagg	tatcaacttt	attatcaagt	catcttatgt	ttttaagaga	tatctatcta	77940
tttacggttt	tgggggtgaca	ttcaaagatc	ttgagaccaa	ttcgacgttc	actaataaat	78000
tggaggccat	caacgtagaa	aaaatagaac	ttatcaaaga	agcatacgcc	aaatatctca	78060
acgatgtaag	agacgggaaa	atagttccat	tatctaaagc	tttagaggcg	gactatgtgg	78120
aatccatggt	atccaacttg	acaaatctta	atatccgaga	gatagaagaa	catatgagac	78180



-40-

aaacgctgat	agatgatcca	gataataacc	tcttgaaaat	ggccaaagcg	ggttataaag	78240
taaatccac	agaactaatg	tatatcttag	gtacgtatgg	acaacaaagg	attgatgggtg	78300
aaccagcaga	gactcgagta	ttgggtagag	ttttacctta	ctatcttcca	gactctaagg	78360
atccagaagg	aagagggttat	attcttaatt	ctttaacaaa	aggattaacg	ggttctcaat	78420
attacttttc	gatgctgggt	gcaagatctc	aatctactga	tatcgtctgt	gaaacatcac	78480
gtaccggaac	actggctaga	aaaatcatta	aaaagatgga	ggatatgggtg	gtcgacggat	78540
acggacaagt	agttataggt	aatacgtca	tcaagtacgc	cgccaattat	accaaaattc	78600
taggctcagt	atgtaaacct	gtagatctta	tctatccaga	tgagtccatg	acttgggtatt	78660
tggaaattag	tgctctgtgg	aataaaaataa	aacagggatt	cgtttactct	cagaaacaga	78720
aacttgcaaa	gaagacattg	gcgcggttta	atttcctagt	attcgtcaaa	cccaccactg	78780
aggataatgc	tattaagggt	aaggatctgt	acgatatgat	tcataacgtc	attgatgatg	78840
tgagagagaa	atacttcttt	acggtatcta	atatagattt	tatggagtat	atattcttga	78900
cgcatcttaa	tccttctaga	attagaatta	caaaagaaac	ggctatcact	atctttgaaa	78960
agttctatga	aaaactcaat	tatactctag	gtggtggaac	tcctattgga	attatttctg	79020
cacagggtatt	gtctgagaag	tttacacaac	aagccctgtc	cagttttcac	actactgaaa	79080
aaagtgggtgc	cgtcaaacaa	aaacttgggt	tcaacgagtt	taataaacttg	actaatttga	79140
gtaagaataa	gaccgaaatt	atcactctgg	tatccgatga	tatctctaaa	cttcaattctg	79200
ttaagattaa	tttcgaattt	gtatgtttgg	gagaattaaa	tccaaacatc	actcttcgaa	79260
aagaaacaga	taggtatgta	gtagatataa	tagtcaatag	attatacatc	aagagagcag	79320
aaataaccga	attagtcgtc	gaatatatga	ttgaacgatt	catctccttt	agcgtcattg	79380
taaaggaatg	gggtatggag	acattcattg	aggacgagga	taatattaga	tttactgtct	79440
acctaaattt	cgttgaaccg	gaagaattga	atcttagtaa	gtttatgatg	gttcttccgg	79500
gggcagccaa	caagggaaaag	attagtaaat	tcaagattcc	tatctctgac	tatacgggat	79560
atgacgactt	caatcaaaca	aaaaagctca	ataagatgac	tgtagaactc	atgaatctaa	79620
aagaattggg	ttctttcgat	ttggaaaacg	tcaacgtgta	tcctggagta	tggaatacat	79680
acgatatctt	cggtatcgag	gccgctcgtg	aatacttgtg	cgaagccatg	ttaaaccact	79740
atggagaagg	gttcgattat	ctgtatcagc	cttgtgatct	tctcgctagt	ttactatgtg	79800
ctagttacga	accagaatca	gtgaataaat	tcaagttcgg	cgcagctagt	actcttaaga	79860
gagctacgtt	cggagacaat	aaagcattgt	taaacgcggc	tcttcataaa	aagtcagaac	79920
ctattaacga	taatagtagc	tgccactttt	ttagcaagg	ccctaataata	ggaactggat	79980
attacaaata	ctttatcgac	ttgggtcttc	tcatgagaat	ggaaaggaaa	ctatctgata	80040
agatatcttc	tcaaaagatc	aaggaaatgg	aagaaacaga	agacttttaa	ttcttatcaa	80100
taacatattt	ttctatgac	tgtcttttaa	acgatggatt	ttccacaaat	gcgcctctca	80160
agtcctcat	agaatgatac	acgtataaaa	aatatagcat	aggcaatgac	tccttatttt	80220
tagacattag	atatgccaaa	atcatagccc	cgcttctatt	tactcccgca	gcacacgaa	80280
ccaacacggg	ctcgtttcgt	tgatcacatt	tagataaaaa	ggcgggttacg	tcgtcaaaat	80340
atttactaat	atcggtagtt	gtatcatcta	ccaacgggtat	atgaataata	ttaatattag	80400
agttaggtaa	tgtatattta	tccatogtca	aattttaaac	atatttgaac	ttactttcag	80460
atgatgggtgc	atccatagca	tttttataat	ttcccaaata	cacattattg	gttacccttg	80520
tcattatagt	gggagatttg	gctctgtgca	tatctccagt	tgaacgtagt	agtaagtatt	80580
tatacaaaact	tttcttatcc	atttataacg	tacaaatgga	taaaactact	ttatcggtaa	80640
acgcgtgttaa	tttagaatac	gttagagaaa	aggctatagt	aggcgtacaa	gcagccaaaa	80700
catcaaacact	tatatctctt	gttattatat	tgcaatttag	tgcgctatta	ctctgggttc	80760
agacgtctga	taatccagtc	tttaatgaat	taacgagata	tatgcgaatt	aaaaatacgg	80820
ttaacgattg	gaaatcatta	acggatagca	aaacaaaatt	agaaagtgat	agaggtagac	80880
ttctagccgc	tggttaaggat	gatataattcg	acttcaaattg	tgtggatttc	ggcgccctatt	80940
ttatagctat	gcgattggat	aagaaaacat	atctgccgca	agctattagg	cgaggtagctg	81000
gagacgcgtg	gatgggttaa	aaggcggcaa	aggctcgatcc	atctgctcaa	caattttgtc	81060
agtatttgat	aaaacacaag	tctaataatg	ttattacttg	tggtaatgag	atgttaaattg	81120
aattagggtta	tagcgggtta	tttatgtcac	cgcattgggtg	ttccgatttt	agtaatatgg	81180
aatagtgtta	gataaatgcg	gtaacgaatg	ttcctgtaag	gaaccataac	agcttagatt	81240
taacgtttaa	gatgagcata	aacataataa	acaaaattac	aatcaaactt	ataacattaa	81300
tatcaaacaa	tccaaaaaat	gaaatcagtg	gagtagtaaa	cgcgtacata	actcctggat	81360
aacggttagc	agctgccgtt	cctattctag	accaaaaatt	cggtttcatg	ttttcgaaac	81420
ggtattctgc	aacaagtcga	ggatcgtggt	ctacatattt	ggcggcatta	tccagtatct	81480

-41-

gcctattgat	cttcatttctg	ttttcaattc	tggctatttc	aaaataaaat	cccgatgata	81540
gacctccaga	ctttataatt	tcattctacga	tgttcagcgc	cgtagtaact	ctaataatat	81600
aggctgataa	gctaaccatca	tacctctctg	tatatgtgaa	tatggcatga	tttttgtcca	81660
ttacaagctc	ggttttaact	ttattgcctg	taataatttc	tctcatctgt	aggatatcta	81720
tttttttgtc	atgcattgcc	ttcaagacgg	gacgaagaaa	cgtaatatcc	tcaataacgt	81780
tatcgttttc	tacaataact	acatattcta	ccttttttatt	ttctaactcg	gtaaaaaaat	81840
tagaatccca	tagggctaaa	tgtctagcga	tatttctttt	cgtttctctc	gtacacatag	81900
tgttacaaaa	ccctgaaaag	aagtgagtat	acttgtcatc	atttctaattg	tttctctccag	81960
tccactgtat	aaacgcataa	tccttgtaat	gatctggatc	atccttgact	accacaacat	82020
ttcttttttc	tggcataaact	tcgttgctct	ttacatcatc	gaacttctga	tcattaatat	82080
gctcatgaac	attaggaaat	gtttctgatg	gaggtctatc	aataactggc	acaacaataa	82140
caggagtttt	caccgccgcc	atttagttat	tgaaattaat	catatacaac	tctttaatac	82200
gagttatatt	ttcgtctatc	cattgtttca	cattgacata	tttcgacaaa	aagatataaa	82260
atgcgtattc	caatgcttct	ctgtttaatg	aattactaaa	atatacaaac	acgtcactgt	82320
ctggcaataa	atgatattct	agaatattgt	aacaatgtaa	ggaaccataa	cagtttagat	82380
ttaacgttaa	agatgagcat	aaacataata	aacaaaatta	caatcaaacc	tataacatta	82440
atatcaaaa	atccaaaaaa	tgaaatcagt	ggagtagtaa	acgcgtacat	aactcctgga	82500
taacgtttag	cattgcgcgt	tcctattcta	gaccaaaaat	ttggtttcat	gttttcgaaa	82560
cggatttctg	caacaagtcg	gggatcgtgt	tctacataatt	tggcggcatt	atccagtatc	82620
tgcttattga	tcttcatttc	gttttcgatt	ctggctattt	caaaaataaaa	tcccgatgat	82680
agacctccag	actttataat	ttcatctacg	atgttcagcg	ccgtagtaac	tctaataata	82740
taggctgata	agctaaccatc	ataccctcct	gtatatgtga	atatggcatg	atttttgtcc	82800
attacaagct	cggtttttaac	tttattgcct	gtaataattt	ctctcatctg	taggatatct	82860
atttttttgt	catgcattgc	cttcaagacg	ggacgaagaa	acgtaatatc	ctcaataacg	82920
ttatcgtttt	ctacaataac	tacataattct	acctttttat	tttctaactc	ggtaaaaaaa	82980
ttagaatccc	atagggctaa	atgtctagcg	atatctcttt	tcgtttctct	tgtacacata	83040
gtgttacaaa	accctgaaaa	gaagtgagta	tacttgtcat	catttctaata	gtttcctcca	83100
gtccactgta	taaacgcata	atccttgtaa	tgatctggat	catccttgac	taccacaaca	83160
tttctttttt	ctggcataac	ttcgttgtcc	tttacatcat	cgaacttctg	atcattaata	83220
tgctcatgaa	cattaggaaa	tgtttctgat	ggaggtctat	caataactgg	cacaacaata	83280
acaggagttt	tcaccgccgc	catttagtta	ttgaaattaa	tcatatacaa	ctctttaata	83340
cgagttatat	tttcgtctat	ccattgtttc	acattttacat	atttcgacaa	aaagatatata	83400
aatgcgtatt	ccaatgcttc	tctgtttta	gaattactaa	aatatacaaa	cacgtcactg	83460
tctggcaata	aatgatatct	tagaatattg	taacaattta	ttttgtattg	cacatgttctg	83520
tgatctatga	gttcttcttc	gaatggcata	ggatctccga	atctgaaaac	gtataaatag	83580
gagttagaat	aataatatct	gagagtattg	gtaatatata	aactctttag	cgggtataatt	83640
agtttttttc	tctcaatttc	tattttttaga	tgtgatggaa	aaatgactaa	ttttgtagca	83700
ttagtatcat	gaactcta	caaaatctta	atatcttctg	cacacgttag	ctctttgaag	83760
tttttaagag	atgcatcagt	tggttctaca	gatggagtag	gtgcaacaat	ttttgttct	83820
acacatgtat	gtactggagc	cattgtttta	actataatgg	tgcttgatc	gaaaaacttt	83880
aatgcagata	gcggaagctc	ttcgccgcga	ctttctacgt	cgtaattggg	ttctaaccgc	83940
gatctctgaa	tggatactag	ttttctaagt	tctaattgtga	ttctctgaaa	atgtaaatcc	84000
aattcctccg	gcattataga	tgtgtataca	tcggtaataa	aaactatagt	atccaacgat	84060
cccttctcgc	aaattctagt	cttaaccaaa	aaatcgtata	taaccacgga	gatggcggtat	84120
ttaagagtgg	attcttctac	cgttttgttc	ttggatgtca	tataggaaac	tataaagtcc	84180
gcactactgt	taagaatgat	tactaacgca	actatatagt	ttaaattag	cattttggaa	84240
acataaaaata	actctgtaga	cgatacttga	ctttcgaata	agtttgcaga	caaacgaaga	84300
agaacagac	ctctctta	ttcagaagaa	aacttttttt	cgtattcctg	acgtctagag	84360
tttatatcaa	taagaaagtt	agaattagt	cgggttaatgt	tgtatttcat	tacccaagtt	84420
tgagatttca	taatattatc	aaaagacatg	ataatattaa	agataaagcg	ctgactatga	84480
acgaaatagc	tatattggtc	gctcaagaat	atagcttctg	taaacgtgga	aacgataact	84540
gtatttttaa	tcacgtcagc	ggcatctaaa	ttaaatatag	gtatatattat	tccacacact	84600
ctacaatatg	ccacaccatc	ttcataataa	ataaattcgt	tagcaaaatt	attaatttta	84660
gtgaaatagt	tagcgtcaac	tttcatagct	tccttcaatc	taatttgatg	ctcacacggt	84720
gcgaattcca	ctctaaccatc	ccttttccat	gcctcaggtt	catcgatctc	tataatatct	84780

-42-

agttttttgc gtttcacaaa cacaggctcg tctctcgcga tgagatctgt atagtaacta 84840  
tgtaaatgat aactagatag aaagatgtag ctatatagat gacgatcctt taagagaggt 84900  
ataataactt taccccaatc agatagactg ttgttatggg cttcggaaaa agaattttta 84960  
taaatttttc cagtattttc caaatatacg tacttaacat ctaaaaaatc cttaatgata 85020  
ataggaatgg ataatccgtc tattttataa agaaatacat atcgcacatt atactttttt 85080  
ttggaaatgg gaataccgat gtgtctacat aaatatgcaa agtctaaata ttttttagag 85140  
aatcttagtt ggtccaaatt cttttccaag tacggtaata gatttttcat attgaacggg 85200  
atcttcttaa tctctgggtc tagttccgca ttaaagatg aaactaagtc actattttta 85260  
taactaacga ttacatcacc tctaaccatca tcatttacca gaatactgat cttcttttgt 85320  
cgtaaatata tgtctaagt gttaaaaaaa agatcataca agttatacgt catttcatct 85380  
gtggatttct tgtcattgaa ggataaaactc gtactaatct cttctttaac agcctgttca 85440  
aatttatatc ctatatacga aaaaatagca accagtgttt gatcatccgc gtcaatattc 85500  
tgttctatcg tagtgataa caatcgtata tcttctctcg tgatagtcca tacgttataa 85560  
agggtgataa cgaaaatatt tttatttcgt gaaataaagt catcgtagga ttttggactt 85620  
atattcgcgt ctagtagata tgcttttatt tttggaatga tctcaattag aatagtctct 85680  
ttagagtcca tttaaagtta caaacaacta ggaaattggg ttatgatgta taattttttt 85740  
agtttttata gattctttat tctatactta aaaaatgaaa ataaatacaa aggttcttga 85800  
gggttgtgtt aaattgaaa atcgtaattg cgtgggtcaat tacgaataaa gcgatactc 85860  
ttaagtttgt atcgtaattg gaaatcagag ctcatctaaa aaatagcgt gaaaataaag ataaaaacga 85980  
aaagatgggt gaaatcagag taataattcc atctactaag cccaaaacca aacgagccac 86040  
ggatattttc ccggaagatg ctactaaaag atcaaccaa aaggaggaag tggaagaaga 86100  
tactctcgt aaaccagcgg ctactaaaag atcaaccaa tctccatctc ctggagtcag 86160  
agtagttata gaggaatatt atcaaccaa tgaaaaaat gctcgatgat agcgacgggg 86220  
cgacattgta gaaagcgtgg ccgctgtaga tcatagtgtc agaagcgatc tctctgacct 86280  
tatggtagaa gttgaagctg gtaaagtaaa tcttaagaaa attattacta gaatctctgc 86340  
aaaggtgggt accgacaata tcgttaaaga agctgggtatc tctagacaat ttacttctat 86400  
agtatcgacg gttctagagg atgttcaagc agtcaccgag ggaaaatcta aagttgttcg 86460  
gactaaagct attacaacac tatctgatct atgcaccgag ttttataaag atggtaaact 86520  
taaaaaagtt aaaacttgta agaagtaaat gcgtgcactt aatccagcgt atgaggtttt 86580  
ctttaccgat aataattttt taaatcctgt atcagacgat gtatatgaac aaacgtggga 86640  
gcaacatggt aaaattccta ctcatttaac agatgtagta aaaggacgta gacaataact 86700  
ggaggcgtta actagattaa tttttgtggg aagcgattca gatcgtatct ttgttagagt 86760  
ttacggaaaa atgcatgtac agaatcgcaa ttaattgttt tataaacaaa aatataaaga aatcgtccac 86820  
atataacggt tatcagttgg cggtttttat gttaatggaa actatgtttt ttattagatt 86880  
agattccaat taatattcta aggagaatga aacagtaggg ttattaacac taaaaataaa 86940  
acacatagaa ataagtcctg atgaaatagt tatcaagttt gtaggaaagg acaaagtttc 87000  
acatgaattt gttgttcata agtctaatag actatataaa ccgctattga aactgacgga 87060  
tgattctagt cccgaagaat ttctgttcaa caaactaagt gaacgaaagg tatacgaatg 87120  
tatcaaacag tttgggtatta gaatcaagga tctccgaacg tatggagtca attatacgtt 87180  
tttatataat ttttggacaa atgtaaagtc catatctcct cttccgtcac caaaaaagtt 87240  
aatagcggtta actatcaaac aaactgctga agtggttaggt catactccat caatttcaaa 87300  
aagagcttat atggcaacga ctatttttaga aatggtaaag gataaaaatt ttttagatgt 87360  
agtatctaaa actacgttcg atgaattcct atctatagtc gtagatcacg ttaaatacatc 87420  
tacggatgga tgatatagat ctttacacaa ataattacaa gaccgataaa tggaaatgga 87480  
taagcgtatg aaatctctcg caatgacagc tttcttcgga gagctaagca cattagatat 87540  
tatggcattg ataattgtcta tattttaaag ccatccaaac aataccattt tttcagtggg 87600  
taaggatggg cagtttatga ttgatttcga atacgataat tataaggctt ctcaatattt 87660  
ggatctgacc ctcaactcga tatctggaga tgaatgcaag actcacgcat cgagtatagc 87720  
cgaacaattg gcgtgtgtgg atattattaa agaggatatt agcgaatata tcaaaaactac 87780  
tccccgtctt aaacgattta taaaaaata cgcctctagc taagtgcaat gattacgaat atataaaga 87900  
agatacagaa aagcttaaaa tagctctagc aaaaactcgt aataaaaacac gatatggatg 87960  
cgcttggtta taagtaaatg aaaaactcgt cgtatataga cgcttttagc aagaatgctt 88020  
ccaacgtagt atcatcttct actattgcga aaataaataa tgaattggaa ctagtattta 88080  
cagaattaga acagaggtct accgcatacg

-43-

ttaagccgcc	attgattact	ttgacaaatg	tagtgaatat	ctctacgatt	caggaatcgt	88140
ttattcgatt	taccgttact	aataaggaag	gtgttaaaat	tagaactaag	attccattat	88200
ctaaggtaga	tgggtctagat	gtaaaaaatg	tacagttagt	agatgctata	gataacatag	88260
tttgggaaaa	gaaatcatta	gtgacggaaa	atcgtcttca	caaagaatgc	ttgttgagac	88320
tatcgacaga	ggaacgcat	atattttttg	attacaagaa	atatggatcc	tctatccgac	88380
tagaattagt	caatcttatt	caagcaaaaa	caaaaaactt	tacgatagac	tttaagctaa	88440
aatattttct	aggatccggt	gcccattcta	aaagttcttt	gttgacgct	attaatcatc	88500
caaagtcaag	gcctaataca	tctctggaaa	tagaattcac	acctagagac	aatgaaacag	88560
ttccatatga	tgaactaata	aaggaattga	cgactctctc	gcgtcatata	tttatggctt	88620
ctccagagaa	tgtaattctt	tctccgccta	ttaacgcgcc	tataaaaacc	tttatgttgc	88680
ctaaacaaga	tatagtaggt	ttggatctgg	aaaatctata	tgccgtaact	aagactgacg	88740
gcattcctat	aactatcaga	gttacatcaa	acgggttgta	ttgttatttt	acacatcttg	88800
gttatattat	tagatatcct	gttaagagaa	taatagattc	cgaagtagta	gtctttgggtg	88860
aggcagttaa	ggataagaac	tggaccgtat	atctcattaa	gctaatagag	cccgtgaatg	88920
ctatcagtga	tagactagaa	gaaagtaagt	atgttgaatc	taaactagtg	gatattttgtg	88980
atcggatagt	attcaagtca	aagaaatacg	aaggtccggt	tactacaact	agtgaagtcg	89040
tcgatatggt	atctacatat	ttaccaaaagc	aaccagaagg	tggtattctg	ttctattcaa	89100
agggacctaa	atctaaccatt	gattttaaaa	tataaaaagga	aaatactata	gaccaaactg	89160
caaatgtagt	atttaggtac	atgtccagtg	aaaccaattat	ctttggagaa	tcgtctatct	89220
ttgtgagta	taagaaat	agcaacgata	aaggctttcc	ttaaagaatat	ggttctggta	89280
agattgtggt	atataacggc	gttaattatc	ttaaataatat	ctattgtttg	gaatatatta	89340
atacacataa	tgaagtgggt	attaagtccg	tgggtgtacc	tattaagttt	atagcagaat	89400
tcttagttaa	tggagaaata	cttaaaccta	gaattgataa	aaccatgaaa	tatattaact	89460
cagaagatta	ttatggaaat	caacataata	tcatagtcga	acatttaaga	gatcaaagca	89520
tcaaaatagg	agatatcttt	aacgaggata	aactatcgga	tgtgggacat	caatacgcca	89580
ataatgataa	attttagatta	aatccagaag	tagttatttt	tacgaataaa	cgaactagag	89640
gaccgttggg	aattttatca	aactacgtca	agactcttct	tatttctatg	tattgttcca	89700
aaacattttt	agacgattcc	aacaaacgaa	aggtattggc	gattgatatt	ggaaacgggtg	89760
ctgacctgga	aaaatacttt	tatggagaga	ttgcgttatt	ggtagcgacg	gatccggatg	89820
ctgatgctat	agctagagga	aatgaaagat	acaacaaatt	aaactctgga	attaaaacca	89880
agtactacaa	atttgactac	attcaggaaa	ctattcgatc	cgatacattt	gtctctagt	89940
tcagagaagt	attctatatt	ggaaagttta	atatcatcga	ctggcagttt	gctatccatt	90000
attcttttca	tccgagacat	tatgctaccg	tcataaataa	cttatccgaa	ctaactgctt	90060
ctggaggcaa	ggtattaatc	actaccatgg	acggagacaa	attatcaaaa	ttacagata	90120
aaaagacttt	tataattcat	aagaatttac	ctagtgcga	aaactatatg	tctgtgaaaa	90180
aaatagctga	gtggtatata	atccatcaac	aatgtctact	cgaatacggg	tttgttcttg	90240
aatacattat	caaaaagaac	gatatagtca	gagtgtttta	aaagtttatt	aatggcgcat	90300
tagataacgt	tgatttctgt	acaattatag	aacgaagtaa	actaaataga	ggagccatta	90360
ctacaatgga	agatagaccg	tctacaaaaa	actttttcga	tggtgtttat	gtcttttcta	90420
aatgtgaagg	tttagatgtc	gaagacttac	ttagttacta	ttctaaatgc	attaaataat	90480
agcggtaaat	aataatatgg	tatgggttct	gatatccccg	gtggatactc	tgtattgtta	90540
tccaatagag	cgatttttgt	tcctatagga	ccttccaact	cgtcttctaa	aaataaaaagt	90600
atagatatat	taataacttt	gtcgggtaac	agaggttcta	ttctatatat	actcttatta	90660
tttataacat	ctggcctggt	cataaataaa	aacttggcga	gtgtaccatt	tgattttctt	90720
tcaaatctag	ccatttgtct	atagatgtga	gctactgtag	catctgggaa	tataagttag	90780
tctaatacta	tatatctctc	tcgaagaagt	tcttgacat	tggacatttt	tttaggaaat	90840
ctgttgagta	aatcagttat	tttttttata	tcgatattga	tatttatact	tttttctgaa	90900
gataataagt	atcccaaagt	cgataacgac	gataacgaag	agcatgtatt	gtctagtttt	90960
cacaatgact	ttatcagatt	aaaatttaaca	aaattaaagg	aattaaatgg	acaagttaga	91020
tatattgtga	ctccagatac	atatggatct	ttatgcgtcg	aatgctggaag	cactgataaaa	91080
cagcaggtg	gtagatatat	agaggtggag	gaatttatag	aagatatgca	gggtattcgta	91140
tgggtgtcta	tatccaatca	tatatctaaa	gatatacccg	ataaacgatt	gtctccgtat	91200
tttgtcattt	atgatatata	cacttttgac	gctttcaaga	atccggtatt	agattcattt	91260
caggtacctc	cgtcgttagg	agatgatagt	catttgacta	tttttaataca		91320
tatcgtaatt	cagtagccag	acaaatgggc	aataatatga			91380

-44-

ttaaaatatt	tattagaaca	tctgattaga	agccactata	gagtttctaa	acataataaca	91440
atagtttagat	acaaggatac	cgaagaatta	aatctaacga	gaatatgtta	taatagagat	91500
aagtttaagg	cgtttgtatt	cgcttggttt	aacggcgttt	cggaaaatga	aaaggtaacta	91560
gatacgtata	aaaaggatc	taatttgata	taatgaattc	agtgaactgt	tcacacgcgc	91620
catatactat	tacttatcac	gatgattggg	aaccagtaat	gagtcaattg	gtagagtttt	91680
ataacgaagt	agccagttgg	ctgctacgag	acgagacgtc	gcctattcct	gataagttct	91740
ttatacagtt	gaaacaaccg	cttagaaata	aacgagtatg	tgtgtgcggt	atagatccgt	91800
atccgaaaga	tggaaactggt	gtaccgttcg	aatcaccaaa	ttttacaaaa	aatcaatta	91860
aggagatagc	ttcatctata	tctagattaa	cggagtaaat	tgattataaa	ggttataacc	91920
ttaatataat	agacgggggt	ataccctgga	attattactt	aagttgtaaa	ttaggagaaa	91980
caaaaagtca	cgcgatctac	tgggataaga	tttccaagtt	actgctgcag	catataacta	92040
aacacgtag	tggttctttat	tgtttgggta	aaacagattt	ctcgaatata	cgggcaaagt	92100
tagaatcccc	ggtaactacc	atagtcggat	atcatccagc	ggctagagac	cgccaattcg	92160
agaaagatag	atcatttgaa	attatcaacg	ttttactgga	attagacaac	aaggcaccta	92220
taaattgggc	tcaaggggtt	atattattaat	gcttttagtga	aatttttaact	tgtgttctaa	92280
atggatgctg	ctatttagagg	taatgatggt	atccttgttc	ttaagactat	aggtgtccc	92340
tcagcgtgca	gacaaaatga	agatccaaga	tttgtagaag	catttaaatg	cgacgagtt	92400
gaaagatata	ttgagataaa	tccagaatgt	acactattcg	aaagtcttag	ggatgaggaa	92460
gcatactcta	tagtcagaat	tttcatggat	gtagatttag	acgcgtgtct	agacgaaata	92520
gattatttaa	cggctattca	agattttatt	atcgaggtgt	caaactgtgt	agctagattc	92580
gcgtttacag	aatgcgggtgc	cattcatgaa	aatgtaataa	aatccatgag	atctaatttt	92640
tcattgacta	agtctacaaa	tagagataaa	acaagttttc	atattatctt	tttagacacg	92700
tataccacta	tggatacatt	gatagctatg	aaacgaacac	tattagaatt	aagtagatca	92760
tctgaaaatc	cactaacaag	atcgatagac	actgccgtat	ataggagaaa	aacaactcct	92820
cgggttgtag	gtactaggaa	aaatccaaat	tgcgacacta	ttcatgtaat	gcaaccaccg	92880
catgataata	tagaagatta	cctatttact	tacgtggata	tgaacaacaa	tagttattac	92940
ttttctctac	aacaacgatt	ggaggattta	gttcctgata	agttatggga	accagggttt	93000
atttcatctcg	aagacgctat	aaaaagagtt	tcaaaaatat	tcattaattc	tataataaac	93060
tttaatgatc	tcgatgaaaa	taattttaca	acggtaccac	tggtcataga	ttacgtaaca	93120
ccttgtgcat	tatgtaaaaa	acgatcgcat	aaacatccgc	atcaactatc	gttggaaaat	93180
ggtgctatta	gaattttaca	aactggtaat	ccacatagtt	gtaaagttaa	aattgttccg	93240
ttggatggta	ataaaactgt	taatattgca	caaagaattt	tagacactaa	ctctgtttta	93300
ttaaccgaac	gaggagacca	tatagtttgg	attaataatt	catggaaatt	taacagcgaa	93360
gaacccttga	taacaaaact	aattttgtca	ataagacatc	aactacctaa	ggaatattca	93420
agcgaattac	tctgtccgag	gaaacgaaag	actgtagaag	ctaacatacg	agacatgtta	93480
gtagatttcag	tggagaccga	tacctatccg	gataaaactc	cgtttaaaaa	tggtgtattg	93540
gacctggtag	acggaatggt	ttactctgga	gatgatgcta	aaaaatatac	gtgtactgta	93600
tcaaccggat	ttaaatttga	cgatacaaa	ttcgtcgaag	acagtccaga	aatggaagag	93660
ttaatgaata	tcattaacga	tatccaacca	ttacggatg	aaaataagaa	aaatagagag	93720
ctatatgaaa	aaacattatc	tagttgttta	tgcggtgcta	ccaaaggatg	tttaacattc	93780
ttttttggag	aaactgcaac	tggaaagtgc	acaaccaaac	gtttgttaaa	gtctgctatc	93840
ggtgacctgt	ttgttgagac	gggtcaaaca	attttaacag	atgtattgga	taaaggacct	93900
aatccattta	tcgctaacat	gcatttgaaa	agatctgtat	tctgtagcga	actacctgat	93960
tttgcattgta	gtgggtcaaa	gaaaatcaga	tctgataata	ttaaaaagtt	gacagaacct	94020
tgtgtcattg	gaagaccgtg	tttctccaat	aaaattaata	atagaaacca	tgcgacaatc	94080
attatcgata	ctaattacaa	acctgttttt	gataggatag	ataacgcatt	aatgagaaga	94140
attgccgtcg	tgcgattcag	aacacacttt	tctcaacctt	ctggtagaga	ggctgctgaa	94200
aataatgacg	cgtacgataa	agtcaaaacta	ttagacgagg	ggttagatgg	taaaatacaa	94260
aataatagat	atagattcgc	atctctatc	ttgttgggtg	aatggtacag	aaaatatcat	94320
gttcctatta	tgaaaactata	tcctacaccc	gaagagattc	ctgactttgc	attctatctc	94380
aaaaataggta	ctctgtttgg	atctagctct	gtaaagcata	ttccattaat	gacggacctc	94440
tccaaaaagg	gatatattat	gtacgataat	ctggtcactc	ttccgttgac	tactttccaa	94500
cagaaaaat	ccaagtattt	taattctaga	ctatttggac	acgatataga	gagcttcac	94560
aatagacata	agaaatttgc	caatgttagt	gatgaatc	tgcaatatat	attcatagag	94620
gatatttcat	ctccgtaaat	atatgctcat	atatttatag	aagatatcac	atatctaaat	94680

-45-

gaataccgga	atcatagatt	tatttgataa	tcatgttgat	agtataccaa	ctatattacc	94740
tcatacagtta	gctactctag	attatctagt	tagaactatc	atagatgaga	acagaagcgt	94800
gttattgttc	catattatgg	gatcaggtaa	aacaataatc	gctttgttgt	tcgccttggt	94860
agcttccaga	tttaaaaagg	tttacattct	agtgccgaac	atcaacatct	taaaaatttt	94920
caattataat	atgggtgtag	ctatgaactt	gtttaatgac	gaattcatag	ctgagaatat	94980
ctttattcat	tccacaacaa	gtttttatct	tcttaattat	aacgataacg	tcattaatta	95040
taacggatta	tctcgctaca	ataactctat	ttttatcggt	gatgaggcac	ataatatctt	95100
tgggaataat	actgggagaac	ttatgaccgt	gataaaaaat	aaaaacaaga	ttcctttttt	95160
actattgtct	ggatctccca	ttactaacac	acctaatact	ctgggtcata	ttatagattt	95220
aatgtccgaa	gagacgatag	attttggtga	aattattagt	cgtggtaaga	aagtaattca	95280
gacacttctt	aacgaacgcg	gtgtgaatgt	acttaaggat	ttgcttaaag	gaagaatatc	95340
atattacgaa	atgcctgata	aagatctacc	aacgataaga	tatcacggac	gtaagtttct	95400
agatactaga	gtagtatatt	gtcacatgtc	taaacttcaa	gagagagatt	atatgattac	95460
tagacgcagc	ctatgttatc	atgaaatggt	tgataaaaaat	atgtataacg	tgtcaatggc	95520
agtattggga	caacttaatc	tgatgaataa	tttagatact	ttatttcagg	aacaggataa	95580
ggaattgtac	ccaaatctga	aaataaataa	tggcgtgtta	tacggagaag	aattggtaac	95640
gttaaacatt	agttccaaat	ttaaataact	tattaatcgg	atacagacac	tcaacggaaa	95700
acattttata	tacttttcta	attctacata	tggcggattg	gtaattaaat	atatcatgct	95760
cagtaatgga	tattctgaat	ataatgggtc	tcagggaact	aatccacata	tgataaacgg	95820
caaaccaaaa	acatttgcta	tcgttactag	taaaatgaaa	tcgtcttttag	aggatctatt	95880
agatgtgtat	aattctcctg	aaaacgatga	tggtagtcaa	ttgatgtttt	tgttttcatc	95940
aaacattatg	tcogaatcct	atactctaaa	agaggtaagg	catatttggt	ttatgactat	96000
cccagatact	ttttctcaat	acaaccaaat	tcttggacga	tctattagaa	aattctctta	96060
cgccgatatt	tctgaaccag	ttaatgtata	tcttttagcc	gccgtatatt	ccgatttcaa	96120
tgacgaagtg	acgtcattaa	acgattacac	acaggatgaa	ttaattaatg	ttttaccatt	96180
tgacatcaaa	aagctgttgt	atctaaaatt	taagacgaaa	gaaacgaata	gaatatactc	96240
tattcttcaa	gagatgtctg	aaacgtattc	tcttccacca	catccatcaa	ttgtaaaagt	96300
tttattggga	gaattggtea	gacaattttt	ttataataat	tctcgtatta	agtataacga	96360
taccaagtta	cttaaaatgg	ttacatcagt	tataaaaaat	aaagaagacg	ctaggaatta	96420
catagatgat	attgtaaacg	gtcacttctt	tgtatcgaat	aaagtatttg	ataaatctct	96480
tttatacaaa	tacgaaaacg	atattattac	agtaccgttt	agactttcct	acgaaccatt	96540
tgtttgggga	gttaactttc	gtaaagaata	taacgtggta	tcttctccat	aaaactgatg	96600
agatatataa	agaaataaat	gtcgagcttt	gttaccaatg	gatacctttc	cgttacattg	96660
gaacctcatg	agctgacgtt	agacataaaa	actaatatta	ggaatgccgt	atataagacg	96720
tatctccata	gagaaattag	tggtaaaatg	gccaaagaaa	tagaaattcg	tgaagacgtg	96780
gaattacctc	tcggcgaaat	agtttaataat	tctgtagtta	taaacgttcc	gtgtgtaata	96840
acctacgcgt	attatcacgt	tggggatata	gtcagaggaa	cattaaacat	cgaagatgaa	96900
tcaaatgtaa	ctattcaatg	tggagattta	atctgtaaac	taagtagaga	ttcgggtact	96960
gtatcattta	gcgattcaaa	gtactgcttt	tttcgaaatg	gtaatgcgta	tgacaatggc	97020
agcgaagtca	ctgccgttct	aatggaggct	caacaaggta	tcgaatctag	ttttgttttt	97080
ctcgcgaata	tcgtcgactc	ataaaaaaga	gaatagcggt	aagtataaac	acgaataacta	97140
tggcaataat	tgcgaaatgtt	ttattctctt	cgataatatt	ttgataatat	gaaaaacatg	97200
tctctctcaa	atcggacaac	catctcataa	aatagttctc	gcgcgctgga	gaggtagttg	97260
ccgctcgtat	aatctctcca	gaataatata	cttgcggtgtc	gtcgttcaat	ttatacggat	97320
ttctatagtt	ctctgttata	taatgcgggt	tgcctcatg	attagacgac	gacaatagtg	97380
ttctaaattt	agatagttga	tcagaatgaa	tgtttatttg	cgttggaata	attatccata	97440
cagcgtctgc	agagtgggtg	atagttgttc	ctagatatgt	aaaataatcc	aacttactag	97500
gcagcaaat	gtctagataa	aatactgaat	caaacggtgc	agacgtattg	gcggatctaa	97560
tggaatccaa	ttgattaaact	atccttttgaa	aatatacatt	tttatgatcc	aatacttgta	97620
agaatataga	aataatgata	agtcctattt	cgtgtttttt	tgcctcttca	taagaactat	97680
attttttctt	attccaatga	acaagattaa	tcttccaga	gtatttgtac	acatctatca	97740
agtgattgga	tccataatcg	tcttcttttc	cccaatatat	atgtagtgat	gataacacat	97800
attcattggg	gagaaaccct	ccacttatat	atcctccttt	aaaattaatc	cttactagtt	97860
ttccagtgtt	ctggatagtg	gttggtttcg	actcattata	atgtatgtct	aacggcttca	97920
atcgcgcggt	agaaattgct	tttttagttt	ctatattaat	aggagatagt	tggtgcggca	97980



tagtaaaaat	gaaatgataa	ctgttttaaaa	atagctctta	gtatgggaat	tacaatggat	98040
gaggaagtga	tatttgaaac	tcctagagaa	ttaatatcta	ttaaacgaat	aaaagatatt	98100
ccaagatcaa	aagacacgca	tgtgtttgct	gcgtgtataa	caagtgcagg	atatccgtta	98160
ataggagcta	gaagaacttc	attcgcgttc	cagggcगतat	tatctcaaca	aaattcगतat	98220
tctatcttta	gagtatccac	taaactatta	cggtttatgt	actacaatga	actaagagaa	98280
atcttttagac	ggttgagaaa	aggttctatc	aacaatatcg	atcctcactt	tgaagagtta	98340
atattattgg	gtggtaaaact	agataaaaag	gaatctatta	aagattgttt	aagaagagaa	98400
ttaaaagagg	aaagtgatga	acgtataaca	gtaaaagaat	ttggaaatgt	aattctaaaa	98460
cttacaacac	gggataaatt	atttaataaa	gtatatataa	gttattgcat	ggcgtgtttt	98520
attaatcaat	cgttggagga	tttatcgcat	actagtattt	acaatgtaga	aattagaaaag	98580
attaaatcat	taaatgattg	tattaacgac	gataaatacg	aatatctgtc	ttatattttat	98640
aatatgctag	ttaatagtaa	atgaactttt	acagatctag	tataattagt	cagattatta	98700
agtataatag	acgactagct	aagtctatta	tttgcgagga	tgactctcaa	attattacac	98760
tcacggcatt	cgttaaccaa	tgcttatggt	gtcataaacg	agtatccgtg	tcgcctattt	98820
tattaactac	tgataacaaa	atattagtat	gtaacagacg	agatagtttt	ctctattctg	98880
aaataattag	aactagaaac	atgttttagaa	agaaacgatt	atttctgaat	tattccaatt	98940
atttgaacaa	acaggaaaaga	agtatactat	cgtcattttt	ttctctagat	ccagctacta	99000
ctgataatga	tagaatagac	gctattttatc	cgggtggcat	acccaaaagg	ggtgagaatg	99060
ttccagagtg	tttatccagg	gaaattaaag	aagaagttaa	tatagacaat	tcttttgtat	99120
tcatagacac	tcggttttttt	attcatggca	tcatagaaga	taccattatt	aataaatttt	99180
ttgaggtaat	cttcttttgtc	ggaagaatat	ctctaacgag	tgatcaaate	attgatacat	99240
ttaaaagtaa	tcatgaaate	aaggatctaa	tattttttaga	tccgaattca	ggtaatggac	99300
tccaatacga	aattgcaaaa	tatgctctag	atactgcaaa	acttaaattgt	tacggccata	99360
gaggatgtta	ttatgataca	ttaaaaaaat	taactgagga	tgattgatta	aaaaatataa	99420
attaattttac	catcgtgtat	ttttataaacg	ggattgtccg	gcataatcatg	tagatagtta	99480
ccgtctacat	cgtatactcg	accatctacg	cccttaaatc	ctctattttat	tgacattaat	99540
ctattagaat	tggaatacca	aatattagta	ccctcaatta	gtttattgggt	aatatttttt	99600
ttagacgata	gatcgatggc	tcttgaaacc	aagggttttc	aaccggactc	attgtcgatc	99660
ggtgagaagt	ctttttcatt	agcatgaate	cattctaatg	atgtatgttt	aaacactcta	99720
aacaattgga	caaattcttt	tgattttgctt	tgaatgattt	caaatagggtc	ttcgtctaca	99780
gtaggcatac	cattagataa	tctagccatt	ataaagtgc	cgtttacata	tctacgttct	99840
ggaggagtta	gaacgtgact	attgagacga	atggctcttc	ctactatctg	acgaagagac	99900
gcctcgttcc	atgtcatatc	taaaatgaag	ataatcatta	ttgagaaaaa	actaataccc	99960
tcgcctccac	tagaagagaa	tacgcattgt	ttaatgcatt	ctccgttagt	gtttgattct	100020
tggttaaact	cagccaccgc	cttgattcta	gtatcttttg	ttctagatga	gaactctata	100080
ttagagatac	caaagacttt	gaaatatagt	aataagattt	ctattcctga	ctgattaaca	100140
aatggttcaa	agactagaca	tttaccatgg	gatgctaata	ttcccaaaca	tacatctata	100200
aatttgacgc	ttttctcttt	taattcagta	aatagagaga	tatcagccgc	actagcatcc	100260
cctttcaata	gttctccctt	tttaaaggta	tctaattgcg	atttagaaaa	ctctctatct	100320
cttaatgaat	ttttaaaatc	attatatagt	gttgctatct	cttgccgcta	ttcgcccgga	100380
tcaogatttt	gtctttcagg	aaagctatcg	aacgtaaaacg	tagtagccat	acgtctcaga	100440
attctaaatg	atgatatacc	tgtttttatt	tcagcgagtt	tagccttttg	ataaatttct	100500
tcttgctttt	tcgacataat	aacgtatcgc	attaatactg	ttttcttagc	gaatgatgca	100560
gacccttcta	cgtcatcaaa	aatagaaaac	tcgttattaa	ctatatacga	acatagtcct	100620
cctagtttgg	agactaattc	tttttcatcg	actagacgtt	tattctcaaa	tagtgattgg	100680
tggtgtaagg	atcctgggtcg	tagtaagtta	accaacatgg	tgaattcttg	cacactattg	100740
acgatagggtg	tagccgataa	acaaatcatc	ttatggtttt	ttaacgcaat	ggtcttagat	100800
aaaaaattat	atactgaacg	agtaggacgg	atcttaccat	cttctttgat	taatgattta	100860
gaaatgaagt	tatgacattc	atcaatgatg	acgcataatc	tactcttgga	attaatagtt	100920
ttgatattag	taaaaaattt	atttctaaaa	ttttgatcat	cgtaattaat	aaaaatacaa	100980
tccttcgtta	tctctggagc	gtatctgagt	atagtgttca	tccaaggatc	ttctatcaaa	101040
gccttttttca	ccaataagat	aatagcccaa	ttcgtataaa	tatccttaag	atgtttgaga	101100
atatatacag	tagtcattgt	tttaccgaca	cccgtttcat	ggaacaataa	aagagaatgc	101160
atactgtcta	atcctaagaa	aactcttgct	acaaaatggt	gataatcctt	gaggcgctact	101220
acgtccgacc	ccatcatctt	aacgggcata	ttagtagttc	tcgtaaggc	ataatcgata	101280

-47-

taggccgcgt	gtgatttact	catttatgag	tgataagtaa	taactatggt	ttaaaaaatca	101340
cagcagtagt	ttaactagtc	ttctctgatg	tttgttttcg	atactttttg	aatcagaagt	101400
catactagaa	ttaaagcaacg	agtgaacgta	atagagagct	tcgtatactc	tattcgaaaa	101460
ctctaagaac	ttattaatga	attccgtatc	cactggattg	tttaaaaatac	taaattgaac	101520
actgttcaca	tcctttccaag	aagaagactt	agtgcgggac	ttaacatgag	acataaataa	101580
atccaaattt	tttttacaaa	catcactagc	caccataatg	gcgctatctt	tcaaccagct	101640
atcgcttacg	catttttagca	gtctaacatt	tttaaagaga	ctacaatata	ttctcatagt	101700
atcgattaca	cctctaccga	ataaagttgg	aagtttaata	atacaatatt	tttcgtttac	101760
aaaatcaa	aatggtcgaa	acacgtcgaa	ggtttaacatc	ttataatcgc	taatgtatag	101820
attgttttca	gtgagatgat	tatttagattt	aatagcatct	cgttcacggt	tgaacagttt	101880
attgcgtgcg	ctgaggtcgg	caactacggc	gtccgcttta	gtactcctcc	cataatactt	101940
tacgctatta	atcttttaaaa	tttcatagac	tttatctaga	tcgctttctg	gtaacatgat	102000
atcatgtgta	aaaagtttta	acatgtcggg	cggcattcta	tttagatcat	taactctaga	102060
aatctgaaga	aagtaattag	ctccgtattc	cagactaggt	aatgggcttt	tacctagaga	102120
cagattaagt	tctggcaatg	tttcataaaa	tggaagaagg	acatgcgttc	cctcccggat	102180
attttttaca	atttcatcca	tttacaactc	tatagtttgt	tttcattatt	attagttatt	102240
atctcccata	atcttggtaa	tacttaccoc	ttgatcgtaa	gataccttat	acaggtcatt	102300
acatacaact	accaattggt	tttgtacata	atagattgga	tgggtgacat	ccatggtgga	102360
ataaactact	cgaacagata	gtttatcttt	ccccctagat	acattagccg	taatagttgt	102420
cggcctaaag	aatatctttg	gtgtaaagtt	aaaagttagg	gttcttggtc	cattattgct	102480
ttttgtcagt	agttcattat	aaattctcga	gatgggtccg	ttctctgaat	atagaacatc	102540
atttccaaat	ctaacttcta	gtctagaaat	aatatcggtc	ttattcttaa	aatctattcc	102600
cttgatgaag	ggatcggtta	tgaacaaatc	cttggccttt	gattcggctg	atctattatc	102660
tccgtttatag	acgttacggt	gactagtcca	aagacttaca	ggaatagatg	tatcgatgat	102720
gttgatacta	tgtgatattg	gagcaaagat	tgttctctta	gtggcatcac	tatatgttcc	102780
agtaatggcg	gaaaactttt	tagaaatggt	atatataaaa	gaattttttc	gtgttccaaa	102840
cattagcaga	ttagtatgaa	gataaacact	catattatca	ggaacattat	caatttttac	102900
atacacatca	gcatcttgaa	tagaaacgat	accatcttct	ggaacctcta	cgatctcggc	102960
agactccgga	taaccagtcg	gtgggccatc	gctaacaata	actagatcat	ccaacaatct	103020
actcacatat	gcatctatat	aatctttttc	atcttgtgag	taccctggat	acgaaataaa	103080
tttattatcc	gtatttccat	aataagggtt	agtataaaca	gagagagatg	ttgccgcgatg	103140
aacttcaggt	acagtcgccg	ttgggttggt	tatttgacct	attactctcc	taggtttctc	103200
tataaacgat	ggtttaattt	gtacattctt	aaccatatat	ccaataaagc	tcaattcagg	103260
aacataaaca	aattctttgt	tgaacgtttc	aaagtcgaac	gaagagtcac	gaataacgat	103320
atcggatact	ggattgaagg	ttaccgttac	ggtaattttt	gaatcggata	gtttaagact	103380
gctgaatgta	tcttccacat	caaacggagt	tttaatatata	acgtatactg	tagatgggtc	103440
tttaatagtg	tcattaggag	ttaggccaat	agaaatatca	ttaagttcac	tagaatatcc	103500
agagtgtttc	aaagcaattg	tattattgat	acaattatta	tataattctt	cgccctcaat	103560
ttcccaaata	acaccgttac	acgaagagat	agatacgtga	ttaatacatt	tatatccaac	103620
atatgggtacg	taactgaatc	ttcccatacc	tttaacttct	ggaagttcca	aactcagaac	103680
caaagtatta	agcgacgtaa	tatactgatc	cctaatttctg	aagctagcga	tagcctgatt	103740
gtctggacca	tcggttggtca	taactccgga	tagagaaata	tattgctggca	tatataaagt	103800
tggaaatttga	ctatcgactg	cgaagacatt	agaccgttta	atagagtcac	ccccaccgat	103860
caaagaatta	atgatagtat	tattcattttt	ctattttaaaa	tggaaaaaagc	ttacaataaa	103920
ctccgtagag	aaatatctat	aatttgtgag	ttttccttaa	agtaacagct	tccgtaaacg	103980
ccgtctttat	ctcttagtag	gtttattgta	tttatgacct	tttcttctac	ttcatagaat	104040
actaaaggca	acaaagaaat	ttttggttct	tctctaagag	ctacgtgaga	cttaaccata	104100
gaagccaacg	aatccctaca	tatttttagaa	cagaaatacc	ctacttcacc	acccttgat	104160
gtctcaatac	taataggtct	aaaaaccaa	tcttgattac	aaaaccaaca	cttatcaatt	104220
acactatttg	tcttaataga	cacatctgcc	atagatttat	aatacttttg	tagtatataa	104280
gcgagtgtct	cttcttttagc	gggcttaaa	actgctttag	gtgctgaaat	aaccacatct	104340
ggaaggctta	ctcgcttagc	catttaatta	cggaaactatt	tttttatact	tctaagagc	104400
aagtagaaaa	cctctcatct	acaaaaacgt	actcgtgtcc	ataatcctct	accatagtta	104460
cacgtttttt	agatctcata	tgtgctaaaa	agttttccca	tactaattgg	ttactattat	104520
ttttcgtata	atttttaaca	gtttgaggtt	ttagattttt	agttacagaa	gtgatatoga	104580



-48-

atatttttato	caaaaagaat	gaataattaa	ttgtcttaga	aggagtgttt	tcttggaaca	104640
agaataccaa	gtgcttaaat	atttctacta	cttcattaat	cttttctgta	ctcagattca	104700
gtttctcatc	ttttacttga	ttgattatnt	caaagactaa	cttataatcc	tttttattta	104760
ttctctcggt	agccttaaga	aaactagata	caaaatttgc	atctacatca	tccgtggata	104820
tttgattttt	ttccatgata	tccaagagtt	ccgagataat	ttctccagaa	cattgatgag	104880
acaataatct	ccgcaataca	tttctcaaat	gaataagttt	attagacacg	tggaagtttg	104940
actttttttg	taccttttgta	cattttttgaa	ataccgactc	gcaaaaaata	caatattcat	105000
atccttggttc	agatactata	ccgttatgtc	tacaaccgct	acataatcgt	agattcatgt	105060
taacactcta	cgtatctcgt	cgtccaatat	tttatataaa	aacattttat	ttctagacgt	105120
tgccagaaaa	tcttgtaata	tttttagttt	tttgggctgt	gaataaagta	tgcgccata	105180
attgtttaccg	tcttccgcca	atatagtagt	taaaattatcc	gcacatgcag	aagaacaccg	105240
cttaggcgga	ttcagtacaa	tggttatatt	ttcgtaccaa	ctcattttaa	tatcataatc	105300
taaaatagtt	ctgtaatatg	tctagcgcta	atataattgat	cataatcctg	tgcataaatt	105360
aagatacaac	aatgtctcga	aatcatcgac	atggcttctt	ccatagttag	aagatcgtcg	105420
tcaaagttag	caacgtgatt	catcaacatt	tgctgttttg	aggcagcaaa	tactgaaccg	105480
tgcgccattca	accattcata	aaaaccatcg	tctgaatcca	ttgataatnt	cttgtactgg	105540
tttttgagag	ctcgcacaa	tctagcattt	ctagctcccg	gattgaaaac	agaaagagga	105600
togtacatcc	agggtccatt	ttctgtaaat	agaatcgtat	aatgtccctt	caagaagata	105660
tcagacgatc	cacatacaaa	gaattggctc	cggagtttgt	aacaaactgc	ggacttttaac	105720
ctatacatga	taccgttttag	cataatttct	ggtgatcagt	caatcggagt	atcatctatt	105780
agagatctaa	agccggtgta	acattctcca	ccaaacatat	tcttattctg	acgtcgttct	105840
acataaaaaca	tcattgctcc	attaacgata	acaggggaat	gaacagcact	acccatcaca	105900
ttagttccca	atggatcaat	gtgtgtaact	ccagaacatc	ttccatagcc	tatgttagga	105960
ggagcgaaca	ccactcttcc	actattgcca	togaatgcca	tagaataaat	atccttggaa	106020
ttgatagaaa	tccgactgtc	ggatgttgtg	atcatcttca	taggattaac	aactatgtat	106080
ggtgccgcct	gaagtttcat	atcgtaactg	atgccgttta	taggtctagc	cacagaaacc	106140
aacgtaggtc	taaatccaac	tatagacaaa	atagaagcca	atatctgttc	ctcatctgtc	106200
ataactttag	agcatccagt	atgaataatc	ttcatttagat	ggggatctac	cgcattcatca	106260
togttacaat	aaaaaattcc	cattctaatg	ttcataattg	cttttcta	catgggtatgc	106320
atgtttgctc	tctgaatctc	tgtggaaatt	agatctgata	cacctgtaat	cactatcgga	106380
ttatcctccg	taagacgatt	aaccaacaac	atataattat	aagactttac	ttttctaaat	106440
tcataaagtt	gctggattag	gctatagggtg	tctccatgta	catacgcggt	ctcgagcgca	106500
ggaagtttaa	taccgaatag	tgccatcaga	ataggatgaa	tatagtaatt	agtttctggt	106560
tttctataaa	taaaagacaa	atcttgtgaa	ctagacatat	cggtaaaatg	catggatttg	106620
aatcgtgtag	tcgacagaag	aatatgatga	ttagatggag	agtataattt	atctaactct	106680
ttgagttggg	caccgattct	aggactagct	cgagaatgaa	taagtactaa	aggatgagta	106740
catttcacag	aaacactagc	attgttcaat	gtgctcttta	catgggtaag	gagttgaaat	106800
agctcgtttc	tatttgttct	gacaatatnt	agtttattca	taatgttaag	catatcctga	106860
atagtaaagt	tagatgtgtc	atacttgttt	gtagtttagat	atttagcaat	tgcattccca	106920
tcatttctca	atctcgtact	ccaatcatgt	gtagatgcta	cttcgtcgat	ggaaaccata	106980
caatcctttt	tgataggctg	ttgagattga	tcatttccctg	cacgttttagg	tttggtacgt	107040
tgatttctag	cccctgcgga	tataaagtca	togtctacaa	tttgggacaa	tgaattgcat	107100
acactacaag	acaaagattt	atcagaagtg	tgaatatgat	cttcactctac	caaagaaaga	107160
gtttgattag	tataactaga	tttttagtct	gcgttagatg	ttaaaaaaac	atcgctattg	107220
accacggctt	ccattattta	tattcgtagt	ttttactcga	aagcgtgatt	ttaatatcca	107280
atcttattac	ttttggaatc	gttcaaaaacc	tttgactagt	tgtagaatnt	gatctatttg	107340
cctacgcgta	tactcccttg	catcatatac	gttcgtcacc	agatcgtttg	tttcggcctg	107400
aagttgggtgc	atatctcttt	caacattcga	catgagatcc	ttaagggcca	tatcgtctag	107460
attttgttga	gatgctgctc	ctggattttg	attttgttgt	gctgttgtag	atactgtacc	107520
accagtaggt	gtaggagtac	atacagtggc	cacaatagga	ggttgagaaa	gtgtaaccgt	107580
tgagtagta	caagaaatac	ttccatccga	ttgttgtgta	catgtagttg	ttggtaacgt	107640
ctgagaaggt	tgggtagatg	gcggcgctcg	cgttttttga	tctttattaa	atttagagat	107700
aatatcctga	acagcattgc	tcggcgctcaa	cgctggaagg	agtgaactcg	ccggcgcatc	107760
agtatcttca	gacagccaat	caaaaagatt	agacatatca	gatgatgtat	tagtttgttg	107820
tcgtgggttt	ggtgtaggag	cagtactact	aggtagaaga	ataggagccg	atgtagctgt	107880

-49-

tgggaaccggc	tgtggagtta	tatgaatagt	tggttgtagc	ggttggatag	gctgtctgct	107940
ggcggccatc	atattatctc	tagctagtgt	ttctcgcaac	tgtctttgat	aatacgactc	108000
ttgagacttt	agtcctatct	caatcgcttc	atcctttttc	gtatccggat	ccttttcttc	108060
agaataatag	attgacgact	ttggtgtaga	ggattctgcc	agcctctgtg	agaacttggt	108120
aaagaagtcc	atttaagggt	ttaaaattga	attgcgatta	taagattaaa	tggcagacac	108180
agacgatatt	atcgactatg	aatccgatga	tctcaccgaa	tacgaggatg	atgaagaaga	108240
ggaagaagat	ggagagtcac	tagaaactag	tgatatagat	cccaaactct	cttataagat	108300
tgtagaatca	gcatccactc	atatagaaga	tgcgcattcc	aatcttaaac	atatagggaa	108360
tcatatatct	gctcttaaac	gacgctatac	tagacgtata	agtcctattg	aaatagcggg	108420
tataatagca	gaaagctata	acttgcttca	acgaggaaga	ttacctctag	tttcagaatt	108480
ttctgacgaa	acgatgaagc	aaaatatgct	acatgtaatt	atacaagaga	tagaggaggg	108540
ttcttgtcct	atagtcacgt	aaaagaacgg	agaattgttg	tcggtaaacg	atthttgacaa	108600
agatgggtcta	aaattccatc	tagactatat	tatcaaaatt	tggaaacttc	aaaaacgata	108660
ttagaattta	tacgaatatc	gttctctaaa	tgtcacaatc	aagtctcgca	tgttcagcaa	108720
ttttattgtcg	tactttatat	cgtgttcatt	aacgatattc	tgcaaaaatag	taatgattct	108780
atcttcccttc	gatatagatt	cttcagagat	tattgtctta	tattctttct	tgttatcaga	108840
tatgaatttg	ataagacttt	gaacattatt	gatacccgct	tgtttaattt	ttctacaga	108900
tatttttagtt	ttggcagatt	ctatcgtatc	tgtcaataga	catccaacat	cgacattcga	108960
cgtcaattgt	ctataaatca	acgtataaat	tttagaaata	acattagcga	attgttgtgc	109020
gttgatgtcg	ttattctgaa	acagtatgat	tttaggtagc	atthttcttaa	caaagagaac	109080
gtattttattg	ttactcagtt	gaacagatga	tatatccaga	ttactaacgc	atctgattcc	109140
gtataccaaa	ctttcagaag	aaatgggtata	caattgtttg	tattcattca	atgtctcttt	109200
ttcagaaatt	agtttagagt	cgaatactgc	aataattttc	aagagatagt	tttcatcaga	109260
taagatttta	tttagttag	atatgataaa	actattgttt	tgttggagaa	cttgatacgc	109320
cgcgttctct	gtagtcgacg	ctctcaaatg	ggaaacaatc	tccattattt	ttttggaatc	109380
ggatactata	tcttcgggtat	cttgacgcag	tctagtatac	atagagttaa	gagagattag	109440
agttttgtaca	tttaagcaaca	tgtctctaaa	tgtggctaca	aacttttctc	ttttcacatc	109500
atctagttta	ttatataccg	atthtcacaac	ggcaccagat	tttaaggaacc	agaatgaaaa	109560
actctgataa	ctacaatatt	tcatcatagt	tacgatttta	tcatcttcta	tagttgggtgt	109620
aatagcgcac	acctttttct	ccaagactgg	aaccaacgct	ataaaaatgt	ttaaatcaaa	109680
atccatatca	acatctgatg	cgctaagacc	agtctcgcgt	tcaagattat	ctttactaat	109740
ggtgacgaac	tcatcgtata	aaactctaag	tttgtccatt	atthattttac	agatttaggt	109800
gtttaatttta	tttgtctctc	tccagagttg	ggatagtatt	tttctaacgt	cggatttata	109860
ttattaggat	ctacgttcat	atgtatcata	atattaatca	tccacgtttt	gataaatcta	109920
tcttttagctt	ctgaaataac	gtattttaaac	aaaggagaaa	aatattttagc	tacggcatca	109980
gacgcaataa	cattttttgt	aaatgtaacg	tatttagacg	acagatcttc	gttaaaaagt	110040
tttccatcta	tgtagaatcc	atcggttggt	aacaccattc	cgcgctcaga	ttgaatagga	110100
gtttgaatag	tttggttttg	aaatagatcc	ttcaataact	tatagttggg	tgggaaaaaa	110160
tcgatttttat	cactagactc	tttctttttt	actatcatta	cctcatgaac	tatttcttga	110220
atgagtatat	gtatttttct	tcttatatcg	gacgcgttca	ttggaaaata	taccatgtcg	110280
ttaaactataa	gaatattttt	atcctcgttt	acaaactgaa	taatatcaga	tgtagttcgt	110340
aaacgaacta	tatcatcacc	agcacaacat	ctaactatat	gatatccact	agtttccttt	110400
agccgttttat	tatcttgttc	catattagca	gtcattccat	catttaagaa	ggcgtcaaag	110460
ataataggga	gaaatgacat	tttggtattc	gttacgactt	tacaaaaatt	aaggatatac	110520
ggacttacta	tcttttttct	aacgtcaatt	tgatgaacac	acgatgaaaa	tgtgcttcta	110580
tgagattgat	catgtagaaa	acaacaaggg	atacaatatt	tccgcatatc	atgaaatata	110640
ttaagaaatc	ccaccttatt	atattttccc	aaaggatcca	tgcacgtaaa	cattatgccg	110700
ttatcattaa	taaagacttc	tttctcatcg	gatctgtaaa	agttgttact	gatttttttc	110760
attccaggat	ctagataaatt	aataatgatg	ggttttctat	tcttattctt	tgtatttttg	110820
catatcctag	accagtaaac	agtttccact	ttggtaaaat	cagcagactt	ttgaacgcta	110880
ttaaacatgg	cattaatggc	aataactaaa	aatgtaaaaat	atthtttctat	gttaggaata	110940
tgggtttttca	ctttaataga	tatatggttt	ttggccaaaa	tgatagatat	ttttttatcc	111000
gaggatagta	aaatattatt	agtcgcgcgt	tctataaaaa	tgaagctagt	ctcgatatcc	111060
aatttttattc	tagaattgat	aggagtcgcc	aaatgtacct	tatacgttat	atctcccttg	111120
atgcgttcca	tttgtgtatc	tatatcggac	acaagatctg	taaatagttt	tacgttatta	111180

-50-

atcatcacgg	tatcgccgtc	gctagataac	gctaattgtac	catccaagtc	ccaaatggag	111240
agattttaact	gttcatcggt	tagaataaaa	tgattaccgg	tcatattaat	aaagtgttca	111300
tcgtatctag	ataacaacga	cttataatta	atgtccaagt	cttgaactcg	ctgaatgata	111360
ttttttaacc	cagttagttt	tagattggta	cgaaatatat	tgttaaactt	tgattctaca	111420
gtaatgtcca	aatctagttg	tggaataact	tccatcaaca	ttgtttcaaa	cttgataata	111480
ttattatcta	catcttcgta	cgatccaaat	tccggaatag	atgtatcgca	cgctctggcc	111540
acccagataa	ccaaaaagtc	acacgctcca	ggatatacat	tgtataaaaa	gctatcgttt	111600
tttagtaggg	tttttttctg	cgtgtatacg	aagggtatga	aaatagtatt	atcaacgtaa	111660
ctatattcca	aattattctt	atgagaatag	ataataatat	cgctcctaat	atctaacaaa	111720
tttcctaaat	atccctttaa	ttgagtcatt	cgaagcgtca	atagaatatg	tctccttaact	111780
atttcgggct	gttgatatatt	taaatgactt	cgtaaaaaat	aatatatggg	cgacttctca	111840
tctatgtaat	catatggagt	gagatatagg	gctcgttcta	cctcctgccc	cttaccacc	111900
tgtaatacca	attgcggaact	tactatataat	cgcataattta	tatcgtgggg	taaagtgaag	111960
atctactacc	gatgatgtaa	gtcttacaat	gttcgaacca	gtaccagatc	ttaatgtgga	112020
ggcctccgta	gaactagggg	aggtaaataat	agatcaaaca	acacctatga	taaaggagaa	112080
tagcgggtttt	atatcccgca	gtagacgtct	attcgcccat	agatctaagg	atgatgagag	112140
aaaactagca	ctacgattct	ttttacaaag	actttatttt	ttagatcata	gagagattca	112200
ttatttggtc	agatgcgttg	acgctgtaaa	agacgtcact	attaccaaaa	aaaataacat	112260
tatcgtggcg	ccttataatag	cacttttaac	tatcgcatca	aaaggatgca	aacttacaga	112320
aacaatgatt	gaagcattct	ttccagaact	atataatgaa	catagtaaga	aattttaaatt	112380
caactctcaa	gtatccatca	tccaagaaaa	actcggatac	cagtttgga	actatcacgt	112440
ttatgatttt	gaaccgtatt	actctacagt	agctctggct	attcgagatg	aacattcatc	112500
tggcattttt	aatatccgtc	aagagagtta	tctggtaagt	tcattatctg	aaataacata	112560
tagattttat	ctaattaatc	taaaatctga	tcttggtcaa	tggagtgcga	gtacggggcg	112620
tgtaattaat	caaagtgtga	atactgtatt	gattacagtg	tatgaaaagt	tacaactggt	112680
catagaaaat	gattcacaat	ttacatgttc	attggctgtg	gaatcaaaac	ttccaataaa	112740
attacttaaa	ataagaaatg	aattatttac	aaaattcatt	aacgagttaa	aaaagaccag	112800
ttcattcaag	ataagcaaac	gcgataagga	tacgctacta	aaatatattta	cttaggactg	112860
gagttagaat	ttatagacga	ctcatttcgt	ttatcattgt	tactattatt	actattacta	112920
tcattattag	tggtggcatt	attagtatct	ttcttgctcat	cttggttcaga	aatatacagc	112980
aatgctatac	ctaatactaa	atacattatc	atgctcgcaa	tggctctaac	aacaacgaac	113040
caaaatgaat	ttggctcgtag	cttttggttca	caaaaatata	taaagaaatg	tctacataaa	113100
tctatggcgc	cattggctac	ttgaaatagc	gccagtcctc	ctacagattt	taatatagct	113160
gtataaacatg	acattttattc	atcatcaaaa	gagacagagt	caccatctgt	catattttaga	113220
tttttttcca	tgtgttcaaa	gtatcctcta	ctcatttcatt	tataatagtt	tatcatactt	113280
agaatatttag	gacggatcaa	tgagtaagac	ttgactagat	cgctcagtagt	aatttggtgca	113340
tcgtctattc	tgcatccgct	tcgtcgaata	atgtatagca	tcgctttgag	attctccata	113400
gctatcaagt	ctttatacaa	tgacatggaa	atatctgtga	atactttata	cttctccaac	113460
atcgatgcct	taacatcatc	gcctacttta	gcattgaaaa	tacgttctat	tgtgtagatg	113520
gatgtagcaa	gattttttaa	caacaatgcc	atcttacacg	atgattgcct	caagtctcca	113580
atcgtttggt	tagaacgatt	agctacagag	tccaatgctt	ggctgactag	catattatta	113640
tctttagaaa	ttgtattctt	caatgaggcg	tttatcatat	ctgtgatttc	gttagtcata	113700
ttacagtctg	actgggttgt	aatgttatcc	aacatatcac	ctatggatac	ggtacacgta	113760
ccagcatttg	taataatcct	atctaagatg	ttgtatggca	ttgcgcagaa	aatatcttct	113820
cctgtaatat	ctccactctc	gataaatcta	ctcagattat	tcttaaatgc	cttattctct	113880
ggagaaaaga	tatcagtgtc	catcatttca	ttaatagtat	acgcagaaaa	gataaccaga	113940
gtatcaattc	tatccaagat	acttatcggt	tccgagtcac	agataatggg	ttcctctcct	114000
tcggggagatc	ctgcatagaa	atatctagga	caatagtttc	tatactgtct	gtaactctga	114060
taatctctaa	agtcactaac	tgataccatg	aaattgagaa	gatcaaacgc	tgaagtaatt	114120
aatttttctg	cctcggtttt	actacaacta	gttttcatca	atgtagtgac	gatgtattgt	114180
ttagttactt	ttggtctaat	actgatgata	gagatattat	tgcttcccat	aatggatctt	114240
ctagtagtca	ccttaagcc	cattgatgcg	aatagcagat	agataaagtc	ttggtagtac	114300
tcctttctaa	tatagtcagg	actacctttg	tcacccaact	ttataccac	ataagccata	114360
acaacctctt	taatagccgt	ttcatgaggt	ttatcagcca	tgagcctgag	tagttggaag	114420
aatctcatga	atcccgctctc	agaaagtcct	atatgcatga	tagattttatc	tttctcggga	114480

-51-

aactctcgta	tagtcataga	tgaaatactc	tttaaagttt	ctgaaataag	attagtaaca	114540
gtcttacctc	cgactactct	aggtaacaaa	caaactctaa	taggtgtttt	ctctgcggag	114600
ataatatcag	aaaggataga	gcaataagta	gtattattgt	gattataaag	accgaataca	114660
taacaggtag	aattttataaa	catcatgtcc	tgaagggttt	tagacttgta	ttcctcgtaa	114720
tccataccgt	cccaaaacat	ggatttggta	actttgatag	ccgtagatct	ttgttccttc	114780
gccaacaggt	taaagaaatt	aataaagaat	ttgttgtttc	tatttatgtc	cacaaattgc	114840
acgtttggaa	gcgccacggt	tacattcact	gcagcatttt	gaggatcgcg	agtatgaagt	114900
acgatgttat	tgtttactgg	tatatctgga	aagaaatcta	ccagtctagg	aataagagat	114960
tgatatcgca	tagaaatagt	aaagtttata	atctcatcat	cgaagagcat	tttgttacca	115020
ttgtaataaa	tatccactct	gtcatatgta	taaatgaagt	actgttcaaa	catgatgaga	115080
tgttttatatg	ttggcatagt	agtgagatcg	acgtttggta	atggcaatgt	attaagatta	115140
actccataat	gtctagcagc	atctgogatg	ttataagcgt	cgtcaaagcg	gggtcgatct	115200
tgtattgtta	tatattgtct	aacacctata	agattatcaa	aatcttgtct	gcttaataca	115260
ccgttaacaa	tttttgccct	gaattctttt	attgggtgcat	taataacatc	cttatagagg	115320
atgtaaaca	aataagtgtt	atcaaagtta	agatctggat	atttcttttc	tgctagaaca	115380
tccattgagt	cggagccatc	tggtttaata	taaccaccga	taaatctagc	tctgtattct	115440
gtatccgtca	atctaattatt	aagaagggtg	tgagtgaag	gtggaagatc	gtaaaagctg	115500
tgagtattaa	tgataggatt	agtttccgaa	ctaagtgtta	ttgggggtatt	aataatatct	115560
atattttccag	cgtaaagtgt	aacattaaac	agttttaatt	cacgtgacgt	ggtatcaatt	115620
aaataattaa	tgcccaattt	ggatatagca	gcctgaagct	catcttgttt	agttacggat	115680
cctaattgagt	tattaagcaa	tatatcgaac	ggatgaacga	aggttgtttt	aagttggtca	115740
catactttgt	aatctagaca	tagatgcgga	agaacggtag	aaactatacg	aaataaatat	115800
tcagagtcct	ctaattgatc	aagagtaact	attgacttaa	taggcatcat	ttatttagta	115860
ttaaatgacg	accgtaccag	tgacggatat	acaaaacgat	ttaattacag	agttttcaga	115920
agataaattat	ccatctaaca	aaaattatga	aataactctt	cgtcaaattgt	ctattctaac	115980
tcacgttaac	aacgtggtag	atagagaaca	taatgccgcc	gtagtgtcat	ctccagagga	116040
aatatcctca	caacttaatg	aagatctatt	tccagatgat	gattcaccgg	ccactattat	116100
cgaacgagta	caacctcata	ctactattat	tgacgatact	ccacctccta	cgtttcgtag	116160
agagttatta	atatcggaac	aacgtcaaca	acgagaaaaa	agatttaata	ttacagtatc	116220
gaaaaatgct	gaagcaataa	tggaatctag	atctatgata	acttctatgc	caacacaaac	116280
accatccttg	ggagtagttt	atgataaaga	taaaagaatt	cagatgttag	aggatgaagt	116340
ggttaatctt	agaaatcaac	gatctaatac	aaaatcatct	gataatttag	ataattttac	116400
caaaatacta	tttggttaaga	ctccgtacaa	atcaacagaa	gttaataagc	gtatagccat	116460
cgttaattat	gcaaatttga	acgggtcccc	cttaacagtc	gaggacttgg	atgtttgttc	116520
ggaggatgaa	atagatagaa	tctataaaac	gattaacaaa	tatcacgaaa	gtagaaaacg	116580
aaaaattatc	gtcactaacg	tgattattat	tgtcataaac	attatcgagc	aggcattgct	116640
aaaactcgga	tttgaagaaa	tcaaaggact	gagtaccgat	atcacttcag	aaattatcga	116700
tgtggagatc	ggagatgact	gcgatgctgt	agcatctaaa	ctaggaatcg	gtaacagtc	116760
ggttcttaat	attgtattgt	ttataactcaa	gatattcggt	aaacgaatta	aaattattta	116820
atttaataca	ttcccatatc	cagacaacaa	tcgtctggat	taatctgttc	ctgtcgtctc	116880
ataccggacg	acatattaat	ctttttatta	gtgggcatct	ttttagatgg	tttctttttc	116940
ccagcattaa	ctgagtcgat	acctagaaga	tcgtgattga	tctctccgac	cattccacga	117000
acttctaatt	ggcgcgtctc	gacggtagca	taaactattt	taccagcatt	agtaacagct	117060
tggacaatct	gaccatccat	cgcattgtac	gatgtagtag	taactgttgt	tctacgtcta	117120
ggagcaccag	aagtattttt	ggagcccttg	gatgttgatg	tagaagaaga	cgaggatttt	117180
gattttgggt	tacatgtaat	acattttgaa	ctctttgatt	ttgtatcaca	tgccgccgga	117240
gtcacatctg	tttgagaatt	aagattattg	ttgcctcctt	tgacggctgc	atctccaccg	117300
atttgcgcta	gtagattttt	aagctgtggt	gtaatcttat	taactgtttc	gatataatca	117360
tcgtaactgc	ttctaacggc	taaatttttt	ttatccgcca	tttagaagct	aaaaatattt	117420
ttatttatgc	agaagattta	actagattat	acaatgaact	aatatgatcc	ttttccagat	117480
tattttacaaa	cttggttctt	tttggttctg	gaggaggcga	atttaaatcc	ggacttggat	117540
tcggattttg	taagttcttg	atcttattat	acatcgagta	taggatggcg	acagtaactg	117600
ctacacaaat	accgatcaaa	agaagaatac	caatcattta	ttgacaataa	cttcactatt	117660
gatcaagtat	gcaatatatc	atcttttcac	taaataagta	gtaataatga	ttcaacaatg	117720
tcgagatata	tggaacgataa	taatttagtt	catggaaata	tcgctatgat	tggtgtgaat	117780

-52-

gactccgcta	actctgtggg	gtgcgcagtg	ctttcccccac	atagaataaaa	ttagcattcc	117840
gactgtgata	ataataccaa	gtataaacgc	cataatactc	aatactttcc	atgtacgagt	117900
gggactggta	gacttactaa	agtcaataaa	ggcgaagata	cacgaaagaa	tcaaaaagaat	117960
gattccagcg	atttagcacgc	cggaaaaata	atttccaatc	ataagcatca	tgtccattta	118020
actaataaaa	attttaaatc	gccgaatgaa	caaagtggaa	tataaaccat	ataaaaacaa	118080
tagtttgtag	tgcaaaaata	atatctattt	ttgttttcga	agatatggta	aaattaaata	118140
gtagtacaca	gcatgttata	actaacagca	gcaacggctc	gtaattactt	atcattttact	118200
agacgaaaag	gtgggtgggat	attttcttgc	tcaataataa	cgaatatatc	acccatccat	118260
tttatgcat	gtttatatac	tctaactctt	aatagatcta	tagacgacgg	gtttaccaac	118320
aatatagatt	ttatcgattc	atctaattta	aacccttcct	taaacgtgaa	tgatctatta	118380
tctggcataa	cgatgacct	acctgatgaa	tccgacaatg	tactgggcca	tgtagaataa	118440
attatcaacg	aattatcgtc	tacgaacatt	tatatcattt	gttttaattt	taggacgcga	118500
ataaatggat	ataaaataga	aaataacaga	tattacaacc	agtgttatgg	ccgcgcccaa	118560
ccaggtaggc	agttttat	tatcttttac	tacaggttct	cctggatgta	cgtcaccaac	118620
ggcggagcta	gttctagtac	aatttagacgt	aagttccgct	tgggaatttt	taaacgctaa	118680
agagttaacg	ttaatcgtgc	acccaacgta	tttcatcta	gttcggtgaa	catcttgatt	118740
ataatataac	cattttctat	ctctagattc	gtcagtgac	tcatgtaacc	aacataacct	118800
aggtcctaaa	tatttatctc	cgggaattaga	ttttggataa	ttcgcgcacc	aacaatttct	118860
atttccttta	tgatcgttac	aaaagacgta	taatgccgta	tccccaaaag	taaaataatc	118920
aggacgaata	attctaataa	actcagaaca	atatctcgca	tccatatgtt	tggagcaaat	118980
atcggaataa	gtagacatag	ccggtttccg	ttttgcacgt	aaccattcta	aacaattggg	119040
gtttccagga	tcgtttctac	aaaatccagt	catgaaatcg	tcacaatgtt	ctgtcttgta	119100
attattatta	aatatttttg	gacagtgttt	ggtattttgtc	ttagaacaac	attttgccac	119160
gctatcacta	tcgccagga	gataatcctt	ttttataaaa	tgacatcggt	gcccggatgc	119220
tatataatca	gtagcgtgtt	ttaaatcctt	aataattcca	ggagttacct	cgttctgata	119280
atagattaat	gatccaggac	gaaatttgaa	agaactacat	ggttctccat	gaattaatac	119340
atattgttta	gcaaattcag	gaactataaa	actactacaa	tgatctatcg	acataccatc	119400
tatcaaacaa	aacttgggtt	taatttctcc	cggagatgtt	tcataatagt	acgtataact	119460
ttcttctgca	aacttaacag	ctctattata	ttcaggataa	ttaaaaccta	attccatata	119520
tttgtctcgt	atatctgcta	ttcctgggtgc	tatttttgatt	ctattaagag	taacagctgc	119580
ccccattctt	aataatcgtc	agtatttaaa	ctgttaaatg	ttggtatatc	aacatctacc	119640
ttatttcccg	cagtataagg	tttgttgcag	gtataactgtt	caggaatggg	tacatttata	119700
cttcttctat	agtcctgtct	ttcgatgttc	atcacattgt	caaagaacag	aataaacaaa	119760
ataatgtaag	aaataatatt	aaatatctgt	gaattcgtaa	atacattgat	tgccataata	119820
attacagcag	ctacaataca	cacaatagac	attcccacag	tggtgccatt	acctccacga	119880
tacatttgag	ttactaagca	ataggttaata	actaagctag	taagaggcaa	tagaaaagat	119940
gagataaata	tcatcaatat	agagattaga	ggagggtctat	atagagccaa	gacgaacaaa	120000
atcaaaccga	gtaacggtct	aacatcatta	tttttgaaga	ttcccaaata	atcattcatt	120060
cctccataat	cgttttgcat	catacctcca	tctttaggca	taaacgattg	ctgctgttcc	120120
tctgtaaaata	aatctttatc	aagcactcca	gcaccgcgag	agaagtcgtc	aagcatattg	120180
taatatctta	aataactcat	ttatatatta	aaaaatgtca	ctattaaaga	tggagtataa	120240
tctttatgcc	gaactaaaaa	aaatgacttg	tggtcaacct	ctaagtcttt	ttaacgaaga	120300
cggggatttc	gtagaagttg	aaccggggtc	atcctttaag	tttctgatac	ctaagggtat	120360
ttacgcctct	ccttcogtaa	agacgagtct	agtattcgag	acattaacaa	cgaccgataa	120420
taaaatcact	agtatcaatc	caacaaatgc	gccaaagtta	tatcctcttc	aacgcaaagt	120480
cgtatctgaa	gtagtttcta	atatgaggaa	aatgatcgaa	tcaaaacgtc	ctctatacat	120540
tactcttcac	ttggcgtgtg	gatttggttaa	gactattacc	acgtgttatc	ttatggctac	120600
acacggtaga	aaaaccgtca	tttgcgtagc	caataaaatg	ttaatacatc	aatggaagac	120660
acaggtagag	gcagtcggat	tggaaacataa	gatatccata	gatggagtaa	gtagtctatt	120720
aaaggaacta	agactcaaa	gtccggatgt	attaatagta	gtcagtagac	atctgacaaa	120780
cgatgccttt	tgtaaatata	tcaataagca	ttatgatttg	ttcatcttgg	atgaatcaca	120840
tacgtataat	ctgatgaaca	atacagcagt	tacaagattt	ttagecgtatt	atcctccgat	120900
gatgtgttat	tttttaactg	ctacacctag	accatctaac	cgaattttatt	gtaacagtat	120960
tattaatatt	gccaaagtta	ccaatctaaa	aaaaactatc	tatgcagtag	atagtttttt	121020
tgagccatat	tccacagata	atattagaca	tatggtaaaa	cgactagatg	gaccatctaa	121080

-53-

taaatatcat	atatataaccg	agaagttatt	atctgtagac	gagcctagaa	atcaacttat	121140
tcttgatacc	ctggtagaag	aattcaagtc	aggaactatt	aatcgcat	tagttattac	121200
taaactacgt	gaacatatgg	tattattcta	caaacgatta	ttagattttt	tggaccaga	121260
ggttgatatt	ataggagacg	cccaaaatag	acgtactcca	gatatggtca	aatcaatcaa	121320
ggaactaaat	agatttatat	tcgtatccac	cttattttat	tccggtactg	gtttagatat	121380
tcctagtttg	gattcgttgt	tcatttgctc	ggcagtaatc	aacaatatgc	aaatagagca	121440
attactaggg	agggtagtgc	gagaaacaga	actattagat	aggacggtat	atgtatttcc	121500
taacacatcc	atcaaagaaa	taaagtacat	gataggaaat	ttcatgcaac	gaattattag	121560
tctgtctgta	gataaactag	gatttaaaca	aaaaagttat	cggaaacatc	aagaatccga	121620
tcccacttct	gcatgtacaa	catcatccag	agaagaacgt	gtattaaata	gaatatttaa	121680
ctcgcaaaat	cgtaagaag	tttaagcgac	gatccgcatg	ctgcgaggc	cagtgtatta	121740
cccccatag	tattaatata	atccaatgat	acttttgtga	tgtcggaat	cttaaccaat	121800
ttagactgac	aggcagaaca	cgcatgcaa	tcatcatcgt	catcgataac	tgtagtcttg	121860
ggcttctttt	tgcgactctt	cattccggaa	cgcacattgg	tgctatccat	ttaggtagta	121920
aaaaataagt	cagaatatgc	cctataacac	gatcgtgcaa	aacctggtat	atcgtctcta	121980
tctttatcac	aatatagtgt	atcgacattt	ttattattat	tgacctcgtt	tatcttggaa	122040
catggaatgg	gaacattttt	gttatcaacg	gccatctttg	ccttaattcc	agatgttgta	122100
aaattataac	taaacagtct	atcatcgaca	caaataaagt	tcttgtttag	acgtttgtag	122160
tttacgtatg	cggctcgttc	gcgtctcatt	ttttcagata	ttgcaggta	tataatatta	122220
aaaataagaa	tgaaataaca	taggattaaa	aataaagtta	tcagtacttc	tagcgtgat	122280
ttaactaact	taaaagaatt	acttagtctg	tacaaaagtt	tgagattttc	agattctgcg	122340
gctatagaaa	agtataattc	tttggtagaa	tggggaacat	ctacttactg	gaaaataggc	122400
gtgcaaaagg	tagctaattg	cgagacgtca	atatctgatt	attatgatga	ggtaaaaaat	122460
aaaccgttta	atattgatcc	gggctattac	atcttcttac	cggatatatt	tgggagcgct	122520
tttattttatt	cgaagggtaa	aaatatggta	gaacttggat	ctggaaactc	ttttcaaata	122580
ccagatgata	tgcgaaagtgc	gtgtaacaaa	gtattagaca	gcgataacgg	aatagacttt	122640
ctgagatttg	ttttgttaaa	caatagatgg	ataatggaag	atgctatatc	aaaatatcag	122700
tctccagtta	atatatttaa	actagctagt	gagtagcgat	taaacatacc	caaataattta	122760
gaaattgaaa	tagaggaaga	cacattat	gacgacgagt	tatactctat	tatagaacgc	122820
tctttcgtatg	ataaatttcc	aaaaatatcc	atatcgtata	ttaggtggg	agaacttaga	122880
cggcaagttg	tagacttttt	caaattctca	ttcatgtata	ttgagttccat	caaggtagat	122940
cgtataggag	ataatatttt	tattcctagc	gttataacaa	aatcaggaaa	aaagatatta	123000
gtaaaagatg	tagaccattt	aatacgatcc	aaggttagag	aacatacatt	tgtaaaagta	123060
aaaaagaaaa	acacattttc	cattttatac	gactatgatg	gaaacgggaa	agaaactaga	123120
ggagaagtaa	taaaacgaat	tatagacact	ataggacgag	actattatgt	taacgggaa	123180
tatttctcta	aggttggtag	tgcaggctta	aagcaattga	ctaataaatt	agatattta	123240
gagtgcgcaa	ctgtcgatga	gttagttgat	gagattaata	aatccggaac	tgtaaaacga	123300
aaaataaaaa	accaatcagc	atttgattta	agcagagaat	gtttgggata	tccagaagcg	123360
gattttataa	cgttagttaa	taacatgcgg	ttcaaaatag	aaaattgtta	ggttgtta	123420
ttcaatattg	aaaatactaa	ttgtttaaat	aaccgagta	ttgaaactat	atatgggaa	123480
tttaaccagt	tcgtctcaat	ctttaatgtc	gtcaccgatg	tcaaaaaaag	attattcgag	123540
tgaataata	tgccgctttg	atatagggtc	aaaaaatcct	gccagaactg	ttttagaagt	123600
caaggataac	tccgttaggg	tattggatat	atcaaaatta	gactggagtt	ctgattggga	123660
aaggcgcata	gctaaagatt	tgtcacaata	tgaatacact	acagttcttc	tagaacgtca	123720
gcctagaagg	tcgccgtatg	ttaaatttat	ctattttatt	aaaggctttt	tatatcatac	123780
atcggctgcc	aaagttat	gcgtctcgcc	tgtcatgtct	ggtaattcat	atagagatcg	123840
aaaaaagaga	tcggtcgaag	cattttottga	ttggatggac	acattcggat	tgcgagactc	123900
cgttccggat	agacgcaat	tagacgatgt	agcggatagt	ttcaatttgg	ctatgagata	123960
cgtattagat	aaatggaata	ctaattatac	accttataat	aggtgtaaat	ctagaaatta	124020
cataaaaaaa	atgtaataac	gttagtaacg	ccattatgga	taatctattt	acctttctac	124080
atgaaataga	agatagatat	gccagaacta	tttttaactt	tcattctaata	agttgcgatg	124140
aaataggaga	tatatatggg	cttatgaaag	aacgcatttc	ctcagaggat	atgttttgata	124200
atatagtgta	taataaagat	atacatcctg	ccattaagaa	actagtgtat	tgcgacatcc	124260
aacttactaa	acacattatt	aatcagaata	cgtatccggg	atttaacgat	tcttcacaag	124320
tgaatgttg	tcattatttc	gacataaact	cagataatag	caatattagc	tctcgtacag	124380



-54-

tagagatatt	tgagagggaa	aagtcattctc	ttgtatcata	tattaaaact	accaataaga	124440
agagaaaggt	caattacggc	gaaataaaga	aaactgttca	tggaggcact	aatgcaaatt	124500
acttttccgg	taaaaagtct	gacgagtatc	tgagtactac	agttagatcc	aacattaatc	124560
aaccttggtg	caaaaccatc	tctaagagga	tgagagttga	tatcattaat	cactctatag	124620
taacgcgtgg	aaaaagctct	atattacaaa	ctatagaaat	tatttttact	aatagaacat	124680
gtgtgaaaat	attcaaggat	tctactatgc	acattattct	atccaaggac	aaggatgaaa	124740
aggggtgtat	acacatgatt	gacaaattat	tctatgtcta	ttataattta	tttctgttgt	124800
tcgaagatat	catccaaaac	gagtacttta	aagaagtagc	taatgttgta	aaccacgtac	124860
tcacggctac	ggcattagat	gagaaattat	tcctaattaa	gaaaatggct	gaacacgatg	124920
tttatggagt	tagcaatttc	aaaataggga	tgtttaacct	gacatttatt	aagtcgttgg	124980
atcataccgt	tttccctctc	ctgttagatg	aggatagcaa	aataaagttt	tttaagggga	125040
aaaagctcaa	tattgtagca	ttacgatctc	tggaggattg	tataaattac	gtgactaaat	125100
ccgagaatat	gatagaaatg	atgaaggaaa	gatcgactat	tttaaatagc	atagatatag	125160
aaacggaatc	ggtagatcgt	ctaaaagaat	tgcttctaaa	atgaaaaaaa	acactaattc	125220
agaaatggat	caacgactag	ggtataagtt	tttggtgcct	gatcctaaag	ccggagtttt	125280
ttatagaccg	ttacatttcc	aatatgtatc	gtatttcta	tttatattgc	atcgattgca	125340
tgaaatcttg	accgtcaagc	ggccactctt	atcgtttaag	aataatacag	aacgaattat	125400
gatagaaatt	agcaatgtta	aagtgactcc	tccagattac	tcacctataa	tcgtagat	125460
taaaggtaag	agttatgacg	cattagccac	gttcactgta	aatatcttta	aagaggtaat	125520
gaccaaagag	ggtatatcca	tcactaaaat	aagtagttat	gagggaaaag	attctcattt	125580
gataaaaatt	ccgctactaa	taggatacgg	gaataaaaat	ccacttgata	cagccaagta	125640
tcttgttcct	aatgtcatag	gtggagtctt	tatcaataaa	caatctgtcg	aaaaagtagg	125700
aattaatcta	gtagaaaaga	ttacaacatg	gccaaaattt	agggttgtta	agccaaactc	125760
attcactttc	tcgttttcc	ccgtatcccc	tcctaattgta	ttaccgacaa	gatatcgcca	125820
ttacaagata	tctctggata	tatcacaaat	ggaagcgttg	aatatatcat	cgacaaagac	125880
atttataacg	gtcaatattg	ttttgctgtc	tcaatattta	tctagagtga	gtctagaatt	125940
cattagacgt	agttttatcat	acgatatgcc	tccagaagtt	gtctatctag	taaacgcgat	126000
aatagatgag	gctaaacgaa	ttactgaatc	tattactgac	tttaattattg	atacatacat	126060
taatgacctg	gtggaagctg	aacacattta	acaaaaatct	cagttaacga	ttaacgagtt	126120
caaatatgaa	atgctgcata	actttttacc	tcatatgaac	tatacacccg	atcaactaaa	126180
gggattttat	atgatattct	tactaagaaa	gtttctctac	tgtatcttcc	acacttctag	126240
atatccagat	agagattcga	tggtttgtca	tcgcatccta	acgtacggca	aatattttga	126300
gacgttgga	catgatgaat	tagagaatta	cataggcaac	atccgaaacg	atatcatgaa	126360
caatcacaag	aacagaggca	cttacgcggt	aaacattcat	gtactaacia	ctcccggact	126420
taatcacgcg	ttttctagct	tattgagtgg	aaagttcaaa	aagtcagacg	gtagttatcg	126480
aacacatcct	cactattcat	ggatgcagaa	tatttctatt	cctaggagtg	ttggatttta	126540
tcggtatcaa	gtaaagattt	caaagatgtt	ttctgtcaga	aaataccatc	caagtcaata	126600
tctttacttt	tgttcatcag	acgttccgga	aagaggtcct	caggtagggt	tagtatctca	126660
attgtctgtc	ttgagttcca	ttacaaatat	actaacgtct	gagtatttgg	atttggaata	126720
gaaaatttgt	gagtatatca	gatcatatta	taaagatgat	ataagttact	ttgaaacagg	126780
atttccaatc	actatagaaa	atgctctagt	cgcatctctt	aatccaaata	tgatatgtga	126840
ttttgtaact	gacttttagac	gtagaaaacg	gatgggatcc	ttcggtaact	tggaggtagg	126900
tattacttta	gttagggatc	acatgaatga	aattcgcatt	aatattggag	cggaagatt	126960
agtcagacca	ttcttggttg	tggataacgg	agagctcatg	atggatgtgt	gtccggagtt	127020
agaaagcaga	ttagacgaca	tgacattctc	tgacattcag	aaagagtttc	cgcatgtcat	127080
cgaaatggta	gatatagaac	aatttacttt	tagtaacgta	tgtgaatcgg	ttcaaaaatt	127140
tagaatgatg	tcaaaggatg	aaagaaagca	atacgattta	tgtgactttc	ctgccgaatt	127200
tagagatgga	tatgtagcat	cttcactagt	gggaatcaat	cacaattctg	gacccagagc	127260
tattcttgga	tgtgctcaag	ctaaacaagc	tatctcttgt	ctgagttcgg	atatacgaaa	127320
taaaatagac	aatggaattc	atttgatgta	tccagagagg	ccaatcgtga	ttagtaaggc	127380
tttagaaaact	tcaaagattg	cggctaattg	cttcggccaa	catgttacta	tagcattaat	127440
gtcgtacaaa	ggtatcaatc	aagaggatgg	aattatcatc	aaaaacaat	ttattcagag	127500
aggggtctc	gatattgtta	cagccaagaa	acatcaagta	gaaattccat	tggaaaactt	127560
taataacaaa	gaaagagata	ggtctaacgc	ctattcaaaa	ttagaaagta	atggattagt	127620
tagactgaat	gctttcttgg	aatccggaga	cgctatggca	cgaaatatct	catcaagaac	127680

-55-

tcttgaagat	gatttttgc	gagataatca	gatttagcttc	gatgtttccg	agaaatatac	127740
cgatatgtac	aaatctcgcg	ttgaacgagt	acaagtagaa	cttactgaca	aagttaagggt	127800
acgagtatta	accatgaaag	aaagaagacc	cattctagga	gacaaattta	ccactagaac	127860
gagtcaaaag	ggaacagtcg	cgtatgtcgc	ggatgaaacg	gaacttccat	acgacgaaaa	127920
tgggtatcaca	ccagatgtca	ttattaattc	tacatccatc	ttctctagaa	aaactatatc	127980
tatgttgata	gaagttat	taacagccgc	atattctgct	aagccgtaca	acaataagggt	128040
agaaaaccga	cctgtctggt	ttcctagtag	taacgaaaca	tccatcgata	catatatgca	128100
attcgctaaa	caatgttatg	agcattcaaa	tccgaaattg	tccgatgaag	aattatcgga	128160
taaaatccttt	tgtgaaaaga	ttctctatga	tcccgaaacg	gataagcctt	atgcatccaa	128220
agtatttttt	ggaccaat	attacttgcg	tctgaggcat	ttaactcagg	acaaggcaac	128280
cgtagatgt	agaggtaaaa	agacgaagct	cattagacag	gcgaatgagg	gacgaaaacg	128340
tggaggagggt	atcaagttcg	gagaaatgga	gagagactgt	ttaatagcgc	atgggtgcagc	128400
caatactatt	acagaagttt	tgaagattc	ggaagaagat	tatcaagatg	tgtatgtttg	128460
tgaaaattgt	ggagacatag	cagcacaaat	caagggtatt	aatacatgtc	ttagatgttc	128520
aaaacttaat	ctctctcctc	tcttaacaaa	aattgatacc	acgcacgtat	ctaaagtatt	128580
tcttactcaa	atgaacgcca	gaggcgtaaa	agtcacaa	gatttcgaac	gaaggcctcc	128640
ttcgctttat	aaaccattag	ataaagtga	tctcaagccg	tcttttctgg	tgtaatattc	128700
tagtttggtg	gtagatacat	atcaatatca	tcaaattcga	gatccgaatt	ataaaatggg	128760
cgtggattgt	taactataga	atcggacgct	tgatattcga	aaatctgtgg	agtttcagggt	128820
tttgggtggag	gtgtaactgc	tacttgggat	actgaagtct	gatattcaga	aagctgtgga	128880
tgttctgggt	cggcatccac	cgtatgggtg	acatcactaa	tcggttcggg	aacgtctgtg	128940
gatggagggtg	ctacttctac	agaacctgta	gcctcagttg	tcaacggaga	tacattttta	129000
atgcgagaaa	atgtataatt	tggtaatggg	ttcttatgtg	gatctgaaga	agaggtaaga	129060
tatctactag	aaagataccg	atcacgttct	agttctcttt	tgtagaactt	aactttttct	129120
ttctccgcat	ctagttgata	ttccaacctc	ttcacgttac	tacgttcaga	ttccaattca	129180
cgttcgcatg	ggttacctcc	gcagttttta	cgagcgattt	cacgttcagc	cttcattcgt	129240
ctctccctct	ctctatcgag	tttatcagag	cagtctttct	gaaggcgatc	gaactccata	129300
aattttctcca	acgctttgat	tgtttccata	gattttccgaa	gttcagcttt	taggactgtg	129360
attctttttc	tttcgaattc	acagctggat	gtacaaccgt	ttccattacc	gccatctcta	129420
agtttctttt	ctagatcggc	aacatttcat	ccccatgcct	tttacattcc	tcgagtctac	129480
tgtcgtcgaa	atatcgttcc	agctcctttt	cgacatcaat	aacttttagca	cgttgtctct	129540
caagctctct	tttgtagtta	tctgattccc	tggcacggtt	aagatcttca	tgcaattgag	129600
tcagctctta	acttctctct	ttgcttcttc	gtcatagtac	gcgcaatcac	tgtgagatcc	129660
attgtttacca	cgtctacact	cggcgagctc	gcgttttaaga	gattcaattt	cccgtttgta	129720
ttggtccatg	tttccattgc	taccaccatt	agattttacag	gctgctagtt	gtcgttcgag	129780
atcagaaata	cgggttttct	tggaaattgat	ttcgtcgatg	tacttggcat	cgaaacactt	129840
attaagttct	ttttccaatt	ctacgatttt	atcttcttctg	cgagtcaatt	ccctcctgta	129900
gtaactatct	gttttgcag	attcacgctc	tctacgtaga	ctttcttgca	agttactaat	129960
ttgttcccta	gcacgtccga	gttttagttt	atatgctgaa	tagagttctg	attcatcctt	130020
tgagcagatc	tctagcgatc	gtttaagatt	cctaattcta	gtcttttagcc	tattttacctc	130080
ctcagaagat	gttccggttac	cgttgcggtt	acactcggtta	agctgtctat	caagatccat	130140
gattctatct	ctaagacggt	gcattctctc	ttccatatca	gcattgcttt	cattattacg	130200
tctgcagtca	ctcaactgtc	tttcaatatc	tgagattcta	tctctaagac	gtcgcattctc	130260
tctctgtttc	ggcattgggt	tcattattac	gtctacagtc	gttcaactgt	ctttcaagat	130320
ctgatattct	agattggagt	ctgctaattc	ctgtagcatt	ttcacggcat	tcactcagtt	130380
gtctttcaag	atctgaaatt	ttagattgga	gtctgctaatt	ctctgtaaga	tttctctctc	130440
cgtctcgcag	gcagtcgggc	aacttattct	ctagttctct	aatacgcgaa	cgcagtgcat	130500
caacttcttg	cgtgtcttcc	tgggtgcgtg	tacattcctc	gagtcctagat	tcgagatctc	130560
taacgcgctg	togttcttcc	tcaagttctc	tgcgtactac	agaaagcgtg	tccttatctt	130620
gttgatattt	agcaatttct	gattctagag	tactgatttt	gcttacgtag	ttactaatat	130680
ttgtcttggtc	cttatcaaga	tctctcttgt	atctgtcgca	ttccttgata	tccctacgaa	130740
gtctggacag	ttcccatctg	acattacgac	gtttatcgat	ttcagctcgg	agatcgatcat	130800
cgcgttggtt	tagccacata	cgaactgagtt	caagttctcg	ttgacaagat	ccatctactt	130860
ttccattctc	aatagtatcc	agttcctttt	ctagttctga	acgcatttct	cgttccctat	130920
caagcgatcc	tctcaattct	cggatagctc	tcttatcaat	ttctaataaa	tctgaacctat	130980



-56-

catctgtccc	atcttgaata	tccctgtggt	ctttgatctc	ttttgtaagt	cggtcgattc	131040
tttcgggttt	ataaacagaa	tccctttcca	aagtccta	cttactgagt	ttatcactaa	131100
gttctgcatt	caattcgggtg	agttttctct	tggtctcttc	caactctgtt	ttaaactctc	131160
cactatttcc	gcattcttcc	tcgcatttat	ctaaccattc	aattagttta	ttaataacta	131220
gttggtaatc	agcgattcct	atagccgttc	ttgtaattgt	gggaacataa	ttaggatctt	131280
ctaattggatt	gtatggcttg	atagcatcat	ctttatcatt	attaggggga	tggacaacct	131340
taattgggtg	gtcctcatct	cctccagtag	cgtgtgggtc	ttcaatacca	gtgttagtaa	131400
taggcttagg	caaagtcttg	tcgtacgcgg	gcacttcctc	atccatcaag	tatttataat	131460
cggttctctac	ttcagaatat	tcttttctaa	gagacgcgac	ttcgggagtt	agtagaagaa	131520
ctctgtttct	gtatctatca	acgctggaat	caatactcaa	gttaaggata	gcgaatacct	131580
catcgtcatc	atccgtatct	tctgaaacac	catcatatga	catttcatga	agtctaactg	131640
attgataaat	agaatcagat	ttagtattaa	acagatcctt	aaccttttta	gtaaacgcac	131700
atgtatatct	tagatctcca	gatttcataa	tatgatcaca	tgccttaaat	gtcagtgtct	131760
ccatgatata	atctggaaca	ctaattgggtg	acgaaaaaga	tacagcacca	tatgctacgt	131820
tgataaataa	atctgaacca	ctaagtagat	aatgattaat	gttaagaaag	aggaaatatt	131880
cagtgtatag	gtatgtcttg	gcgtcatatc	ttgtactaaa	cacgctaaac	agtttggttaa	131940
tgtgatcaat	ttccaataga	ttaatatag	cagcggaat	accaacaaac	atattaccac	132000
atccgtatct	tctatgaata	tcacatatca	tgttaaaaaa	tcttgataga	agagcgaata	132060
tctcgtctga	cttaagttagt	cgtagtccag	cagcaacata	agtcataact	gtaaatagaa	132120
catactttcc	tgtagtgttg	attctagact	ccacatcaac	accattatta	aaaatagttt	132180
tatatacatc	tttaatctgc	tctcgtttaa	tcgtcgaacg	ttctagtata	cggaaacact	132240
ttgatttctt	atctgtagtt	aatgacttag	tgatatcacg	aagaatatta	cgaattacac	132300
ttcttggttt	tcttgagaga	cctgattccag	aactcaactc	atcgttccat	agtttttcta	132360
cctcagtggc	gaaatctttg	gagtgtcttg	tacatttttc	aataagggtc	gtgacctcca	132420
tttattataa	aaaattttatt	caaaacttaa	ctacaatcgg	gtaattataa	aatcgtagat	132480
ctcccatgtg	gcggaatact	accatctatc	gcattgtggt	ggacagttagg	taattggcat	132540
gggaacagta	atgtttgcat	atttatcttt	cttgccagta	ttactgcata	ttgtcccaat	132600
gtttcgtatg	gatgttctaa	cctatcaact	gccgctgtat	cacaacaata	gtgtccgatg	132660
aaattaagat	tatgatccaa	tgtgtttaat	atatgattat	caagtcttat	acgatccgag	132720
tcttttttga	caggatcagg	ttcttctaca	ggaagaagtt	tcggcctctt	atgatattca	132780
tgtctgggaa	acggtggtct	aggggtgaggc	tccggtatcg	gagtgggttt	tggattataa	132840
tcacatcgt	ctatgacatc	atcttcgact	tcgatattta	ttttgctatc	ttgatgatgt	132900
cctgtatcag	ttgcattttc	agcaactcgac	tgaatattag	cgcattcatt	gtctattatt	132960
accatatttc	taaaccctaa	atgtatgtgt	tgaacatcag	tactatcggt	gatgagctct	133020
atagcatgaa	ttcgcttata	gttatcggtg	ttatcttctg	tcaccttagc	aattcctttt	133080
ttattaaact	ctacataatc	atatccattt	ctattgtttg	ttctaataa	aacgagtata	133140
gcacatttgc	taaatttttc	aatagtatca	aaaacagaat	atcctaaacc	atataatata	133200
tattcaggaa	cactcaaaact	aaatgtccag	gattctccta	aatacgtaaa	ctttaatagt	133260
gcgaaatcat	tcaaaaatct	accacttata	gatagatagt	acataaatgc	gtatagtagt	133320
ctacctatct	ctttattatg	aaaaccggca	ttacgatcat	atatgtcgtg	atatacctgt	133380
gatccgttta	cgttaaacca	taaatacatg	ggtgatccta	taaacatgaa	tttatttcta	133440
attctcagag	ctatagttaa	ttgaccgtgt	aatatttgc	tacatgcata	cttgatacgc	133500
ttattaataa	gattttttatc	attgctcggt	atttcagaat	cgtatatata	aggagtacca	133560
tcgtgattct	taccagatat	tatacaaaat	actatatata	aaatatattg	accacgttta	133620
gtaatcatat	aaatgtttta	cgtttttaaat	tttgatttca	atgatccatt	atcatacgtc	133680
atcatggtct	tgtaatatcc	attcttttaa	atataatatt	gtgttagcca	ttgcattgga	133740
gtcctaata	gagattttct	attctcatcc	atttttaggat	aggctttcat	aaagtcctta	133800
ataacttcgt	gaataatgtt	tctatgtttt	ctactgatgc	atgtatttgc	ttcgattttt	133860
ttatcccatg	tttcatctat	catagattta	aacgcagtaa	tgctcgcaac	attaacatct	133920
tgaaccgttg	gtacaattcc	gttccataaa	tttataatgt	tcgccattta	tataactcat	133980
tttttgaata	tactttttaat	taacaaaaga	gtaagtac	tcatatggac	gccgtccagt	134040
ctgaacatca	atcttttttag	ccagagatat	cctagccgct	cttagagttt	cagcgtgatt	134100
ttccaacctta	aatagaactt	catcgttgcg	tttacaacac	ttttctatct	gttcaaactt	134160
tggtgttaca	ttagtaatct	ttttttccaa	attagttagc	cggtgtttga	gagtttcctc	134220
attgctgctc	tcacgtgctt	taacaattgc	ttcgcgttta	gcctctggct	tttttagcagc	134280

-57-

ctttgtagaa	aaaaattcag	ttgctggaat	tgcaagatcg	tcattctccg	ggaaaagagt	134340
tccgtccatt	taaagtacag	attttagaaa	ctgacactct	gcgttattta	tatttggtac	134400
aacacatgga	ttataaatat	tgatgttaat	aacatcagaa	aatgtaaagt	ctatacattg	134460
ttgcatcggt	ttaaattttc	taatggatct	agtattattg	ggtccaactt	ctgcctgaaa	134520
tccaaatatg	gaagcggata	caaaaccgtt	tcctggataa	accacacatc	tccacttttg	134580
ctttacatca	gaaattgtgt	cgttgacatc	ttgaactctc	ctatctaattg	ccggtgttcc	134640
acctatagat	tttgaatatt	cgaatgctgc	atgagtagca	ttaaattcct	taatattgcc	134700
ataattttca	tattattgagt	aaccctggat	aaaaagttaa	cacaccgcag	ccgtcgtac	134760
cacaataaaa	aaaattgata	gagagttcat	ttataatcta	ttagaagctg	acaaaatttt	134820
tttacacgca	tcagacaatg	ctttaataaa	tagttcaaca	tctacttttg	tcatatcgaa	134880
ccgatgggat	gattctaacc	tagaattaca	tccgaaaaag	ttgactatgt	tcatagtcac	134940
taagtcatta	acaaacaaca	ttccagactc	tggtattataa	gacgatactg	tttcgtcaca	135000
attacctacc	ttaatcatgt	gattatgaat	attggctatt	agagcacctt	ctaagaaatc	135060
tataatatct	ttgaaacacg	atttaaaatc	aaaccacgaa	tatacttcta	cgaagaaagt	135120
tagttttacc	ataggagaaa	taactataaa	tggtagatcta	aatacaaaaat	ccggatctat	135180
gatagtttta	acattattat	attctctatt	aaatacctcc	acatctaaaa	atgttaattt	135240
tgaaactatg	tcttcgttta	ttaccgtacc	tgaactaaac	gctataagct	ctattgtttg	135300
agaactcttt	aaacgatatt	cttgaaatac	atgtaacaaa	gtttccttta	actcggtcgg	135360
tttatctacc	atagttacag	aattttgtatc	cttatctata	atataaataat	caaaatcgta	135420
taaagttata	taattatcgc	gttcagattg	ggatcttttc	aaatagacta	aaaaccccat	135480
ttctctagta	agtatcttat	gtatatgttt	gtaaaatatac	ttcatgggtg	gaatatgctc	135540
taccgcagtt	agccattcct	cattgacagc	ggtagatgta	ttagacaaaa	ctattccaat	135600
gtttaacaag	ggccatttta	cgagattatt	aaatccttgt	ttgataaatg	tagccaatga	135660
gggttcgagt	tcaacgacga	ttgaattctc	ttcccgcgga	tgctgcatga	tgaacgcagg	135720
gatgttggtc	gattgatttg	gaattctttt	tcgacttttt	gtttatatta	aatattttaa	135780
aattttatagc	ggatagcaat	tcattgtacca	cggataatgt	agacgcgtat	tgccgcgtac	135840
tatctttatt	attagataaa	tttatcaata	aatgtgagaa	gtttgcctcg	ttaaaggtctt	135900
ccattttaaat	attatataaa	catttggtgtt	tgtaacttat	tcgtctttta	tggaatagtt	135960
ttttactagt	aaagctgcaa	ttacacactt	tgtccgtaaa	acataaatat	aaacaccagc	136020
ttttatcaat	cgttccaaaa	agtcgacggc	ggacattttt	aacatggcat	ctatttttaa	136080
tacacttagg	tttttggaag	aaacatcatt	ttataattgt	aacgattcaa	taactaaaga	136140
aaagattaa	attaacata	agggaaatgtc	atattgtattt	tataagccaa	agcattctac	136200
cgttggttaa	tacttgctcg	gaggaggtat	atatcatgat	gatttggttg	tattggggaa	136260
ggtaacaatt	aataatctaa	agatgatgct	atttttacatg	gatttatcat	atcatggagt	136320
gacaagtagt	ggagcaattt	acaaattggg	atcgtctatc	gatagacttt	ctctaaatag	136380
gactattggt	acaaaagtta	ataattatga	tgatacattt	tttgacgacg	atgattgatc	136440
gctattgcac	aattttgttt	ttgtactttc	taatataagt	tttaggttct	ttttcatatg	136500
agaatattga	tttactaaaa	tatctatggt	taacttttgt	tctatgacgt	ccttatcggc	136560
ggtatcggta	catatacgta	attcaccttc	acaaaatacg	gagtcttcga	taataatagc	136620
caatcgatta	ttggatctag	ctgtctgtat	catattcaac	atgttttaata	tatcctttcg	136680
tttccccttt	acaggcatcg	atcgtagcat	attttccgcg	tctgatattg	aaatgttaaa	136740
actacaaaaa	tgcgtaatgt	tagcccgctc	taatatgggt	acgtgtctat	aagtttgga	136800
tagtagaata	atagacgtgt	ttaaatgcct	tccaaagtgt	aagaattcta	ttagagtatt	136860
gcattttgat	agtttatcgc	ctacatcatc	aaaaataagt	aaaaagtgtg	ctgatttttt	136920
atgattttgt	gcgacagcaa	tacatttttc	tatgttactt	ttagtctgta	tcagattata	136980
ttctagagat	tcctgactac	taacgaaatt	aatatgattt	ggccaaatgt	atccatcata	137040
atctgggtta	taaacgggtg	taaacagaa	tatatgttta	tattttttta	ctagtgtaga	137100
aaacagagat	agtaaataga	tagttttttc	agatccagat	cctcctgtta	aaaccattct	137160
aaacggcatt	tttaataaat	tttctcttga	aaattgtttt	tcttggaac	aattcataat	137220
tatatattaca	gttactaaat	taatttgata	ataaatcaaa	atatggaaaa	ctaaggttgt	137280
tagtagggag	gagaacaaag	aaggcacatc	gtgatataaa	taacattttat	tatcatgatg	137340
acaccagaaa	acgacgaaga	gcagacatct	gtgttctccg	ctactgttta	cggagacaaa	137400
attcagggaa	agaataaacg	caaacgcgtg	attgggtctat	gtattagaat	atctatgggt	137460
atttcactac	tatctatgat	taccatgtcc	gcgtttctca	tagtgccgct	aatcaatgc	137520
atgtctgcta	acgaggctgc	tattactgac	gccgctgttg	ccgttgctgc	tgcatcatct	137580

-58-

actcatagaa	agggttgcgtc	tagcactaca	caatatgato	acaaagaaag	ctgtaatggt	137640
ttatattacc	agggttccttg	ttatatatta	cattcagact	accagttatt	ctcggatgct	137700
aaagcaaatt	gcactgcgga	atcatcaaca	ctacccaata	aatccgatgt	cttgactacc	137760
tggctcattg	attatgttga	ggatacatgg	ggatctgatg	gtaatocaat	tacaaaaact	137820
acatccgatt	atcaagattc	tgatgtatca	caagaagtta	gaaagtattt	ttgtgttaaa	137880
acaatgaact	aatattttatt	tttgtacatt	aataaatgaa	atcgcttaat	agacaaaactg	137940
taagtagggt	taagaagttg	tcgggtgccg	ccgctataat	gatgatactc	tcaaccatta	138000
ttagtggcat	aggaacattt	ctgcattaca	aagaagaact	gatgcctagt	gcttgcgcca	138060
atggatggat	acaatacgat	aaacattggt	atttagatac	taacattaaa	atgtctacag	138120
ataatgcggg	ttatcagtg	cgtaaattac	gagctagatt	gcctagacct	gatactagac	138180
atctgagagt	attgttttagt	atTTTTtata	aagattattg	ggtaagttta	aaaaagacca	138240
atgataaatg	gttagatatt	aataatgata	aagatataga	tattagttaa	ttaacaaatt	138300
ttaaacaact	aaacagtacg	acggatgctg	aagcgtgtta	tatatacaag	tctggaaaac	138360
tgggttaaaac	agtatgtaaa	agtactcaat	ctgtactatg	tgttaaaaaa	ttctacaagt	138420
gacaacaaaa	aatgaattaa	taataagtcg	ttaacgtacg	ccgccatgga	cgccgcgttt	138480
gttattactc	caatgggtgt	gttgactata	acagatacat	tgtatgatga	tctcgatatc	138540
tcaatcattg	accttatagg	accatacatt	ataggttaaca	taaaaactgt	ccaaatagat	138600
gtacgggata	taaaatattc	cgacatgcaa	aaatgctact	ttagctataa	gggttaaaata	138660
gttccctcagg	attctaataga	tttggctaga	ttcaacattt	atagcatttg	tgccgcatac	138720
agatcaaaaa	ataccatcat	catagcatgc	gactatgata	tcattgttaga	tatagaagat	138780
aaacatcagc	cattttatct	attcccatct	attgatgttt	ttaacgctac	aatcatagaa	138840
gcgtataacc	tgtatacagc	tggagattat	catctaatac	tcaatccttc	agataatctg	138900
aaaatgaaat	tgtcgtttta	ttcttcattc	tgcatatcag	acggcaatgg	atggatcata	138960
attgatggga	aatgcaatag	taatttttta	tcataaaaagt	tgtaaagtaa	ataataaaaac	139020
aataaaatatt	gaactagtag	tacgtatatt	gagcaatcag	aatgatgct	ggtacctctt	139080
atcacgggtga	ccgtagtgtc	gggaacaata	ttagtatggt	atatattata	tatttgtagg	139140
aaaaagatac	gtactgtcta	taatgacaat	aaaattatca	tgacaaaatt	aaaaaagata	139200
aagagttcta	attccagcaa	atctagtaaa	tcaactgata	gcgaatcaga	ctgggaggat	139260
cactgtagtg	ctatggaaca	aaacaatgac	gtagataata	tttctaggaa	tgagatattg	139320
gacgatgata	gcttcgctgg	tagtttaata	tgggataacg	aatccaatgt	tatggcgctt	139380
agcacagaa	acatttacga	tagtggtgct	ggaagcacgc	tgctaataaa	taatgatcgt	139440
aatgaacaga	ctattttatca	gaacactaca	gtagtaatta	atgaaacgga	gactgttgaa	139500
gtacttaatg	aagataccaa	acagaatcct	aactattcat	ccaatccttt	cgtaaattat	139560
aataaaaacca	gtattttag	caagtcaaat	ccgtttatta	cagaacttaa	caataaattt	139620
agtgagaata	atccgtttag	acgagcacat	acgcatgatt	atcttaataa	gcaagaacaa	139680
gatcatgaac	acgatgatat	agaatcatcg	gtcgtatcat	tggtgtgatt	agtttccttt	139740
ttataaaaatt	gaagtaatat	ttagtattat	tgctgcgctc	acgttgtaca	aatggagata	139800
ttccctgtat	tccgcatctt	taaaattagc	aattttattg	ctaataatga	ctgtagatat	139860
tatatagata	cagaacatca	aaaaattata	tctgatgaga	tcaatagaca	gatggatgaa	139920
acgggtacttc	ttaccaacat	cttaagcgta	gaagttgtaa	atgacaatga	gatgtaccat	139980
cttattcctc	atagattatc	gacgattata	ctctgtatta	gttctgtcgg	aggatgtgtt	140040
atctctatag	ataatgacat	caatggcaaa	aatattctaa	cctttcccat	tgatcatgct	140100
gtaatcatat	cccactgag	taaatgtgtc	gtagttaagca	agggtcctac	aaccatattg	140160
gttggttaaag	cggatatacc	tagcaaacga	ttggtaacat	cgtttacaaa	cgacatacta	140220
tatgtaaaaca	atctgtcact	gattaattat	ttgccgttgt	ctgtattcat	tattagacga	140280
gtcaccgact	atttggtatg	acacatatgc	gatcagatat	ttgctaataa	taagtgggat	140340
tcccttataa	ccatcgacga	taagcaatat	cctattccat	caaactgtat	aggatgtgcc	140400
tctgccaaagt	acataaattc	tagcatcgag	caagatactt	taatccatgt	ttgtaacctc	140460
gagcatccgt	tcgactcagt	atacaaaaaa	atgcagtcgt	acaattctct	acctatcaag	140520
gaacaaatat	tgtacggtag	aattgataat	ataaatatga	gcattagtat	ttctgtggat	140580
taatatagatt	ctagtatggg	gatcattaat	catctctaatt	ctctaataac	ctcataaaaac	140640
gaaaaaaaag	ctattatcaa	atactgtacg	gaatggattc	attctcttct	ctttttatga	140700
aactctgttg	tatatctact	gataaaaactg	gaagcaaaaa	atctgataga	aagaataaga	140760
ataagatcaa	ggatttatatg	gaacacgatt	attataaaaat	aacaatagtt	cctgggttctt	140820
cttccacgctc	tactagctcg	tggattatata	cacatgccta	gtaatagtct	ctttgcgctg	140880

-59-

acggaaagca	gactagaaat	aacaggctaa	aatgttcaga	caccataata	gttcccaacc	140940
cagataataa	cagagttcca	tcaacacatt	cctttaaact	caatcccaaa	cccaaaaccg	141000
ttaaaatgta	tccggccaat	tgatagtaga	taatgaggtg	tacagcgcat	gataatttac	141060
acagtaacca	aaatgaaaat	acttttagtaa	ttataagaaa	tatagacggt	aatgtcatca	141120
tcaacaatcc	gataaatatgc	ctgagagtaa	acattgacgg	ataaaacaaa	aatgctccgc	141180
ataactctat	catggcaata	acacaaccaa	atacttgtaa	gattcctaaa	ttagtagaaa	141240
atacaacgaa	tatcgatgta	taagtgatct	cgagaaataa	taagaataaa	gtaatgcccc	141300
taaagataaa	catcaacatt	gtttggtaat	cattaaacca	attagtatga	agttgaacta	141360
atttcacagt	agatttttatt	ccagtgttat	cctgcgatgt	ataagtacct	ggtaagatat	141420
cTTTTatattc	cataatcaat	gagacatcac	tatctgataa	cgaatgaagt	ctagcactag	141480
tatgccatttt	acttaatat	gtcgtcttgg	aagttttatt	ataagttaaa	atatcatggt	141540
tatccaatttt	ccatctaata	tactttgtcg	gattatctat	agtacacgga	ataatgatgg	141600
tatcattaca	tgctgtatac	tctatggtct	ttgtagttgt	tataacaacc	aacgtataga	141660
ggtatatcaa	cgatattcta	actcttgaca	ttttttattt	attttaaagt	atacctttgt	141720
tattttatttt	attctatttt	gctaaccggt	ttgaatggca	taagtttgaa	acgagtgaag	141780
aaataatttc	tacttactta	ttagacgacg	tattatacac	gggtgttaat	ggggcggtat	141840
acacattttc	aaataataaaa	ctaaacaaaa	ctggtttaac	taataataat	tatataacaa	141900
catctataaa	agtagaggat	gcggataagg	atacattagt	atgcggaacc	aataacggaa	141960
atcccaaatg	ttggaaaata	gacggttcag	acgacccaaa	acatagaggt	agaggatcacg	142020
ctccttatca	aaatagcaaa	gtaacgataa	tcagtcacaa	cggatgtgta	ctatctgaca	142080
taaacatatc	aaaagaagga	attaaacgat	ggagaagatt	tgacggacca	tgtggttatg	142140
atttattcac	ggcgggataac	gtaattccaa	aagatggttt	acgaggagca	ttcgtcgata	142200
aagacgggtac	ttatgacaaa	gtttacattc	ttttcactga	tactatcggc	tcaaagagaa	142260
ttgtcaaaat	tcogtatata	gcacaaattgt	gcctaaacga	cgaaggtggt	ccatcatcat	142320
tgtctagtca	tcatgggtcg	acgtttctca	aagtcgaatt	agaatgtgat	atcgacggaa	142380
gaagttatag	acaaattatt	cattctagaa	ctataaaaac	agataatgat	acgatactat	142440
atgtattctt	cgatagtctt	tattccaagt	ccgcattatg	taoctattct	atgaatacca	142500
ttaaacaatc	tttttctacg	tcaaaattgg	aaggatatac	aaagcaattg	ccgtctccag	142560
ctcctgggtat	atgtttacca	gctggaaaag	ttgttccaca	taccacgttt	gaagtcatag	142620
aacaatataa	tgtactagat	gatattataa	agcctttatc	taaccaacct	atcttcgaag	142680
gaccgtctgg	tgttaaatgg	ttcgatataa	aggagaagga	aatgaacat	cgggaatata	142740
gaataatact	cataaaagaa	aattctatat	attcgttcga	tacaaaatct	aaacaaactc	142800
gtagctcgca	agtcgatgcg	cgactatttt	cagtaatggt	aactgcgaaa	ccgttatttta	142860
tagcagatat	agggatagga	gtaggaatgc	gcacaaatgaa	aaaaataact	aaaatgtaat	142920
cttaatcgag	tacaccacac	gacaaatgaac	aaacataaga	cagattatgc	tggttatgct	142980
tgctgcgtaa	tatgcggtct	aattgtcgga	attatttttta	cagcgacact	attaaaaagt	143040
gtagaacgta	aattagttca	tacaccatta	atagataaaa	cgataaaaaga	tgcatatatt	143100
agagaagatt	gtcctactga	ctggataaag	tataataata	aatgtatcca	tttatctact	143160
gatcgaaaaa	cctgggagga	aggacgtaat	gcattgcaaag	ctctaaattc	aaattcggat	143220
ctaattaaga	tagagactcc	aaacgagtta	agtttttttaa	gaagccttag	acgaggctat	143280
tgggtaggag	aatccgaaat	attaaaccag	acaaccccat	ataattttat	agctaagaat	143340
gccacgaaga	atggaactaa	aaaacggaaa	tatatattgta	gcacaacgaa	tactcccaaa	143400
ctgcattcgt	gttacctat	ataacaatta	cactacattt	ttatcatacc	actacttcgg	143460
ttagatgttt	tagaaaaaaa	taaatatcgc	cgtaccgttc	ttgtttttat	aaaaataaca	143520
attaacaatt	atcaaatttt	ttcttttaata	ttttacgtgg	ttgaccattc	ttggtggttaa	143580
aataatctct	tagtggttga	atggaatgct	gtttaatggt	tccacactca	tcgtatatatt	143640
tgacgtatgt	agtcacatcg	tttacgcaat	agtcagactg	tagttctatc	atgcttccta	143700
catcagaagg	aggaacagtt	ttaaagtctc	ttggtttttaa	tctattaccg	ttagttttca	143760
tgaaatcctt	tgttttatcc	acttcacatt	ttaaataaat	gtccactata	cattctttttg	143820
ttaattttac	tagatcgtca	tgggtcatag	aatttatagg	ttccgtagtc	catggatcca	143880
aactagcaaa	cttcgcgtat	acggtatcgc	gattagtgtg	tacaccaact	gtatgaaaaat	143940
taagaaaaca	gtttaataaa	tcaacagaaa	tatttaatcc	tccgtttgat	acagatgcgc	144000
catatttatg	gatttcggat	tcacacggtg	tttgtctgag	gtgttcgtct	agtgttgctt	144060
ctacgtaaac	ttcgattccc	atatattctt	tattgtcaga	atcgcatacc	gatttatcat	144120
catacactgt	ttgaaaacta	aatggtatac	acatcaaaat	aataaataat	aacgagtaca	144180

-60-

ttctgcaata	ttgttatcgt	aattggaaaa	atagtgttcg	agtgagttgg	attatgtgag	144240
tattggattg	tatatTTTTat	tttatatttt	gtaataagaa	taaaatgcta	atgtcaagtt	144300
tattccaata	gatgtcttat	taaaaacata	tataataaat	aacaatggct	gaatggcata	144360
aaattatcga	ggatatctca	aaaaataata	agttcgagga	tgccgccatc	gttgattaca	144420
agactacaaa	gaatgttcta	gctgctattc	ctaacagaac	at ttgccaag	attaatccgg	144480
gtgaaattat	tcctctcctc	actaatcgta	atattctaaa	acctcttatt	ggtcagaaat	144540
attgtattgt	atatactaac	tctctaattg	atgagaacac	gtatgctatg	gagttgctta	144600
ctgggtacgc	ccctgtatct	ccgatcgta	tagcgagaac	tcataccgca	cttatatttt	144660
tgatgggtaa	gccaacaaca	tcagagcgtg	acgtgtatag	aacgtgtaga	gatcacgcta	144720
cccggtgtacg	tgcaactggg	aattaaaata	aaaagtaata	ttcatatgta	gtgtcaattt	144780
taaatgatga	tgatgaaatg	gataatatcc	atattgacga	tgtcaataat	gccggtattg	144840
gcatacagtt	catcgatttt	tagattttcat	tcagaggatg	tggaattatg	ttatgggcat	144900
ttgtattttt	ataggatcta	taatgtagta	aatataaaat	ataatccgca	tattccatat	144960
agatataaatt	ttattaatcg	cacgttaacc	gtagatgaac	tagacgataa	tgtctttttt	145020
acacatgggt	at ttttttaa	acacaaatat	ggttcactta	atcctagttt	gattgtctca	145080
ttatcaggaa	acttaaaata	taatgatata	caatgctcag	taaatgtatc	gtgtctcatt	145140
aaaaattttg	caacgagtac	atctactata	ttaacatcta	aacataagac	ttattctcta	145200
catcggtcca	cgtgtattac	tataatagga	tacgattcta	ttatatggta	taaagatata	145260
aatgacaagt	ataatgacat	ctatgatttt	actgcaatat	gtatgcta	agcgtctaca	145320
ttgatagtga	ccatatacgt	gtttaaaaaa	ataaaaaatga	actcttaatt	atgctatgct	145380
attagaaatg	gataaaatca	aaattacggg	tgattcaaaa	attggtaatg	ttgttaccat	145440
atcgtataac	ttggaaaaga	taactattga	tgtcacacct	aaaaagaaaa	aagaaaaagg	145500
tgtattatta	gcgcaatcag	ttgctgtcga	agaggcaaaa	gatgtcaagg	tagaagaaaa	145560
aaatattatc	gatattgaag	atgacgatga	tatggatgta	gaaagcgcat	aatacgatct	145620
ataaaaaata	gtatataaat	actttttatt	tactgtactc	ttactgtgta	gtggtgatac	145680
cctactcgat	tattttttta	aaaaaaaaaat	acttattctg	attcttctaa	ccatttccgt	145740
gttcggttcga	atgcccacatc	gacgtcaaa	ataggggagt	agttaaaatc	tagttctgca	145800
ttgttggtac	acaccttaaa	tgtagtgttg	gatattctca	acgtatagtt	gttgagtagt	145860
gatgggtttt	taaatagaat	tctcttcata	tcattcttgc	acgcgtacat	ttttagcatc	145920
catcttgga	accttaactt	tcgagggttat	tggttggtgga	tcttctacaa	tatctatgac	145980
tctgatttct	tgaacatcat	ctgcactaat	taacagtttt	actatatacc	tgccatagaaa	146040
tcgggcacca	ccagtaaccg	cgtacacggc	cattgctgcc	actcataata	tcagactact	146100
tattctattt	tactaaataa	tggctgtttg	tataatagac	cacgataata	tcagaggagt	146160
tatttacttt	gaaccagtc	atggaaaaga	taaagtttta	ggatcagtta	ttggattaaa	146220
atccggaacg	tatagtttga	taattcatcg	ttacggagat	attagtcaag	gatgtgattc	146280
cataggcagt	ccagaaatat	ttatcggtaa	catctttgta	aacagatatg	gtgtagcata	146340
tgtttatttt	gatacagatg	taaatatatc	tacaattatt	ggaaaggcgt	tatctatttc	146400
aaaaaatgat	cagagattag	cgtgtggagt	tattgggtatt	tcttacataa	atgaaaagat	146460
aatacatttt	cttacaatta	acgagaatgg	cgtttgatat	atcagttaat	gcgtctaaaa	146520
caataaatgc	attagttttac	ttttctactc	agcaaaataa	attagtcata	cgtaaatgaag	146580
ttaatgatac	acactacact	gtcgaatttg	atagggacaa	agtagttgac	acgtttattt	146640
catataatag	acataatgac	accatagaga	taagaggggt	gcttccagag	gaaactaata	146700
ttggttgccg	gggttaatac	ccgggttagta	tgacttactt	gtataataag	tatagtttta	146760
aactgatttt	agcagaatat	ataagacaca	gaaatactat	atccggcaat	atttattcgg	146820
cattgatgac	actagatgat	ttggctatta	aacagtatgg	agacattgat	ctattatttt	146880
atgagaaact	taaagtagac	tcgatttcgg	gactatttga	ctttgtcaac	tttgtaaagg	146940
atatgatatg	ttgtgattct	agaatagtag	tagctctatc	tagtctagta	tctaaacatt	147000
gggaattgac	aaataaaaaag	tataggtgta	tggcattagc	cgaacatata	tctgatagta	147060
ttccaatatc	tgagctatct	agactacgat	acaatctatg	taagtatcta	cgcgacaca	147120
ctgagagcat	agaggataaa	tttgattatt	tgaagacga	tgattctgtc	acatgttctg	147180
ccgtaaccga	cagggaacg	gatgtataat	tttttttaaa	gcgtgaagga	tatgataaaa	147240
aatataattg	ttgtattttat	cccatccaa	tcaccttata	tgattctgta	acacaataaa	147300
ggagtcttat	agatgtatag	aggtcagata	ctggtttgat	aaactgttta	ttccacataa	147360
gtatgtttga	ctttatgggt	agaccgcgt	actttaacaa	atcactgaaa	attggagtta	147420
ggtattgacc	tctcagaatc	agttgccgtt	ctggaacatt	aaatgtattt	tttatgatat	147480

-61-

actccaacgc	atztatgtgg	gcatacaaca	agtcattact	aatggaatat	tccaagagtt	147540
ttagttgtct	agtattttaac	aagagaagag	atltcaacag	actgtttatg	aactcgaatg	147600
ccgcctcatt	gtcgtttata	ttgatgatgt	cgaattctcc	caatatcatc	accgatgagt	147660
agctcatctt	gttatcggga	tccaagtttt	ctaaagatgt	cattaaacc	tcgatcatga	147720
atggatttat	catcatcggt	tttatgttgg	acatgagctt	agtcggtttg	tccacatcta	147780
tagaagatga	tttctgaatt	atltcatata	tctctctctt	taactccagg	aacttgctcag	147840
gatgggtctac	tttaatatgt	tctcgtctaa	gagatgaaaa	tctttggatg	gttgccacgcg	147900
acttttctct	aaaggatgac	gttgcccaag	atcctctctt	aaatgaatcc	atcttatcct	147960
tggacaagat	ggacagtcta	ttttccttag	atggtttaaat	atltttgtta	cccatgatct	148020
ataaaggtag	acctaatcgt	ctcggatgac	catatatltta	ttttcagttt	tattatacgc	148080
ataaattgta	aaaaatatgt	taggtttaca	aaaatgtctc	gtggggcatt	aatcgttttt	148140
gaaggattgg	acaaatctgg	aaaaacaaca	caatgtatga	acatcatgga	atctataccg	148200
gcaaacacga	taaaaatatct	taactttcct	cagagatcca	ctgtcactgg	aaaaatgata	148260
gatgactatc	taactcgtaa	aaaaacctat	aatgatcata	tagttaatct	attatltttgt	148320
gcaaatagat	gggagtttgc	atctltttata	caagaacaac	tagaacaggg	aattacttta	148380
atagttgata	gatacgcatt	ttctggagta	cgtatgccg	ccgctaaagg	cgcgtaaatg	148440
actctcagta	agagttatga	atctgggattg	cctaaaccgc	acttagttat	attcctggaa	148500
tctggtagca	aagaaattaa	tagaaacgtc	ggcgaggaaa	tttatgaaga	tggttacattc	148560
caacaaaagg	tattacaaga	atataaaaaa	atgattgaag	aaggagatat	tcattggcaa	148620
attatlttctt	ctgaattcga	ggaagatgta	aagaaggagt	tgattaagaa	tatagttata	148680
gaggctatac	acacggttac	tggaccagtg	gggcaactgt	ggatgtaata	gtgaaattac	148740
atlttttata	aatagatgtt	agtacagtgt	tataaatgga	tgaagcatat	tactctggca	148800
acttggaatc	agtactcgga	tacgtgtccg	atatgcatac	cgaactcgca	tcaatatctc	148860
aattagttat	tgccaagata	gaaactatag	ataatgatat	attaacaag	gacattgtaa	148920
atltttatcat	gtgtagatca	aacttggtata	atccatttat	ctctlttccta	gatactgtat	148980
atactattaa	aaataactag	ttataagttt	gaatccgtca	atlttgattc	caaaattgaa	149040
tggactgggg	atgggtctata	caatatatcc	cttaaaaatt	atggcatcaa	gacgtggcaa	149100
acaatgtata	caaatgtacc	agaaggaaaca	tacgacatat	ccgcatttcc	aaagaatgat	149160
ttcgtatctt	tctgggttaa	atltgaacaa	ggcgattata	aagtggaga	gtattgtacg	149220
ggactatgcg	tcgaagtaaa	aattggacca	ccgactgtaa	cattaactga	atacgacgac	149280
catatcaatt	tgtacatcga	gcattccgtat	gctactagag	gtagcaaaaa	gattcctatt	149340
tacaaaacgcg	gtgacatgtg	tgatatctac	ttgttgtata	cggctaactt	cacattccga	149400
gattctaaag	aaccagtacc	atatgatatac	gatgactacg	attgcacgtc	tacaggttgc	149460
agcatagact	ttgtcacaa	agaaaaagtg	tgcggtgacg	cacagggagc	cacagaaggg	149520
tttctcgaaa	aaattactcc	atggagttcg	aaagtatgtc	tgacacctaa	aaagagtgtta	149580
tatacatgcg	caattagatc	caaagaagat	gttcccaatt	tcaaggacaa	aatggccaga	149640
gttatcaaga	gaaaatttaa	tacacagtct	caatcttatt	taactaaatt	tctcggttagc	149700
acatcaaatg	atgttaccac	ttttcttagc	atgcttaact	tgactaaata	ttcataatta	149760
tttttttata	atgatacaaa	aacgaaataa	aactgcata	tatacactgg	ttaacgcctt	149820
tataggctct	aaccattttc	aagatgaggt	ccctgattat	agtccttctg	ttccctctta	149880
tcactctactc	catgtctatt	agacgatgtg	agaagactga	agaggaaaca	tggggattga	149940
aaatagggtt	gtgtataatt	gccaaagatt	tctatccga	aagaactgat	tgcatgtgtc	150000
atctcccaac	tgcaagtga	ggattgataa	ctgaaggcaa	tggattcagg	gatatacgaa	150060
acaccgataa	attataaaaa	aagcaatgtg	tccgctgttt	ccgttaataa	tactatltttc	150120
gtaactggcg	gattattcat	aaataactct	aatagcacga	tcgtggacat	ttataaagac	150180
aaacaatggg	cgattataga	aatggctagg	gtatatcacg	gcattcgactc	gacatttgga	150240
atgttatatt	ttgccggagg	tctatccgtt	accgaacaat	atggtaattt	agagaaaaac	150300
aacgagatat	cttggttaca	tcctagaacg	aataagtggg	ttgatatttc	atatactatt	150360
tataagatat	ccatatcatc	attgtgtaaa	ctaaataacg	tcttctatgt	atlttagtaag	150420
gacattggat	atgtggaaaa	gtatgatgtt	gcattggaag	tagtacatga	tcgtctcccc	150480
gctataaagg	cattatcaac	ttctccttat	tgattgaaaa	tgaaaaatata	aatagttttt	150540
atgtatagca	gtattaccct	atagttttat	tgcttactac	taacatggat	acagatgtta	150600
caaatgtaga	agatatcata	aatgaaatag	atagagagaa	agaagaaata	ctaaaaaatg	150660
tagaaattga	aaataataaa	aacattaaca	agaatcatcc	caatgaatat	attagagaag	150720
cactcgttat	taataaccagt	agtaatagtg	attccattga	taaagaagtt	atagaatgta	150780



-62-

tcagtcacga	tgtaggaata	tagatcatat	ctactaattt	ttataatcga	tacaaaacat	150840
aaaaaacaac	tcgttattac	atagcaggca	tggaaatcct	caagtattgt	tttgataacg	150900
atggcaagaa	atggattatc	ggaaatactt	tatatctctg	taattcaata	ctctataagg	150960
tcagaaaaaa	tttcactagt	tcgttctaca	attacgtaat	gaagatagat	cacaaatcac	151020
acaagccatt	gttgtctgaa	atacgattct	atatactctg	attggatcct	ttgactatcg	151080
acaactggac	acgggaacgt	ggtataaagt	atltggctat	tccagatctg	tatggaattg	151140
gagaaaccga	tgattatatg	ttcttcgtta	taaagaattc	gggaagagta	ttcgccccaa	151200
aggatactga	atcagtcctc	gaagcatgcg	tcactatgat	aaacacgtta	gagttttatac	151260
actctcgagg	atltacccat	ggaaaaatag	aaccgaggaa	tatactgatt	agaaaataac	151320
gtcttttact	aattgactat	tctagaacta	acaaactata	caagagtggga	aactcacata	151380
tagattacaa	cgaggacatg	ataacttcag	gaaatatcaa	ttatatgtgt	gtagacaatc	151440
atcttggagc	aacagtttca	agacgaggag	atlttagaaat	gttgggatat	tgcatgatag	151500
aatggttcgg	tggcaaactt	ccatggaaaa	acgaaagtag	tataaaagta	ataaaacaaa	151560
aaaaagaata	taaaaaattt	atagctactt	tctttgagga	ctgttttctc	gaaggaaatg	151620
aacctctgga	attagttaga	tatatagaat	tagtatacac	gttagattat	tctcaaaactc	151680
ctaattatga	cagactacgt	aaactgttta	tacaagattg	aaattatatt	cttttttttta	151740
tagagtgtgg	gatgtttacg	gatatctaata	attaatatta	gactatctct	atcgcgctac	151800
acgaccaata	tcgattacta	tggatatctt	ctatgaaagg	agagaatgta	tttatttctc	151860
cagcgtcaat	ctcgtcagta	ttgacaatac	tgtattatgg	agctaattgga	tccactgctg	151920
aacagctatc	aaaatatgta	gaaacggagg	agaacacgga	taaggtttagc	gctcagaata	151980
tctcattcaa	atccatgaat	aaagtatatg	ggcgatattc	tgccgtgttt	aaagattcct	152040
tttttgagaaa	aattggcgat	aagtttcaaa	ctgttgactt	cactgattgt	cgcactatag	152100
atgcaatcaa	caagtgtgta	gatatacttta	ctgaggggaa	aatcaatcca	ctattgggatg	152160
aaccattgtc	tcctagcaat	tagtgccgta	tacttttaaag	caaaatgggt	gacgccattc	152220
gaaaaggaat	ttaccagtga	ttatcccttt	tacgtatctc	cgacggaaat	ggtagacgta	152280
agtatgatgt	ctatgtacgg	caaggcattt	aatcacgcac	ctgtaaaaga	atcatttcggc	152340
aacttttcaa	tcatagaact	gccatatggt	ggagatacta	gtatgatggg	cattcttcca	152400
gacaagattg	atggattaga	atccatagaa	caaaatctaa	cagatacaaa	ttttaagaaa	152460
tggtgtgact	ttatggatgc	tatgtttata	gatgttcaca	ttcccaagtt	taaggtaaca	152520
ggctcgtata	atctggtgga	tactctagta	aagtcaggac	tgacagaggt	gttcggttca	152580
actggagatt	atagcaatat	gtgtaattta	gatgtgagtg	tcgacgctat	gatccacaaa	152640
acgtatatag	atgtcaatga	agagtataca	gaagcagctg	cagcaacttc	tgtactagtg	152700
gcagactgtg	catcaacaat	tacaaatgag	ttctgtgcag	atcatccgtt	catctatgtg	152760
attagggcatg	ttgatggaaa	aattcttttc	ggttggtagat	attgctctcc	gacaactaat	152820
tgtttaacct	tttttttaaa	aaaaacaatg	ggtgatggat	acacttgatg	gtataatgat	152880
gaatgaacgc	gatgtttctg	taagcggttg	caccggaata	ctattcatgg	aaatgttttt	152940
ccgttacaat	aaaaatagta	tcaacaatca	actaatgtat	gatataatta	atagcgtatc	153000
tataagtgtg	gctaattata	gatatagaag	ctgcttttaa	cgacgatggg	atatacatcc	153060
gtagaaatat	gattaacaag	ttgtacggat	acgcactctc	aactactatt	ggcacgatcg	153120
ctggaggtgt	ttgttattat	ctgttgatgc	atctagttag	tttgtataaa	taattatttc	153180
aataactag	ttaaaatttt	aagattttta	atgtataaaa	aactaataac	gtttttattt	153240
gtaataggtg	cattagcatc	ctattcgaat	aatgagtaca	ctccgtttta	taaactgagt	153300
gtaaaactct	atatagatgg	agtagataat	atagaaaatt	catatactga	tgataataat	153360
gaattgggtg	taaattttta	agagtacaca	atltctatta	ttacagagtc	atgacgacgc	153420
ggatttgatt	ccatagatat	agatgttata	aacgactata	aaattattga	tatgtatacc	153480
attgactcgt	ctactattca	acgcagaggt	cacacgtgta	gaatatctac	caaattatca	153540
tgccattatg	ataagtaccc	ttatatccac	aaatatgatg	gtgatgagcg	acaatattct	153600
attactgcag	agggaaaaatg	ctataaaagga	ataaaatatg	aaataagtat	gatcaacgat	153660
gatactctat	tgagaaaaca	tactcttaaa	attggatcta	cttatatat	tgatcgtcat	153720
ggacatagta	atacatatta	ttcaaaaat	gatttttttaa	aattttaaaat	atattatcac	153780
ttcagtgaca	gtagtcaaat	aacaaacaac	accatgagat	atattataat	tctcgcagtt	153840
ttgttcatta	atagtataca	cgctaaaata	actagtata	agtttgaatc	cgtcaatttt	153900
gattccaaaa	ttgaatggac	tggggatggg	ctatacaata	tatcccttaa	aaattatggc	153960
atcaagacgt	ggcaaacaat	gtatacaaat	gtaccagaag	gaacatacga	catatccgca	154020
tttccaaaga	atgatttcgt	atctttctgg	gttaaatgtg	aacaaggcga	ttataaagtg	154080

-63-

gaagagtatt	gtacgggact	atgcgtcgaa	gtaaaaattg	gaccaccgac	tgtaacattg	154140
actgaatacg	acgaccatat	caatttgtac	atcgagcatc	cgtatgctac	tagaggtagc	154200
aaaaagattc	ctattttacaa	acgcggtgac	atgtgtgata	tctacttggt	gtatacggct	154260
aacttcacat	tccgagattc	taaagaacca	gtaccatatg	atatacgatga	ctacgattgc	154320
acgtctacag	ggttcgagcat	agactttgtc	acaacagaaa	aagtgtgcgt	gacagcacag	154380
ggagccacag	aagggtttct	cgaaaaaatt	actccatgga	gttcgaaagt	atgtctgaca	154440
cctaaaaaga	gtgtatatatac	atgcgcaatt	agatccaaag	aagatgttcc	caattttcaag	154500
gacaaaatgg	ccagagttat	caagagaaaa	tttaatacac	agtctcaatc	ttattttaact	154560
aaattttctcg	gtagcacatc	aaatgatggt	accacttttc	ttagcatgct	taacttgact	154620
aaatatcat	aactaatttt	tattaatgat	acaaaaacga	aataaaaactg	catattatac	154680
actgggttaac	gcccattatag	gctctaacca	ttttcaagat	gagggtccctg	attatagtcc	154740
ttctgttccc	ctccatgtct	attagacgat	gtgagaagac	tgaagaggaa	acatggggat	154800
tgaaaatagg	gtttgtgtata	attgccaaaag	atTTTTtatcc	cgaagaagact	gattgcagtg	154860
ttcatctccc	aactgcaagt	gaaggattga	taactgaagg	caatggattc	agggatatac	154920
gaaacaccga	taaattataa	aaaaagcaat	gtgtccgctg	tttccgttaa	taatactatt	154980
ttcgttaactg	gcggtattatt	cataaataac	tctaatagca	cgatcgtgga	cattttataaa	155040
gacaaacaat	ggtcgattat	agaaatggct	agggtatatc	acggcatcga	ctcgacattt	155100
ggaatgttat	atTTTTgccc	aggtctatcc	gttaccgaac	aatatggtaa	tttatagaaa	155160
aacaacgaga	tatcttgtta	caatcctaga	acgaataagt	ggtttgatat	ttcatatact	155220
atTTataaga	tatccatatac	atcatttgtgt	aaactaaata	acgtcttcta	tgtattttagt	155280
aaggacattg	gatatgtgga	aaagtatgat	ggtgcatgga	agttagtaca	tgatcgtctc	155340
cccgtataaa	aggcattatc	aacttctcct	tattgattga	aaatgaaaat	ataaatagtt	155400
tttatgtata	gcagtattac	cctatagttt	tattgcttac	tactaacatg	gatacagatg	155460
ttacaaatgt	agaagatatc	ataaatgaaa	tagatagaga	gaaagaagaa	atactaaaaa	155520
atgtagaaat	tgaaaataat	aaaaacatta	acaagaatca	tcccaatgaa	tatatagag	155580
aagcactcgt	tattaatacc	agtagtaata	gtgattccat	tgataaagaa	gttatagaat	155640
gtatcagtca	cgatgtagga	atatagatca	tatctactaa	tttttataat	cgatacaaaa	155700
cataaaaaaac	aactcgttat	tacatagcag	gcatggaatc	cttcaagtat	tgTTTTgata	155760
acgatggcaa	gaaatggatt	atcggaaata	ctttatatcc	tggttaattca	atactctata	155820
aggtcagaaa	aaatttccact	agttcgttct	acaattacgt	aatgaagata	gatcacaaat	155880
cacacaagcc	attgttgtct	gaaatacga	tctatatatac	tgtattggat	cctttgacta	155940
tgcgaaactg	gacacgggaa	cgtgggtataa	agtatttggc	tattccagat	ctgtatggaa	156000
ttggagaaac	catgtgatta	tatgttcttc	gttataaaga	attcgggaag	agtattcgcc	156060
ccaaaggata	ctgaatcagt	cttcgaaagca	tgctcacta	tgataaacac	gttagagttt	156120
atacactctc	gaggatttac	ccatggaaaa	atgaaccga	ggaatataat	attaaaactt	156180
accacgtaaa	acttaaaatt	taaaatgata	tttcattgac	agatagatca	cacattatga	156240
actttcaagg	acttgtgtta	actgacaatt	gcaaaaatca	atgggtcgtt	ggaccattaa	156300
taggaaaagg	tggatttggt	agtatttata	ctactaatga	caataattat	gtagtataaa	156360
tagagcccaa	agctaacgga	tcattatttta	cgaacaggc	atTTttatact	agagtactta	156420
aaccatccgt	tatcgaagaa	tggaaaaaat	ctcacaatat	aaagcacgta	ggtcttatca	156480
cgtgcaaggc	atTTgttcta	tacaaatcca	ttaatgtgga	atatacgattc	ttggtaatta	156540
atagattagg	tgcagatcta	gatgcggtga	tcagagccaa	taataataga	ctacccaaaa	156600
ggtcgggtgat	gttgatcgga	atcgaaatct	taaataccat	acaatttatg	cacgagcaag	156660
gatattctca	cggagatatt	aaagcgagta	atatagtctt	agatcaaata	gataagaata	156720
aattatatct	agtggattac	ggattgggtt	ctaaattcat	gtctaattggc	gaacatgttc	156780
catttataag	aaatccaaat	aaaatggata	acggtactct	agaattttaca	cctatagatt	156840
cgcataaagg	atacgttgta	tctagacgtg	gagatctaga	aacacttgga	tattgtatga	156900
ttagatgggt	gggagggtatc	ttaccatgga	ctaagatatc	tgaacaaaag	aattgtgcat	156960
tagtaagtgc	cacaaaacag	aaatatgtaa	acaatactgc	gactttgtta	atgaccagtt	157020
tgcaatatgc	acctagagaa	ttgctgcaat	atattaccat	ggtaaactct	ttgacatatt	157080
ttgaggaacc	caattacgac	aagtttcggc	acataattaat	gcagggtgta	tattattaag	157140
tgtgggtgtt	ggtcgataaa	aattaaaaaa	taacttaatt	tattattgat	ctcgtgtgta	157200
caaccgaaat	catggcgatg	ttttacgcac	acgctctcgg	tgggtacgac	gagaatcttc	157260
atgcctttcc	tggaaatatca	tcgactgttg	ccaatgatgt	caggaaatat	tctgttgtgt	157320
cagtttataa	taacaagtat	gacattgtaa	aagacaaaata	tatgtgggtg	tacagtcagg	157380



-64-

tgaacaagag	atatattgga	gcaactgctgc	ctatgtttga	gtgcaatgaa	tatctacaaa	157440
ttggaaatcc	gatccatgat	caagaaggaa	atcaaactctc	tatcatcaca	tatcgccaca	157500
aaaactacta	tgctctaagc	ggaatcgggt	acgagagtct	agacttggtg	ttggaaggag	157560
tagggattca	tcatcacgta	cttgaaacag	gaaacgctgt	atatggaaaa	gttcaacatg	157620
attattctac	tatcaaagag	aaggccaaa	aaatgagtgc	acttagtcca	ggacctatca	157680
tcgattacca	cgtctggata	ggagattgta	tctgtcaagt	tactgctgtg	gacgtacatg	157740
gaaaggaaat	tatgaaaatg	agattcaaaa	aggggtcggt	gcttcgcgac	ccaaatctgg	157800
taaaagttaa	acttggggag	aatgatacag	aaaatccttc	ttctactata	tcggcgacac	157860
catcgaggta	accacctctc	tgggaagacag	cgtgaataat	gtactcatga	aacgtttgga	157920
aactatacgc	catatgtggt	ctgttgata	tgatcatttt	gatattgtga	atggtaaaga	157980
atgctgttat	gtgcatacgc	atttgtctaa	tcaaaatctt	ataccgagta	ctgtaaaaac	158040
aaattttgtac	atgaagacta	tgggcatcatg	cattcaaatg	gattccatgg	aagctctaga	158100
gtatcttagc	gaactgaagg	aatcagggtgg	atggagtcctc	agaccagaaa	tgcagggaatt	158160
tgaatatcca	gatggagtgg	aagacactga	atcaattgag	agattggtag	aggagttctt	158220
caatagatca	gaacttcagg	ctgggtgaatc	agtc aaat	ggtaattcta	ttaatgttaa	158280
acatacatct	gtttcagcta	agcaactaag	aacacgtata	cggcagcagc	ttccttctat	158340
actctcatct	tttaccacaa	caaaggggtgg	atatttgttc	attggagtgtg	ataataatc	158400
acacaaagta	tttggattca	cgggtgggtta	cgactacctc	agactgatag	agaatgatata	158460
agaaaagcat	atcaaaagac	tttgtgttgt	gtatttctgt	gagaagaaa	aggacatcaa	158520
gtacgcgtgt	cgattcatca	aggtatataa	acctggggat	gaggctacct	cgacatacgt	158580
gtgcgctatc	aaagtggaaa	gatgctgttg	tgctgtgttt	gcagattggc	cagaatcatg	158640
gtatatggat	actaatggta	tcaagaagta	ttctccagat	gaatgggtgt	cacatataaa	158700
attttaatta	atgtaactat	agagaacaaa	taataagggt	gtaatatcat	atagacaata	158760
actaacaatt	aattagtaac	tgttatctct	tttttaatta	accaactaac	tatataccta	158820
ttaatacatc	gtaattatag	ttcttaacct	ctattaatca	ttaattcgct	tccttaattt	158880
tttataaact	aacattgtta	attgaaaagg	gataaacatgt	tacagaatat	aaattatata	158940
tggatttttt	taaaaaggaa	atacttgact	ggagtataata	tttatctctt	cattatatag	159000
cacgcgtgtt	ttccaatttt	tccacatccc	atataataca	ggattataat	ctcgttcgaa	159060
catacgagaa	agtggataaa	acaatagtgtg	atattttatc	taggttgcca	aattttattcc	159120
atatttttaga	atatggggaa	aatattctac	atattttattc	tatggatgat	gctaatacga	159180
atattataat	tttttttcta	gatagagtat	taaatatata	taagaacggg	tcattttatac	159240
acaatctcgg	gttatcatca	tccattaata	taaaagaata	tgtatatcaa	ttagtttaata	159300
atgatcatcc	agataaatagg	ataagactaa	tgcttgaaaa	tggacgtaga	acaagacatt	159360
ttttgtccta	tatatcagat	acagtttaata	tctatatatg	tatttttaata	aatcatggat	159420
tttatataga	tgccgaagac	agttacgggt	gtacattatt	acatagatgt	atatatcaact	159480
ataagaaatc	agaatcagaa	tcatacaatg	aattaattaa	gatattgtta	aataatggat	159540
cagatgtaga	taaaaaagat	acgtacggaa	acacaccttt	tatcctatta	tgtaaacacg	159600
atatcaacaa	cgtggaattg	tttgagatat	gttttagagaa	tgctaataata	gactctgtag	159660
actttaatag	atatacacct	cttcattatg	tctcatgtcg	taataaatat	gattttgtaa	159720
agttattaat	ttctaaagga	gcaaatgtta	atgcgcgtaa	taaatctcgga	actactccat	159780
tttattgtgg	aattatacac	ggtatctcgc	ttataaaact	atattttggaa	tcagacacag	159840
agttagaaat	agataatgaa	catatagtcc	gtcatttaaat	aatttttgat	gctgttgaat	159900
ctttagatta	tctattatcc	agaggagtta	ttgatattaa	ctatcgtact	atatacaacg	159960
aaacatctat	ttacgacgct	gtcagttata	atgcgtataa	tacgttggtc	tatctattaa	160020
acaaaaatgg	tgatttttgag	acgattacta	ctagtggatg	tacatgtatt	tcggaagcag	160080
tcgcaaacaa	caacaaaata	ataatggaag	tactattgtc	taaacgacca	tccttgaaaa	160140
ttatgataca	gtctatgata	gcaattacta	aacataaaca	gcataatgca	gattttattga	160200
aaatgtgtat	aaaatatact	gcgtgtatga	cogattatga	tactcttata	gatgtacagt	160260
cgctacagca	atataaatgg	tatattttta	gatgtttcga	tgaaatagat	atcatgaaga	160320
gatgttatat	aaaaaataaa	actgtattcc	aattagtttt	ttgtatcaaa	gacattaata	160380
ctttaatgag	atacggtaaa	catccttctt	tcgtgaaatg	cactagtctc	gacgtatacg	160440
gaagtcgtgt	acgtaatatc	atagcatcta	ttagatatcg	tcagagatta	attagtctat	160500
tatccaagaa	gctggatcct	ggagataaat	ggctcgtgtt	tcctaacgaa	ataaaatata	160560
aaatatttga	aaactttaac	gataacgaac	tatccacata	tctaaaaatc	ttataaacat	160620
tattaaaaata	taaaatctaa	gtaggataaa	atcacactac	atcattgttt	ccttttagtg	160680

ctcgacagtg	tatactat	ttaacgctca	taaataaaaa	tgaaaacgat	ttccgttggt	160740
acgttggtat	gcgtactacc	tgctgttggt	tattcaacat	gtactgtacc	cactatgaat	160800
aacgctaaat	taacgtctac	cgaaacatcg	tttaatgata	accagaaagt	tacgtttaca	160860
tgtgatcagg	gatatcattc	tttggatcca	aatgctgtct	gtgaaacaga	taaatggaaa	160920
tacgaaaatc	catgcaaaaa	aatgtgcaca	gtttctgatt	atgtctctga	actatataat	160980
aaaccgctat	acgaagtga	ttccaccatg	acactaagtt	gcaacggcga	aacaaaaatat	161040
tttcgttgcg	aagaaaaaaa	tggaataact	tcttggaatg	atactgttac	gtgtccta	161100
gcggaatg	aacctcttca	attagaacac	ggatcggtgc	aaccagttaa	agaaaaatac	161160
tcatttgggg	aatatatgac	tatcaactgt	gatgttggat	atgaggttat	tggtgcttcg	161220
tacataagtt	gtacagctaa	ttcttggaa	gttattccat	catgtcaaca	aaaatgtgat	161280
atgccgtctc	tatctaacgg	attaatttcc	ggatctacat	tttctatcgg	tggcggtata	161340
catcttagtt	gtaaaagtgg	ttttacacta	acggggctctc	catcatccac	atgtatcgac	161400
ggtaaatgga	atcccatact	cccaatatgt	gtacgaacta	acgaaaaatt	tgatccagtg	161460
gatgatggtc	ccgacgatga	gacagatttg	agcaaactct	cgaagacgt	tgtacaatat	161520
gaacaagaaa	tagaatcggt	agaagcaact	tatcatataa	tcatagtggc	gttgacaatt	161580
atgggctga	tattttta	ctcgttata	gtattagttt	gttcctgtga	caaaaaata	161640
gaccaatata	agttccataa	attgttaccg	taaatataaa	tccgttaaaa	taattaataa	161700
tttaataaca	aacaagtatc	aaaagattaa	agacttatag	ctagaatcaa	ttgagatg	161760
ttcttcagtg	gatgttgata	tctacgatgc	cgttagagca	tttttactca	ggcactatta	161820
taacaagaga	tttattgtgt	atggaagaag	taacgccata	ttacataata	tatacaggct	161880
atttacaaga	tgcgccgtta	taccgttcga	tgatatagta	cgtactatgc	caaatgaatc	161940
acgtgttaaa	caatgggtga	tggtatacact	taatgggtata	atgatgaatg	aacgcgatgt	162000
ttctgtaagc	gttggcaccg	gaatactatt	catggaaatg	tttttcgatt	acaataaaaa	162060
tagtatcaac	aatcaactaa	tgtatgatat	aattaatagc	gtatctataa	ttctagctaa	162120
tgagagatat	agaagcgctt	ttaacgcaga	tggtatatac	atccgtagaa	atatgattaa	162180
caagttgtac	ggatacgcac	ctctaactac	tattggcacg	atcgctggag	gtgtttgtta	162240
ttatctgttg	atgcatctag	ttagtttgta	taaataatta	tttcaatata	ctagttaaaa	162300
ttttaagatt	ttaaatgtat	aaaaaactaa	taacgttttt	atttgtaata	ggtgcattag	162360
catcctattc	gaataatgag	tacactccgt	ttaataaaact	gagtgtaaaa	ctctatatag	162420
atggagtaga	taatatagaa	aattcatata	ctgatgataa	taatgaattg	gtgttaaatt	162480
ttaaagagta	cacaatttct	attattacag	agtcatgcga	cgtcggattt	gattccatag	162540
atatagatgt	tataaacgac	tataaaatta	ttgatatgta	taccattgac	tcgtctacta	162600
ttcaacgcag	aggtcacacg	tgtagaatat	ctaccaaatt	atcatgccat	tatgataagt	162660
acccttatat	tcacaaatat	gatggtagtg	agcgacaata	ttctattact	gcagagggaa	162720
aatgctataa	aggaataaaa	tatgaaataa	gtatgatcaa	cgatgatact	ctattgagaa	162780
aacatactct	taaaattgga	tctacttata	tatttgatcg	tcatggacat	agtaatacat	162840
attattcaaa	atatgatttt	taaaaattta	aaatatatta	tcacttcagt	gacagtagtc	162900
aaataacaaa	caacaccatg	agatatatta	taattctcgc	agttttgttc	attaatagta	162960
tacatgctaa	aataactagt	tataagtttg	aatccgtcaa	ttttgattcc	aaaattgaat	163020
ggactgggga	tggtctatac	aatatatccc	ttaaaaatta	tggcatcaag	acgtggcaaa	163080
caatgtatac	aaatgtacca	gaaggaacat	acgacatatc	cgcatttcca	agaatgatt	163140
tcgtatcttt	ctgggttaaa	tttgaacaag	gcgattataa	agtggaagag	tattgtacgg	163200
gactatgcgt	cgaagtataa	attggaccac	cgactgtaac	attgactgaa	tacgacgacc	163260
ataaacagaa	aaagtgtg	tgacagcaca	gggagccaca	gaagggtttc	tcgaaaaaat	163320
tactccatgg	agttcgaaag	tatgtctgac	acctaaaaag	agtgtatata	catgcgcaat	163380
tagatccaaa	gaagatgttc	ccaatttcaa	ggacaaaatg	gccagagtta	tcaagagaaa	163440
atttaataca	cagtctcaat	cttattttaac	taaatttctc	ggtagcacat	caaatgatgt	163500
taccactttt	cttagcatgc	ttactttgac	taaatattca	taactaattt	ttattaatga	163560
tacaaaaacg	aaataaaaact	gcataattata	cactgggttaa	cgcccttata	ggctctaacc	163620
attttcaaga	tgaggtcctc	gattatagtc	cttctgttcc	cctctatcat	ctactccatg	163680
tctattagag	gatgtgagaa	gactgaagag	gaacatggg	gattgaaaat	aggggtgtgt	163740
ataattgcca	aagattttcta	tcccgaaaga	actgattgca	gtgttcac	cccaactgca	163800
agtgaaggat	tgataactga	aggcaatgga	ttcagggata	tacgaaacac	cgataaatta	163860
taaaaaaagc	aatgtgtccg	ctgtttccgt	taataatact	attttcgtaa	ctggcggatt	163920
attcataaat	aactctaata	gcacgatcgt	ggttaacaat	atggaaaaac	ttgacattta	163980

-66-

taaagacaaa	caatgggtcga	ttatagaaat	gcctatggct	agggtatatc	acggcattga	164040
ctcgacattt	ggaatgttat	attttgccgg	aggtctatcc	gttaccgaac	aatatggtaa	164100
tttagagaaa	aacaacgaga	tatcttggtta	caatcctaga	acgaataagt	ggtttgatat	164160
ttcatatact	at ttataaga	tatccatatac	atcattgtgt	aaactaaata	acgtcttcta	164220
tgtattttagt	aaggacattg	gatatgtgga	aaagtatgat	gggtgcatgga	agttagtaca	164280
tgatcgtctc	cccgtctataa	aggcattatac	aacttctcct	tattgattga	aaatataaat	164340
agttttttatg	tatagcagta	ttaccctata	gtttttattgc	ttactactaa	catggataca	164400
gatgtttacaa	atgtagaaga	tatcataaat	gaaatagata	gagagaaaaga	agaaatacta	164460
aaaaatgtag	aaattgaaaa	taataaaaac	at taacaaga	atcatcccaa	tgaatatatt	164520
agagaagcac	tcgtttattaa	taccagtagt	aatagtgatt	ccattgataa	agaagttata	164580
gaatgtatca	gtcacgatgt	aggaatatag	atcatatcta	ctaatttttta	taatcgatac	164640
aaaacataaa	aaacaactcg	ttattacata	gcaggcatgg	aatccttcaa	gtattgtttt	164700
gataacgatg	gcaagaaatg	gattatcgga	aatactttat	attctggtaa	ttcaatactc	164760
tataagggtca	gaaaaaattt	cactagttcg	ttctacaatt	acgtaatgaa	gatagatcac	164820
aaatcacaca	agccattgtt	gtctgaaata	cgattctata	tatctgtatt	ggatcctttg	164880
actatcgaca	actggacacg	ggaacgtggt	ataaagtatt	tggctattcc	agatctgtat	164940
ggaattggag	aaaccgatga	ttatatgttc	ttcgtttataa	agaattcggg	aagagtattc	165000
gccccaaagg	atactgaatc	agtccttcgaa	gcattcgctca	ctatgataaa	cacgttagag	165060
tttatacact	ctcgaggatt	tacccatgga	aaaaatagaac	cgagggaatat	actgattaga	165120
aataaacgtc	tttactaat	tgactattct	agaactaaca	aactatacaa	gagtggaaac	165180
tcacatatag	attacaacga	ggacatgata	acttcaggaa	atatcaatta	tatgtgtgta	165240
gacaatcatc	ttggagcaac	agtttcaaga	cgaggagatt	tagaaatgtt	gggatattgc	165300
atgatagaat	ggttcgggtg	caaacttcca	tggaaaaacg	aaagtagtat	aaaagtaata	165360
aaacaaaaaa	aagaatataa	aaaattttata	gctactttct	ttgaggactg	ttttcctgaa	165420
ggaaatgaac	ctctggaatt	agttagatat	atagaattag	tatacacgtt	agattattct	165480
caaactocta	attatgcag	actacgtaaa	ctgttttatac	aagattgaaa	ttatatctct	165540
tttttttatag	agtgtggtag	tgttacggat	atctaattatt	aatattagac	tatctctatc	165600
gcgctacacg	accaatatcg	attactatgg	atatcttcta	tgaaaggaga	gaatgtattt	165660
at ttctccag	cgtcaatctc	gtcagtattg	acaatactgt	attatggagc	taatggatcc	165720
actgctgaac	agctatcaaa	atatgtagaa	acggaggaga	acacggataa	ggtagcgct	165780
cagaatatct	cattcaaatc	catgaataaa	gtatatgggc	gatattctgc	cgtgttttaa	165840
gattcctttt	tgagaaaaat	tggcgataag	tttcaaactg	ttgacttcac	tgattgtcgc	165900
actatagatg	caatcaacaa	gtgtgtagat	atctttactg	aggggaaaaat	caatccacta	165960
ttggatgaac	attgtgtctc	tagcaattag	tgccgtatac	tttaaagcaa	aatgggtgac	166020
gccattcgaa	aaggaaattta	ccagtgatta	tcccttttac	gtatctccga	cggaaatggg	166080
agacgtaagt	atgatgtcta	tgtacggcaa	ggcatttaat	cacgcactctg	taaaaagaatc	166140
attcggcaac	ttttcaatca	tagaactgcc	atatgttgga	gatactagta	tgatgggtcat	166200
tcttccagac	aagattgatg	gattagaatc	catagaacaa	aatctaacag	atacaaattt	166260
taagaaatgg	tgtgacttta	tggatgctat	gtttatagat	gttcacattc	ccaagtttaa	166320
ggtaacaggc	tcgtataatc	tgggtggatac	tctagtaaag	tcaggactga	cagagggtgtt	166380
cggttcaact	ggagattata	gcaatatgtg	taatttagat	gtgagtgtcg	acgctatgat	166440
ccacaaaacg	tatatagatg	tcaatgaaga	gtatacagaa	gcagctgcag	caacttctgt	166500
actagtggca	gactgtgcat	caacaattac	aaatgagttc	tgtgcagatc	atccgttcat	166560
ctatgtgatt	aggcatgttg	atggaaaaat	tcttttcggt	ggtagatatt	gctctccgac	166620
aactaattgt	taaccatttt	ttttaaaaaa	aatagaaaaa	acatgtggta	ttagtgcagg	166680
tcgttggtct	tccaattgca	attggtaaga	tgacggccaa	ctttagtacc	cacgtctttt	166740
caccacagca	ctgtggatgt	gacagactga	ccagtattga	tgacgtcaaa	caatgtttga	166800
ctgaatatat	ttattgggtcg	tcctatgcat	accgcaacag	gcaatgcgct	ggacaattgt	166860
attccacact	cctctctttt	agagatgatg	cggaaattag	gttcacogac	attcgcgcagc	166920
tggttaaaaa	tatgccgtgg	gatgatgtca	aagattgtac	agaaatcatc	cgttggtata	166980
taccggatga	gcaaaaaac	atcagagata	tttcggccat	catcggactt	tgtgcatatg	167040
ctgctactta	ctggggagggt	gaagaccatc	ccactagtaa	cagtcctgaac	gcattgtttg	167100
tgatgcttga	gatgctaaat	tacgtggatt	ataacatcat	attccggcgt	atgaattgat	167160
gagttgtaca	tcttgacatt	ttctttcttc	tcttctccct	ttcttctctt	ctcccttctt	167220
ccctcttctc	cctttccag	aaacaaactt	ttttaccac	tataaaaataa	aatgagtata	167280

-67-

ctacctgtta	tattttctttc	tatatattttt	tattcttcat	tcgttcagac	ttttaacgcg	167340
tctgaatgta	tcgacaaagg	gcaatatattt	gcatcattca	tggagttaga	aaacgagcca	167400
gtaatcttac	catgtcctca	aataaatacg	ctatcatccg	gatataatat	attagatatt	167460
ttatgggaaa	aacgaggagc	ggataatgat	agaattatac	cgatagataa	tggtagcaat	167520
atgctaattc	tgaacccgac	acaatcagac	tctgggtattt	atatatgcat	taccacgaac	167580
gaaacctact	gtgacatgat	gtcgttaaatt	ttgacaatcg	tgtctgtctc	agaatcaaatt	167640
atagattttta	tctcgtatcc	acaaatagta	aatgagagat	ctactggcga	aatggtatgt	167700
cccaatatta	atgcatttat	tgctagtaac	gtaaacgcag	atatttatatg	gagcggacat	167760
cgacgcctta	gaaataagag	acttaaacaa	cggacacctg	gaattattac	catagaagat	167820
gttagaaaaa	atgatgctgg	ttattataca	tgtgtttttg	aatatatata	cggtaggcaa	167880
acataaacg	taaccagaat	tgtaaaatta	gaggtacggg	ataaaataat	accttctact	167940
atgcaattac	cagatggcat	tgtaacttca	ataggtagta	atttgactat	tgcatcgttg	168000
agacctccca	caacggatgc	agacgtcttt	tggataagta	atggtatgta	ttacgaagaa	168060
gatgatgggg	acggaaacgg	tagaataagt	gtagcaaata	aaatctatat	gaccgataag	168120
agacgtgtta	ttacatcccg	gttaaaccatt	aatcctgtca	aggaagaaga	tgctacaacg	168180
tttacgtgta	tggcgttttac	tattcctagc	atcagcaaaa	cagttactgt	tagtataacg	168240
tgaatgtatg	ttgttatcatt	tccatgtcaa	ttaggtttat	aagaattttt	atacattatc	168300
ttccaacaaa	caattgacga	acgtattgct	atgatttaact	cccacgatac	tatgcatatt	168360
attaatcatt	aacttgacga	ctatacctag	tgctattttg	acatactcat	gttcttgtgt	168420
aattgcggta	tctatattat	taaagtacgt	aaatctagct	atagttttat	tattttaattt	168480
tagataatat	accgtctcct	tattttttaa	aattgccaca	tcctttatta	aatcatgaat	168540
gggaattttct	atgtcatcgt	tagtatattg	tgaacaacaa	gagcagatat	ctataggaaa	168600
gggtggaatg	cgatacattg	atctatgtag	ttttaaaaca	cacgcgaact	ttgaagaatt	168660
tatataaatc	attccatcga	tacatccttc	tatgttgaga	tgtatatatc	caggaattcg	168720
tttattaata	tcgggaaatg	tataaaactaa	aacattgccc	gaaagcgggtg	cctctatctg	168780
cgttatatacc	gttcttaact	tacaaaatgt	aaccaatacc	tttgcatgac	ttgttttgtt	168840
cggcaacggt	agttttaaact	tgacgaatgg	attaatttaca	atagcatgat	cgcgcgactc	168900
attaagtttt	tttaacttta	cgcccttgta	tgttttttaca	gagactttat	ctaaatttct	168960
agtgtttgta	tgtgtttata	atataacggg	atatagaacc	gaatcaocta	ccttagatac	169020
ccaattacat	tttatcagat	ccagataata	aacaaatttt	gtcgccctaa	ctaattctat	169080
attgtttatat	atttttacaat	tggttatgat	atcatgtaat	aacttggagt	ctaacgcgca	169140
tcgtcgtacg	tttatacaat	tgtgatttag	tgtagtatat	ctacacatgt	atttttccgc	169200
actatagtat	tctggactag	tgataaaact	atcgttatat	ctatcttcaa	tgaactcatc	169260
gagatattgc	tctctgtcat	attcatacac	ctgcataaac	tttctagaca	tcttacaact	169320
cgtgtttattt	ttcatatcatt	ttcatatatt	tacgggtata	tcaaagatgt	tagattagtt	169380
aatgggaatc	gtctataata	atgaatatta	aacaattata	tgaggacttt	taccacaaag	169440
catcataaaa	atgagtcgtc	gtctgattta	tgtttttaaat	atcaaccgca	aatcaactca	169500
taaaatacaa	gagaatgaaa	tatatacata	tttttagtcat	tgcaatatag	accatacttc	169560
tacagaactt	gattttgttag	ttaaaaacta	tgatctaaac	agacgacaac	ctgtaactgg	169620
gtatactgca	ctacactgct	atttgtataa	taattacttt	acaaacgatg	tactgaagat	169680
attattaaat	catggagtgg	atgtaacgat	gaaaaccagt	agcggacgta	tgctgtttta	169740
tatatgtctt	actagatggt	gtaatatctt	acatgatgta	gtgatagata	tgatagacaa	169800
agataaaaaac	cacttattac	atagagacta	ttccaacctta	ttactagagt	atataaaaac	169860
tcgttacatg	ttattaaagg	aagaggatat	cgatgagaac	atagtatoca	ctttatttaga	169920
taaggggaatc	gatacctaact	ttaaacaaga	cggatataca	gcgttacatt	attattattt	169980
gtgtctcgca	cacgttttata	aaccaggtga	gtgtagaaaa	ccgataacga	taaaaaaggc	170040
caagcgaatt	atttctttgt	ttatacaaca	tggagctaatt	ctaaacgcgt	tagataattg	170100
tggtaataca	ccattccatt	tgtatcttag	tattgaaatg	tgtaataata	ttcatatgac	170160
taaaatgctg	ttgaactttta	atccgaattt	cgaaatatgt	aataatcatg	gattaacgcc	170220
tatactatgt	tatataactt	cgcactacat	acaacacgat	attcttggtta	tggttaataca	170280
tcactatgaa	acaaatggtg	gagaaatgcc	gagatagtag	cgtcgtatga	tcgtattcga	170340
gtttatcaaa	acataattcta	cacgtccggc	agatttcgata	acttatttga	tgaatagggt	170400
taaaaatata	aatatattata	cccgctatga	aggaaagaca	ttattacacg	tagcatgtga	170460
atataataat	acacacgtaa	tagattatct	tatacgtatc	aacggagata	taaatgcgtt	170520
aaccgacaat	aacaaacacg	ctacacaact	cattatagat	aacaaagaaa	attccccata	170580

-68-

taccattaat	tgtttactgt	atatacttag	atatattgta	gataagaatg	tgataagatc	170640
gttgggtggat	caacttccat	ctctacctat	cttcgatata	aaatcatttg	agaaattcat	170700
atcctactgt	atactttttag	atgacacatt	ttacgatagg	cacgttaaga	atcgcgattc	170760
taaaacgtat	cgatacgcac	tttcaaaata	catgtcgttt	gataaatacg	atgggtataat	170820
aactaaatgt	cacgacgaaa	caatgttact	caaactgtcc	actgttctag	acactacact	170880
atatgcagtt	ttaagatgtc	ataattcgag	aaagttaaga	agatacctca	acgagttaaa	170940
aaaatataat	aacgataagt	cctttaaaaat	atatttcta	attatgaatg	agagatacct	171000
taatgtatat	tataaagata	tgtacgtgtc	aaaggtatat	gataaactat	ttcctgtttt	171060
cacagataaa	aattgtctac	taacattact	accttcagaa	attatatacg	aaatattata	171120
catgctgaca	attaacgatc	tttataatat	atcgtatcca	cctaccaaaag	tatagttgta	171180
tttttctcat	gcatgtgtgt	taaaaaaact	gatattatat	aaatattttta	gtgccgtata	171240
ataaagatga	cgatgaaaat	gatggtacat	atatattttcg	tatcattatt	gttattgcta	171300
ttccacagtt	acgccataga	catcgaaaat	gaaatcacag	aattcttcaa	taaaatgaga	171360
gatactctac	cagctaaaaga	ctctaaatgg	ttgaatccag	catgtatgtt	cggaggcaca	171420
atgaatgata	tagccgctct	aggagagcca	ttcagcgcaa	agtgtcctcc	tattgaagac	171480
agtcttttat	cgcacagata	taaagactat	gtgggttaaat	gggagaggct	agaaaagaat	171540
agacggcgac	aggtttctaa	taaacgtgtt	aaacatgggtg	atttatggat	agccaactat	171600
acatctaaat	tcagtaaacg	taggtatttg	tgcacgttaa	ctacaaagaa	tggtgactgt	171660
gttcagggtta	tagttagatc	tcataattaaa	aaacctcctt	catgcattcc	aaaaacatat	171720
gaactaggta	ctcatgataa	gtatggcata	gacttatact	gtggaattct	ttacgcaaaa	171780
cattataata	atataacttg	gtataaagat	aataaggaaa	ttaatatcga	cgacattaag	171840
tattcacaaa	cgggaaagga	attaattatt	cataatccag	agttagaaga	tagcggaaga	171900
tacgactgtt	acgttcatta	cgacgacgtt	agaatcaaga	atgatatcgt	agtatcaaga	171960
tgtaaaatac	ttacggttat	accgtcacaa	gaccacaggt	ttaaactaat	actagatccg	172020
aaaatcaacg	taacgatagg	agaacctgcc	aatataacat	gcactgctgt	gtcaacgtca	172080
ttattgatcg	acgatgtact	gattgaatgg	gaaaatccat	ccgatgggt	tataggattc	172140
gattttgatg	tatactctgt	tttaactagt	agagggcgta	tcaccgaggc	gacctgtgac	172200
tttgaaaatg	ttactgaaga	atataatagg	aatacatata	aatgtcgtgg	acacaactat	172260
tattttgaaa	aaacctttac	aactacagta	gtattggagt	aaatatacaa	tgcatttttta	172320
tatacattac	tgaattatta	ttactgaatt	attattactg	aattattatt	aattatatcg	172380
tattttgtgt	atagaatgga	tgaagatacg	cgactatcta	ggtatttgta	tctcaccgat	172440
agagaacata	taaatgtaga	ctctattaaa	cagttgtgta	aaatatcaga	tcctaatagca	172500
tgttatatag	gtggatgtac	ggctttacat	gagtactttt	ataattatag	atcagtcac	172560
ggaaaaataca	agtatagata	caacggttac	tatcaatatt	attcatctag	cgattatgaa	172620
aatataatag	aatattatta	tgatagaact	ggtagaaca	gtgagagtga	taatatatca	172680
atcaaaacag	aatatgaatt	ctatgatgaa	acacaagatc	aaagtacaca	actagtaggt	172740
tacgacatta	aactcaaaac	caatgaggat	gatttttatg	ctatgataga	tcagtgggtg	172800
tccatgatta	tatagatgaa	tcaattata	aagtagtata	tggaagagag	tctcacgtaa	172860
gatggcgagg	tatatggcaa	gaacataatg	atggcggtata	cagtatagga	aaggagtgca	172920
tagataaatat	atacgaagac	aaccataacc	tagacgaatt	ctacaagata	gacagcgat	172980
cagatgtaga	tgacgcggaa	cacatatctc	cgataactaa	aaaaccatag	aatcagttga	173040
tgataataacc	tacatttcta	atcttccgta	taccatcaaa	tacaaaatat	tcgagcaaca	173100
ataagtattt	tttatacctt	taaaactgat	aaataaattt	tttctagtga	tattttggca	173160
agatgagaat	cctatttctc	atcgctttca	tgtatgggtg	tggtcactca	tatgttaacg	173220
cgggttgaaac	caaatgtcca	aatctagaca	ttgtaacatc	ttctggagaa	tttcattgtt	173280
caggatgtgt	ggaacatatg	cctgagttta	gctatatgta	ttggttggca	aaggatatga	173340
aatcgagcga	ggataccaag	tttatagaac	atctgggtga	tggtcatcaa	gaagatgaaa	173400
ccgttcgtac	cacagatagt	ggaatcgta	ctctacgtaa	agtccttcat	gtaaccgata	173460
ctaataaatt	tgataattat	aggttcactt	gtgtcctcac	tacgatagat	ggcgtttcaa	173520
aaaagaatat	ttggctgaag	tagtgcggtc	tactattttt	atttatgata	taatctaagt	173580
gaattaatatt	gaattgatat	ttatccaata	ctaagatta	tattagaatc	aaattaatct	173640
tttatacgag	aaaaataaac	gacatacgta	gtcaacaaat	taaacttttt	atttattagt	173700
taactagctt	atagaacttg	ctcattgtta	tgtttctaaa	acgggtacgg	catataggac	173760
aattatccga	cgcaccggtt	tctcttcgtg	ttctatgcca	tatattgatg	catgttatgc	173820
aaaatatatg	agtacacgaa	tccaataaac	caaagtatct	atcgttttga	gtaaacact	173880

-69-

tcatagcaaa	ttccacattc	tttttcttta	cttactctat	acacgtcctc	gtattttattt	173940
agtattttga	tgatatccaa	ctcagaaatg	gttggtgtat	tattgggtgt	atagggtatta	174000
ttagctatgt	accaatttac	caaccctctt	aatattgatt	gataatcaca	tcggttatcc	174060
aatcaataac	cacattaata	actaaattgt	agtgtatata	tagaccatat	atgtttctat	174120
ttttttgaca	gttacgtata	gtttcagtaa	gttttgattg	ttgtattcct	gtatctctag	174180
ataagttagt	catatagtc	cttccggcga	tacgtttttt	ccaagcccga	aattgattag	174240
ccaaatgtgt	atttattttt	gtgatattga	tataatattt	cggataatgc	atactgttag	174300
tcttatatca	tttggttcat	ctatgtattg	taatattgtt	acatgatcta	tagatgatgt	174360
attgattttg	gcaggatcga	attccatatc	cgcgactaaa	cagtgaaaaa	aatgtaaata	174420
cttttttaaat	tttaaatag	taaaactttt	ttttattttt	tatgattcca	aaaatactga	174480
atacaaagtc	ctaaattata	aatatggaga	tcatactacc	acaacttatt	attatgtata	174540
caaggccggt	gtaatagata	gatatatata	attctattac	accggcagac	aattaccgac	174600
cggattttgt	cgttaccac	ataccgtata	atatgtaata	tacaattcca	taaccattg	174660
acagttgtta	tacatcaaaa	ttgcaattct	tttgattacg	atgttataag	aatgtagtta	174720
attgatgtat	gatgttaatg	tgtcctcttt	cctcttataa	catcgtaatc	aaaaactttt	174780
ttataatata	tacctaataa	tgtgtcttaa	tagttctcgt	gattcgtcaa	acaatcattc	174840
ttataaaaaa	taataaagca	acgtaaaaac	acataaaaa	aagcgtaaact	aataagacaa	174900
tggatattta	cgacgataaa	gggtctacaga	ctattaaact	gtttaataat	gaatttgatt	174960
gtataaggaa	tgacatcaga	gaattattta	aacatgtaac	tgattccgat	agtatacaac	175020
ttccgatgga	agacaattct	gatattatag	aaaatatcag	aaaaatacta	tatagacgat	175080
taaaaaatgt	agaatgtgtt	gacatcgata	acacaataac	ttttatgaaa	tacgatccaa	175140
atgatgataa	taagcgtacg	tgttctaatt	gggtaccctt	aactaataac	tatatggaat	175200
attgtctagt	aatatatattg	gaaacaccga	tatgtggagg	caaaaataaaa	ttataaccacc	175260
ctacaggaag	tataaagtcg	gataaggata	ttatgtttgc	aaagactcta	gactaagata	175320
gacagcgtat	cagatgtgat	tgacgcggaa	cacatatctc	ctataactaa	tgatgtatct	175380
acacaaacat	gggaaaagaa	atcagagtta	gatagataca	tggaatcgta	tcctcgtcac	175440
agatatagta	aacattctgt	atttaaggga	ttttctgata	aagttagaaa	aaatgattta	175500
gacatgaatg	tggtaaaaga	attactttct	aacgggtgcat	ctctaacaat	caaggatagc	175560
agtaataagg	atccaattgc	tgtttatttt	agaagaacga	taatgaattt	agaaatgatt	175620
gatattatta	acaaacatac	aactattgat	gaacgaaagt	atatagtaca	ctcctatcta	175680
aaaaattata	gaaatttcga	ttatccattt	ttcagggaagt	tagttttgac	taataaacat	175740
tgtctcaaca	attattataa	tataagcgac	agcaaataatg	gaacaccgct	acatatattg	175800
gcgtctaata	aaaaattaat	aactccta	tacatgaagt	tattagtgt	taacggaaat	175860
gatataaacg	cacgaggtga	agatacacaa	atgcgaacca	actcagaaat	ggttggttga	175920
ttattgggtg	tataggtatt	attagctatg	taccaattta	ccaaccctct	taatatgtat	175980
tgataatcac	atcggttctc	caattaataa	ctaaattgta	gtgtatata	agaccatata	176040
tgtttctatt	tttttgacag	ttacgtatag	tttcagtaag	ttttgattgt	tgtattcctg	176100
tatctctaga	taagttagtc	atatagtc	ttccggcgat	acgttttttc	caagcccga	176160
attgattagc	caaattgtga	tttatttttg	tgatattgat	ataatatttc	ggataatgca	176220
tactgttagt	cttatatcat	ttgggttcac	tatgtattgt	aatattgtta	catgatctat	176280
agatgatgta	ttgatttttg	caggatcgaa	ttccatatcc	gcgactaaac	agtgaaaaaa	176340
atgtaaatac	tttttaaat	ttaaattagt	aaaacttttt	tttatttttt	atgattccaa	176400
aaatactgaa	tacaaagtcc	ttaaattataa	atatggagat	catactacca	caacttatta	176460
ttatgtatac	aaggccggtg	taatagatag	atatatataa	ttctattaca	ccggcagaca	176520
attaccgacc	ggtattttgtc	gttaccaaca	taccgtataa	tatgtaatat	acaattccat	176580
aaccattga	cagttgttat	acatcaaaat	tgcaattctt	ttgattacga	tgttataaga	176640
atgtagttaa	ttgatgtatg	atgttaatgt	gtcctctttc	ctcttataac	atcgtaatca	176700
aaaacttttt	tataatatat	acctaataat	gtgtcttaat	agttctcgtg	attcgtcaaa	176760
caatcattct	tataaaatat	aataaagcaa	cgtaaaaaca	cataaaaaata	agcgtaacta	176820
ataagacaat	ggatattttac	gacgataaag	gtctacagac	tattaaactg	tttaataatg	176880
aatttgattg	tataagggaat	gacatcacag	aattatttaa	acatgtaact	gattccgata	176940
gtatacaact	tccgatggaa	gacaattctg	atattataga	aaatatcaga	aaaatactat	177000
atagacgatt	aaaaaatgta	gaatgtgttg	acatcgataa	cacaataact	tttatgaaat	177060
acgatccaaa	tgatgataat	aagcgtacgt	gttctaattg	ggtaccctta	actaataact	177120
atatggaata	ttgtctagta	atatattttg	aaacaccgat	atgtggaggc	aaaataaaat	177180



-70-

tataccaccc	tacaggaaat	ataaagtcgg	ataaggatat	tatgtttgca	aagactctag	177240
acttttaa	aacgaaagt	ttaactggac	gtaaaacaat	tgccgttcta	gacatatccg	177300
tttcatata	tagatcaatg	actactattc	actacaacga	cgacgttgat	atagatatac	177360
atactgata	aaatggaaaa	gagttatggt	attgtttatat	aacaatagat	gacattact	177420
tggttgatgt	ggaaactata	ggagttatag	tcaatagatc	tggaaaatgt	ctgttagtaa	177480
ataaccatct	aggtataggt	atcggttaaag	ataaacgtat	aagcgatagt	tttggagatg	177540
tatgtatgga	tacaatattt	gacttttctg	aagcacgaga	gttatttttca	ttactaatg	177600
atgataacag	gaatatagca	tgggacactg	ataaactaga	cgatgatata	gatatatgga	177660
ctcccgctc	agaagatgat	tacaaaatttc	tttctagact	agtattgtat	gcaaaatctc	177720
aatcggatac	tgtatttgac	tattatgttc	ttactgggtga	tacggaacca	cccactgtat	177780
tcatttttcaa	ggtaactaga	ttttacttta	atatgccgaa	ataaaaaatt	tttgtataat	177840
atctagaggt	agaggtattg	tttagataaa	tacaaataac	atagatacat	cgcatactta	177900
gcattttttat	aaatatacat	aagacataca	ctttatacat	ttttgtaaaa	atactcataa	177960
aaaaatttat	aaaaattatg	gcacaacccat	atcttggtata	ggtagtttag	ttcgtcgagt	178020
gaacctataa	acagataata	gacaacacat	aataatgcct	actaatatac	gcataatacc	178080
gggagatggg	atatatgacg	ttgtagtgtt	tgggttttct	gaacgttgat	agtctactaa	178140
tactacatgc	tgacatctaa	tgccgtgtata	accatgagag	catctacaat	acataccgct	178200
aatatctcta	gcgtggatac	agtcaccgtg	taaacataat	ccatctccct	ctggaccgca	178260
taatctgata	gctggaatat	ctgttgtagc	gtttgttaatt	tctggcaatg	tcgtttcgat	178320
agcgttacca	ctatcggcga	atgatctgat	tatcatagca	gcgaacaaca	acatcagata	178380
atztatcaac	atttttgatg	gattctgtgt	ttatgctgtt	tctcagtgtg	tgtttatgac	178440
aagattggga	atttttatatt	attaattcag	taatataaac	taataatata	ttgttaattg	178500
tgtaaataat	ataaaaaata	caatacaata	ttgaatgtgt	tgctgttaaa	aatgtatgtg	178560
ttaataataa	agaataaaa	aaatgagtat	gatcatttta	gataacgatt	gattttatca	178620
ttaccgcttc	tcttttatat	tctttgctta	cggaaacctat	atttagaaac	atctactaac	178680
aattttttat	gcttgcatata	ttaatgggat	gtaatatgat	tgattgtgta	cgcaatacca	178740
atttgttaag	tatgaatacg	gggtacaaac	ataaattgaa	atttaacatt	atttatttat	178800
gatataatc	gttatcgtta	gggtctatacc	atggatatct	ttaaagaact	aatcttaaaa	178860
caccctgatg	aaaatgtttt	gatttctcca	gtttccattt	tatctacttt	atctattcta	178920
aatcatggag	cagctgggtc	tacagctgaa	caactatcaa	aatatataga	gaatatgaat	178980
gagaatacac	ccgatgacaa	taatgatgac	atggaggtag	atattccgta	ttgtgcgaca	179040
ctagctaccg	caaataaaa	atacggtagc	gatagtatcg	agttccacgc	ctccttcccta	179100
caaaaaataa	aagcgaattt	tcaaactgta	aacttttaata	atgctaacca	aacaaaggaa	179160
ctaatacaacg	aatgggttaa	gacaatgaca	aatggtaaaa	ttaattcctt	attgactagt	179220
ccgctatcca	ttaataactcg	tatgacagtt	gttagcgccg	tccatttttaa	agcaatgttg	179280
aaatatccat	tttctaaaca	tcttacatat	acagacaagt	tttatatttc	taagaatata	179340
gttaccagcg	ttgatatgat	ggtgggtacc	gagaataact	tgcaatatgt	acataattaat	179400
gaattattcg	gaggattctc	tattatcgat	attccatacg	agggaaactc	tagtatggta	179460
attatactac	cggacgacat	agaagggtata	tataacatag	aaaaaaatat	aacagatgaa	179520
aaattttaaaa	aatgggtgtg	tatgttatct	actaaaagta	tagacttgta	tatgccaaag	179580
tttaaagtgg	aaatgacaga	accgtataat	ctggtagcga	ttttagaaaa	tttaggactt	179640
actaatatat	tcggatatta	tcgagatttt	agcaagatgt	gtaatgaaac	tatcactgta	179700
gaaaaatttc	tacatacgac	gtttatagat	gttaatgagg	agtatacaga	agcatcggcc	179760
gttacaggag	tattttacgat	taacttttctg	atgggtatct	gtacgaaggt	ctacataaac	179820
catccattca	tgtacatgat	taaagacacc	acaggacgta	tactttttat	agggaaatac	179880
tgctatccgc	aataaatata	aacaaataga	cttttataaa	gagtcttcaa	cgataagtat	179940
atcgacatac	tacttatgct	gcgaaagatt	ctgaacgaga	acgactatct	caccctcttg	180000
gatcatatcc	gcactgctaa	atactaaatc	tccactacac	tttttatcat	cttatgagga	180060
atgattgcct	tcgtgaaata	ggaataatta	gcaccagaat	agctatggat	tattgtggta	180120
gagagtgcac	tattctatgt	cgtctactgg	atgaagatgt	gacgtacaaa	aaaataaaa	180180
tagaaattga	aacgtgtcac	aacttatcaa	aacatataga	tagacgagga	aacaatgcgc	180240
tacattgtta	cgtctccaat	aaatgcgata	cagacattaa	gattgttctc	tcgaggagtc	180300
gagagacttt	gtagaaacaa	cgaaggatta	actccgctag	gagtatacag	taagcataga	180360
tacgtaaaat	ctcagattgt	gcactactg	atatccagct	attcaaattc	ctctaacgaa	180420
ctcaagtcga	atataaatga	tttcgatctg	tattcggata	atatacgactt	acgtctgcta	180480

-71-

aaatacctaa	ttgtggataa	acggatacgt	ccgtccaaga	atacgaatta	tgcaatcaat	180540
gggtctcgat	tggtggatat	atacgtaacg	acgcctaata	cgagaccaga	agtattgcta	180600
tggtctctta	aatcagaatg	ttacagcacc	ggttacgtat	ttcgtacctg	tatgtacgac	180660
agtgatatgt	gtaagaactc	tcttcattac	tatatatcgt	ctcatagaga	atctcaatct	180720
ctatccaagg	atgtaattaa	atgtttgatc	gataacaatg	tttccatcca	tggcagagac	180780
gaaggaggat	ctttacccat	ccaatactac	tggtctttct	caaccataga	tatagagatt	180840
gttaaattat	tattaataaaa	ggatgtggac	acgtgtagag	tatacgacgt	cagccctata	180900
ttagaggcgt	attatctaaa	caagcgattt	agagtaaccc	catataatgt	agacatggaa	180960
atcgttaatc	ttcttattga	gagacgtcat	actcttgctg	acgtaatgcg	tagtattact	181020
tcgtacgatt	ccagagaata	taaccactac	atcatcgata	acattctaaa	gagattttaga	181080
caacaggatg	tacaagccat	gttgataaac	tacttacatt	acggcgatat	ggtcgttcga	181140
tgcatgttag	ataacggaca	acaactatcc	tctgcacgac	tactttgtta	ataataatct	181200
cgctgatgta	aacgtcgtaa	ggtttatcgt	ggaaaatatg	gacacgcggc	tgtaaatacac	181260
gtatcgaaca	atggccgtct	atgtatgtac	ggctctgatat	tatcgagatt	taataattgc	181320
gggtatcact	gttatgaaac	catactgata	gatgtatttg	atatactaag	caagtacatg	181380
gatgatatag	atatgatcga	taactctact	atattacgcg	gtcgatgtca	ataatataca	181440
atttgcaaa	cgggtattgg	aatatggagc	gaagtgcacg	ctcgataatc	aatacggcca	181500
tccagaaaag	cagttaccaa	agagaaaaca	aaacgaagct	agttgattta	ttactgagtt	181560
accatccac	tctagagact	atgattgacg	cattttaatag	agatatacgc	tatctatata	181620
ctgaaccatt	attcgcctgt	atcagatacg	ccttaatcct	agatgatgat	tttccttcta	181680
aagtaaagta	tgatatcgcc	ggctgctata	aggaactaaa	gcgctataga	gtagacatta	181740
atagaatgaa	gaatgtctac	atatcaggcg	tctccatggt	tgatatatta	tttaaacgaa	181800
gcaaacgcca	caaattgaga	tacgcaaaga	atccgacatc	aaatgggtaca	aaaaagaact	181860
aacgtccatc	attacagaaa	ctgtaaagaa	caatgagagg	atcgactcca	tagtggacaa	181920
cattaataca	gacgataact	tgatttcgaa	attaccatct	gagataactt	attactccat	181980
taaataattt	atcatggagc	gataatgtcc	tgtttcattt	gtttccatga	catattacaa	182040
aatcgattcc	gtccaagatg	ataaaaaacat	ttaccggcat	cataaacacg	gagtttattt	182100
tatatgtctc	gcataaacat	tactaaaaaa	atatattgtc	gataacttga	tttcgaaatt	182160
acccatggag	atactttatt	actccattaa	ataatttatc	atggagcgat	aatgtcctgt	182220
ttcatttggt	tocatgacat	attacaaaat	cgattccgtc	caagatgata	aaaacattta	182280
ccggcatcat	aaacacggag	tttattttat	atgtctcgca	taaacattac	taaaaaata	182340
tattgttctg	tttttctttc	acatctttta	ttatgaaaaa	gtaaatcatt	atgagatgga	182400
cgagattgta	cgcacgttc	gcgacagtat	gtggtacata	cctaacgtat	ttatggacga	182460
cggtaagaat	gaaggtcacg	tttctgtcaa	caatgtctgt	catatgtatt	ttacgttctt	182520
tgatgtggat	acatcgtctc	atctgtttta	gctagtattt	aaacactgcg	atctgaataa	182580
acgaggtaac	tctccattac	attgctatac	gatgaataca	cgattttaatc	catctgtatt	182640
aaagatatgt	ttacaccacg	gcatgcgtaa	ctttgatagc	aaggatgacc	actatcaatc	182700
gataacaaga	tctttgatat	actaacggac	accattgatg	acttttagtaa	atcatccgat	182760
ctattgctgt	gttatcttag	atataaaattc	aatgggagct	taaactatta	cgttctgtac	182820
aaaggatccg	accctaattg	cgccgacgag	gatgaactca	cttctcttca	ttactactgt	182880
aaacacatat	ccacgttcta	cgaaagcaat	tattacaagt	taagtcacac	taagatgcga	182940
gccgagaagc	gattcatcta	cgcgataata	gattatggag	caaacattaa	cgcggttaca	183000
cacttacctt	caacagtata	ccaaacatag	tctctgtgtg	gtgtatgctc	ttttatctcg	183060
aggagccgat	acgaggatac	gtaataatct	tgattgtaca	cccatcatgg	aacgattgtg	183120
caacagggtca	tattctcata	atgttactca	attggcacga	acaaaaggaa	gaaggacaac	183180
atctacttta	tctattcata	aaacataatc	aaggatacac	tctcaatata	ctacgggtatc	183240
tattagatag	gttcgacatt	cagaaagacg	aatactataa	taccgccttt	caaaattgta	183300
acaacaatgt	tgccatcatc	atcggatagc	acatcaacct	tccgactaaa	gacggtattc	183360
gacttggtgt	ttgaaaacag	aaacatcata	tacaaggcgg	atgttgtgaa	tgacatcatc	183420
caccacagac	tgaaagtatc	tctacctatg	attaaatcgt	tgttctacaa	gatgtctctc	183480
cctacgacga	ttactacgta	aaaaagatac	tagcctactg	cctattaagg	gacgagtcat	183540
tcgcggaact	acatagtaaa	ttctgtttta	acgaggacta	taaaagtgtg	tttatgaaaa	183600
atatatcatt	cgataagata	gattccatca	tcgtgacata	agtcgcctca	aagagattcg	183660
aatctccgac	accgacctgt	atacggtatc	acagctatct	taaagccata	cattcagaca	183720
gtcacatttc	atttcccatg	tacgacgatc	tcatagaaca	gtgccatcta	tcgatggagc	183780



-72-

gtaaaagtaa	actcgctcgac	aaagcactca	ataaattaga	gtctaccatc	ggtcaatcta	183840
gactatcgta	tttgccctccg	gaaattatgc	gcaatatcat	ctaaacagta	tggtgtacgg	183900
aaagaacccat	tacaaatatt	atccatgata	gaaagaaaat	atctatatga	ttggagaagt	183960
aggaaacagg	aacaagacaa	cgattactac	attattaaat	catgaagtcc	gtattatact	184020
cgtatatatt	gtttctctca	tgtataataa	taaacggaag	agatatagca	ccgcatgcac	184080
catccgatgg	aaagtgtaaa	gacaacgaat	acaaacgcca	taattttgtgt	ccgggaacat	184140
acgcttccag	attatgcgat	agcaagacta	acacacgatg	tacgccgtgt	ggttcgggta	184200
ccttcacatc	tgcgaataat	catttaccgg	cttgtctaa	ttgtaacgga	agacgcgatc	184260
gtgtaacacg	actcacaata	gaatctgtga	atgctctccc	ggatattatt	gtcttctcaa	184320
aggatcatcc	ggatgcaagg	catgtgtttc	ccaaacaaaa	tgtggaatag	gatacggagt	184380
atccggagac	gtcatctgtt	ctccgtgtgg	tctcggaaca	tattotcaca	ccgtctcttc	184440
cgcagataaa	tgcgaacccg	taccagaaa	tacgtttaac	tatatcgatg	tggaaattaa	184500
cctgtatcca	gttaacgaca	cgctgtgtac	tccgacgacc	actaccggtc	tcagcgaatc	184560
catctcaacg	tccgaactaa	ctattactat	gaatcataaa	gactgtaatc	ccgtatttcg	184620
tgatggatac	ttctccggtt	ttaataaggt	agcgacttca	ggtttcttta	caggagaaa	184680
gtgtgcactc	tgaatttoga	gattaaatgc	aataacaaag	attcttcttc	caaacagtta	184740
acgaaagcaa	agaatgatac	tatcatgccg	cattcggaga	cagtaactct	agtgggcgac	184800
atctatatat	tatatagtaa	taccaatact	caagactacg	aaactgatac	aatctcttat	184860
catgtgggta	atgttctcga	tgtcgatagc	catatgcccg	gtagtctcga	tatacataaa	184920
ctgatcacta	attccaaacc	caccactttt	ttatagtaag	tttttcaccc	ataaataata	184980
aatacaataa	ttaatttctc	gtaaaagtag	aaaatatatt	ctaattttat	gcacggtaag	185040
gaagtagaat	cataaagaac	agtactcaat	caatagcaat	tatgaaacaa	tatatcgtcc	185100
tggcatgcat	gtgcctggcg	gcagctgcta	tgcctgccag	tcttcagcaa	tcctcctcat	185160
cctcctcctc	gtgtacggaa	gaagaaaaca	aacatcatat	gggaatcgat	gttattatca	185220
aagtacacaa	gcaagaccaa	acaccgacca	atgataagat	ttgccaatcc	gtaacggaaa	185280
ttacagagtc	agagtcagat	ccagatcccg	aggtggaatc	agaagatgat	tccacatcag	185340
tccagagtg	agatccctct	accacttatt	actccatcat	cgggtggagg	ctgagaatga	185400
actttggatt	caccaaagt	cctcagatta	aatccatctc	agaatccgct	gatggaaaca	185460
cagtgaatgc	tagattgtcc	agcgtgtccc	caggacaagg	taaggactct	cccgcgatca	185520
ctcatgaaga	agctcttgct	atgatcaaag	actgtgaagt	gtctatcgac	atcagatgta	185580
gcgaagaaga	gaaagacagc	gacatcaaga	cccattccagt	actcgggtct	aacatctctc	185640
ataagaaagt	gagttacgaa	gatatcatcg	gttcaacgat	cgtcgatata	aaatgcgtca	185700
agaatctaga	gttttagcgt	cgtatcggag	acatgtgcaa	ggaatcatct	gaacttgagg	185760
tcaaggatgg	attcaagtat	gtcgacggat	cggcatctga	aggtgcaacc	gatgatactt	185820
cactcatcga	ttcaacaaaa	ctcaaagcgt	gtgtctgaat	cgataactct	attcatctga	185880
aattggatga	gtagggttaa	tccaacgatt	caggcacacc	acgaattaaa	aaagtgtacc	185940
ggacactata	ttccggtttg	caaaaacaaa	atgttcttaa	ctacattcac	aaaaagttac	186000
ctctcgcgac	ttcttctttt	tctgtctcaa	tagtgtgata	cgattatgac	actattccta	186060
ttcctattcc	tatttctctt	cagagtatca	caaaaatatt	aaacctcttt	ctgatgggtc	186120
cataaaaaaa	gtttttacaaa	aatattttta	ttctctttct	ctctttgatg	gtctcataaa	186180
aaaagtttta	caaaaatatt	tttattctct	ttctctcttt	gatgggtctca	taaaaaaagt	186240
tttacaaaaa	tattttttatt	ctctttctct	cttttgatgg	ctcataaaaa	aagttttaca	186300
aaaatatttt	tattctcttt	ctctctttga	tgggtctcata	aaaaaagttt	tacaaaaata	186360
tttttattct	ctttctctct	ttgatgggtc	cataaaaaaa	gtttttacaaa	aatattttta	186420
ttctctttct	ctctttgatg	gtctcataaa	aaaagtttta	caaaaatatt	tttattctct	186480
ttctctcttt	gatgggtctca	taaaaaaagt	tttacaaaaa	tattttttatt	ctctttctct	186540
ctttgatgg	ctcataaaaa	aagttttaca	aaaatatttt	tattctcttt	ctctctttga	186600
tgggtctcata	aaaaaagttt	tacaaaaata	tttttattct	ctttctctct	ttgatgggtc	186660
cataaaaaaa	gtttttacaaa	aatattttta	ttctctttct	ctctttgatg	gtctcataaa	186720
aaaagtttta	caaaaatatt	tttattctct	ttctctcttt	gatgggtctca	taaaaaaagt	186780
tttacaaaaa	tattttttatt	ctctttctct	ctttgatgg	ctcataaaaa	aagttttaca	186840
aaaatatttt	tatt					186854

-73-

<211> 1131  
 <212> DNA  
 <213> Human Herpesvirus-1

<300>  
 <308> GenBank No. NC\_00180  
 <309> 2004-01-13

<400> 35  
 atggcttcgt acccctgcc tcaacacgcg tctgcgttcg accaggctgc gcgttctcgc 60  
 ggccataaca accgacgtac ggcgttgccg cctcgccggc aacaaaaagc cacggaagtc 120  
 cgcctggagc agaaaatgcc cacgctactg cgggtttata tagacgggtc ccacgggatg 180  
 gggaaaacca ccaccacgca actgctgggtg gccctgggtt cgcgcgacga tatcgtctac 240  
 gtacccgagc cgatgactta ctggcgggtg ttgggggctt ccgagacaat cgcgaacatc 300  
 tacaccacac aacaccgcct cgaccagggt gagatatcgg cgggggacgc ggcggtggtg 360  
 atgacaagcg cccagataac aatgggcatg ctttatgccg tgaccgacgc cgttctgggt 420  
 cctcatatcg ggggggaggg tgggagctca catgccccgc ccccgccct caccctcatc 480  
 ttcgaccgce atcccacgc cgccctcctg tgctaccggc ccgcgcgata cttatggggc 540  
 agcatgaccc cccaggccgt gctggcgctt gtggccctca tcccgccgac cttggccggc 600  
 acaaacatcg tgttgggggc ccttccggag gacagacaca tcgaccgcct ggccaaacgc 660  
 cagcgccccg gcgagcggtg tgacctggct atgctggccg cgattcgccg cgtttatggg 720  
 ctgcttgcca atacggtgcg gtatctgcag ggcggcgggt cgtggcgagg ggattgggga 780  
 cagctttcgg gggcgccgtg gccgccccag ggtgccgagc cccagagcaa cgcgggcca 840  
 cgaccccata tcggggacac gttatttacc ctgtttcggg ccccgaggt gctggcccc 900  
 aacggcgacc tgtataacgt gtttgccctg gctttggacg tcttggccaa acgcctccgt 960  
 cccatgcatg tctttatcct ggattacgac caatcgccc cgggtgccc ggacgccctg 1020  
 ctgcaactta cctccgggat ggtccagacc cacgtcacca cccaggctc cataccgacg 1080  
 atctgcgacc tggcgcgcac gtttgcccg gagatggggg aggctaactg a 1131

<210> 36  
 <211> 376  
 <212> PRT  
 <213> Human Herpesvirus-1

<300>  
 <308> GenBank No. NP\_04462  
 <309> 2004-01-13

<400> 36  
 Met Ala Ser Tyr Pro Cys His Gln His Ala Ser Ala Phe Asp Gln Ala  
 1 5 10 15  
 Ala Arg Ser Arg Gly His Asn Asn Arg Arg Thr Ala Leu Arg Pro Arg  
 20 25 30  
 Arg Gln Gln Lys Ala Thr Glu Val Arg Leu Glu Gln Lys Met Pro Thr  
 35 40 45  
 Leu Leu Arg Val Tyr Ile Asp Gly Pro His Gly Met Gly Lys Thr Thr  
 50 55 60  
 Thr Thr Gln Leu Leu Val Ala Leu Gly Ser Arg Asp Asp Ile Val Tyr  
 65 70 75 80  
 Val Pro Glu Pro Met Thr Tyr Trp Arg Val Leu Gly Ala Ser Glu Thr  
 85 90 95  
 Ile Ala Asn Ile Tyr Thr Thr Gln His Arg Leu Asp Gln Gly Glu Ile  
 100 105 110  
 Ser Ala Gly Asp Ala Ala Val Val Met Thr Ser Ala Gln Ile Thr Met  
 115 120 125



(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
26 May 2005 (26.05.2005)

PCT

(10) International Publication Number  
**WO 2005/047458 A3**

(51) International Patent Classification<sup>7</sup>: C12N 7/04,  
A61K 35/76, C12N 15/863, A61K 35/74, C12Q 1/02

(US). ZHANG, Qian [CN/US]; 88348D Via Sanoma, San  
Diego, CA 92037 (US).

(21) International Application Number:  
PCT/US2004/019866

(74) Agents: SEIDMAN, Stephanie, L. et al.; Fish and  
Richardson P.C., 12390 El Camino Real, San Diego, CA  
92130 (US).

(22) International Filing Date: 18 June 2004 (18.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
03013826.7 18 June 2003 (18.06.2003) EP  
03018478.2 14 August 2003 (14.08.2003) EP  
03024283.8 22 October 2003 (22.10.2003) EP

(81) Designated States (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US (patent), UZ, VC, VN, YU,  
ZA, ZM, ZW.

(63) Related by continuation (CON) or continuation-in-part  
(CIP) to earlier applications:

US 03013826.7 (CON)  
Filed on 18 June 2003 (18.06.2003)  
US 03018478.2 (CON)  
Filed on 14 August 2003 (14.08.2003)  
US 03024283.8 (CON)  
Filed on 22 October 2003 (22.10.2003)

(84) Designated States (*unless otherwise indicated, for every  
kind of regional protection available*): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*):  
GENELUX CORPORATION [US/US]; 3030 Bunker  
Hill Street, Suite 310, San Diego, CA 92109 (US).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): SZALAY, Aladar,  
A. [US/US]; 7704 North Fork Road, Highland, CA 92346  
(US). TIMIRYASOVA, Tatyana [RU/US]; 7524 Char-  
mant Drive #525, San Diego, CA 92122 (US). YU, Yong,  
A. [CN/US]; 11111 Via Abajo #A, San Diego, CA 92129

(88) Date of publication of the international search report:  
15 September 2005

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: MODIFIED RECOMBINANT VACCINA VIRUSES AND OTHER MICROORGANISMS, USES THEREOF

(57) Abstract: Recombinant *vaccinia* viruses useful as tumor-specific delivery vehicle for cancer gene therapy and vaccination  
Therapeutic methods and microorganisms therefore are provided. The microorganisms are designed to accumulate in immunopriv-  
ileged tissues and cells, such as in tumors and other proliferating tissue and in inflamed tissues, compared to other tissues, cells and  
organs, so that they exhibit relatively low toxicity to host organisms. The microorganisms also are designed or modified to result  
in leaky cell membranes of cells in which they accumulate, resulting in production of antibodies reactive against proteins and other  
cellular products and also permitting exploitation of proliferating tissues, particularly tumors, to produce selected proteins and other  
products.. Methods for making tumor specific antibodies and also methods of making gene products encoded by the microorganism  
as well as antibodies reactive therewith are provided.



WO 2005/047458 A3

# INTERNATIONAL SEARCH REPORT

'US2004/019866

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N7/04 A61K35/76 C12N15/863 A61K35/74 C12Q1/02

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 92/22327 A (UNIV CALIFORNIA) 23 December 1992 (1992-12-23)	1, 6, 7, 10-31, 33-36, 39-41, 43-50, 54-57, 60-62, 64-76, 78-81, 83-88, 90-94, 96-102
Y	page 3, line 31 - page 5, line 9  ----- -/--	2-5, 8, 9, 32, 37, 38, 82, 95

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*8\* document member of the same patent family

Date of the actual completion of the international search

14 June 2005

Date of mailing of the international search report

07. 07. 2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Sitch, W

## INTERNATIONAL SEARCH REPORT

PCT/US2004/019866

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE BIOSIS 'Online!  BIOSCIENCES INFORMATION SERVICE,  PHILADELPHIA, PA, US; May 2000 (2000-05),  MUKHERJEE SUTAPA ET AL:  "Replication-restricted vaccinia as a  cytokine gene therapy vector in cancer:  Persistent transgene expression despite  antibody generation"  XP002257646  Database accession no. PREV200000285526  abstract  &amp; CANCER GENE THERAPY,  vol. 7, no. 5, May 2000 (2000-05), pages  663-670,  ISSN: 0929-1903</p>	
X	<p>DATABASE BIOSIS 'Online!  BIOSCIENCES INFORMATION SERVICE,  PHILADELPHIA, PA, US; July 1998 (1998-07),  SIVANANDHAM MUTHUKUMARAN ET AL: "Colon  cancer cell vaccine prepared with  replication-deficient vaccinia viruses  encoding B7.1 and interleukin-2 induce  antitumor response in syngeneic mice"  XP002324951  Database accession no. PREV199800394715</p>	<p>1,6,7,  10-31,  33-36,  39-41,  43-50,  54-57,  60-62,  64-76,  78-81,  83-88,  90-94,  96-102</p>
Y	<p>abstract</p> <p>&amp; CANCER IMMUNOLOGY IMMUNOTHERAPY,  vol. 46, no. 5, July 1998 (1998-07), pages  261-267,  ISSN: 0340-7004</p> <p style="text-align: center;">-----  -/--</p>	<p>2-5,8,9,  32,37,  38,82,95</p>

## INTERNATIONAL SEARCH REPORT

PCT/US2004/019866

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	TARTAGLIA J ET AL: "NYVAC: A HIGHLY ATTENUATED STRAIN OF VACCINIA VIRUS" VIROLOGY, ACADEMIC PRESS, ORLANDO, US, vol. 188, no. 1, 1 May 1992 (1992-05-01), pages 217-232, XP002027067 ISSN: 0042-6822	1,6,7, 10-31, 33-36, 39-41, 43-50, 54-57, 60-62, 64-76, 78-81, 83-88, 90-94, 96-102
Y	page 217 abstract page 219, left-hand column, paragraph 4 page 220, right-hand column, last paragraph - page 221, left-hand column, line 1 page 221, right-hand column, paragraph 2 page 227, right-hand column, paragraph 6 - page 228, left-hand column, paragraph 1 page 228; table 6 page 230, right-hand column, paragraph 1	2-5,8,9, 32,37, 38,82,95
X	----- DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; January 2000 (2000-01), PUHLMANN MARKUS ET AL: "Vaccinia as a vector for tumor-directed gene therapy: Biodistribution of a thymidine kinase-deleted mutant" XP002257647 Database accession no. PREV200000179026  abstract & CANCER GENE THERAPY, vol. 7, no. 1, January 2000 (2000-01), pages 66-73, ISSN: 0929-1903	1,6,7, 10-31, 33-36, 39-41, 43-50, 54-57, 60-62, 64-76, 78-81, 83-88, 90-94, 96-102
X	----- DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; December 2002 (2002-12), ZEH HERBERT J ET AL: "Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers." XP002262641 Database accession no. PREV200300070352  abstract	1,6,7, 10-31, 33-36, 39-41, 43-50, 54-57, 60-62, 64-76, 78-81, 83-88, 90-94, 96-102
	-/--	

## INTERNATIONAL SEARCH REPORT

PCT/US2004/019866

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	& CANCER GENE THERAPY, vol. 9, no. 12, December 2002 (2002-12), pages 1001-1012, ISSN: 0929-1903 -----	
Y	TIMIRYASOVA TATYANA M ET AL: "Construction of recombinant vaccinia viruses using PUV-inactivated virus as a helper" BIOTECHNIQUES, vol. 31, no. 3, September 2001 (2001-09), pages 534-540, XP008022947 ISSN: 0736-6205 cited in the application	2-5,8,9, 32,37, 38,82,95
X	the whole document	23-30, 33-36, 39-41, 43-50, 54-57, 60-62, 64-76, 78-88, 90-102
Y	----- TIMIRYASOVA ET AL: "VISUALIZATION OF VACCINIA VIRUS INFECTION USING THE RENILLA-LUCIFERASE-GFP FUSION PROTEIN" PROCEEDINGS OF THE 11TH INTERNATIONAL SYMPOSIUM ON BIOLUMINESCENCE AND CHEMILUMINESCENCE, 2000, pages 457-460, XP008023166 cited in the application	2-5,8,9, 32,37, 38,82,95
X	page 457, paragraph 2	23-30, 33-36, 39-41, 43-50, 54-57, 60-62, 64-76, 78-88, 90-102
	page 457, paragraph 4 - page 458, paragraph 1 ----- -/--	



## INTERNATIONAL SEARCH REPORT

PCT/US2004/019866

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>MCCART J ANDREA ET AL: "Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes"  CANCER RESEARCH,  vol. 61, no. 24,  15 December 2001 (2001-12-15), pages  8751-8757, XP002331814  ISSN: 0008-5472</p> <p>page 8751  abstract</p>	<p>1,6,7,  10-31,  33-36,  39-41,  43-50,  54-57,  60-62,  64-76,  78-81,  83-88,  90-94,  96-102</p>
X	<p>WO 00/73479 A (THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE) 7 December 2000 (2000-12-07)</p> <p>page 35 - page 44; examples 1-14</p>	<p>1,6,7,  10-31,  33-36,  39-41,  43-50,  54-57,  60-62,  64-76,  78-81,  83-88,  90-94,  96-102</p>
X	<p>PUHLMANN MARKUS ET AL: "Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy"  HUMAN GENE THERAPY,  vol. 10, no. 4, 1 March 1999 (1999-03-01),  pages 649-657, XP002331815  ISSN: 1043-0342</p> <p>page 649  abstract  page 650, left-hand column, paragraph 3  page 651, left-hand column, last paragraph - right-hand column, paragraph 1  page 653, left-hand column, last paragraph - page 654, right-hand column, last paragraph</p> <p>-----  -/--</p>	<p>1,6,7,  10-31,  33-36,  39-41,  43-50,  54-57,  60-62,  64-76,  78-81,  83-88,  90-94,  96-102</p>

## INTERNATIONAL SEARCH REPORT

PCT/US2004/019866

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>US 6 491 905 B1 (SORSCHER ERIC J ET AL) 10 December 2002 (2002-12-10)</p> <p>column 2, line 50 - line 63 column 4, line 65 - column 5, line 16 column 32 - column 34; examples 25,26</p>	<p>23-30, 39-60, 63-77, 83-90, 96-102</p>
X	<p>DATABASE EMBASE 'Online! ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1974, COLLINS J L ET AL: "Suppression of SV40 tumors after immunization with Group A Streptococcus pyogenes and Bordetella pertussis" XP002331817 Database accession no. EMB-1975014814 abstract &amp; CANCER RESEARCH 1974, vol. 34, no. 5, 1974, pages 932-937,</p>	<p>23-30, 39-60, 63-77, 83-90, 96-102</p>
X	<p>DATABASE EMBASE 'Online! ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1995, FENG X ET AL: "The antitumor activity of a mixed bacterial vaccine against mouse hepatoma" XP002331818 Database accession no. EMB-1995319198 abstract &amp; CHINESE PHARMACEUTICAL JOURNAL 1995 CHINA, vol. 30, no. 7, 1995, pages 405-407, ISSN: 1001-2494</p>	<p>23-30, 39-60, 63-77, 83-90, 96-102</p>
X	<p>DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1980, YAMAMOTO A ET AL: "PRODUCTION OF L FORMS OF STREPTOCOCCUS-PYOGENES AND THEIR ANTI TUMOR EFFECTS" XP002331819 Database accession no. PREV198171075184 abstract &amp; JAPANESE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 50, no. 5, 1980, pages 383-388, ISSN: 0021-5031</p>	<p>23-30, 39-60, 63-77, 83-90, 96-102</p>

-/--

## INTERNATIONAL SEARCH REPORT

PCT/US2004/019866

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE MEDLINE 'Online!  US NATIONAL LIBRARY OF MEDICINE (NLM),  BETHESDA, MD, US;  1 October 1980 (1980-10-01),  TANAKA R ET AL: "Preliminary evaluation of  intratumoral injection of a Streptococcus  pyogenes preparation in patients with  malignant brain tumors."  XP002331820  Database accession no. NLM6998559  abstract  &amp; CANCER. 1 OCT 1980,  vol. 46, no. 7,  1 October 1980 (1980-10-01), pages  1688-1694,  ISSN: 0008-543X</p> <p>-----</p>	<p>23-30,  39-60,  63-77,  83-90,  96-102</p>
X	<p>WO 03/014380 A (SZALAY, ALADAR, A; YU,  YONG, A; SHABAHANG, SHAHROKH; TIMIRYASOVA,  TATY) 20 February 2003 (2003-02-20)  cited in the application</p> <p>page 52, last paragraph - page 53,  paragraph 2  figures 9,10  page 55, paragraph 2 - page 71, paragraph  2  page 85, paragraph 1 - page 88, paragraph  1</p> <p>-----</p>	<p>23-30,  39-60,  63-77,  83-90,  96-102</p>
P,X	<p>EP 1 369 491 A (GENELUX GMBH)  10 December 2003 (2003-12-10)</p> <p>the whole document</p> <p>-----</p>	<p>23-30,  39-60,  63-77,  83-90,  96-102</p>
P,X	<p>YU YONG A ET AL: "Visualization of tumors  and metastases in live animals with  bacteria and vaccinia virus encoding  light-emitting proteins."  NATURE BIOTECHNOLOGY,  vol. 22, no. 3, March 2004 (2004-03),  pages 313-320, XP002331816  ISSN: 1087-0156  cited in the application  the whole document</p> <p>-----</p>	<p>23-30,  39-60,  63-77,  83-90,  96-102</p>
	-	-/--

# INTERNATIONAL SEARCH REPORT

PCT/US2004/019866

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>YU Y A ET AL: "OPTICAL IMAGING: BACTERIA, VIRUSES, AND MAMMALIAN CELLS ENCODING LIGHT-EMITTING PROTEINS REVEAL THE LOCATIONS OF PRIMARY TUMORS AND METASTASES IN ANIMALS"</p> <p>ANALYTICAL AND BIOANALYTICAL CHEMISTRY, DE,</p> <p>vol. 377, no. 6, November 2003 (2003-11), pages 964-972, XP008045750</p> <p>ISSN: 1618-2642</p> <p>the whole document</p>	<p>23-30, 39-60, 63-77, 83-90, 96-102</p>
A	<p>DATABASE BIOSIS 'Online!</p> <p>BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1989,</p> <p>SHIMIZU Y ET AL: "SIGNIFICANCE OF PRIMING OF HOSTS WITH VIRUS IN THE TUMOR-SPECIFIC IMMUNOTHERAPY MODEL UTILIZING VIRUS-REACTIVE HELPER T CELL ACTIVITY"</p> <p>XP002331821</p> <p>Database accession no. PREV198988132538</p> <p>abstract</p> <p>&amp; JOURNAL OF JAPAN SOCIETY FOR CANCER THERAPY,</p> <p>vol. 24, no. 5, 1989, pages 1007-1014,</p> <p>ISSN: 0021-4671</p>	

# INTERNATIONAL SEARCH REPORT

PCT/US2004/019866

## Box II Observations where certain claims were found unsearchable (Continuation of Item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 20-29, 65, 66, 73-82, 96-102 (all completely) and claim 31 (partially) are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of Item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-22, 31, 32, 37, 38 (all completely); 23-30, 33-36, 39-41, 43-50, 54-57, 60-62, 64-76, 78-88, 90-102 (all partially)

A recombinant vaccinia or other poxvirus wherein at least the TK and HA genes thereof are modified, methods of producing the same, and the use thereof

---

2. claims: 23-30, 33-36, 39-41, 43-50, 54-57, 60-62, 64-76, 78-88, 90-102 (all partially)

A recombinant vaccinia virus wherein the F3 gene thereof is modified, methods of producing the same, and the use thereof, and wherein the virus is other than any included in invention 1

---

3. claims: 23-30, 33-36, 39-41, 43-50, 54-57, 60-62, 64-76, 78-81, 83-88, 90-94, 96-102 (all partially)

A recombinant vaccinia virus wherein the TK gene thereof is modified, methods of producing the same, and the use thereof, and wherein the virus is other than any included in either of inventions 1 and 2

---

4. claims: 23-30, 33-36, 39-41, 43-50, 54-57, 60-62, 64-76, 78-81, 83-88, 90-94, 96-102 (all partially)

A recombinant vaccinia virus wherein the HA gene thereof is modified, methods of producing the same, and the use thereof, and wherein the virus is other than any included in any of inventions 1-3

---

5. claims: 42, 51-53, 58, 59, 63, 77, 89 (all completely); 23-30, 39-41, 43-50, 54-57, 60, 64-76, 83-88, 90, 96-102 (all partially)

Use of a microorganism in eliminating or inhibiting growth of immunoprivileged cells or tissues, a means for production of a polypeptide or RNA or compound via the use of a microorganism, use of a microorganism in inducing autoimmunization, a method for producing antibodies using a microorganism, kits related thereto, and wherein said microorganism is other than any included in any of inventions 1-4

---

# INTERNATIONAL SEARCH REPORT

Information on patent family members

PCT/US2004/019866

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9222327	A	23-12-1992	US 5718902 A WO 9222327 A1	17-02-1998 23-12-1992
WO 0073479	A	07-12-2000	AU 5446700 A CA 2375189 A1 EP 1180157 A1 WO 0073479 A1 US 2003031681 A1	18-12-2000 07-12-2000 20-02-2002 07-12-2000 13-02-2003
US 6491905	B1	10-12-2002	US 6017896 A US 5552311 A US 2003077268 A1 US 2003134819 A1 CA 2171618 A1 DE 69431911 D1 DE 69431911 T2 EP 0715523 A1 JP 9502612 T WO 9507718 A2	25-01-2000 03-09-1996 24-04-2003 17-07-2003 23-03-1995 30-01-2003 28-05-2003 12-06-1996 18-03-1997 23-03-1995
WO 03014380	A	20-02-2003	EP 1281772 A1 EP 1281767 A2 BR 0211546 A CA 2456055 A1 EP 1414994 A2 WO 03014380 A2 US 2003059400 A1 US 2005069491 A1 US 2004234455 A1	05-02-2003 05-02-2003 13-07-2004 20-02-2003 06-05-2004 20-02-2003 27-03-2003 31-03-2005 25-11-2004
EP 1369491	A	10-12-2003	EP 1369491 A1 AU 2003236696 A1 CA 2488227 A1 WO 03104485 A2 EP 1509617 A2	10-12-2003 22-12-2003 18-12-2003 18-12-2003 02-03-2005

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**